The Fauci COVID-19 Dossier

The Fauci/COVID-19 Dossier
This document is prepared for humanity by Dr. David E. Martin.
Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 1

The Fauci/COVID-19 Dossier
This document is prepared for humanity by Dr. David E. Martin.
This work was supported, in part, by a fund-raising effort in which approximately 330 persons contributed funds in support
of the New Earth technology team and Urban Global Health Alliance. It is released under a Creative Commons license CC-
BY-NC-SA. Any derivative use of this dossier must be made public for the benefit of others. All documents, references and
disclosures contained herein are subject to an AS-IS representation. The author does not bear responsibility for errors in
the public record or references therein. Throughout this document, uses of terms commonly accepted in medical and
scientific literature do not imply acceptance or rejection of the dogma that they represent.
Background:
Over the past two decades, my company – M·CAM – has been monitoring possible violations of the 1925 Protocol for
the Prohibition of the Use in War of Asphyxiating, Poisonous, or other Gases, and of Bacteriological Methods of Warfare
(the Geneva Protocol) 1972 Convention on the Prohibition of the Development, Production, and Stockpiling of
Bacteriological and Toxin Weapons and Their Destruction (the BTWC). In our 2003-2004 Global Technology
Assessment: Vector Weaponization M·CAM highlighted China’s growing involvement in Polymerase Chain Reaction
(PCR) technology with respect to joining the world stage in chimeric construction of viral vectors. Since that time, on a
weekly basis, we have monitored the development of research and commercial efforts in this field, including, but not
limited to, the research synergies forming between the United States Centers for Disease Control and Prevention (CDC),
the National Institutes for Allergies and Infectious Diseases (NIAID), the University of North Carolina at Chapel Hill (UNC),
Harvard University, Emory University, Vanderbilt University, Tsinghua University, University of Pennsylvania, many other
research institutions, and their commercial affiliations.
The National Institute of Health’s grant AI23946-08 issued to Dr. Ralph Baric at the University of North Carolina at
Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on
synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic
enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21,
2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit.1 In one
of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full
length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on a composite of DNA segments.
“Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of
the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV)
that contained the expected marker mutations inserted into the component clones.”2
On April 19, 2002 – the Spring before the first SARS outbreak in Asia – Christopher M. Curtis, Boyd Yount, and Ralph
Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first
public record of the claims, they sought to patent a means of producing, “an infectious, replication defective,
coronavirus.” This work was supported by the NIH grant referenced above and GM63228. In short, the U.S. Department
of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between
1999 and 2002 before SARS was ever detected in humans.
1 U.S. Provisional Application No. 60/206,537, filed May 21, 2000

2 https://www.pnas.org/content/100/22/12995
Against this backdrop, we noted the unusual patent prosecution efforts of the CDC, when on April 25, 2003 they sought
to patent the SARS coronavirus isolated from humans that had reportedly transferred to humans during the 2002-2003
SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did not deter CDC in their efforts. Their
application, updated in 2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their
patent from manipulating SARS CoV, developing tests or kits to measure SARS coronavirus in humans or working with
their patented virus for therapeutic use. Work associated with this virus by their select collaborators included
considerable amounts of chimeric engineering, gain-of-function studies, viral characterization, detection, treatment
(both vaccine and therapeutic intervention), and weaponization inquiries.
In short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852 patent (Claim 1), no research in the United
States could be conducted without permission or infringement.
We noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient of millions of dollars of U.S. research
grants from several federal agencies but also sat on the World Health Organization’s International Committee on
Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In this capacity, he was both responsible for
determining “novelty” of clades of virus species but directly benefitted from determining declarations of novelty in the
form of new research funding authorizations and associated patenting and commercial collaboration. Together with
CDC, NIAID, WHO, academic and commercial parties (including Johnson & Johnson; Sanofi and their several coronavirus
patent holding biotech companies; Moderna; Ridgeback; Gilead; Sherlock Biosciences; and, others), a powerful group of
interests constituted what we would suggest are “interlocking directorates” under U.S. anti-trust laws.
These entities also were affiliated with the WHO’s Global Preparedness Monitoring Board (GPMB) whose members were
instrumental in the Open Philanthropy-funded global coronavirus pandemic “desk-top” exercise EVENT 201 in October
2019. This event, funded by the principal investor in Sherlock Biosciences and linking interlocking funding partner, the
Bill and Melinda Gates Foundation into the GPMB mandate for a respiratory disease global preparedness exercise to be
completed by September 2020 alerted us to anticipate an “epidemic” scenario. We expected to see such a scenario
emerge from Wuhan or Guangdong China, northern Italy, Seattle, New York or a combination thereof, as Dr. Zhengli Shi
and Dr. Baric’s work on zoonotic transmission of coronavirus identified overlapping mutations in coronavirus in bat
populations located in these areas.
This dossier is by no means exhaustive. It is, however, indicative the numerous criminal violations that may be
associated with the COVID-19 terrorism. All source materials are referenced herein. An additional detailed breakdown
of all the of individuals, research institutions, foundations, funding sources, and commercial enterprises can be accessed
upon request.

Contents
35 U.S.C. § 101 ........................................................................................................................................................................ 5
18 U.S.C. §2339 C et seq. – Funding and Conspiring to Commit Acts of Terror .................................................................... 7
18 U.S.C. § 2331 §§ 802 – Acts of Domestic Terrorism resulting in death of American Citizens ......................................... 10
18 U.S.C. § 1001 – Lying to Congress .................................................................................................................................... 12
15 U.S.C. §1-3 – Conspiring to Criminal Commercial Activity ............................................................................................... 16
15 U.S.C. §8 – Market Manipulation and Allocation............................................................................................................. 20
15 U.S.C. § 19 – Interlocking Directorates ............................................................................................................................ 21
35 U.S.C. §200 - 206 – Disclosure of Government Interest .................................................................................................. 23
21 C.F.R. § 50.24 et seq., Illegal Clinical Trial ........................................................................................................................ 25
The Commercial Actors ......................................................................................................................................................... 27

35 U.S.C. § 101
From Justice Clarence Thomas’ opinion for the majority
Section 101 of the Patent Act provides: "Whoever invents or discovers any new and useful ... composition of matter,
or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements
of this title." 35 U.S.C. § 101.
We have "long held that this provision contains an important implicit exception[:] Laws of nature, natural
phenomena, and abstract ideas are not patentable." Mayo, 566 U.S., at ___, 132 S.Ct., at 1293 (internal quotation
marks and brackets omitted). Rather, "`they are the basic tools of scientific and technological work'" that lie beyond
the domain of patent protection. Id., at ___, 132 S.Ct., at 1293. As the Court has explained, without this exception,
there would be considerable danger that the grant of patents would "tie up" the use of such tools and thereby "inhibit
future innovation premised upon them." Id., at ___, 132 S.Ct., at 1301. This would be at odds with the very point of
patents, which exist to promote creation. Diamond v. Chakrabarty, 447 U.S. 303, 309, 100 S.Ct. 2204, 65 L.Ed.2d 144
(1980) (Products of nature are not created, and "`manifestations... of nature [are] free to all men and reserved
exclusively to none'").3
In their majority opinion in 2013, the U.S. Supreme Court made it abundantly clear that the Court had “long held” that
nature was not patentable. Merely isolating DNA does not constitute patentable subject matter. In their patent, the
CDC made false and misleading claims to the United States Patent & Trademark Office by stating that, “A newly isolated
human coronavirus has been identified as the causative agent of SARS, and is termed SARS-CoV.”4 No “causal” data was
provided for this statement.
When they filed their patent application on April 25, 2003 their first claim (and the only one that survived to ultimate
issuance over the objection of the patent examiner in 2006 and 2007) was the genome for SARS CoV.
While this patent is clearly illegal under 35 U.S.C. §101, not only did the CDC insist on its granting over non-final and final
rejections, but they also continued to pay maintenance fees on the patent after the 2013 Supreme Court decision
confirmed that it was illegal.
In addition, the CDC patented the detection of SARS CoV using a number of methods including reverse transcription
polymerase chain reaction (RT-PCR). With this patent, they precluded anyone outside of their licensed or conspiring
interest from legally engaging in independent verification of their claim that they had isolated a virus, that it was a
causative agent for SARS, or that any therapy could be effective against the reported pathogen.
It is important to note that the CDC’s patent applications were also rejected in non-final and final rejections for
ineligibility under 35 U.S.C. § 102 for being publicly disclosed prior to their own filing. In the first non-final rejection, the
USPTO stated that the CDC’s genome was published in four Genbank accession entries on April 14, 18, and 21, 2003 with
identity ranging from 96.8% to 99.9% identical sequences.5 Dr. Fauci knew, and failed to disclose evidence that the CDC
patent was illegal, based on work he had funded in the years leading up to the SARS outbreak.
After seeking an illegal patent, petitioning to override the decision of an examiner to reject it, and ultimately prevailing
with the patent’s grant, the CDC lied to the public by stating they were controlling the patent so that it would be
“publicly available”.6 Tragically, this public statement is falsified by the simple fact that their own publication in
3 Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)
4 U.S. Patent 7,220,852
5 USPTO Non-Final Rejection File #10822904, September 7, 2006, page 4.
6
https://apnews.com/article/145b4e8d156cddc93e996ae52dc24ec0
Genbank had, in fact, made it public domain and thereby unpatentable. This fact, confirmed by patent examiners, was
overridden by CDC in a paid solicitation to override the law.
While not covered under 35 U.S.C. §101, Dr. Fauci’s abuse of the patent law is detailed below. Of note, however, is his
willful and deceptive use of the term “vaccine” in patents and public pronouncements to pervert the meaning of the
term for the manipulation of the public.
In the 1905 Jacobson v. Mass case, the court was clear that a PUBLIC BENEFIT was required for a vaccine to be
mandated. Neither Pfizer nor Moderna have proved a disruption of transmission. In Jacobson v. Massachusetts, 197 U.S.
11 (1905), the court held that the context for their opinion rested on the following principle:
“This court has more than once recognized it as a fundamental principle that 'persons and property are subjected to all
kinds of restraints and burdens in order to secure the general comfort, health, and prosperity of the state…”
The Moderna and Pfizer “alleged vaccine” trials have explicitly acknowledged that their gene therapy technology has no
impact on viral infection or transmission whatsoever and merely conveys to the recipient the capacity to produce an S1
spike protein endogenously by the introduction of a synthetic mRNA sequence. Therefore, the basis for the
Massachusetts statute and the Supreme Court’s determination is moot in this case.
Further, the USPTO, in its REJECTION of Anthony Fauci's HIV vaccine made the following statement supporting their
rejection of his bogus "invention"

18 U.S.C. §2339 C et seq. – Funding and Conspiring to Commit Acts of Terror
Indirectly, unlawfully and willfully provides or collects funds with the intention that such funds be used, or with the
knowledge that such funds are to be used, in full or in part, in order to carry out—
(A) an act which constitutes an offense within the scope of a treaty specified in subsection (e)(7), as
implemented by the United States, or
(B) any other act intended to cause death or serious bodily injury to a civilian, or to any other person not
taking an active part in the hostilities in a situation of armed conflict, when the purpose of such act, by its
nature or context, is to intimidate a population, or to compel a government or an international
organization to do or to abstain from doing any act….
By no later than April 11, 2005, Dr. Anthony Fauci was publicly acknowledging the association of SARS with bioterror
potential. Leveraging the fear of the anthrax bioterrorism of 2001, he publicly celebrated the economic boon that
domestic terror had directed towards his budget. He specifically stated that NIAID was actively funding research on a
“SARS Chip” DNA microarray to rapidly detect SARS (something that was not made available during the current
“pandemic”) and two candidate vaccines focused on the SARS CoV spike protein.7 Led by three Chinese researchers
under his employment – Zhi-yong Yang, Wing-pui Kong, and Yue Huang – Fauci had at least one DNA vaccine in animal
trials by 2004.8 This team, part of the Vaccine Research Center at NIAID, was primarily focused on HIV vaccine
development but was tasked to identify SARS vaccine candidates as well. Working in collaboration with Sanofi, Scripps
Institute, Harvard, MIT and NIH, Dr. Fauci’s decision to unilaterally promote vaccines as a primary intervention for
several designated “infectious diseases” precluded proven therapies from being applied to the sick and dying.9
The CDC and NIAID led by Anthony Fauci entered into trade among States (including, but not limited to working with
EcoHealth Alliance Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy
of Sciences) through the 2014 et seq National Institutes of Health Grant R01AI110964 to exploit their patent rights. This
research was known to involve surface proteins in coronavirus that had the capacity to directly infect human respiratory
systems. In flagrant violation of the NIH moratorium on gain of function research, NIAID and Ralph Baric persisted in
working with chimeric coronavirus components specifically to amplify the pathogenicity of the biologic material.
By October 2013, the Wuhan Institute of Virology 1 coronavirus S1 spike protein was described in NIAID’s funded work
in China. This work involved NIAID, USAID, and Peter Daszak, the head of EcoHealth Alliance. This work, funded under
R01AI079231, was pivotal in isolating and manipulating viral fragments selected from sites across China which contained
high risk for severe human response.10
By March 2015, both the virulence of the S1 spike protein and the ACE II receptor was known to present a considerable
risk to human health. NIAID, EcoHealth Alliance and numerous researchers lamented the fact that the public was not
sufficiently concerned about coronavirus to adequately fund their desired research.11
Dr. Peter Daszak of EcoHealth Alliance offered the following assessment:
7 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320336/
10 Ge, XY., Li, JL., Yang, XL. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535–538
(2013).
11 Forum on Medical and Public Health Preparedness for Catastrophic Events; Forum on Drug Discovery, Development, and Translation; Forum on
Microbial Threats; Board on Health Sciences Policy; Board on Global Health; Institute of Medicine; National Academies of Sciences, Engineering,
and Medicine. Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and
Private-Sector Partnerships: Workshop Summary. Washington (DC): National Academies Press (US); 2016 Feb 12. 6, Developing MCMs for
Coronaviruses. Available from: https://www.ncbi.nlm.nih.gov/books/NBK349040/
“Daszak reiterated that, until an infectious disease crisis is very real, present, and at an emergency threshold, it is often
largely ignored. To sustain the funding base beyond the crisis, he said, we need to increase public understanding of the
need for MCMs such as a pan-influenza or pan-coronavirus vaccine. A key driver is the media, and the economics follow
the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at
the end of process, Daszak stated.”12
Economics will follow the hype.
The CDC and NIAID entered into trade among States (including, but not limited to working with University of North
Carolina, Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of
Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National
Natural Science Foundation of China Award 81290341 (Zheng-Li Shi) et al. 2015-2016. These projects took place during
a time when the work being performed was prohibited by the United States National Institutes of Health.
The public was clearly advised of the dangers being presented by NIAID-funded research by 2015 and 2016 when the
Wuhan Institute of Virology material was being manipulated at UNC in Ralph Baric’s lab.
“The only impact of this work is the creation, in a lab, of a new, non-natural risk,” agrees Richard Ebright, a molecular
biologist and biodefence expert at Rutgers University in Piscataway, New Jersey. Both Ebright and Wain-Hobson are
long-standing critics of gain-of-function research.
In their paper, the study authors also concede that funders may think twice about allowing such experiments in the
future. "Scientific review panels may deem similar studies building chimeric viruses based on circulating strains too risky
to pursue," they write, adding that discussion is needed as to "whether these types of chimeric virus studies warrant
further investigation versus the inherent risks involved”.
But Baric and others say the research did have benefits. The study findings “move this virus from a candidate emerging
pathogen to a clear and present danger”, says Peter Daszak, who co-authored the 2013 paper. Daszak is president of the
EcoHealth Alliance, an international network of scientists, headquartered in New York City, that samples viruses from
animals and people in emerging-diseases hotspots across the globe.
Studies testing hybrid viruses in human cell culture and animal models are limited in what they can say about the threat
posed by a wild virus, Daszak agrees. But he argues that they can help indicate which pathogens should be prioritized for
further research attention.”13
Knowing that the U.S. Department of Health and Human Services (through CDC, NIH, NIAID, and their funded
laboratories and commercial partners) had patents on each proposed element of medical counter measures and their
funding, Dr. Fauci, Dr. Gao (China CDC), and Dr. Elias (Bill and Melinda Gates Foundation) conspired to commit acts of
terror on the global population – including the citizens of the United States – when, in September 2019, they published
the following mandate:
“Countries, donors and multilateral institutions must be prepared for the worst. A rapidly spreading pandemic due to a
lethal respiratory pathogen (whether naturally emergent or accidentally or deliberately released) poses additional
preparedness requirements. Donors and multilateral institutions must ensure adequate investment in developing
innovative vaccines and therapeutics, surge manufacturing capacity, broad-spectrum antivirals and appropriate non-
pharmaceutical interventions. All countries must develop a system for immediately sharing genome sequences of any
12 Ibid.
13 https://www.nature.com/news/engineered-bat-virus-stirs-debate-over-risky-research-%201.18787
new pathogen for public health purposes along with the means to share limited medical countermeasures across
countries.
Progress indicator(s) by September 2020
• Donors and countries commit and identify timelines for: financing and development of a universal influenza
vaccine, broad spectrum antivirals, and targeted therapeutics. WHO and its Member States develop options for
standard procedures and timelines for sharing of sequence data, specimens, and medical countermeasures for
pathogens other than influenza.
• Donors, countries and multilateral institutions develop a multi-year plan and approach for strengthening R&D
research capacity, in advance of and during an epidemic.
• WHO, the United Nations Children’s Fund, the International Federation of Red Cross and Red Crescent Societies,
academic and other partners identify strategies for increasing capacity and integration of social science
approaches and researchers across the entire preparedness/response continuum.”14
As if to confirm the utility of the September 2019 demand for “financing and development of” vaccine and the fortuitous
SARS CoV-2 alleged outbreak in December of 2019, Dr. Fauci began gloating that his fortunes for additional funding were
likely changing for the better. In a February 2020 interview in STAT, he was quoted as follows:
““The emergence of the new virus is going to change that figure, likely considerably, Fauci said. “I don’t know how much
it’s going to be. But I think it’s going to generate more sustained interest in coronaviruses because it’s very clear that
coronaviruses can do really interesting things.””15
14 https://apps.who.int/gpmb/assets/annual_report/GPMB_annualreport_2019.pdf (page 8)
15 https://www.statnews.com/2020/02/10/fluctuating-funding-and-flagging-interest-hurt-coronavirus-research/
18 U.S.C. § 2331 §§ 802 – Acts of Domestic Terrorism resulting in death of
American Citizens
Section 802 of the USA PATRIOT Act (Pub. L. No. 107-52) expanded the definition of terrorism to cover "domestic," as
opposed to international, terrorism. A person engages in domestic terrorism if they do an act "dangerous to human
life" that is a violation of the criminal laws of a state or the United States, if the act appears to be intended to: (i)
intimidate or coerce a civilian population; (ii) influence the policy of a government by intimidation or coercion;
Dr. Anthony Fauci has intimidated and coerced a civilian population and sought to influence the policy of a government
by intimidation and coercion.
With no corroboration, Dr. Anthony Fauci promoted16 Professor Neil Ferguson’s computer simulation derived claims
that,
“The world is facing the most serious public health crisis in generations. Here we provide concrete estimates of the
scale of the threat countries now face.
“We use the latest estimates of severity to show that policy strategies which aim to mitigate the epidemic might
halve deaths and reduce peak healthcare demand by two-thirds, but that this will not be enough to prevent health
systems being overwhelmed. More intensive, and socially disruptive interventions will therefore be required to
suppress transmission to low levels. It is likely such measures – most notably, large scale social distancing – will need
to be in place for many months, perhaps until a vaccine becomes available.” 17
Reporting to the President that as many as 2.2 million deaths may result from a pathogen that had not yet been isolated
and could not be measured with any accuracy, Dr. Fauci intimidated and coerced the population and the government
into reckless, untested, and harmful acts creating irreparable harm to lives and livelihoods.18 Neither the Imperial
College nor the “independent” Institute for Health Metrics and Evaluation (principally funded by the Bill and Melinda
Gates Foundation)19 had any evidence of success in estimating previous burdens from coronavirus but, without
consultation or peer-review, Dr. Fauci adopted their terrifying estimates as the basis for interventions that are explicitly
against medical advice.
 The imposition of social distancing was based on computer simulation and environmental models with NO
disease transmission evidence whatsoever.
 The imposition of face mask wearing was directly against controlled clinical trial evidence and against the
written policy in the Journal of the American Medical Association.
“Face masks should not be worn by healthy individuals to protect themselves from acquiring respiratory
infection because there is no evidence to suggest that face masks worn by healthy individuals are
effective in preventing people from becoming ill.”20
 In both the Imperial College and the IHME simulations, quarantines were modeled for the sick, not the healthy.
16 https://www.cato.org/blog/did-mitigation-save-two-million-lives
17 https://www.imperial.ac.uk/news/196234/covid-19-imperial-researchers-model-likely-impact/
18 https://www.npr.org/2020/03/31/823916343/coronavirus-task-force-set-to-detail-the-data-that-led-to-extension-of-guideline
19 https://www.gatesfoundation.org/Media-Center/Press-Releases/2017/01/IHME-Announcement
20
https://jamanetwork.com/journals/jama/fullarticle/2762694?fbclid=IwAR2RE-c4V-fhUodui0JQRbiHRcgEJuDKG_21N4oL5zAfciQfWCyHAsetJmo
Insisting on vaccines while blockading the emergency use of proven pharmaceutical interventions may have contributed
to the death of many patients and otherwise healthy individuals.21
Using the power of NIAID during the alleged pandemic, Dr. Anthony Fauci actively suppressed proven medical
countermeasures used by, and validated in scientific proceedings, that offered alternatives to the products funded by his
conspiring entities for which he had provided direct funding and for whom he would receive tangible and intangible
benefit.
21 https://www.reuters.com/investigates/special-report/health-coronavirus-usa-cost/
18 U.S.C. § 1001 – Lying to Congress
(a)Except as otherwise provided in this section, whoever, in any matter within the jurisdiction of the executive,
legislative, or judicial branch of the Government of the United States, knowingly and willfully—
(1) falsifies, conceals, or covers up by any trick, scheme, or device a material fact;
(2) makes any materially false, fictitious, or fraudulent statement or representation; or
(3) makes or uses any false writing or document knowing the same to contain any materially false, fictitious,
or fraudulent statement or entry;
shall be fined under this title, imprisoned not more than 5 years or, if the offense involves international or domestic
terrorism (as defined in section 2331), imprisoned not more than 8 years, or both. If the matter relates to an offense
under chapter 109A, 109B, 110, or 117, or section 1591, then the term of imprisonment imposed under this section
shall be not more than 8 years.
On October 22, 2020, the United States Government Accountability Office (GAO) published a report entitled:
BIOMEDICAL RESEARCH: NIH Should Publicly Report More Information about the Licensing of Its Intellectual Property.
In this document, the authors reported that the National Institutes of Health (NIH) received, “up to $2 billion in royalties
from its contributions to 34 drugs sold from 1991-2019.”22
A casual review of the NIH Office of Technology Transfer report of active licenses23 appears to conflict with the GAO
report on several important facts. Conspicuously absent from the GAO report are over 30 patents associated with active
compounds generating billions of dollars in revenue. Why would it be that the GAO and the NIH couldn’t agree on
something as simple as drugs generating income for NIH?
Since the passage of the Bayh Dole Act (Pub. L. 96-517, December 12, 1980), federally funded research has been an
economic bonanza for U.S. universities, federal agencies, and their selected patronage. For the first decade following
Bayh Dole, NIH funding doubled from $3.4 billion to $7.1 billion. A decade later, it doubled again to $15.6 billion. In the
wake of September 2001, the National Institute for Allergy and Infectious Diseases (NIAID) saw its direct budget increase
over 300% without accounting for DARPA funds of as much as $1.7 billion annually from 2005 forward. In 2020, NIH’s
budget was over $41 billion.
What has become of the $763 billion of taxpayer funds allocated to making America healthier since inventors have been
commercially incentivized? Who has been enriched?
The answer, regrettably, is that no accountability exists to answer these questions.
The NIH is the named owner of at least 138 patents since 1980.
The United States Department of Health and Human Services is the named owner of at least 2,600 patents.
NIAID grants or collaboration have resulted in 2,655 patents and patent applications of which only 95 include an
assignment to the Department of Health and Human Services as an owner. Most of these patents are assigned to
universities thereby making the ultimate commercial beneficiaries entirely opaque. One of the largest holders is SIGA
Technologies (NASDAQ: SIGA) who, while publicly reporting close affiliation with NIAID, is not referenced in the NIH GAO
report. SIGA’s CEO, Dr. Phillip L. Gomez spent 9 years at NIAID developing its vaccine program for HIV, SARS, Ebola,
West Nile Virus, and Influenza before exiting to commercial ventures. While their technology is clearly derived from
NIAID science, the company reports revenue from NIAID but no royalty or commercial payments to NIH or any of its
programs.
22 https://www.gao.gov/products/GAO-21-52
23 https://www.ott.nih.gov/reportsstats/hhs-license-based-vaccines-therapeutics
NIAID’s Director, Dr. Anthony Fauci is listed as an inventor on 8 granted U.S. patents. None of them are reported in
NIAID, NIH, or GAO reports of active licensing despite the fact that Dr. Fauci reportedly was compelled to get paid for his
interleukin-2 “invention” – payments he reportedly donated to an unnamed charity.24
Of the 21 patents listed in the U.S. Food and Drug Administration’s (FDA) Orange book itemized in the GAO report, none
of Dr. Anthony Fauci’s patents are listed. Furthermore, none of the NIAID patents are listed despite clear evidence that
Gilead Sciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) have generated over $2 billion annually
from sales that were the direct result of NIAID funded science. Missing from the GAO report are 2 patents for Velclade®
which has been generating sales in excess of $2.18 billion annually for several years. None of the patents for Yescarta®
are listed in the GAO report. None of the Lumoxiti® patents are listed in the GAO report. None of the Kepivance®
patents are listed in the GAO report. In violation of 37 USC §410.10 and 35 USC §202(a), over 13 of the 21 patents in the
GAO report fail to disclose government interest despite being the direct result of NIH funding.
Dr. Anthony Fauci’s Own Patent Track Record:
US Patent 6,190,656 and 6,548,055 Immunologic enhancement with intermittent interleukin-2 therapy
A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected
intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in
peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows
the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in
peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This
intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-
retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2
administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this
approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by
delivering a genetically engineered retroviral vector directly to the patient.
This application is a continuation of U.S. patent application Ser. No. 08/487,075, filed Jun. 7, 1995, now abandoned,
which is a continuation in part of U.S. patent application Ser. No. 08/063,315, filed May 19, 1993, now issued as U.S. Pat.
No. 5,419,900, and U.S. patent application Ser. No. 08/452,440, filed May 26, 1995, now issued as U.S. Pat. No.
5,696,079, which is the National Stage filed under 35 USC 371 of PCT/US94/05397, filed May 19, 1994, the contents of
which are incorporated herein by reference.
Filed May 19, 1993
Issued a Final Rejection January 20, 1998. Rejected after abandonment August 14, 1998 and April 12, 1999. Reduced
and modified claims granted May 8, 2000.
This family of patents was the basis of Fauci’s lie to the British Medical Journal in which he falsely stated:
“Dr Anthony Fauci told the BMJ that as a government employee he was required by law to put his name on the patent for
the development of interleukin 2 and was also required by law to receive part of the payment the government received
for use of the patent. He said that he felt it was inappropiate (sic) to receive payment and donated the entire amount to
charity.”25
He was not “required by law” to commit fraud on the patent office and then get paid for it!
25 Ibid.
US Patent 6,911,527 HIV related peptides
This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1
infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling
progression to AIDS.
Filed May 6, 1999
Rejected as unpatentable January 22, 2003. Issued with a final rejection on July 15, 2004 after submitting
reconsideration requests. Modified and restricted claims allowed September 29, 2004.
US Patent 7,368,114 Fusion protein including of CD4
Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a
portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy
chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of
the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed
herein are methods for using these CD4 fusion proteins.
Filed October 24, 2002
Rejected as unpatentable August 18, 2006. Paid appeal to overturn examiner’s findings February 15, 2007. Rejected
again May 11, 2007. On October 10, 2007 applicants further narrowed the construction of what was clearly not a patent
and the USPTO granted less than half the claims that had been sought in the original filing.
US Patent 9,896,509, 9,193,790 and 9,441,041 Use of antagonists of the interaction between HIV GP120 and
.alpha.4.beta.7 integrin
Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an
HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and .alpha.4
integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist, thereby treating the HIV infection. In several
examples, the .alpha.4 integrin antagonist is a monoclonal antibody that specifically binds to a .alpha.4, .beta.1 or
.beta.7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to
reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that
interferes with the interaction of gp120 and .alpha.4 integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin
antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.
Rejected May 22, 2017 as Double Patenting. In their response, the applicants acknowledge the illegal act and seek only
those components of their application that extend beyond the life of the issued patents. On October 11, 2017, the limited
claims were issued.
A sample of the convoluted flow of funds that evades public disclosure.
U.S. Patent 8,999,351 was issued to Tekmira Pharmaceuticals Corporation in Burnaby, British Columbia. In their patent,
they disclose that their research was supported by a grant from the National Institute of Allergy and Infectious Disease
(Grant HHSN266200600012C). Ironically, this $23 million grant was awarded in 2006 to Alnylam Pharmaceuticals, Inc.,
not to Tekmira.26
26
https://www.technologynetworks.com/genomics/news/alnylam-awarded-23-million-us-government-contract-to-develop-rnai-therapeutics-
186097
In 2012, Alnylam agreed to pay Tekmira $65 million to settle legal disputes including a $1 billion damages claim for
“relentless and egregious” misappropriation of Tekmira’s trade secrets. From the patent filing’s earliest priority of
November 10, 2008, there is no public record stating Tekmira as the beneficiary of this NIAID grant. Notwithstanding,
the lipid nanoparticle technology developed from this grant is the technology now used in the Moderna COVID-19
intervention. In their 10-Q filing, Alnylam reports to have a license to technology from Arbutus – formerly Tekmira –
which has accused Acuitas of misappropriating trade secrets and licensing them to Moderna and Pfizer’s collaboration
with BioNTech.
Additional references can be found at:
https://www.ott.nih.gov/nih-and-its-role-technology-transfer
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206288Orig1s000TAltr.pdf
https://www.gao.gov/assets/720/710287.pdf
https://grantome.com/search?q=%22National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases%22

15 U.S.C. §1-3 – Conspiring to Criminal Commercial Activity
Every contract, combination in the form of trust or otherwise, or conspiracy, in restraint of trade or commerce among
the several States, or with foreign nations, is declared to be illegal. Every person who shall make any contract or
engage in any combination or conspiracy hereby declared to be illegal shall be deemed guilty of a felony, and, on
conviction thereof, shall be punished by fine not exceeding $100,000,000 if a corporation, or, if any
other person, $1,000,000, or by imprisonment not exceeding 10 years, or by both said punishments, in the discretion
of the court.
The National Institute of Health’s grant AI23946-08 issued to Dr. Ralph Baric at the University of North Carolina at
Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on
synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic
enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21,
2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit.27 In
one of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full
length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on a composite of DNA segments.
“Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of
the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV)
that contained the expected marker mutations inserted into the component clones.”28
On April 19, 2002 – the Spring before the first SARS outbreak in Asia – Christopher M. Curtis, Boyd Yount, and Ralph
Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first
public record of the claims, they sought to patent a means of producing, “an infectious, replication defective,
coronavirus.” This work was supported by the NIH grant referenced above and GM63228. In short, the U.S. Department
of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between
1999 and 2002 before SARS was ever detected in humans.
Against this backdrop, we noted the unusual patent prosecution efforts of the CDC, when on April 25, 2003 they sought
to patent the SARS coronavirus isolated from humans that had reportedly transferred to humans during the 2002-2003
SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did not deter CDC in their efforts. Their
application, updated in 2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their
patent from manipulating SARS CoV, developing tests or kits to measure SARS coronavirus in humans or working with
their patented virus for therapeutic use. Work associated with this virus by their select collaborators included
considerable amounts of chimeric engineering, gain-of-function studies, viral characterization, detection, treatment
(both vaccine and therapeutic intervention), and weaponization inquiries.
In short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852 patent (Claim 1), no research in the United
States could be conducted without permission or infringement.
We noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient of millions of dollars of U.S. research
grants from several federal agencies but also sat on the World Health Organization’s International Committee on
Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In this capacity, he was both responsible for
determining “novelty” of clades of virus species but directly benefitted from determining declarations of novelty in the
form of new research funding authorizations and associated patenting and commercial collaboration. Together with
CDC, NIAID, WHO, academic and commercial parties (including Johnson & Johnson; Sanofi and their several coronavirus
patent holding biotech companies; Moderna; Ridgeback; Gilead; Sherlock Biosciences; and, others), a powerful group of
interests constituted what we would suggest are “interlocking directorates” under U.S. anti-trust laws.
27 U.S. Provisional Application No. 60/206,537, filed May 21, 2000

28 https://www.pnas.org/content/100/22/12995
1986-1990 NIAID Grant AI 23946 leading to patent U.S. 7,279,327 “Methods for Producing Recombinant
Coronavirus” Filed 2002 and issued 2007 https://patents.google.com/patent/US7279327B2/ru
The paper first published from the NIAID grant is

https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf
1990 Pfizer files U.S. Patent 6,372,224 on a vaccine for the S-protein on coronavirus November 14, 2000
which was abandoned April 2010 making it public domain.
1990s Work focused on CoV association with cardiomyopathy (see above)
Early reference to the “emergence” of CoV as a respiratory pathogen in

https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf
2000 Ralph Baric AI23946 and GM63228 from the National Institutes of Health actively working recombinant
CoV
2001 National Institute of Health, Allergy and Infectious diseases. “Reverse Genetics with a Coronavirus
Infectious cDNA Construct.” 4/1/2001-3/31/005 $1.0 million total costs/yr. RS Baric, PI
2002 Asia CoV SARS outbreak
2003 April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent on the RNA
sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S.
Department of Health and Human Services the ability to control the commercial exploitation of SARS
coronavirus.
Dr. Anthony Fauci appointed to the Bill and Melinda Gates Foundation’s Global Grand Challenges
Scientific Advisory Board (served through 2010).
April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response and patent US7,151,163
https://www.sbir.gov/node/305319
July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued
on November 17, 2009. https://patents.google.com/patent/US7618802B2
Dana Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal antibody to neutralize SARS
CoV. This research is supported by several NIH grants including National Institutes of Health Grants
A128785, A148436, and A1053822.
2004 January 6, 2004 – SARS and Bioterrorism linked at Bioterrorism and Emerging Infectious Diseases:
antimicrobials, therapeutics and immune modulators.
https://tks.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=706
At this conference, the term “The New Normal” was introduced by Merck
FAUCI AND BARIC start making money!!! National Institutes of Health, Allergy and Infectious Diseases.
SARS Reverse Genetics. AI059136-01. $1.7 million total costs, RS Baric, PI. 10% effort. 4/1/04- 3/31/09.
The project develops a SARS-CoV full length infectious cDNA, the development of SARS-CoV replicon
particles expressing heterologous genes, and seeks to adapt SARS-CoV to mice, producing a pathogenic
mouse model for SARS-CoV infection.
National Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling the SARS Coronavirus
Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09. $2.1 million
November 22, 2004 University of Hong Kong patents SARS associated spike protein on CoV and
pursues patent US 7,491,489
2005 DARPA gets in on the game Synthetic Coronaviruses. Biohacking: Biological Warfare Enabling
Technologies, June 2005. Washington, DC. DARPA/MITRE sponsored event. Invited Speaker
Review timeline from https://www.youtube.com/watch?v=rO_EeYB0i0U and

https://www.davidmartin.world/wp-content/uploads/2020/04/20APRBotWslides.pdf
2008 Biodefense Grant U54 AI057157 commences with $10,189,682 to UNC Chapel Hill
https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104
2009 Biodefense Grant U54 AI057157 continues with $5,448,656 to UNC Chapel Hill (non-competitive grant
from NIAID)
from NIAID)
Patent issuance for SARS coronavirus patents peak post the Asia outbreak at 391 issued patents.
August 6, 2010, Moderna (prior to its establishment) files U.S. Patent 9,447,164 which attracted the
investment of (and “inventorship” for) venture capitalists at Flagship Ventures. This patent grew out of
the work of Dr. Jason P. Schrum of Harvard Medical School supported by National Science Foundation
Grant #0434507. While the application claims priority to August 2010, the application didn’t get
finalized until October, 2015. On November 4, 2015, the USPTO issued a non-final rejection on this
original patent rejecting all claims.
https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507 with reference to the grant funding
in
https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf
2011 Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February taking with it all
of its SARS technology.
Biodefense Grant U54 AI057157 continues with $7,344,820 to UNC Chapel Hill (non-competitive grant
from NIAID)
2012 MERS isolated in Egypt
Biodefense Grant U54 AI057157 continues with $7,627,657 to UNC Chapel Hill (non-competitive grant
from NIAID)
from NIAID)
2014 April 23, 2014, Moderna files patent on nucleic acid vaccine with Patents US9872900 and US10022435

2015 Moderna signs a vaccine development agreement with NIAID and executes it with the lead on the
mRNA-1273 lead developer and inventor Guiseppe Ciaramella.
https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html
2016 NIH through Scripps Institute and Dartmouth College file patent application WO 2018081318A1
“Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology that overlaps (and is
used in tandem with) Moderna’s technology.
https://patents.google.com/patent/WO2018081318A1/en Lead Inventor Barney Scott Graham was well
known to Moderna as he’s the person at NIH that Moderna “e-mailed” to get the sequence for SARS
CoV-2 according to Moderna’s report here (“In January 2020, once it was discovered that the infection in
Wuhan was caused by a novel coronavirus, Bancel quickly emailed Dr. Barney Graham, deputy director
of the Vaccine Research Center at the National Institutes of Health, asking him to send the genetic
sequence for the virus.”) https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html
In addition, co-inventor Jason McLellan worked with Graham on a vaccine patent jointly owned with the
Chinese government filed in Australia in 2013
https://patents.google.com/patent/AU2014231357A1/en?inventor=Jason+MCLELLAN.
2017 August – Sanofi buys Protein Science Corp with considerable SARS patent holdings
2018 June – Sanofi buys Ablynx with considerable SARS patent holdings
2019 March, https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technology-to-create-

affordable-molecular-diagnostics/ funded by Open Philanthropy – the same organization that would be
the financial sponsor of the Event 201 “table-top” exercise that laid out the entire “pandemic” plan in
October 2019.

15 U.S.C. §8 – Market Manipulation and Allocation
Every combination, conspiracy, trust, agreement, or contract is declared to be contrary to public policy, illegal, and
void when the same is made by or between two or more persons or corporations, either of whom, as agent or
principal, is engaged in importing any article from any foreign country into the United States, and when such
combination, conspiracy, trust, agreement, or contract is intended to operate in restraint of lawful trade, or free
competition in lawful trade or commerce, or to increase the market price in any part of the United States of any
article or articles imported or intended to be imported into the United States, or of any manufacture into which such
imported article enters or is intended to enter. Every person who shall be engaged in the importation of goods or any
commodity from any foreign country in violation of this section, or who shall combine or conspire with another to
violate the same, is guilty of a misdemeanor, and on conviction thereof in any court of the
United States such person shall be fined in a sum not less than $100 and not exceeding $5,000, and shall be further
punished by imprisonment, in the discretion of the court, for a term not less than three months nor exceeding twelve
months.
Through non-competitive grant awards to UNC Chapel Hill’s Ralph Baric, to selection of the Bio-Safety Level 4 laboratory
locations, to the setting of prices for Remdesivir and mRNA therapies from Moderna and Pfizer, NIAID, CDC, and the U.S.
Department of Health and Human Services have been involved in allocating Federal funds to conspiring parties without
independent review.
Around March 12, 2020, in an effort to enrich their own economic interests by way of securing additional funding from
both Federal and Foundation actors, the CDC and NIAID’s Dr Fauci elected to suspend testing and classify COVID-19 by
capricious symptom presentation alone. Forcing the public to rely on The COVID Tracking Project – funded by the
Bloomberg, Zuckerberg and Gates Foundation and presented by a media outlet (The Atlantic) – not a public health
agency – Dr. Fauci used fraudulent testing technology (RT-PCR) to conflate “COVID cases” with positive PCR tests in the
living while insisting that COVID deaths be counted by symptoms alone. This perpetuated a market demand for his
desired vaccine agenda which was recited by him and his conspiring parties around the world until the present. Not
surprisingly, this was necessitated by the apparent fall in cases that constituted Dr. Fauci’s and others’ criteria for
depriving citizens of their 1st Amendment rights.

15 U.S.C. § 19 – Interlocking Directorates
(1) No person shall, at the same time, serve as a director or officer in any two corporations (other than banks, banking
associations, and trust companies) that are—
(A) engaged in whole or in part in commerce; and
(B) by virtue of their business and location of operation, competitors, so that the elimination of competition
by agreement between them would constitute a violation of any of the antitrust laws; if each of the
corporations has capital, surplus, and undivided profits aggregating more than $10,000,000 as adjusted
pursuant to paragraph (5) of this subsection.
Dr. Fauci is on the Leadership Council of the Bill and Malinda Gates Global Vaccine Action Plan
Dr. Fauci while controlling the economic dispensation of Federal research funding, Dr. Fauci has been, and continues to
be, on the World Health Organization’s Global Preparedness Monitoring Board. He is joined on this board by the
conflicted donor from the Bill and Melinda Gates Foundation’s Dr. Chris Elias and the State Council of China’s Dr. George
F. Gao of the Chinese CDC. This GPMB stipulated that all member states must take part in a global simulation of the
release of a respiratory pathogen.
Dr. Baric is one of the primary beneficiaries of U.S. Federal funds, runs a BSL-4 facility and sits on the International
Committee on Taxonomy of Virus Coronaviridae Working Group tasked to confirm the presence of absence of the
pathogen for which he is directly compensated.
As referenced in the section covering violations of 18 U.S.C. § 1001 above, numerous undisclosed commercial
relationships exist between funded researchers, their funding agencies, and commercial interests in which disclosed and
undisclosed commercial terms exist. A complete list of all potential implicated parties is listed in the section below
entitled “The Commercial Actors”.
It appears that, during the period of patent enforcement and after the Supreme Court ruling confirming that patents on
genetic material were illegal, the CDC and National Institute of Allergy and Infectious Diseases led by Anthony Fauci
(hereinafter “NIAID” and "Dr Fauci", respectively) entered into trade among States (including, but not limited to working
with Ecohealth Alliance Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese
Academy of Sciences) through the 2014 et seq National Institutes of Health Grant R01AI110964 to exploit their patent
rights.
It further appears that, during the period of patent enforcement and after the Supreme Court ruling confirming that
patents on genetic material was illegal, the CDC and National Institute of Allergy and Infectious Diseases (hereinafter
“NIAID”) entered into trade among States (including, but not limited to working with University of North Carolina,
Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences
represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National Natural
Science Foundation of China Award 81290341 (Zheng-Li Shi) et al. 2015-2016.
It further appears that, during the period of patent enforcement and after the Supreme Court ruling confirming that
patents on generic material was illegal, the CDC and NIAID entered into trade among States (including, but not limited to
working with University of North Carolina, Chapel Hill) and with foreign nations to conduct chimeric construction of
novel coronavirus material with specific virulence properties prior to, during, and following the determination made by
the National Institutes for Health in October 17, 2014 that this work was not sufficiently understood for its biosecurity
and safety standards.
In this inquiry, it is presumed that the CDC and its associates were: a) fully aware of the work being performed using
their patented technology; b) entered into explicit or implicit agreements including licensing, or other consideration;
and, c) willfully engaged one or more foreign interests to carry forward the exploitation of their proprietary technology

when the U.S. Supreme Court confirmed that such patents were illegal and when the National Institutes of Health issued
a moratorium on such research.
Reportedly, in January 2018, the U.S. Embassy in China sent investigators to Wuhan Institute of Virology and found that,
“During interactions with scientists at the WIV laboratory, they noted the new lab has a serious shortage of
appropriately trained technicians and investigators needed to safely operate this high-containment laboratory.” The
Washington Post reported that this information was contained in a cable dated 19 January 2018. Over a year later, in
June 2019, the CDC conducted an inspection of Fort Detrick’s U.S. Army Medical Research Institute of Infectious Diseases
(hereinafter “USAMRIID”) and ordered it closed after alleging that their inspection found biosafety hazards. A report in
the journal Nature in 2003 (423(6936): 103) reported cooperation between CDC and USAMRIID on coronavirus research
followed by considerable subsequent collaboration. The CDC, for what appear to be the same type of concern identified
in Wuhan, elected to continue work with the Chinese government while closing the U.S. Army facility.
The CDC reported the first case of SARS-CoV like illness in the United States in January 2020 with the CDC’s Epidemic
Intelligence Service reporting 650 clinical cases and 210 tests. Given that the suspected pathogen was first implicated in
official reports on December 31, 2019, one can only conclude that CDC: a) had the mechanism and wherewithal to
conduct tests to confirm the existence of a “novel coronavirus”; or, b) did not have said mechanism and falsely reported
the information in January. It tests credulity to suggest that the WHO or the CDC could manufacture and distribute tests
for a “novel” pathogen when their own subsequent record on development and deployment of tests has been shown to
be without reliability

35 U.S.C. §200 - 206 – Disclosure of Government Interest
35 U.S.C. §202 (c)(6)
An obligation on the part of the contractor, in the event a United States patent application is filed by or on its behalf
or by any assignee of the contractor, to include within the specification of such application and any patent issuing
thereon, a statement specifying that the invention was made with Government support and that the Government has
certain rights in the invention.
Over 5000 patents and patent applications have included reference to SARS Coronavirus dating back to priority dates of
1998. They are summarized below.
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 total
file 0 0 0 0 0 120 338 290 328 297 256 188 198 207 244 371 407 466 451 416 326 199 9 file 5111
issue 0 0 0 0 0 1 63 135 179 224 275 334 391 61 8 314 431 420 504 513 449 578 231 issue 5111
priority 10 12 29 38 129 506 487 408 335 370 279 256 303 279 322 330 348 342 208 95 25 0 0 priority 5111
total 10 12 29 38 129 627 888 833 842 891 810 778 892 547 574 1015 1186 1228 1163 1024 800 777 240 total 15333
On July 23, 2020, the Patent Trial and Appeal Board of the United States Patent and Trademark Office rejected
Moderna’s efforts to invalidate U.S. Patent 8,058,069. This patent, owned by Arbutus Biopharma Corp (principally
owned by Roivant Science Ltd), covers the lipid nanoparticle (LNP) required to deliver an mRNA vaccine. Some of the
core technology was based on work originally done at the University of British Columbia and was first licensed in 1998.
mRNA-1273 – the experimental vaccine developed by Moderna for COVID-19 – uses the LNP technology that Moderna
thought it had licensed from Acuitas Therapeutics Inc., a firm developed by a former principal of Arbutus’ prior company
Tekmira. That license did not authorize Moderna to use the technology for the COVID-19 vaccine.
M·CAM and Knowledge Ecology International have independently confirmed that Moderna has violated U.S. law in
failing to disclose the U.S. government’s funding interest in their patents and patent applications. While this negligence
impacts all of Moderna’s over 130 granted U.S. patents, it is particularly problematic for U.S. Patent 10,702,600 (‘600)
which is the patent relating to, “a messenger ribonucleic acid (mRNA) comprising an open reading frame encoding a
betacoronavirus (BetaCoV) S protein or S protein subunit formulated in a lipid nanoparticle.” The specific claims
addressing the pivot to the SARS Coronavirus were patented on March 28, 2019 – 9 months before the SARS CoV-2

outbreak! Both the patent and the DARPA funding for the technology were disclosed in scientific publication (New
England Journal of Medicine) but the government funds were not acknowledged in the patent.
In 2013, the Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program awarded grant funding to
Moderna Therapeutics for the development of a new type of vaccine based on messenger RNA. The initial DARPA grant
was W911NF-13-1-0417. The company used that technology to develop its COVID-19 vaccine, currently undergoing
Phase I clinical trials in conjunction with NIH.29
Under the Federal Acquisition Regulation (FAR) rules, contractor to the Federal Government must provide information
regarding intellectual property infringement issues as part of their contract. Under FAR §27.201-1(c) and (d), the
Government both requires a notice of infringement or potential infringement as well as retention of economic liability
for patent infringements. Specifically, in FAR §52.227.3 (a), the “Contractor shall indemnify the Government and its
officers, agents, and employees against liability, including costs for infringement of any United States Patent…”. In
addition to the patents cited by the USPTO in their examination of ‘600, M·CAM has identified fourteen other issued
patents preceding the ‘600 patent which were used by patent examiners to limit patents arising from the same funded
research including patents sought by CureVac.
In short, while Moderna enjoys hundreds of millions of dollars of funding allegiance and advocacy from Anthony Fauci
and his NIAID, since its inception, it has been engaged in illegal patent activity and demonstrated contempt for U.S.
Patent law. To make matters worse, the U.S. Government has given it financial backing in the face of undisclosed
infringement risks potentially contributing to the very infringement for which they are indemnified.
29 https://crsreports.congress.gov/product/pdf/IN/IN11446
21 C.F.R. § 50.24 et seq., Illegal Clinical Trial
It is unlawful to conduct medical research (even in the case of emergency) without a series of steps taken to:
a. Establish the research with a duly authorized and independent institutional review board;
b. Secure informed consent of all participants including a statement of risks and benefits; and,
c. Engage in consultation with the community in which the study is to be conducted.
Dr. Anthony Fauci has forced upon the healthy population of the United States an unlawful clinical trial in which the U.S.
Department of Health and Human Services are extrapolating epidemiologic data. No informed consent has been sought
or secured for any of the “medical countermeasures” forced upon the population and no independent review board – as
defined by the statute – has been empaneled.
Through April 2020, the official recommendation by the Journal of the American Medical Association was
unambiguous.
“Face masks should not be worn by healthy individuals to protect themselves from acquiring respiratory infection
because there is no evidence to suggest that face masks worn by healthy individuals are effective in preventing people
from becoming ill.”30
Part of that lack of evidence in fact showed that cloth facemasks actually increased influenza-linked illness.31
In contravention to established science, States, municipalities, and businesses have violated the legal requirements for
the promulgation of medical counter measures during a public health emergency stating a “belief” that face masks limit
the spread of SARS CoV-2. To date, not a single study has confirmed that a mask prevented the transmission of, or the
infection by SARS CoV-2.
All parties mandating the use of facemasks are not only willfully ignoring established science but are engaging in what
amounts to a whole population clinical trial. This conclusion is reached by the fact that facemask use and COVID-19
incidence are being reported in scientific opinion pieces promoted by the United States Centers for Disease Control and
Prevention and others.32
Social distancing of up to 6 feet has been promoted as a means of preventing person-to-person transmission of
influenza-like viruses. While one study hypothesized that infection could happen in a 6 foot range, the study explicitly
states that person-to-person transfer was not tested and viability of the virus at 6 feet was not even a subject of the
investigation.33 That did not stop the misrepresentation of the study to be used as the basis for an unverified medical
counter measure of social distancing. To date, no study has established the efficacy of social distancing to modify the
transmission of SARS CoV-2. Public health officials have referenced:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907354/#CR43
In contravention to established science, States, municipalities, and businesses have violated the legal requirements for
the promulgation of medical counter measures during a public health emergency stating a “belief” that social distancing
of a healthy population limits the spread of SARS CoV-2. To date, not a single study has confirmed that social distancing
of any population prevented the transmission of, or the infection by SARS CoV-2.
30 https://jamanetwork.com/journals/jama/fullarticle/2762694
32 https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover-guidance.html
33 Werner E. Bischoff, Katrina Swett, Iris Leng, Timothy R. Peters, Exposure to Influenza Virus Aerosols During Routine Patient Care, The Journal of
Infectious Diseases, Volume 207, Issue 7, 1 April 2013, Pages 1037–1046, https://doi.org/10.1093/infdis/jis773
It is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product or service can prevent, treat, or cure
human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-
controlled human clinical studies, substantiating that the claims are true at the time they are made. As a result, every
party promoting the use of face masks is violating the FTC Act.
All of these laws have been broken. All relevant authorities in the United States must cease and desist the use of face
masks until the matters above are rectified.

The Commercial Actors
SARS coronavirus is a new topic for many individuals. Since 1999, the ability to manipulate and exploit coronavirus for a
variety of purposes has attracted the attention of individuals, institutions and commercial organizations in public, private,
and not-for-profit sectors. The following is the list of over 5,100 patents and patent applications filed for the express
purpose of controlling some aspect of the SARS coronavirus.
File Issu
d e
Priori Dat Dat
PATENT Title Owner ty e e
25- 30- 12-
US9995706 Amperometric gas sensor Steris Corporation Jun- Sep Jun-
12 -14 18
25- 30- 12-
US9995705 Amperometric gas sensor Steris Corporation Jun- Sep Jun-
12 -14 18
20- 19- 12-
US9994558 Multicyclic compounds and methods of using same Karyopharm Therapeutics Inc. Sep- Sep Jun-
13 -14 18
7- 7- 12-
Heterocyclic modulators of lipid synthesis for use against cancer and
US9994550 3-V Biosciences, Inc. Jan- Jan Jun-
viral infections
14 -15 18
31- 31- 12-
Immunogenic compositions comprising silicified virus and methods
US9993543 Portland State University Jan- Jan Jun-
of use
13 -14 18
12- 29-
13-
US9982257 Chiral control WAVE LIFE SCIENCES LTD. Jul- May
Jul-12
13 -18
14- 1- 29-
US9982241 Recombinant HCMV and RHCMV vectors and uses thereof Oregon Health & Science University May- Oct May
10 -15 -18
5- 5- 29-
The United States of America, as represented by the
US9982025 Monomeric griffithsin tandemers Jun- Jun May
Secretary, Department of Health and Human Services
13 -14 -18
12- 26- 29-

Compositions, comprising improved Il-12 genetic constructs and
US9981036 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Dec- Feb May
vaccines, immunotherapeutics and methods of using the same
11 -16 -18
28- 28- 22-

US9975885 Broad-spectrum non-covalent coronavirus protease inhibitors PURDUE RESEARCH FOUNDATION Apr- Apr May
16 -17 -18
25- 25- 22-
US9974850 Immunogenic compositions and uses thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Mar- Mar May
15 -16 -18
14- 14- 22-
US9974848 Tetanus toxoid and CCL3 improve DC vaccines Duke University Nov- Nov May
13 -14 -18
22- 21- 22-
US9974845 Combination of vaccination and inhibition of the PD-1 pathway CureVac AG Feb- Feb May
13 -14 -18
27- 27- 15-
US9970061 Bioagent detection oligonucleotides IBIS BIOSCIENCES, INC. Dec- Dec May
11 -12 -18
28- 13- 15-
US9969793 Compositions and methods for the treatment of immunodeficiency ADMA Biologics, Inc. Oct- Nov May
14 -17 -18
8- 7- 8-
LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-
US9963718 VIRATHERAPEUTICS GMBH Oct- Apr May
producing cells for the therapy of tumors
08 -17 -18
29- 21- 8-
Composition for use in decreasing the transmission of human
US9963611 Innonix Technologies, Incorporated May- May May
pathogens
09 -10 -18
23- 11- 8-
US9963427 Dithiol mucolytic agents PARION SCIENCES, INC. Aug- Mar May
13 -16 -18
3- 2- 8-
US9962439 Injectable vaccine composition NITTO DENKO CORPORATION Oct- Oct May
13 -14 -18
20- 6- 1-
US9957302 Treating cancer with viral nucleic acid Mayo Foundation for Medical Education and Research Feb- Jul- May
07 15 -18
17- 4- 1-
Virus-like particles, methods of preparation, and immunogenic
US9957300 Emory University May- May May
compositions
02 -15 -18
13- 1- 1-
Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel
US9957238 Parion Sciences, Inc. Dec- Mar May
blocking compounds
13 -17 -18
6- 24-
11-
US9951317 Highly efficient influenza matrix (M1) proteins NOVAVAX, INC. Oct Apr-
Jul-03
-16 18

27- 25- 24-
US9951124 Antibody producing non-human mammals MERUS N.V. Jun- Jan Apr-
08 -13 18
6- 12- 24-
US9951122 Antibodies against influenza virus and methods of use thereof BURNHAM INSTITUTE FOR MEDICAL RESEARCH Dec- Aug Apr-
07 -13 18
2- 1- 24-
US9950062 Compounds and compositions as TLR activity modulators GLAXOSMITHKLINE BIOLOGICALS SA Sep- Sep Apr-
09 -10 18
18- 13- 17-
Coronavirus, nucleic acid, protein, and methods for the generation
US9945856 AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V. Aug- Aug Apr-
of vaccine, medicaments and diagnostics
03 -14 18
14- 7- 17-
Use of a fluorescent material to detect failure or deteriorated
US9945780 GEN-PROBE INCORPORATED Jun- Jun Apr-
performance of a fluorometer
12 -13 18
2- 17-
Construction of pool of interfering nucleic acids covering entire RNA 23-
US9944928 York Yuan Yuan Zhu Jul- Apr-
target sequence and related compositions Jul-07
15 18
27- 30- 17-
US9944695 Antibody producing non-human mammals Merus N.V. Jun- Apr Apr-
08 -14 18
28- 5- 17-
US9944686 Treatment of tumors with recombinant interferon alpha SUPERLAB FAR EAST LIMITED Feb- Sep Apr-
01 -13 18
1- 29- 17-
US9944649 Compounds and compositions as toll-like receptor 7 agonists Novartis Ag May- Apr Apr-
14 -15 18
17- 16- 17-
Cationic steroid antimicrobial diagnostic, detection, screening and
US9943614 BRIGHAM YOUNG UNIVERSITY Jun- Jun Apr-
imaging methods
08 -09 18
5- 4- 10-
Isothiazolopyrimidinones, pyrazolopyrimidinones, and
US9938300 Forma Therapeutics, Inc. Feb- Feb Apr-
pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
15 -16 18
18- 23- 10-

Substituted imidazoquinolines, imidazopyridines, and
US9938275 3M Innovative Properties Company Jun- Jan Apr-
imidazonaphthyridines
04 -17 18
29- 27- 10-
US9938258 Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof Karyopharm Therapeutics Inc. Nov- Nov Apr-
12 -13 18
5- 4- 3-
US9932351 Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors Forma Therapeutics, Inc. Feb- Feb Apr-
15 -16 18
11- 13- 3-
Therapeutic hydroxypyridinones, hydroxypyrimidinones and
US9932323 Rutgers, The State University of New Jersey Sep- Jan Apr-
hydroxypyridazinones
12 -17 18
31- 14- 3-
Antiviral activity from medicinal mushrooms and their active
US9931316 Not Available Mar- Sep Apr-
constituents
15 -15 18
8- 1- 27-
NAD analogs and methods of using said NAD analogs in determining Biolog Life Science Institute Forshungslabor und
US9926340 Apr- Apr Mar
ribosylation of proteins with PARP mutants Biochemica-Vertrieb GmbH
15 -16 -18
Anionically modified polyallylamine derivative, use of anionically

modified polyallylamine derivative as medicine, particularly for
propylaxis and treatment of infections of respiratory tract caused by 25- 27-
29-
US9925215 human metapneumovirus (hMPV), human rhinoviruses (HRV), and UNIWERSYTET JAGIELLONSKI Oct Mar
Jul-14
infection by influenza virus type A (IAV) and pharmaceutical -17 -18
composition comprising the anionically modified polyallylamine
derivative
21- 6- 20-
US9920314 Compositions for and methods of identifying antigens President and Fellows of Harvard College Feb- May Mar
06 -15 -18
28- 20- 20-
US9920128 Synthetic antiserum for rapid-turnaround therapies The Johns Hopkins University Jan- Jan Mar
15 -16 -18
28- 10- 20-
Methods of treating and prophylactically protecting mammalian
US9919034 TAMIR BIOTECHNOLOGY, INC. Mar- Jun Mar
patients infected by viruses classified in Baltimore group V
14 -15 -18
24- 21- 13-
Systems and methods for distinguishing optical signals of different
US9915613 GEN-PROBE INCORPORATED Feb- Mar Mar
modulation frequencies in an optical signal detector
11 -14 -18
25- 27- 13-
FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY
US9914976 Methods and compositions for prostate cancer metastasis Mar- May Mar
(FA
11 -16 -18
15- 15- 13-
Treatment of evolving bacterial resistance diseases including
US9913801 YOUR ENERGY SYSTEMS, LLC Feb- Mar Mar
Klebsiella pneumoniae with liposomally formulated glutathione
13 -13 -18
8- 1- 6-
Efficient deep sequencing and rapid genomic speciation of RNA
US9909176 The Johns Hopkins University Sep- Sep Mar
viruses (vRNAseq)
14 -15 -18
26- 16- 6-
US9908946 Generation of binding molecules Merus N.V. Sep- Sep Mar
11 -15 -18
16- 19- 6-
US9908675 Powdered pouch and method of making same MONOSOL, LLC Apr- Jul- Mar
12 16 -18

4- 15- 6-
US9907796 Methods of treating tumoral diseases, or bacterial or viral infections INHIBIKASE THERAPEUTICS, INC. Oct- Sep Mar
12 -16 -18
29- 5- 20-
US9895692 Sample-to-answer microfluidic cartridge Micronics, Inc. Jan- Aug Feb
10 -15 -18
29- 29- 20-
US9895411 Analogs of C5a and methods of using same BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Jun- Jun Feb
10 -11 -18
1- 30- 20-
US9895341 Inflammation and immunity treatments Ocean Spray Cranberries, Inc. Apr- Mar Feb
11 -12 -18
26- 26- 20-
US9894888 Transgenic immunodeficient mouse expressing human SIRP-alpha INSTITUT PASTEUR Mar- Mar Feb
12 -13 -18
23- 20- 13-
US9890419 Nanoreporters and methods of manufacturing and use thereof NanoString Technologies, Inc. Dec- May Feb
05 -16 -18
15- 15- 13-
US9890408 Multiple displacement amplification IBIS BIOSCIENCES, INC. Oct- Oct Feb
09 -10 -18
5- 19- 13-
US9890362 Compositions, methods and uses for inducing viral growth Takeda Vaccines, Inc. Dec- Sep Feb
08 -14 -18
26- 25- 13-
Methods for increasing the infectivity of viruses utilizing alkyne-
US9890361 LIFE TECHNOLOGIES CORPORATION Jan- Jan Feb
modified fatty acids
12 -13 -18
20- 20- 13-
US9890206 H1N1 flu virus neutralizing antibodies Medigen Biotechnology Corporation Aug- Aug Feb
15 -15 -18
14- 12- 13-
US9890169 Triazolinone compounds as HNE inhibitors CHIESI FARMACEUTICI S.P.A. Dec- Dec Feb
15 -16 -18
15- 14- 13-
US9890124 Benzazepine sulfonamide compounds Hoffmann-La Roche Inc. Dec- Jun Feb
15 -17 -18
1- 28- 13-
US9889194 Immunogenic composition for MERS coronavirus infection New York Blood Center, Inc. Mar- Feb Feb
13 -14 -18
24- 23- 6-
US9885092 Materials and methods for detection of HPV nucleic acids QIAGEN GAITHERSBURG INC. Feb- Feb Feb
11 -12 -18
19- 6-
19-
US9885082 Embodiments of a probe and method for targeting nucleic acids University of Idaho Jul- Feb
Jul-11
12 -18
12- 6-
13-
US9885037 Chiral control WAVE LIFE SCIENCES LTD. Jul- Feb
Jul-12
13 -18
20- 20- 6-
US9884895 Methods and compositions for chimeric coronavirus spike proteins The University of North Carolina at Chapel Hill Mar- Mar Feb
14 -15 -18
9- 8- 6-
Anti-viral compounds, pharmaceutical compositions, and methods of
US9884876 Kineta, Inc. May- May Feb
use thereof
14 -15 -18
15- 5- 6-
US9884129 Release of agents from cells The Brigham and Women's Hospital, Inc. Oct- Jan Feb
09 -15 -18
3- 3- 6-
Esters of short chains fatty acids for use in the treatment of
US9884032 PROPONENT BIOTECH GMBH Oct- Mar Feb
immunogenic disorders
12 -16 -18
1- 31- 6-
US9884026 Modular particles for immunotherapy YALE UNIVERSITY Nov- Oct Feb
13 -14 -18
23- 23- 30-
Method of determining, identifying or isolating cell-penetrating
US9880151 Phylogica Limited May- May Jan-
peptides
11 -12 18
12- 29- 30-
US9879026 Substituted spirocycles Boehringer Ingelheim International GmbH Sep- Nov Jan-
14 -16 18
11- 15- 30-
US9879003 Host targeted inhibitors of dengue virus and other viruses Dana-Farber Cancer Institute, Inc. Apr- Mar Jan-
12 -13 18
29- 5- 30-
Dendrimer like amino amides possessing sodium channel blocker
US9878988 PARION SCIENCES, INC. May- Jan Jan-
activity for the treatment of dry eye and other mucosal diseases
12 -16 18
18- 17- 23-

US9873678 Chemical compounds AstraZeneca AB Mar- Mar Jan-
14 -15 18
21- 19- 23-
US9873674 C-Rel inhibitors and uses thereof CORNELL UNIVERSITY Sep- Sep Jan-
12 -13 18
23- 5- 23-
US9872900 Nucleic acid vaccines ModernaTX, Inc. Apr- Apr Jan-
14 -16 18
24- 3- 23-
Compositions and methods for treating and preventing porcine
US9872898 Ohio State Innovation Founation Apr- Oct Jan-
reproductive and respiratory syndrome
12 -16 18
24- 20- 23-
TLR5 ligands, therapeutic methods, and compositions related
US9872895 Emory University Sep- Sep Jan-
thereto
10 -11 18

7- 16-
Compositions and methods for â€œresistance-proofâ€ SiRNA 8-Jul-
US9868952 Sirnaomics, Inc. Jul- Jan-
therapeutics for influenza 12
13 18
12- 12- 16-
US9868740 Pyrimidinone compounds which are HNE inhibitors CHIESI FARMACEUTICI S.p.A. Jun- Jun Jan-
14 -14 18
10- 10- 16-
US9868736 Deubiquitinase inhibitors and methods for use of the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN Oct- Oct Jan-
13 -14 18
4- 25- 16-
US9867882 Carbohydrate conjugates as delivery agents for oligonucleotides Alnylam Pharmaceuticals, Inc. Dec- Aug Jan-
07 -15 18
12- 22- 16-
US9867877 Methods for preparing squalene NOVARTIS AG May- Nov Jan-
10 -16 18
31- 26- 9-
US9862706 Compounds CHIESI FARMACEUTICI S.p.A. May- May Jan-
16 -17 18
9- 23- 9-
US9861614 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. May- Jun Jan-
12 -15 18
3- 13- 2-
US9856254 Alkoxy substituted imidazoquinolines 3M Innovative Properties Company Oct- Jun Jan-
03 -16 18
3- 2-
Substituted benzofuranyl and benzoxazolyl compounds and uses 3-Jul-
US9856241 Karyopharm Therapeutics Inc. Jul- Jan-
thereof 13
14 18
9- 8- 2-
US9856228 Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors PROZYMEX A/S Sep- Sep Jan-
13 -14 18
30- 30- 2-
US9856224 Stable sodium channel blockers PARION SCIENCES, INC. Jun- Jan Jan-
14 -17 18
20- 2-
28-
US9855287 Anti-viral azide containing compounds LIFE TECHNOLOGIES CORPORATION Aug Jan-
Jul-10
-15 18
3- 6- 2-
US9855284 Pharmaceutical compositions and methods Pop Test Oncology LLC Aug- Dec Jan-
15 -16 18
17- 16- 26-
US9849143 Broad spectrum antiviral and methods of use The Burlington HC Research Group, Inc. Apr- Feb Dec
06 -17 -17
17- 17- 19-
Fusion proteins, recombinant bacteria, and methods for using
US9845342 Spogen Biotech Inc. Sep- Sep Dec
recombinant bacteria
14 -15 -17
14- 14- 12-
US9840731 Preservation of biological materials in non-aqueous fluid media Gentegra, LLC Mar- Mar Dec
13 -14 -17
22- 12-
Variant AAV and compositions, methods and uses for gene transfer 22-
US9840719 The Children's Hospital of Philadelphia Jul- Dec
to cells, organs and tissues Jul-13
14 -17
5- 4- 12-
Quinazolinones and azaquinazolinones as ubiquitin-specific protease
US9840491 FORMA Therapeutics, Inc. Feb- Feb Dec
7 inhibitors
15 -16 -17
15- 12-
Acetylenedicarboxyl linkers and their uses in specific conjugation of 15-
US9839687 SUZHOU M-CONJ BIOTECH CO., LTD. Jul- Dec
a cell-binding molecule Jul-15
15 -17
27- 27- 5-
US9834812 Probe kit for detecting a single strand target nucleotide sequence Fondazione Istituto Italiano Di Tecnologia Dec- Dec Dec
12 -13 -17
7- 7- 5-
US9834791 CRISPR-related methods and compositions with governing gRNAS Editas Medicine, Inc. Nov- Nov Dec
13 -14 -17
7- 6- 5-
Hand, foot, and mouth vaccines and methods of manufacture and
US9834757 Takeda Vaccines, Inc. Nov- Nov Dec
use thereof
14 -15 -17
Amino acid sequences directed against envelope proteins of a virus 5- 29- 5-

US9834595 and polypeptides comprising the same for the treatment of viral Ablynx N.V. Jun- Oct Dec
diseases 08 -15 -17
13- 1- 5-
US9833504 Virus-like particles and process for preparing same Folia Biotech Inc. May- May Dec
11 -12 -17
2- 15- 5-
US9833492 Combinations of a caspase inhibitor and an antiviral agent Centre National de la Recherche Scientifique Nov- May Dec
07 -15 -17
30- 19- 5-
US9832998 Antiviral compositions Long Island University May- Mar Dec
07 -15 -17
18- 10- 28-
US9828382 Pyrimidinone compounds as human neutrophil elastase inhibitors Chiesi Farmaceutici S.p.A. Dec- May Nov
12 -16 -17
1- 28-
Pyrrolo-pyrrole carbamate and related organic compounds, 3-Jul-
US9828379 ABIDE THERAPEUTICS, INC. Jul- Nov
pharmaceutical compositions, and medical uses thereof 13
14 -17
23- 22- 28-
US9828370 Compositions and methods for inhibiting kinases INHIBIKASE THERAPEUTICS, INC. Apr- Apr Nov
15 -16 -17
2- 31- 28-
US9828346 N-myristoyl transferase inhibitors University of Dundee Sep- Aug Nov
08 -15 -17

24- 25- 28-
Isatin derivatives, pharmaceutical compositions thereof, and
US9828342 CITY OF HOPE Feb- Feb Nov
methods of use thereof
12 -13 -17
1- 30- 28-
Intradermal delivery of immunological compositions comprising toll-
US9827190 GLAXOSMITHKLINE BIOLOGICALS SA Feb- Jan Nov
like receptor 7 agonists
13 -14 -17
9- 26- 21-
Means and methods for influencing the stability of antibody ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT
US9822339 Dec- Aug Nov
producing cells VAN AMSTERDAM
05 -15 -17
21- 21- 21-
US9822173 Heterodimeric immunoglobulins AMGEN INC. Nov- Nov Nov
12 -13 -17
18- 18- 21-
Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41
US9822165 DANA-FARBER CANCER INSTITUTE, INC. Jun- Jun Nov
membrane proximal external region
09 -10 -17
9- 23- 21-
Method of preventively treating a subject at the risk of developing
US9822155 Xiangxue Group (Hong Kong) Company Limited May- Aug Nov
infections of a respiratory virus
13 -16 -17
23- 21-
The Board of Trustees of the Leland Stanford Junior 23-
US9822127 GAK modulators as antivirals Jul- Nov
University Jul-14
15 -17
6- 14- 21-
US9822065 Benzazepine dicarboxamide compounds Hoffmann-La Roche Inc. Mar- Feb Nov
15 -17 -17
30- 21-
31-
US9821052 Reverse genetics systems Seqirus UK Limited Jul- Nov
Jul-09
10 -17
28- 21- 21-
US9821051 Reducing hospitalization in elderly influenza vaccine recipients Seqirus UK Limited Oct- Oct Nov
10 -11 -17
19- 11- 14-
Compositions for increasing polypeptide stability and activity, and
US9816078 SOLIS BIODYNE OÃœ Nov- Mar Nov
related methods
09 -16 -17
28- 8- 14-
US9815886 Compositions and methods for the treatment of immunodeficiency ADMA BIOLOGICS, INC. Oct- Jan Nov
14 -15 -17
24- 8- 14-
Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-
US9815805 ASTRAZENECA AB Jan- Nov Nov
carboxamides as dipeptidyl peptidase 1 inhibitors
14 -16 -17
4- 22- 14-
US9814777 Targeting lipids Arbutus Biopharma Corporation Dec- Oct Nov
07 -13 -17
6- 25- 7-
Use of live cell inteferometry with reflective floor of observation
US9810683 The Regents of the University of California May- Nov Nov
chamber to determine changes in mass of mammalian cells
09 -13 -17
6- 6- 7-
US9809845 Methods and reagents for amplifying nucleic acids Aug- Aug Nov
12 -12 -17
29- 18- 7-
US9809796 Animal protein-free media for cultivation of cells Baxalta GmbH Oct- May Nov
04 -17 -17
23- 22- 7-
University of Washington Through its Center for
US9809632 Universal protein tag for double stranded nucleic acid delivery Oct- Oct Nov
Commercialization
13 -14 -17
8- 5- 7-
US9809591 Heterocyclic modulators of lipid synthesis 3-V Biosciences, Inc. Mar- Oct Nov
11 -15 -17
26- 25- 7-
US9808490 Induced hepatocytes and uses thereof ACCELERATED BIOSCIENCES CORP. Nov- Nov Nov
14 -15 -17
6- 6- 31-
Microarray-based assay integrated with particles for analyzing
US9803236 CapitalBio Corporation Aug- Aug Oct-
molecular interactions
10 -10 17
25- 27- 31-
US9803197 Particle-nucleic acid conjugates and therapeutic uses related thereto Emory University Jun- Feb Oct-
12 -13 17
21- 23- 31-
US9802937 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH Apr- Apr Oct-
11 -12 17
31- 26- 31-
US9802919 Compounds CHIESI FARMACEUTICI S.p.A. May- May Oct-
16 -17 17
21- 21- 31-
US9801948 Antimicrobial compositions and methods of use thereof Yale University Sep- Sep Oct-
11 -12 17
10- 6- 31-
US9801947 Methods and compositions for enhancing immune response 3M INNOVATIVE PROPERTIES COMPANY Apr- Oct Oct-
03 -14 17
20- 11- 31-
US9801935 Soluble needle arrays for delivery of influenza vaccines SEQIRUS UK LIMITED Aug- Oct Oct-
10 -16 17
6- 31-
6-Jul-
US9801897 Delivery of RNA to trigger multiple immune pathways GLAXOSMITHKLINE BIOLOGICALS SA Jul- Oct-
10
11 17
1- 30- 24-
Non-target amplification method for detection of RNA splice-forms in
US9797000 QIAGEN GAITHERSBURG INC. May- Apr Oct-
a sample
09 -10 17
3- 28- 24-
US9796979 Oligonucleotide modulators of the toll-like receptor pathway Quark Pharmaceuticals Inc. Mar- Jul- Oct-
11 16 17

20- 7- 24-
US9796735 Boron-containing small molecules Anacor Pharmaceuticals, Inc. Jun- Nov Oct-
07 -14 17
17- 15- 24-
Lipidated immune response modifier compound compositions,
US9795669 3M INNOVATIVE PROPERTIES COMPANY Aug- Dec Oct-
formulations, and methods
10 -15 17
23- 24-
Delivery of self-replicating RNA using biodegradable polymer 6-Jul-
US9795668 GlaxoSmithKline Biologicals S.A. Nov Oct-
particles 10
-15 17
5- 11- 24-
High-yield transgenic mammalian expression system for generating
US9795666 Academia Sinica Sep- Feb Oct-
virus-like particles
06 -15 17
30- 15- 17-
US9791437 Multianalyte assay Nexus Dx, Inc. Apr- Jun Oct-
07 -15 17
30- 31- 17-
D-amino acid derivative-modified peptidoglycan and methods of use
US9789180 The Regents of the University of California Nov- Mar Oct-
thereof
12 -16 17
15- 14- 10-
US9786050 Stain-free histopathology by chemical imaging The Board of Trustees of the University of Illinois Mar- Mar Oct-
13 -14 17
7- 2- 10-
US9783595 Neutralizing GP41 antibodies and their use Nov- Aug Oct-
11 -16 17
16- 13- 10-
US9782470 Method of obtaining thermostable dried vaccine formulations Merck Sharp & Dohme Corp. Oct- Oct Oct-
13 -14 17
20- 7- 10-
Methods of treating or preventing inflammation and hypersensitivity
US9782434 Sonoma Pharmaceuticals, Inc. Jan- Jul- Oct-
with oxidative reductive potential water solution
06 15 17
3- 2- 26-
US9770504 Generating peptoid vaccines The Board of Regents of the University of Texas System May- May Sep
13 -14 -17
7- 26-
6-Jul-
US9770463 Delivery of RNA to different cell types GLAXOSMITHKLINE BIOLOGICALS SA Jun Sep
10
-11 -17
28- 10- 19-
System and method for DNA sequencing and blood chemistry
US9765395 Nanomedical Diagnostics, Inc. Apr- Apr Sep
analysis
14 -15 -17
27- 29- 19-
US9765133 Antibody producing non-human mammals Merus N.V. Jun- Apr Sep
08 -14 -17
25- 14- 19-
US9765071 Substituted imidazo ring systems and methods 3M INNOVATIVE PROPERTIES COMPANY Nov- Mar Sep
03 -16 -17
18- 18- 19-
US9764027 Outer membrane vesicles GLAXOSMITHKLINE BIOLOGICALS SA Sep- Sep Sep
12 -13 -17
8- 21- 12-
University of Pittsburghâ€”Of the Commonwealth System of
US9759723 B-cell antigen presenting cell assay Apr- Mar Sep
Higher Education
10 -16 -17
14- 11- 12-
US9758840 Parasite detection via endosymbiont detection IBIS BIOSCIENCES, INC. Mar- Mar Sep
10 -11 -17
2- 1- 12-
US9758820 Organism identification panel BioFire Diagnostics, LLC Apr- Apr Sep
07 -08 -17
10- 14- 12-
US9758775 TAL effector-mediated DNA modification Iowa State University Research Foundation, Inc. Dec- Apr Sep
09 -14 -17
4- 16- 12-
US9758568 Oligopeptide-free cell culture media Baxalta GmbH Jan- Nov Sep
06 -15 -17
30- 2- 12-
Yeast strain for the production of proteins with terminal alpha-1,3-
US9758553 MERCK SHARP & DOHME CORP. May- Jul- Sep
linked galactose
08 14 -17
11- 7- 12-
US9757478 Mutant protease biosensors with enhanced detection characteristics Promega Corporation May- Jan Sep
10 -16 -17
22- 30- 12-
US9757470 Peptides for assisting delivery across the blood brain barrier Children's Medical Center Corporation May- Apr Sep
06 -14 -17
17- 13- 12-
US9757446 Influenza virus vectors and uses therefor FLUGEN, INC. Mar- Mar Sep
14 -15 -17
1- 21- 12-
Treatment of viral infections by modulation of host cell metabolic
US9757407 The Trustees of Princeton University Jun- Dec Sep
pathways
07 -15 -17
13- 15- 5-
US9751945 Sortase-modified VHH domains and uses thereof Whitehead Institute for Biomedical Research Apr- Apr Sep
12 -13 -17
21- 21- 5-
Bunyaviruses with segmented glycoprotein precursor genes and
US9750798 STICHTING WAGENINGEN RESEARCH May- May Sep
methods for generating these viruses
13 -14 -17
16- 16- 5-
US9750797 Sustained release vaccine composition VIRBAC CORPORATION Jun- Jun Sep
04 -05 -17
3- 5- 5-
Circulation of components during microfluidization and/or
US9750690 NOVARTIS AG Dec- Sep Sep
homogenization of emulsions
09 -14 -17

25- 20- 29-
System and method for detecting, collecting, analyzing, and
US9746985 Georgetown University Feb- Apr Aug
communicating event-related information
08 -11 -17
8- 11- 29-
US9746459 Antigen presenting cell assay Apr- Oct Aug
Higher Education
10 -13 -17
2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-
15- 14- 29-
D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin-
US9745306 Respivert Limited Mar- Mar Aug
4(3H)-one derivatives and their use as phosphoinositide 3-kinase
13 -14 -17
inhibitors
8- 27- 29-
Quality control methods for oil-in-water emulsions containing
US9744231 NOVARTIS AG Nov- Aug Aug
squalene
06 -13 -17
4- 28- 29-
Vaccines and immunotherapeutics using IL-28 and compositions and
US9744229 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Apr- Apr Aug
methods of using the same
08 -14 -17
6- 29-
6-Jul-
US9744183 Nucleic acid prodrugs and methods of use thereof WAVE LIFE SCIENCES LTD. Jul- Aug
09
10 -17
21- 28- 22-
US9738894 Short interfering RNA (siRNA) analogues Roche Innovation Center Copenhagen A/S Mar- Mar Aug
03 -16 -17
21- 20- 22-
US9738624 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. Jun- Jun Aug
13 -14 -17
30- 20- 22-
Adeno-associated virus (AAV) glades, sequences, vectors containing
US9737618 The Trustees of the University of Pennsylvania Sep- Jul- Aug
same, and uses therefor
03 15 -17
19- 15- 22-
US9737593 Carbon nanotube compositions and methods of use thereof Yale University Mar- Mar Aug
08 -13 -17
21- 20- 15-
US9730997 Alphavirus vectors for respiratory pathogen vaccines Novartis Vaccines and Diagnostics, Inc. May- Aug Aug
04 -14 -17
12- 12- 15-
US9730912 Pharmaceutical compounds ASTEX THERAPEUTICS LIMITED Oct- Oct Aug
06 -07 -17
27- 26- 8-
US9727810 Spatially addressable molecular barcoding Cellular Research, Inc. Feb- Feb Aug
15 -16 -17
10- 3- 8-
US9726607 Systems and methods for detecting multiple optical signals GEN-PROBE INCORPORATED Mar- Mar Aug
05 -14 -17
6- 6- 8-
Methods and compositions for identification of source of microbial
US9725770 The Regents of the University of California Mar- Mar Aug
contamination in a sample
12 -13 -17
4- 13- 8-
US9725487 Compositions and methods for measles virus inhibition Autoimmune Technologies, LLC Nov- May Aug
03 -15 -17
29- 29- 1-
Tissue preferential codon modified expression cassettes, vectors
US9719106 The Trustees of the University of Pennsylvania Apr- Apr Aug
containing same, and uses thereof
13 -14 -17
8- 8- 1-
US9719083 Bioagent detection methods IBIS BIOSCIENCES, INC. Mar- Mar Aug
09 -10 -17
12- 11- 1-
US9718774 Indole carboxamide derivatives as P2X7 receptor antagonist IDORSIA PHARMACEUTICALS LTD Dec- Dec Aug
12 -13 -17
1- 1- 1-
US9717755 Method of treating inflammation Cytosorbents Corporation Apr- Apr Aug
10 -11 -17
16- 16- 1-
US9717749 Production of stable non-polyadenylated RNAs Massachusetts Institute of Technology Oct- Oct Aug
12 -13 -17
15- 17- 1-
US9717732 Drug combination VERONA PHARMA PLC Mar- Mar Aug
13 -14 -17
29- 30- 25-
US9714411 Animal protein-free media for cultivation of cells Baxalta GmbH Oct- Nov Jul-
04 -15 17
28- 2- 25-
US9714283 Compositions and methods for the treatment of immunodeficiency ADMA BIOLOGICS, INC. Oct- Jul- Jul-
14 15 17
13- 25-
29-
US9714226 Hydrazide containing nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. Nov Jul-
Jul-11
-15 17
13- 13- 25-
US9713641 Anti-TIGIT antigen-binding proteins and methods of use thereof Potenza Therapeutics, Inc. Feb- Feb Jul-
17 -17 17
Methods for treating pulmonary emphysema using substituted 2- 14- 1- 25-

US9713606 Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- Boehringer Ingelheim International GmbH Mar- Dec Jul-
amides inhibitors of cathepsin C 13 -15 17
15- 14- 18-

US9708375 Inhibitory polypeptides specific to WNT inhibitors Amgen Inc. Mar- Mar Jul-
13 -14 17
17- 17- 18-
Methods of modulating immune responses by modifying Akt3
US9707278 Augusta University Research Institute, Inc. Apr- Apr Jul-
bioactivity
14 -15 17

20- 9- 11-
Influenza hemagglutinin-specific monoclonal antibodies for
US9701736 New York Blood Center, Inc. Oct- Oct Jul-
preventing and treating influenza virus infection
10 -14 17
9- 8- 11-
US9701638 Therapeutic hydroxyquinolones Rutgers, The State University of New Jersey Nov- Nov Jul-
12 -13 17
3- 22- 11-
Arranging interaction and back pressure chambers for
US9700616 NOVARTIS AG Dec- Mar Jul-
microfluidization
09 -16 17
17- 17- 11-
US9700614 Intranasal vaccination dosage regimen Eurocine Vaccines AB Dec- Dec Jul-
12 -13 17
15- 17- 11-
Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor
US9700558 VERONA PHARMA PLC Mar- Mar Jul-
antagonist
13 -14 17
1- 28- 4-
US9696247 Sample fixation and stabilisation RNASSIST LTD. Mar- Feb Jul-
13 -14 17
29- 4-
Method for production of reprogrammed cell using chromosomally 16-
US9695445 ID Pharma Co., Ltd. Jul- Jul-
unintegrated virus vector Jul-08
15 17
12- 11- 4-
US9695135 Therapeutic catechols Rutgers, The State University of New Jersey May- May Jul-
14 -15 17
17- 8- 4-
3,5-diamino-6-chloro-N-(n-(4-phenylbutyl)carbamimidoyl)pyrazine-
US9695134 Parion Sciences, Inc. Dec- Jan Jul-
2-carboxamide compounds
12 -15 17
24- 4- 27-
Mixed cell diagnostic systems for detection of respiratory, herpes
US9689018 Diagnostic Hybrids, Inc. Apr- Aug Jun-
and enteric viruses
98 -14 17
26- 11- 27-
Methods and compositions for the treatment of cancer or other
US9688982 CITY OF HOPE Jan- Oct Jun-
diseases
07 -13 17
15- 15- 27-
US9687536 Methods and compositions for intranasal delivery SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. Apr- Apr Jun-
10 -11 17
1- 15- 20-
US9683256 Biological specimen collection and transport system Longhorn Vaccines and Diagnostics, LLC Oct- Dec Jun-
07 -15 17
16- 20-
17-
US9683017 Inhibitory peptides of viral infection UNIVERSITY TENNESSEE RESEARCH FOUNDATION Jul- Jun-
Jul-14
15 17
17- 17- 20-
US9682133 Disrupted adenovirus-based vaccine against drugs of abuse CORNELL UNIVERSITY Mar- Mar Jun-
10 -11 17
17- 30- 13-
Adeno-associated virus (AAV) serotype 8 sequences, vectors
US9677089 The Trustees of the University of Pennsylvania Dec- Mar Jun-
containing same, and uses therefor
01 -16 17
2- 8- 13-
Chimeric T cell receptor comprising carbonic anhydrase IX (G250)
US9676867 Dana-Farber Cancer Institute Inc. Dec- May Jun-
antibody
05 -13 17
16- 14- 13-
US9676857 Soluble engineered monomeric Fc Mar- Mar Jun-
12 -13 17
24- 7- 13-
US9676727 Myxovirus therapeutics, compounds, and uses related thereto Children's Healthcare of Atlanta, Inc. Oct- Jul- Jun-
11 16 17
25- 13-
Methods for inducing an immune response via buccal and/or 26-
US9675550 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Jan Jun-
sublingual administration of a vaccine Jul-10
-13 17
30- 28- 6-
US9670507 Directed evolution and in vivo panning of virus vectors The University of North Carolina at Chapel Hill Apr- Jun Jun-
08 -16 17
6- 5- 6-
Substituted bicyclic dihydropyrimidinones and their use as inhibitors
US9670166 Boehringer Ingelheim International GmbH Feb- Aug Jun-
of neutrophil elastase activity
13 -16 17
2- 31- 6-
US9669092 Antagonism of the VIP signaling pathway Emory University Feb- Jan Jun-
11 -12 17
Nucleic acid comprising or coding for a histone stem-loop and a 15- 15- 6-
US9669089 poly(A) sequence or a polyadenylation signal for increasing the CureVac AG Feb- Feb Jun-
expression of an encoded pathogenic antigen 12 -13 17
26- 25- 6-
US9669088 Vaccination with multiple clades of H5 influenza A virus Seqirus UK Limited Nov- Nov Jun-
07 -08 17
24- 26- 30-
The Arizona Board of Regents on Behalf of The University
US9661856 Synergy of plant antimicrobials with silver Aug- Aug May
of Arizona
12 -13 -17
20- 10- 23-
US9657278 Methods to produce bunyavirus replicon particles Stichting Dienst Landbouwkundig Onderzoek Sep- Jul- May
10 15 -17
23- 23- 23-
GM-CSF and IL-4 conjugates, compositions, and methods related
US9657076 Children's Healthcare of Atlanta, Inc. Oct- Oct May
thereto
12 -13 -17
4- 4- 23-
US9657048 Enantiomers of the 1â€²,6â€²-isomer of neplanocin A Auburn University Aug- Aug May
14 -15 -17

27- 23-
Substituted bicyclic dihydropyrimidinones and their use as inhibitors 31-
US9657015 Boehringer Ingelheim International GmbH Jul- May
of neutrophil elastase activity Jul-14
15 -17
27- 12- 23-
Chemically and metabolically stable dipeptide possessing potent
US9655896 PARION SCIENCES, INC. Jun- Jan May
sodium channel blocker activity
11 -15 -17
6- 23-
6-Jul-
US9655845 Oil-in-water emulsions that contain nucleic acids GlaxoSmithKline Biologicals, S.A. Jul- May
11
12 -17
6- 4- 23-
US9655367 Disinfecting composition and wipes with reduced contact time LONZA, INC. Nov- Nov May
13 -14 -17
31- 19- 16-
The United States of America as Represented by the
US9651543 Malaria antigen screening method Aug- Apr May
Secretary of the Navy
05 -13 -17
5- 15- 16-
US9650685 Selective detection of human rhinovirus Dec- Dec May
08 -14 -17
8- 8- 16-
LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-
US9650649 VIRATHERAPEUTICS GMBH Oct- Oct May
producing cells for the therapy of tumors
08 -09 -17
8- 16-
13-
US9649324 Use of tylvalosin as antiviral agent CAMBRIDGE UNIVERSITY TECHNICAL SERVICES Jun May
Jul-06
-15 -17
11- 3- 16-
Therapeutic uses of selected pyrimidine compounds with anti-Mer
US9649309 The University of North Carolina at Chapel Hill Apr- Apr May
tyrosine kinase activity
14 -15 -17
18- 12- 9-
US9644180 Synthetic membrane-receiver complexes RUBIUS THERAPEUTICS, INC. Nov- Jun May
13 -15 -17
30- 27- 9-
Method of preventing or treating sinusitis with oxidative reductive
US9642876 SONOMA PHARMACEUTICALS, INC. Dec- Oct May
potential water solution
03 -15 -17
4- 4- 9-
Combinations of TGFÎ² and COX-2 inhibitors and methods for their
US9642873 Sirnaomics, Inc. May- May May
therapeutic application
10 -11 -17
27- 5- 2-
Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral
US9637524 The Regents of the University of California Feb- Nov May
delivery vector
09 -14 -17
19- 18- 2-
US9637491 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH Oct- Oct May
12 -13 -17
6- 2-
6-Jul-
US9636410 Cationic oil-in-water emulsions GLAXOSMITHKLINE BIOLOGICALS SA Jul- May
11
12 -17
24- 24- 2-
US9636397 Adjuvant compositions and related methods Vaxliant, LLC Mar- Mar May
15 -16 -17
28- 27- 2-
US9636370 AAV vectors targeted to oligodendrocytes The University of North Carolina at Chapel Hill Sep- Sep May
12 -13 -17
19- 28- 25-
Compositions for and methods of inducing mucosal immune
US9629907 The Trustees of the University of Pennsylvania Nov- Oct Apr-
responses
04 -11 17
8- 19- 18-
US9624173 Heterocyclic modulators of lipid synthesis 3-V Biosciences, Inc. Mar- Mar Apr-
11 -15 17
10- 18-
Immunomodulation by controlling expression levels of microRNAs in The Board of Trustees of the Leland Stanford Junior 14-
US9623040 Jul- Apr-
dendritic cells University Jul-14
15 17
14- 14- 11-
US9618508 Flow cytometry analysis of materials adsorbed to metal salts GlaxoSmithKline Biologicals SA Dec- Dec Apr-
10 -11 17
28- 28- 11-
US9618476 System and method for electronic biological sample analysis NANOMEDICAL DIAGNOSTICS, INC. Apr- Apr Apr-
14 -14 17
23- 18- 11-
US9618429 Polymer stabilization of chromogen solutions Ventana Medical Systems, Inc. Jan- Jan Apr-
12 -13 17
Chimeric polynucleotides and polypeptides enabling the secretion of 24- 23- 4-

US9611481 a polypeptide of interest in combination with exosomes and uses UNIVERSITE DE MONTPELLIER Sep- Sep Apr-
thereof 09 -10 17
12- 12- 4-
Double-stranded oligonucleotide molecules to DDIT4 and methods
US9611474 QUARK PHARMACEUTICALS, INC. Sep- Sep Apr-
of use thereof
12 -13 17
24- 15- 28-
US9605276 Replication defective adenovirus vector in vaccination Etubics Corporation Aug- Mar Mar
12 -13 -17
24- 22- 28-
US9603864 Substituted nucleosides, nucleotides and analogs thereof Alios BioPharma, Inc. Jun- Jun Mar
14 -15 -17
11- 3- 28-
US9603850 MerTK-specific pyrazolopyrimidine compounds The University of North Carolina at Chapel Hill Apr- Apr Mar
14 -15 -17
10- 9- 21-
US9599606 ADP-ribose detection reagents The Board of Regents of the University of Texas System Jun- Jun Mar
14 -15 -17
3- 28- 21-
US9598459 Pharmaceutical compositions and methods Pop Test Oncology LLC Aug- Jul- Mar
15 16 -17

6- 28- 21-
US9597333 Benzazepine dicarboxamide compounds Hoffmann-La Roche Inc. Mar- Sep Mar
15 -16 -17
7- 6- 14-
Use of the chromosome 19 microRNA cluster (C19MC) for treating University of Pittsburghâ€”Of the Commonwealth System of
US9593334 Mar- Mar Mar
viral disease and promoting authophagy Higher Education
12 -13 -17
2- 1- 14-
US9593331 Double-stranded nucleic acid molecule for gene expression control Osaka City University Nov- Nov Mar
11 -12 -17
17- 13- 14-
Chloro-pyrazine carboxamide derivatives with epithelial sodium
US9593084 Parion Sciences, Inc. Dec- Dec Mar
channel blocking activity
12 -13 -17
28- 27- 14-
Immunization regimen with E4-deleted adenovirus prime and E1-
US9592284 The Trustees of the University of Pennsylvania Apr- Apr Mar
deleted adenovirus boost
04 -05 -17
14- 14- 14-

Compositions with modified nucleases targeted to viral nucleic acids
US9592277 Avirid, Inc. Apr- Apr Mar
and methods of use for prevention and treatment of viral diseases
04 -05 -17
31- 7-
31-
US9588069 Methods for performing thermal melt analysis GEN-PROBE INCORPORATED Jul- Mar
Jul-12
13 -17
17- 16- 7-
US9587250 Trustees of the University of Pennsylvania Dec- Jan Mar
01 -15 -17
9- 4- 7-
US9586998 Methods of propagating monkey adenoviral vectors GenVec, Inc. Nov- Aug Mar
09 -15 -17
13- 19- 7-
Arylalkyl- and aryloxyalkyl-substituted epthelial sodium channel
US9586911 Parion Sciences, Inc. Dec- Dec Mar
blocking compounds
13 -14 -17
3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6- 27- 18- 7-

US9586910 pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyra Parion Sciences, Inc. Jun- Dec Mar
zine-2-carboxamide 11 -13 -17
3- 14- 7-
Hydrazino 1H-imidazoquinolin-4-amines and conjugates made
US9585968 3M Innovative Properties Company Jun- Aug Mar
therefrom
11 -15 -17
22- 22- 7-
Immunogenic compositions in particulate form and methods for
US9585953 MUCOSIS B.V. Mar- Mar Mar
producing the same
11 -12 -17
9- 6- 7-
US9585874 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. May- Jan Mar
12 -16 -17
17- 17- 7-
US9585849 Broad spectrum antiviral and methods of use The Burlington HC Research Group, Inc. Apr- Apr Mar
06 -07 -17
8- 8- 28-
US9580474 Polyionic papilloma virus-like particle (VLP) vaccines THE JOHNS HOPKINS UNIVERSITY Sep- Sep Feb
10 -11 -17
CENTRE DE INVESTIGACION BIOMEDICA EN RED 13- 13- 28-
Methods and reagents for efficient and targeted delivery of
US9580468 BIOINGENIERA BIOMATERIALS Y NANOMEDICINA (CIBER Jan- Jan Feb
therapeutic molecules to CXCR4 cells
BBN) 11 -12 -17
6- 15- 28-
US9580429 Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy AstraZeneca AB Dec- Sep Feb
04 -14 -17
1- 1- 21-
US9574189 Enzymatic encoding methods for efficient synthesis of large libraries Nuevolution A/S Dec- Dec Feb
05 -06 -17
21- 24- 21-
US9574181 Influenza virus reassortment method Seqirus UK Limited May- Oct Feb
10 -14 -17
16- 16- 21-
US9573955 Compounds Chiese Farmaceutici S.p.A. Dec- Dec Feb
13 -14 -17
11- 11- 21-
Therapeutic hydroxypyridinones, hydroxypyrimidinones and
US9573938 Rutgers, The State University of New Jersey Sep- Sep Feb
hydroxypyridazinones
12 -13 -17
29- 5- 21-
US9572899 Compositions for enhancing transport of molecules into cells AVI BIOPHARMA, INC. Apr- Nov Feb
03 -08 -17
12- 11- 21-
US9572864 Compositions and uses of lectins Emory University Feb- Dec Feb
10 -15 -17
16- 5- 21-
US9572823 Boron-containing small molecules Anacor Pharmaceuticals, Inc. Feb- Apr Feb
05 -16 -17
19- 15- 14-
US9567336 Conjugated TLR7 and/or TLR8 and TLR2 agonists INVIVOGEN Nov- Mar Feb
12 -13 -17
22- 21- 14-
US9566326 Adjuvanted influenza vaccines for pediatric use Seqirus UK Limited Feb- Jun Feb
08 -13 -17
24- 24- 14-
US9566291 Nutritional composition comprising indigestible oligosaccharides N.V. Nutricia Aug- Aug Feb
04 -05 -17
16- 20- 14-
US9566290 Boron-containing small molecules Anacor Pharmaceuticals, Inc. Feb- Apr Feb
05 -16 -17

16- 17- 14-
US9566289 Boron-containing small molecules Anacor Pharmaceuticals, Inc. Feb- Feb Feb
05 -16 -17
10- 9- 14-
US9565857 Antimicrobial solutions Board of Regents, The University of Texas System Sep- Sep Feb
10 -11 -17
21- 21- 7-
US9562110 Bispecific antibody Wuhan YZY Biopharma Co., Ltd. Nov- Nov Feb
12 -12 -17
18- 18- 7-
US9561263 Treatment of inflammatory illnesses with ACE2 Apeiron Biologics AG Dec- Dec Feb
07 -08 -17
The United States of America, as represented by the 6- 4- 31-
US9556237 Antiviral rift valley fever virus peptides and methods of use Secretary of the Army, on behalf of the U.S. Army Medical Dec- Jun Jan-
Research Institute of Infectious Diseases 12 -15 17
18- 17- 31-
US9556229 Modification of peptides using a bis(thioether)arylbridge approach The Regents of the University of California May- May Jan-
12 -13 17
15- 4- 31-
US9556184 Phosphoinositide 3-kinase inhibitors Respivert, Ltd. Mar- Dec Jan-
13 -15 17
18- 17- 31-
US9556117 Indole carboxamide derivatives as P2X7 receptor antagonists ACTELION PHARMACEUTICALS LTD. Dec- Dec Jan-
12 -13 17
11- 3- 31-
Therapeutic uses of selected pyrrolopyrimidine compounds with
US9555031 The University of North Carolina at Chapel Hill Apr- Apr Jan-
anti-mer tyrosine kinase activity
14 -15 17
11- 3- 31-
Therapeutic uses of selected pyrazolopyrimidine compounds with
US9555030 The University of North Carolina at Chapel Hill Apr- Apr Jan-
anti-Mer tyrosine kinase activity
14 -15 17
18- 13- 24-
US9550773 3M Innovative Properties Company Jun- Apr Jan-
04 -15 17
5- 28- 24-
US9550757 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. Mar- Jun Jan-
10 -13 17
3- 31- 24-
US9549949 Antiviral agent NBC MESHTEC, INC. Sep- Aug Jan-
08 -09 17
16- 11- 24-
US9549938 Boron-containing small molecules Anacor Pharmaceuticals, Inc. Feb- Mar Jan-
05 -16 17
Chimeric polynucleotides and polypeptides enabling secretion of a 18- 18- 17-

US9546371 polypeptide of interest in association with exosomes and use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE Mar- Mar Jan-
for the production of immunogenic compositions 08 -09 17
13- 8- 17-
US9546184 Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY Aug- Jun Jan-
08 -15 17
2- 29- 17-
Substituted quinazolin-4-ones for inhibiting ubiquitin specific
US9546150 HYBRIGENICS SA Sep- Aug Jan-
protease 7
11 -12 17
12- 23- 17-
US9545440 Methods for preparing squalene NOVARTIS AG May- Oct Jan-
10 -15 17
12- 10- 10-
US9540373 Substituted spirocycles Boehringer Ingelheim International GmbH Sep- Sep Jan-
14 -15 17
9- 10-
27-
US9539321 HMGB1-derived peptides enhance immune response to antigens The Regents of the University of California Mar Jan-
Jul-10
-15 17
3- 3- 10-
US9539217 Nanoparticle compositions Allertein Therapeutics, LLC Apr- Apr Jan-
13 -14 17
21- 26- 3-
Pyrimidine derivatives and their use in the treatment of cancer and
US9533978 Sumitomo Dainippon Pharma Co., Ltd May- Aug Jan-
further diseases
09 -14 17
Methods for designing and preparing vaccines comprising directed 16- 16- 3-
US9533037 sequence polymer compositions via the directed expansion of Declion Holdings LLC Oct- Oct Jan-
epitopes 07 -08 17
25- 27- 27-

US9529974 Georgetown University Feb- Jul- Dec
08 11 -16
31- 1- 27-
The United States of America, as represent by the
US9527903 Engineered antibody constant domain molecules Jan- Oct Dec
08 -13 -16
8- 8- 27-
US9526803 Diagnostic chewing gum for pathogens Julius-Maximilians-Universitaet Wuerzburg Mar- Mar Dec
12 -13 -16
19- 17- 27-
US9526700 Composition for inactivating an enveloped virus VIROBLOCK SA May- Nov Dec
06 -14 -16
15- 15- 20-
Peptides, conjugates and method for increasing immunogenicity of a
US9522962 Academisch Ziekenhuis Leiden h.o.d.n. LUMC Mar- Mar Dec
vaccine
10 -11 -16
24- 21- 20-

US9522894 AstraZeneca AB Jan- Jan Dec
14 -15 -16

8- 2- 20-
EV576 for use in the treatment of viral infections of the respiratory
US9522171 Volution Immuno Pharmaceuticals SA Jan- Jan Dec
tract
10 -15 -16
24- 9- 13-
US9518093 Topical formulation of arginine-rich cyclic antimicrobial peptides NOVABIOTICS LIMITED Feb- Nov Dec
06 -15 -16
22- 10- 13-
US9518083 Gadd45beta targeting agents Imperial Innovations Limited Oct- Feb Dec
09 -15 -16
10- 10- 13-
US9517263 Benzonaphthyridine-containing vaccines GlaxoSmithKline Biologicals SA Jun- Jun Dec
09 -10 -16
20- 19- 13-
US9517205 Soluble needle arrays for delivery of influenza vaccines Seqirus UK Limited Aug- Aug Dec
10 -11 -16
30- 30- 6-
US9512471 Methods and kits for detecting human papillomavirus DIACARTA Inc Jun- Jun Dec
10 -10 -16
8- 6- 6-
US9512443 Recombinant expression of multiprotein complexes using polygenes ETH ZURICH Nov- Nov Dec
05 -06 -16
27- 29- 6-
Fusion proteins of ciliate granule lattice proteins, granular protein
US9512181 Tetragenetics, Inc. May- May Dec
particles thereof, and uses therefor
11 -12 -16
31- 30- 6-
US9511070 Heterocyclyl carboxamides for treating viral diseases NovaDrug, LLC Aug- Aug Dec
12 -13 -16
29- 29-
SiRNA compositions and methods for treatment of HPV and other 29-
US9506063 Sirnaomics, Inc. Jan Nov
infections Jul-10
-13 -16
8- 7- 29-
US9504747 Lipids and lipid compositions for the delivery of active agents Novartis AG Mar- Mar Nov
13 -14 -16
21- 10- 29-
Agent for the prophylaxis and treatment of highly pathogenic
US9504673 LTD â€œValenta-Intellektâ€ May- May Nov
infectious diseases
09 -10 -16
1- 16- 29-
US9504255 Physical antimicrobial method NMS TECHNOLOGIES CO., LTD. Aug- Jul- Nov
12 13 -16
22- 15- 22-
Cells and methodology to generate non-segmented negative-strand
US9499799 Centre National De La Recherche Scientifique Dec- Oct Nov
RNA viruses
06 -13 -16
21- 23- 22-
US9499535 Kinase inhibitors ORIGENIS GMBH Apr- Apr Nov
11 -12 -16
24- 24- 22-
US9499489 Myxovirus therapeutics, compounds, and uses related thereto Children's Healthcare of Atlanta, Inc. Oct- Oct Nov
11 -12 -16
2- 2- 22-
Method of using oxidative reductive potential water solution in
US9498548 Oculus Innovative Sciences, Inc. May- May Nov
dental applications
05 -06 -16
21- 13- 22-
Genetically modified human umbilical cord perivascular cells for
US9498544 Tissue Regeneration Therapeutics Inc. Apr- Mar Nov
prophylaxis against or treatment of biological or chemical agents
08 -15 -16
4- 3- 22-
US9498527 Vaccine composition NITTO DENKO CORPORATION Apr- Apr Nov
12 -13 -16
8- 7- 15-
US9494571 Methods of testing for intracellular pathogens Novartis AG Mar- Mar Nov
10 -11 -16
17- 16- 15-
US9493788 The Trustees of the University of Pennsylvania Dec- Jan Nov
01 -15 -16
25- 23- 15-
GITR antibodies and methods of inducing or enhancing an immune
US9493572 GITR, Inc. Mar- Mar Nov
response
05 -15 -16
14- 13- 15-
Compositions and methods for treating clostridium difficile-
US9493518 National Health Research Institutes Mar- Mar Nov
associated diseases
13 -14 -16
2- 15-
13-
US9492528 Influenza virus-like particles (VLPS) comprising hemagglutinin MEDICAGO INC. Jul- Nov
Jul-07
09 -16
14- 14- 15-
Use of salt of an acetylsalicylic acid for the treatment of viral
US9492413 Ventaleon GMBH Jan- Jan Nov
infections
08 -09 -16
25- 28- 8-
US9489495 GEORGETOWN UNIVERSITY Feb- Aug Nov
08 -08 -16
28- 28- 8-
US9487838 Oligonucleotide probe for the detection of adenovirus QIAGEN HAMBURG GMBH Dec- Dec Nov
10 -10 -16
6- 21- 8-
Exosome-mediated diagnosis of hepatitis virus infections and
US9487837 MOREHOUSE SCHOOL OF MEDICINE Oct- Jan Nov
diseases
08 -14 -16
3- 1- 8-
US9487778 Oligonucleotide modulators of the toll-like receptor pathway QUARK PHARMACEUTICALS, INC. Mar- Mar Nov
11 -12 -16
30- 12- 8-
US9487749 Use of methylsulfonylmethane (MSM) to modulate microbial activity Biogenic Innovations, LLC Oct- Aug Nov
09 -14 -16

9- 5- 8-
US9487528 Compounds Chiesi Farmaceutici S.p.A. Jun- Jun Nov
14 -15 -16
13- 21- 8-
Antimicrobial solutions containing dichloride monoxide and methods
US9486479 Oculus Innovative Sciences, Inc. Mar- Jul- Nov
of making and using the same
07 14 -16
12- 8- 1-
Compositions and methods for detecting and identifying nucleic acid
US9481912 Longhorn Vaccines and Diagnostics, LLC Sep- Oct Nov
sequences in biological samples
06 -13 -16
19- 10- 1-
US9481724 hDC-sign binding peptides Sloan-Kettering Institute for Cancer Research Dec- Dec Nov
11 -12 -16
Ingenane-type diterpene compound, and pharmaceutical 19- 28- 1-

KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND
US9481630 composition for treating or preventing viral infectious diseases Oct- Sep Nov
BIOTECHNOLOGY
containing same 11 -12 -16
21- 21- 25-

US9476090 Signal propagation biomolecules, devices and methods STC.UNM May- May Oct-
13 -14 16
30- 31- 25-
The Research Foundation for The State University of New
US9476032 Attenuated viruses useful for vaccines Mar- Mar Oct-
York
07 -08 16
28- 2- 25-
Nucleic acid molecules encoding moonoclonal antibodies speceific
US9475872 ImmunoQure AG Dec- Jan Oct-
for IL17F
11 -13 16
7- 7- 25-
US9475862 Neutralizing GP41 antibodies and their use Nov- Nov Oct-
11 -12 16
14- 29- 25-
US9475832 Phosphonates with reduced toxicity for treatment of viral infections The Regents of the University of California Apr- Sep Oct-
10 -14 16
3- 1- 25-
Heterobifunctional linkers with polyethylene glycol segments and
US9475804 3M Innovative Properties Company Jun- Jun Oct-
immune response modifier conjugates made therefrom
11 -12 16
27- 25-
US9475779 Boehringer Ingelheim International GmbH Jul- Oct-
15 16
6- 4- 25-
US9475775 Benzazepine dicarboxamide compounds Hoffmann-La Roche Inc. Mar- Mar Oct-
15 -16 16
22- 29- 25-
Methods for pathogen inactivation in blood using UV irradiation
US9474844 Hemalux LLC Oct- Dec Oct-
while minimizing heat transfer thereto
14 -15 16
Broad-spectrum antivirals against 3C or 3C-like proteases of 27- 27- 25-

US9474759 picornavirus-like supercluster: picornaviruses, caliciviruses and Kansas State University Research Foundation Sep- Sep Oct-
coronaviruses 11 -12 16
6- 6- 18-
US9469876 Circulating biomarkers for metastatic prostate cancer Caris Life Sciences Switzerland Holdings GmbH Apr- Apr Oct-
10 -11 16
23- 11-
11-
US9464276 Highly efficient influenza matrix (M1) proteins Novavax, Inc. Feb Oct-
Jul-03
-15 16
9- 21- 11-
Peptides having activity of inhibiting infections of respiratory viruses
US9464123 XIANGXUE GROUP (HONG KONG) COMPANY LIMITED May- Feb Oct-
and use of the same
13 -14 16
3- 11- 11-
Arranging interaction and back pressure chambers for
US9463240 NOVARTIS AG Dec- Jul- Oct-
microfluidization
09 14 16
29- 29- 4-
Quantitative measurement of nano/micro particle endocytosis with
US9459247 Academia Sinica Mar- Mar Oct-
cell mass spectrometry
10 -11 16
25- 26- 4-
US9459233 Amperometric gas sensor Steris Corporation Jun- Feb Oct-
12 -13 16
25- 23- 4-
US9458492 Methods and cells for identifying RIG-I pathway regulators Kineta, Inc. Feb- Feb Oct-
11 -12 16
21- 23- 4-
Recombinant influenza virus-like particles (VLPs) produced in
US9458470 MEDICAGO INC. Jan- Jan Oct-
transgenic plants expressing hemagglutinin
08 -13 16
15- 15- 4-
US9458184 Compositions of TLR7 and/or TLR8 agonists conjugated to lipids INVIVOGEN Jun- Mar Oct-
12 -13 16
27- 4-
US9458113 Boehringer Ingelheim International GmbH Jul- Oct-
15 16
24- 23- 4-
US9457074 Ohio State Innovation Foundation Apr- Feb Oct-
12 -15 16
2- 22- 27-
US9453043 Nucleic acid chemical modifications ALNYLAM PHARMACEUTICALS, INC. Mar- Jan Sep
09 -15 -16
4- 15- 27-
THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF
US9452973 Modulators of the relaxin receptor 1 May- Mar Sep
TRUSTEES
12 -13 -16
4- 27-
Influenza virus-like particles (VLPS) comprising hemagglutinin 13-
US9452210 MEDICAGO INC. Jan Sep
produced within a plant Jul-07
-13 -16

18- 27- 20-
Methods for concurrent identification and quantification of an
US9447462 IBIS BIOSCIENCES, INC. Feb- Jan Sep
unknown bioagent
04 -14 -16
12- 14- 20-
US9447132 Highly active nucleoside derivative for the treatment of HCV Achillion Pharmaceuticals, Inc. Apr- Apr Sep
13 -14 -16
22- 7- 20-
US9447097 4-amino-imidazoquinoline compounds Hoffmann-La Roche Inc. Apr- Apr Sep
14 -16 -16
25- 8- 20-
US9446062 Methods of treating ischemia-reperfusion injury with siRNAs Quark Pharmaceuticals, Inc. Oct- Jan Sep
06 -15 -16
27- 21- 13-
Antibody-nanoparticle conjugates and methods for making and
US9442107 Ventana Medical Systems, Inc. Apr- Apr Sep
using such conjugates
10 -15 -16
18- 6- 13-
US9441247 TC-83-derived alphavirus vectors, particles and methods ALPHAVAX, INC. May- Jul- Sep
04 15 -16
1- 31- 13-
US9440960 Substituted oxetanes and their use as inhibitors of cathepsin C Boehringer Ingelheim International GmbH Aug- Jul- Sep
14 15 -16
27- 13-
US9440930 Boehringer Ingelheim International GmbH Jul- Sep
15 -16
30- 6- 6-
US9435795 Enhanced deposition of chromogens utilizing pyrimidine analogs Ventana Medical Systems, Inc. Dec- Oct Sep
10 -14 -16
21- 20- 6-
US9435000 Primate T-lymphotropic viruses Johns Hopkins University Feb- Sep Sep
05 -13 -16
24- 21- 6-
Methods, compounds and systems for detecting a microorganism in
US9434997 Lawrence Livermore National Security, LLC Aug- Aug Sep
a sample
07 -08 -16
30- 9- 6-
Peptide compositions and methods for inhibiting herpesvirus
US9434769 The Administrators of the Tulane Educational Fund Oct- Jul- Sep
infection
09 14 -16
26- 28- 6-
Compositions and methods for activating innate and allergic
US9433672 ID Biomedical Corporation of Quebec Apr- Apr Sep
immunity
12 -14 -16
10- 30-
The United States of America, as represented by the 2-Jul-
US9430610 Re-sequencing pathogen microarray Apr Aug
Secretary of the Navy 04
-08 -16
24- 27- 30-
US9428739 Norovirus and Sapovirus antigens NOVARTIS VACCINES AND DIAGNOSTICS, INC. Mar- Nov Aug
01 -12 -16
30- 1- 30-
Polypeptides and uses thereof for treatment of autoimmune
US9428574 COMPUGEN LTD. Jun- Jul- Aug
disorders and infection
11 12 -16
16- 18- 30-
US9428571 Antibodies and processes for preparing the same TAIGA BIOTECHNOLOGIES, INC. May- Mar Aug
08 -15 -16
26- 30-
29-
US9428490 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. Jul- Aug
Jul-11
12 -16
12- 7- 30-
US9428439 Hydrobenzamide derivatives as inhibitors of Hsp90 ASTEX THERAPEUTICS LTD. Oct- Jan Aug
06 -14 -16
6- 6- 30-
US9426989 Organic peroxide compounds for microorganism inactivation NOVARTIS AG May- May Aug
10 -11 -16
7- 26- 23-
US9422367 Antigenic GM-CSF peptides and antibodies to GM-CSF Morphotek, Inc. Feb- Nov Aug
06 -13 -16
24- 24- 23-
Immunostimulatory combinations of TLR ligands and methods of The United States of America, as represented by the
US9421254 Sep- Sep Aug
use Secretary, Department of Health and Human Services
07 -08 -16
1- 16- 16-
US9416416 Biological specimen collection/transport compositions and methods Longhorn Vaccines and Diagnostics, LLC Oct- Dec Aug
07 -11 -16
30- 16-
Capture primers and capture sequence linked solid supports for 31-
US9416409 IBIS BIOSCIENCES, INC. Jul- Aug
molecular diagnostic tests Jul-09
10 -16
20- 18- 16-
Covalently linked thermostable kinase for decontamination process
US9416396 The Secretary of State for Health Feb- Feb Aug
validation
08 -09 -16
24- 23- 16-
US9415392 Slip chip device and methods The University of Chicago Mar- Mar Aug
09 -10 -16
11- 8- 16-
US9415087 Compositions and methods for treating coronavirus infection Ludwig-Maximilians-Universitaet Muenchen Mar- May Aug
14 -15 -16
3- 3- 16-
Esters of short chains fatty acids for use in the treatment of
US9415033 PROPONENT BIOTECH GMBH Oct- Oct Aug
immunogenic disorders
12 -13 -16
15- 16- 9-
Polypeptides and polynucleotides, and uses thereof for treatment of
US9409987 COMPUGEN LTD Apr- Apr Aug
immune related disorders and cancer
11 -12 -16
20- 18- 9-
US9409917 Heterocyclic amide derivatives as P2X7 receptor antagonists ACTELION PHARMACEUTICALS LTD. Jan- Jan Aug
12 -13 -16

15- 27- 9-
US9409870 Compounds CHIESI FARMACEUTICI S.p.A. Dec- Nov Aug
14 -15 -16
16- 15- 9-
US9408908 Combination adjuvant formulation Not Available Oct- Feb Aug
08 -13 -16
15- 15- 9-
Homogenous suspension of immunopotentiating compounds and
US9408907 GlaxoSmithKline Biologicals SA Dec- Dec Aug
uses thereof
09 -10 -16
22- 21- 2-
US9404160 Methods for the detection of microorganisms Becton, Dickinson and Company Dec- Dec Aug
09 -10 -16
20- 5- 2-
US9403868 Crystalline tripeptide epoxy ketone protease inhibitors Onyx Therapeutics, Inc. Mar- Mar Aug
09 -15 -16
30- 22- 2-
US9402921 Directed evolution and in vitro panning of virus vectors The University of North Carolina at Chapel Hill Apr- Oct Aug
08 -14 -16
3- 1- 2-
US9402878 Depsipeptide and uses thereof NovoBiotic Pharmaceuticals, LLC Dec- Jul- Aug
12 15 -16
23- 23- 2-
US9402812 Methods for the preparation of liposomes Indu Javeri Sep- Sep Aug
09 -10 -16
16- 14- 19-
US9394092 Powdered pouch and method of making same MONOSOL, LLC Apr- Mar Jul-
12 -13 16
30- 30- 19-
US9393564 Bioagent detection systems, devices, and methods IBIS BIOSCIENCES, INC. Mar- Mar Jul-
09 -10 16
28- 28- 19-
US9393295 Nanoparticles for use in pharmaceutical compositions Novartis AG Apr- Apr Jul-
08 -09 16
2- 1- 19-
US9393215 Nanoparticles for use in immunogenic compositions Novartis AG Dec- Dec Jul-
05 -06 16
10- 28- 12-
Method for propagating adenoviral vectors encoding inhibitory gene
US9388429 GenVec, Inc. Nov- May Jul-
products
05 -14 16
6- 19- 12-
Systems and methods for identifying Replikin Scaffolds and uses of
US9388234 Not Available Jun- Jun Jul-
said Replikin Scaffolds
03 -13 16
21- 21- 12-
US9388198 Heterocyclic amide derivatives as P2X7 receptor antagonists ACTELION PHARMACEUTICALS LTD. Jan- Jan Jul-
14 -14 16
22- 21- 12-
US9388197 Heterocyclic amide derivatives as P2X7 receptor antagonists ACTELION PHARMACEUTICALS LTD. Jan- Jan Jul-
13 -14 16
2- 1- 12-
Chimeric viruses presenting non-native surface proteins and uses
US9387242 Icahn School of Medicine at Mount Sinai Dec- Dec Jul-
thereof
05 -06 16
25- 20- 5-
US9382590 Methods and compositions for prostate cancer metastasis Mar- May Jul-
(FAMU)
11 -15 16
27- 4- 5-
CpG oligonucleotide analogs containing hydrophobic T analogs with
US9382545 COLEY PHARMACEUTICAL GMBH Sep- Oct Jul-
enhanced immunostimulatory activity
06 -13 16
6- 6- 5-
Derivatives of steroid benzylamines, having an antiparasitic
US9382288 Justus-Liebig-Universitat Giessen Oct- Oct Jul-
antibacterial, antimycotic and/or antiviral action
10 -11 16
7- 9- 5-
US9381244 VISTA modulators for diagnosis and treatment of cancer KING'S COLLEGE LONDON Sep- Sep Jul-
12 -13 16
25- 14- 5-
VLPS derived from cells that do not express a viral matrix or core
US9381239 Novavax, Inc. May- Apr Jul-
protein
07 -14 16
8- 8- 5-
US9381226 Methods and compositions related to inhibition of viral entry UNIVERSITY OF UTAH RESEARCH FOUNDATION Feb- Feb Jul-
07 -08 16
20- 15- 5-
US9381220 Sceletium extract and uses thereof H. L. Hall & Sons Limited Mar- Jul- Jul-
09 14 16
6- 5-
6-Jul-
US9380785 Antiviral resin member NBC MESHTEC, INC. Jul- Jul-
11
12 16
14- 14- 28-
Human monoclonal antibody with specificity for Dengue virus
US9376486 DSO National Laboratories Dec- Dec Jun-
serotype 1 E protein and uses thereof
10 -11 16
18- 17- 28-
US9376398 Carboxylic acid compounds Astrazeneca Aktiebolag May- May Jun-
12 -13 16
14- 13- 28-
Conjugates of GM-CSF and IL-7, compositions and methods related
US9375465 Children's Healthcare of Atlanta, Inc. Nov- Nov Jun-
thereto
11 -12 16
10- 22- 21-
System for processing contents of a receptacle to detect an optical
US9372156 GEN-PROBE INCORPORATED Mar- Feb Jun-
signal emitted by the contents
05 -11 16
23- 11- 21-
US9371563 Nanoreporters and methods of manufacturing and use thereof NanoString Technologies, Inc. Dec- Mar Jun-
05 -13 16

4- 11- 21-
US9370582 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. Dec- Jul- Jun-
07 14 16
4- 11- 21-
US9370581 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. Dec- Jul- Jun-
07 14 16
28- 10- 21-
US9370570 Polychlorinated biphenyls and squalene-containing adjuvants Novartis AG Dec- Dec Jun-
07 -13 16
31- 1- 21-
Method of providing patient specific immune response in
US9370531 New York University Aug- Sep Jun-
amyloidoses and protein aggregation disorders
07 -08 16
18- 17- 14-
US9365577 Pyrimidinone compounds as human neutrophil elastase inhibitors Chiesi Farmaceutici S.p.A. Dec- Dec Jun-
12 -13 16
3- 30- 14-
US9365567 Alkoxy substituted imidazoquinolines 3M Innovative Properties Company Oct- Sep Jun-
03 -14 16
31- 28- 14-
US9365523 Imidazolyl amide compounds and uses related thereto Children's Healthcare of Atlanta, Inc. Mar- Mar Jun-
11 -12 16
23- 9- 14-
US9365506 Compounds and compositions as TLR2 agonists NOVARTIS AG Mar- Jul- Jun-
10 14 16
24- 22- 14-
US9364511 Antiviral preparations obtained from a natural cinnamon extract RAMOT AT TEL-AVIV UNIVERSITY LTD. Dec- Jun Jun-
03 -06 16
22- 20- 7-
US9359360 TLR agonists The Regents of The University of California Aug- Nov Jun-
05 -12 16
9- 11- 7-
Decreasing potential iatrogenic risks associated with influenza
US9358280 Novartis AG Sep- Jan Jun-
vaccines
04 -13 16
16- 7- 31-
US9353133 Boron-containing small molecules Anacor Pharmaceuticals, Inc. Feb- Mar May
05 -14 -16
4- 22- 31-
US9352048 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. Dec- Jul- May
07 14 -16
5- 5- 24-
Method and kit for preparation of sample for use in nucleic acid
US9347055 EIKEN KAGAKU KABUSHIKI KAISHA Nov- Nov May
amplification
07 -08 -16
2- 19- 24-
US9346866 Inhibition of tace activity with cyclic peptides The Regents of the University of California Jun- Sep May
11 -14 -16
23- 29- 24-
Substituted 4-pyridones and their use as inhibitors of neutrophil
US9346794 Boehringer Ingelheim International GmbH Aug- Dec May
elastase activity
12 -15 -16
5- 23- 24-
US9346769 Tetrazolones as inhibitors of fatty acid synthase Infinity Pharmaceuticals, Inc. May- Aug May
10 -13 -16
23- 13- 24-
US9346753 Dithiol mucolytic agents PARION SCIENCES, INC. Aug- Aug May
13 -14 -16
9- 7- 24-
IPNV-ISAV bivalent vaccine using a virus-like particle-based
US9345760 Advanced Bionutrition Corporation Sep- Sep May
platform and methods of using the same
11 -12 -16
23- 2- 17-
US9340507 Boehringer Ingelheim International GmbH Aug- Sep May
elastase activity
12 -15 -16
11- 5- 17-
US9339561 Mutant protease biosensors with enhanced detection characteristics PROMEGA CORPORATION May- May May
10 -14 -16
31- 31- 17-
US9339525 Inhibition of biofilm organisms Novabiotics Limited Mar- Mar May
09 -10 -16
22- 22- 10-
US9334268 4-amino-imidazoquinoline compounds HOFFMAN-LA ROCHE INC. Apr- Apr May
14 -15 -16
25- 11- 3-
US9328110 Substituted imidazo ring systems and methods 3M INNOVATIVE PROPERTIES COMPANY Nov- Mar May
03 -14 -16
Selective inhibitors of ubiquitin specific protease 7, the 15- 17- 3-

US9328093 pharmaceutical compositions thereof and their therapeutic HYBRIGENICS SA Jan- Sep May
applications 10 -14 -16
Use of phenylmethimazoles, methimazole derivatives, and

16- 9- 3-
tautomeric cyclic thiones for the treatment of
US9326972 Ohio University Mar- Feb May
autoimmune/inflammatory diseases associated with toll-like
04 -12 -16
receptor overexpression
8- 8- 26-
University of Pittsburgh - Of the Commonwealth System of
US9322827 B-cell antigen presenting cell assay Apr- Apr Apr-
Higher Education
10 -11 16
19- 19- 26-
Compositions for increasing polypeptide stability and activity, and
US9321999 SOLIS BIODYNE OÃœ Nov- Nov Apr-
related methods
09 -10 16
20- 22- 26-
Activatable toxin complexes comprising a cleavable inhibitory
US9321847 RAMOT at Tel Aviv University Ltd. Sep- Aug Apr-
peptide
10 -11 16

1- 13- 26-
US9321831 RSV-specific binding molecules and means for producing them MedImmune Limited Jun- Sep Apr-
07 -13 16
7- 19- 26-
Peptides shared among lethal cancers and therapeutic compositions
US9320784 Not Available Aug- Jul- Apr-
comprising said peptides
09 12 16
7- 7- 26-
US9320748 Immunologically useful arginine salts Novartis AG Mar- Mar Apr-
12 -13 16
1- 1- 19-
US9315530 Adsorption of immunopotentiators to insoluble metal salts Novartis AG Sep- Sep Apr-
10 -11 16
27- 27- 12-
Luminophore-labeled molecules coupled with particles for
US9310375 CapitalBio Corporation Oct- Oct Apr-
microarray-based assays
10 -10 16
Device and method for reducing spread of microorganisms and 14- 12-
17-
US9310088 airborne health hazardous matter and/or for protection from Technical University of Denmark Jul- Apr-
Jul-09
microorganisms and airborne health hazardous matter 10 16
7- 4- 12-
US9309325 Antibodies and methods of use thereof The Regents of the University of California May- May Apr-
09 -10 16
30- 27- 5-
US9303068 The Regents of the University of California Nov- Nov Apr-
thereof
12 -13 16
17- 16- 5-
US9303000 Olefin containing nuclear transport modulators and uses thereof KARYOPHARM THERAPEUTICS INC. Jan- Jan Apr-
11 -12 16
21- 11- 29-
US9297010 Short interfering RNA (siRNA) analogues Roche Innovation Center Copenhagen A/S Mar- Feb Mar
03 -14 -16
22- 22- 29-
US9295732 Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists INVIVOGEN Feb- Feb Mar
13 -13 -16
24- 24- 29-
US9295708 Modified release formulations for oprozomib Onyx Therapeutics, Inc. Oct- Oct Mar
12 -13 -16
18- 29-
6-Jul-
US9295646 Cationic oil-in-water emulsions Novartis AG Sep Mar
10
-11 -16
13- 22-
13-
US9291628 Direct clone analysis and selection technology Dublin City University Jul- Mar
Jul-10
11 -16
1- 22-
2-Jul-
US9291597 Detecting targets using mass tags and mass spectrometry VENTANA MEDICAL SYSTEMS, INC. Jul- Mar
10
11 -16
11- 12- 22-
US9290794 Mutant protease biosensors with enhanced detection characteristics PROMEGA CORPORATION May- Nov Mar
10 -12 -16
26- 25- 22-
US9290786 Monoclonal antibody production by EBV transformation of B cells Institute for Research in Biomedicine Feb- Apr Mar
03 -13 -16
15- 14- 22-
US9290760 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. Sep- Sep Mar
10 -11 -16
10- 14- 22-
US9290745 Luciferase biosensor PROMEGA CORPORATION Oct- Feb Mar
03 -14 -16
23- 23- 22-
US9290545 Compositions and methods for the treatment of viral infections Dana-Farber Cancer Institute, Inc. Jan- Jul- Mar
08 10 -16
6- 9- 22-
US9290459 Boehringer Ingelheim International GmbH Feb- Nov Mar
13 -15 -16
27- 22-
Substituted dihydropyrimidinones and their use as inhibitors of 31-
US9290457 Boehringer Ingelheim International GmbH Jul- Mar
neutrophil elastase activity Jul-14
15 -16
14- 11- 22-
US9289487 II-key/antigenic epitope hybrid peptide vaccines Antigen Express, Inc. Sep- Jan Mar
99 -05 -16
19- 19- 15-
Application of highly conserved domain sequences from viral
US9284560 Biocross Institute of Molecular Medicine (Nantong) Co., Ltd. Sep- Sep Mar
genome as template to design therapeutic sliRNAs
11 -11 -16
Vaccines and immunotherapeutics comprising IL-15 receptor alpha 14- 6- 8-

US9278128 and/or nucleic acid molecules encoding the same, and methods for The Trustees of the University of Pennsylvania Sep- Jan Mar
using the same 09 -14 -16
10- 10- 8-
US9278126 Influenza vaccines with reduced amounts of squalene Seqirus UK Limited Feb- Feb Mar
09 -10 -16
12- 11- 1-
Compositions, comprising improved IL-12 genetic constructs and
US9272024 The Trustees of the University of Pennsylvania Dec- Dec Mar
vaccines, immunotherapeutics and methods of using the same
11 -12 -16
30- 30- 1-
Shelf stable, reduced corrosion, ready to use peroxycarboxylic acid
US9271494 Ecolab USA, Inc. Aug- Aug Mar
antimicrobial compositions
07 -07 -16
15- 17- 23-
US9266844 Suppression of SARS replication by SARS helicase inhibitors The Curators of the University of Missouri Jun- Jun Feb
12 -13 -16

9- 9- 23-
US9266843 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. May- May Feb
12 -13 -16
22- 22- 23-
Systems and methods for pathogen inactivation in blood using UV
US9265876 Hemalux Technologies LLC Oct- Oct Feb
irradiation while minimizing heat transfer thereto
14 -14 -16
29- 9- 16-
US9260398 PARION SCIENCES, INC. May- Dec Feb
12 -14 -16
20- 20- 9-
US9255144 Anti-IL-18 antibodies and their uses MedImmune Limited Dec- Dec Feb
10 -11 -16
15- 23- 9-
Adjuvancy and immune potentiating properties of natural products
US9255140 NEW YORK BLOOD CENTER, INC. Jun- Mar Feb
of Onchocerca volvulus
04 -09 -16
28- 3- 9-
Systems and methods for identifying replikin scaffolds and uses of
US9254315 Not Available Apr- Feb Feb
said replikin scaffolds
04 -10 -16
31- 31- 9-
US9254265 Small liposomes for delivery of immunogen encoding RNA NOVARTIS AG Aug- Aug Feb
10 -11 -16
14- 14- 2-
US9249427 Recombinant HCMV and RHCMV vectors and uses thereof Oregon Health & Science University May- Nov Feb
10 -12 -16
7- 4- 2-
US9249195 Reovirus vaccines and methods of use therefor Vanderbilt University Apr- Apr Feb
10 -11 -16
11- 5- 2-
US9248201 Mutant protease biosensors with enhanced detection characteristics PROMEGA CORPORATION May- May Feb
10 -14 -16
8- 8- 2-
Different serotypes of vesicular stomatitis virus as expression
US9248178 Not Available Jun- Jun Feb
vectors for immunization regimens
09 -10 -16
17- 16- 26-
US9242980 3M Innovative Properties Company Aug- Aug Jan-
10 -11 16
24- 5- 19-
Compositions, methods, and kits for isolating and analyzing nucleic
US9238809 QIAGEN GAITHERSBURG, INC. Sep- Aug Jan-
acids using an anion exchange material
09 -10 16
17- 16- 12-
US9234175 Creating bioengineered lymph nodes H. Lee Moffitt Cancer Center and Research Institute, Inc. Nov- Nov Jan-
09 -10 16
9- 16- 12-
Replikin-based compounds for prevention and treatment of influenza
US9233148 Not Available Jan- Oct Jan-
and methods of differentiating infectivity and lethality in influenza
09 -09 16
15- 14- 5-
US9227977 Phosphoinositide 3-kinase inhibitors Respivert Ltd. Mar- Mar Jan-
13 -14 16
29- 2- 29-
US9222075 Animal protein-free media for cultivation of cells Baxalta GmbH Oct- May Dec
04 -14 -15
20- 29-
22-
US9221832 Heterocyclic amide derivatives as P2X7 receptor antagonists ACTELION PHARMACEUTICALS LTD. Jul- Dec
Jul-11
12 -15
21- 12- 29-
Substituted pyridones and pyrazinones and their use as inhibitors of
US9221807 Boehringer Ingelheim International GmbH Feb- Feb Dec
neutrophil elastase activity
14 -15 -15
9- 14- 29-
US9220768 Novartis AG Sep- Oct Dec
vaccines
04 -11 -15
2- 11- 22-
Arrayed detector system for measurement of influenza immune
US9217745 University of Rochester May- Jul- Dec
response
08 13 -15
27- 22-
27-
US9217157 Recombinant influenza viruses and uses thereof Icahn School of Medicine at Mount Sinai Jul- Dec
Jul-09
10 -15
1- 16- 22-
US9216192 Toll-like receptor agonist formulations and their use VentiRx Pharmaceuticals, Inc. Aug- Jul- Dec
08 12 -15
1- 15-
Lipoparticles comprising proteins, methods of making, and using the 30-
US9213027 Integral Molecular, Inc. Nov Dec
same Jul-03
-13 -15
1- 7- 15-
Biological specimen collection and transport system and method of
US9212399 Longhorn Vaccines and Diagnostics, LLC Oct- Jan Dec
use
07 -14 -15
28- 15-
26-
US9212205 Nucleic acid binding compounds and methods of use University of Rochester Jul- Dec
Jul-07
08 -15
16- 16- 8-
US9206396 Methods and devices for quantitative viral assays Wisconsin Alumni Research Foundation Nov- Nov Dec
05 -06 -15
10- 8-
29-
US9206158 Hydrazide containing nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. Jun Dec
Jul-11
-15 -15
19- 18- 1-
US9200329 Rapid epidemiologic typing of bacteria BioFire Diagnostics, LLC May- May Dec
08 -09 -15

18- 15- 1-
Phosphate-modified oligonucleotide analogs with enhanced
US9200287 AdiuTide Pharmaceuticals GmbH May- May Dec
immunostimulatory activity
07 -08 -15
26- 9- 1-
US9200280 CITY OF HOPE Jan- Jun Dec
diseases
07 -14 -15
26- 14- 1-
US9200279 CITY OF HOPE Jan- Jan Dec
diseases
07 -14 -15
7- 16- 1-
US9200074 Antibodies to IL-1 R1 and methods of making them MEDIMMUNE LIMITED Nov- Apr Dec
08 -14 -15
1- 27- 1-
US9199981 Compounds and compositions as C-kit kinase inhibitors NOVARTIS AG Sep- Aug Dec
11 -12 -15
12- 12- 1-
US9199897 Methods for preparing squalene NOVARTIS AG May- May Dec
10 -11 -15
24- 1- 1-
Targeting opposite strand replication intermediates of single-
US9198927 ALNYLAM PHARMACEUTICALS, INC. Sep- Mar Dec
stranded viruses by RNAI
04 -10 -15

US9193780 and polypeptides comprising the same for the treatment of viral Ablynx N.V. Jun- Jun Nov
diseases 08 -09 -15
7- 24-
Delivery of self-replicating RNA using biodegradable polymer 6-Jul-
US9192661 Novartis AG Jun Nov
particles 10
-11 -15
28- 17-
20-
US9187748 Compositions and methods for silencing ebola virus gene expression Not Available Mar Nov
Jul-09
-14 -15
27- 25- 17-
US9187426 Organic compounds Novartis AG Jun- Jun Nov
08 -09 -15
30- 17- 17-
US9186419 Directed evolution and in vitro panning of virus vectors The University of North Carolina at Chapel Hill Apr- Jan Nov
08 -14 -15
9- 29- 17-
Immune stimulatory oligonucleotide analogs containing modified
US9186399 AdiutTide Pharmaceuticals GmbH Oct- Sep Nov
sugar moieties
07 -08 -15
22- 20- 10-
US9181303 Treatment of bacterial infections with cyclic antimicrobial peptides NovaBiotics Limited Dec- Jun Nov
05 -14 -15
17- 19- 10-
Inhibition of biofilm formation by 1,2,3,4,6-penta-O-galloyl-D-
US9181290 CHANG GUNG UNIVERSITY Jun- Sep Nov
glucopyranose
11 -11 -15
14- 14- 3-
US9175047 Peptidomimetic macrocycles Aileron Therapeutics, Inc. Jan- Jan Nov
09 -10 -15
26- 28- 3-
Phorbol type diterpene compound, pharmaceutical composition for KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND
US9174925 Oct- Sep Nov
treatment or prevention of viral infectious diseases including same BIOTECHNOLOGY
11 -12 -15
28- 18- 27-

US9169318 Neutralizing molecules to viral antigens Sea Lane Biotechnologies, Inc. Mar- Jul- Oct-
08 11 15
30- 11- 27-
Oxidative reductive potential water solution and methods of using
US9168318 Oculus Innovative Sciences, Inc. Dec- Aug Oct-
the same
03 -04 15
8- 30- 27-
Methods for treating juvenile arthritis with ant-bile salt-stimulated
US9168299 LIPUM AB Apr- Oct Oct-
lipase (BSSL) antibodies
09 -13 15
18- 18- 27-
Inhibitors of long and very long chain fatty acid metabolism as
US9168269 THE TRUSTEES OF PRINCETON UNIVERSITY Feb- Feb Oct-
broad spectrum anti-virals
10 -11 15
4- 14- 20-
US9163222 Mutations in OAS1 genes Kineta Two, LLC May- Nov Oct-
05 -12 15
3- 3- 20-
US9163065 Depsipeptide and uses thereof NovoBiotic Pharmaceuticals, LLC Dec- Dec Oct-
12 -13 15
30- 22- 20-
US9161976 Immunotherapy comprising TLR9 ligand and CD40 ligand Trustees of Dartmouth College Dec- Oct Oct-
02 -12 15
2- 29- 13-
US9156811 N-myristoyl transferase inhibitors Univeristy of Dundee Sep- Aug Oct-
08 -09 15
2- 4- 13-
US9155309 Virus inactivating sheet NBC MESHTEC, INC. Oct- Oct Oct-
09 -10 15
14- 14- 6-
Targeted whole genome amplification method for identification of
US9149473 IBIS BIOSCIENCES, INC. Sep- Sep Oct-
pathogens
06 -07 15
27- 6-
Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and 27-
US9149445 THE TRUSTEES OF PRINCETON UNIVERSITY Jul- Oct-
associated enzymes for treatment of viral infections Jul-09
10 15
26- 26- 29-
US9145588 Generation of binding molecules MERUS BIOPHARMACEUTICALS B.V. Sep- Sep Sep
11 -12 -15

1- 5- 29-
US9145585 Method for using permuted nucleic acid probes Ventana Medical Systems, Inc. Sep- Aug Sep
06 -14 -15
3- 26- 29-
US9145410 Pyrazolopyridines and analogs thereof 3M Innovative Properties Company Oct- Jan Sep
03 -12 -15
28- 29-
28-
US9144575 Anti-viral azide containing compounds LIFE TECHNOLOGIES CORPORATION Jul- Sep
Jul-10
11 -15
12- 22-
26-
US9139833 Modified small interfering RNA molecules and methods of use Arrowhead Research Corporation Mar Sep
Jul-02
-13 -15
25- 25- 22-
US9139647 Diagnosis and treatment of cancer using anti-TM4SF20 antibody FORERUNNER PHARMA RESEARCH CO., LTD. Dec- Dec Sep
08 -09 -15
THE GOVERNMENT OF THE HONG KONG SPECIAL 20- 22- 22-
US9139620 Feline morbillivirus and uses thereof ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF Jan- Jan Sep
CHINA 12 -13 -15
28- 28- 22-
US9138472 CD40L vaccines, compositions, and methods related thereto EMORY UNIVERSITY Sep- Sep Sep
10 -11 -15
16- 16- 15-
Method and apparatus for two-step surface-enhanced raman
US9134247 REAL-TIME ANALYZERS, INC. Dec- Dec Sep
spectroscopy
11 -11 -15
9- 9- 15-
US9133248 Methods of propagating monkey adenoviral vectors GenVec, Inc. Nov- Nov Sep
09 -10 -15
29- 28- 15-
US9132423 Sample-to-answer microfluidic cartridge Micronics, Inc. Jan- Jan Sep
10 -11 -15
18- 18- 15-
US9132175 Bacillus based delivery system and methods of use The Curators of the University of Missouri Apr- Apr Sep
11 -11 -15
1- 1- 8-
US9128101 Biomarkers for theranostics Caris Life Sciences Switzerland Holdings GmbH Mar- Mar Sep
10 -11 -15
16- 8-
Method for production of reprogrammed cell using chromosomally 16-
US9127256 DNAVEC CORPORATION Jul- Sep
unintegrated virus vector Jul-08
09 -15
9- 8- 8-
US9127251 Dec- Dec Sep
05 -06 -15
16- 12- 8-
Substrates for chromogenic detection and methods of use in
US9127028 Ventana Medical Systems, Inc. Aug- Aug Sep
detection assays and kits
10 -11 -15
13- 8-
Immunostimulatory compositions comprising liposome-encapsulated Industry Academic Cooperation Foundation, Hallym 17-
US9125952 Aug Sep
oligonucleotides and epitopes University Jul-09
-14 -15
4- 20- 25-
US9115093 Boehringer Ingelheim International GmbH Mar- Feb Aug
13 -14 -15
Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical 6- 26- 25-

US9115065 compositions thereof, and methods for treating hemorrhagic fever Kineta, Inc. Dec- Feb Aug
viruses, including infections associated with Arenaviruses 04 -13 -15
20- 20- 18-

US9109199 Methods to produce bunyavirus replicon particles STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK Sep- Sep Aug
10 -11 -15
13- 18-
15-
US9107970 Method and a filter for capturing airborne agents Not Available Jul- Aug
Jul-08
09 -15
3- 1- 18-
US9107958 3M Innovative Properties Company Jun- Jun Aug
therefrom
11 -12 -15
28- 8- 18-
US9107906 Compositions and methods for the treatment of immunodeficiency ADMA BIOLOGICS, INC. Oct- Jan Aug
14 -15 -15
5- 15- 18-
US9107904 Immunostimulatory compositions and methods of use thereof Massachusetts Institute of Technology Apr- Mar Aug
12 -13 -15
31- 31- 11-
US9102938 2â€² and 5â€² modified monomers and oligonucleotides ALNYLAM PHARMACEUTICALS, INC. Mar- Mar Aug
11 -11 -15
15- 28- 11-
US9102911 High density self-contained biological analysis BioFire Diagnostics, LLC May- Jan Aug
09 -13 -15
12- 13- 11-
US9102741 GAS57 mutant antigens and GAS57 antibodies Novartis AG Sep- Oct Aug
07 -14 -15
12- 7- 11-
US9102740 Cna-B domain antigens in vaccines against gram positive bacteria NOVARTIS AG Jan- Jun Aug
09 -13 -15
13- 13- 11-
Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel
US9102633 Parion Sciences, Inc. Dec- Dec Aug
blocking compounds
13 -13 -15
23- 20- 11-
US9102624 Boehringer Ingelheim International GmbH Aug- Aug Aug
elastase activity
12 -13 -15

14- 14- 11-
US9101597 Immunoprotective primary mesenchymal stem cells and methods Autoimmune Technologies, LLC Mar- Mar Aug
13 -13 -15
The United States of America as represented by the 27- 11-
Use of a pneumococcal P4 peptide for enhancing 31-
US9101582 Secretary of the Department of Health and Human Mar Aug
opsonophagocytosis in response to a pathogen Jul-08
Services, Centers for Disease Control and Prevention -13 -15
28- 31- 4-
US9096585 Antiviral compounds and uses thereof Icahn School of Medicine at Mount Sinai May- May Aug
10 -11 -15
9- 9- 4-
US9096543 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. May- May Aug
12 -13 -15
18- 17- 28-
US9090897 Production of IFN-lambda by conventional dendritic cells Bavarian Nordic A/S Dec- Dec Jul-
09 -10 15
23- 23- 21-
US9085641 Peptides regulating the surface expression of the T cell receptor Max-Delbruck-Centrum Fur Molekulare Medizin Jun- Jun Jul-
06 -07 15
1- 9- 21-
US9084808 Modified small interfering RNA molecules and methods of use Arrowhead Research Corporation Oct- May Jul-
04 -14 15
25- 21-
Antiviral compositions comprising ethanol extract of Tetracera The Catholic University of Korea Industry-Academic 24-
US9084758 Aug Jul-
scandens and use thereof Cooperation Foundation Jul-12
-14 15
6- 6- 14-
US9080209 Non-mass determined base compositions for nucleic acid detection IBIS BIOSCIENCES, INC. Aug- Aug Jul-
09 -10 15
12- 30- 14-
Compositions and methods for rapid, real-time detection of
US9080204 Longhorn Vaccines and Diagnostics, LLC Sep- Dec Jul-
influenza a virus (H1N1) Swine 2009
06 -11 15
21- 13- 14-
US9079965 Bispecific antibody Wuhan YZY Biopharma Co., LTD. Nov- Mar Jul-
12 -14 15
18- 28- 14-
US9079943 TC-83-derived alphavirus vectors, particles and methods ALPHAVAX, INC. May- Mar Jul-
04 -14 15
29- 14-
29-
US9079865 Hydrazide containing nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. Jul- Jul-
Jul-11
12 15
7- 7- 14-
US9078885 Respiratory disease treatment Pulmagen Therapeutics (Inflammation) Limited Aug- Apr Jul-
08 -14 15
15- 14- 14-
Therapeutic agent for accelerating recovery of animal under medical
US9078868 DAIICHI SANKYO COMPANY, LIMITED Jan- Jan Jul-
treatment
10 -11 15
14- 11- 7-
Method of using substituted 2-Aza-bicyclo[2.2.2]octane-3-carboxylic
US9073869 Boehringer Ingelheim International GmbH Mar- Sep Jul-
acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
13 -14 15
27- 27- 7-
US9072738 PARION SCIENCES, INC. Jun- Jun Jul-
11 -12 15
20- 21- 7-
Methods of treating or preventing inflammation and hypersensitivity
US9072726 Oculus Innovative Sciences, Inc. Jan- Dec Jul-
with oxidative reductive potential water solution
06 -09 15
21- 21- 7-
US9072702 Reverse genetics using non-endogenous pol I promoters Novartis AG May- May Jul-
09 -10 15

US9067873 compositions thereof, and methods for treating hemorrhagic fever Kineta Four, LLC Dec- Dec Jun-
viruses, including infections associated with arenaviruses 04 -13 15
13- 30-
13-
US9066964 Use of tylvalosin as antiviral agent Cambridge University Technical Services Jul- Jun-
Jul-06
07 15
The United States of America as represented by the 2- 25- 23-
Method for detection of antigen-specific antibodies in biological
US9063150 Secretary of the Department of Health and Human Sep- Aug Jun-
samples
Services, Centers for Disease Control Prevention 08 -09 15
16- 15- 23-
US9061001 Combination adjuvant formulation Dalhousie University Oct- Oct Jun-
08 -09 15
4- 8- 16-
US9056900 Compositions and methods for coronavirus inhibition Autoimmune Technologies, LLC. Nov- Aug Jun-
03 -13 15
20- 22- 16-
US9056898 Attenuated RNA virus and applications thereof Washington University Sep- Sep Jun-
07 -08 15
2- 19- 16-
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
US9056071 Compounds and methods for preventing or treating a viral infection Nov- Jun Jun-
(C.N.R.S.)
07 -13 15
25- 23- 9-
US9051619 Methods and compositions for prostate cancer metastasis Mar- Mar Jun-
(FAMU)
11 -12 15
21- 21- 9-
US9051564 Compositions for and methods of identifying antigens President and Fellows of Harvard College Feb- Feb Jun-
06 -07 15
20- 24- 9-
US9051353 Crystalline tripeptide epoxy ketone protease inhibitors Onyx Therapeutics, Inc. Mar- Sep Jun-
09 -13 15

7- 19- 9-
US9050376 Conjugates of synthetic TLR agonists and uses therefor The Regents of the University of California Feb- Jun Jun-
07 -14 15
7- 2- 2-
US9046523 Rapid bioluminescence detection system THE SECRETARY OF STATE FOR HEALTH Jan- Aug Jun-
09 -13 15
26- 28- 2-
US9045855 Anti-viral member NBC Meshtec, Inc. Dec- Dec Jun-
08 -09 15
17- 4- 2-
Virus-like particles, methods of preparation, and immunogenic
US9045727 EMORY UNIVERSITY May- Apr Jun-
compositions
02 -06 15
16- 16- 2-
US9045472 Imidazoquinoline compounds ASTRAZENECA AB Dec- Dec Jun-
10 -11 15
2- 1- 2-
US9045470 Compounds and compositions as TLR activity modulators IRM LLC Sep- Sep Jun-
09 -10 15
8- 6- 2-
Immunogenic compositions and methods of using the compositions
US9044420 IMMUNE DESIGN CORP. Apr- Apr Jun-
for inducing humoral and cellular immune responses
11 -12 15
27- 27- 26-
US9040310 Ventana Medical Systems, Inc. Apr- Apr May
10 -11 -15
25- 26- 19-
Virally-inactivated growth factors-containing platelet lysate depleted
US9034646 ZHENG YANG BIOMEDICAL TECHNOLOGY CO., LTD. May- Nov May
of PDGF and VEGF and preparation method thereof
10 -12 -15
8- 8- 19-
Nucleic acid molecules encoding rantes, and compositions
US9034313 Inovio Pharmaceuticals, Inc. Feb- Feb May
comprising and methods of using the same
10 -11 -15
1- 3- 12-
Treatment of viral infections by modulation of host cell metabolic
US9029413 The Trustees of Princeton University Jun- Apr May
pathways
07 -12 -15
17- 13- 12-
3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl)
US9029382 Parion Sciences, Inc. Dec- Dec May
pyrazine-2-carboxamide compounds
12 -13 -15
11- 11- 12-
US9029315 Soluble PD-1 variants, fusion constructs, and uses thereof The University of Hong Kong Nov- Nov May
10 -11 -15
23- 20- 12-
Synergistic bacterial compositions and methods of production and
US9028841 Seres Health, Inc. Nov- Mar May
use thereof
12 -14 -15
7- 20- 12-
US9028837 Methods and compositions for poxvirus A35R protein East Carolina University Jun- Dec May
12 -12 -15
25- 1- 12-
Methods of inducing or enhancing an immune response in a subject
US9028823 GITR, Inc. Mar- Mar May
by administering agonistic GITR binding antibodies
05 -13 -15
25- 20- 5-
US9024001 Alphavirus replicon packaging constructs Novartis Vaccines and Diagnostics, Inc. May- May May
04 -05 -15
14- 11- 5-
US9023855 Compounds Chiesi Farmaceutici S.p.A. Sep- Feb May
11 -14 -15
1- 22- 5-
US9023839 Compounds and compositions as c-kit kinase inhibitors IRM LLC Sep- Apr May
11 -14 -15
15- 18- 28-
US9017699 New York Blood Center, Inc. Jun- Feb Apr-
04 -10 15
10- 10- 28-
US9017696 Adenovirus vectors Isis Innovation Limited Apr- Apr Apr-
07 -08 15
31- 31- 21-
Compositions and methods using siRNA molecules and siRNA
US9012622 Not Available Dec- Dec Apr-
cocktails for the treatment of breast cancer
08 -09 15
1- 31- 21-
Transportable vacuum assisted decontamination unit and
US9011767 STERIS Inc. Apr- Mar Apr-
decontamination process
13 -14 15
18- 9- 14-
US9006264 3M Innovative Properties Company Jun- Sep Apr-
04 -13 15
19- 17- 14-
Compositions and methods for diminishing viral infection and
US9006194 Drexel University Dec- Dec Apr-
inflammation associated with viral infection
08 -09 15
9- 9- 14-
Academish Medisch Centrum Bij de Universiteit van
US9005974 Means and methods for influencing the stability of cells Dec- Dec Apr-
Amsterdam
05 -05 15
24- 24- 14-
US9005665 Ohio State Innovation Foundation Apr- Apr Apr-
12 -13 15
21- 20- 14-
Genetically modified human umbilical cord perivascular cells for
US9005599 Tissue Regeneration Therapeutics Inc. Apr- Apr Apr-
prophylaxis against or treatment of biological or chemical agents
08 -09 15
19- 7-
29-
US8999996 Hydrazide containing nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. Mar Apr-
Jul-11
-14 15

19- 14- 7-
Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1]
US8999975 Boehringer Ingelheim International GmbH Sep- Sep Apr-
heptane-3-carboxamide inhibitors of cathepsin C
11 -12 15
7- 7- 7-
US8999678 Method of increasing the function of an AAV vector The Trustees of the University of Pennsylvania Apr- Apr Apr-
05 -06 15
27- 7-
27-
US8999349 HMGB1-derived peptides enhance immune response to antigens The Regents of the University of California Jul- Apr-
Jul-10
11 15
30- 30- 7-
US8999316 Antiviral compounds Long Island University May- May Apr-
07 -08 15
22- 22- 31-
US8993717 Gadd45beta targeting agents Imperial Innovations Limited Oct- Oct Mar
09 -10 -15
24- 11- 31-
US8993581 Methods for treating viral disorders Trustees of Boston University Sep- Jun Mar
09 -13 -15
20- 31-
Methods, compositions, and kits for the selective activation of 20-
US8993295 The General Hospital Corporation Jul- Mar
protoxins through combinatorial targeting Jul-06
07 -15
24- 31-
11-
US8992939 Highly efficient influenza matrix (M1) proteins Novavax, Inc. Oct Mar
Jul-03
-11 -15
14- 12- 24-
Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-
US8987249 Boehringer Ingelheim International GmbH Mar- Mar Mar
cyano-methyl)-amides inhibitors of Cathepsin C
13 -14 -15
21- 24-
12-
US8987191 Bioactive peptides and methods of using same Compugen Ltd. Jun Mar
Jul-07
-13 -15
US8986933 Selective detection of human rhinovirus Secretary of the Department of Health and Human Dec- Dec Mar
Services, Centers for Disease Control 08 -08 -15
23- 22- 24-
Compositions comprising oriented, immobilized macromolecules and
US8986926 NanoString Technologies, Inc. Dec- Dec Mar
methods for their preparation
05 -06 -15
16- 18- 24-
US8986702 Antibodies and processes for preparing the same Taiga Biotechnologies, Inc. May- May Mar
08 -09 -15
29- 29- 17-

US8980898 Parion Sciences, Inc. May- May Mar
12 -13 -15
20- 16- 17-

US8980338 Sceletium extract and uses thereof H.L. Hall & Sons Limited Mar- Mar Mar
09 -10 -15
5- 12- 17-
High-yield transgenic mammalian expression system for generating
US8980281 Academia Sinica Sep- Feb Mar
virus-like particles
06 -10 -15
2- 2- 10-
US8975389 Nucleic acid chemical modifications Alnylam Pharmaceuticals, Inc. Mar- Mar Mar
09 -10 -15
26- 21- 3-
US8969362 9-substituted 8-oxoadenine compound AstraZeneca Aktiebolag Mar- Oct Mar
04 -13 -15
18- 17- 3-
Pharmaceutical product comprising a p38 kinase inhibitor and a
US8969350 Astrazeneca AB Dec- Dec Mar
second active ingredient
08 -09 -15
23- 23- 24-
Chemical modifications of monomers and oligonucleotides with
US8962580 Alnylam Pharmaceuticals, Inc. Sep- Sep Feb
cycloaddition
08 -09 -15
17- 13- 24-
US8962332 The Trustees of the University of Pennsylvania Dec- Sep Feb
01 -13 -15
17- 31- 24-
US8962330 The Trustees of the University of Pennsylvania Dec- Oct Feb
01 -07 -15
31- 5- 24-
National University Corporation Tokyo Medical and Dental
US8961983 Mucosal vaccine using cationic nanogel Oct- Sep Feb
University
08 -14 -15
25- 25- 24-
US8961477 Delivery of immune response modifier compounds 3M Innovative Properties Company Aug- Aug Feb
03 -04 -15
15- 15- 17-
US8956863 Agents from cells The Brigham and Women's Hospital, Inc. Oct- Oct Feb
09 -10 -15
24- 24- 17-
Constructs binding to phosphatidylserine and their use in disease
US8956616 Board of Regents, The University of Texas System Jan- Jan Feb
treatment
05 -06 -15
4- 11- 10-
US8951768 Mutations in OAS1 genes Kineta Two, LLC May- Jul- Feb
05 11 -15
22- 21- 10-
US8951528 Immune response modifier conjugates 3M Innovative Properties Company Feb- Feb Feb
06 -07 -15
26- 26- 3-
Personal glucose meters for detection and quantification of a broad
US8945943 The Board of Trustees of the University of Illinois May- May Feb
range of analytes
10 -11 -15
21- 20- 3-
US8945904 Influenza virus reassortment Novartis AG May- May Feb
10 -11 -15

14- 11- 3-
Condensation products based on bicyclic or polycyclic aromatics or
US8945610 BASF SE Nov- Nov Feb
heteroaromatics
07 -08 -15
5- 2- 27-
US8940864 Stabilized therapeutic small helical antiviral peptides New York Blood Center, Inc. Oct- Oct Jan-
06 -07 15
30- 1- 27-
US8940501 Methods for ligation and uses thereof Whitehead Institute for Biomedical Research Jan- Feb Jan-
09 -10 15
5- 2- 20-
US8937154 Stabilized therapeutic small helical antiviral peptides New York Blood Center, Inc. Oct- Feb Jan-
06 -12 15
6- 6- 13-
US8933210 Label-free functional nucleic acid sensors for detecting target agents The Board of Trustees of the University of Illinois Oct- Oct Jan-
10 -11 15
6- 31- 13-
US8933019 Antiviral cell-penetrating peptides New York Blood Center, Inc. May- Oct Jan-
08 -12 15
12- 12- 23-
US8916552 Pharmaceutical combinations Astex Therapeutics Limited Oct- Oct Dec
06 -07 -14
6- 8- 23-
Method for identifying and validating dominant T helper cell epitopes
US8916340 The John Hopkins University Jan- Jan Dec
using an HLA-DM-assisted class II binding assay
06 -07 -14
16- 22- 9-
Antisense antiviral compound and method for treating ssRNA viral
US8906872 Sarepta Therapeutics, Inc. Sep- Dec Dec
infection
04 -11 -14
27- 1- 9-
Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral
US8906863 The Regents of the University of California Feb- Sep Dec
delivery vector
09 -11 -14
27- 29- 9-
US8906862 Multiple antigen delivery system using hepatitis E virus-like particle National Institute of Infectious Disease Feb- Aug Dec
09 -11 -14
31- 30- 2-
US8901071 Compounds and their use Novabiotics Limited Mar- Mar Dec
10 -11 -14
20- 20- 2-
Influenza hemagglutinin-specific monoclonal antibodies for
US8900585 New York Blood Center, Inc. Oct- Oct Dec
preventing and treating influenza virus infection
10 -11 -14
3- 3- 25-
US8895629 Circulation of components during homogenization of emulsions Novartis AG Dec- Dec Nov
09 -10 -14
3- 22- 25-
US8895577 Compounds and compositions as TLR activity modulators Not Available Mar- Apr Nov
08 -13 -14
17- 14- 25-
US8895570 Purine derivatives AstraZeneca AB Dec- Dec Nov
10 -11 -14
20- 30- 25-
US8895534 Boron containing small molecules Anacor Pharmaceuticals, Inc. Jun- Jul- Nov
07 10 -14
15- 14- 25-
US8895295 High density self-contained biological analysis Biofire Diagnostics, LLC Nov- Nov Nov
06 -07 -14
14- 12- 18-
Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides
US8889708 Boehringer Ingelheim International GmbH Mar- Mar Nov
inhibitors of cathepsin C
13 -14 -14
27- 14- 18-
Pyrazinone derivatives, pharmaceutically acceptance salts thereof
US8889692 AstraZeneca AB Jun- Sep Nov
and their uses
07 -12 -14
16- 30- 18-
US8889656 Boron-containing small molecules Anacor Pharmaceuticals, Inc. Feb- Apr Nov
05 -13 -14
19- 18- 18-
US8889398 Composition for inactivating an enveloped virus Viroblock SA May- May Nov
06 -07 -14
16- 18-
Immunostimulatory compositions comprising liposome-encapsulated Industry Academic Cooperation Foundation, Hallym 17-
US8889181 Jun Nov
oligonucleotides and epitopes University Jul-09
-10 -14
24- 28- 18-
Anticancer agent containing dendritic cell having RNA virus
US8889118 DNA VEC Research Inc. Jun- Apr Nov
transferred thereinto
04 -05 -14
15- 15- 18-
US8889117 Modular nanoparticles for adaptable vaccines Yale University Feb- Feb Nov
07 -08 -14
7- 7- 11-
US8884020 Indole compounds Ironwood Pharmaceuticals, Inc. Aug- Aug Nov
06 -07 -14
12- 12- 11-
US8883790 Pharmaceutical combinations Astex Therapeutics Limited Oct- Oct Nov
06 -07 -14
5- 7- 11-
Method of preparing adenosine-resistant anti-tumor T lymphocytes
US8883500 Northeastern University Dec- Dec Nov
for adoptive immunotherapy
08 -09 -14
20- 20- 11-
US8883481 Reverse genetics methods for virus rescue Novartis AG Oct- Oct Nov
09 -10 -14
23- 14- 11-
US8883477 Oligoadenylate synthetase (OAS) Kineta Two, LLC Nov- Jun Nov
05 -13 -14

28- 27- 11-
Methods and compositions for production of recombinant protein in
US8882484 Bayer HealthCare LLC May- May Nov
HBX-expressing mammalian cells
08 -09 -14
28- 2- 4-
US8881040 Georgetown University Aug- Dec Nov
08 -09 -14
14- 12- 4-
Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-
US8877775 Boehringer Ingelheim International GmbH Mar- Mar Nov
cyano-methyl)-amides inhibitors of cathepsin C
13 -14 -14
23- 4-
Therapeutic antibodies for treatment and prophylaxis of 25-
US8877187 Avianax, LLC Nov Nov
transmittable viral diseases Jul-05
-10 -14
23- 31- 4-
US8877060 Methods for removing pathogens from a platelet preparation Biovec Transfusion, LLC Nov- Oct Nov
10 -11 -14
3- 3- 28-
US8871816 Methods for producing vaccine adjuvants Novartis AG Dec- Dec Oct-
09 -10 14
8- 8- 28-
US8871790 Heterocyclic modulators of lipid synthesis 3-V Biosciences, Inc. Mar- Mar Oct-
11 -12 14
14- 12- 28-
Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-
US8871783 Boehringer Ingelheim International GmBh Mar- Mar Oct-
methyl)-amides inhibitors of cathepsin C
13 -14 14
3- 1- 28-
US8871782 Alkoxy substituted imidazoquinolines 3M Innovative Properties Company Oct- Oct Oct-
03 -04 14
28- 28- 28-
US8871503 Construct Isis Innovation Limited Mar- Mar Oct-
06 -07 14
5- 4- 28-
US8871487 Compositions, methods and uses for inducing viral growth Takeda Vaccines, Inc. Dec- Dec Oct-
08 -09 14
30- 28- 28-
US8871442 Enhanced deposition of chromogens Ventana Medical Systems, Inc. Dec- Dec Oct-
10 -11 14
29- 29- 21-
N-terminally modified tetrapeptide derivatives having a C-terminal
US8865865 Philipps-Universitat Marburg Oct- Oct Oct-
arginine mimetic
08 -09 14
23- 22- 21-
US8865166 Antibodies to IL-17A and uses thereof MedImmune Limited Jun- Jun Oct-
06 -07 14
6- 3- 14-
US8859568 Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy Astrazeneca AB Dec- Nov Oct-
04 -10 14
23- 1- 14-
US8859251 Oligoadenylate synthetase (OAS) Kineta Two, LLC Nov- Jul- Oct-
05 13 14
27- 27- 14-
US8858958 Adjuvant comprising aluminum, oligonucleotide and polycation Novartis AG Aug- Aug Oct-
09 -10 14
12- 14- 14-
US8858957 GAS57 mutant antigens and GAS57 antibodies Novartis AG Sep- Mar Oct-
07 -13 14
24- 24- 7-
US8854617 Compounds and markers for surface-enhanced Raman scattering Julius-Maximilians-Universitat Wurzburg Sep- Sep Oct-
07 -08 14
5- 4- 7-
US8853382 Expression of antibody or a fragment thereof in lactobacillus Hera Pharmaceuticals, Inc. Aug- Aug Oct-
10 -11 14
23- 22- 30-
US8846710 Method of preferentially inducing the biosynthesis of interferon 3M Innovative Properties Company Feb- Feb Sep
05 -06 -14
31- 23- 30-
US8846697 Purine analogs The Regents of the University of California May- Apr Sep
06 -07 -14
14- 11- 30-
US8846643 Phosphonates with reduced toxicity for treatment of viral infections The Regents of the University of California Apr- Oct Sep
10 -12 -14
Modulation of replicative fitness by deoptimization of synonymous
US8846051 Secretary of the Department of Health and Human Oct- Oct Sep
codons
Services, Centers for Disease Control and Prevention 04 -05 -14
30- 16- 23-
US8841100 Use of methylsulfonylmethane (MSM) to modulate microbial activity Biogenic Innovations, LLC Oct- Feb Sep
09 -11 -14
5- 5- 23-
US8840899 Use of mTOR inhibitors to enhance T cell immune responses Emory University Aug- Aug Sep
08 -09 -14
12- 12- 23-
Rapid expression cloning of human monoclonal antibodies from
US8840890 University of Maryland, Baltimore Nov- Nov Sep
memory B cells
08 -09 -14
23- 23- 23-
Method of treating second and third degree burns using oxidative
US8840873 Oculus Innovative Sciences, Inc. Mar- Mar Sep
reductive potential water solution
05 -06 -14
3- 28- 23-
Electrochemistry and electrogenerated chemiluminescence with a
US8840774 Board of Regents of the University of Texas System Jun- Oct Sep
single faradaic electrode
05 -13 -14
18- 26- 16-
US8835107 Amsterdam Institute of Viral Genomics B.V. Aug- Jul- Sep
03 10 -14

20- 30- 16-
Methods of treating or preventing peritonitis with oxidative
US8834445 Oculus Innovative Sciences, Inc. Jan- Mar Sep
reductive potential water solution
06 -12 -14
11- 12- 9-
SiRNA compositions and methods for potently inhibiting viral
US8828962 Xiangxue Group (Hong Kong) Company Limited Dec- Dec Sep
infection
08 -11 -14
4- 4- 9-
US8828956 Carbohydrate conjugates as delivery agents for oligonucleotides Alnylam Pharmaceuticals, Inc. Dec- Dec Sep
07 -12 -14
18- 14- 9-
Method of treating an ischemia-reperfusion injury-related disorder
US8828940 Compugen Ltd. Sep- Dec Sep
by administering GPCR ligands
06 -10 -14
28- 27- 9-
Cytotoxic T cell epitope peptide for SARS coronavirus, and use Japan as Represented by Director-General of National
US8828929 Nov- Nov Sep
thereof Institute of Infectious Diseases
08 -09 -14
24- 1- 9-
Mixed cell diagnostic systems for detection of respiratory, herpes
US8828673 Diagnostic Hybrids Inc Apr- Mar Sep
and enteric viruses
98 -12 -14
1- 11- 9-
US8828659 Method for producing nucleic acid probes Ventana Medical Systems, Inc. Sep- Mar Sep
06 -13 -14
5- 9-
7-Jul-
US8828407 Chimaeric protein The Pirbright Institute Jul- Sep
09
10 -14
29- 9-
30-
US8828406 Influenza viruses and uses thereof Icahn School of Medicine at Mount Sinai Jul- Sep
Jul-09
10 -14
20- 20- 2-
US8822512 Crystalline tripeptide epoxy ketone protease inhibitors Onyx Therapeutics, Inc. Mar- Sep Sep
09 -11 -14
Compositions and uses thereof for the treatment of acute 20- 20- 2-
US8822409 respiratory distress syndrome (ARDS) and clinical disorders Phylogica Limited Jun- Jun Sep
associated with therewith 07 -08 -14
24- 2-
9-Jul-
US8821897 Viral adjuvants The University of North Carolina at Chapel Hill Nov Sep
04
-10 -14
Methods for controlling SR protein phosphorylation, and antiviral 26- 19- 26-
US8816089 agents whose active ingredients comprise agents that control SR Masatoshi Hagiwara Dec- Nov Aug
protein activity 03 -12 -14
2- 7- 26-
Methods for treating viral infection using IL-28 and IL-29 cysteine
US8816053 ZymoGenetics, Inc. Apr- Sep Aug
mutants
04 -12 -14
7- 29- 26-
US8815837 Respiratory disease treatment Pulmagen Therapeutics (Inflammation) Limited Aug- Jun Aug
08 -12 -14
3- 3- 26-
US8815831 Treatment of Acinetobacter with alginate oligomers and antibiotics Algipharma AS Jun- Jun Aug
09 -10 -14
10- 3- 26-
US8815611 Surface for label independent detection and method thereof Corning Incorporated Apr- Apr Aug
08 -09 -14
4- 26- 26-
US8815249 Ii-key/antigenic epitope hybrid peptide vaccines Antigen Express, Inc. Sep- Jul- Aug
99 10 -14
29- 16- 26-
US8815244 Method for production of antibody using ostrich Japan Science and Technology Agency Aug- Aug Aug
05 -11 -14
24- 23- 19-
US8809377 Deubiquitinase inhibitors and methods for use of the same The Regents of the University of Michigan Sep- Sep Aug
10 -11 -14
Compounds (cystein based lipopeptides) and compositions as TLR2 23- 23- 19-
US8808703 agonists used for treating infections, inflammations, respiratory Not Available Mar- Mar Aug
diseases etc 10 -11 -14
15- 19- 19-

US8808686 Adjuvant-sparing multi-dose influenza vaccination regimen Novartis AG Jun- Sep Aug
06 -11 -14
29- 17- 12-
US8802853 Arylalkenyl and arylalkynyl substituted imidazoquinolines 3M Innovative Properties Company Dec- Dec Aug
03 -04 -14
30- 17- 12-
Materials and methods for prevention and treatment of RNA viral
US8802647 University of South Florida Apr- Sep Aug
diseases
02 -12 -14
30- 29- 12-
Peptide compositions and methods for inhibiting herpesvirus
US8802106 The Administrators of the Tulane Educational Fund Oct- Oct Aug
infection
09 -10 -14
15- 18- 5-
Anti-TSG101 antibodies and their uses for treatment of viral
US8796423 Eli Lilly and Company Nov- Apr Aug
infections
06 -08 -14
7- 8- 29-
US8790655 Conjugates of synthetic TLR agonists and uses therefor The Regents of The University of California Feb- Jan Jul-
07 -13 14
27- 26- 22-
Compositions and methods for reducing or protecting against
US8785408 Quark Pharmaceuticals, Inc. Jun- Jun Jul-
delayed graft function (DGF)
07 -08 14
22- 22- 22-
US8785375 Cyclic antimicrobial peptides for treating bacterial infections Novabiotics Ltd. Dec- Aug Jul-
05 -12 14

13- 13- 22-
Antimicrobial solutions containing dichlorine monoxide and methods
US8784900 Oculus Innovative Sciences, Inc. Mar- Mar Jul-
of making and using the same
07 -08 14
12- 12- 15-
US8779132 Pharmaceutical compounds Astex Therapeutics Limited Oct- Oct Jul-
06 -07 14
25- 24- 15-
Hydroxylamine and oxime substituted imidazoquinolines,
US8778963 3M Innovative Properties Company Nov- Nov Jul-
imidazopyridines, and imidazonaphthyridines
03 -04 14
4- 1- 15-
US8778846 Composition, device and associated method General Electric Company Dec- Mar Jul-
06 -07 14
15- 1- 15-
US8778845 Composition, device and associated method Genral Electric Company Dec- Mar Jul-
05 -07 14
18- 15-
Immunogenic compositions for gram positive bacteria such as 29-
US8778358 Novartis Vaccines and Diagnostics, Inc. Oct Jul-
Streptococcus agalactiae Jul-04
-10 14
3- 3- 15-
US8778275 Methods for producing vaccine adjuvants Novartis AG Dec- Dec Jul-
09 -10 14
26- 25- 8-
US8772471 Targeted delivery of siRNA Immune Disease Institute Jan- Jan Jul-
07 -08 14
Pyrimidline derivatives having immune modulating properties that 22- 16- 1-

US8765939 act via TLR7 for the treatment of viral or allergic diseases and AstraZeneca AB Nov- Aug Jul-
cancers 07 -12 14
28- 14- 1-
US8765704 Modified small interfering RNA molecules and methods of use Novartis AG Feb- Dec Jul-
08 -11 14
4- 1- 1-
US8765643 Composition, device and associated method General Electric Company Dec- Mar Jul-
06 -07 14
31- 31- 1-
US8765146 Adenoviral vector-based malaria vaccines GenVec, Inc. Aug- Aug Jul-
05 -06 14
6- 24- 1-
US8765138 Antiviral and antibacterial activity from medicinal mushrooms Not Available Jan- Sep Jul-
04 -08 14
29- 16- 1-
US8765133 Method of producing anti-CD166 antibody in ostrich Japan Science and Technology Agency Aug- Aug Jul-
05 -11 14
24- 25- 24-
Oligonucleotide compound and method for treating nidovirus
US8759307 Sarepta Therapeutics, Inc. Dec- Apr Jun-
infections
03 -08 14
15- 23- 24-
US8758763 Archaeal polar lipid aggregates for administration to animals National Research Council of Canada Dec- Jan Jun-
06 -13 14
29- 27- 24-
US8758680 Method and device for cleaning air Not Available Sep- Sep Jun-
10 -11 14
1- 19- 17-
US8754071 Compounds and compositions as c-kit kinase inhibitors Not Available Sep- Sep Jun-
11 -13 14
21- 20- 17-
Modified phage for displaying post-translationally modified proteins
US8754015 University of Rochester Nov- Nov Jun-
and uses thereof
06 -07 14
22- 22- 10-
US8748567 Method for delivery across the blood brain barrier Children's Medical Center Corporation May- May Jun-
06 -07 14
7- 16- 10-
Use of SIRT1 activators or inhibitors to modulate an immune
US8748464 The J. David Gladstone Institutes Feb- Jul- Jun-
response
08 10 14
26- 9- 10-
US8748405 City of Hope Jan- Sep Jun-
diseases
07 -11 14
29- 16- 10-
US8748156 Animal protein-free media for cultivation of cells Baxter Healthcare SA Oct- Apr Jun-
04 -13 14
15- 28- 3-
US8741813 Composition, device and associated method General Electric Company Dec- Feb Jun-
05 -07 14
22- 16- 3-
US8741653 Single recombination system and methods of use Emergent Product Development GmbH Dec- Dec Jun-
08 -09 14
7- 14- 3-
US8741604 Nucleic acid molecule encoding a specific IL-1R1 antibody Medimmune Limited Nov- Sep Jun-
08 -12 14
4- 26- 3-
Quantitative nuclease protection assay (QNPA) and sequencing
US8741564 HTG Molecular Diagnostics, Inc. May- Apr Jun-
(QNPS) improvements
11 -12 14
27- 26- 3-
US8741311 Methods and compositions for immunization against virus Academia Sinica Mar- Mar Jun-
09 -10 14
6- 6- 27-
US8735567 Multi-targeted RNAi therapeutics for scarless wound healing of skin Not Available Nov- Nov May
07 -08 -14
11- 11- 27-
US8735559 Mutant protease biosensors with enhanced detection characteristics Promega Corporation May- May May
10 -11 -14

30- 23- 27-
US8735421 Imidazoquinolinyl sulfonamides 3M Innovative Properties Company Dec- Dec May
03 -04 -14
26- 24- 27-
US8735410 Quinazoline derivatives as tyrosine kinase inhibitors AstraZeneca AB Feb- Feb May
05 -06 -14
1- 5- 27-
US8735348 Casein derived peptides and uses thereof Peptera Ltd. Mar- Sep May
00 -12 -14
14- 28- 27-
Device including altered microorganisms, and methods and systems
US8734823 The Invention Science Fund I, LLC Dec- May May
of use
05 -10 -14
14- 20-
The Board of Trustees of the Leland Stanford Junior 19-
US8728793 Amphipathic alpha-helical peptide compositions as antiviral agents Jul- May
University Jul-07
08 -14
16- 23- 13-
US8722917 Boron-containing small molecules Anacor Pharmaceuticals, Inc. Feb- Jan May
05 -12 -14
24- 6- 13-
Biphenyloxyacetic acid derivatives for the treatment of respiratory
US8722741 AstraZeneca AB Aug- Dec May
disease
04 -11 -14
23- 21- 13-

Caffeoylquinic acid derivatives containing nitrogen, and preparation Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical
US8722725 Mar- Mar May
method, pharmaceutical composition and usage thereof Factory
07 -08 -14
24- 24- 6-
US8718948 Gen-Probe Incorporated Feb- Feb May
11 -12 -14
20- 6-
20-
US8716464 Compositions and methods for silencing Ebola virus gene expression Not Available Jul- May
Jul-09
10 -14
24- 24- 6-
US8716461 Human parvovirus Blood Systems, Inc. May- May May
04 -05 -14
24- 13- 29-
US8710224 Heterocyclic compounds as CCR2B antagonists AstraZeneca AB Dec- Sep Apr-
04 -13 14
5- 7- 29-
Methods of preventing and treating viral infections by inhibiting the
US8709730 Icahn School of Medicine at Mount Sinai Apr- Apr Apr-
deISGylation activity of OTU domain-containing viral proteins
07 -08 14
6- 23- 29-
Use of deuterium oxide for the treatment of virus-based diseases of
US8709496 D2 Bioscience Group Ltd. Jan- May Apr-
the respiratory tract
10 -12 14
22- 26- 29-
Compositions and methods for activating innate and allergic
US8709447 ID Biomedical Corporation of Quebec Oct- Apr Apr-
immunity
03 -12 14
18- 6- 29-
US8709441 TC-83-derived alphavirus vectors, particles and methods Alphavax, Inc. May- Jul- Apr-
04 10 14
11- 11- 22-
US8704169 Direct impact ionization (DII) mass spectrometry Oct- Oct Apr-
11 -11 14
11- 10- 22-
Cleaning composition for treating tissue for transplantation derived
US8703748 CG BIO Co., Ltd. Feb- Feb Apr-
from human/animal
09 -10 14
27- 26- 22-
Inactivation of a pathogen in a sample by a treatment with formalin
US8703467 Baxter Healthcare SA May- May Apr-
and UV light
04 -05 14
3- 31- 22-
Electrochemistry and electrogenerated chemiluminescence with a
US8702958 Board of Regents of the University of Texas System Jun- May Apr-
single faradaic electrode
05 -12 14
24- 24- 15-
Amide substituted imidazopyridines, imidazoquinolines, and
US8697873 3M Innovative Properties Company Mar- Mar Apr-
04 -05 14
10- 10- 15-
US8697853 TAL effector-mediated DNA modification Iowa State University Research Foundation, Inc. Dec- Jan Apr-
09 -13 14
12- 10- 15-
US8697659 Analogues of glycolipids useful as immunoadjuvants Luigi Panza Oct- Oct Apr-
07 -08 14
28- 28- 15-
US8697140 Virucidal disinfectant B. Braun Medical AG Jan- May Apr-
05 -09 14
25- 27- 15-
VLPs derived from cells that do not express a viral matrix or core
US8697088 Novavax, Inc. May- May Apr-
protein
07 -08 14
4- 6- 15-
Influenza vaccines including combinations of particulate adjuvants
US8697087 Novartis AG Nov- Nov Apr-
and immunopotentiators
05 -06 14
25- 24- 8-
US8691837 Substituted imidazo ring systems and methods 3M Innovative Properties Company Nov- Nov Apr-
03 -04 14
14- 13- 8-
US8691826 Compounds Chiesi Farmaceutici S.p.A. Sep- Sep Apr-
11 -12 14
5- 4- 8-
US8691781 Compositions for treating respiratory viral infections and their use Sirnaomics, Inc. Nov- Nov Apr-
04 -05 14

27- 25- 8-
US8691777 Combination therapy Emory University Jan- Jan Apr-
11 -12 14
10- 9- 1-
4,4-disubstituted piperidine derivatives useful as inhibitors of
US8686152 Janssen Pharmaceutica NV Mar- Mar Apr-
dipeptidyl peptidase-1 (DPP-1)
10 -11 14
14- 28- 25-
Device including altered microorganisms, and methods and systems
US8682619 The Invention Science Fund I, LLC Dec- May Mar
of use
05 -10 -14
4- 4- 25-
US8679839 Cell line from rousettus as host cell for pathogen amplification Probiogen AG Mar- Mar Mar
08 -09 -14
3- 3- 25-
US8678184 Methods for producing vaccine adjuvants Novartis AG Dec- Dec Mar
09 -10 -14
26- 25- 25-
US8678002 Devices and methods for decreasing human pathogen transmission Filligent Limited Jun- Jun Mar
07 -08 -14
21- 22- 18-
US8673983 Melanins synthesized chemically or via enzyme catalysis Loyola University Chicago Dec- Dec Mar
07 -08 -14
12- 12- 18-
US8673932 Oxime substituted imidazo-containing compounds 3M Innovative Properties Company Aug- Aug Mar
03 -04 -14
Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino- 2- 17- 16- 18-

US8673907 butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4- AstraZeneca AB Dec- Dec Mar
ylpropyl) amino] methyl }phenyl) acetate and their use in therapy 07 -08 -14
13- 13- 18-

The Board of Trustees of the Leland Stanford Junior
US8673904 Epoxide inhibitors of cysteine proteases Jun- Jun Mar
University
06 -07 -14
10- 24- 18-
US8673558 Luciferase biosensor Promega Corporation Oct- Apr Mar
03 -12 -14
18- 18- 18-
Composition with sterilizing activity against bacteria, fungus and
US8673331 GP&E Nov- Nov Mar
viruses, application thereof and method for preparation thereof
11 -11 -14
9- 8- 11-
US8669263 Use of TAM receptor inhibitors as antimicrobials Salk Institute for Biological Studies Nov- Mar Mar
07 -13 -14
3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6- 27- 26- 11-

US8669262 pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyra Parion Sciences, Inc. Jun- Jun Mar
zine-2-carboxamide 11 -12 -14
1- 19- 11-
US8669240 Longhorn Vaccines & Diagnostics, LLC Oct- Mar Mar
use
07 -13 -14

US8664274 compositions thereof, and methods for treating hemorrhagic fever Siga Technologies, Inc. Dec- Jul- Mar
viruses, including infections associated with arena viruses 04 11 -14
11- 30- 4-
US8664218 Pharmaceutical compounds Astex Therapeutics Ltd. Apr- Jan Mar
08 -13 -14
11- 11- 4-
siRNA compositions and methods for potently inhibiting viral
US8664188 Xiangxue Group (Hong Kong) Company Limited Dec- Dec Mar
infection
08 -09 -14
10- 1- 4-
US8663922 Systems and methods for detecting multiple optical signals Gen-Probe Incorporated Mar- Jun Mar
05 -10 -14
15- 15- 25-
US8658767 Lipidated polyepitope vaccines National Health Research Institutes Nov- Nov Feb
10 -11 -14

US8658697 compositions thereof, and methods for treating hemorrhagic fever Siga Technologies, Inc. Dec- Oct Feb
viruses, including infections associated with arenaviruses 04 -10 -14
11- 10- 25-

US8658666 Substituted imidazoquinolines and imidazonaphthyridines 3M Innovative Properties Company Feb- Feb Feb
05 -06 -14
19- 19- 25-
US8658178 Carbon nanotube compositions and methods of use thereof Yale University Mar- Mar Feb
08 -09 -14
21- 22- 18-
US8653252 Short interfering RNA (siRNA) analogues Santaris Pharma A/S Mar- Mar Feb
03 -04 -14
12- 12- 18-
US8653084 Hydrobenzamide derivatives as inhibitors of Hsp90 Astex Therapeutics Ltd. Oct- Oct Feb
06 -07 -14
8- 18-
Compositions and methods comprising phosphatidylethanolamine- 15-
US8653034 Board of Regents, The University of Texas System May Feb
binding peptide derivatives Jul-02
-08 -14
27- 18-
Defective ribosomal products in blebs (DRibbles) and methods of 29-
US8652836 Providence Health System Jul- Feb
use to stimulate an immune response Jul-05
06 -14

12- 26- 18-
Compositions and methods for detecting, identifying and
US8652782 Longhorn Vaccines & Diagnostics, LLC Sep- Apr Feb
quantitating mycobacterial-specific nucleic acids
06 -11 -14
5- 18-
7-Jul-
US8652533 Durable biocides and disinfectants Mitsui Norin Co., Ltd. Jul- Feb
04
05 -14
5- 26- 11-
US8648076 Cysteine protease inhibitors and their therapeutic applications Hybrigenics SA Aug- Jul- Feb
05 06 -14
28- 28- 11-
US8647676 Antimicrobial composition from copepods Nofima Ingrediens Oct- Oct Feb
08 -09 -14

US8642596 compositions thereof, and methods for treating hemorrhagic fever Siga Technologies, Inc. Dec- Dec Feb
viruses, including infections associated with arena viruses 04 -05 -14
21- 21- 4-
US8642260 Single quantum-dot based aptameric nanosensors The Research Foundation of the City University of New York Oct- Oct Feb
08 -09 -14
29- 28- 21-
US8633322 Alkynyl derivatives useful as DPP-1 inhibitors Janssen Pharmaceutica NV Oct- Oct Jan-
09 -10 14
28- 27- 21-
Compounds for preventing or treating viral infections and methods
US8633308 The Governors of The University of Alberta Feb- Feb Jan-
of use thereof
07 -08 14
30- 29- 21-
US8632764 Directed evolution and in vivo panning of virus vectors University of North Carolina at Chapel Hill Apr- Apr Jan-
08 -09 14
6- 6- 14-
Compounds that modulate negative-sense, single-stranded RNA
US8629283 Icahn School of Medicine at Mount Sinai Mar- Mar Jan-
virus replication and uses thereof
08 -09 14
6- 2- 14-
US8629271 Compounds AstraZeneca AB Feb- Apr Jan-
08 -12 14
15- 14- 14-
US8629098 Compositions and methods for adoptive and active immunotherapy Yale University Jan- Jan Jan-
08 -09 14
28- 2- 14-
US8628786 Polychlorinated biphenyls and squalene-containing adjuvants Novartis AG Dec- Dec Jan-
07 -11 14
Vaccines and immunotherapeutics comprising IL-15 receptor alpha 14- 14- 7-

US8624011 and/or nucleic acid molecules encoding the same, and methods for The Trustees of the University of Pennsylvania Sep- Sep Jan-
using the same 09 -10 14
24- 4- 7-
US8623419 Technology for preparation of macromolecular microspheres Ansun Biopharma, Inc. Jan- Nov Jan-
06 -11 14
17- 18- 7-
US8623382 Immunogenic compositions for inducing an immune response to HIV Wyeth LLC Jun- Jan Jan-
04 -11 14
8- 24- 7-
US8623364 Antigenic GM-CSF peptides and antibodies to GM-CSF Morphotek, Inc. Feb- Oct Jan-
06 -12 14
20- 20- 31-
US8617838 Fluorescent proteins and related methods and compounds University of Massachusetts Sep- Sep Dec
04 -05 -13
10- 10- 24-
US8615368 Method for determining the amount of an analyte in a sample Gen-Probe Incorporated Mar- Mar Dec
05 -06 -13
13- 14- 17-
Highly active glycoproteins-process conditions and an efficient
US8609370 Glycotope GmbH Feb- Feb Dec
method for their production
04 -05 -13
23- 23- 17-
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
US8609101 Theraclone Sciences, Inc. Apr- Apr Dec
neutralizing antibodies
09 -10 -13
20- 22- 10-
US8604215 Crystalline tripeptide epoxy ketone protease inhibitors Onyx Therapeutics, Inc. Mar- Mar Dec
09 -10 -13
16- 27- 10-
Methods of treating cancer with human monoclonal antibodies
US8603469 Genmab A/S Dec- Dec Dec
against interleukin 8
02 -11 -13
6- 6- 3-
US8599383 Optical cytometry The Regents of the University of California May- May Dec
09 -09 -13
14- 12- 3-
US8598192 Hydroxylamine substituted imidazoquinolines 3M Innovative Properties Company Nov- Nov Dec
03 -04 -13
22- 23- 3-
RNAi modulation of RSV, PIV and other respiratory viruses and uses
US8598134 South Alabama Medical Science Foundation Oct- Jul- Dec
thereof
04 10 -13
4- 29- 3-
US8598116 Treatment of influenza virus infection Educational Fund and Autoimmune Technologies, LLC Nov- May Dec
03 -12 -13
17- 5- 3-
Anti-microbial composition exhibiting residual anti-microbial
US8598106 Byotrol PLC Sep- Jul- Dec
properties on a surface
07 11 -13
8- 6- 3-
Methods for treating rheumatoid arthritis with anti-bile salt-
US8597650 HERNELL OLLE Apr- Apr Dec
stimulated lipase (BSSL) antibodies
09 -10 -13

13- 3- 26-
Vaccines and immunotherapeutics using codon-optimized IL-15 and
US8592567 The Trustees of the University of Pennsylvania Jan- May Nov
methods for using the same
06 -12 -13
17- 26-
1-Jul-
US8592391 Method for therapeutic, clinical and veterinary use poly-ICLC SALAZAR ANDRES Oct Nov
03
-08 -13
29- 18- 19-
US8586770 Unsaturated steroid compounds Harbor Therapeutics, Inc. Sep- Feb Nov
04 -11 -13
22- 21- 19-
Cells and methodology to generate non-segmented negative-strand
US8586364 Institut Pasteur Dec- Dec Nov
RNA viruses
06 -07 -13
10- 10- 19-
US8586363 TAL effector-mediated DNA modification Iowa State University Research Foundation, Inc. Dec- Dec Nov
09 -10 -13
26- 26- 12-
US8581584 Membrane proteins, mechanisms of action and uses thereof Florida State University Research Foundation May- May Nov
10 -11 -13
31- 30- 12-
US8580927 Engineered antibody constant domain molecules Jan- Jan Nov
08 -09 -13
27- 27- 12-
US8580268 Coley Pharmaceutical GmbH Sep- Sep Nov
06 -07 -13
1- 29- 29-
US8569283 Compounds and compositions as c-Kit kinase inhibitors LIU XIAODONG Sep- Aug Oct-
11 -12 13
1- 30- 22-
US8562996 RSV-specific binding molecules and means for producing them MedImmune Limited Jun- May Oct-
07 -08 13
8- 6- 22-
Quality control methods for oil-in-water emulsions containing
US8562943 Novartis AG Nov- Nov Oct-
squalene
06 -07 13
2- 2- 15-
System and method to predict the global spread of infectious agents
US8560339 Kamran Khan Apr- Apr Oct-
via commercial air travel
07 -08 13
28- 27- 15-
Synthetic apolipoprotein E mimicking polypeptides and methods of
US8557767 UAB Research Foundation Aug- Aug Oct-
use
07 -08 13
9- 9- 15-
US8557248 Methods and compositions for treating malaria Cyvax, Inc. Aug- Aug Oct-
10 -11 13
20- 16- 8-
US8552051 Use of pharmaceutical compositions containing mesembrenone H. L. Hall & Sons Limited Mar- Mar Oct-
09 -10 13
18- 16- 8-
US8552032 Bicyclic derivatives useful as inhibitors of DPP-1 Janssen Pharmaceutica NV Dec- Dec Oct-
09 -10 13
13- 13- 8-
US8551968 Methods for generation of antibodies National Jewish Health Mar- Mar Oct-
07 -08 13
19- 8-
11-
US8551756 Avian influenza chimeric VLPS Novavax, Inc. Jan Oct-
Jul-03
-10 13
23- 28- 8-
Device including bone cage and method for treatment of disease in
US8551750 The Invention Science Fund I, LLC Apr- Jul- Oct-
a subject
09 09 13
23- 23- 8-
Device including bone cage and method for treatment of disease in
US8551749 The Invention Science Fund I, LLC Apr- Apr Oct-
a subject
09 -09 13
11- 8-
21-
US8551738 Systems and methods for rapid identification of nucleic acid variants Ibis Biosciences, Inc. Nov Oct-
Jul-05
-09 13
28- 6- 8-
Treatment of tumors and viral diseases with recombinant interferon
US8551469 Superlab Far East Limited Feb- Oct Oct-
alpha
01 -08 13
5- 5- 1-
US8546432 Tetrazolones as inhibitors of fatty acid synthase Infinity Pharmaceuticals, Inc. May- May Oct-
10 -11 13
30- 25- 1-
US8546383 Chiral fused [1,2]imidazo[4,5-c] ring compounds 3M Innovative Properties Company Dec- May Oct-
04 -12 13
11- 25- 1-
US8546082 Methods for identification of sepsis-causing bacteria Ibis Biosciences, Inc. Sep- May Oct-
03 -07 13
24- 26- 24-
Compositions and methods using siRNA molecules for treatment of
US8541568 BIGNER DARELL D May- May Sep
gliomas
08 -09 -13
3- 5- 24-
Aminothiazole derivatives as human stearoyl-CoA desaturase
US8541457 Xenon Pharmaceuticals Inc. Jun- Jun Sep
inhibitors
05 -06 -13
18- 21- 24-
US8541438 3M Innovative Properties Company Jun- Dec Sep
04 -10 -13
21- 1- 24-
US8541221 Primate T-lymphotropic viruses Johns Hopkins University Feb- Jul- Sep
05 10 -13
Vectors expressing SARS immunogens, compositions containing 20- 21- 24-

US8541003 such vectors or expression products thereof, methods and assays Protein Sciences Corporation Jun- Jun Sep
for making and using 03 -04 -13

Decontaminating composition having simultaneously bactericidal, 29- 29- 10-
US8529968 fungicidal and virocidal properties, methods for obtaining and using Hightech Bio-Activities Holding GmbH Mar- Mar Sep
said composition 04 -05 -13
23- 22- 3-
Phenoxyacetic acid derivatives useful for treating respiratory
US8524715 Astrazeneca AB Nov- Nov Sep
diseases
04 -05 -13
10- 9- 3-
Methods and devices for determining a cell characteristic, and
US8524488 The Regents of the University of California Sep- Mar Sep
applications employing the same
02 -05 -13
18- 3-
20-
US8524241 Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A The General Hospital Corporation Jul- Sep
Jul-07
08 -13
13- 13- 27-
US8519106 Monoclonal human tumor-specific antibody University of Zurich Mar- Mar Aug
07 -08 -13
8- 7- 13-
National University Corporation, Hamamatsu University
US8507545 Cytotoxic T cell activator comprising EP4 agonist May- May Aug
School of Medicine
07 -08 -13
3- 13-
5-Jul-
US8507544 Bi-aryl amide compounds as CRTh2 receptor modulators Astrazeneca AB Jul- Aug
07
08 -13
4- 4- 13-
US8507455 Folate conjugates Alnylam Pharmaceuticals, Inc. Dec- Dec Aug
07 -08 -13
29- 28- 13-
US8506968 SARS vaccine compositions and methods of making and using them Eli Lilly and Company Jun- Dec Aug
00 -09 -13
22- 20- 13-
US8506966 Adjuvanted influenza vaccines for pediatric use Novartis AG Feb- Feb Aug
08 -09 -13
5- 4- 6-
US8501746 Organic compounds Novartis AG Jun- Jun Aug
06 -07 -13
7- 6-
3-Jul-
US8501699 Bicyclic nucleosides and nucleotides as therapeutic agents Biota Scientific Management Pty Ltd Sep Aug
08
-12 -13
10- 3- 6-
US8501461 System for performing multi-formatted assays Gen-Probe Incorporated Mar- Dec Aug
05 -09 -13
6- 28- 30-
US8497405 Process for dispersing vaporous hydrogen peroxide STERIS Inc. Mar- Feb Jul-
07 -13 13
28- 28- 30-
US8497112 Method for producing viral vaccines Baxter Healthcare SA Aug- Aug Jul-
07 -08 13
6- 10- 23-
Systems and methods for identifying replikin scaffolds and uses of
US8494781 BOGOCH ELENORE S Jun- Dec Jul-
said replikin scaffolds
03 -10 13
11- 23-
12-
US8492329 Bioactive peptides and methods of using same Compugen Ltd. Jul- Jul-
Jul-07
08 13
14- 14- 16-
US8486959 Dibenzo[f,h]isoquinoline derivatives National Health Research Institutes Jan- Jan Jul-
10 -11 13
23- 1- 16-
US8486678 Pharmaceutical compositions for the treatment of virus infection Kineta Two, LLC Nov- Feb Jul-
05 -12 13
Arrayed imaging reflectometry (air) sensor chip comprising 2- 1- 16-

US8486619 influenza hemagglutinin (HA) polypeptides suitable for the detection University of Rochester May- May Jul-
of antiviral immune responses 08 -09 13
15- 15- 16-

US8486420 Live virus vaccines Children's Hospital, Inc. Feb- Feb Jul-
05 -06 13
18- 16- 9-
Substituted benzothiazole and benzoxazole derivatives useful as
US8481547 Janssen Pharmaceutica NV Dec- Dec Jul-
inhibitors of DPP-1
09 -10 13
22- 21- 9-
Method for chromogenic detection of two or more target molecules
US8481270 Ventana Medical Systems, Inc. Aug- Aug Jul-
in a single sample
08 -09 13
25- 30- 9-
US8481255 Scytovirin domain 1 related polypeptides May- Sep Jul-
05 -11 13
Amide and carbamate derivatives of N-{2-[4-amino-2- 9- 8- 2-

US8476292 (ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1- 3M Innovative Properties Company Sep- Sep Jul-
dimethylethyl}methanesulfonamide and methods 05 -06 13
21- 20- 2-
US8476288 Salts 756 AstraZeneca AB May- May Jul-
09 -10 13
14- 2-
30-
US8476265 Compounds-801 AstraZeneca AB Sep Jul-
Jul-10
-12 13
14- 18- 25-
Method and medicament for inhibiting the infection of influenza
US8470771 Institute of Microbiology, Chinese Academy of Sciences Nov- Dec Jun-
virus
07 -07 13
18- 30- 25-
Method of treatment of bacterial infection by administration of poly-
US8470769 Novabiotics, Ltd. Aug- Nov Jun-
lysine
04 -11 13

10- 19- 25-
US8470346 Anti-viral pharmaceutical compositions Mast Therapeutics, Inc. Dec- May Jun-
03 -11 13
Industry-Academic Cooperation Foundation, Yonsei 13- 13- 25-
Recombinant SARS-CoV nsp12 and the use of thereof and the
US8470335 University Kookmin University Industry Academy Jun- Jun Jun-
method for producing it
Cooperation Foundation 08 -08 13
6- 5- 18-
Some 2-pyrazinone derivatives and their use as inhibitors of
US8466284 Astra Zeneca AB Nov- Nov Jun-
neutrophile elastase
07 -08 13
3- 27- 18-
US8466167 Compounds and compositions as TLR activity modulators IRM LLC Mar- Feb Jun-
08 -09 13
13- 12- 18-
RNA sequence motifs in the context of defined internucleotide
US8466124 Coley Pharmaceutical GmbH Aug- Jun Jun-
linkages inducing specific immune modulatory profiles
07 -12 13
12- 12- 18-
US8465751 Cnaâ€”B domain antigens in vaccines against gram positive bacteria Novartis AG Jan- Jan Jun-
09 -10 13
14- 13- 11-
US8461125 Compositions and methods to treat asthma The Children's Hospital of Philadelphia Feb- Aug Jun-
08 -10 13
9- 10- 11-
Decreasing potential iatrogenic risks associated with vaccines and
US8460914 Novartis AG Sep- Jan Jun-
vaccine antigens
04 -13 13
6- 20- 11-
US8460605 Decontaminant dispenser suitable for use as a projectile STERIS Inc. Mar- Feb Jun-
07 -08 13
30- 4-
31-
US8455483 Compoundsâ€”801 AstraZeneca AB Jul- Jun-
Jul-09
10 13
10- 22- 28-
US8450471 TAL effector-mediated DNA modification Iowa State University Research Foundation, Inc. Dec- Mar May
09 -12 -13
4- 14- 28-
US8450467 Carbohydrate conjugates as delivery agents for oligonucleotides Alnylam Pharmaceuticals, Inc. Dec- Dec May
07 -11 -13
5- 5- 28-
US8450350 Triazoles as inhibitors of fatty acid synthase Infinity Pharmaceuticals, Inc. May- May May
10 -11 -13
9- 6- 28-
Coiled-coil lipopeptide helical bundles and synthetic virus-like
US8450284 Universitaet Zuerich Dec- Dec May
particles
06 -07 -13
31- 25- 28-
The United States of America as Represented by the
US8450055 Malaria antigen screening method Aug- Aug May
Secretary of the Navy
05 -06 -13
25- 25- 21-
Mutant botulinum neurotoxin serotype A polypeptide and uses
US8445650 Thomas Jefferson University Sep- Sep May
thereof
07 -08 -13
7- 21-
B7-DC variants immunogenic compositions and methods of use 13-
US8445447 The Johns Hopkins University Mar May
thereof Jul-07
-12 -13
RNA virus infection inhibitor, method for inhibition of infection by 16- 16- 21-
US8444961 RNA virus, RNA virus infection-inhibiting product, and use as RNA Sekisui Chemical Co., Ltd. Jun- Jun May
virus infection inhibitor 09 -10 -13
16- 14-
17-
US8440704 Quercetin-containing compositions Quercegen Pharmaceuticals LLC Dec May
Jul-06
-09 -13
24- 11- 14-
US8440649 Phenanthroindolizidine analogues National Health Research Institutes Feb- Feb May
09 -10 -13
16- 1- 14-
US8440642 Boron-containing small molecules Anacor Pharmaceuticals, Inc. Feb- Sep May
05 -11 -13
10- 22- 14-
US8440432 Tal effector-mediated DNA modification Iowa State University Research Foundation, Inc. Dec- Mar May
09 -12 -13
10- 22- 14-
US8440431 TAL effector-mediated DNA modification Iowa State University Research Foundation, Inc. Dec- Mar May
09 -12 -13
29- 10- 14-
US8440408 Animal protein-free media for cultivation of cells Baxter Healthcare S.A. Oct- Dec May
04 -10 -13
8- 6- 7-
US8436178 Imidazoquinolines with immuno-modulating properties AstraZeneca AB May- May May
07 -08 -13
2- 1- 7-
US8436024 2-pyridone compounds Astrazeneca AB Oct- Oct May
09 -10 -13
24- 24- 30-
Microparticles containing biodegradable polymer and cationic
US8431160 Novartis AG Feb- Feb Apr-
polysaccharide for use in immunogenic compositions
06 -07 13
The United States of America as represented by the 31- 30-
Use of a pneumococcal P4 peptide for enhancing 31-
US8431134 Secretary of the Department of Health and Human Jul- Apr-
opsonophagocytosis in response to a pathogen Jul-08
Services, Centers for Disease Control and Prevention 09 13
30- 29- 23-
US8426565 Dendritic cell marker and uses thereof Walter and Eliza Hall Institute of Medical Research Aug- Aug Apr-
07 -08 13
1- 31- 16-
US8420798 Method for producing nucleic acid probes Ventana Medical Systems, Inc. Sep- Aug Apr-
06 -07 13

27- 27- 16-
US8420784 Interleukin 10 receptor, (IL-10R) antibodies Kyowa Hakko Kirin Co., Ltd. May- May Apr-
08 -09 13
4- 4- 16-
Cell-penetrating SOCS polypeptides that inhibit cytokine-induced
US8420096 Vanderbilt University Mar- Mar Apr-
signaling
04 -05 13
18- 16-
20-
US8420094 Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A The General Hospital Corporation Jul- Apr-
Jul-07
08 13
6- 21- 9-
US8415394 Astrazeneca AB Oct- Dec Apr-
disease
05 -11 13
9- 7- 9-
US8415361 Use of TAM receptor inhibitors as antimicrobials The Salk Institute for Biological Studies Nov- Nov Apr-
07 -08 13
1- 1- 9-
US8415330 Longhorn Vaccines & Diagnostics, LLC Oct- Oct Apr-
use
07 -12 13
11- 9-
1-Jul-
US8415309 Bicyclic nucleosides and nucleotides as therapeutic agents Biota Scientific Managment Pty Ltd Jan Apr-
09
-12 13
29- 29- 9-
US8415118 Porcine DC-SIGN, ICAM-3 and LSECtin and uses thereof Virginia Tech Intellectual Properties, Inc. Oct- Oct Apr-
07 -08 13
10- 10- 9-
Methods and computer systems for identifying target-specific
US8415102 NanoString Technologies, Inc. Apr- Apr Apr-
sequences for use in nanoreporters
07 -08 13

US8410149 compositions thereof, and methods for treating hemorrhagic fever Siga Technologies Inc. Dec- Oct Apr-
viruses, including infections associated with arenaviruses 04 -10 13
8- 6- 2-
2-pyrazinone derivatives for the treatment of disease or condition in
US8410114 AstraZeneca AB May- Jan Apr-
which inhibition of neutrophil elastase activity is beneficial
06 -12 13
21- 14- 2-
US8409589 Mutant forms of streptolysin O Novartis AG Dec- Sep Apr-
07 -11 13
12- 10- 19-
US8399651 Nucleic acids encoding GAS57 mutant antigens Novartis AG Sep- Sep Mar
07 -12 -13
29- 22- 19-
US8398992 Methods and compositions for polytopic vaccination Polytopos LLC Apr- Dec Mar
05 -11 -13
21- 26- 12-
US8394986 Phenoxiacetic acid derivatives AstraZeneca AB Aug- Jul- Mar
03 11 -13
11- 7- 12-
US8394945 Compositions for use in identification of bacteria Ibis Biosciences, Inc. Sep- Mar Mar
03 -07 -13
28- 27- 12-
Sequential delivery of immunogenic molecules via adenovirus and
US8394386 The Trustees of the University of Pennsylvania Apr- Apr Mar
adeno-associated virus-mediated administrations
04 -05 -13
20- 20- 9-
US7829712 Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase Xenon Pharmaceuticals Inc. Sep- Sep Nov
04 -05 -10
6- 5- 9-
US7829707 Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in therapy AstraZeneca AB Dec- Dec Nov
04 -05 -10
8- 7- 9-
US7829302 Method for detecting the specificity of activated lymphocyte HU JUN Dec- Dec Nov
03 -04 -10
3- 18- 26-
Methods and apparatus to prevent, treat, and cure the symptoms of
US7820210 Inhalation, Inc. Apr- Mar Oct-
nausea caused by chemotherapy treatments of human cancers
00 -08 10
25- 27- 12-

US7812135 GITR-binding antibodies TOLERRX, Inc. Mar- Mar Oct-
05 -06 10
18- 18- 28-
US7803918 Amsterdam Institute of Viral Genomics B.V. Aug- Aug Sep
03 -04 -10
22- 20- 28-
Homopiperazine compounds that inhibit ribosomal frameshifting by Sungkyunkwan University Foundation For Corporate
US7803796 Dec- Dec Sep
binding to RNA pseudoknot structure of SARS coronavirus Collaboration
06 -07 -10
20- 20- 28-
Methods of constructing biodiverse gene fragment libraries and
US7803765 Phylogica Limited Feb- Feb Sep
biological modulators isolated therefrom
04 -04 -10
30- 12- 21-
US7799800 Lipid-modified immune response modifiers 3M Innovative Properties Company Oct- Aug Sep
03 -04 -10
21- 24- 14-
US7794998 Primate T-lymphotropic viruses Johns Hopkins University Feb- Feb Sep
05 -07 -10
10- 10- 14-
US7794659 Signal measuring system having a movable signal measuring device Gen-Probe Incorporated Mar- Mar Sep
05 -06 -10
22- 25- 7-
US7790878 Alnylam Pharmaceuticals, Inc. Oct- Jun Sep
thereof
04 -09 -10

17- 6- 7-
US7790449 The Trustees of the University of Pennsylvania Dec- Sep Sep
containing the same, and uses therefor
01 -07 -10
15- 7-
Methods, combinations and kits for treating viral infections using 15-
US7790159 Board of Regents, The University of Texas System Aug Sep
immunoconjugates and antibodies to aminophospholipids Jul-02
-03 -10
13- 14- 31-
Double-stranded ribonucleic acid with increased effectiveness in an
US7786290 Alnylam Pharmaceuticals, Inc. Jun- Jun Aug
organism
03 -04 -10
24- 8- 31-
Human virus causing severe acute respiratory syndrome (SARS)
US7785775 Versitech Limited Mar- Jun Aug
and uses thereof
03 -07 -10
20- 19- 31-
US7785612 Polyamino acid for use as adjuvant Masanori Baba Apr- Apr Aug
05 -06 -10
27- 22- 24-
US7781226 Particle on membrane assay system The Board of Regents of the University of Texas System Feb- Dec Aug
04 -04 -10
29- 7- 24-
Supports for assaying analytes and methods of making and using
US7781203 Corning Incorporated Dec- Jun Aug
thereof
05 -06 -10
20- 20- 17-
US7777036 Heterocyclic derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. Sep- Sep Aug
04 -05 -10
26- 26- 17-
Bioinformatically detectable group of novel regulatory viral and viral
US7777022 Rosetta Genomics, Ltd. Nov- May Aug
associated oligonucleotides and uses thereof
02 -04 -10
US7776521 Coronavirus isolated from humans Secretary of the Department of Health and Human Apr- May Aug
5- 7- 3-
Water soluble boronic acid fluorescent reporter compounds and
US7767817 FANG HAO Sep- Sep Aug
methods of use thereof
03 -04 -10
20- 20- 3-
Heterocyclic derivatives and their use as stearoyl-CoA desaturase
US7767677 Xenon Pharmaceuticals Inc. Sep- Sep Aug
inhibitors
04 -05 -10
17- 9- 3-
US7767658 Vaccine composition Aventis Pasteur SA Nov- Jan Aug
03 -08 -10
16- 16- 3-
US7767657 Boron-containing small molecules Anacor Pharmaceuticals, Inc. Feb- Aug Aug
05 -06 -10
14- 14- 3-
US7767210 RNA virus vaccines and methods The Board of Regents of the University of Oklahoma Dec- Dec Aug
05 -06 -10
29- 27-
29-
US7763618 Pyridyl derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. Jul- Jul-
Jul-03
04 10
22- 24- 20-
Modified polymerases and attenuated viruses and methods of use
US7758868 The Penn State Research Foundation Dec- Dec Jul-
thereof
06 -07 10
9- 13-
30-
US7754711 Pyridazine derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. Feb Jul-
Jul-03
-05 10
25- 24- 6-
US7750123 Antibodies against SARS-CoV and methods of use thereof Dana Farber Cancer Institute, Inc. Nov- Nov Jul-
03 -04 10
2- 19- 6-
US7749445 Method and apparatus for analyzing bioprocess fluids BioScale, Inc. May- Dec Jul-
05 -06 10
16- 29-
17-
US7745486 Quercetin-containing compositions Quercegen Pharma LLC Jul- Jun-
Jul-06
07 10
20- 18- 29-
US7745442 Methods of reducing risk of infection from pathogens Parion Sciences, Inc. Aug- Aug Jun-
03 -04 10
12- 13- 29-
US7745147 Methods and uses of antibodies in the purification of interferon ViraNative AB Feb- Feb Jun-
05 -06 10
20- 21- 29-
US7745119 System for detecting polynucleotides Investigen, Inc. May- Nov Jun-
03 -05 10
8- 8- 29-
US7745118 Comparative genomic resequencing Roche Nimblegen, Inc. Apr- Apr Jun-
04 -05 10
8- 8- 22-
US7741450 Antibodies to GM-CSF Morphotek Inc. Feb- Feb Jun-
06 -07 10
26- 25- 22-
US7741360 Bi-aryl or aryl-heteroaryl substituted indoles AstraZeneca AB May- May Jun-
06 -07 10
21- 21- 22-
US7740858 SARS-CoV-specific B-cell epitope and applications thereof National Taiwan University Sep- Sep Jun-
04 -04 10
24- 22- 15-
US7737135 AstraZeneca AB Aug- Aug Jun-
disease
04 -05 10
2- 2- 15-
US7736850 Strain of SARS-associated coronavirus and applications thereof Centre National de la Recherche Scientifique Dec- Dec Jun-
03 -04 10

23- 17- 8-
US7732177 Oligoadenylate Synthetase (OAS) Illumigen Biosciences, Inc. Nov- Nov Jun-
05 -06 10
21- 19- 8-
US7731978 Mutant forms of streptolysin O Novartis AG Dec- Dec Jun-
07 -08 10
19- 21- 1-
US7728110 Antibodies to SARS coronavirus Amgen, Inc. May- May Jun-
06 -07 10
25- 19- 25-
US7725565 Georgetown University Feb- Nov May
communicating event related information
08 -08 -10
12- 12- 25-
US7723570 Edible vaccines expressed in soybeans SoyMeds, Inc. Oct- Oct May
04 -05 -10
12- 3- 25-
Assay for SARS coronavirus by amplification and detection of the
US7723041 Becton, Dickinson and Company Sep- Feb May
replicase sequence
03 -09 -10
20- 20- 25-
Compositions and methods for treatment of severe acute respiratory
US7722886 Wyeth May- May May
syndrome (SARS)
04 -04 -10
15- 11-
Combinations and kits for cancer treatment using selected 15-
US7714109 Board of Regents, The University of Texas System Aug May
antibodies to aminophospholipids Jul-02
-03 -10
27- 26- 11-
Methods and compositions for use in diagnosing and characterizing
US7713515 R.E.D. Laboratories N.V. May- May May
diseases involving abnormal apoptosis
03 -04 -10
18- 16- 4-
Substituted indole derivatives for pharmaceutical compositions for
US7709521 AstraZeneca AB Aug- Aug May
treating respiratory diseases
03 -04 -10
9- 3- 4-
US7709511 Benzothiazolone derivatives AstraZeneca AB Aug- Aug May
05 -06 -10
22- 13- 4-
US7709188 Multi-allelic detection of SARS-associated coronavirus Birch Biomedical Research LLC Aug- Aug May
03 -04 -10
19- 19- 20-
US7700782 Compounds 569 AstraZeneca AB Dec- Dec Apr-
07 -07 10
24- 24- 20-
Use of chimeric receptors in a screening assay for identifying
US7700728 Schering Corporation Mar- Mar Apr-
agonists and antagonists of cell receptors
05 -06 10
23- 27- 20-
US7700727 Compositions and kits for detecting pathogen infection Biokit, S.A. Dec- Apr Apr-
03 -05 10
Peptidomimetics that mimic a conformational-dependent 9- 11- 20-

The United States of America as represented by the
US7700273 neutralizing epitope of the human immunodeficiency virus (HIV) Apr- Apr Apr-
Department of Health and Human Services
CCR5 coreceptor 04 -05 10
15- 15- 20-

US7700120 New York Blood Center Jun- Jun Apr-
04 -05 10
2- 13-
3-Jul-
US7696406 Expression of a recombinant transgene Board of Trustees Operating Michigan State University Jul- Apr-
03
04 10
20- 13-
22-
US7696330 Binding molecules against SARS-coronavirus and uses thereof Crucell Holland B.V. Jan Apr-
Jul-03
-06 10
17- 16- 6-
US7691877 Pharmaceuticals Pfizer Inc. Feb- Feb Apr-
06 -07 10
Hazardous substance removing method, hazardous substance 28- 21- 6-

US7691646 removing material used therein such as air filter, mask, wipe sheet, Daikin Industries, Ltd. Mar- Nov Apr-
and the like, and storage method thereof 03 -08 10
2- 2- 6-
US7691599 Mammalian genes involved in viral infection and tumor suppression Zirus, Inc. May- May Apr-
02 -03 10
2- 19- 6-
US7691390 Viral protein CHANG MING-FU Mar- Sep Apr-
04 -07 10
27- 25- 30-
US7687535 Substituted 3-sulfur indoles AstraZeneca AB May- May Mar
03 -04 -10
16- 30-
9-Jul-
US7687475 RNA interference in respiratory epithelial cells University of Iowa Research Foundation Oct Mar
04
-07 -10
26- 20- 23-
Microporous materials, methods, and articles for localizing and
US7682688 University of Utah Research Foundation Nov- Nov Mar
quantifying analytes
02 -03 -10
16- 26- 16-
US7678774 Treating severe acute respiratory syndrome Hemispherx Biopharma May- Jan Mar
03 -07 -10
15- 16-
Liposomes coated with selected antibodies that bind to 15-
US7678386 Board of Regents the University of Texas Aug Mar
aminophospholipids Jul-02
-03 -10
19- 14- 9-
Fluorene derivatives, composition containing said derivatives and
US7674795 Aventis Pharma SA May- Nov Mar
the use thereof
05 -07 -10

10- 10- 2-
RNA-dependent DNA polymerase from Geobacillus
US7670807 East Tennessee State Univ. Research Foundation Mar- Mar Mar
stearothermophilus
04 -04 -10
31- 3- 2-
US7670565 Building decontamination with vaporous hydrogen peroxide Steris Inc Jan- Mar Mar
03 -08 -10
1- 1- 23-
US7666996 Casein derived peptides and uses thereof Peptera Pharmaceuticals Ltd Mar- Mar Feb
00 -04 -10
18- 17- 23-
Methods for concurrent identification and quantification of an
US7666592 Ibis Biosciences, Inc. Feb- Feb Feb
unknown bioagent
04 -05 -10
4- 2- 16-
3D-structure model of SARS coronavirus 3CL protease and anti- Shanghai Institute of Materia Medica, Chinese Academy of
US7662860 Jun- Dec Feb
SARS drugs Sciences
03 -05 -10
12- 12- 19-
US7648997 Hydroxylamine substituted imidazoquinolines Coley Pharmaceutical Group, Inc. Aug- Aug Jan-
03 -04 10
2- 2- 19-
Method and apparatus for detection of analyte using an acoustic
US7648844 BioScale, Inc. May- May Jan-
device
05 -06 10
14- 12-
22-
US7645881 Methods for treating hepatitis C PTC Therapeutics, Inc. Jul- Jan-
Jul-04
05 10
4- 3- 5-
US7642350 Purine derivatives Pfizer Limited May- May Jan-
05 -06 10
18- 20- 22-
US7636637 Variable length probe selection Roche NimbleGen, Inc. Jun- Jun Dec
04 -05 -09
23- 23- 22-
US7635557 Enzymatic diagnostic test for SARS and other viral diseases MND Diagnostic Ltd. Jun- Jun Dec
03 -04 -09
1- 17- 22-
The United States of America as represented by the
US7635485 Method of accelerated vaccination against Ebola viruses Aug- Jan Dec
Department of Health and Human Services
03 -06 -09
2- 2- 15-
Methods and apparatus for detecting viruses using an acoustic
US7632638 BioScale, Inc. May- May Dec
device
05 -06 -09
2- 8- 8-
Neutralizing monoclonal antibodies against severe acute respiratory
US7629443 New York Blood Center, Inc. Jun- Feb Dec
syndrome-associated coronavirus
04 -06 -09
29- 29- 8-
US7629385 Sphingolipid-derived pharmaceutical compositions Jado Technologies GmbH Jun- Jun Dec
04 -05 -09
2- 2- 8-
Methods and apparatus for detecting bacteria using an acoustic
US7629137 BioScale, Inc. May- May Dec
device
05 -06 -09
Method of collecting nasopharyngeal cells and secretions for 26- 20- 8-

US7629114 diagnosis of viral upper respiratory infections and screening for World Sense Technology Limited Aug- Aug Dec
nasopharyngeal cancer 03 -04 -09
15- 1-
Cancer treatment methods using selected immunoconjugates for 15-
US7625563 Board of Regents, The University of Texas System Aug Dec
binding to aminophospholipids Jul-02
-03 -09
28- 28- 1-
US7625492 Charge-based water filtration systems The University of Wyoming Research Corporation Jan- Jan Dec
03 -04 -09
28- 28- 1-
US7625428 Bioagent air filtration systems The University of Wyoming Research Corporation Jan- Jan Dec
03 -04 -09
6- 24-
Computer-implemented biological sequence identifier system and The United States of America as represented by the 2-Jul-
US7623997 Jun Nov
method Secretary of the Navy 04
-06 -09
16- 27- 24-
US7622559 Human monoclonal antibodies against interleukin 8 (IL-8) Genmab A/S Dec- Jun Nov
02 -07 -09
5- 5- 24-
US7622125 Polycistronic HIV vector constructs Novartis Vaccines and Diagnostics, Inc. May- May Nov
04 -05 -09
15- 24-
Cancer treatment methods using selected antibodies to 15-
US7622118 Board of Regents, The University of Texas System Aug Nov
-03 -09
5- 6- 24-
US7622112 Anti-SARS monoclonal antibodies Not Available Dec- Dec Nov
03 -04 -09
18- 17- 17-
US7619067 Evolved interferon-alpha polypeptides Maxygen, Inc. May- May Nov
05 -06 -09
19- 17-
Compositions of coronaviruses with a recombination-resistant 21-
US7618802 The University of North Carolina at Chapel Hill Jan Nov
genome Jul-03
-06 -09
10- 5- 17-
Proteome epitope tags and methods of use thereof in protein
US7618788 Millipore Corporation May- Feb Nov
modification analysis
02 -04 -09
19- 17-
21-
US7618635 Super-antigen fusion proteins and the use thereof Healthbanks Biotech Co., Ltd. Jul- Nov
Jul-04
05 -09
2- 2- 10-
Method and apparatus for detecting estradiol and metabolites
US7615381 BioScale, Inc. May- May Nov
thereof using an acoustic device
05 -06 -09

15- 10-
15-
US7615223 Selected immunoconjugates for binding to aminophospholipids Board of Regents, The University of Texas System Aug Nov
Jul-02
-03 -09
2- 2- 3-
Method and apparatus for therapeutic drug monitoring using an
US7611908 BioScale, Inc. May- May Nov
acoustic device
05 -06 -09
15- 3-
Compositions and methods for treating viral infections using 15-
antibodies and immunoconjugates to aminophospholipids Jul-02
-03 -09
29- 20-
30-
US7605161 Pyridyl derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. Jul- Oct-
Jul-03
04 09
10- 8- 20-
US7605135 Baicalin as a treatment for SARS infection The University of Hong Kong Nov- Nov Oct-
03 -04 09
15- 1- 20-
US7604960 Transient protein expression methods Crucell Holland B.V. Apr- Jun Oct-
99 -07 09
5- 16- 20-
US7604801 Methods for detecting parvovirus infections The Research Foundation of State University of New York May- Oct Oct-
03 -08 09
20- 13- 6-
US7598382 Aryl substituted imidazoquinolines Coley Pharmaceutical Group, Inc. Dec- Jan Oct-
02 -06 09
2- 2- 6-
Methods and apparatus for detecting cardiac injury markers using
US7598094 BioScale, Inc. May- May Oct-
an acoustic device
05 -06 09
9- 8- 6-
US7598072 Assay to detect viral uncoating Wisconsin Alumni Research Foundation Dec- Dec Oct-
03 -04 09
26- 26- 6-
US7597936 Method of producing a pigmented composite microporous material University of Utah Research Foundation Nov- May Oct-
02 -04 09
27- 10- 29-
US7595381 Method for detecting SARS coronavirus Eiken Kagaku Kabushiki Kaisha Jun- Jun Sep
03 -08 -09
27- 10- 29-
US7595163 Method for detecting SARS coronavirus Eiken Kagaku Kabushiki Kaisha Jun- Jun Sep
03 -08 -09
20- 20- 22-
Pyridazine-piperazine compounds and their use as stearoyl-CoA
US7592343 Xenon Pharmaceuticals Inc. Sep- Sep Sep
desaturase inhibitors
04 -05 -09
22- 14- 22-
US7592322 Alnylam Pharmaceuticals, Inc. Oct- Jun Sep
thereof
04 -05 -09
20- 11- 22-
The Board of Trustees of the University of Illinois, a body
US7592008 Membrane scaffold proteins Nov- Jan Sep
corporate and politic of the State of Illinois
00 -05 -09
20- 27- 15-
US7589092 Prodrugs of heteroaryl compounds Koronis Pharmaceuticals, Incorporated Jun- Dec Sep
03 -06 -09
28- 26- 8-
US7585647 Nucleic acid encoding recombinant interferon WEI GUANGWEN Aug- Aug Sep
03 -04 -09
17- 23- 1-
The Trustees of Columbia University In the City of New
US7582740 Methods and kits for detecting SARS-associated coronavirus Apr- Jan Sep
York
03 -04 -09
16- 16- 1-
US7582621 Boron-containing small molecules Anacor Pharmaceuticals, Inc. Feb- Feb Sep
05 -06 -09
31- 31- 25-
US7579396 Polymer composite Eastman Kodak Company Jan- Jan Aug
07 -07 -09
2- 1- 25-
US7579359 1-alkoxy 1H-imidazo ring systems and methods 3M Innovative Properties Company Sep- Sep Aug
04 -05 -09
9- 11- 11-
Detection, characterization and treatment of viral infection and
US7572621 Canadian Blood Services Apr- Oct Aug
methods thereof
03 -05 -09
15- 11-
Combined cancer treatment methods using selected antibodies to 15-
US7572448 Board of Regents, The University of Texas System Aug Aug
-03 -09
15- 11-
15-
US7572442 Selected antibody compositions for binding to aminophospholipids Board of Regents, The University of Texas System Jul- Aug
Jul-02
03 -09
Method for controlling SR protein phosphorylation, and antiviral 26- 24- 4-

US7569536 agents whose active ingredients comprise agents that control SR Masatoshi Hagiwara Dec- Dec Aug
protein activity 03 -04 -09
9- 8- 4-
US7569384 Albumin fusion proteins Human Genome Sciences, Inc. Feb- Aug Aug
04 -06 -09
13- 13- 23-
US7550140 Antibody to the human OX40 receptor Crucell Holland B.V. Jun- Jun Jun-
02 -03 09
20- 20- 16-
Bicyclic heterocyclic derivatives and their use as inhibitors of
US7547698 Xenon Pharmaceuticals Inc. Sep- Sep Jun-
stearoyl-coadesaturase (SCD)
04 -05 09
10- 10- 16-
Method for reducing the presence of amplification inhibitors in a
US7547516 Gen-Probe Incorporated Mar- Mar Jun-
reaction receptacle
05 -06 09

24- 24- 16-
High-throughput diagnostic assay for the human virus causing
US7547512 The University of Hong Kong Mar- Mar Jun-
severe acute respiratory syndrome (SARS)
03 -04 09
3- 1- 9-
US7544697 Pyrazolopyridines and analogs thereof Coley Pharmaceutical Group, Inc. Oct- Apr Jun-
03 -05 09
19- 4- 2-
US7541436 Interferon-alpha polypeptides and conjugates Maxygen, Inc. May- May Jun-
04 -07 09
19- 14- 2-
US7541163 Interferon-alpha polypeptides and conjugates Maxygen, Inc. May- Aug Jun-
04 -07 09
19- 13- 12-
US7531630 Interferon-alpha polypeptides and conjugates Maxygen, Inc. May- Sep May
04 -06 -09
19- 13- 12-
US7531324 Interferon-alpha polypeptides and conjugates Maxygen, Inc. May- Sep May
04 -06 -09
22- 7- 21-
US7521424 Albumin fusion proteins Human Genome Sciences, Inc. Jan- Jul- Apr-
03 05 09
12- 13- 21-
Assay for SARS coronavirus by amplification and detection of the
US7521185 Becton, Dickinson and Company Sep- Sep Apr-
replicase sequence
03 -04 09
29- 7-
30-
US7514436 Pyridazine derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. Jul- Apr-
Jul-03
04 09
15- 31-
Compositions comprising phosphatidylethanolamine-binding 15-
US7511124 Board of Regents, The University of Texas System Aug Mar
peptides linked to anti-viral agents Jul-02
-03 -09
10- 8- 17-
Yissum Research Development Company of the Hebrew
US7504384 Use of lipid conjugates in the treatment of infection Jan- Sep Mar
University of Jerusalem
00 -05 -09
6- 6- 17-
Protease inhibitors for coronaviruses and SARS-CoV and the use
US7504382 Cytovia, Inc. May- May Mar
thereof
03 -04 -09
17- 17- 17-
Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-
US7504205 The Burnham Institute May- May Mar
dependent kinase and a target for SARS therapy
04 -05 -09
18- 30- 17-
US7504097 Interferon-alpha polypeptides and conjugates Maxygen, Inc. Nov- Oct Mar
02 -06 -09
24- 23- 3-
US7498409 Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists Schering Corporation Mar- Mar Mar
05 -06 -09
18- 30- 3-
US7498152 Interferon-alpha polypeptides and conjugates Maxygen, Inc. Nov- Oct Mar
02 -06 -09
14- 24-
15-
US7495011 Anti-coronavirus drug aRigen Pharmaceuticals, Inc. Jul- Feb
Jul-03
04 -09
4- 3- 17-
US7491793 Influenza virus inhibiting peptides The Administrators of the Tulane Educational Fund Nov- Nov Feb
03 -04 -09
26- 17-
Artificial cpg single-stranded oligodeoxynucleotide and antiviral use 25-
US7491706 Changchun Huapu Biotechnology Co., Ltd. Jul- Feb
thereof Jul-03
04 -09
20- 15- 17-
Methods of generating chimeric adenoviruses and uses for such
US7491508 The Trustees of the University of Pennsylvania Jun- Jun Feb
chimeric adenoviruses
03 -04 -09
Synthetic peptide targeting critical sites on the SARS-associated 22- 28- 17-
US7491489 coronavirus spike protein responsible for viral infection and method The University of Hong Knog Nov- Oct Feb
of use thereof 04 -05 -09
9- 10- 17-
US7491397 Receptor binding polypeptides National Health Research Institutes Jan- Jan Feb
04 -05 -09
18- 30- 10-
US7488801 Interferon-alpha polypeptides and conjugates Maxygen, Inc. Nov- Oct Feb
02 -06 -09
18- 30- 10-
02 -06 -09
18- 30- 10-
02 -06 -09
27- 27- 3-
US7485432 Selective modulation of TLR-mediated biological activity 3M Innovative Properties Company Feb- Feb Feb
03 -04 -09
28- 12- 27-
US7482334 Therapeutic treatment methods Hollis-Eden Pharmaceuticals, Inc. Aug- Feb Jan-
02 -07 09
9- 9- 27-
Inhibition of SARS coronavirus infection with clinically approved
US7482149 Genome Institute of Singapore Jun- Jun Jan-
antiviral drugs
03 -04 09
25- 25- 20-
Peptides and peptidomimetics having immune-modulating, anti-
US7479484 Takeda Pharmaceutical Company Limited Jun- Jun Jan-
inflammatory, and anti-viral activity
03 -04 09
26- 25- 30-
Use of Ulinastatin and its pharmaceutical composition for treating
US7470666 Guangdong Techpool Biochem. Pharma. Co., Ltd. May- May Dec
severe acute respiratory syndrome
03 -04 -08

US7470548 removing material used therein such as air filter, mask, wipe sheet, Daikin Industries, Ltd. Mar- Mar Dec
and the like, and storage method thereof 03 -04 -08
29- 29- 23-

US7468418 Compositions for enhancing transport of molecules into cells AVI BioPharma., Inc. Apr- Apr Dec
03 -04 -08
16- 15- 16-
Hydrolytically-resistant boron-containing therapeutics and methods
US7465836 Anacor Pharmaceuticals, Inc. Jun- Jun Dec
of use
03 -04 -08
8- 8- 9-
Inhibitors of cysteine proteases, the pharmaceutical compositions
US7462615 Hybrigenics SA Dec- Dec Dec
thereof and their therapeutic applications
05 -05 -08
10- 13- 2-
Proteome epitope tags and methods of use thereof in protein
US7460960 Epitome Biosystems, Inc. May- Nov Dec
modification analysis
02 -03 -08
29- 25-
30-
US7456180 Piperazine derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. Jul- Nov
Jul-03
04 -08
15- 25-
Methods and compositions for treating viral infections using 15-
antibodies and immunoconjugates to aminophospholipids Jul-02
-03 -08
21- 23- 18-
US7452542 Live attenuated coronavirus vaccines Vanderbilt University May- May Nov
04 -05 -08
5- 5- 4-
US7445889 Methods for detecting parvovirus infections The Research Foundation of State University of New York May- May Nov
03 -04 -08
6- 4- 28-
US7442761 Replikin peptides and uses thereof BOGOCH ELENORE S Jun- Jun Oct-
03 -04 08
24- 28- 28-
US7442508 Methods for detection and production of influenza viruses Diagnostic Hybrids, Inc. Apr- Apr Oct-
98 -06 08
Method for preparation of large volume batches of poly-ICLC with 1- 21-

3-Jul-
US7439349 increased biological potency; therapeutic, clinical and veterinary Not Available Jul- Oct-
02
uses thereof 03 08
29- 10- 21-

US7439052 Method of making modified immunodeficiency virus particles Lipid Sciences Jun- Apr Oct-
00 -06 08
20- 28- 14-
Systems for detection and production of respiratory, herpes and
US7435588 Diagnostic Hybrids, Inc. Sep- Apr Oct-
enteric viruses
05 -06 08
8- 8- 14-
High throughput screening method of drug for physiologically active
US7435538 CellFree Sciences Co., Ltd. Sep- Sep Oct-
protein
03 -04 08
1- 1- 7-
US7432045 Method of inhibiting influenza infection with antiviral peptides Wisconsin Alumni Research Foundation Dec- Dec Oct-
03 -04 08
19- 14- 30-
Inhibition of SARS-associated coronavirus (SCoV) infection and
US7429656 The University of Hong Kong May- Jun Sep
replication by RNA interference
03 -06 -08
30- 29- 23-
Methods and kits for identifying target nucleotides in mixed
US7427479 Applera Corporation Apr- Apr Sep
populations
04 -05 -08
7- 9-
Computational method for identifying adhesin and adhesin-like 20-
US7424370 Council of Scientific and Industrial Research Feb Sep
proteins of therapeutic potential Jul-04
-05 -08
29- 20- 5-
US7407663 Modified immunodeficiency virus particles Lipid Sciences, Inc. Jun- Jun Aug
00 -03 -08
29- 21- 5-
Modified viral particles with immunogenic properties and reduced
US7407662 Lipid Sciences, Inc. Jun- Jun Aug
lipid content
00 -04 -08
Nebulizer formulations of dehydroepiandrosterone and methods of 17- 17- 29-

US7405207 treating asthma or chronic obstructive pulmonary disease using Epigenesis Pharmaceuticals, Inc. Jun- Jun Jul-
compositions thereof 02 -03 08
6- 27- 29-
US7405046 Compositions and methods for treatment of rhinovirus The Quigley Corporation Aug- Oct Jul-
01 -06 08
27- 15- 15-
US7399588 Method for detecting SARS coronavirus Eiken Kagaku Kabushiki Kaisha Jun- Jun Jul-
03 -04 08
4- 4- 8-
US7396914 SARS nucleic acids, proteins, antibodies, and uses thereof University of Massachusetts Aug- Aug Jul-
03 -04 08
14- 14- 1-
US7393856 Anti-viral uses of borinic acid complexes Anacor Pharmaceuticals, Inc. Jun- Jun Jul-
04 -05 08
1- 1-
1-Jul-
US7393638 Assay system and methods for detecting SARS-CV AsiaGEN Corporation Jul- Jul-
03
03 08
30- 30- 17-
US7387271 Immunostimulatory combinations 3M Innovative Properties Company Dec- Dec Jun-
02 -03 08

15- 10-
Anti-viral treatment methods using phosphatidylethanolamine- 15-
US7384909 Board of Regents, The University of Texas System Aug Jun-
binding peptides linked to anti-viral agents Jul-02
-03 08
15- 27-
Anti-viral treatment methods using phosphatidylethanolamine- 15-
US7378386 Board of Regents, The University of Texas System Aug May
binding peptide derivatives Jul-02
-03 -08
PCR primer set for detecting severe acute respiratory syndrome 12- 24- 20-
US7375210 (SARS)-Coronavirus, method and kit for detecting SARS- Samsung Electronics Co., Ltd. Dec- Nov May
Coronavirus using the same 03 -04 -08
24- 24- 20-

Human virus causing severe acute respiratory syndrome (SARS)
US7375202 The University of Hong Kong Mar- Mar May
and uses thereof
03 -04 -08
13- 12- 20-
Methods and compositions related to IRM compounds and Toll-like
US7375180 3M Innovative Properties Company Feb- Feb May
receptor 8
03 -04 -08
30- 30- 20-
Method and kit for the detection of a novel coronoavirus associated
US7374883 QIAGEN Diagnostics GmbH Apr- Apr May
with the severe acute respiratory syndrome (SARS)
03 -04 -08
20- 20- 13-
US7371850 Method and composition for reducing expression of ROCK-II Myriad Genetics, Inc. Aug- Aug May
03 -04 -08
16- 13-
21-
US7371837 Human virus causing respiratory tract infection and uses thereof The University of Hong Kong May May
Jul-04
-05 -08
28- 13-
Compositions and methods for diagnosing and treating severe acute 29-
US7371525 The Chinese University of Hong Kong Jul- May
respiratory syndrome (SARS) Jul-03
04 -08
22- 24- 22-
Isolation and characterization of the precursor virus of human SARS
US7361747 The University of Hong Kong May- May Apr-
virus: SARS-associated corona virus-like virus
03 -04 08
31- 29- 22-
US7361304 Building decontamination with vaporous hydrogen peroxide Steris Inc. Jan- Jan Apr-
03 -04 08
13- 12- 15-
US7358068 Antiviral oligonucleotides Replicor, Inc. Sep- Sep Apr-
02 -03 08
30- 30- 8-
Materials and methods for prevention and treatment of RNA viral
US7354908 University of South Florida Apr- Apr Apr-
diseases
02 -03 08
8- 8-
8-Jul-
US7354551 Room decontamination with hydrogen peroxide vapor Steris Inc Jul- Apr-
04
04 08
3- 27- 18-
Methods and apparatus to prevent, treat, and cure the symptoms of
US7344740 Inhalation, Inc. Apr- Nov Mar
nausea caused by chemotherapy treatments of human cancers
00 -04 -08
17- 15- 18-

US7344720 Vaccine composition Sanofi Pasteur SA Nov- Nov Mar
03 -04 -08
28- 26- 4-
Compositions and methods for the treatment of severe acute
US7339051 Isis Pharmaceuticals, Inc. Apr- Apr Mar
respiratory syndrome (SARS)
03 -04 -08
29- 26-
30-
US7335658 Pyridazine derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. Jul- Feb
Jul-03
04 -08
22- 19-
22-
US7332475 Preventive or therapeutic composition for viral infectious disease Kyowa Hakko Kogyo Co., Ltd. Jul- Feb
Jul-03
04 -08
17- 17- 19-
US7332294 CXCL10-based diagnosis and treatment of respiratory illnesses University Health Network Aug- Aug Feb
04 -04 -08
9- 22-
Characterization of the earliest stages of the severe acute 9-Jul-
US7320857 Chinese National Human Genome Center at Shanghai Jul- Jan-
respiratory syndrome (SARS) virus and uses thereof 04
04 08
19- 18- 15-
US7318918 Interferon-alpha polypeptides and conjugates Maxygen, Inc. May- May Jan-
04 -05 08
18- 19- 1-
US7314613 Interferon-alpha polypeptides and conjugates Maxygen, Inc. Nov- May Jan-
02 -04 08
22- 21- 25-
Compositions for use in identification of viral hemorrhagic fever
US7312036 ISIS Pharmaceuticals, Inc. Mar- Mar Dec
viruses
04 -05 -07
11- 20-
9-Jul-
US7297786 RNA interference in respiratory epitheial cells University of Iowa Research Foundation Jul- Nov
04
05 -07
20- 20- 6-
Methods of generating chimeric adenoviruses and uses for such
US7291498 The Trustees of the University of Pennsylvania Jun- Jun Nov
chimeric adenoviruses
03 -03 -07
16- 16- 16-
US7282568 Human monoclonal antibodies against interleukin 8 (IL-8) Genmab A/S Dec- Dec Oct-
02 -03 07
17- 25- 16-
US7282199 The Trustees of the University of Pennsylvania Dec- Apr Oct-
01 -03 07
24- 24- 11-
Diagnostic assay for the human virus causing severe acute
US7267942 The University of Hong Kong Mar- Mar Sep
respiratory syndrome (SARS)
03 -04 -07

7- 7- 28-
Production of silver sulfate grains using organo-sulfate or organo-
US7261867 Eastman Kodak Company Apr- Apr Aug
sulfonate additives
06 -06 -07
15- 24-
15-
US7247303 Selected antibody CDRs for binding to aminophospholipids Board of Regents, The University of Texas System Aug Jul-
Jul-02
-03 07
20- 31- 17-
US7244732 Prodrugs of heteroaryl compounds Koronis Pharmaceuticals, Incorporated Jun- Mar Jul-
03 -04 07
21- 21- 29-
Prenylation inhibitors reduce host cell permissiveness to viral
US7223787 Board of Regents, The University of Texas System Oct- Oct May
replication
03 -03 -07
US7220852 Coronavirus isolated from humans Secretary of the Department of Health and Human Apr- Apr May
11- 10- 27-
Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl
US7183300 AGARWAL ATUL Nov- Nov Feb
thiazole ureas and analogues thereof
04 -05 -07
6- 14- 23-
Compositions and methods for reducing the transmissivity of
US7166435 The Quigley Corporation Aug- Dec Jan-
illnesses
01 -04 07
7- 3- 16-
US7163947 1-Amino 1H-imidazoquinolines 3M Innovative Properties Company Mar- Sep Jan-
03 -04 07
28- 28- 19-
Antiviral agents for the treatment, control and prevention of
US7151163 Sequoia Pharmaceuticals, Inc. Apr- Apr Dec
infections by coronaviruses
03 -04 -06
20- 22- 19-
US7151091 Compositions and methods for preventing infection La Jolla Biosciences LLC Sep- Sep Dec
02 -03 -06
29- 26- 12-
Method of treating or inhibiting the development of brain
US7148248 NOZAKI MASAKO Nov- Nov Dec
inflammation and sepsis
02 -03 -06
19- 19- 31-
Inhibition of SARS-associated coronavirus (SCoV) infection and
US7129223 The University of HongKong May- May Oct-
replication by RNA interference
03 -04 06
3- 3- 31-
Compositions and methods for detecting severe acute respiratory
US7129042 Diagnostic Hybrids, Inc. Nov- Nov Oct-
syndrome coronavirus
03 -03 06
29- 29- 3-
US7115563 Composition and its therapeutic use Insignion Holding Limited May- May Oct-
02 -03 06
20- 18- 15-
US7091214 Aryl substituted Imidazoquinolines 3M Innovative Properties Co. Dec- Dec Aug
02 -03 -06
Methods and apparatus to prevent, treat and cure infections of the 3- 2- 23-
US7048953 human respiratory system by pathogens causing severe acute Inhalation, Inc. Apr- May May
respiratory syndrome (SARS) 00 -03 -06
28- 17- 4-
US7023593 Apparatus for forming nano-grating device Industrial Technology Research Institute Nov- Mar Apr-
03 -04 06
24- 30- 20-
US6946291 Mixed cell diagnostic systems Diagnostic Hybrids, Inc. Apr- Mar Sep
98 -04 -05
18- 4-
US20200176 METHODS AND DEVICES FOR NUCLEIC ACID-BASED REAL-TIME 19-
Not Available Jul- Jun-
079 DETERMINATION OF DISEASE STATES Jul-17
18 20
MICROSCOPIC BODY ENCLOSING METHOD, MICROSCOPIC BODY 29- 28- 4-

US20200173
DETECTION METHOD, AND MICROSCOPIC BODY DETECTION JAPAN SCIENCE AND TECHNOLOGY AGENCY Mar- Mar Jun-
925
DEVICE 17 -18 20
19- 13- 4-
US20200172 COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND
Not Available Nov- Sep Jun-
883 ACTIVITY, AND RELATED METHODS
09 -19 20
3- 2- 4-
US20200172
DHFR TUNABLE PROTEIN REGULATION Not Available Mar- Sep Jun-
879
17 -19 20
16- 4-
US20200172 15-
RSV F PROTEIN COMPOSITIONS AND METHOD FOR MAKING SAME GLAXOSMITHKLINE BIOLOGICALS, SA Aug Jun-
600 Jul-09
-17 20
12- 5- 4-
US20200172
DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS Hoffmann-La Roche Inc. Jun- Feb Jun-
513
16 -20 20
5- 4-
US20200172 CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC 12-
HANGZHOU DAC BIOTECH CO., LTD. Feb Jun-
480 AGENTS Jul-12
-20 20
19- 18- 4-
US20200171
Method of Treating Respiratory Tract Infection Not Available May- May Jun-
085
17 -18 20
26- 4-
US20200171 FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST 31-
Not Available Jan Jun-
060 FILOVIRUSES AND FLAVIVIRUSES Jul-17
-18 20
METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC 1- 30- 28-

US20200166 The U.S.A., as represented by the Secretary, Department
ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING Sep- Jan May
505 of Health and Human Services
NEODYMIUM MAGNETS 15 -20 -20
7- 6- 28-
US20200165 ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR
Spark Therapeutics, Inc. Jun- Jun May
632 rAAV VECTOR PRODUCTION
17 -18 -20

29- 28- 28-
US20200165
COMPOSITIONS FOR THE TREATMENT OF DISEASE Not Available Apr- Apr May
630
16 -17 -20
1- 31- 28-
US20200165
VIRUS LIKE PARTICLE The University of Leeds Jun- May May
613
17 -18 -20
6- 28-
US20200165 7-Jul-
CRISPR SYSTEM BASED ANTIVIRAL THERAPY MASSACHUSETTS INSTITUTE OF TECHNOLOGY Jul- May
594 17
18 -20
27- 28-
US20200165 27-
NEW CHIMERIC ENZYMES AND THEIR APPLICATIONS Not Available Jul- May
585 Jul-17
18 -20
2- 21- 28-
US20200165 CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF
Not Available Dec- Oct May
357 USE THEREOF
05 -19 -20
18- 11- 28-
US20200164
MICROSPOTTING DEVICE Not Available Apr- Oct May
334
12 -19 -20
15- 5- 28-
US20200164
Methods and Compositions for Inhibiting Akt3 Not Available Jan- Feb May
067
16 -20 -20
27- 27- 28-

US20200164 TRIMERIC S1-CD40L FUSION PROTEIN VACCINE AGAINST MIDDLE
King Abdulaziz University Nov- Nov May
058 EAST RESPIRATORY SYNDROME-CORONAVIRUS
18 -18 -20
12- 12- 28-

US20200164
PUM 1 PROTEIN AS TARGET FOR VIRUS INHIBITION Not Available Apr- Apr May
020
17 -17 -20
26- 26- 28-
US20200163
LIPID NANOPARTICLE MRNA VACCINES Not Available Oct- Oct May
878
16 -17 -20
19- 19- 21-
US20200157 METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME
Not Available Nov- Nov May
600 AMPLIFICATION
18 -18 -20
29- 29- 21-
US20200157
ANTI-PD-L1 ANTIBODIES AND USES THEREOF Not Available Mar- Mar May
222
18 -19 -20
30- 28- 21-
US20200157
ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES Not Available Jun- Jan May
221
16 -20 -20
30- 30- 21-

US20200155 ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS
Not Available Sep- Jan May
704 CONTAINING SAME, AND USES THEREFOR
03 -20 -20
22- 26- 21-

US20200155
MODIFIED VIRUS-LIKE PARTICLES OF CMV Not Available Oct- Nov May
699
14 -19 -20
24- 21-
US20200155 27-
VACCINE COMPOSITIONS Not Available Jan May
667 Jul-17
-20 -20
10- 26- 21-
US20200155
INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE Not Available Feb- Jun May
664
09 -19 -20
26- 25- 21-
US20200155 COMBINATION IMMUNOTHERAPIES COMPRISING IL-15
Not Available May- May May
662 SUPERAGONISTS
17 -18 -20
23- 22- 21-
US20200155 COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER
Not Available Sep- Nov May
660 NANOPARTICLE DELIVERY
15 -19 -20
8- 7- 21-
US20200155 EV576 For Use in the Treatment of Viral Infections of the
Volution Immuno Pharmaceuticals SA Jan- Jun May
646 Respiratory Tract
10 -19 -20
13- 14-
US20200149 14-
ENGINEERED TSC2 Not Available Jul- May
062 Jul-17
18 -20
22- 22- 14-
US20200149
Transbiotic Regulation of Bacterial Gene Expression Not Available May- May May
048
17 -18 -20
16- 10- 14-
US20200148
ANTIBODIES AND PROCESSES FOR PREPARING THE SAME Not Available May- Oct May
749
08 -19 -20
26- 10- 14-
US20200147
VACCINATION OF IMMUNOCOMPROMISED SUBJECTS Not Available Sep- Jan May
203
14 -20 -20
2- 2- 14-
US20200147 COMPOSITIONS AND METHODS FOR TUMOR VACCINATION AND
Not Available Jun- Jun May
193 IMMUNOTHERAPY INVOLVING HER ANTIGENS
17 -18 -20
COMPOSITIONS OF CRACC FUSIONS AND METHODS FOR 18- 18- 14-

US20200147
MODULATING AN IMMUNE RESPONSE AGAINST CANCERS, Not Available Sep- Sep May
171
INFECTIONS DISEASES AND DISORDERS 18 -19 -20
26- 25- 7-
US20200140 MULTIFUNCTIONAL ANTIBODY-LIGAND TRAPS TO MODULATE
547 IMMUNE TOLERANCE
17 -18 -20
26- 25- 7-
US20200140
Engineering Virus-like Nanocarriers for Biomolecule Delivery Not Available Oct- Oct May
493
18 -19 -20
13- 6- 7-
US20200140
HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS AZIENDA OSPEDALIERA UNIVERSITARIA SENESE Feb- Jan May
398
15 -20 -20

2- 1- 7-
US20200138
Genetically Attenuated Nucleic Acid Vaccine Not Available Jun- Jun May
937
17 -18 -20
2- 1- 7-
US20200138
Phenotypically Wild-Type and Genetically Attenuated Viruses Not Available Jun- Jun May
936
17 -18 -20
7- 6- 7-
US20200138 METHODS OF TREATING PAIN AND/OR INFLAMMATORY DISORDERS
818 USING LAPATINIB
18 -19 -20
METHODS FOR TREATING PULMONARY EMPHYSEMA USING

14- 19- 7-
US20200138 SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC
Not Available Mar- Dec May
780 ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF
13 -19 -20
CATHEPSIN C
14- 14- 30-

US20200131 CONTROL OF TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES
Not Available Mar- Mar Apr-
518 PRODUCED IN CELL CULTURE
17 -18 20
30- 29- 30-
US20200129
CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND TAIHO PHARMACEUTICAL CO., LTD. Jun- Jun Apr-
487
17 -18 20
22- 31- 23-
US20200127
RNA TARGETING METHODS AND COMPOSITIONS Salk Institute for Biological Studies Aug- Dec Apr-
954
17 -18 20
ACCURATE, RAPID AND CONVENIENT SINGLE-STEP DISEASE 13- 13- 23-

US20200124
DIAGNOSTIC METHOD USING SELF-AMPLIFICATION PRINCIPLE OF CELLEMEDY CO., LTD Apr- Apr Apr-
599
DETECTION SIGNAL 17 -18 20
AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE 5- 1- 23-

US20200123
PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME Ablynx N.V. Jun- Aug Apr-
233
FOR THE TREATMENT OF VIRAL DISEASES 08 -19 20
22- 18- 23-

US20200123
Inhibition Of TCR Signaling With Peptide Variants Not Available Oct- Dec Apr-
205
18 -19 20
13- 13- 23-
US20200123
COMPOSITIONS COMPRISING CURONS AND USES THEREOF FLAGSHIP PIONEERING INNOVATIONS V, INC. Jun- Jun Apr-
203
17 -18 20
26- 22- 16-

US20200115 CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND
Not Available Apr- Oct Apr-
448 CHIMERIC STIMULATING RECEPTORS AND USES THEREOF
17 -19 20
23- 29- 16-

US20200115 ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES
Not Available Oct- Oct Apr-
434 THEREOF
15 -19 20
23- 21- 16-
US20200113 CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS
Not Available Jun- Jun Apr-
996 ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSES
17 -18 20
26- 26- 16-
US20200113
PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTS Not Available May- May Apr-
967
17 -17 20
16- 16-
US20200113 LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA 6-Jul-
GLAXOSMITHKLINE BIOLOGICALS SA Dec Apr-
831 MOLECULES 11
-19 20
31- 16- 16-
US20200113 PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING
GLAXOSMITHKLINE BIOLOGICALS S.A. Aug- Dec Apr-
830 RNA
11 -19 20
12- 18- 9-
US20200109
IN VIVO DELIVERY OF OLIGONUCLEOTIDES Not Available Dec- Dec Apr-
403
11 -19 20
6- 22- 9-
US20200108
METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES Not Available Apr- Nov Apr-
136
07 -19 20
3- 3- 2-
US20200102 TRANSKINGDOM PLATFORM FOR THERAPEUTIC NUCLEIC ACID
Not Available Apr- Oct Apr-
558 DELIVERY
17 -19 20
10- 28- 2-
US20200102
TAL EFFECTOR-MEDIATED DNA MODIFICATION Not Available Dec- Aug Apr-
550
09 -19 20
POXVIRUS-PLASMODIUM RECOMBINANTS, COMPOSITIONS 30- 11- 2-

US20200102
CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND Not Available Dec- Sep Apr-
544
METHODS OF MAKING AND USING THE SAME 13 -19 20
6- 5- 2-
US20200102 TUMOR NECROSIS FACTOR RECEPTOR (TNFR) BINDING PROTEIN
Not Available Apr- Apr Apr-
362 COMPLEX WITH IMPROVED BINDING AND BIOACTIVITY
17 -18 20
10- 2-
US20200102 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS 3-Jul-
Not Available Jul- Apr-
292 AND USES THEREOF 13
19 20
1- 22- 2-
US20200101 ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE
158 THEREOF
15 -19 20
6- 6- 2-
US20200101
MVA-BN AND AD26.ZEBOV OR AD26.FILO PRIME-BOOST REGIMEN Not Available Apr- Apr Apr-
153
17 -18 20
12- 12- 2-
US20200101
PDE5 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY Not Available Jun- Jun Apr-
142
17 -18 20

27- 26- 2-
US20200101
METHODS OF TREATMENT OF INFECTIONS USING BACTERIA Not Available Sep- Sep Apr-
119
18 -19 20
3- 21- 2-
US20200101
PHARMACEUTICAL COMPOSITIONS AND METHODS Not Available Aug- Nov Apr-
087
15 -19 20
31- 31- 2-
US20200100
TRAIT SELECTION IN AVIANS Not Available May- May Apr-
480
17 -18 20
30- 30- 26-
US20200095 ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE
Not Available Mar- Mar Mar
324 THEREOF
17 -18 -20
20- 18- 26-
US20200093
MODIFIED PEDV SPIKE PROTEIN Not Available Sep- Sep Mar
919
18 -19 -20
19- 19- 26-

US20200093 PLASMODIUM SPOROZOITE NPDP PEPTIDES AS VACCINE AND
Not Available Apr- Apr Mar
909 TARGET NOVEL MALARIA VACCINES AND ANTIBODIES BINDING TO
17 -18 -20
11- 3- 26-
US20200093 ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC
Not Available Sep- Jun Mar
855 OXIDE
17 -19 -20
17- 30- 26-
US20200093
Broad Spectrum Antiviral and Methods of Use Not Available Apr- Apr Mar
841
06 -19 -20
22- 19-
US20200087 PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM 14-
Not Available Nov Mar
655 OXIDES Jul-15
-19 -20
31- 31- 19-
US20200087 OPTIMIZED HUMAN CLOTTING FACTOR IX GENE EXPRESSION
Not Available May- May Mar
646 CASSETTES AND THEIR USE
17 -18 -20
10- 25- 19-
US20200087
INFLUENZA VIRUS AND TYPE 1 DIABETES Istituto Zooprofilattico Sperimentale delle Venezie Oct- Jul- Mar
630
12 19 -20
10- 27- 19-
US20200087 The United States of America,as represented by the
GRIFFITHSIN MUTANTS Feb- Nov Mar
359 Secretary,Department of Health and Human Services
15 -19 -20
25- 19-
US20200087 29-
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available Apr Mar
313 Jul-11
-19 -20
1- 27- 19-
US20200087 Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted
Not Available Mar- Feb Mar
298 Benzamide Groups
17 -18 -20
5- 25- 19-
US20200087 QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-
Not Available Feb- Nov Mar
280 SPECIFIC PROTEASE 7 INHIBITORS
15 -19 -20
30- 27- 19-
US20200086
DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTION Not Available Jun- Dec Mar
324
16 -18 -20
7- 25- 19-
US20200085 APPARATUS, METHOD AND SYSTEM FOR SELECTIVELY AFFECTING THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
Mar- Nov Mar
984 AND/OR KILLING A VIRUS NEW YORK
11 -19 -20
7- 14- 19-
US20200085
VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER Not Available Sep- May Mar
947
12 -19 -20
PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC 31- 29- 19-

US20200085
CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR CureVac AG Jan- Aug Mar
943
PEPTIDE ANTIGEN 12 -19 -20
19- 19- 19-

US20200085
IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS Not Available Apr- Apr Mar
872
17 -18 -20
5- 5- 19-
US20200085
EPIDERMAL MRNA VACCINE Not Available Aug- Aug Mar
852
15 -16 -20
14- 12- 19-
US20200085 NANOPARTICLE VACCINE ADJUVANT AND METHODS OF USE
Not Available Sep- Jul- Mar
756 THEREOF
18 19 -20
11- 19- 12-
US20200080 METHODS AND COMPOSITIONS FOR ENRICHMENT OF
Not Available Dec- Nov Mar
141 AMPLIFICATION PRODUCTS
13 -19 -20
18- 19- 12-
US20200080 Methods for Autocatalytic Genome Editing and Neutralizing
Not Available Sep- Sep Mar
111 Autocatalytic Genome Editing and Compositions Thereof
15 -16 -20
20- 20- 12-
US20200079 DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A
Hangzhou DAC Biotech Co., Ltd. Apr- Apr Mar
820 CELL BINDING MOLECULE
16 -16 -20
Substituted 2,4 diamino-quinoline as new medicament for fibrosis, 5- 1- 12-

US20200079
autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related Not Available Sep- Aug Mar
781
diseases 18 -19 -20
1- 1- 12-
US20200078
COMPOSITIONS AND METHODS TO REDUCE PATHOGENESIS Not Available May- May Mar
335
17 -18 -20
5- 2- 5-
US20200072 MEDIA ELABORATED WITH NEWLY SYNTHESIZED ANTIBODIES
Not Available May- Apr Mar
836 (MENSA) AND USES THEREOF
14 -19 -20
30- 29- 5-
US20200071
RNA-BASED DELIVERY SYSTEMS WITH LEVELS OF CONTROL Not Available Aug- Aug Mar
723
18 -19 -20

20- 8- 5-
US20200071
BISPECIFIC ANTIBODY Not Available Nov- Apr Mar
421
13 -19 -20
6- 6- 5-
US20200069
CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE Hangzhou DAC Biotech Co., Ltd. Apr- Apr Mar
814
17 -17 -20
17- 17- 27-
US20200062 ALKYL PYRROLOPYRIMIDINE ANALOGS AND METHODS OF MAKING
Not Available Nov- Nov Feb
764 AND USING SAME
16 -17 -20
12- 4- 27-
US20200061
METHODS FOR PREPARING SQUALENE Not Available May- Nov Feb
187
10 -19 -20
25- 25- 27-
US20200061
PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE The Scripps Research Institute Oct- Oct Feb
185
16 -17 -20
9- 11- 27-
US20200060 CATIONIC NANOPARTICLES FOR ENHANCING INFECTIOUS
Not Available Dec- Dec Feb
981 CAPACITY OF LIVE VIRUSES
16 -17 -20
8- 25- 20-
US20200056 METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING
Not Available Nov- Oct Feb
221 ADSORPTION MEDIA
13 -19 -20
28- 27- 20-
US20200056 NOVEL ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND
Not Available Feb- Feb Feb
159 USES THEREFOR
17 -18 -20
8- 25- 20-
US20200055 MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA
Not Available Sep- Oct Feb
927 AND VIRAL INFECTION
16 -19 -20
8- 25- 20-
16 -19 -20
7- 15- 20-
US20200054 IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE
Not Available Jan- Jul- Feb
731 THEREOF
14 19 -20
9- 7- 20-
US20200054
DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY St. Jude Children's Research Hospital Dec- Dec Feb
660
16 -17 -20
17- 16- 20-
US20200054
HIGH DENSITY ANALOG MULTIPEXING EnLiSense, LLC Aug- Aug Feb
259
18 -19 -20
METHODS FOR REAL-TIME MULTIPLEX ISOTHERMAL DETECTION 8- 24- 13-

US20200048
AND IDENTIFICATION OF BACTERIAL, VIRAL, AND PROTOZOAN Not Available May- Aug Feb
722
NUCLEIC ACIDS 15 -19 -20
13- 13- 13-

US20200048
VIRUS-LIKE PARTICLES AND USES THEREOF Not Available Mar- Mar Feb
649
17 -18 -20
18- 13-
US20200048 6-Jul-
IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA GLAXOSMITHKLINE BIOLOGICALS SA Oct Feb
636 10
-19 -20
29- 22- 13-
US20200046 DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC
Not Available Dec- Aug Feb
865 CAVITATION
17 -19 -20
27- 4- 13-
US20200046 METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST
Academia Sinica Mar- Jun Feb
826 VIRUS
09 -19 -20
15- 2- 13-
US20200046
SPECIFIC AKT3 INHIBITOR AND USES THEREOF Not Available Jan- Oct Feb
692
16 -19 -20
8- 6- 6-
US20200040 HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID
Not Available Feb- May Feb
408 IDENTIFICATION
16 -19 -20
30- 29- 6-
US20200040
CHIMERIC MOLECULES AND USES THEREOF Not Available Mar- Mar Feb
042
17 -18 -20
DEVICES, PROCESSES, AND SYSTEMS FOR DETERMINATION OF

29- 29- 6-
US20200038 NUCLEIC ACID SEQUENCE, EXPRESSION, COPY NUMBER, OR
Not Available Mar- Mar Feb
871 METHYLATION CHANGES USING COMBINED NUCLEASE, LIGASE,
17 -18 -20
POLYMERASE, AND SEQUENCING REACTIONS
9- 16- 6-
US20200038
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available May- May Feb
373
12 -19 -20
6- 14- 30-
US20200033 EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS
Not Available Oct- Oct Jan-
343 INFECTIONS AND DISEASES
08 -19 20
26- 6- 30-
US20200032 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
Not Available Jan- Mar Jan-
255 OR OTHER DISEASES
07 -19 20
4- 30- 30-
US20200031
NOVEL DEPSIPEPTIDES AND USES THEREOF Not Available Apr- Mar Jan-
871
17 -18 20
23- 26- 30-
US20200031
COMPOSITIONS AND METHODS FOR INHIBITING KINASES Not Available Apr- Jun Jan-
819
15 -19 20
17- 8- 30-
US20200030 Lipidated Immune Response Modifier Compound Compositions,
Not Available Aug- Jul- Jan-
441 Formulations, and Methods
10 19 20

17- 16- 30-
US20200030
ZOONOTIC DISEASE RNA VACCINES ModernaTX, Inc. Mar- Mar Jan-
432
17 -18 20
9- 15- 30-
US20200030
COMBINATION OF VACCINATION AND OX40 AGONISTS CureVac AG Sep- Apr Jan-
422
16 -19 20
30- 29- 23-

US20200024 NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH
Not Available Mar- Mar Jan-
616 ENHANCED HUMAN PANCREATIC TROPISM
18 -19 20
3- 1- 23-
US20200024
NOVEL DEPSIPEPTIDE AND USES THEREOF Not Available Dec- Aug Jan-
310
12 -19 20
8- 7- 16-
US20200020 Method for Establishing Machine Learning Model for Predicting
Not Available Dec- Dec Jan-
420 Toxicity of siRNA to Certain Type of Cells and Application Thereof
16 -17 20
7- 28- 16-
US20200017 CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN
Not Available Nov- Aug Jan-
926 MICROBIOME AND COMPONENTS THEREOF
13 -19 20
COMPOSITIONS FOR REPROGRAMMING CELLS INTO DENDRITIC 5- 5- 16-

US20200017
CELLS OR ANTIGEN PRESENTING CELLS, METHODS AND USES Not Available Apr- Apr Jan-
832
THEREOF 17 -18 20
14- 16- 16-

US20200017
MODULAR TETRAVALENT BISPECIFIC ANTIBODY PLATFORM Not Available Oct- Oct Jan-
588
16 -17 20
23- 22- 16-
US20200017 SELF-ASSEMBLING PROTEIN NANOPARTICLES WITH BUILT-IN SIX-
554 HELIX BUNDLE PROTEINS
17 -18 20
12- 16-
US20200017 ADAMANTANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS 12-
Not Available Jul- Jan-
514 INFECTION Jul-18
18 20
CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- 24- 19- 16-

US20200017
OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 Not Available Jan- Mar Jan-
455
INHIBITORS 14 -19 20
10- 24- 16-

US20200016
LOADING VIALS Not Available Nov- Sep Jan-
589
11 -19 20
12- 16-
US20200016 Production of Immune-Response-Stimulating Aerosols By Non- 13-
286 Thermal Plasma Treatment Of Airborne Pathogens Jul-18
19 20
29- 9- 16-
US20200016
Compositions For Enhancing Transport Of Molecules Into Cells Not Available Apr- Apr Jan-
280
03 -19 20
24- 22- 16-
US20200016
METHODS FOR TREATING VIRAL DISORDERS TRUSTEES OF BOSTON UNIVERSITY Sep- Jul- Jan-
161
09 19 20
9- 7- 9-
US20200010 METHODS AND COMPOSITIONS FOR ENRICHMENT OF
Not Available Oct- Jun Jan-
883 AMPLIFICATION PRODUCTS
15 -19 20
10- 9- 9-
US20200010 NUCLEASE FUSIONS FOR ENHANCING GENOME EDITING BY
519 HOMOLOGY-DIRECTED TRANSGENE INTEGRATION
17 -18 20
13- 13- 9-
US20200009 NANOPARTICLE VACCINES WITH NOVEL STRUCTURAL
Not Available Jun- Jun Jan-
244 COMPONENTS
18 -19 20
18- 16- 2-
US20200002
ERYTHROID CELLS COMPRISING PHENYLALANINE HYDROXYLASE Not Available Nov- Sep Jan-
674
13 -19 20
10- 2-
US20200000 SYNTHETIC NANOPARTICLES FOR DELIVERY OF 15-
Not Available Apr Jan-
931 IMMUNOMODULATORY COMPOUNDS Jul-16
-19 20
1- 10- 26-
US20190391
COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMES Not Available May- Sep Dec
150
15 -19 -19
1- 19- 26-
US20190390
BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEM Longhorn Vaccines and Diagnostics, LLC Oct- Jun Dec
249
07 -17 -19
21- 20- 26-
US20190390
GENE EDITING REAGENTS WITH REDUCED TOXICITY Not Available Apr- Apr Dec
229
16 -17 -19
12- 12- 26-
US20190390
SYNTHETIC REVERSE TRANSCRIPTASES AND USES THEREOF Not Available Apr- Apr Dec
179
16 -17 -19
2- 3- 26-
US20190390 NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH
Not Available Dec- Jul- Dec
176 ENHANCED HUMAN SKELETAL MUSCLE TROPISM
15 19 -19
26- 29- 26-

US20190389
ANTIVIRAL COMPOUNDS AND METHODS Biotron Limited Jun- Aug Dec
816
03 -19 -19
1- 30- 26-
US20190388
METHODS AND COMPOSITIONS FOR IMMUNOMODULATION Not Available Apr- Aug Dec
473
14 -19 -19
27- 19- 19-
US20190382
VIRAL METHODS OF MAKING GENETICALLY MODIFIED CELLS Not Available Oct- Apr Dec
799
16 -19 -19

4- 25- 19-
US20190382 GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF
THE UNIVERSITY OF NOTTINGHAM Apr- Jul- Dec
433 FOR USE IN THERAPY
14 19 -19
9- 9- 19-
US20190381
HYBRID CARRIERS FOR NUCLEIC ACID CARGO Not Available Jun- Jun Dec
180
16 -17 -19
28- 27- 19-
US20190381 PAN FILOVIRUS VACCINE COMPOSITIONS AND METHODS OF
Not Available Mar- Mar Dec
162 MAKING
16 -17 -19
22- 29- 19-
US20190381 COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1
CureVac AG Feb- Aug Dec
155 PATHWAY
13 -19 -19
2- 3- 19-
US20190380
PREVENTION AND TREATMENT OF VIRAL INFECTIONS Not Available Jun- Jul- Dec
995
16 19 -19
12- 28- 19-
US20190380
MOBILE CLINICS Baylor College of Medicine Nov- Aug Dec
891
14 -19 -19
4- 8- 12-
US20190376 MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS
Not Available Apr- Feb Dec
151 AND USE THEREOF FOR DETECTING NUCLEIC ACIDS
12 -19 -19
18- 23- 12-

US20190376 PLATELETS COMPRISING EXOGENOUS POLYPEPTIDES AND USES
Not Available Nov- Aug Dec
034 THEREOF
13 -19 -19
9- 8- 12-
US20190375 HSP FUSION PROTEIN WITH ANTI-CHEMOREPELLANT AGENT FOR
Not Available Sep- Sep Dec
801 TREATMENT OF INFECTIOUS DISEASE
16 -17 -19
22- 21- 12-

US20190374 COMPOSITIONS AND METHODS FOR DELIVERY OF
Not Available Feb- Feb Dec
650 POLYMER/BIOMACROMOLECULE CONJUGATES
17 -18 -19
20- 20- 12-

US20190374 MEDICAL USE OF INTERFERON-LAMBDA FOR THE TREATMENT OF
Not Available Dec- Dec Dec
610 FIBROSIS
16 -17 -19
27- 19- 12-
US20190374
VIRAL METHODS OF T CELL THERAPY Not Available Oct- Apr Dec
576
16 -19 -19
1- 1- 5-
US20190370 SYSTEM FOR DETERMINING PUBLIC SENTIMENT TOWARDS
Not Available Jun- Jun Dec
834 PATHOGENS
18 -18 -19
27- 26- 5-
US20190367 COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE
Not Available Oct- Apr Dec
553 RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1
17 -19 -19
30- 19- 5-
US20190367 PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC
525 PROTEASE 7 INHIBITORS
14 19 -19
13- 5-
HANGZHOU DAC BIOTECH CO., LTD. Aug Dec
453 AGENTS Jul-12
-19 -19
21- 13- 5-
US20190365
AAV VECTORS TARGETED TO THE CENTRAL NERVOUS SYSTEM Not Available Nov- Jun Dec
925
14 -19 -19
4- 3- 5-
US20190365
PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS Not Available Jun- Jun Dec
756
18 -19 -19
25- 25- 28-
US20190359
VIRAL SYNTHETIC NUCLEIC ACID SEQUENCES AND USE THEREOF Not Available Jan- Jan Nov
990
17 -18 -19
ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND 5- 18- 28-

US20190359
PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 Not Available Feb- Jul- Nov
635
INHIBITORS 15 19 -19
5- 18- 28-
US20190359 THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7
Not Available Feb- Jul- Nov
629 INHIBITORS
15 19 -19
12- 12- 28-
US20190358 STOMACH ACID-STABLE AND MUCIN-BINDING PROTEIN-POLYMER
Not Available Jan- Jan Nov
335 CONJUGATES
17 -18 -19
19- 19- 28-
US20190358
ANTIGEN-ADJUVANT COUPLING REAGENTS AND METHODS OF USE Not Available Dec- Dec Nov
312
17 -18 -19
ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2)

OR ANGIOTENSIN-(1-7)-BIOENCAPSULATED IN PLANT CELLS 18- 29- 28-
US20190358
ATTENUATES PULMONARY HYPERTESNIONS, CARDIAC Not Available Oct- May Nov
304
DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND 13 -19 -19
EXPOERIMENTALLY INDUCED OCULAR DISORDERS
19- 12- 28-

US20190358
Lipids and Lipid Compositions for the Delivery of Active Agents Not Available Dec- Aug Nov
170
13 -19 -19
10- 12- 21-
US20190352
GENOME EDITING REAGENTS AND THEIR USE Not Available Feb- Feb Nov
639
17 -18 -19
22- 21- 21-
US20190352
METHOD FOR PURIFYING VIRUS Not Available Dec- Dec Nov
615
16 -17 -19

16- 30- 21-
US20190352 CD137 ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING
Not Available Sep- Jan Nov
608 LYMPHOCYTE SELECTION
13 -19 -19
7- 7- 21-
US20190352 HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT
Colorado State University Research Foundation Nov- Aug Nov
357 PROTEIN-PROTEIN INTERACTIONS
14 -19 -19
6- 28- 14-
Not Available Oct- Jun Nov
08 -19 -19
30- 26- 14-
US20190345
ARTIFICIAL NUCLEIC ACID MOLECULES CureVac AG Dec- Jul- Nov
504
14 19 -19
20- 15- 14-
US20190345
CIRCULAR RNAS AND THEIR USE IN IMMUNOMODULATION Not Available Jun- Jun Nov
503
16 -17 -19
5- 14-
US20190345 PURIFICATION OF NUCLEIC ACIDS USING METAL-TITANIUM 14-
Not Available Jul- Nov
481 OXIDES Jul-15
19 -19
9- 9- 14-
US20190345 BROAD SPECTRUM VACCINE, PREPARING METHOD AND
Tianjin Dongya Biological Technology Co., Ltd. May- May Nov
221 APPLICATION THEREOF
18 -18 -19
1- 24- 14-
US20190345 COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7
Not Available May- Jul- Nov
166 AGONISTS
14 19 -19
16- 14-
US20190343 6-Jul-
DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS GLAXOSMITHKLINE BIOLOGICALS, SA Jul- Nov
862 10
19 -19
13- 5- 7-
US20190337 POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC
Not Available Feb- Jun Nov
990 PROTEINS AND THEIR USE IN GENE THERAPY
15 -19 -19
19- 27- 7-
US20190336
PARALLELIZED SAMPLE HANDLING Not Available Apr- Mar Nov
969
13 -19 -19
9- 9- 7-
US20190336
HYBRID CARRIERS FOR NUCLEIC ACID CARGO CureVac AG Jun- Jun Nov
611
16 -17 -19
9- 9- 7-
US20190336
CATIONIC CARRIERS FOR NUCLEIC ACID DELIVERY CureVac AG Jun- Jun Nov
608
16 -17 -19
8- 17- 7-
US20190336 METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE
Not Available Jan- May Nov
597 RESPONSES
13 -19 -19
13- 7-
US20190336 USE OF XIBORNOL AS ACTIVE AGENT IN THE TREATMENT OF VIRAL 15-
ABIOGEN PHARMA S.P.A. Jul- Nov
456 INFECTIONS Jul-16
17 -19
1- 22- 31-
US20190330 ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF
Not Available Dec- Jan Oct-
618 LARGE LIBRARIES
05 -19 19
8- 21- 31-
US20190330
CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF Not Available Sep- Jun Oct-
572
16 -19 19
16- 12- 31-
US20190330
Boron-Containing Small Molecules Anacor Pharmaceuticals, Inc. Feb- Jul- Oct-
245
05 19 19
18- 10- 31-
US20190330
Chemical Compounds Not Available Mar- May Oct-
187
14 -19 19
28- 31-
US20190330 HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND 29-
Not Available Nov Oct-
164 USES THEREOF Jul-11
-18 19
9- 31-
HANGZHOU DAC BIOTECH CO., LTD. May Oct-
149 AGENTS Jul-12
-19 19
10- 10- 31-
US20190328 IMMUNOTHERAPEUTIC PRODUCT AND MDSC MODULATOR
Transgene SA Oct- Oct Oct-
869 COMBINATION THERAPY
16 -17 19
17- 31-
US20190328 IMMUNOGENIC COMPOSITION FOR MERS CORONAVIRUS 28-
865 INFECTION Jul-14
-17 19
28- 15- 31-
US20190328
AAV Vectors Targeted to Oligodendrocytes Not Available Sep- Jul- Oct-
804
12 19 19
12- 28- 24-
US20190323 PCR Ready Compositions and Methods for Screening Biological
Longhorn Vaccines and Diagnostics, LLC Sep- Jun Oct-
068 Samples
06 -19 19
24- 25- 24-
US20190322
PRODUCTION OF VIRUSES IN CELL CULTURE Not Available Nov- Jan Oct-
989
15 -19 19
13- 2- 24-
US20190322 COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY
Not Available May- Jul- Oct-
725 CONSTRUCTS AND USES THEREOF
14 19 19
11- 9- 24-
US20190321 IMMUNOMODULATORY COMPOSITIONS, PROCESSES FOR MAKING
NantBio, Inc. Nov- Nov Oct-
481 THE SAME, AND METHODS FOR INHIBITING CYTOKINE STORMS
16 -17 19
2- 30- 24-
US20190321 ENGINEERED B CELLS AND RELATED COMPOSITIONS AND
Juno Therapeutics, Inc. Dec- Nov Oct-
403 METHODS
16 -17 19

17- 10- 17-
US20190316 COMPOSITION COMPRISING A GENE VECTOR THAT SELECTIVELY
Not Available Apr- Jun Oct-
109 DEPLETES P16 POSITIVE SENESCENT CELLS
12 -19 19
18- 30- 17-
US20190316
ERYTHROID CELLS COMPRISING ARGINASE Not Available Nov- May Oct-
091
13 -19 19
18- 30- 17-
US20190316
ERYTHROID CELLS COMPRISING ARGININE DEIMINASE RUBIUS THERAPEUTICS, INC. Nov- May Oct-
090
13 -19 19
18- 10- 17-
US20190316
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available Nov- May Oct-
089
13 -19 19
16- 10- 17-
US20190315 ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING
Not Available Sep- Jun Oct-
840 VARIANT FC REGIONS, AND METHODS OF USE
16 -19 19
26- 17-
US20190315 VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR 27-
Not Available Jul- Oct-
807 INDUCING THE EXPRESSION OF ANTIBODIES Jul-16
17 19
1- 18- 17-
US20190314 POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN
CureVac AG Apr- Jun Oct-
496 IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT
14 -19 19
6- 30- 17-
US20190314
Vaccines Including Antigen From Four Strains of Influenza Virus Not Available Dec- Nov Oct-
483
06 -18 19
28- 21- 17-
US20190314 VACCINES AGAINST INFECTIOUS DISEASES CAUSED BY POSITIVE
Medigen, Inc. Nov- Nov Oct-
482 STRANDED RNA VIRUSES
16 -17 19
25- 23- 17-
US20190314
IMMUNOGENIC COMPOSITIONS AND USES THEREOF Not Available Mar- Apr Oct-
480
15 -19 19
2- 27- 17-
US20190314
MOLECULAR VACCINES FOR INFECTIOUS DISEASE Not Available Oct- Jun Oct-
471
08 -19 19
3- 7- 17-
US20190314 CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE
Not Available Aug- Jun Oct-
455 AND INFECTIOUS DISEASES
17 -19 19
5- 25- 17-
US20190314
PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS Not Available Dec- Mar Oct-
372
16 -19 19
4- 10-
US20190310 AIRBORNE AGENT COLLECTORS, METHODS, SYSTEMS AND 22-
Not Available Mar Oct-
168 DEVICES FOR MONITORING AIRBORNE AGENTS Jul-14
-19 19
9- 25- 10-
US20190309
CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS MASSACHUSETTS INSTITUTE OF TECHNOLOGY Dec- Feb Oct-
357
16 -19 19
18- 4- 10-
US20190309
ERYTHROID CELLS COMPRISING SERINE DEHYDRATASE Not Available Nov- Jun Oct-
262
13 -19 19
18- 4- 10-
US20190309
ERYTHROID CELLS COMPRISING LYSINE OXIDASE Not Available Nov- Jun Oct-
261
13 -19 19
6- 20- 10-
US20190309 Optimized Human Clotting Factor VIII Gene Expression Cassettes
Not Available Feb- May Oct-
048 and Their Use
15 -19 19
29- 22- 10-
US20190309
CRYPTIC POLYPEPTIDES AND USES THEREOF Not Available Jan- Apr Oct-
039
15 -19 19
30- 24- 10-
US20190308 PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-
Not Available Dec- Jun Oct-
14 -19 19
11- 13- 10-
US20190308
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS Not Available Nov- Nov Oct-
969
16 -17 19
17- 13- 10-

US20190308 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL)
Parion Sciences, Inc. Dec- Mar Oct-
943 PYRAZINE-2- CARBOXAMIDE COMPOUNDS
12 -19 19
20- 10- 10-

US20190307
IMMUNE COMPLEX The Rockefeller University Mar- May Oct-
878
15 -19 19
21- 20- 10-
US20190307 ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF INFECTIONS
Not Available Oct- Oct Oct-
722 LINKED TO CORONAVIRUSES
16 -17 19
4- 4- 3-
US20190298 ALBUMIN-BINDING IMMUNOMODULATORY COMPOSITIONS AND THE UNITED STATES OF AMERICA, as represented by the
May- May Oct-
824 METHODS OF USE THEREOF Secretary, Department of Health and Human Serv
16 -17 19
27- 26- 3-
US20190298 METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE
Invirsa, Inc. Mar- Mar Oct-
752 (ADPR)
18 -19 19
11- 21- 3-
US20190298 Nucleotide and Nucleoside Therapeutic Compositions and Uses
Not Available Sep- Nov Oct-
750 Related Thereto
13 -18 19
19- 19- 26-
US20190293
NON-RADIOACTIVE CYTOTOXICITY ASSAYS Not Available Sep- Sep Sep
656
16 -17 -19
23- 22- 26-
US20190292 DNA LOGIC-GATED PROXIMITY ASSEMBLY CIRCUIT FOR
Rutgers, The State University of New Jersey Mar- Mar Sep
580 BIOCHEMICAL SENSING
18 -19 -19

17- 8- 26-
US20190292 ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES,
The Trustees of the University of Pennsylvania Dec- Apr Sep
563 VECTORS CONTAINING SAME, AND USES THEREFOR
01 -19 -19
SCALABLE METHODS FOR PRODUCING RECOMBINANT ADENO- 1- 1- 26-

US20190292
ASSOCIATED VIRAL (AAV) VECTOR IN SERUM-FREE SUSPENSION SPARK THERAPEUTICS, INC. Dec- Dec Sep
561
CELL CULTURE SYSTEM SUITABLE FOR CLINICAL USE 15 -16 -19
9- 9- 26-
US20190292
MODULATION OF IFI16 AND STING ACTIVITY Not Available Aug- Aug Sep
236
16 -17 -19
3- 19- 26-
US20190292
Cyclic Di-Nucleotide Induction of Type I Interferon Not Available May- Feb Sep
216
13 -19 -19
11- 26- 26-
US20190292 HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER
Dana-Farber Cancer Institute, Inc. Apr- Jan Sep
178 VIRUSES
12 -18 -19
2- 31- 26-
US20190290
Composition for Promoting Production of Immunostimulatory Factor Kyoto University Aug- Jul- Sep
674
16 17 -19
24- 24- 19-
US20190285
METABALOMICS AND VIRAL DIAGNOSTICS SUITE Excision Biotherapeutics, Inc. May- May Sep
632
16 -17 -19
21- 30- 19-
US20190284
REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS Not Available May- Jan Sep
575
09 -19 -19
15- 24- 19-
US20190284 DETECTION OF T CELL EXHAUSTION OR LACK OF T CELL
Not Available May- May Sep
531 COSTIMULATION AND USES THEREOF
15 -19 -19
29- 22- 19-
US20190284
ASSEMBLED GLYCOPROTEINS Not Available Sep- Sep Sep
230
16 -17 -19
14- 30- 19-
US20190282 IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND
AUTOIMMUNE TECHNOLOGIES, LLC Mar- May Sep
694 METHODS
13 -19 -19
1- 29- 19-
US20190282
Method Of Treating Inflammation Not Available Apr- May Sep
608
10 -19 -19
2- 5- 12-
US20190276
COMPOSITION AND METHODS OF TREATING B CELL DISORDERS Not Available Sep- Sep Sep
523
16 -17 -19
8- 8- 12-
US20190275
SYSTEM FOR THE PRODUCTION OF CELLS AND/OR CELL PRODUCTS Not Available Nov- Nov Sep
519
16 -17 -19
5- 5- 12-
US20190275 STRUCTURE OF GII.4 NOROVIRUS PROTEASE - DESIGN OF BROAD-
Not Available Oct- Oct Sep
101 SPECTRUM PROTEASE INHIBITORS
16 -17 -19
8- 11- 5-
US20190269
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS Not Available Mar- Oct Sep
694
11 -18 -19
15- 20- 5-
US20190269
Specific Akt3 Inhibitor and Uses Thereof Not Available Jan- May Sep
672
16 -19 -19
24- 29-
US20190264 25-
PHASING Wave Life Sciences Ltd. Jul- Aug
267 Jul-16
17 -19
18- 10- 29-
US20190264
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available Nov- May Aug
177
13 -19 -19
26- 25- 29-
US20190263 FC VARIANTS WITH ENHANCED BINDING TO FCRN AND
Not Available Jan- Jan Aug
934 PROLONGED HALF-LIFE
18 -19 -19
18- 7- 29-
US20190262
Cationic Oil-In-Water Emulsions GLAXOSMITHKLINE BIOLOGICALS, SA Sep- Mar Aug
448
11 -19 -19
20- 20- 29-
US20190262 METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL
Not Available Oct- Oct Aug
371 INFECTIONS
16 -17 -19
ANTIBODY SPECIFICALLY BINDING TO AN ISOLATED PEPTIDE 10- 10- 22-

US20190256
DERIVED FROM VIMENTIN OR A FRAGMENT BINDING TO THE Not Available Jun- Jun Aug
585
PEPTIDE 15 -16 -19
24- 3- 22-
US20190256 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS The U.S.A., as represented by the Secretary, Department
Feb- May Aug
579 IMMUNOGENS, ANTIBODIES, AND THEIR USE of Health and Human Services
15 -19 -19
16- 1- 22-
US20190255 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE
Not Available Sep- Feb Aug
085 VIRUS INFECTIONS
15 -19 -19
2- 22-
US20190254 6-Jul-
OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS GLAXOSMITHKLINE BIOLOGICALS S.A. May Aug
968 11
-19 -19
20- 19- 15-
US20190250 MULTI-CONFIGURABLE SENSING ARRAY AND METHODS OF USING
Board of Regents, The University of Texas System Oct- Oct Aug
153 SAME
16 -17 -19
16- 20- 15-
US20190248
HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) Not Available Dec- Feb Aug
883
02 -19 -19
30- 30- 15-
US20190248 POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF
Not Available Jun- Apr Aug
866 AUTOIMMUNE DISORDERS AND INFECTION
11 -18 -19

23- 21- 15-
865 THEREOF
15 -16 -19
29- 23- 15-
US20190247 METHOD AND SYSTEM FOR DECONTAMINATING SMALL
Not Available Dec- Apr Aug
529 ENCLOSURES
17 -19 -19
20- 16- 15-
US20190247 ADJUVANTED INFLUENZA B VIRUS VACCINES FOR PEDIATRIC
Not Available Oct- Nov Aug
489 PRIMING
11 -18 -19
14- 23- 15-
US20190247
Dimethyl Fumarate and Vaccination Regimens Biogen MA Inc. Mar- Apr Aug
485
14 -19 -19
1- 12- 15-
US20190247
METHODS AND COMPOSITIONS FOR IMMUNOMODULATION Not Available Apr- Apr Aug
440
14 -19 -19
26- 23- 15-
US20190247
TREATMENT OF INFECTIOUS DISEASES CHILDREN'S MEDICAL CENTER CORPORATION Jan- Apr Aug
367
15 -19 -19
15- 15- 8-
US20190241 ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE
Not Available Mar- Apr Aug
646 TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTION
17 -19 -19
30- 22- 8-
US20190241
INHIBITION OF TCR SIGNALING WITH PEPTIDE VARIANTS Not Available Sep- Oct Aug
618
09 -18 -19
22- 28- 8-
US20190240
HPIV3 RNA VACCINES ModernaTX, Inc. Oct- Mar Aug
317
15 -19 -19
28- 25- 1-
US20190233 PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PARAFFIN
Not Available Aug- Feb Aug
447 EMBEDDED TISSUE USING CAGED HAPTENS
15 -19 -19
23- 20- 1-
US20190232
METHODS AND COMPOSITIONS FOR DETECTING ANALYTES Not Available Sep- Sep Aug
282
16 -17 -19
17- 13- 1-
US20190231
MASK NBC MESHTEC INC. Oct- Oct Aug
004
16 -17 -19
GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING 28- 30- 25-
US20190225
LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA Not Available Oct- Nov Jul-
986
VIRUS SPIKE PROTEIN 05 -18 19
10- 4- 25-
US20190225 METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA
Not Available Aug- Aug Jul-
971 MOLECULE
15 -16 19
29- 28- 25-
US20190224
COMPOSITIONS FOR THE TREATMENT OF DISEASE Not Available Apr- Apr Jul-
339
16 -17 19
13- 25-
US20190223 14-
ANTIMICROBIAL GEOPOLYMER COMPOSITIONS Not Available Jul- Jul-
445 Jul-16
17 19
16- 29- 18-
US20190220 DETERMINING EXPLANATIONS FOR PREDICTED LINKS IN
Not Available Jan- Mar Jul-
524 KNOWLEDGE GRAPHS
18 -18 19
16- 17- 18-
US20190219
Assay for Detecting TH1 and TH2 Cell Populations Not Available May- Dec Jul-
563
14 -18 19
2- 28- 18-
US20190218
METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR The Trustees of the University of Pennsylvania Oct- Mar Jul-
574
07 -19 19
16- 15- 18-
US20190218 ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING
Not Available Sep- Sep Jul-
277 VARIANT FC REGIONS, AND METHODS OF USE
16 -17 19
17- 17- 18-
US20190218 3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide
207 Derivatives and Their Use as PAK or NAMPT Modulators
15 -16 19
21- 1- 18-
US20190216 METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED
CureVac AG Aug- Apr Jul-
951 PROTEINS
13 -19 19
22- 28- 18-
US20190216
HMPV RNA VACCINES ModernaTX, Inc. Oct- Mar Jul-
917
15 -19 19
2- 15- 18-
US20190216
TRANSGENIC VERO-CD4/CCR5 CELL LINE Not Available Oct- Feb Jul-
915
15 -19 19
20- 20- 18-
US20190216 Regimens and Compositions for AAV-Mediated Passive
Not Available Apr- Mar Jul-
841 Immunization of Airborne Pathogens
11 -19 19
13- 27- 11-
US20190211
COMPOSITIONS COMPRISING CURONS AND USES THEREOF Not Available Jun- Mar Jul-
361
17 -19 19
DNA MOLECULES PRODUCING CUSTOM DESIGNED REPLICATING 5- 4- 11-

US20190211
AND NON-REPLICATING NEGATIVE STRANDED RNA VIRUSES AND Not Available Jan- Jan Jul-
355
USES THERE OF 15 -16 19
19- 19- 11-

US20190211
SMALL MOLECULES HAVING ANTIVIRAL PROPERTIES General Research Laboratory Aug- Aug Jul-
024
16 -17 19

2- 12- 11-
US20190209 MANUFACTURE OF SURFACTANT-CONTAINING COMPOSITIONS
Not Available Dec- Mar Jul-
678 WITH ENHANCED STABILITY
14 -19 19
3- 2- 11-
US20190209
OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. Jun- Jun Jul-
604
16 -17 19
22- 31- 4-
US20190207
RNA TARGETING METHODS AND COMPOSITIONS Salk Institute for Biological Studies Aug- Dec Jul-
890
17 -18 19
28- 19- 4-
US20190204 APPLICATION OF CLICK CHEMISTRY FOR SIGNAL AMPLIFICATION
Not Available Jun- Dec Jul-
330 IN IHC AND ISH ASSAYS
16 -18 19
2- 31- 4-
US20190203 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) BASED
Not Available Jan- Dec Jul-
268 ASSAY FOR DETECTING MICROBES
18 -18 19
24- 25- 4-
US20190203
PRODUCTION OF VIRUSES IN AVIAN EGGS Not Available Nov- Jan Jul-
186
15 -19 19
5- 21- 4-
US20190203
Avian Cells for Improved Virus Production Not Available Jun- Dec Jul-
170
13 -18 19
COMPOSITIONS AND METHODS FOR IDENTIFICATION, 20- 20- 4-

US20190202
ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING Not Available Sep- Sep Jul-
929
USP10 BIOMARKERS AND MODULATORS 16 -17 19
7- 15- 4-
US20190202
CORONAVIRUS PROTEINS AND ANTIGENS Phibro Animal Health Corporation Feb- Mar Jul-
868
14 -19 19
4- 8- 4-
US20190202
ENANTIOMERS OF THE 1',6'-ISOMER OF NEPLANOCIN A Not Available Aug- Mar Jul-
854
14 -19 19
29- 11- 4-
Not Available Dec- Sep Jul-
565 CAVITATION
17 -18 19
29- 29- 4-
Not Available Dec- Dec Jul-
564 CAVITATION
17 -17 19
28- 28- 4-
US20190201
Aptamer Compositions and Methods of Use Thereof Not Available Dec- Dec Jul-
552
17 -18 19
7- 5- 4-
US20190201 2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR
Atea Pharmaceuticals, Inc. Sep- Mar Jul-
433 RNA VIRUS TREATMENT
16 -19 19
30- 12- 4-
US20190201 DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER
Not Available Jan- Mar Jul-
352 NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY
15 -19 19
3- 3- 4-
US20190201 HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE
Not Available Dec- Jan Jul-
337 ADJUVANTS
09 -19 19
24- 24- 27-
US20190194
Systemic inflammatory and pathogen biomarkers and uses therefor Not Available Aug- Aug Jun-
728
16 -17 19
5- 4- 27-
US20190194
METHOD AND KIT FOR DETECTING PATHOGENIC MICROORGANISM JAPAN SCIENCE AND TECHNOLOGY AGENCY Sep- Sep Jun-
717
16 -17 19
1- 1- 27-
US20190194
METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION Takeda Pharmaceutical Company Limited Sep- Sep Jun-
628
16 -17 19
3- 3- 27-
US20190194 IDENTIFICATION OF VSIG3/VISTA AS A NOVEL IMMUNE
BIO-TECHNE CORPORATION Aug- Aug Jun-
322 CHECKPOINT AND USE THEREOF FOR IMMUNOTHERAPY
16 -17 19
25- 19- 27-

US20190194 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS
Not Available Apr- Nov Jun-
299 NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
14 -18 19
26- 1- 27-
US20190194 FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS SUBSTITUTED
Not Available Aug- Aug Jun-
226 WITH GUANIDINO GROUPS
16 -17 19
30- 27-
US20190194 1-Jul-
COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION Arrakis Therapeutics, Inc. Jun Jun-
150 16
-17 19
11- 11- 27-
US20190192
REGULATED BIOCIRCUIT SYSTEMS Not Available Apr- Apr Jun-
691
16 -17 19
4- 1- 27-
US20190192
Methods of Populating a Gastrointestinal Tract Not Available Feb- Aug Jun-
581
13 -18 19
6- 7- 20-
US20190187 ASSAY FOR QUANTITATION OF PROTEINS AND PEPTIDES USING
UVic Industry Partnerships Inc. Jun- Apr Jun-
151 STABLE ISOTOPE STANDARDS
16 -17 19
28- 19- 20-
US20190187 COLORS FOR CHROMOGENIC IHC AND ISH STAINING WITH MULTI-
Not Available Jun- Dec Jun-
130 DYE QUINONE METHIDE AND TYRAMIDE CONJUGATES
16 -18 19
5- 20- 20-
US20190185 LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES
CapitalBio Corporation Dec- Nov Jun-
922 FOR MICROARRAY-BASED ASSAYS
13 -18 19

3- 2- 20-
US20190185 DIET CONTROLLED EXPRESSION OF A NUCLEIC ACID ENCODING
Not Available Jun- Jun Jun-
832 CAS9 NUCLEASE AND USES THEREOF
16 -17 19
1- 28- 20-
US20190184 MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND
Not Available Nov- Feb Jun-
067 APPLICATIONS
15 -19 19
4- 20- 20-
US20190184 CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR
Not Available Dec- Nov Jun-
018 OLIGONUCLEOTIDES
07 -18 19
13- 27- 20-

US20190183 METHODS AND REAGENTS FOR EFFICIENT AND TARGETED
Not Available Jan- Feb Jun-
968 DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS
11 -19 19
12- 29- 20-

US20190183
SYSTEMIC IN VIVO DELIVERY OF OLIGONUCLEOTIDES Not Available Jun- Oct Jun-
918
13 -18 19
21- 13- 13-
US20190177 RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS)
Not Available Jan- Dec Jun-
739 PRODUCED IN TRANSGENIC PLANTS
08 -18 19
23- 23- 13-
US20190175
Adenoviral Vector Not Available Jun- Jun Jun-
716
16 -17 19
31- 13- 13-
US20190175
INHIBITION OF BIOFILM ORGANISMS Not Available Mar- Feb Jun-
528
09 -19 19
9- 9- 6-
US20190169 PORTABLE MOLECULAR DIAGNOSTIC DEVICE AND METHODS FOR
Click Diagnostics, Inc. Nov- Nov Jun-
677 THE DETECTION OF TARGET VIRUSES
17 -18 19
7- 24- 6-
US20190169 CRISPR-RELATED METHODS AND COMPOSITIONS WITH
EDITAS MEDICINE, INC. Nov- Jan Jun-
639 GOVERNING gRNAS
13 -19 19
22- 25- 6-
US20190169
RNA TARGETING METHODS AND COMPOSITIONS Salk Institute for Biological Studies Aug- Jan Jun-
595
17 -19 19
15- 6- 6-
US20190167
Methods and Compositions for Inhibiting Akt3 Not Available Jan- Feb Jun-
787
16 -19 19
4- 9- 6-
US20190167 EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT FOR
Not Available Nov- Jul- Jun-
786 ADJUVANTING SPLIT INFLUENZA VACCINES
05 18 19

14- 8- 6-
Not Available Mar- Feb Jun-
13 -19 19
CATHEPSIN C
4- 30- 6-
US20190166 METHOD FOR PRODUCING A PROTEIN PHOSPHOLIPID COMPLEX
Not Available Dec- Nov Jun-
866 FROM A CRUSTACEAN CATCH
17 -18 19
1- 1- 30-
US20190160 Novel Polygonum Cuspidatum Extracts and Their Use as
Not Available Oct- Feb May
129 Photodynamic Inactivating Agents
15 -19 -19
31- 30- 30-
US20190160
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available Dec- Dec May
063
15 -16 -19
17- 7- 23-
US20190154
DETECTION DEVICE AND DETECTION METHOD Kabushiki Kaisha Toshiba Nov- Mar May
687
17 -18 -19
6- 6- 23-
US20190154
BIOAEROSOL DETECTION SYSTEMS AND METHODS OF USE Not Available Apr- Apr May
550
16 -17 -19
29- 28- 23-
US20190153
COMPOSITIONS FOR THE TREATMENT OF DISEASE Not Available Apr- Apr May
471
16 -17 -19
21- 5- 23-
US20190153
Heterodimeric Immunoglobulins Not Available Nov- Feb May
086
12 -19 -19
29- 21- 23-
US20190151 DEVICES AND METHODS FOR THE DETECTION OF MOLECULES
Click Diagnostics, Inc. Jun- Dec May
844 USING A FLOW CELL
16 -18 -19
8- 8- 23-
US20190151 RNA-BASED LOGIC CIRCUITS WITH RNA BINDING PROTEINS,
Kyoto University Sep- Sep May
474 APTAMERS AND SMALL MOLECULES
14 -15 -19
6- 9- 16-
US20190144
ENHANCED METHODS OF RIBONUCLEIC ACID HYBRIDIZATION Not Available Dec- Jan May
930
13 -19 -19
15- 15- 16-
US20190144
DEVICES FOR CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS Not Available Mar- Mar May
929
17 -18 -19
18- 19- 16-
US20190144
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES RUBIUS THERAPEUTICS, INC. Nov- Nov May
827
13 -18 -19
13- 12- 16-
US20190144 ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR
556 SUPERFAMILY ANTIBODIES
16 -17 -19
28- 28- 16-

US20190144 ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE
Not Available Apr- Apr May
484 THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO
16 -17 -19

10- 15- 16-
US20190142 INFLUENZA VACCINE REGIMENS FOR PANDEMIC ASSOCIATED
Not Available Feb- Oct May
929 STRAINS
09 -18 -19
27- 26- 16-
US20190142
LOW-ADDITIVE INFLUENZA VACCINES Not Available Jun- Jun May
927
07 -18 -19
11- 9- 9-
US20190136
DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTION Not Available May- Nov May
226
16 -18 -19
17- 6- 9-
US20190136
Replication Conditional Virus that Specifically Kills Senescent Cells Not Available Apr- Jul- May
215
12 18 -19
18- 17- 9-
US20190135
TRI-SEGMENTED PICHINDE VIRUSES AS VACCINE VECTORS Not Available May- May May
875
16 -17 -19
19- 19- 9-
US20190135 COMPOSITIONS AND METHODS FOR TREATING DISEASES BY
Not Available Dec- Dec May
873 INHIBITING EXOSOME RELEASE
16 -18 -19
12- 7- 9-
US20190135
DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS Hoffmann-La Roche Inc. Jun- Dec May
788
16 -18 -19
6- 4- 9-
US20190134 GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and
214 Uses Thereof
16 -17 -19
9- 9- 9-
US20190134 USE OF TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND
SALK INSTITUTE FOR BIOLOGICAL STUDIES Nov- Aug May
193 TAM ACTIVATORS AS IMMUNOSUPPRESSORS
07 -18 -19
4- 10- 9-
US20190134 INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION
Not Available Nov- Jul- May
186 ADJUVANT
05 18 -19
3- 8- 9-
US20190134
PHARMACEUTICAL COMPOSITIONS AND METHODS Not Available Aug- Jan May
062
15 -19 -19
24- 7- 2-
US20190128
QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION Not Available Feb- Nov May
893
14 -18 -19
31- 13- 2-
US20190128 SYSTEM FOR MEASURING OPTICAL SIGNAL DETECTOR
Not Available Dec- Dec May
810 PERFORMANCE
15 -18 -19
13- 13- 2-
US20190127
METHODS AND COMPOSITIONS FOR REDUCING VIRUS INFECTIVITY University of Vermont and State Agricultural College Apr- Apr May
441
16 -17 -19
24- 7- 2-
US20190127
QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION Not Available Feb- Nov May
405
14 -18 -19
12- 20- 2-
US20190127
CHARGED LINKERS AND THEIR USES FOR CONJUGATION HANGZHOU DAC BIOTECH CO., LTD. Aug- Dec May
401
16 -18 -19
12- 20- 2-
US20190127
400
16 -18 -19
12- 20- 2-
US20190127
399
16 -18 -19
18- 18- 2-
US20190125 COLD ADAPTED AND VIRULENCE FACTOR DELETED LIVE
Not Available Apr- Apr May
858 ATTENUATED VACCINE SUITABLE FOR MUCOSAL DELIVERY
16 -17 -19
13- 13- 2-
US20190125 Antimicrobial and Antiviral Agent, Antimicrobial and Antiviral
Murata Manufacturing Co., Ltd. Jun- Dec May
806 Member, and Method for Producing Antimicrobial and Antiviral Agent
16 -18 -19
2- 27- 2-
US20190125
PREVENTION AND TREATMENT OF VIRAL INFECTIONS Not Available Jun- Nov May
724
16 -18 -19
5- 25-
US20190119 CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID 31-
Not Available Nov Apr-
744 SUPPORTS FOR MOLECULAR DIAGNOSTIC TESTS Jul-09
-18 19
15- 26- 25-
US20190119 COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE
Not Available Aug- Oct Apr-
743 VARIANTS
16 -18 19
8- 7- 25-
US20190119 METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND
Not Available Sep- Sep Apr-
701 COMPOSITIONS THEREOF
17 -18 19
23- 24- 25-
US20190119
COMPOSITIONS AND METHODS FOR INHIBITING KINASES Not Available Apr- Oct Apr-
266
15 -18 19
18- 23- 25-
US20190119
CARBOXYLIC ACID COMPOUNDS Sumitomo Dainippon Pharma Co., Ltd. May- Oct Apr-
220
12 -18 19
15- 1- 25-
US20190117
MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES Not Available Feb- Oct Apr-
793
07 -18 19
6- 31- 25-
US20190117
USE OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS Indiana University Research and Technology Corporation May- Oct Apr-
702
14 -18 19
4- 12- 18-
US20190112 TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES,
596 KITS AND ASSAYS
12 -18 19
28- 24- 18-
US20190112 USING SORTASES TO INSTALL CLICK CHEMISTRY HANDLES FOR
Whitehead Institute for Biomedical Research Jun- Sep Apr-
394 PROTEIN LIGATION
11 -18 19

6- 6- 18-
US20190111
A PEPTIDE WITH ABILITY TO PENETRATE CELL MEMBRANE Ewha University - Industry Collaboration Foundation Apr- Apr Apr-
141
16 -17 19
5- 5- 11-
US20190105 PORTABLE PATHOGEN ANALYSIS SYSTEM FOR DETECTING
653 WATERBORNE PATHOGENS
17 -18 19
METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC 16- 16- 11-
US20190105
DINUCLEOTIDE AND USE OF SAID PARTICLES FOR TREATING Not Available Mar- Mar Apr-
381
CANCER 16 -16 19
3- 11-
US20190105 28-
Anti-Viral Azide Containing Compounds Not Available Dec Apr-
334 Jul-10
-18 19
22- 21- 4-
US20190100 Chu Strasbourg, Les HÃ´pitaux Universitaires de
Humanized Anti-Claudin-1 Antibodies and Uses Thereof Mar- Mar Apr-
586 Strasbourg
16 -17 19
4- 10- 4-
US20190099
Targeting Lipids Arbutus Biopharma Corporation Dec- Oct Apr-
493
07 -17 19
14- 27- 4-
US20190099
RECOMBINANT HCMV AND RHCMV VECTORS AND USES THEREOF Not Available May- Apr Apr-
479
10 -18 19
11- 6- 28-
US20190094 METHODS AND COMPOSITIONS FOR DETECTING SINGLE T CELL
224 RECEPTOR AFFINITY AND SEQUENCE
16 -17 -19
6- 28-
US20190091 6-Jul-
CATIONIC OIL-IN-WATER EMULSIONS GLAXOSMITHKLINE BIOLOGICALS, SA Dec Mar
329 11
-18 -19
11- 23- 28-
US20190091 METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-
TRUSTEES OF BOSTON UNIVERSITY Mar- Apr Mar
221 INDUCED CONDITIONS
10 -18 -19
8- 15- 21-
Not Available Sep- Nov Mar
16 -18 -19
15- 17- 21-
US20190085
Alpha-Ketoamide Inhibitors Of Cysteine Proteases Not Available Sep- Sep Mar
024
17 -18 -19
7- 7- 21-
US20190085 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND
013 USES RELATED THERETO
16 -17 -19
17- 23- 21-
US20190084 CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL
Parion Sciences, Inc. Dec- Aug Mar
943 SODIUM CHANNEL BLOCKING ACTIVITY
12 -18 -19
22- 22- 21-
US20190083
METHOD FOR PRODUCING RNA MOLECULE COMPOSITIONS Not Available Dec- Dec Mar
602
15 -16 -19
30- 22- 21-
US20190083
IMMUNOSTIMULATORY COMBINATIONS Not Available Dec- Oct Mar
592
02 -18 -19
11- 24- 21-
US20190083 MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF
Not Available Jun- Jul- Mar
569 VIRAL INFECTIONS
15 18 -19
10- 21-
US20190083 COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR 11-
Not Available Jul- Mar
525 AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS Jul-17
18 -19
10- 10- 21-

US20190083 N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related
520 Thereto
16 -17 -19
2- 4- 21-
US20190083 CONTROLLED-RELEASE PEPTIDE COMPOSITIONS AND USES
Not Available Dec- Dec Mar
408 THEREOF
11 -18 -19
23- 21- 21-
US20190083
OIL-IN-WATER EMULSIONS INCLUDING RETINOIC ACID NOVARTIS AG Dec- Dec Mar
397
15 -16 -19
9- 8- 14-
US20190078 DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH
Novartis AG Sep- Nov Mar
060 INFLUENZA VACCINES
04 -18 -19
29- 29- 14-
US20190078
Animal Protein-Free Media for Cultivation of Cells Baxalta GmbH Oct- Oct Mar
051
04 -18 -19

US20190077
PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME Ablynx N.V. Jun- Oct Mar
847
FOR THE TREATMENT OF VIRAL DISEASES 08 -17 -19
23- 13- 14-

US20190077 BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH SECONDARY
Hoffmann-La Roche Inc. May- Nov Mar
764 AMIDE FUNCTION
16 -18 -19
23- 13- 14-
US20190077 BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY
Hoffmann-La Roche Inc. May- Nov Mar
763 AMIDE FUNCTION
16 -18 -19
4- 11- 14-
US20190076 VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND
Not Available Apr- Sep Mar
520 COMPOSITIONS AND METHODS OF USING
08 -18 -19
11- 11- 14-
US20190076 ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC
468 OXIDE
17 -17 -19

5- 2- 7-
15 -18 -19
5- 2- 7-
15 -18 -19
5- 2- 7-
15 -18 -19
5- 2- 7-
15 -18 -19
5- 2- 7-
15 -18 -19
5- 2- 7-
15 -18 -19
4- 31- 28-
US20190062 MULTIVALENT VACCINES FOR RABIES VIRUS AND
Not Available Apr- Mar Feb
785 CORONOVIRUSES
16 -17 -19
22- 27- 28-
US20190062
RNA TARGETING METHODS AND COMPOSITIONS Salk Institute for Biological Studies Aug- Mar Feb
724
17 -18 -19
22- 28-
US20190062 11-
HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS Not Available Mar Feb
713 Jul-03
-18 -19
25- 20- 28-
US20190062 CONSERVED HEMAGGLUTININ EPITOPE, ANTIBODIES TO THE
Not Available Aug- Jun Feb
408 EPITOPE, AND METHODS OF USE
08 -18 -19
FUSION PROTEINS FOR PROMOTING AN IMMUNE RESPONSE, 7- 28- 28-

US20190062
NUCLEIC ACIDS ENCODING SAME, AND METHODS OF MAKING AND Not Available Sep- Aug Feb
380
USE THEREOF 12 -18 -19
2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A]PYRIDINE 10- 7- 28-

US20190062
DERIVATIVES AS BLOCKERS OF TASK-1 AND TASK-2 CHANNELS, BAYER PHARMA AKTIENGESELLSCHAFT Dec- Dec Feb
326
FOR THE TREATMENT OF SLEEP-RELATED BREATHING DISORDERS 15 -16 -19
26- 24- 28-

US20190062
PI-Kinase Inhibitors with Anti-Infective Activity Not Available Feb- Feb Feb
323
16 -17 -19
27- 27- 28-
US20190060 PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR The United States of America, as represented by the
Feb- Feb Feb
435 INDUCING AN IMMUNE RESPONSE Secretary, Dept of Health and Human Service
16 -17 -19
6- 28-
US20190060 INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF 31-
Not Available Nov Feb
364 THERAPY Jul-15
-18 -19
6- 28-
363 THERAPY Jul-15
-18 -19
25- 5- 28-
US20190060
ENHANCED EXPRESSION OF RNA VECTORS UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH Mar- Sep Feb
262
13 -18 -19
17- 28-
US20190060 24-
Technology for the Preparation of Microparticles Not Available Oct Feb
239 Jul-07
-18 -19
20- 20- 21-
US20190056 Clean Rooms Having Dilute Hydrogen Peroxide (DHP) Gas and
Synexis LLC Apr- Apr Feb
122 Methods of Use Thereof
15 -16 -19
24- 24- 21-
US20190055
ANTI-VIRAL DRUG DORING INTERNATIONAL GMBH Feb- Feb Feb
256
16 -17 -19
31- 22- 21-
US20190055
GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS Not Available Aug- Oct Feb
241
15 -18 -19
23- 24- 21-
US20190055
COMPOSITIONS AND METHODS FOR INHIBITING KINASES Not Available Apr- Oct Feb
234
15 -18 -19
30- 2- 21-
03 -18 -19
4- 22- 21-
US20190054
ANTIVIRAL AGENT AND ANTIVIRAL FOOD EDUCATIONAL CORPORATION MUKOGAWA GAKUIN Mar- Nov Feb
127
16 -16 -19
5- 21-
122 THERAPY Jul-15
-18 -19
10- 21- 14-
US20190049 CONTINUOUS PROCESS FOR PERFORMING MULTIPLE NUCLEIC
Not Available Mar- Jun Feb
378 ACID AMPLIFICATION ASSAYS
05 -18 -19
23- 16- 14-
US20190048 CHEMICAL MODIFICATIONS OF MONOMERS AND
Not Available Sep- Aug Feb
344 OLIGONUCLEOTIDES WITH CYCLOADDITION
08 -18 -19
30- 25- 14-
US20190048 PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC
Not Available Jun- Oct Feb
082 POLYPEPTIDES
16 -18 -19

10- 10- 14-
US20190048
CARGOMERS CERENIS THERAPEUTICS HOLDING SA Aug- Aug Feb
049
17 -18 -19
16- 18- 14-
US20190048
Boron-Containing Small Molecules Anacor Pharmaceuticals, Inc. Feb- Oct Feb
026
05 -18 -19
1- 2- 14-
US20190046
MATERIALS WITH IMPROVED PROPERTIES Not Available Nov- Nov Feb
690
15 -16 -19
9- 9- 14-
US20190046
ALBUMIN BINDING PEPTIDE CONJUGATES AND METHODS THEREOF Not Available Aug- Aug Feb
654
17 -18 -19
2- 1- 14-
US20190046 COMPOSITION FOR IMMUNITY INDUCTION PROMOTION AND
NITTO DENKO CORPORATION Feb- Feb Feb
635 VACCINE PHARMACEUTICAL COMPOSITION
16 -17 -19
8- 9- 7-
US20190040 FULLY INTEGRATED HAND-HELD DEVICE TO DETECT SPECIFIC
Not Available Jan- Jan Feb
451 NUCLEIC ACID SEQUENCES
16 -17 -19
3- 7-
US20190040 4-Jul-
NOVEL NUCLEIC ACID MOLECULES Not Available Jul- Feb
378 17
18 -19
23- 3- 7-
US20190040 TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR
Not Available Nov- Aug Feb
370 DELIVERY OF CRISPR/CAS9
15 -18 -19
5- 19- 7-
US20190040
Method for Preventing and Treating Hyperpermeability Not Available Mar- Oct Feb
105
09 -18 -19
4- 2- 7-
US20190038 MESENCHYMAL STEM CELLS AS VACCINE ADJUVANTS AND
Longeveron LLC Feb- Feb Feb
742 METHODS FOR USING THE SAME
16 -17 -19
30- 9- 31-
US20190032
ARTIFICIAL NUCLEIC ACID MOLECULES CureVac AG Dec- Jul- Jan-
077
13 18 19
21- 12- 31-
US20190032
COMPOSITIONS FOR AND METHODS OF IDENTIFYING ANTIGENS Not Available Feb- Feb Jan-
041
06 -18 19
13- 15- 31-
Not Available May- Oct Jan-
14 -18 19
30- 5- 31-
US20190031
NOVEL MONOTHIOL MUCOLYTIC AGENTS Not Available Jan- Sep Jan-
679
15 -18 19
29- 27- 31-
US20190031
TETRAHYDRONAPHTHALENE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. Jan- Jan Jan-
605
16 -17 19
8- 7- 31-
US20190030 sirna/Nanoparticle Formulations for Treatment of Middle-East
Sirnaomics, Inc. Sep- Sep Jan-
187 Respiratory Syndrome Coronaviral Infection
15 -16 19
27- 27- 31-
US20190030 BACTERIAL STRAIN AS AGENTS FOR PREVENTING AND/OR
Not Available Jan- Jan Jan-
094 TREATING RESPIRATORY DISORDERS
16 -17 19
8- 25- 24-
US20190025 University of Pittsburgh - Of the Commonwealth System of
ANTIGEN PRESENTING CELL ASSAY Apr- Sep Jan-
292 Higher Education
10 -18 19
7- 7- 24-
US20190024
PROCESS FOR THE IN VIVO PRODUCTION OF RNA IN A HOST CELL Not Available Aug- Aug Jan-
096
15 -15 19
25- 28- 24-
US20190023 GITR Antibodies And Methods Of Inducing Or Enhancing An Immune
Not Available Mar- Jun Jan-
799 Response
05 -18 19
28- 5- 24-
US20190023 METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH
Not Available Dec- Oct Jan-
779 DESIRED SPECIFICITY
11 -18 19
29- 21- 24-
US20190023 COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN
Not Available Oct- Sep Jan-
769 INFECTION
12 -18 19
30- 2- 24-
Not Available Sep- Oct Jan-
03 -18 19
23- 4- 24-
216 THEREOF
15 -18 19
27- 26- 24-
US20190022
Attenuated Infectious Bronchitis Virus Not Available Jan- Jan Jan-
214
16 -17 19
29- 29- 24-
US20190022
MERS-CoV Vaccine Not Available Nov- Jun Jan-
213
13 -18 19
26- 16- 24-
US20190022 N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related
116 Thereto
14 -15 19
11- 10- 17-
US20190017 METHOD OF DIRECT TARGET SEQUENCING USING NUCLEASE
HTG Molecular Diagnostics, Inc. Feb- Feb Jan-
112 PROTECTION
16 -17 19
17- 26- 17-

Not Available Dec- Sep Jan-
01 -18 19

8- 19- 17-
US20190017
CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF Not Available Sep- Sep Jan-
000
16 -18 19
7- 7- 17-
US20190016 ANTIBODIES THAT POTENTLY NEUTRALIZE HEPATITIS B VIRUS
785 AND USES THEREOF
15 -16 19
23- 2- 17-
US20190016 GM-CSF and IL-4 Conjugates, Compositions, and Methods Related
772 Thereto
12 -18 19
31- 29- 17-
US20190016
MULTICYCLIC COMPOUNDS AND USES THEREOF Not Available Dec- Dec Jan-
710
15 -16 19
31- 30- 17-
US20190016
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available Dec- Dec Jan-
690
15 -16 19
30- 25- 17-

Not Available Sep- Jul- Jan-
03 18 19
5- 19- 17-
US20190015 IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE
Not Available Apr- Jul- Jan-
522 THEREOF
12 18 19
23- 27- 17-
US20190015
NUCLEIC ACID VACCINES ModernaTX, Inc. Apr- Sep Jan-
501
14 -18 19
13- 17-
US20190015 13-
Lipid Disulfide Prodrugs and Uses Related Thereto Not Available Jul- Jan-
432 Jul-17
18 19
30- 16- 10-
US20190010
ATTENUATED VIRUSES USEFUL FOR VACCINES Not Available Mar- Jul- Jan-
469
07 18 19
15- 2- 10-
US20190010 COMPOSITION COMPRISED OF ANTIGEN LINKED TO A TNF
Not Available Mar- Aug Jan-
240 SUPERFAMILY LIGAND
13 -18 19
13- 4- 10-
US20190010 ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL
Parion Sciences, Inc. Dec- Apr Jan-
132 SODIUM CHANNEL BLOCKING COMPOUNDS
13 -18 19
31- 11- 10-
US20190008 NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES
CureVac AG Jan- Jun Jan-
954 FOR IMMUNOSTIMULATION
12 -18 19
23- 16- 10-
US20190008
NUCLEIC ACID VACCINES ModernaTX, Inc. Apr- Jul- Jan-
948
14 18 19
9- 17- 10-
US20190008
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available May- Jul- Jan-
833
12 18 19
4- 3-
US20190004 DETECTING TARGETS USING MASS TAGS AND MASS 2-Jul-
Not Available Aug Jan-
061 SPECTROMETRY 10
-18 19
9- 31- 3-
US20190002 ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND
Kineta, Inc. May- Jan Jan-
477 METHODS OF USE THEREOF
14 -18 19
31- 29- 3-
US20190002 SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS
15 -16 19
5- 19- 3-
US20190002
Lipids and Lipid Compositions for the Delivery of Active Agents Not Available Sep- Sep Jan-
393
14 -18 19
8- 13- 3-
US20190001 ADDITIVE COMPOSITIONS FOR PIGMENTED DISINFECTION AND
Not Available Dec- Jul- Jan-
010 METHODS THEREOF
14 18 19
23- 27- 3-
US20190000
NUCLEIC ACID VACCINES ModernaTX, Inc. Apr- Jul- Jan-
959
14 18 19
4- 3-
US20190000 POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS 28-
eXion labs Inc. Sep Jan-
745 OF USE THEREOF Jul-16
-18 19
22- 21- 27-
US20180372 METHODS OF IDENTIFYING IMMUNE CELLS IN PD-L1 POSITIVE
Not Available Nov- May Dec
747 TUMOR TISSUE
15 -18 -18
27- 21- 27-
US20180372 ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR
Not Available Apr- Jun Dec
733 MAKING AND USING SUCH CONJUGATES
10 -18 -18
1- 26- 27-
US20180371
METHODS FOR RNA QUANTIFICATION Not Available Jun- May Dec
536
15 -16 -18
APTAMERS, NUCLEIC ACID MOLECULES, POLYNUCLEOTIDES, 10- 1- 27-

US20180371
SYNTHETIC ANTIBODIES COMPOSITIONS FOR DETECTING PRRS Not Available Dec- Dec Dec
461
VIRUSES AND TREATING PRRS VIRUS INFECTION 15 -16 -18
4- 28- 27-
US20180371
MEANS AND METHODS FOR INFLUENCING THE STABILITY OF CELLS Not Available Dec- Aug Dec
410
09 -18 -18
8- 29- 27-
US20180369 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE
Not Available Mar- Aug Dec
386 AGENTS
13 -18 -18
1- 27-
US20180369 RECOMBINANT VIRUS LIKE PARTICLES USING BOVINE 2-Jul-
Not Available Jul- Dec
364 IMMUNODEFICIENCY VIRUS GAG PROTEIN 15
16 -18

23- 19- 27-
US20180368
ANTIMICROBIAL COMPOSITIONS AND METHODS Not Available Sep- Jun Dec
417
14 -18 -18
24- 4- 20-
US20180365 METHODS AND SYSTEMS FOR MULTIPLE TAXONOMIC
Not Available Apr- Oct Dec
375 CLASSIFICATION
15 -17 -18
6- 15- 20-
US20180363 STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF
Not Available Oct- May Dec
027 RIBONUCLEIC ACID
06 -18 -18
4- 2- 20-
US20180362
REGULATION OF CYTOKINE PRODUCTION Not Available Dec- Dec Dec
625
15 -16 -18
8- 8- 20-
US20180360 METHODS FOR EXPANDING A POPULATION OF ALVEOLAR
Not Available Dec- Dec Dec
877 MACROPHAGES IN A LONG TERM CULTURE
15 -16 -18
2- 23- 20-
US20180360 FILM DOSAGE FORM WITH EXTENDED RELEASE MUCOADHESIVE
Intelgenx Corp. Dec- Aug Dec
736 PARTICLES
13 -18 -18
7- 6- 13-
US20180355
COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES Not Available Jun- Jun Dec
017
17 -18 -18
21- 13-
US20180353 26-
METHOD FOR INACTIVATING VIRUSES USING ELECTRON BEAMS Not Available Aug Dec
594 Jul-13
-18 -18
13- 9- 6-
US20180346
ANTI-PD-L1 ANTIBODIES AND USES THEREOF Not Available Jun- Aug Dec
574
16 -18 -18
13- 9- 6-
US20180346
ANTI-PD-L1 ANTIBODIES AND USES THEREOF Not Available Jun- Aug Dec
573
16 -18 -18
HUMAN RESPIRATORY SYNCYTIAL VIRUS CONSENSUS ANTIGENS, 10- 6- 6-

US20180346
NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, Not Available Apr- Aug Dec
522
AND METHODS OF USING THE SAME 12 -18 -18
27- 28- 6-
US20180346
PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTS Not Available Nov- Nov Dec
516
15 -16 -18

US20180346
PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 Not Available Feb- Feb Dec
485
INHIBITORS 15 -18 -18
5- 1- 6-
Not Available Feb- Mar Dec
480 INHIBITORS
15 -18 -18
16- 8- 6-
US20180344 RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN
Children's Healthcare of Atlanta, Inc. Apr- Aug Dec
877 EXPRESSION IN LIVER AND USE THEREOF
15 -18 -18
20- 20- 6-
US20180344 METHODS AND COMPOSITIONS FOR COMBINATION
Not Available Apr- Apr Dec
832 IMMUNOTHERAPY
15 -16 -18
17- 26- 6-
US20180344
Broad Spectrum Antiviral and Methods of Use Not Available Apr- Dec Dec
751
06 -17 -18
9- 9- 29-
US20180340
CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS MASSACHUSETTS INSTITUTE OF TECHNOLOGY Dec- Mar Nov
219
16 -18 -18
9- 9- 29-
US20180340
CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS MASSACHUSETTS INSTITUTE OF TECHNOLOGY Dec- Mar Nov
218
16 -18 -18
28- 26- 29-
US20180340 SAMPLE ANALYSIS, PRESENCE DETERMINATION OF A TARGET
Not Available Aug- Aug Nov
215 SEQUENCE
15 -16 -18
24- 23- 29-
US20180340
PRODUCTION OF VIRUSES IN AVIAN EGGS Not Available Nov- Nov Nov
154
15 -16 -18
24- 23- 29-
US20180340
PRODUCTION OF VIRUSES IN CELL CULTURE Not Available Nov- Nov Nov
153
15 -16 -18
30- 24- 29-
Not Available Dec- May Nov
14 -18 -18
30- 18- 29-
Not Available Dec- Jan Nov
14 -18 -18
14- 7- 29-
US20180339
PEPTIDOMIMETIC MACROCYCLES Not Available Jan- Jun Nov
014
09 -18 -18
17- 15- 22-
US20180334
CORONAVIRUSES EPITOPE-BASED VACCINES RAMOT AT TEL-AVIV UNIVERSITY LTD. Sep- Sep Nov
480
15 -16 -18
12- 9- 22-
US20180333 Compositions, Comprising Improved Il-12 Genetic Constructs And
485 Vaccines, Immunotherapeutics And Methods Of Using The Same
11 -18 -18
26- 21- 15-

US20180327 MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION
Not Available Feb- May Nov
800 OF B CELLS
03 -18 -18

20- 18- 15-
US20180327
STABILIZED REAGENTS FOR GENOME MODIFICATION Not Available Nov- Nov Nov
738
15 -16 -18
8- 12- 15-
US20180327
CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF Not Available Sep- Jun Nov
697
16 -18 -18
1- 23- 15-
US20180327 RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING
Not Available Jun- Jul- Nov
484 THEM
07 18 -18
4- 20- 15-
Not Available Dec- Nov Nov
07 -17 -18
17- 24- 15-
US20180326 LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND
Not Available Aug- Jul- Nov
051 COMPOSITIONS, FORMULATIONS, AND METHODS
10 18 -18
22- 20- 15-
US20180326
COMBINATION PIV3/HMPV RNA VACCINES ModernaTX, Inc. Oct- Jul- Nov
045
15 18 -18
NSP10 SELF-ASSEMBLING FUSION PROTEINS FOR VACCINES, 13- 13- 15-

US20180326
THERAPEUTICS, DIAGNOSTICS AND OTHER NANOMATERIAL Not Available Oct- Oct Nov
044
APPLICATIONS 15 -16 -18
16- 16- 15-

US20180326
VACCINE COMPOSITIONS Not Available Sep- Sep Nov
039
15 -16 -18
28- 24- 15-
US20180325 ANTIMICROBIAL COMPOSITIONS AND METHODS WITH NOVEL
OXISCIENCE, LLC Aug- Jul- Nov
076 POLYMERIC BINDING SYSTEM
14 18 -18
6- 4- 8-
US20180321
VIRAL BIOMARKERS AND USES THEREFOR Not Available Nov- Nov Nov
242
15 -16 -18
30- 28- 8-
US20180319 DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION
Not Available Oct- Oct Nov
811 AND THEIR USE FOR TREATING VIRAL INFECTIONS
15 -16 -18
4- 8-
Not Available Dec Nov
-17 -18
3- 30- 8-
US20180318 COMPOSITIONS AND METHODS FOR IMPROVING VIRAL VECTOR
Not Available Dec- Nov Nov
447 EFFICIENCY
15 -16 -18
15- 15- 8-
US20180318
METHOD OF TREATMENT USING ONCOLYTIC VIRUSES Not Available Jun- Jun Nov
366
15 -16 -18
4- 4- 8-
US20180318 Immune Cells with DNMT3A Gene Modifications and Methods
Not Available Nov- Nov Nov
350 Related Thereto
15 -16 -18
6- 20- 1-
US20180312 ANTIBODIES AGAINST INFLUENZA VIRUS AND METHODS OF USE
Not Available Dec- Mar Nov
575 THEREOF
07 -18 -18
9- 9- 1-
US20180312
OPTIMIZED NUCLEIC ACID MOLECULES Not Available Nov- Nov Nov
545
15 -16 -18
RECOMBINANT HUMAN/BOVINE PARAINFLUENZA VIRUS 3 20- 20- 1-

US20180312 The United States of America, as represented by the
(B/HPIV3) EXPRESSING A CHIMERIC RSV/BPIV3 F PROTEIN AND Jan- Jan Nov
544 Secretary, Dept. of Health and Human Services
USES THEREOF 15 -16 -18
11- 11- 1-
US20180311
MICRONEEDLE COMPOSITIONS AND METHODS OF USING SAME Not Available Jan- Jul- Nov
338
16 18 -18
1- 26- 1-
US20180311
Method of Treating Inflammation Not Available Apr- Jun Nov
273
10 -18 -18
12- 12- 25-
US20180305 CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS FOR MALARIA
Not Available Apr- Apr Oct-
773 DETECTION
17 -18 18
30- 30- 25-
US20180305
Pathogen biomarkers and uses therefor Not Available Sep- Sep Oct-
760
15 -16 18
13- 25-
US20180305 13-
HIDE1 COMPOSITIONS AND METHODS Not Available Jul- Oct-
451 Jul-15
16 18
19- 9- 25-
US20180305 COMPOSITIONS AND METHODS FOR TREATING DISEASES BY
Not Available Dec- Jul- Oct-
412 INHIBITING EXOSOME RELEASE
16 18 18
22- 25- 25-
US20180305
IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHDOS Not Available Dec- Jun Oct-
357
06 -18 18
19- 18- 25-
US20180305
NOVEL KINASE INHIBITORS Not Available Oct- May Oct-
356
12 -18 18
10- 30- 25-
US20180303
Compositions and Methods for the Prevention of Microbial Infections Not Available Nov- Nov Oct-
874
11 -17 18
30- 2- 25-
Not Available Jan- Jul- Oct-
15 18 18
30- 17- 25-

US20180303 TREATMENT COMPOSITIONS PROVIDING AN ANTIMICROBIAL
090 BENEFIT
15 -16 18

METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC 1- 8- 20-
ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING Sep- Aug Sep
NEODYMIUM MAGNETS 15 -16 -18
18- 29- 20-

US20180265
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available Nov- Mar Sep
847
13 -18 -18
8- 21- 20-
US20180265 LIQUID LOADING COMPOSITION, METHOD OF MAKING AND USE
Not Available Sep- May Sep
822 THEREOF
16 -18 -18
15- 15- 20-
US20180265 Anti-pneumococcal hyperimmune globulin for the treatment and
Not Available Mar- Mar Sep
574 prevention of pneumococcal infection
17 -17 -18
11- 26- 20-
Dana-Farber Cancer Institute, Inc. Apr- Jan Sep
507 VIRUSES
12 -18 -18
8- 31- 20-
US20180264 MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF The Government of the USA as represented by the
Oct- May Sep
098 SYNONYMOUS CODONS Secretary of the Dept. of Health and Human Service
04 -18 -18
2- 22- 13-
US20180258 Methods Of Treating Inflammation Associated Airway Diseases And
Not Available Jan- May Sep
162 Viral Infections
15 -18 -18
13- 11- 13-
US20180258
Optimized Crosslinkers for Trapping a Target on a Substrate Not Available Nov- May Sep
160
15 -18 -18
28- 14- 13-
US20180258 COMPOSITIONS AND METHODS FOR THE TREATMENT OF
Not Available Oct- May Sep
159 IMMUNODEFICIENCY
14 -18 -18
28- 2- 13-
US20180258 RECOMBINANT SUPER-COMPOUND INTERFERON AND USES
Not Available Feb- Mar Sep
151 THEREOF
01 -18 -18
5- 28- 6-
US20180251 COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL
Not Available Dec- Dec Sep
737 GROWTH
08 -17 -18
16- 30- 6-
US20180251
HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) Not Available Dec- Apr Sep
540
02 -18 -18

US20180251
OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 Not Available Jan- Sep Sep
436
11- 1- 6-
US20180250 PAPAYA MOSAIC VIRUS COMPOSITIONS AND USES THEREOF FOR
Not Available Feb- May Sep
602 STIMULATION OF THE INNATE IMMUNE RESPONSE
14 -18 -18
20- 12- 6-
US20180250
SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES Not Available Aug- Oct Sep
381
10 -17 -18
19- 9- 30-
Not Available Nov- Oct Aug
09 -17 -18
27- 27- 30-
US20180245
VIRAL VACCINES AND METHODS OF FORMING THE SAME Not Available Feb- Feb Aug
053
17 -18 -18
19- 18- 30-
US20180244
NOVEL METHODS OF GENERATING ANTIBODIES Rutgers, The State University of New Jersey Aug- Aug Aug
759
15 -16 -18
24- 24- 30-
US20180244 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS The United States of America, as Represented by the
Feb- Feb Aug
756 IMMUNOGENS, ANTIBODIES, AND THEIR USE Secretary, Dept. of Health and Human Services
15 -16 -18
31- 26- 30-
US20180244 IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING SUBSTITUTED
Not Available Aug- Aug Aug
669 GUANIDINE GROUPS
15 -16 -18
17- 17- 30-
US20180244 CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE
660 INHIBITORS
15 -16 -18
25- 22- 30-
347 THEREOF
15 -16 -18
29- 23-
US20180237 31-
METHODS OF ANALYZING VIRUS-DERIVED THERAPEUTICS American International Biotechnology, LLC Jul- Aug
835 Jul-15
16 -18
8- 5- 23-
US20180237
IMPROVEMENTS IN OR RELATING TO DNA RECOMBINATION The Regents of the University of California Aug- Aug Aug
788
15 -16 -18
28- 22- 23-
US20180237
ARTIFICIAL NUCLEIC ACID MOLECULES CUREVAC AG Aug- Aug Aug
786
15 -16 -18
11- 11- 23-
US20180237 PAN-EBOLA AND PAN-FILOVIRUS PROTECTIVE EPITOPES,
Integrated BioTherapeutics, Inc. Mar- Mar Aug
502 ANTIBODIES, AND ANTIBODY COCKTAILS
15 -16 -18
31- 26- 23-
US20180237
GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS Not Available Aug- Aug Aug
435
15 -16 -18
16- 23-
US20180236 31-
REVERSE GENETICS SYSTEMS Not Available Oct Aug
058 Jul-09
-17 -18
14- 19- 23-
US20180236
Tetanus Toxoid and CCL3 Improve DC Vaccines Duke University Nov- Apr Aug
054
13 -18 -18

(S,E)-3-(6-AMINOPYRIDIN-3-YL)-N-((5-(4-(3-FLUORO-3-
18- 18- 23-
US20180235 METHYLPYRROLIDINE-1-CARBONYL)PHENYL)-7-(4-
948 FLUOROPHENYL)BENZOFURAN-2-YL)METHYL)ACRYLAMIDE FOR THE
15 -16 -18
TREATMENT OF CANCER
27- 13- 16-

US20180230
BIOAGENT DETECTION OLIGONUCLEOTIDES Not Available Dec- Apr Aug
521
11 -18 -18
24- 24- 16-
US20180230 ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN
Northwestern University Jan- Jan Aug
447 CONVERTING ENZYME 2 (ACE2)
17 -18 -18
DEVICES, SYSTEM AND METHOD TO CONTROL THE DELIVERY OF 11- 11- 16-
US20180228
ORAL MEDICATIONS TO ENSURE THEY ARE EFFICACIOUS , TAKEN Not Available Aug- Aug Aug
695
AS PRESCRIBED, AND TO AVOID UNWANTED SIDE EFFECTS 15 -16 -18
10- 7- 9-
US20180223 METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING
GenVec, Inc. Nov- Sep Aug
290 INHIBITORY GENE PRODUCTS
05 -17 -18
18- 9- 9-
US20180222 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND
3M Innovative Properties Company Jun- Apr Aug
906 IMIDAZONAPHTHYRIDINES
04 -18 -18
3- 3- 9-
US20180221 IMMUNOGENIC COMPOSITIONS, ANTIGEN SCREENING METHODS,
464 AND METHODS OF GENERATING IMMUNE RESPONSES
15 -16 -18
15- 19- 2-
US20180216
HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS Not Available Nov- Mar Aug
164
06 -18 -18
18- 29- 2-
US20180216
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available Nov- Mar Aug
067
13 -18 -18
27- 2-
US20180215 27-
Antibody Derivatives with Conditionally Enabled Effector Function Not Available Jul- Aug
831 Jul-15
16 -18
29- 29- 2-
US20180215
CRYPTIC POLYPEPTIDES AND USES THEREOF Not Available Jan- Jan Aug
801
15 -16 -18
20- 27- 2-
US20180215
TREATING CANCER WITH VIRAL NUCLEIC ACID Mayo Foundation for Medical Education and Research Feb- Mar Aug
794
07 -18 -18
15- 2-
US20180214 17-
Selective Inhibitors Of i-NOS For Use Against Viral Infection UCL Business PLC Jul- Aug
430 Jul-15
16 -18
23- 11- 26-
US20180209 Method of Determining, Identifying or Isolating Cell-Penetrating
Not Available May- Dec Jul-
960 Peptides
11 -17 18
18- 19- 26-
US20180208
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available Nov- Mar Jul-
897
13 -18 18
13- 13- 26-
US20180208
ANTI-PD-L1 ANTIBODIES AND USES THEREOF Not Available Jun- Jun Jul-
659
16 -17 18
20- 19- 26-
US20180208
METHODS FOR ENHANCING AN IMMUNE RESPONSE Not Available Jan- Jan Jul-
653
17 -18 18
22- 5- 26-
US20180207
ADJUVANTED INFLUENZA VACCINES FOR PEDIATRIC USE Not Available Feb- Mar Jul-
258
08 -18 18
12- 19- 26-
US20180207 PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR
GlaxoSmithKline Intellectual Property (No. 2) Limited May- Mar Jul-
145 TREATING INFECTIOUS DISEASES
14 -18 18
14- 19-
US20180201 COMPOSITIONS AND METHODS FOR DETECTION OF GENETIC 14-
CapitalBio Corporation Jul- Jul-
998 DEAFNESS GENE MUTATION Jul-15
15 18
26- 13- 19-
US20180201
METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES Not Available Jan- Mar Jul-
907
12 -18 18
7- 19-
US20180201 ANTIBODIES HAVING SPECIFICITY TO MYOSIN 18A AND USES 7-Jul-
Not Available Jul- Jul-
687 THEREOF 15
16 18
17- 20- 19-
US20180200
Methods and Compositions for Inhibiting Akt3 Not Available Jan- Feb Jul-
365
17 -18 18
17- 27- 19-
3M Innovative Properties Company Aug- Nov Jul-
10 -17 18
31- 12- 19-
US20180200 Antiviral Activity from Medicinal Mushrooms and Their Active
Not Available Mar- Mar Jul-
224 Constituents
15 -18 18
1- 3- 19-
US20180200
Modular Particulars for Immunotherapy Not Available Nov- Jan Jul-
196
13 -18 18
7- 12-
US20180196 7-Jul-
INFLUENZA POTENCY ASSAYS Not Available Jul- Jul-
061 15
16 18
13- 12- 12-
US20180195
METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION Takeda Vaccines, Inc. Feb- Feb Jul-
048
15 -16 18

15- 13- 12-
US20180194 ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR
Not Available May- May Jul-
850 SUPERFAMILY ANTIBODIES
15 -16 18
15- 13- 12-

US20180194 POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR
Not Available Apr- Nov Jul-
829 TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER
11 -17 18
17- 8- 12-
US20180194
Sulfinylphenyl or Sulfonimidoylphenyl Benzazepines Hoffmann La-Roche Inc. Sep- Mar Jul-
735
15 -18 18
15- 12-
US20180193 15-
DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS Not Available Jul- Jul-
477 Jul-15
16 18
6- 5-
US20180187 Variant AAV and Compositions, Methods and Uses for Gene Transfer 22-
The Children's Hospital of Philadelphia Dec Jul-
213 to Cells, Organs and Tissues Jul-13
-17 18
9- 7- 5-
US20180187 METHODS AND COMPOSITIONS FOR COMBINATION
Not Available Jan- Jan Jul-
211 IMMUNOTHERAPY
15 -16 18
7- 27- 5-
US20180187 HAND, FOOT, AND MOUTH VACCINES AND METHODS OF
Takeda Vaccines, Inc. Nov- Oct Jul-
165 MANUFACTURE AND USE THEREOF
14 -17 18
18- 20- 5-
US20180187
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available Nov- Feb Jul-
154
13 -18 18
18- 20- 5-
US20180187
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available Nov- Feb Jul-
153
13 -18 18
16- 15- 5-
US20180187 DISINFECTING AQUEOUS FOAM, PROCESS FOR PREPARING SAME COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX
Jun- Jun Jul-
131 AND USE THEREOF ENERGIES ALTERNATIVES
15 -16 18
26- 24- 5-
US20180186
NOVEL VACCINES IN PREVENTION AND TREATMENT OF MALARIA Not Available Jun- Jun Jul-
897
15 -16 18
28- 28- 5-
US20180186 PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PAFFAFIN
Not Available Aug- Feb Jul-
821 EMBEDDED TISSUE USING CAGED HAPTENS
15 -18 18
1- 27- 5-
Not Available May- Feb Jul-
802 AGONISTS
14 -18 18
HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL 3- 26- 5-

US20180186
SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE 3M Innovative Properties Company Jun- Feb Jul-
792
THEREFROM 11 -18 18
16- 29- 5-
US20180186
Powdered Pouch And Method Of Making Same MONOSOL, LLC Apr- Dec Jul-
534
12 -17 18
24- 14- 5-
US20180185 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING
Not Available Apr- Dec Jul-
469 PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME
12 -17 18
3- 29- 5-
US20180185
Pharmaceutical Compositions and Methods Not Available Aug- Nov Jul-
392
15 -17 18
19- 17- 5-
US20180185 METHODS AND COMPOSITIONS FOR TREATING HERPESVIRUS
Not Available Jun- Jun Jul-
15 -16 18
14- 22- 28-
US20180180 USE OF A FLUORESCENT MATERIAL TO DETECT FAILURE OR
Not Available Jun- Feb Jun-
544 DETERIORATED PERFORMANCE OF A FLUOROMETER
12 -18 18
26- 22- 28-
US20180179
GENERATION OF BINDING MOLECULES Merus N.V. Sep- Nov Jun-
300
11 -17 18
26- 24- 28-
US20180179 PROTEINS COMPRISING A MUTATED LAIR-1 FRAGMENT AND USES
274 THEREOF
15 -16 18
23- 31- 28-
US20180177
METHODS OF MAKING AND USING LIVE ATTENUATED VIRUSES Not Available Sep- Oct Jun-
863
15 -17 18
26- 24- 28-
US20180177
ANTIGENICALLY MATCHED INFLUENZA VACCINES Not Available Jun- Jun Jun-
862
15 -16 18
11- 7- 28-
US20180177 VACCINE CONTAINING VIRUS INACTIVATED BY GREEN TEA
860 EXTRACT, AND PREPARATION METHOD THEREFOR
15 -16 18
10- 10- 14-
US20180163 PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC
Human Services Jun- Jun Jun-
182 ACID-CONTAINING COMPOSITIONS
15 -16 18
18- 13- 14-
US20180162
Chemical Compounds Not Available Mar- Dec Jun-
838
14 -17 18
5- 11- 14-
Not Available Feb- Dec Jun-
15 -17 18
10- 10- 14-
US20180161 NOVEL PROTEIN STRUCTURE USED FOR EFFICIENT ANTIBODY
Not Available Dec- Dec Jun-
425 PRODUCTION IN IMMUNIZATION
14 -15 18

NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-
15- 8- 14-
US20180161 LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL
CureVac AG Feb- Feb Jun-
422 FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC
12 -18 18
ANTIGEN
14- 13- 14-

US20180161 GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR
279 OPROZOMIB AND PROCESS TO MAKE THEREOF
16 -17 18
26- 25- 14-
US20180160
Transgenic Immunodeficient Mouse Expressing Human SIRP-alpha Institut Pasteur Mar- Jan Jun-
662
12 -18 18
4- 3- 31-
US20180149
DIAGNOSIS AND TREATMENT OF MERS-RELATED RENAL DISEASE Not Available Jun- Jun May
659
15 -16 -18
30- 29- 31-
US20180148
ARTIFICIAL NUCLEIC ACID MOLECULES Not Available Dec- Dec May
727
14 -15 -18
26- 14- 24-
Not Available Jan- Jun May
07 -17 -18
31- 30- 24-
US20180142
DELIVERY OF BIOMOLECULES TO IMMUNE CELLS Not Available Oct- Oct May
198
14 -15 -18
27- 12- 24-
US20180142
ANTIBODY PRODUCING NON-HUMAN ANIMALS Merus N.V. Jun- Jan May
006
08 -18 -18
27- 12- 24-
US20180142
005
08 -18 -18
27- 11- 24-
US20180142
004
08 -18 -18
27- 9- 24-
US20180142
003
08 -18 -18
27- 5- 24-
US20180142
002
08 -18 -18
29- 12- 24-
US20180140
ANALOGS OF C5a AND METHODS OF USING SAME Not Available Jun- Jan May
659
10 -18 -18
16- 31- 24-
US20180140
PRODUCTION OF STABLE NON-POLYADENYLATED RNAS Massachusetts Institute of Technology Oct- Jul- May
625
12 17 -18
29- 23- 24-
US20180140 METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF
Not Available Nov- Oct May
580 BRAIN INFLAMMATION AND SEPSIS
02 -17 -18
23- 2- 17-
US20180135 NANOREPORTERS AND METHODS OF MANUFACTURING AND USE
Not Available Dec- Jan May
099 THEREOF
05 -18 -18
13- 13- 17-
US20180135
MEMBRANE-RECEIVER COMPLEX THERAPEUTICS Not Available May- May May
012
15 -16 -18
16- 26- 17-
US20180134
HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) Not Available Dec- Apr May
783
02 -16 -18
27- 12- 17-
US20180134
770
08 -18 -18
7- 1- 17-
US20180133 INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY
Not Available Mar- Nov May
246 DISEASES
12 -17 -18
7- 6- 10-
US20180127 IMPROVED COMPOSITIONS AND METHODS FOR DETECTION OF
836 VIRUSES
15 -16 -18
7- 29- 10-
EDITAS MEDICINE, INC. Nov- Nov May
783 GOVERNING gRNAS
13 -17 -18
21- 10-
Not Available Jun May
-17 -18
7- 6- 10-
Takeda Vaccines, Inc. Nov- Nov May
14 -15 -18
15- 13- 10-
US20180125 PRIME-BOOST REGIMENS INVOLVING ADMINISTRATION OF AT
952 LEAST ONE mRNA CONSTRUCT
15 -16 -18
7- 20- 10-
Not Available Mar- Sep May
883 DISEASES
12 -17 -18
4- 22- 26-
US20180112
C-CBL MUTATIONS AND USES THEREOF Not Available Jun- Mar Apr-
270
10 -16 18
2- 2- 26-
US20180111 MODULATORS OF ACTIVIN AND METHODS FOR MODULATING
Not Available Dec- Jun Apr-
991 IMMUNE RESPONSES AND T FOLLICULAR HELPER CELLS
14 -17 18

DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL 29- 20- 26-
US20180111
BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER Not Available May- Dec Apr-
907
MUCOSAL DISEASES 12 -17 18
31- 18- 26-

US20180110 METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN
Not Available Aug- Dec Apr-
845 AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS
07 -17 18
18- 6- 19-
US20180105
Bivalent siRNA Chimeras and Methods of Use Thereof Not Available Oct- Oct Apr-
815
16 -17 18
17- 15- 19-
US20180105
ANTI-TYRO3 ANTIBODIES AND USES THEREOF Not Available Apr- Apr Apr-
596
15 -16 18
7- 3- 19-
US20180105
HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS Not Available Apr- Jan Apr-
514
16 -18 18
27- 15- 19-

US20180104 CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE
PARION SCIENCES, INC. Jun- Dec Apr-
241 POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY
11 -17 18
17- 15- 12-

US20180100 METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS
181 FOR USE IN PRACTICING THE SAME
15 -16 18
17- 14- 12-
US20180099 FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR
Not Available Sep- Dec Apr-
999 USING RECOMBINANT BACTERIA
14 -17 18
26- 26- 12-
US20180098
TREATMENT OF INFECTIOUS DISEASES CHILDREN'S MEDICAL CENTER CORPORATION Jan- Jan Apr-
972
15 -16 18
7- 5-
US20180092 28-
Anti-Viral Azide Containing Compounds Not Available Dec Apr-
932 Jul-10
-17 18
27- 7- 29-
US20180087 MAXIMIZING DNA YIELD OF BLOOD SPECIMENS COLLECTED IN
049 RAPID CLOT TUBES
16 -17 -18
28- 13- 29-
Not Available Oct- Nov Mar
14 -17 -18
23- 1- 29-
Not Available Oct- Dec Mar
457 THEREOF
15 -17 -18
4- 15- 29-
US20180085 STING (Stimulator of Interferon Genes), A Regulator of Innate
Not Available Aug- Sep Mar
432 Immune Responses
08 -17 -18
5- 29-
US20180085 6-Jul-
DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS GLAXOSMITHKLINE BIOLOGICALS, SA Oct Mar
388 10
-17 -18
19- 15- 22-
US20180079
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS Not Available Mar- Mar Mar
746
15 -16 -18
25- 25- 22-
US20180078 COMPOSITIONS AND METHODS FOR DELIVERY OF
625 BIOMACROMOLECULE AGENTS
15 -16 -18
21- 18- 22-
US20180078
IMMEDIATE RELEASE FORMULATIONS FOR OPROZOMIB AMGEN INC. Sep- Sep Mar
532
16 -17 -18
BIODEGRADABLE POLYMERIC PARTICLES ENCAPSULATING AN 16- 15- 22-

US20180078
ACTIVE AGENT, PHARMACEUTICAL COMPOSITIONS AND USES Not Available Sep- Sep Mar
507
THEREOF 16 -17 -18
18- 16- 15-

US20180073 METHODS AND COMPOSITIONS FOR LABELING TARGETS AND
073 HAPLOTYPE PHASING
15 -16 -18
2- 9- 15-
US20180072 CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF
Not Available Dec- May Mar
813 USE THEREOF
05 -17 -18
8- 17- 15-
Not Available Sep- Nov Mar
16 -17 -18
30- 2- 15-
US20180072 COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL
Not Available Mar- Feb Mar
752 COMPOSITION THEREOF, ITS PREPARATION AND USE
15 -16 -18
24- 25- 15-

US20180071
Technology for Preparation of Macromolecular Microspheres Not Available Jan- Sep Mar
219
06 -17 -18
7- 31- 8-
US20180067 ENDOSCOPIC APPARATUS FOR THERMAL DISTRIBUTION ELECTRONICS AND TELECOMMUNICATIONS RESEARCH
Sep- May Mar
299 MONITORING INSTITUTE
16 -17 -18
15- 15- 8-
US20180066 Detection of T Cell Exhaustion or Lack of T Cell Costimulation and
Not Available May- Nov Mar
228 Uses Thereof
15 -17 -18
8- 6- 8-
US20180066
CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF Not Available Sep- Sep Mar
216
16 -17 -18
26- 21- 8-
US20180065 HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE
981 ADENOSINE-A2B-RECEPTOR
15 -16 -18

Composition for Treatment or Prevention of Infectious Inflammatory 26- 25- 8-
US20180064
Diseases, or Composition for Immune Enhancement, Comprising Not Available Feb- Aug Mar
790
Tryptophanyl-tRNA Synthetase as an Active Ingredient 15 -17 -18
ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF

ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE AS
MEDICINE, PARTICULARLY FOR PROPYLAXIS AND TREATMENT OF
25- 8-
US20180064 INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN 29-
Not Available Oct Mar
752 METAPNEUMOVIRUS (HMPV), HUMAN RHINOVIRUSES (HRV), AND Jul-14
-17 -18
INFECTION BY INFLUENZA VIRUS TYPE A (IAV) AND
PHARMACEUTICAL COMPOSITION COMPRISING THE ANIONICALLY
MODIFIED POLYALLYLAMINE DERIVATIVE
1- 14- 1-
US20180058
SAMPLE FIXATION AND STABILISATION Not Available Mar- Aug Mar
988
13 -17 -18
15- 1- 1-
Not Available Aug- Nov Mar
871 VARIANTS
16 -17 -18
7- 27- 1-
US20180057
METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR Not Available Apr- Oct Mar
841
05 -17 -18
25- 9- 1-
US20180057 Particle-Nucleic Acid Conjugates and Therapeutic Uses Related
Not Available Jun- Oct Mar
817 Thereto
12 -17 -18
30- 29- 1-
US20180057 PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC
Not Available Jun- Sep Mar
594 POLYPEPTIDES
16 -17 -18
9- 2- 1-
US20180057 ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND
509 THIAZOLONAPHTHYRIDINES
05 -17 -18
23- 7- 1-
US20180057
COMPOSITIONS AND METHODS FOR INHIBITING KINASES Not Available Apr- Nov Mar
488
15 -17 -18
3- 7- 1-
DISPLAY PLATFORM FROM BACTERIAL SPORE COAT PROTEINS Mar- Aug Mar
925 Secretary, Department of Health and Human Serv
15 -15 -18
3- 26- 1-
US20180055 CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION
Not Available Dec- Jun Mar
769 AND/OR HOMOGENIZATION OF EMULSIONS
09 -17 -18
10- 5- 22-
US20180051
TAL EFFECTOR-MEDIATED DNA MODIFICATION Not Available Dec- Oct Feb
267
09 -17 -18
10- 21- 22-
US20180051
TAL EFFECTOR-MEDIATED DNA MODIFICATION Not Available Dec- Aug Feb
266
09 -17 -18
30- 22-
US20180050 6-Jul-
DELIVERY OF RNA TO DIFFERENT CELL TYPES GLAXOSMITHKLINE BIOLOGICALS, SA Aug Feb
059 10
-17 -18
12- 11- 15-
US20180044 ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN
Not Available Dec- Dec Feb
687 EXPRESSION
14 -15 -18
5- 4- 15-
US20180044 PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I
Prozymex A/S Mar- Mar Feb
328 INHIBITORS
15 -16 -18
17- 21- 15-
US20180043
INFLUENZA VIRUS VECTORS AND USES THEREFOR Not Available Mar- Aug Feb
007
14 -17 -18
28- 21- 8-
US20180037 SYSTEM AND METHOD FOR DNA SEQUENCING AND BLOOD
Nanomedical Diagnostics, Inc. Apr- Aug Feb
952 CHEMISTRY ANALYSIS
14 -17 -18
3- 1- 8-
US20180037
ENZYME-INDEPENDENT MOLECULAR INDEXING Not Available Aug- Aug Feb
942
16 -17 -18
8- 8- 8-
US20180037
CANCER INITIATING CELL AND USE THEREOF Not Available Aug- Aug Feb
871
16 -16 -18
18- 21- 8-
US20180037 STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF
DANA-FARBER CANCER INSTITUTE, INC. Jun- Sep Feb
636 USE
09 -17 -18
2- 2- 8-
US20180037
ENGINEERED POLYPEPTIDES AND USES THEREOF Not Available Aug- Aug Feb
634
16 -17 -18
METHODS AND COMPOSITIONS FOR TREATING AND/OR

22- 21- 8-
US20180037 PREVENTING A DISEASE OR DISORDER ASSOCIATED WITH
Institute of Biophysics, Chinese Academy of Sciences Aug- Aug Feb
617 ABNORMAL LEVEL AND/OR ACTIVITY OF THE IFP35 FAMILY OF
14 -15 -18
PROTEINS
27- 25- 8-
US20180036
FLAVIVIRUS REPLICONS Not Available Feb- Feb Feb
398
15 -16 -18

23- 23- 8-
US20180036
OIL/SURFACTANT MIXTURES FOR SELF-EMULSIFICATION GLAXOSMITHKLINE BIOLOGICALS, SA Feb- Feb Feb
237
15 -16 -18
27- 18- 1-
US20180031 METHOD FOR SELECTING A SINGLE CELL EXPRESSING A
Merus N.V. Jun- Jul- Feb
555 HETEROGENEOUS COMBINATION OF ANTIBODIES
08 17 -18
27- 29- 1-
US20180030
Polypeptide Assemblies and Methods for the Production Thereof Not Available Feb- Feb Feb
429
15 -16 -18
18- 13- 1-
US20180030
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available Nov- Oct Feb
411
13 -17 -18
22- 30- 1-
US20180028
Peptides for Assisting Delivery Across the Blood Brain Barrier Children's Medical Center Corporation May- Jun Feb
677
06 -17 -18
13- 12- 1-
US20180028 IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION
Transgene SA Feb- Feb Feb
626 THERAPY
15 -16 -18
METHODS OF TREATING OR PREVENTING INFLAMMATION AND 20- 10- 1-

US20180028
HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL SONOMA PHARMACEUTICALS, INC. Jan- Oct Feb
562
WATER SOLUTION 06 -17 -18
27- 1-
US20180028 24-
Technology for the Preparation of Microparticles Not Available Jun Feb
449 Jul-07
-17 -18
27- 1-
US20180028 POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS 28-
eXion labs Inc. Jul- Feb
431 OF USE THEREOF Jul-16
17 -18
29- 22- 25-
US20180023
ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS Not Available Oct- Sep Jan-
048
04 -17 18
13- 12- 25-
US20180022 POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Feb- Feb Jan-
781 PROTEINS AND THEIR USE IN GENE THERAPY (CNRS)
15 -16 18
16- 25-
US20180021 12-
Conjugates of Cell Binding Molecules with Cytotoxic Agents Hangzhou DAC Biotech Co., Ltd. Apr Jan-
448 Jul-12
-14 18
10- 10- 18-
GRIFFITHSIN MUTANTS Feb- Feb Jan-
15 -16 18
20- 28- 18-
US20180016
Boron-Containing Small Molecules Not Available Jun- Sep Jan-
285
07 -17 18
13- 12- 18-
US20180016
HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS Not Available Feb- Feb Jan-
243
15 -16 18
14- 18-
US20180015 SYNTHETIC NANOPARTICLES FOR DELIVERY OF 15-
174 IMMUNOMODULATORY COMPOUNDS Jul-16
17 18
30- 28- 18-

15 -16 18
2- 26- 11-
US20180010
ORGANISM IDENTIFICATION PANEL Not Available Apr- Jul- Jan-
167
07 17 18
12- 15- 11-
US20180010 DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4
Quark Pharmaceuticals Inc. Sep- Feb Jan-
125 AND METHODS OF USE THEREOF
12 -17 18
31- 22- 11-
US20180009
NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. May- Sep Jan-
787
16 -17 18
28- 28- 11-
US20180008 RNA VIRUS ATTENUATION BY ALTERATION OF MUTATIONAL
689 ROBUSTNESS AND SEQUENCE SPACE
15 -16 18
18- 16- 4-
US20180002 FLUOROGENIC PROBES AND THEIR USE IN QUANTITATIVE
743 DETECTION OF TARGET RNA SEQUENCES
16 -17 18
7- 8- 4-
NEUTRALIZING GP41 ANTIBODIES AND THEIR USE Nov- Sep Jan-
406 Secretary, Department of Health and Human
11 -17 18
30- 14- 4-
US20180000 D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND
Not Available Nov- Sep Jan-
12 -17 18
15- 15- 4-
US20180000 METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C
926 VIRUS
15 -16 18
26- 15- 4-
US20180000
Induced Hepatocytes and Uses Thereof Not Available Nov- Sep Jan-
868
14 -17 18
10- 4-
US20180000 METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL 26-
Not Available May Jan-
724 AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE Jul-10
-17 18
18- 29- 28-

US20170369
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available Nov- Mar Dec
843
13 -17 -17
16- 16- 28-
US20170369
Cyclic Compounds and Uses Thereof Not Available Dec- Dec Dec
470
14 -15 -17

29- 10- 28-
US20170368
Compositions For Enhancing Transport Of Molecules Into Cells Not Available Apr- Jan Dec
203
03 -17 -17
SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT 15- 8- 28-

US20170368
LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE The Children's Hospital of Philadelphia Mar- Sep Dec
201
SYSTEM 13 -17 -17
21- 6- 28-
US20170368 COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL
Not Available Aug- Jun Dec
167 DISORDERS
12 -16 -17
4- 7- 21-
US20170362
OLIGOPEPTIDE-FREE CELL CULTURE MEDIA Not Available Jan- Aug Dec
300
06 -17 -17
19- 21- 21-
US20170362
CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF Not Available Dec- Dec Dec
297
14 -15 -17
17- 29- 21-

Parion Sciences, Inc. Dec- Jun Dec
12 -17 -17
3- 29- 21-
US20170362
HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS Not Available Aug- Jun Dec
170
07 -17 -17
16- 18- 21-

US20170360 NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS
Not Available Feb- Aug Dec
962 RESISTANT TO PRE-EXISTING HUMAN NEUTRALIZING ANTIBODIES
16 -17 -17
21- 20- 21-

US20170360
AAV Vectors Targeted to the Central Nervous System Not Available Nov- Nov Dec
960
14 -15 -17
3- 2- 21-
US20170360 VACCINE PHARMACEUTICAL COMPOSITION FOR CELL-MEDIATED
NITTO DENKO CORPORATION Sep- Sep Dec
908 IMMUNITY CONTAINING BISPHOSPHONATES
14 -15 -17
17- 16- 21-

US20170360
PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF Not Available Jun- Jun Dec
881
16 -17 -17
22- 22- 21-
US20170360
METHODS FOR TREATING IMMUNE-MEDIATED VIRAL INFECTIONS MIDDLE TENNESSEE STATE UNIVERSITY Dec- Dec Dec
875
14 -15 -17
15- 2- 14-
US20170358
STAIN-FREE HISTOPATHOLOGY BY CHEMICAL IMAGING Not Available Mar- Aug Dec
082
13 -17 -17
8- 23- 14-
US20170354 MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF
Not Available Oct- Aug Dec
727 SYNONYMOUS CODONS
04 -17 -17
16- 16- 7-
US20170348 NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS The Board of Trustees of the Leland Stanford Junior
Feb- Feb Dec
433 RESISTANT TO PRE-EXISTING HUMAN NEUTRALIZING ANTIBODIES University
16 -17 -17
30- 7-
US20170348 SYSTEM AND METHOD FOR DELIVERING GENETIC MATERIAL OR 30-
402 PROTEIN TO CELLS Jul-14
15 -17
16- 18- 7-
US20170348
Plant Extract and Its Therapeutic Use Not Available May- Jul- Dec
369
08 17 -17
11- 15- 30-
US20170342 RECOMBINANT SELF-REPLICATING POLYCISTRONIC RNA
GLAXOSMITHKLINE BIOLOGICALS, SA Oct- Aug Nov
442 MOLECULES
11 -17 -17
31- 16- 30-
US20170342
MOLECULAR INDEXING OF INTERNAL SEQUENCES Not Available May- May Nov
405
16 -17 -17
31- 26- 30-
US20170342
NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. May- May Nov
056
16 -17 -17
1- 19- 30-
US20170340
Anti-TIGIT Antigen-Binding Proteins and Methods of Use Thereof Not Available Oct- Jun Nov
735
15 -17 -17
22- 11- 30-
US20170340
COMBINATION PIV3/HMPV RNA VACCINES ModernaTX, Inc. Oct- Aug Nov
725
15 -17 -17
3- 3- 30-
US20170340 METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE
Not Available Sep- Sep Nov
721 RESPONSES
14 -15 -17
31- 26- 30-
US20170340
NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. May- May Nov
611
16 -17 -17
27- 2- 23-
US20170337
SPATIALLY ADDRESSABLE MOLECULAR BARCODING Not Available Feb- Aug Nov
459
15 -17 -17
4- 19- 23-
US20170336
Multiplex Immuno Screening Assay Institut Pasteur May- Jul- Nov
412
12 17 -17
8- 9- 23-
US20170336 The University of Pittsburgh - Of the Commonwealth
B-CELL ANTIGEN PRESENTING CELL ASSAY Apr- Aug Nov
411 System of Higher Education
10 -17 -17
15- 15- 23-
US20170335
Methods and Systems of Multi-Assay Processing and Analysis Not Available Mar- Mar Nov
408
16 -17 -17

6- 6- 23-
US20170335 METHODS AND COMPOSITIONS FOR IDENTIFICATION OF SOURCE
Not Available Mar- Jul- Nov
374 OF MICROBIAL CONTAMINATION IN A SAMPLE
12 17 -17
16- 26- 23-

US20170334
HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) Not Available Dec- Apr Nov
984
02 -16 -17
NON-HUMAN PRIMATE-DERIVED PAN-EBOLA AND PAN-FILOVIRUS 28- 27- 23-

US20170334
MONOCLONAL ANTIBODIES DIRECTED AGAINST ENVELOPE Not Available Oct- Oct Nov
973
GLYCOPROTEINS 14 -15 -17
31- 30- 23-

US20170334 2',2'-DIHALO NUCLEOSIDE ANALOGS FOR TREATMENT OF THE
941 FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER
14 -15 -17
2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-
15- 27- 23-
US20170334 PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUORO-MET
RESPIVERT LTD. Mar- Jul- Nov
919 HYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR
13 17 -17
USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS
3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6- 27- 1- 23-

US20170334
PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL) Parion Sciences, Inc. Jun- Mar Nov
864
CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE 11 -17 -17
8- 23- 23-
US20170333 ADDITIVE COMPOSITIONS FOR PIGMENTED DISINFECTION AND
586 METHODS THEREOF
14 -15 -17
21- 1- 23-
Not Available May- Aug Nov
13 -17 -17
10- 9- 23-
US20170333
PROBIOTIC THERAPEUTIC APPLICATIONS Not Available Nov- Nov Nov
494
14 -15 -17
8- 23-
US20170333 28-
Anti-Viral Azide Containing Compounds Not Available Aug Nov
457 Jul-10
-17 -17
12- 11- 23-
US20170333
MOBILE CLINICS Baylor College of Medicine Nov- Nov Nov
267
14 -15 -17
1- 30- 16-
US20170328
SAMPLE FIXATION AND STABILISATION Not Available Mar- May Nov
819
13 -17 -17
8- 31- 16-
US20170327
POLYIONIC PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES Not Available Sep- Jan Nov
543
10 -17 -17
17- 7- 16-
Parion Sciences, Inc. Dec- Mar Nov
12 -17 -17
3- 3- 16-
US20170327
DIHYDRONAPHTHALENE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. Dec- Dec Nov
439
14 -14 -17
16- 15- 16-
US20170326 RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN
Children's Healthcare of Atlanta, Inc. Apr- Apr Nov
256 EXPRESSION IN LIVER AND USE THEREOF
15 -16 -17
12- 12- 16-
US20170326
Throat solution for treatment of cold, flu and sore throat Not Available May- May Nov
123
16 -16 -17
25- 27- 9-
US20170322 SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING,
Georgetown University Feb- Jul- Nov
682 AND COMMUNICATING EVENT-RELATED INFORMATION
08 17 -17
8- 20- 9-
ANTIGEN PRESENTING CELL ASSAY Apr- Jul- Nov
10 17 -17
6- 6- 9-
US20170321
Recombinant RNA Viruses and Uses Thereof Icahn School of Medicine at Mount Sinai Jun- Apr Nov
192
10 -17 -17
10- 27- 9-
3M INNOVATIVE PROPERTIES COMPANY Apr- Jul- Nov
712 RESPONSE
03 17 -17
13- 12- 9-
US20170319
TRI-SEGMENTED ARENAVIRUSES AS VACCINE VECTORS Not Available Nov- Nov Nov
673
14 -15 -17
9- 24- 9-
US20170319
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available May- Jan Nov
551
12 -17 -17
29- 28- 2-
US20170313
DIRECT EXPRESSION OF ANTIBODIES Not Available Oct- Oct Nov
765
14 -15 -17
28- 28- 2-
US20170313 BROAD-SPECTRUM NON-COVALENT CORONAVIRUS PROTEASE
Purdue Research Foundation Apr- Apr Nov
685 INHIBITORS
16 -17 -17
22- 20- 2-
US20170312
MODIFIED VIRUS-LIKE PARTICLES OF CMV SAIBA GMBH Oct- Oct Nov
371
14 -15 -17

2- 2- 2-
US20170312
MANUFACTURE OF SURFACTANT-CONTAINING COMPOSITIONS Not Available Dec- Dec Nov
357
14 -15 -17
16- 12- 26-
US20170308
BIOSECURITY SCREENING SYSTEM AND METHOD Not Available Oct- Oct Oct-
679
14 -15 17
28- 8- 26-
US20170307
CHEMICALLY DIFFERENTIATED SENSOR ARRAY Nanomedical Diagnostics, Inc. Apr- May Oct-
562
14 -17 17
17- 1- 26-
Not Available Dec- May Oct-
01 -17 17
9- 2- 26-
US20170306 MEANS AND METHODS FOR INFLUENCING THE STABILITY OF
Not Available Dec- Jun Oct-
293 ANTIBODY PRODUCING CELLS
05 -17 17
CHIMERIZATION AND CHARACTERIZATION OF A MONOCLONAL 27- 27- 26-

US20170306
ANTIBODY WITH POTENT NEUTRALIZING ACTIVITY ACROSS NATIONAL UNIVERSITY OF SINGAPORE Mar- Mar Oct-
001
MULTIPLE INFLUENZA A H5N1 CLADES 14 -15 17
13- 1- 26-
US20170305 ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL
Parion Sciences, Inc. Dec- Mar Oct-
13 -17 17
22- 21- 26-
US20170304 PRINTED CIRCUIT BOARD HEATER FOR AN AMPLIFICATION
Click Diagnostics, Inc. Apr- Apr Oct-
829 MODULE
16 -17 17
6- 6- 26-
US20170304
AAV-Based Gene Therapy Not Available Oct- Oct Oct-
466
14 -15 17
10- 7- 26-
US20170304 METHODS AND COMPOSITIONS FOR INHALATION DELIVERY OF
459 CONJUGATED OLIGONUCLEOTIDE
14 -15 17
26- 25- 26-
US20170304
VACCINATION OF IMMUNOCOMPROMISED SUBJECTS Not Available Sep- Sep Oct-
429
14 -15 17
10- 9- 26-
US20170304
POLYMER ADJUVANT Oxford University Innovation Limited Oct- Oct Oct-
420
14 -15 17
15- 13- 26-
US20170304 TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE
Marine Polymer Technologies, Inc. Apr- Mar Oct-
354 NANOFIBERS
11 -17 17
6- 13- 19-
Not Available Oct- Dec Oct-
08 -16 17
1- 30- 19-
US20170298
ANTI-VIRAL PEPTIDES Not Available Oct- Sep Oct-
100
14 -15 17
16- 16- 19-
US20170296
Conjugates of Cell Binding Molecules with Cytotoxic Agents Hangzhou DAC Biotech Co., Ltd. Apr- Apr Oct-
663
14 -14 17
1- 28- 19-
US20170296
Method of Treating Inflammation Not Available Apr- Jun Oct-
574
10 -17 17
29- 20- 12-
US20170292 TISSUE PREFERENTIAL CODON MODIFIED EXPRESSION
Not Available Apr- Jun Oct-
132 CASSETTES, VECTORS CONTAINING SAME, AND USES THEREOF
13 -17 17
26- 25- 12-

US20170290 METHODS AND COMPOSITIONS FOR INTRA-NASAL IMMUNIZATION
Bavarian Nordic A/S Sep- Sep Oct-
909 WITH RECOMBINANT MVA ENCODING FLAGELLIN
14 -15 17
1- 28- 5-
US20170281
Device to Kill Micro-Organisms Inside the Respiratory Tract Not Available Apr- Mar Oct-
966
16 -17 17
3- 2- 5-
US20170281 BISPHOSPHONATE-CONTAINING VACCINE PHARMACEUTICAL
NITTO DENKO CORPORATION Sep- Sep Oct-
759 COMPOSITION FOR HUMORAL IMMUNITY
14 -15 17
17- 28-
US20170275 13-
CHIRAL CONTROL Not Available Mar Sep
621 Jul-12
-17 -17
27- 27- 28-
US20170275
CULTURE MEDIUM Koninklijke Nederlandse Akademie Van Wetenschappen Nov- Nov Sep
592
14 -15 -17
4- 7- 28-
US20170275 GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF
THE UNIVERSITY OF NOTTINGHAM Apr- Apr Sep
323 FOR USE IN THERAPY
14 -15 -17
18- 14- 28-
US20170275
BENZAZEPINE SULFONAMIDE COMPOUNDS Hoffmann-La Roche Inc. Dec- Jun Sep
253
14 -17 -17
5- 4- 28-
US20170275
Lipids and Lipid Compositions for the Delivery of Active Agents Novartis AG Sep- Sep Sep
243
14 -15 -17
5- 4- 28-
US20170274
MODIFIED BAT INFLUENZA VIRUSES AND THEIR USES Not Available Sep- Sep Sep
064
14 -15 -17
28- 17- 28-
US20170274
AAV Vectors Targeted to Oligodendrocytes Not Available Sep- Apr Sep
024
12 -17 -17

29- 18- 21-
US20170267
Animal Protein-Free Media for Cultivation of Cells Baxalta GmbH Oct- May Sep
969
04 -17 -17
25- 21-
US20170267 17-
INHIBITORY PEPTIDES OF VIRAL INFECTION Not Available May Sep
722 Jul-14
-17 -17
30- 30- 21-
US20170267
STABLE SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. Jun- Jan Sep
649
14 -17 -17
2- 6- 21-
US20170266
TRANSGENIC VERO-CD4/CCR5 CELL LINE Not Available Oct- Apr Sep
272
15 -17 -17
15- 5- 21-
US20170266
DRUG COMBINATION Not Available Mar- Jun Sep
190
13 -17 -17

14- 6- 21-
Not Available Mar- Jun Sep
13 -17 -17
CATHEPSIN C
10- 19- 14-

US20170261 CONTINUOUS PROCESS FOR PERFORMING MULTIPLE NUCLEIC
Not Available Mar- May Sep
431 ACID AMPLIFICATION ASSAYS
05 -17 -17
4- 17- 14-
US20170260
ENANTIOMERS OF THE 1',6'-ISOMER OF NEPLANOCIN A Not Available Aug- May Sep
223
14 -17 -17
26- 23- 14-
US20170260
ANTIVIRAL COMPOUNDS AND METHODS Biotron Limited Jun- May Sep
147
03 -17 -17
3- 2- 14-
US20170259
DEGRADABLE MATERIALS AND PACKAGING MADE FROM SAME MONOSOL, LLC Oct- Oct Sep
976
14 -15 -17
2- 22- 14-
US20170258
Antagonism of the VIP Signaling Pathway Not Available Feb- May Sep
904
11 -17 -17
29- 26- 14-
US20170258
MERS-CoV Vaccine Not Available Nov- Nov Sep
893
13 -14 -17
6- 7-
US20170253 11-
HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS Not Available Oct Sep
861 Jul-03
-16 -17
1- 1- 7-
US20170252 POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN
Not Available Apr- Apr Sep
430 IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT
14 -15 -17
7- 7- 7-
US20170252
PROTEIN-CHAPERONED T-CELL VACCINES Not Available Mar- Mar Sep
417
16 -17 -17
1- 12- 31-
NUEVOLUTION A/S Dec- Dec Aug
688 LARGE LIBRARIES
05 -16 -17
16- 9- 31-
SOLUBLE ENGINEERED MONOMERIC FC Mar- May Aug
12 -17 -17
29- 28- 31-
US20170247 STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES
Not Available Feb- Feb Aug
423 TO TREAT INFECTION
16 -17 -17
1- 5- 31-
US20170246
MATERIALS WITH IMPROVED PROPERTIES Not Available Nov- May Aug
347
15 -17 -17
22- 17- 24-
US20170241
METHOD FOR THE IMMOBILIZATION OF BIOMOLECULES Not Available Feb- Feb Aug
998
16 -17 -17
22- 22- 24-
US20170240
ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY Not Available Feb- Feb Aug
639
16 -17 -17
1- 5- 24-
Not Available Nov- May Aug
397 APPLICATIONS
15 -17 -17
28- 2- 24-
US20170239 METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL
Not Available Mar- Mar Aug
364 ENTRY
11 -17 -17
20- 6- 24-
US20170239 COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL
Not Available Feb- Jun Aug
349 DISORDERS
15 -16 -17
30- 9- 24-
US20170239 METHOD OF PREVENTING OR TREATING SINUSITIS WITH
SONOMA PHARMACEUTICALS, INC. Dec- May Aug
291 OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION
03 -17 -17
7- 3- 17-
US20170234
MEMBRANE-ASSISTED PURIFICATION Accelerate Diagnostics, Inc. Mar- May Aug
781
11 -17 -17
8- 8- 10-
US20170226 HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID
593 IDENTIFICATION
16 -16 -17
13- 13- 10-
US20170226
APTAMERS FOR BINDING FLAVIVIRUS PROTEINS National University of Singapore Nov- Nov Aug
511
13 -14 -17
1- 2- 10-
Not Available Nov- Nov Aug
232 APPLICATIONS
15 -16 -17

20- 18- 10-
US20170226
BISPECIFIC ANTIBODY Not Available Nov- Jan Aug
222
13 -17 -17
23- 19- 10-
US20170226 GM-CSF and IL-4 Conjugates, Compositions, and Methods Related
Not Available Oct- Apr Aug
173 Thereto
12 -17 -17
VACCINE PHARMACEUTICAL COMPOSITION FOR SUPPRESSING 4- 4- 10-

US20170224
APOPTOSIS OF CTL OR INHIBITING SUPPRESSION OF INDUCTION NITTO DENKO CORPORATION Aug- Aug Aug
813
OF CTL 14 -15 -17
LIQUID IMMUNITY INDUCTION-PROMOTING COMPOSITION AND 4- 4- 10-

US20170224
VACCINE PHARMACEUTICAL COMPOSITION THAT INCLUDE NITTO DENKO CORPORATION Aug- Aug Aug
812
THROMBOSIS TREATMENT DRUG 14 -15 -17
24- 10-
US20170224 6-Jul-
OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS GLAXOSMITHKLINE BIOLOGICALS SA Apr Aug
616 11
-17 -17
31- 10- 3-
US20170219 United States of America as Represented by the Secretary
MALARIA ANTIGEN SCREENING METHOD Aug- Apr Aug
560 of the Navy
05 -17 -17
2- 1- 3-
US20170216 VACCINE PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL
NITTO DENKO CORPORATION Oct- Oct Aug
431 ADMINISTRATION
14 -15 -17
IMMUNE-INDUCTION-PROMOTING COMPOSITION INCLUDING 4- 4- 3-

US20170216
NUCLEAR RECEPTOR LIGAND, AND VACCINE PHARMACEUTICAL NITTO DENKO CORPORATION Aug- Aug Aug
430
COMPOSITION 14 -15 -17
4- 4- 3-
US20170216 COMPOSITION FOR ENHANCING INDUCTION OF HUMORAL
NITTO DENKO CORPORATION Aug- Aug Aug
429 IMMUNITY, AND VACCINE PHARMACEUTICAL COMPOSITION
14 -15 -17
23- 3-
US20170216 23-
Coronavirus Not Available Jul- Aug
427 Jul-14
15 -17
7- 7- 3-
US20170216
METAL NANOCLUSTERS AND USES THEREOF Not Available Aug- Aug Aug
348
14 -15 -17
ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF

ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE AS
MEDICINE, PARTICULARLY FOR PROPYLAXIS AND TREATMENT OF
29- 3-
US20170216 INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN 29-
UNIWERSYTET JAGIELLONSKI Jul- Aug
347 METAPNEUMOVIRUS (HMPV), HUMAN RHINOVIRUSES (HRV), AND Jul-14
15 -17
INFECTION BY INFLUENZA VIRUS TYPE A (IAV) AND
PHARMACEUTICAL COMPOSITION COMPRISING THE ANIONICALLY
MODIFIED POLYALLYLAMINE DERIVATIVE
31- 26- 27-

US20170212 BIOSENSORS FOR THE DETECTION OF INFECTION AND
ULISSE BIOMED SRL Jan- Jan Jul-
116 ASSOCIATED MALADIES
14 -15 17
23- 10- 27-
US20170212
POLYMER STABILIZATION OF CHROMOGEN SOLUTIONS Not Available Jan- Apr Jul-
019
12 -17 17
29- 7- 27-
US20170211 LCMV-GP-VSV-Pseudotyped Vectors and Tumor-Infiltrating Virus-
Not Available Jun- Apr Jul-
096 Producing Cells for the Therapy of Tumors
11 -17 17
7- 27- 27-
US20170211 USE OF THE CHROMOSOME 19 MICRORNA CLUSTER (C19MC) FOR University of Pittsburgh - Of the Commonwealth System of
Mar- Jan Jul-
069 TREATING MICROBIAL DISEASE AND PROMOTING AUTHOPHAGY Higher Education
12 -17 17
6- 5- 27-
US20170211 METHOD AND APPARATUS FOR AUTOMATED PROCESSING OF
058 POOLED SAMPLES
14 -15 17
18- 5- 27-
US20170209
MICROSPOTTING DEVICE Not Available Apr- Jan Jul-
844
12 -17 17
5- 27-
US20170209 DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL- 15-
Suzhou M-Conj Biotech Co., Ltd. Apr Jul-
595 BINDING MOLECULE Jul-15
-17 17
13- 10- 27-

11 -17 17
19- 17- 27-

US20170209
Carbon Nanotube Compositions and Methods of Use Thereof Not Available Mar- Mar Jul-
570
08 -17 17
COMPOSITIONS WITH MODIFIED NUCLEASES TARGETED TO VIRAL 14- 10- 27-

US20170209
NUCLEIC ACIDS AND METHODS OF USE FOR PREVENTION AND Not Available Apr- Mar Jul-
376
TREATMENT OF VIRAL DISEASES 04 -17 17
2- 31- 20-
US20170205
POLYMERS AND CONJUGATES COMPRISING THE SAME Not Available Oct- Mar Jul-
399
14 -17 17

21- 20-
US20170204 21-
Constrained proteins and uses therefor Not Available Jul- Jul-
143 Jul-14
15 17
11- 13- 20-
US20170204 THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY Sep- Jan Jul-
083 AND HYDROXYPYRIDAZINONES
12 -17 17
5- 20-
Suzhou M-Conj Biotech Co., Ltd. Apr Jul-
-17 17
23- 20-
US20170202 6-Jul-
CATIONIC OIL-IN-WATER EMULSIONS GLAXOSMITHKLINE BIOLOGICALS, SA Mar Jul-
960 11
-17 17
24- 23- 20-
US20170202
ADJUVANT COMPOSITIONS AND RELATED METHODS Not Available Mar- Mar Jul-
959
15 -17 17
15- 17- 20-
US20170202
Methods and Compositions for Inhibiting Akt3 Not Available Jan- Jan Jul-
956
16 -17 17
22- 30- 20-
US20170202
Adjuvanted Influenza Vaccines for Pediatric Use Not Available Feb- Dec Jul-
955
08 -16 17
29- 20-
US20170202 DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND 29-
Providence Health & Services - Oregon Dec Jul-
949 METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE Jul-05
-16 17
15- 17- 20-

US20170202 Specific Akt3 Inhibitor and Uses Thereof Cross-Reference to Related
829 Applications
16 -17 17
8- 27- 13-
Novartis AG Mar- Sep Jul-
979 AGENTS
13 -16 17
14- 13-
US20170196 PRIME-BOOST REGIMENS WITH A TLR4 AGONIST ADJUVANT AND A 15-
Not Available Jul- Jul-
954 LENTIVIRAL VECTOR Jul-14
15 17
31- 23- 6-
US20170191 Systems and Methods for Analyzing a Sample and for Monitoring the
Not Available Dec- Dec Jul-
933 Performance of an Optical Signal Detector
15 -16 17
7- 18- 6-
US20170191
METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR Not Available Apr- Jan Jul-
079
05 -17 17
16- 26- 6-
US20170190
HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) CORMORANT PHARMACEUTICALS AB Dec- Apr Jul-
770
02 -16 17
17- 19- 6-
3M Innovative Properties Company Aug- Aug Jul-
10 -16 17
16- 14- 22-

US20170175 METHODS FOR USING A 5'-EXONUCLEASE TO INCREASE
140 HOMOLOGOUS RECOMBINATION IN EUKARYOTIC CELLS
15 -16 17
10- 22-
US20170173 POINT OF CARE POLYMERASE CHAIN REACTION DEVICE FOR 11-
585 DISEASE DETECTION Jul-14
15 17
3- 22-
US20170173 ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC 15-
SUZHOU M-CONJ BIOTECH CO., LTD. Mar Jun-
176 CONJUGATION OF A CELL-BINDING MOLECULE Jul-15
-17 17
3- 22-
SUZHOU M-CONJ BIOTECH CO., LTD. Mar Jun-
-17 17
3- 6- 22-
US20170173 HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES
Not Available Jun- Mar Jun-
164 MADE THEREFROM
11 -17 17
6- 13- 15-
Not Available Oct- Dec Jun-
08 -16 17
9- 24- 15-
US20170168 QUANTITATIVE ANALYSIS METHOD BASED ON AIR PRESSURE
XIAMEN UNIVERSITY Jun- Sep Jun-
044 MEASURING
14 -14 17
14- 12- 15-
US20170166
NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. Dec- Dec Jun-
574
15 -16 17
1- 13- 15-
US20170165
Anti-TIGIT Antigen-Binding Proteins and Methods of Use Thereof Not Available Oct- Feb Jun-
366
15 -17 17
11- 23- 15-
US20170165 IMMUNOSTIMULATORY COMBINATIONS OF TLR LIGANDS AND
Not Available Aug- Aug Jun-
359 METHODS OF USE
10 -16 17
24- 15- 15-
US20170165
REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION Not Available Aug- Feb Jun-
341
12 -17 17
9- 9- 15-
US20170165 USE OF GSK-3 INHIBITORS OR ACTIVATORS WHICH MODULATE
Not Available Apr- Apr Jun-
230 PD-1 OR T-BET EXPRESSION TO MODULATE T CELL IMMUNITY
14 -15 17
23- 8-
US20170160 APPARATUS AND SYSTEM FOR PERFORMING THERMAL MELT 31-
Not Available Feb Jun-
218 ANALYSES AND AMPLIFICATIONS Jul-12
-17 17

30- 15- 8-
Not Available Sep- Feb Jun-
03 -17 17
2- 2- 8-
US20170159 Novel Recombinant Adeno-Associated Virus Capsids with Enhanced
026 Human Skeletal Muscle Tropism
15 -16 17
25- 27- 8-
US20170158 MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS
752 NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF
14 -15 17
12- 8-
262 AGENTS Jul-12
12 17
17- 16- 8-
US20170157
Broad Spectrum Antiviral and Methods of Use Not Available Apr- Feb Jun-
151
06 -17 17
28- 28- 1-
US20170152
CHARGED LINKERS AND THEIR USES FOR CONJUGATION Hangzhou DAC Biotech Co., Ltd. Feb- Feb Jun-
274
14 -14 17
23- 1-
US20170152 23-
GAK MODULATORS AS ANTIVIRALS Katholieke Universiteit Leuven Jul- Jun-
271 Jul-14
15 17
13- 1-
SUZHOU M-CONJ BIOTECH CO., LTD. Feb Jun-
-17 17
25- 25- 1-
US20170151 SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF
Not Available Nov- Nov Jun-
291 PRODUCTION AND USE THEREOF
13 -14 17
23- 22- 25-
US20170145 TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR
394 DELIVERY OF CRISPR/CAS9
15 -16 -17
4- 25- 25-
US20170144
MODULATORS OF THE RELAXIN RECEPTOR 1 Not Available May- Aug May
984
12 -16 -17
3- 25-
SUZHOU M-CONJ BIOTECH CO., LTD Feb May
-17 -17
13- 12- 25-
US20170143
IMMUNOGENIC COMBINATIONS GLAXOSMITHKLINE SA Jun- Jun May
820
14 -15 -17
11- 4- 25-
Advanced Inhalation Therapies (AIT) Ltd. Sep- Jan May
758 DISEASES
13 -17 -17
24- 2- 25-
US20170143 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS
Not Available Jun- Feb May
749 THEREOF
14 -17 -17
25- 7- 18-
US20170137 GITR ANTIBODIES AND METHODS OF INDUCING OR ENHANCING
527 AN IMMUNE RESPONSE
05 -16 -17
22- 18-
US20170137 29-
Nuclear Transport Modulators And Uses Thereof Not Available Jul- May
430 Jul-11
16 -17
28- 8- 18-
US20170136
NEUTRALIZING MOLECULES TO VIRAL ANTIGENS Not Available Mar- Jun May
118
08 -16 -17
11- 30- 18-
US20170136 THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE
The University of North Carolina at Chapel Hill Apr- Jan May
043 COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY
14 -17 -17
27- 12- 11-
Not Available Apr- Sep May
10 -16 -17
29- 11-
Not Available Jul- May
200 THERAPY Jul-15
16 -17
20- 11-
US20170129 REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND 25-
Kolltan Pharmaceuticals, Inc. Sep May
947 LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYL SERINE Jul-12
-16 -17
18- 23- 11-

Not Available Jun- Jan May
04 -17 -17
3- 6- 11-
US20170128
Pharmaceutical Compositions and Methods Not Available Aug- Dec May
465
15 -16 -17
THE UNITED STATES OF AMERICA, AS REPRESENTED BY 8- 7- 4-
US20170122 PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN
THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN Aug- Aug May
853 VIVO
SERV 14 -15 -17
3- 15- 4-
US20170121
NOVEL DEPSIPEPTIDE AND USES THEREOF Not Available Dec- Jun May
372
12 -16 -17
20- 11- 4-
US20170119
SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES Not Available Aug- Oct May
872
10 -16 -17
27- 24- 4-
US20170119
LOW-ADDITIVE INFLUENZA VACCINES Not Available Jun- Jun May
871
07 -16 -17
29- 4-
US20170119 31-
MODIFIED CELLS AND METHODS OF THERAPY Not Available Jul- May
820 Jul-15
16 -17

8- 11- 4-
US20170119
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS Not Available Mar- Nov May
786
11 -16 -17
5- 22- 4-
US20170119
TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE Not Available May- Apr May
734
10 -16 -17
MINERAL FUNCTIONAL WATER, METHOD FOR PRODUCING THE 17- 6- 4-

US20170118
SAME, AND METHOD FOR CONTROLLING UNICELLULAR Riken Techno System Co., Ltd. Sep- Dec May
995
ORGANISMS AND/OR VIRUSES 14 -16 -17
12- 12- 27-

HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF Jun- Jun Apr-
14 -15 17
7- 6- 27-
US20170112
VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER Not Available Sep- Jun Apr-
929
12 -16 17
2- 2- 20-
US20170107
Modified Antimicrobial Peptides Not Available Apr- Apr Apr-
254
14 -15 17
18- 17- 20-
US20170107
Chemical Compounds AstraZeneca AB Mar- Mar Apr-
195
14 -15 17
17- 13- 20-
US20170106
INFLUENZA VIRUS VECTORS AND USES THEREFOR Not Available Mar- Mar Apr-
077
14 -15 17
CLEAVAGE AND EXCHANGE OF MAJOR HISTOCOMPATIBILITY 6- 5- 13-

US20170101
COMPLEX LIGANDS EMPLOYING AZOBENZENE-CONTAINING Not Available Jun- Jun Apr-
459
PEPTIDES 14 -15 17
12- 12- 13-

US20170101
NOVEL COMPOUNDS CHIESI FARMACEUTICI S.p.A. Jun- Jun Apr-
413
14 -14 17
6- 22- 13-
US20170100
METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES Not Available Apr- Jul- Apr-
474
07 16 17
12- 8- 13-
US20170100 PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2)
May- May Apr-
385 TREATING INFECTIOUS DISEASES LIMITED
14 -15 17
28- 20- 6-
US20170096
Modified Adenovirus Hexon Protein and Uses Thereof Not Available Apr- Dec Apr-
646
06 -16 17
20- 20- 6-
US20170096 METHODS AND COMPOSITIONS FOR CHIMERIC CORONAVIRUS
The University of North Carolina at Chapel Hill Mar- Mar Apr-
455 SPIKE PROTEINS
14 -15 17
14- 9- 6-
US20170096 PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF
Not Available Apr- Sep Apr-
10 -16 17
20- 19- 6-
US20170096
Multicyclic Compounds And Methods Of Using Same Karyopharm Therapeutics Inc. Sep- Sep Apr-
417
13 -14 17
31- 31- 6-
US20170095 INTEGRATED MICROFLUIDIC DEVICE FOR TARGET AMPLIFICATION
CapitalBio Corporation Mar- Mar Apr-
818 AND MICROARRAY DETECTION
14 -15 17
1- 30- 6-
US20170095 Novel Polygonum Cuspidatum Extracts and Their Use as
Not Available Oct- Sep Apr-
521 Photodynamic Inactivating Agents
15 -16 17
24- 24- 30-
US20170089
QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION Not Available Feb- Aug Mar
911
14 -16 -17
17- 20- 30-

Not Available Dec- Oct Mar
01 -16 -17
21- 2- 30-
US20170088 Recombinant Influenza Virus-Like Particles (VLPs) Produced in
Medicago Inc. Jan- Sep Mar
848 Transgenic Plants Expressing Hemagglutinin
08 -16 -17
9- 12- 30-
Not Available Feb- Dec Mar
05 -16 -17
3- 12- 30-
US20170086
ANTIVIRAL AGENT Not Available Sep- Dec Mar
463
08 -16 -17
16- 15- 23-
US20170082
Assay for Detecting TH1 and TH2 Cell Populations Not Available May- May Mar
608
14 -15 -17
31- 19- 23-
US20170082
MALARIA ANTIGEN SCREENING METHOD Not Available Aug- Apr Mar
607
05 -13 -17
13- 23-
US20170081 PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM 14-
Not Available Jul- Mar
655 OXIDES Jul-15
16 -17
31- 2- 23-
ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES Jan- Dec Mar
08 -16 -17
13- 13- 23-
14 -15 -17

17- 17- 23-
US20170080
OIL/SURFACTANT MIXTURES FOR SELF-EMULSIFICATION Not Available Mar- Mar Mar
084
14 -15 -17
23- 23- 23-
US20170080
METHODS OF MAKING AND USING LIVE ATTENUATED VIRUSES Not Available Sep- Sep Mar
079
15 -16 -17
24- 3- 23-
Not Available Apr- Oct Mar
12 -16 -17
5- 23-
US20170079 24-
Technology for the Preparation of Microparticles Not Available Dec Mar
920 Jul-07
-16 -17
23- 23- 23-
US20170079 COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER
916 NANOPARTICLE DELIVERY
15 -16 -17
TRANSGENIC MICE HAVING A HUMAN MAJOR HISTOCOMPATIBILITY 17- 23-

US20170079 30-
COMPLEX (MHC) PHENOTYPE, EXPERIMENTAL USES AND INSTITUT PASTEUR Jul- Mar
253 Jul-03
APPLICATIONS 12 -17
1- 25- 16-
US20170073 Compositions and Methods for Detecting and Quantifying Nucleic
Longhorn Vaccines and Diagnostics, LLC Oct- Nov Mar
738 Acid Sequences in Blood Samples
07 -16 -17
11- 8- 16-
US20170073
METHODS AND COMPOSITIONS FOR LIBRARY NORMALIZATION Not Available Sep- Sep Mar
730
15 -16 -17
8- 2- 16-
Not Available Nov- Nov Mar
13 -16 -17
6- 5- 16-
US20170073 Method for Identifying and Validating Dominant T Helper Cell
Not Available Jan- Dec Mar
390 Epitopes Using an HLA-DM-Assisted Class II Binding Assay
06 -14 -17
12- 29- 16-
US20170073
NOVEL SUBSTITUTED SPIROCYCLES Not Available Sep- Nov Mar
352
14 -16 -17
12- 22- 16-
US20170072
METHODS FOR PREPARING SQUALENE Not Available May- Nov Mar
053
10 -16 -17
2- 22- 16-
US20170071 METHOD OF USING OXIDATIVE REDUCTIVE POTENTIAL WATER
OCULUS INNOVATIVE SCIENCES, INC. May- Nov Mar
980 SOLUTION IN DENTAL APPLICATIONS
05 -16 -17
16- 16- 16-
US20170071 METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE
964 VIRUS INFECTIONS
15 -16 -17
3- 28- 16-
US20170071
NOVEL NANOPARTICLE COMPOSITIONS Not Available Apr- Nov Mar
867
13 -16 -17
30- 7- 9-
US20170067
ATTENUATED VIRUSES USEFUL FOR VACCINES Not Available Mar- Sep Mar
030
07 -16 -17
2- 9-
US20170067 31-
MODIFIED CELLS AND METHODS OF THERAPY Not Available Sep Mar
021 Jul-15
-16 -17
16- 18- 9-
US20170066
BORON-CONTAINING SMALL MOLECULES Not Available Feb- Nov Mar
788
05 -16 -17
16- 18- 9-
US20170066
787
05 -16 -17
7- 5- 9-
US20170066
SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS Not Available Mar- Mar Mar
731
14 -15 -17
14- 9-
US20170065 METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS 2-Jul-
Not Available Sep Mar
706 VECTOR FOR USE WITH MULTIPLE VACCINATIONS 07
-16 -17
14- 9-
US20170065 Sequential administration of a replication defective adenovirus 2-Jul-
Not Available Sep Mar
693 vector in vaccination protocols 07
-16 -17
8- 22- 9-
US20170065 EV576 FOR USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE
Volution Immuno Pharmaceuticals SA Jan- Jul- Mar
677 RESPIRATORY TRACT
10 16 -17
29- 9-
US20170065 31-
MODIFIED CELLS AND METHODS OF THERAPY Not Available Aug Mar
636 Jul-15
-16 -17
18- 18- 2-
US20170058
BACTERIAL IDENTIFICATION IN CLINICAL INFECTIONS Not Available Feb- Feb Mar
430
14 -15 -17
1- 3- 2-
US20170058
SYSTEMS AND METHODS FOR ANALYZING VIRAL NUCLEIC ACIDS Not Available Sep- Feb Mar
365
15 -16 -17
9- 8- 2-
US20170057 ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND
Kineta, Inc. May- May Mar
14 -15 -17
1- 29- 2-
NOVARTIS AG May- Apr Mar
968 AGONISTS
14 -15 -17

US20170057
OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 Not Available Jan- Nov Mar
938

20- 8- 23-
US20170052 Covalently Linked Thermostable Kinase for Decontamination Process
Not Available Feb- Jul- Feb
190 Validation
08 16 -17
28- 7- 23-
Not Available Dec- Sep Feb
11 -16 -17
20- 20- 23-
US20170051
H1N1 FLU VIRUS NEUTRALIZING ANTIBODIES MEDIGEN BIOTECHNOLOGY CORPORATION Aug- Aug Feb
046
15 -15 -17
30- 30- 23-
US20170051
ADENOVIRUS COMPRISING AN ALBUMIN-BINDING MOIETY Not Available Apr- Apr Feb
022
14 -15 -17
3- 28- 23-
US20170051
PHARMACEUTICAL COMPOSITIONS AND METHODS Not Available Aug- Jul- Feb
007
15 16 -17
13- 8- 23-
US20170049 ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORINE MONOXIDE
OCULUS INNOVATIVE SCIENCES, INC. Mar- Nov Feb
813 AND METHODS OF MAKING AND USING THE SAME
07 -16 -17
15- 16-
Not Available Aug Feb
-16 -17
24- 26- 16-
US20170044 PCR Ready Compositions and Methods for Detecting and Identifying
Longhorn Vaccines and Diagnostics, LLC Aug- Oct Feb
595 Nucleic Acid Sequences
07 -16 -17
16- 23- 16-
US20170044
ANTIBODIES AND PROCESSES FOR PREPARING THE SAME Not Available May- Aug Feb
237
08 -16 -17
1- 29- 16-
NOVARTIS AG May- Apr Feb
168 AGONISTS
14 -15 -17
29- 16-
US20170042 COMPOSITIONS HAVING MEANS FOR TARGETING AT LEAST ONE 22-
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS Jul- Feb
994 ANTIGEN TO DENDRITIC CELLS Jul-11
16 -17
11- 27- 16-
HEMAQUEST PHARMACEUTICALS, INC. Mar- Oct Feb
10 -16 -17
12- 25- 9-
US20170039
Compositions, processes and algorithms for microbial detection Not Available Nov- Oct Feb
316
03 -04 -17
23- 13- 9-
US20170039 BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE
IOGENETICS, LLC Mar- Sep Feb
314 BINDING
10 -12 -17
7- 19- 9-
US20170038
AIR CURTAIN DEVICE Not Available Aug- Nov Feb
085
15 -15 -17
5- 29- 9-
US20170037 NUCLEIC ACID DETECTION OR QUANTIFICATION METHOD USING
Not Available Feb- Jan Feb
457 MASK OLIGONUCLEOTIDE, AND DEVICE FOR SAME
14 -15 -17
2- 3- 9-
US20170037 CHIMERIC VIRUSES PRESENTING NON-NATIVE SURFACE PROTEINS
Icahn School of Medicine at Mount Sinai Dec- Mar Feb
05 -16 -17
15- 12- 9-
US20170037 METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELL, GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH,
Nov- Nov Feb
376 COMPOSITION USED IN METHOD, AND USES THEREOF CHINESE ACADEMY OF SCIENCES
13 -14 -17
8- 26- 9-
US20170037 RECOMBINANT EXPRESSION OF MULTIPROTEIN COMPLEXES USING
Not Available Nov- Oct Feb
090 POLYGENES
05 -16 -17

US20170037
SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE 3M Innovative Properties Company Jun- Oct Feb
045
THEREFROM 11 -16 -17
11- 11- 9-
US20170035
Multi-Functional Mucosal Vaccine Platform Not Available Feb- Feb Feb
878
14 -15 -17
7- 5- 9-
US20170035 Compositions and Methods for Inhibiting Pro-Inflammatory Cytokine
Not Available Aug- Aug Feb
845 Gene Expression
15 -16 -17
26- 31- 2-
US20170029
POLYTAG PROBES Not Available Feb- Mar Feb
877
10 -16 -17
30- 28- 2-
US20170029
ARTIFICIAL NUCLEIC ACID MOLECULES CureVac AG Dec- Jun Feb
847
13 -16 -17
14- 1- 2-
US20170029 HUMAN MONOCLONAL ANTIBODY WITH SPECIFICITY FOR DENGUE
Not Available Dec- Jun Feb
489 VIRUS SEROTYPE 1 E PROTEIN AND USES THEREOF
10 -16 -17
30- 3- 2-
Not Available Sep- Aug Feb
03 -16 -17
4- 11- 2-
US20170028
VACCINE COMPOSITION NITTO DENKO CORPORATION Apr- Oct Feb
054
12 -16 -17
7- 7- 2-
US20170027 United States Government as represented by the
Methods of Treating Coronavirus Infection Apr- Apr Feb
975 Secretary, Department of Health and Human Services
14 -15 -17

24- 18- 2-
US20170027
METHODS FOR TREATING VIRAL DISORDERS Not Available Sep- Feb Feb
944
09 -15 -17
8- 23- 26-
US20170022
METHODS OF TESTING FOR INTRACELLULAR PATHOGENS Novartis AG Mar- Sep Jan-
577
10 -16 17
17- 17- 26-
US20170022
NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN, KU LEUVEN R&D Apr- Apr Jan-
242
14 -15 17
30- 31- 26-
US20170021 D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND
Not Available Nov- Mar Jan-
12 -16 17
1- 13- 26-
US20170020
METHODS AND COMPOSITIONS FOR IMMUNOMODULATION Not Available Apr- Mar Jan-
926
14 -15 17
18- 17- 19-
US20170016 COMPOSITIONS AND METHODS FOR ENRICHING POPULATIONS OF
Not Available May- May Jan-
048 NUCLEIC ACIDS
15 -16 17
1- 19-
US20170015 2-Jul-
STABILIZED ANTI-MICROBIAL PEPTIDES Not Available Jul- Jan-
716 15
16 17
12- 12- 19-
US20170014
COMBINATION OF VACCINATION AND OX40 AGONISTS Not Available Mar- Mar Jan-
496
14 -14 17
6- 28- 19-
US20170014
Benzazepine Dicarboxamide Compounds Hoffmann-La Roche Inc. Mar- Sep Jan-
423
15 -16 17
25- 23- 12-

Georgetown University Feb- Sep Jan-
131 AND COMMUNICATING EVENT RELATED INFORMATION
08 -16 17
6- 20- 12-
08 -16 17
21- 28- 12-
US20170009
Short Interfering RNA (siRNA) Analogues Not Available Mar- Mar Jan-
237
03 -16 17
29- 19- 12-
Not Available Nov- Sep Jan-
02 -16 17
1- 5-
US20170002 1-Jul-
PEPTIDOMIMETIC MACROCYCLES Not Available Jul- Jan-
042 15
16 17
23- 9- 5-
US20170000 CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES
Not Available Jun- Aug Jan-
878 THEREFOR
10 -16 17
14- 13- 5-
US20170000
Dimethyl Fumarate and Vaccination Regimens Not Available Mar- Mar Jan-
873
14 -15 17
28- 25- 29-
US20160376 COMPOSITIONS AND METHODS FOR INDUCING AN ENHANCED
Bavarian Nordic A/S Nov- Nov Dec
596 IMMUNE RESPONSE USING POXVIRUS VECTORS
13 -14 -16
26- 21- 29-
US20160376
A NOVEL SARS IMMUNOGENIC COMPOSITION BAYLOR COLLEGE OF MEDICINE Nov- Nov Dec
321
13 -14 -16
4- 22- 29-
US20160375
TARGETING LIPIDS Tekmira Pharmaceuticals Corporation Dec- Oct Dec
137
07 -13 -16
15- 5- 29-
US20160375 HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING
132 COMPOUNDS AND USES THEREOF
09 16 -16
25- 22-
US20160369 TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) LIBRARIES 1-Jul-
The Board of Regents of the University of Texas System Jun Dec
268 AND METHODS OF SYNTHESIS AND USE 13
-14 -16
9- 23- 22-
US20160368 METHOD OF PREVENTIVELY TREATING A SUBJECT AT THE RISK OF
Not Available May- Aug Dec
956 DEVELOPING INFECTIONS OF A RESPIRATORY VIRUS
13 -16 -16
3- 22-
14 -16
12- 12- 22-
US20160367
Systemic In Vivo Delivery of Oligonucleotides OncoImmunin, Inc. Jun- Jun Dec
587
13 -14 -16
17- 10- 22-
US20160367 ORAL SENSOR ALERTING AND COMMUNICATION SYSTEM AND
Not Available Jun- Sep Dec
188 DEVELOPERS' TOOL KIT
15 -15 -16
25- 25- 15-
US20160363
AMPEROMETRIC GAS SENSOR Not Available Jun- Aug Dec
557
12 -16 -16
26- 26- 15-
US20160362
PHOTO-SELECTIVE METHOD FOR BIOLOGICAL SAMPLE ANALYSIS Not Available Feb- Aug Dec
730
14 -16 -16
7- 10- 15-
US20160362 Identification and Attenuation of the Immunosuppressive Domains
Not Available Oct- Jun Dec
454 in Fusion Proteins of Enveloped RNA Viruses
11 -16 -16
11- 13- 15-
US20160361 MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF
15 -16 -16

23- 2- 15-
US20160361
Methods for the Preparation of Liposomes Not Available Sep- Aug Dec
259
09 -16 -16
31- 9- 8-
Not Available Aug- Jun Dec
07 -16 -16
8- 2- 8-
Not Available Feb- Jun Dec
428 ENTRY
07 -16 -16
9- 6- 8-
US20160354
Nuclear Transport Modulators and Uses Thereof Not Available May- Jan Dec
347
12 -16 -16
29- 31- 1-
US20160348 EXTRACTION AND PRESERVATION OF NUCLEIC ACID MOLECULES THE UNITED STATES OF AMERICA, as represented by the
May- May Dec
153 FROM PATHOGENS Secretary, Department of Health and Human Serv
15 -16 -16
18- 11- 1-
US20160348
TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS Not Available May- Aug Dec
132
04 -16 -16
27- 26- 1-
US20160348 CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with
Not Available Sep- May Dec
115 Enhanced Immunostimulatory Activity
06 -16 -16
2- 11- 1-
US20160348
NUCLEIC ACID CHEMICAL MODIFICATIONS Not Available Mar- Aug Dec
110
09 -16 -16
15- 29- 1-
Not Available Apr- Feb Dec
11 -16 -16
VSTM5 POLYPEPTIDES AND USES THEREOF AS A DRUG FOR 11- 10- 1-

US20160347
TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE Not Available Sep- Mar Dec
814
RELATED DISEASES 13 -16 -16
27- 1-
US20160347 6-Jul-
NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF Not Available May Dec
784 09
-16 -16
1- 21- 1-
US20160346 TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL
Not Available Jun- Dec Dec
309 METABOLIC PATHWAYS
07 -15 -16
6- 20- 24-
Not Available Oct- May Nov
06 -16 -16
6- 5- 24-
US20160340 SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE
Not Available Feb- Aug Nov
319 AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
13 -16 -16
7- 4- 24-
US20160339
CORONAVIRUS PROTEINS AND ANTIGENS MJ Biologics, Inc. Feb- Aug Nov
097
14 -16 -16
20- 19- 24-
US20160338 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND
3-V Biosciences, Inc. Dec- Dec Nov
998 COMBINATIONS THEREOF
13 -14 -16
3- 28- 17-
US20160333 OLIGONUCLEOTIDE MODULATORS OF THE TOLL-LIKE RECEPTOR
356 PATHWAY
11 16 -16
8- 18- 17-
US20160333
Antigenic GM-CSF Peptides and Antibodies to GM-CSF Not Available Feb- Jul- Nov
089
06 16 -16
7- 2- 17-
NEUTRALIZING GP41 ANTIBODIES AND THEIR USE Nov- Aug Nov
11 -16 -16
23- 5- 17-
US20160331
NUCLEIC ACID VACCINES Moderna Therapeutics, Inc. Apr- Apr Nov
828
14 -16 -16
ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2)

OR ANGIOTENSIN-(1-7) BIOENCAPSULATED IN PLANT CELLS 18- 18- 17-
US20160331
ATTENUATES PULMONARY HYPERTENSION, CARDIAC DYSFUNCTION Not Available Oct- Apr Nov
816
AND DEVELOPMENT OF AUTOIMMUNE AND EXPERIMENTALLY 13 -16 -16
INDUCED OCULAR DISORDERS
1- 21- 17-
US20160331
TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE Not Available Aug- Dec Nov
758
08 -15 -16
6- 5- 10-
US20160327
CAPACITIVE LIQUID CRYSTAL BIOSENSORS Not Available May- May Nov
506
15 -16 -16
30- 18- 10-

US20160327 A METHOD OF PREDICTING A PERFORMANCE CHARACTERISTIC OF
Not Available Dec- Dec Nov
484 A PLANT OR YEAST HYDROLYSATE AND ITS USE
13 -14 -16
25- 27- 10-

US20160326 METHODS AND COMPOSITIONS FOR PROSTATE CANCER
Not Available Mar- May Nov
598 METASTASIS
11 -16 -16
16- 19- 10-
US20160326
POWDERED POUCH AND METHOD OF MAKING SAME Not Available Apr- Jul- Nov
325
12 16 -16

16- 15- 10-
US20160326 NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES AGAINST
233 HEPATITIS B VIRUS SURFACE ANTIGEN
14 -15 -16
7- 7- 10-
US20160326 HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FOR USE
141 AGAINST CANCER AND VIRAL INFECTIONS
14 -15 -16
30- 18- 10-
US20160325
BIOAGENT DETECTION SYSTEMS, DEVICES, AND METHODS Not Available Mar- Jul- Nov
283
09 16 -16
5- 16- 10-
US20160324
Use of mTOR Inhibitors to Enhance T Cell Immune Responses Not Available Aug- May Nov
834
08 -16 -16
1- 1- 3-
US20160320
COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMES Not Available May- May Nov
390
15 -15 -16
29- 29- 3-
US20160318 Chimeric Virus-Like Particles Incorporating Fusion GPI Anchored
Not Available Apr- Apr Nov
985 GM-CSF and IL-4 Conjugates
15 -16 -16
30- 2- 3-
US20160318
NOVEL PRODRUGS OF DITHIOL MUCOLYTIC AGENTS PARION SCIENCES, INC. Apr- May Nov
861
15 -16 -16
23- 1- 3-
US20160317
NUCLEIC ACID VACCINES Moderna Therapeutics, Inc. Apr- Apr Nov
647
14 -16 -16
7- 7- 3-
637 THEREOF
14 -15 -16
12- 27- 3-
US20160317
METHODS OF TREATING CANCER AND OTHER DISORDERS Not Available Nov- Jun Nov
496
10 -16 -16
19- 17- 3-
US20160317
Lipids and Lipid Compositions for the Delivery of Active Agents Not Available Dec- Dec Nov
458
13 -14 -16
23- 21- 27-
US20160312 METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME
276 AMPLIFICATION
15 -16 16
24- 12- 27-
US20160311 Constructs Binding to Phosphatidylserine and Their Use in Disease
Not Available Jan- Jul- Oct-
886 Treatment and Imaging
05 16 16
26- 30- 27-
US20160311
NOVEL ANTIBIOTICS Not Available May- Nov Oct-
835
11 -15 16
23- 22- 27-
US20160311
COMPOSITIONS AND METHODS FOR INHIBITING KINASES Not Available Apr- Apr Oct-
816
15 -16 16
19- 17- 27-
US20160311
Lipids and Lipid Compositions for the Delivery of Active Agents Not Available Dec- Dec Oct-
759
13 -14 16
24- 7- 27-
US20160310
Myxovirus Therapeutics, Compounds, and Uses Related Thereto Not Available Oct- Jul- Oct-
511
11 16 16
18- 20-
US20160305 13-
DIRECT CLONE ANALYSIS AND SELECTION TECHNOLOGY Not Available Feb Oct-
936 Jul-10
-16 16
11- 11- 20-
Not Available Dec- Dec Oct-
954 VARIANTS
13 -14 16
6- 5- 20-
US20160304
Enhanced Methods of Ribonucleic Acid Hybridization Not Available Dec- Dec Oct-
942
13 -14 16
30- 28- 20-
US20160304
Directed Evolution and In Vivo Panning of Virus Vectors Not Available Apr- Jun Oct-
904
08 -16 16
30- 28- 20-
US20160304
ARTIFICIAL NUCLEIC ACID MOLECULES CureVac AG Dec- Jun Oct-
883
13 -16 16
10- 27- 20-
GenVec, Inc. Nov- Jun Oct-
05 -16 16
5- 4- 20-
US20160304
PROCESS FOR PREPARING INFLUENZA VACCINES Crucell Holland B.V. Dec- Dec Oct-
586
13 -14 16
30- 29- 20-
Not Available Jun- Feb Oct-
11 -16 16
13- 20-
US20160304 Hydrazide Containing Nuclear Transport Modulators and Uses 29-
472 Thereof Jul-11
-15 16
2- 21- 20-
US20160303 Compositions And Method For Treatment Of Inflammatory Bowel
Not Available Jun- Apr Oct-
194 Disease
11 -16 16
1- 31- 20-
US20160303
MODULAR PARTICLES FOR IMMUNOTHERAPY Not Available Nov- Oct Oct-
052
13 -14 16
8- 1- 13-
US20160299 NAD ANALOGS AND METHODS OF USING SAID NAD ANALOGS IN Biolog Life Science Institute Forschungslabor und
Apr- Apr Oct-
141 DETERMINING RIBOSYLATION OF PROTEINS WITH PARP MUTANTS Biochemica-Vertrieb GmbH
15 -16 16
5- 2- 13-
CapitalBio Corporation Dec- Dec Oct-
13 -14 16

1- 28- 13-
US20160296
Immunogenic Composition for MERS Coronavirus Infection Not Available Mar- Feb Oct-
617
13 -14 16
25- 25- 13-
US20160296
IMMUNOGENIC COMPOSITIONS AND USES THEREOF Not Available Mar- Mar Oct-
616
15 -16 16
13- 12- 13-
US20160295 GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF
844 USE THEREOF
15 -16 16
24- 13- 6-
US20160292 SYSTEMS AND METHODS FOR ORDERING LABORATORY TESTS AND
Not Available Oct- Apr Oct-
393 PROVIDING RESULTS THEREOF
13 -16 16
30- 29- 6-
US20160289
METHODS AND COMPOSITIONS FOR COMBINATORIAL BARCODING Not Available Mar- Mar Oct-
740
15 -16 16
27- 9- 6-
US20160289
ORGANIC COMPOUNDS NOVARTIS AG Jun- Oct Oct-
191
08 -15 16
24- 25- 6-
US20160288
Slip Chip Device and Methods Not Available Mar- May Oct-
121
09 -16 16
3- 2- 6-
US20160287
INJECTABLE VACCINE COMPOSITION NITTO DENKO CORPORATION Oct- Oct Oct-
697
13 -14 16
18- 7- 6-
US20160287 COMPOSITIONS AND METHODS FOR TREATING IMMUNE AND VIRAL
Massachusetts Institute of Technology Nov- Nov Oct-
622 DISORDERS AND MODULATING PROTEIN-RNA INTERACTION
13 -14 16
US20160281
LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA Not Available Oct- Jun Sep
109
VIRUS SPIKE PROTEIN 05 -16 -16
3- 13- 29-
US20160280
ALKOXY SUBSTITUTED IMIDAZOQUINOLINES Not Available Oct- Jun Sep
707
03 -16 -16
24- 24- 29-
US20160279
ADJUVANT COMPOSITIONS AND RELATED METHODS Not Available Mar- Mar Sep
237
15 -16 -16
6- 6- 29-
US20160279
IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY Not Available Nov- Nov Sep
193
13 -14 -16
24- 24- 29-
US20160279 PULSE INHALATION OF NITRIC OXIDE FOR TREATING
Not Available Mar- Mar Sep
165 RESPIRATORY DISEASES
15 -16 -16
1- 3- 29-
US20160279
Method of Treating Inflammation Not Available Apr- Jun Sep
163
10 -16 -16
27- 23- 29-
US20160278
Immunocompromised Ungulates Not Available Oct- Mar Sep
349
08 -15 -16
11- 11- 22-

US20160272 VSTM5 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF
Not Available Sep- Sep Sep
707 CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASES
13 -14 -16
21- 21- 22-

US20160271 BUNYAVIRUSES WITH SEGMENTED GLYCOPROTEIN PRECURSOR
Stichting Dienst Landbouwkundig Onderzoek May- May Sep
241 GENES AND METHODS FOR GENERATING THESE VIRUSES
13 -14 -16
14- 14- 22-

US20160271
Tetanus Toxoid and CCL3 Improve DC Vaccines Duke University Nov- Nov Sep
240
13 -15 -16
18- 27- 22-
US20160271 INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID
Not Available Feb- Oct Sep
137 METABOLISM AS BROAD SPECTRUM ANTI-VIRALS
10 -15 -16
8- 19- 15-
US20160267 METHODS OF PREDICTING CANCER LETHALITY USING REPLIKIN
Not Available Aug- May Sep
244 COUNTS
08 -16 -16
23- 20- 15-
Not Available Dec- May Sep
025 THEREOF
05 -16 -16
9- 15-
US20160264 COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS 20-
Not Available Oct Sep
971 GENE EXPRESSION Jul-09
-15 -16
4- 28- 15-
Not Available Apr- Jul- Sep
962 KITS AND ASSAYS
12 15 -16
7- 6- 15-
US20160263 RED BLOOD CELL MEMBRANE-DERIVED MICROPARTICLES AND University of Pittsburgh - Of the Commonwealth System of
Nov- Nov Sep
156 THEIR USE FOR THE TREATMENT OF LUNG DISEASE Higher Education
13 -14 -16
9- 9- 8-
US20160258 CHIPS, DETECTION SYSTEMS, AND METHODS FOR MULTIPLEX
949 PNEUMOCOCCUS SEROLOGY
13 -14 -16
GENETICALLY ENGINEERED ENUCLEATED ERYTHROID CELLS 18- 17- 8-

US20160257
COMPRISING A PHENYLALANINE AMMONIA LYASE RECEIVER Not Available Nov- May Sep
932
POLYPEPTIDE 13 -16 -16
6- 4- 8-
US20160257
Benzazepine Dicarboxamide Compounds Hoffmann-La Roche Inc. Mar- Mar Sep
653
15 -16 -16

24- 25- 8-
US20160256
Slip Chip Device and Methods Not Available Mar- May Sep
870
09 -16 -16
11- 8-
US20160256 6-Jul-
Cationic Oil-In-Water Emulsions Not Available Mar Sep
541 10
-16 -16
27- 26- 1-
US20160253
SPATIALLY ADDRESSABLE MOLECULAR BARCODING Not Available Feb- Feb Sep
584
15 -16 -16
19- 11- 1-
Not Available Nov- Mar Sep
09 -16 -16
9- 9- 1-
Novartis AG Sep- May Sep
04 -16 -16
14- 7- 1-
US20160251
PEPTIDOMIMETIC MACROCYCLES Not Available Jan- Apr Sep
399
09 -16 -16
18- 10- 1-
US20160251
NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. Dec- May Sep
362
12 -16 -16
18- 11- 1-
US20160251
CARBOXYLIC ACID COMPOUNDS Astrazeneca Aktiebolag May- May Sep
319
12 -16 -16
14- 18- 1-
US20160250
Conjugates of GM-CSF and IL-7, and Compositions Thereof Not Available Nov- May Sep
326
11 -16 -16
14- 7- 1-
US20160250
PEPTIDOMIMETIC MACROCYCLES Not Available Jan- Apr Sep
278
09 -16 -16
3- 3- 1-
US20160250 ESTERS OF SHORT CHAINS FATTY ACIDS FOR USE IN THE
Not Available Oct- Mar Sep
168 TREATMENT OF IMMUNOGENIC DISORDERS
12 -16 -16
14- 14- 18-
US20160238 METHODS AND COMPOSITIONS FOR CORONAVIRUS DIAGNOSTICS
601 AND THERAPEUTICS
13 -14 -16
30- 27- 18-
US20160238 METHOD FOR SELECTING A SINGLE CELL EXPRESSING A
Merus B.V. May- Apr Aug
600 HETEROGENEOUS COMBINATION OF ANTIBODIES
03 -16 -16
27- 26- 18-
US20160237
CRISPR-RELATED METHODS AND COMPOSITIONS Editas Medicine, Inc. Sep- Sep Aug
455
13 -14 -16
23- 4- 18-
US20160237 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL
Not Available Jan- May Aug
123 INFECTIONS
08 -16 -16
10- 10- 18-
US20160237 DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE
082 SAME
13 -14 -16
12- 26- 18-

US20160235 Compositions, Comprising Improved Il-12 Genetic Constructs And
Not Available Dec- Feb Aug
840 Vaccines, Immunotherapeutics And Methods Of Using The Same
11 -16 -16
16- 16- 18-

US20160235 THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE
837 EAST RESPIRATORY SYNDROME VIRUS (MERS CoV)
13 -14 -16
10- 27- 18-

US20160235
INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE Seqirus UK Limited Feb- Jan Aug
835
09 -16 -16
24- 18-
US20160235 24-
Technology for the Preparation of Microparticles Not Available Mar Aug
675 Jul-07
-16 -16
17- 17- 11-
US20160230 Lentiviral Vectors Having a Mutated Integrase Protein and uses
Not Available Sep- Sep Aug
190 Thereof
13 -14 -16
6- 5- 11-
US20160229 Optimized Human Clotting Factor VIII Gene Expression Cassettes
904 and Their Use
15 -16 -16

US20160229
PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 Not Available Feb- Feb Aug
872
5- 4- 11-
864 INHIBITORS
15 -16 -16
5- 4- 11-
15 -16 -16
3- 2- 11-
US20160228
NASAL MUCOSAL VACCINE COMPOSITION NITTO DENKO CORPORATION Oct- Oct Aug
540
13 -14 -16
23- 23- 11-
US20160228 Use of EGFR Pathway Inhibitors to Increase Immune Responses to
Emory University Sep- Sep Aug
533 Antigens
13 -14 -16
16- 13- 11-
US20160228 METHOD OF OBTAINING THERMOSTABLE DRIED VACCINE
Merck Sharp & Dohme Corp. Oct- Oct Aug
532 FORMULATIONS
13 -14 -16
16- 20- 11-
US20160228
BORON-CONTAINING SMALL MOLECULES Not Available Feb- Apr Aug
463
05 -16 -16

14- 15- 4-
US20160222 CONSTRUCTS AND METHODS FOR DELIVERING MOLECULES VIA
Not Available Mar- Apr Aug
414 VIRAL VECTORS WITH BLUNTED INNATE IMMUNE RESPONSES
13 -16 -16
23- 22- 4-
US20160222
Universal Protein Tag for Double Stranded Nucleic Acid Delivery Not Available Oct- Oct Aug
072
13 -14 -16
30- 29- 4-
US20160222
NOVEL MONOTHIOL MUCOLYTIC AGENTS PARION SCIENCES, INC. Jan- Jan Aug
023
15 -16 -16
22- 7- 4-
US20160222
4-AMINO-IMIDAZOQUINOLINE COMPOUNDS Hoffmann-La Roche Inc. Apr- Apr Aug
010
14 -16 -16
29- 27- 4-
US20160221
Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof Not Available Nov- Nov Aug
994
12 -13 -16
13- 12- 4-
US20160220
ANTIGEN AND METHOD FOR PRODUCTION THEREOF Not Available Sep- Sep Aug
664
13 -14 -16
11- 10- 4-
US20160220 NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND
Not Available Sep- Sep Aug
595 USES RELATED THERETO
13 -14 -16
USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND

16- 19- 4-
US20160220 TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF
Not Available Mar- Feb Aug
536 AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-
04 -16 -16
LIKE RECEPTOR OVEREXPRESSION
28- 20- 28-

US20160215
SYNTHETIC ANTISERUM FOR RAPID-TURNAROUND THERAPIES Not Available Jan- Jan Jul-
282
15 -16 16
16- 16- 28-
US20160215 CD137 ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING
262 LYMPHOCYTE SELECTION
13 -14 16
1- 7- 28-
US20160213 ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL
GlaxoSmithKline Biologicals SA Sep- Apr Jul-
776 SALTS
10 -16 16
3- 2- 28-
US20160213
MUCOSAL VACCINE COMPOSITION NITTO DENKO CORPORATION Oct- Oct Jul-
773
13 -14 16
19- 5- 28-
US20160213 CARBON NANOTUBE COMPOSITIONS AND METHODS OF USE
Not Available Mar- Apr Jul-
761 THEREOF
08 -16 16
28- 27- 28-
US20160213
COMPOSITIONS AND METHODS FOR INHIBITING VIRAL INFECTION Not Available Jan- Jan Jul-
647
15 -16 16
24- 28- 28-
US20160213
MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB Not Available Oct- Jan Jul-
610
12 -16 16
5- 5- 21-
US20160207 FC-CONTAINING MOLECULES EXHIBITING PREDICTABLE,
AMGEN INC. Sep- Sep Jul-
980 CONSISTENT, AND REPRODUCIBLE GLYCOFORM PROFILES
13 -14 16
2- 2- 21-
US20160207 NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL
Hangzhou DAC Biotech Co., Ltd Sep- Sep Jul-
949 BINDING MOLECULE
13 -13 16
9- 8- 21-
US20160207 PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I
PROZYMEX A/S Sep- Sep Jul-
900 INHIBITORS
13 -14 16
19- 19- 21-

US20160206 IMMUNOGENIC MIDDLE EAST RESPIRATORY SYNDROME
729 CORONAVIRUS (MERS-CoV) COMPOSITIONS AND METHODS
13 -14 16
22- 5- 21-
CureVac AG Feb- Apr Jul-
719 PATHWAY
13 -16 16
16- 5- 21-
US20160206
BORON-CONTAINING SMALL MOLECULES Not Available Feb- Apr Jul-
638
05 -16 16
31- 28- 21-
US20160206
Inhibition of Biofilm Organisms NOVABIOTICS LIMITED Mar- Mar Jul-
575
09 -16 16
8- 21- 14-
B-CELL ANTIGEN PRESENTING CELL ASSAY Apr- Mar Jul-
10 -16 16
9- 17- 14-
US20160201
DIAGNOSIS AND TREATMENT OF INCIPIENT DIABETES Not Available Jan- Nov Jul-
110
15 -15 16
17- 30- 14-

01 -16 16
3- 22- 14-
US20160199 ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR
486 MICROFLUIDIZATION
09 -16 16
21- 21- 14-
US20160199 METHOD OF REDUCING ANTIGENIC DRIFT OR REASSORTMENT OF
Hemispherx Biopharma, Inc. Aug- Aug Jul-
449 VIRUSES IN A HOST ANIMAL USING ALPHA INTERFERON
13 -14 16

26- 25- 14-
US20160199
Induced Hepatocytes and Uses Thereof Not Available Nov- Nov Jul-
416
14 -15 16
25- 17- 14-
US20160199
HALIDES IN THE TREATMENT OF PATHOGENIC INFECTION THE UNIVERSITY OF IOWA RESEARCH FOUNDATION Jan- Dec Jul-
407
08 -15 16
2- 31- 7-
US20160194 Methods Of Treating Inflammation Associated Airway Diseases And
Not Available Jan- Dec Jul-
387 Viral Infections
15 -15 16
25- 14- 7-
US20160194
SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS Not Available Nov- Mar Jul-
322
03 -16 16
23- 11- 7-
US20160194
DITHIOL MUCOLYTIC AGENTS PARION SCIENCES, INC. Aug- Mar Jul-
278
13 -16 16
29- 5- 7-
US20160193
SAMPLE-TO-ANSWER MICROFLUIDIC CARTRIDGE Not Available Jan- Aug Jul-
603
10 -15 16
3- 2- 7-
US20160193
MUCOSAL VACCINE COMPOSITION NITTO DENKO CORPORATION Oct- Oct Jul-
327
13 -14 16
11- 5- 7-
US20160193
MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS Novartis AG Sep- Nov Jul-
321
06 -15 16
7- 17- 7-
US20160193 PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC
Not Available Aug- Mar Jul-
315 COMPOSITIONS COMPRISING SAID PEPTIDES
09 -16 16
13- 5- 7-
US20160192
HYDROGEN-CONTAINING ANTIMICROBIAL AGENT Not Available Aug- Aug Jul-
658
13 -14 16
30- 29- 30-
14 -15 16
30- 29- 30-
14 -15 16
17- 17- 30-
US20160184
INTRANASAL VACCINATION DOSAGE REGIMEN Not Available Dec- Dec Jun-
424
12 -13 16
16- 11- 30-
US20160184
BORON-CONTAINING SMALL MOLECULES Not Available Feb- Mar Jun-
334
05 -16 16
8- 23-
US20160177 METHOD FOR PRODUCTION OF REPROGRAMMED CELL USING 16-
Not Available Mar Jun-
337 CHROMOSOMALLY UNINTEGRATED VIRUS VECTOR Jul-08
-16 16
9- 11- 23-
US20160177
Expression Tools for Multiprotein Applications Not Available Mar- Dec Jun-
336
04 -15 16
17- 15- 23-
Not Available Aug- Dec Jun-
10 -15 16
12- 11- 23-
US20160175
Compositions and Uses of Lectins Emory University Feb- Dec Jun-
394
10 -15 16
10- 10- 23-
US20160175
Use of Immune Suppressive Domains as Medicaments Not Available Apr- Apr Jun-
387
13 -14 16
PROTECTIVE MASKS WITH COATING COMPRISING DIFFERENT

23- 10- 23-
US20160174 ELECTROSPUN FIBERS INTERWEAVED WITH EACH OTHER,
631 FORMULATIONS FORMING THE SAME, AND METHOD OF
14 -15 16
PRODUCING THEREOF
24- 9- 16-
US20160168
Cyclic Antimicrobial Peptides NOVABIOTICS LIMITED Feb- Nov Jun-
203
06 -15 16
15- 27- 16-
US20160168
NOVEL COMPOUNDS CHIESI FARMACEUTICI S.p.A. Dec- Nov Jun-
101
14 -15 16
21- 19- 16-
US20160166 METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED
CureVac AG Aug- Feb Jun-
710 PROTEINS
13 -16 16
10- 10- 16-
US20160166
Use of Immune Suppressive Peptides as Adjuvants Not Available Apr- Apr Jun-
676
13 -14 16
26- 8- 9-
Not Available Feb- Feb Jun-
258 OF B CELLS
03 -16 16
9- 2- 9-
US20160160
IMMUNOTHERAPY USING STEM CELLS Not Available Dec- Dec Jun-
178
14 -15 16
IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (V- 5- 7- 9-

US20160159
R) AND USE THEREOF TO PRODUCE VISTA/VSIG8 AGONISTS AND Not Available Dec- Dec Jun-
927
ANTAGONISTS 14 -15 16
18- 7- 9-
US20160158
PREPARATION OF INFLUENZA VIRUS VACCINE ANTIGENS Novartis AG Mar- Dec Jun-
341
08 -15 16

27- 4- 9-
US20160158 INFLUENZA VACCINES CONTAINING HEMAGGLUTININ AND MATRIX
Not Available Jan- Dec Jun-
340 PROTEINS
06 -15 16
24- 9-
US20160158 26-
METHOD FOR INACTIVATING VIRUSES USING ELECTRON BEAMS Not Available Jul- Jun-
339 Jul-13
14 16
12- 14- 9-
US20160158 TREATMENT OF MULTIPLE EVOLVING BACTERIAL RESISTANCE
CHILDREN'S HEALTHCARE OF ATLANTA, INC. Nov- Aug Jun-
308 DISEASES WITH LIPOSOMALLY FORMULATED GLUTATHIONE
13 -14 16
4- 4- 9-
US20160158
Methods of Populating a Gastrointestinal Tract Not Available Feb- Feb Jun-
294
13 -14 16
5- 7- 9-
US20160158 PROTEIN VESICLES AND METHODS OF MAKING AND USING
154 THEREOF
14 -15 16
19- 11- 2-
US20160153
Rapid Epidemiologic Typing of Bacteria Not Available May- Nov Jun-
034
08 -15 16

US20160152
PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME Ablynx N.V. Jun- Oct Jun-
693
FOR THE TREATMENT OF VIRAL DISEASES 08 -15 16
7- 9- 2-
US20160152 HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT
COLORADO STATE UNIVERSITY RESEARCH FOUNDATION Nov- Nov Jun-
676 PROTEIN-PROTEIN INTERACTIONS
14 -15 16
23- 9- 2-
US20160152 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL
Not Available Jan- Feb Jun-
667 INFECTIONS
08 -16 16
21- 20- 2-
US20160152
Nuclear Transport Modulators and Uses Thereof Karyopharm Therapeutics Inc. Jun- Jun Jun-
596
13 -14 16
16- 17- 2-
US20160151
BORON-CONTAINING SMALL MOLECULES Not Available Feb- Feb Jun-
399
05 -16 16
17- 19- 26-
US20160146
RECEPTORS FOR B7-H4 Not Available May- May May
806
13 -14 -16
26- 26- 26-
US20160146
Method of monitoring cellular trafficking of peptides Not Available Jun- Jun May
786
13 -14 -16
9- 23- 26-
US20160145
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available May- Jun May
246
12 -15 -16
4- 26-
US20160144 Compositions and Imaging Methods Comprising Detectably Labeled 15-
Not Available Feb May
061 Phosphatidylethanolamine-Binding Peptides Jul-02
-16 -16
28- 19-
Not Available Dec May
143 SPECTROMETRY 10
-15 -16
12- 7- 19-
US20160137
GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES Not Available Sep- Aug May
702
07 -15 -16
PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC 1- 19-

US20160137 3-Jul-
COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL Not Available Jul- May
649 13
USES THEREOF 14 -16
30- 20- 19-

US20160135 SHELF STABLE, REDUCED CORROSION, READY TO USE
Not Available Aug- Jan May
453 PEROXYCARBOXYLIC ACID ANTIMICROBIAL COMPOSITIONS
07 -16 -16
26- 16- 12-
US20160130
GENERATION OF BINDING MOLECULES Merus B.V. Sep- Sep May
367
11 -15 -16
22- 21- 12-
Not Available Feb- Feb May
345 PATHWAY
13 -14 -16
23- 29- 12-
US20160130 SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF
Not Available Aug- Dec May
265 NEUTROPHIL ELASTASE ACTIVITY
12 -15 -16
14- 17- 12-
US20160129 IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND
AUTOIMMUNE TECHNOLOGIES, LLC Mar- Jul- May
110 METHODS
13 15 -16
7- 6- 12-
14 -15 -16
30- 10- 12-
US20160129
Immunostimulatory Combinations Not Available Dec- Sep May
095
02 -15 -16
3- 5- 12-
Novartis AG Dec- Sep May
09 -14 -16
15- 16- 5-
US20160122 COMPOSITION COMPRISED OF ANTIGEN LINKED TO A TNF
Not Available Mar- Mar May
412 SUPERFAMILY LIGAND
13 -14 -16

REPLIKIN-BASED COMPOUNDS FOR PREVENTION AND TREATMENT 23- 2- 5-
US20160122
OF INFLUENZA AND METHODS OF DIFFERENTIATING INFECTIVITY Not Available Apr- Dec May
397
AND LETHALITY IN INFLUENZA 09 -15 -16
16- 5-
US20160122 ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND 16-
312 METHODS OF USE THEREOF Jul-13
14 -16

US20160122
BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER PARION SCIENCES, INC. May- Jan May
306
MUCOSAL DISEASES 12 -16 -16
27- 21- 28-

10 -15 16
11- 7- 28-
US20160115 MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION
Not Available May- Jan Apr-
522 CHARACTERISTICS
10 -16 16
28- 2- 28-
Not Available Oct- Jul- Apr-
14 15 16
19- 18- 28-
US20160114
PARALLELIZED SAMPLE HANDLING Not Available Apr- Apr Apr-
322
13 -14 16
28- 8- 28-
Not Available Oct- Jan Apr-
14 -15 16
14- 1- 28-
US20160114
RECOMBINANT HCMV AND RHCMV VECTORS AND USES THEREOF Not Available May- Oct Apr-
027
10 -15 16
11- 10- 28-
US20160114 THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR
022 FILOVIRUSES INCLUDING EBOLAVIRUS AND MARBURG VIRUS
14 -15 16
11- 2- 28-
Not Available Mar- Jun Apr-
10 -15 16
24- 23- 28-
US20160113 COMPOSITIONS AND METHODS FOR INHIBITING BACTERIAL AND
920 VIRAL PATHOGENS
14 -15 16
3- 3- 28-
US20160113
NOVEL NANOPARTICLE COMPOSITIONS Not Available Apr- Apr Apr-
881
13 -14 16
3- 5- 28-
Novartis AG Dec- Sep Apr-
09 -14 16
1- 15- 21-
US20160108
Biological Specimen Collection and Transport System Longhorn Vaccines and Diagnostics, LLC Oct- Dec Apr-
463
07 -15 16
14- 5- 21-
US20160108 TARGETED WHOLE GENOME AMPLIFICATION METHOD FOR
Not Available Sep- Oct Apr-
461 IDENTIFICATION OF PATHOGENS
06 -15 16
5- 3- 21-
US20160108
AVIAN CELLS FOR IMPROVED VIRUS PRODUCTION Not Available Jun- Jun Apr-
359
13 -14 16
5- 5- 21-
MONOMERIC GRIFFITHSIN TANDEMERS Jun- Jun Apr-
13 -14 16
17- 17- 21-
US20160108 FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR
Not Available Sep- Sep Apr-
096 USING RECOMBINANT BACTERIA
14 -15 16
16- 21- 21-
US20160108
BORON-CONTAINING SMALL MOLECULES Not Available Feb- Dec Apr-
063
05 -15 16
8- 6- 21-
842 AGENTS
13 -14 16
28- 22- 14-
US20160102
MODIFIED ADENOVIRUS HEXON PROTEIN AND USES THEREOF Not Available Apr- May Apr-
295
06 -15 16
8- 5- 14-
US20160102
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS 3-V BIOSCIENCES, INC. Mar- Oct Apr-
091
11 -15 16
24- 24- 14-
US20160101
PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF Not Available Sep- Sep Apr-
145
14 -15 16
8- 28- 7-
US20160096 METHODS FOR TREATING JUVENILE ARTHRITIS WITH ANTI-BILE
Not Available Apr- Sep Apr-
899 SALT-STIMULATED LIPASE (BSSL) ANTIBODIES
09 -15 16
7- 23- 7-
US20160096
BINDING MEMBERS-513 Not Available Nov- Oct Apr-
895
08 -15 16
5- 2- 7-
Not Available Apr- Jul- Apr-
936 THEREOF
12 15 16
21- 6- 31-
US20160090
COMPOSITIONS FOR AND METHODS OF IDENTIFYING ANTIGENS Not Available Feb- May Mar
589
06 -15 -16

15- 4- 31-
US20160090
Phosphoinositide 3-Kinase Inhibitors Respivert Ltd. Mar- Dec Mar
389
13 -15 -16
8- 16- 24-
EXTHERA MEDICAL CORPORATION Nov- Oct Mar
13 -15 -16
29- 29- 24-
US20160083 TISSUE PREFERENTIAL CODON MODIFIED EXPRESSION
748 CASSETTES, VECTORS CONTAINING SAME, AND USES THEREOF
13 -14 -16
29- 30- 24-
US20160083
ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS Not Available Oct- Nov Mar
689
04 -15 -16
11- 8- 24-
US20160082 COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN Mar- May Mar
074 INFECTION
14 -15 -16

14- 1- 24-
Not Available Mar- Dec Mar
13 -15 -16
CATHEPSIN C
23- 22- 24-

US20160081
ANTIMICROBIAL COMPOSITIONS AND METHODS Not Available Sep- Sep Mar
346
14 -15 -16
5- 5- 17-
US20160077 Media Elaborated with Newly Synthesized Antibodies (MENSA) and
094 Uses Thereof
14 -15 -16
8- 1- 17-
US20160076 Efficient Deep Sequencing and Rapid Genomic Speciation of RNA
094 Viruses (vRNAseq)
14 -15 -16
24- 15- 17-
US20160076
REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION Not Available Aug- Mar Mar
053
12 -13 -16
12- 10- 17-
US20160075
NOVEL SUBSTITUTED SPIROCYCLES Not Available Sep- Sep Mar
704
14 -15 -16
METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC 16- 16- 17-
US20160074
DINUCLEOTIDE AND USE OF SAID PARTICLES FOR INDUCING Not Available Sep- Sep Mar
507
IMMUNE RESPONSE 14 -15 -16
23- 17-
US20160074 DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE 6-Jul-
Not Available Nov Mar
506 POLYMER PARTICLES 10
-15 -16
7- 30- 17-
US20160074 Clottable Concentrate Of Platelet Growth Factors And Preparation
Zheng Yang Biomedical Technology Co., LTD. Jan- Nov Mar
481 Method Thereof
08 -15 -16
7- 10-
US20160068 Compositions and Methods for "Resistance-Proof" SiRNA 8-Jul-
Sirnaomics, Inc. Jul- Mar
843 Therapeutics for Influenza 12
13 -16
3- 16- 10-
US20160068
OLIGOPEPTIDE-FREE CELL CULTURE MEDIA Not Available Jan- Nov Mar
587
07 -15 -16
14- 14- 10-
US20160068
PEPTIDOMIMETIC MACROCYCLES Not Available Jan- Sep Mar
573
09 -15 -16
3- 2- 10-
US20160067
GENERATING PEPTOID VACCINES The Board of Regents of the University of Texas System May- May Mar
333
13 -14 -16
9- 26- 3-
US20160060 MEANS AND METHODS FOR INFLUENCING THE STABILITY OF
Not Available Dec- Aug Mar
598 ANTIBODY PRODUCING CELLS
05 -15 -16
6- 9- 3-
13 -15 -16
6- 9- 3-
13 -15 -16
2- 31- 3-
US20160060
N-MYRISTOYL TRANSFERASE INHIBITORS UNIVERSITY OF DUNDEE Sep- Aug Mar
224
08 -15 -16
26- 26- 3-
US20160058 PLANT EXTRACTS AND RELATED COMPOSITIONS, METHODS AND
Not Available Aug- Aug Mar
814 SYSTEMS
14 -14 -16
14- 24- 3-
US20160058 WEAR RESISTANT ANTIMICROBIAL COMPOSITIONS AND METHODS
Not Available Dec- Sep Mar
012 OF USE
10 -15 -16
28- 28- 3-
US20160058 ANTIMICROBIAL COMPOSITIONS AND METHODS WITH NOVEL
Not Available Aug- Aug Mar
008 POLYMERIC BINDING SYSTEM
14 -15 -16
28- 15- 25-
US20160054
CHEMICALLY DIFFERENTIATED SENSOR ARRAY Nanomedical Diagnostics, Inc. Apr- Oct Feb
312
14 -15 -16
27- 27- 25-
US20160053 PROBE KIT FOR DETECTING A SINGLE STRAND TARGET
Fondzione Istituto Italiano Di Tecnolgia Dec- Dec Feb
308 NUCLEOTIDE SEQUENCE
12 -13 -16
18- 9- 25-
US20160053
BACILLUS BASED DELIVERY SYSTEM AND METHODS OF USE Not Available Apr- Sep Feb
222
11 -15 -16

22- 19- 25-
US20160052 RADIOLABELED CATIONIC STEROID ANTIMICROBIALS AND
BRIGHAM YOUNG UNIVERSITY Aug- Aug Feb
959 DIAGNOSTIC METHODS
14 -15 -16
4- 25- 25-
Not Available Dec- Aug Feb
07 -15 -16
12- 23- 25-
US20160051
METHODS FOR PREPARING SQUALENE Not Available May- Oct Feb
670
10 -15 -16
21- 21- 25-
US20160051 COMPOSITIONS AND METHODS FOR SELECTIVELY MODULATING
669 TREGS
14 -15 -16
21- 21- 18-
US20160046
HETERODIMERIC IMMUNOGLOBULINS Not Available Nov- Nov Feb
705
12 -13 -16
23- 23- 18-
US20160046 GM-CSF AND IL-4 CONJUGATES, COMPOSITIONS, AND METHODS
Not Available Oct- Oct Feb
687 RELATED THERETO
12 -13 -16
30- 27- 18-
US20160045 METHOD OF PREVENTING OR TREATING SINUSITIS WITH
OCULUS INNOVATIVE SCIENCES, INC. Dec- Oct Feb
547 OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION
03 -15 -16
2- 23- 11-
US20160041 ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA
Not Available May- Oct Feb
168 IMMUNE RESPONSE
08 -15 -16
12- 12- 11-
US20160040
In Vivo Delivery of Oligonucleotides OncoImmunin Inc. Dec- Dec Feb
161
11 -12 -16
8- 21- 11-
US20160039
SINGLE-CHAIN ANTIPARALLEL COILED COIL PROTEINS Complix NV Dec- Aug Feb
867
08 -15 -16
4- 4- 11-
US20160039
ENANTIOMERS OF THE 1',6'-ISOMER OF NEPLANOCIN A Not Available Aug- Aug Feb
860
14 -15 -16
2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-
PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2- 15- 14- 11-
US20160039
(TRIFLUOROMETHYL)BENZYL) QUINAZOLIN-4(3H)-ONE Not Available Mar- Mar Feb
826
DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE 13 -14 -16
INHIBITORS
27- 11-
US20160039 SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE 31-
Not Available Jul- Feb
812 AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY Jul-14
15 -16
15- 14- 4-
US20160032 VECTORS COMPRISING STUFFER/FILLER POLYNUCLEOTIDE
THE CHILDREN'S HOSPITAL OF PHILADELPHIA Mar- Mar Feb
319 SEQUENCES AND METHODS OF USE
13 -14 -16
1- 31- 4-
US20160031 SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF
Not Available Aug- Jul- Feb
861 CATHEPSIN C
14 15 -16
27- 4-
15 -16
27- 4-
15 -16
27- 4-
15 -16
27- 4-
US20160031 SUBSTITUTED DIHYDROPYRIMIDINONES AND THEIR USE AS 31-
825 INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY Jul-14
15 -16
14- 14- 4-
US20160030 METHODS AND COMPOSITIONS FOR MODULATING REGULATORY T
443 CELL FUNCTION
13 -14 -16
28- 1- 28-
US20160025
METHOD FOR ELECTRONIC BIOLOGICAL SAMPLE ANALYSIS Nanomedical Diagnostics, Inc. Apr- Oct Jan-
675
14 -15 16
21- 28-
US20160025 AIRBORNE AGENT COLLECTORS, METHODS, SYSTEMS AND 22-
603 DEVICES FOR MONITORING AIRBORNE AGENTS Jul-14
15 16
21- 7- 28-
US20160024
REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS NOVARTIS AG May- May Jan-
525
09 -15 16
15- 14- 28-
US20160024
Inhibitory Polypeptides Specific to WNT Inhibitors Not Available Mar- Mar Jan-
158
13 -14 16
15- 14- 28-
US20160022 RODENT HEPADNAVIRUS CORES WITH REDUCED CARRIER-
801 SPECIFIC ANTIGENICITY
13 -14 16
16- 21-
US20160016 17-
INHIBITORY PEPTIDES OF VIRAL INFECTION Not Available Jul- Jan-
999 Jul-14
15 16
21- 21-
US20160016 21-
STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT Not Available Jul- Jan-
986 Jul-14
15 16

15- 14- 21-
US20160016 Exo Olefin-Containing Nuclear Transport Modulators and Uses
916 Thereof
13 -14 16
24- 2- 21-
US20160015 Constructs Binding to Phosphatidylserine and Their Use in Disease
Not Available Jan- Feb Jan-
826 Treatment and Imaging
05 -15 16
17- 21-
US20160015 18-
IMMUNOSTIMULATORY COMBINATIONS AND USE THEREOF Not Available Jul- Jan-
803 Jul-14
15 16
30- 15- 14-
US20160011
MULTIANALYTE ASSAY Not Available Apr- Jun Jan-
183
07 -15 16
METHODS AND COMPOSITIONS FOR PAPER-BASED AND HYBRID 10- 14-

US20160008 10-
MICROFLUIDIC DEVICES INTEGRATED WITH NUCLEIC ACID University of Texas at El Paso Jul- Jan-
809 Jul-14
AMPLIFICATION FOR DISEASE DIAGNOSIS 15 16
8- 2- 14-
US20160008 METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE
Not Available Jan- Aug Jan-
461 RESPONSES
13 -14 16
14- 14- 14-
US20160008
NANOPARTICLE-BASED COMPOSITIONS Not Available Mar- Mar Jan-
451
13 -14 16
10- 14-
US20160008 IMMUNOMODULATION BY CONTROLLING EXPRESSION LEVELS OF 14-
397 MICRORNAS IN DENDRITIC CELLS Jul-14
15 16
15- 17- 14-
US20160008
DRUG COMBINATION VERONA PHARMA PLC Mar- Mar Jan-
363
13 -14 16
16- 11- 7-
US20160003
Apparatus for two-step surface-enhanced raman spectroscopy REAL-TIME ANALYZERS, INC Dec- Sep Jan-
747
11 -15 16
20- 10- 7-
US20160002
METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLES Not Available Sep- Jul- Jan-
608
10 15 16
25- 24- 7-
US20160000
Nanoparticle Delivery of TLR Agonists and Antigens Not Available Feb- Feb Jan-
905
13 -14 16
15- 17- 7-
US20160000
DRUG COMBINATION VERONA PHARMA PLC Mar- Mar Jan-
790
13 -14 16
6- 14- 7-
US20160000 Antiviral Activity from Medicinal Mushrooms and their Active
Not Available Jan- Sep Jan-
754 Constituents
04 -15 16
27- 27- 31-
US20150377
IN SITU AFFINITY MATURATION OF ANTIBODIES Not Available Feb- Feb Dec
887
13 -14 -15
28- 14- 31-
US20150376 MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS
ARROWHEAD RESEARCH CORPORATION Feb- May Dec
621 OF USE
08 -15 -15
METHODS OF TREATING VIRAL INFECTIONS, PARTICULARLY

RABIES, MERS-COV, INFLUENZA, EBOLA, CHIKUNGUNYA, 28- 10- 31-
US20150376
VENEZUELAN EQUINE ENCEPHALITUS, CANINE PARVOVIRUS, TAMIR BIOTECHNOLOGY, INC. Mar- Jun Dec
584
ADENOVIRUS, RESPIRATORY SYNCYTIAL VIRUS, RHINOVIRUS, AND 14 -15 -15
POXVIRUS IN MAMMALIAN PATIENTS
30- 30- 31-

US20150376
STABLE SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. Jun- Jun Dec
145
14 -15 -15
23- 2- 31-
Not Available Aug- Sep Dec
12 -15 -15
20- 31-
US20150374 28-
Anti-Viral Azide Containing Compounds Not Available Aug Dec
723 Jul-10
-15 -15
TREATMENT OF EVOLVING BACTERIAL RESISTANCE DISEASES 15- 15- 31-

US20150374
INCLUDING KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY YOUR ENERGY SYSTEMS, LLC Feb- Mar Dec
626
FORMULATED GLUTATHIONE 13 -13 -15
19- 17- 24-

US20150369 DETECTION OF VIRAL DISEASES USING A BIOCHIP THAT
806 CONTAINS GOLD NANOPARTICLES
14 -15 -15
11- 11- 24-
US20150368
METHODS FOR PRODUCING ANTIBODIES Not Available Feb- Feb Dec
661
13 -14 -15
22- 10- 24-
US20150368
GADD45BETA TARGETING AGENTS Not Available Oct- Feb Dec
294
09 -15 -15
24- 22- 24-
US20150366 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS
888 THEREOF
14 -15 -15
1- 30- 24-
US20150366 INTRADERMAL DELIVERY OF IMMUNOLOGICAL COMPOSITIONS
Not Available Feb- Jan Dec
796 COMPRISING TOLL-LIKE RECEPTOR AGONISTS
13 -14 -15

6- 17-
US20150361 MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS 26-
Not Available Aug Dec
432 OF USE Jul-02
-15 -15
22- 21- 17-
US20150361 HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR
Not Available Jan- Jan Dec
097 ANTAGONISTS
13 -14 -15
22- 21- 17-
Not Available Jan- Jan Dec
096 ANTAGONISTS
13 -14 -15
31- 31- 17-
US20150359 IMMUNOGENIC COMPOSITIONS COMPRISING SILICIFIED VIRUS
PORTLAND STATE UNIVERSITY Jan- Jan Dec
871 AND METHODS OF USE
13 -14 -15
17- 17-
US20150359 24-
Technology for the Preparation of Microparticles Not Available Jun Dec
746 Jul-07
-15 -15
10- 9- 10-
US20150355
ADP-RIBOSE DETECTION REAGENTS The Board of Regents of the University of Texas System Jun- Jun Dec
172
14 -15 -15
16- 15- 10-
US20150353
CAS9-NUCLEIC ACID COMPLEXES AND USES RELATED THERETO Not Available Jan- Jan Dec
905
13 -14 -15
28- 24- 10-
US20150353
17-Substituted Steroid Compounds Not Available Aug- Aug Dec
596
02 -15 -15
9- 5- 10-
US20150353
NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. Jun- Jun Dec
561
14 -15 -15
3- 14- 10-
3M INNOVATIVE PROPERTIES COMPANY Jun- Aug Dec
218 MADE THEREFROM
11 -15 -15
18- 17- 3-
US20150344 INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR
ACTELION PHARMACEUTICALS LTD Dec- Dec Dec
425 ANTAGONISTS
12 -13 -15
17- 17- 3-
US20150343 METHODS OF MODULATING IMMUNE RESPONSES BY MODIFYING
Not Available Apr- Apr Dec
028 AKT3 BIOACTIVITY
14 -15 -15
7- 30- 26-
US20150337 SINGLE CELL ANALYSIS OF T CELLS USING HIGH-THROUGHPUT
Not Available May- Apr Nov
369 MULTIPLEX AMPLIFICATION AND DEEP SEQUENCING
14 -15 -15
29- 26-
US20150337 METHOD FOR PRODUCTION OF REPROGRAMMED CELL USING 16-
Not Available Jul- Nov
334 CHROMOSOMALLY UNINTEGRATED VIRUS VECTOR Jul-08
15 -15
6- 4- 26-
US20150337 ANTIVIRAL RIFT VALLEY FEVER VIRUS PEPTIDES AND METHODS OF The United States of America, as represented by the
Dec- Jun Nov
015 USE Secretary of the Army, on behalf of the United
12 -15 -15
8- 27- 26-
US20150335 Immunogenic Composition and Methods of Using the Compositions
Not Available Apr- Apr Nov
733 for Inducing Humoral and Cellular Immune Responses
11 -15 -15
27- 18- 26-
Academia Sinica Mar- Feb Nov
728 VIRUS
09 -14 -15
5- 4- 26-
US20150335
Methods for Modulating Sirtuin Enzymes Not Available May- May Nov
657
14 -15 -15
25- 8- 19-
US20150329
NOVEL siRNAS AND METHODS OF USE THEREOF Not Available Oct- Jan Nov
866
06 -15 -15
9- 4- 19-
US20150329
METHODS OF PROPAGATING MONKEY ADENOVIRAL VECTORS GenVec, Inc. Nov- Aug Nov
834
09 -15 -15
24- 5- 19-
US20150328
METHODS FOR TREATING VIRAL DISORDERS Not Available Sep- Aug Nov
282
09 -15 -15
15- 16- 12-
US20150322
High density self-contained biological analysis Not Available Nov- Jul- Nov
491
06 15 -15
15- 12-
Robert Yongxin Zhao Jul- Nov
15 -15
28- 28- 12-
US20150322 HUMAN ANTIBODY SPECIFIC TO HUMAN METAPNEUMOVIRUS, OR
137 ANTIGEN-BINDING FRAGMENT THEREOF
13 -14 -15
12- 11- 12-
US20150322
THERAPEUTIC CATECHOLS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY May- May Nov
022
14 -15 -15
12- 11- 12-
US20150322 INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR
ACTELION PHARMACEUTICALS LTD Dec- Dec Nov
008 ANTAGONIST
12 -13 -15
A COMPOSITION FOR PREVENTING OR TREATING AN RNA VIRAL 7- 7- 12-

US20150320
INFECTION COMPRISING SAMHD1 OR A NUCLEIC ACID MOLECULE SNU R&DB FOUNDATION Jan- Jan Nov
842
ENCODING THE SAMHD1 13 -13 -15
6- 6- 12-
US20150320
USE OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS Not Available May- May Nov
801
14 -15 -15
30- 20- 5-
Not Available Sep- Jul- Nov
03 15 -15

16- 16- 5-
US20150315
PRODUCTION OF STABLE NON-POLYADENYLATED RNAS Massachusetts Institute of Technology Oct- Oct Nov
574
12 -13 -15
15- 5-
Dr. Robert Yongxin Zhao Jul- Nov
15 -15
3- 1- 5-
US20150313
NOVEL DEPSIPEPTIDE AND USES THEREOF Not Available Dec- Jul- Nov
960
12 15 -15
8- 5-
US20150313 13-
USE OF TYLVALOSIN AS ANTIVIRAL AGENT CAMBRIDGE UNIVERSITY TECHNICAL SERVICES Jun Nov
929 Jul-06
-15 -15
26- 6- 5-
US20150313
ANTIVIRAL COMPOUNDS AND METHODS Biotron Limited Jun- Feb Nov
909
03 -15 -15
28- 28- 29-
US20150309 SYSTEM AND METHOD FOR ELECTRONIC BIOLOGICAL SAMPLE
NANOMEDICAL DIAGNOSTICS, INC. Apr- Apr Oct-
018 ANALYSIS
14 -14 15
28- 10- 29-
US20150307 SYSTEM AND METHOD FOR DNA SEQUENCING AND BLOOD
Nanomedical Diagnostics, Inc. Apr- Apr Oct-
936 CHEMISTRY ANALYSIS
14 -15 15
6- 13- 29-
US20150307 NON-MASS DETERMINED BASE COMPOSITIONS FOR NUCLEIC ACID
Not Available Aug- Jul- Oct-
935 DETECTION
09 15 15
23- 29-
US20150307 11-
HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS Not Available Feb Oct-
849 Jul-03
-15 15
23- 29-
US20150307 12-
BIOACTIVE PEPTIDES AND METHODS OF USING SAME Not Available Feb Oct-
572 Jul-07
-15 15
31- 30- 29-
US20150307
NOVEL MUCOLYTIC AGENTS PARION SCIENCES, INC. Aug- Aug Oct-
530
12 -13 15
9- 29-
US20150306 HMGB1-DERIVED PEPTIDES ENHANCE IMMUNE RESPONSE TO 27-
The Regents of the University of California Mar Oct-
213 ANTIGENS Jul-10
-15 15
18- 12- 29-
US20150306
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available Nov- Jun Oct-
212
13 -15 15
17- 17- 29-
US20150306
VACCINE COMPOSITION FOR NAIVE SUBJECTS Not Available Dec- Dec Oct-
205
12 -13 15

US20150306
HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL OCULUS INNOVATIVE SCIENCES, INC. Jan- Jul- Oct-
137
WATER SOLUTION 06 15 15
6- 1- 22-
US20150301
CIRCULATING BIOMARKERS FOR DISEASE Not Available Apr- Jul- Oct-
055
10 15 15
18- 6- 22-
US20150299
TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS Not Available May- Jul- Oct-
728
04 15 15
CONSTRUCTION OF POOL OF INTERFERING NUCLEIC ACIDS 2- 22-

US20150299 7-Jul-
COVERING ENTIRE RNA TARGET SEQUENCE AND RELATED BIOMICS BIOTECHNOLOGIES CO., LTD. Jul- Oct-
707 08
COMPOSITIONS 15 15
10- 10- 22-

US20150299 ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE
INFLUENZA VIRUS AND TYPE 1 DIABETES Oct- Oct Oct-
667 VENEZIE
12 -13 15
20- 6- 22-
US20150299
TREATING CANCER WITH VIRAL NUCLEIC ACID Not Available Feb- Jul- Oct-
271
07 15 15
22- 22- 22-
US20150299
4-AMINO-IMIDAZOQUINOLINE COMPOUNDS HOFFMANN-LA ROCHE INC. Apr- Apr Oct-
194
14 -15 15
17- 8- 22-
US20150299 3,5-DIAMINO-6-CHLORO-N-(4-PHENYLBUTYL)CARBAMIMIDOYL)
PARION SCIENCES, INC. Dec- Jan Oct-
142 PYRAZINE-2-CARBOXAMIDE COMPOUNDS
12 -15 15
10- 27- 22-

US20150297
Novel Adenovirus Vectors Not Available Apr- Apr Oct-
700
07 -15 15
13- 12- 22-
US20150297
COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ENTRY Children Medical Center Corporation Dec- Dec Oct-
677
12 -13 15
29- 29- 22-
US20150297
ANALOGS OF C5a AND METHODS OF USING SAME BOARD PF REGENTS OF THE UNIVERSITY OF NEBRASKA Jun- Jun Oct-
668
10 -11 15
11- 3- 15-
US20150291
MERTK-SPECIFIC PYRIMIDINE COMPOUNDS Not Available Apr- Apr Oct-
609
14 -15 15
11- 3- 15-
US20150291
MERTK-SPECIFIC PYRROLOPYRIMIDINE COMPOUNDS Not Available Apr- Apr Oct-
606
14 -15 15
11- 3- 15-
US20150291
MERTK-SPECIFIC PYRAZOLOPYRIMIDINE COMPOUNDS Not Available Apr- Apr Oct-
605
14 -15 15
9- 8- 15-
US20150291
THERAPEUTIC HYDROXYQUINOLONES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY Nov- Nov Oct-
531
12 -13 15

USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN
23- 8- 15-
US20150290 COMBINATION WITH (DEOXY)NUCLEOSIDE OR
Not Available Nov- Nov Oct-
235 (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND
12 -13 15
HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS
23- 21- 15-

US20150290
TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS Not Available Mar- Apr Oct-
234
07 -15 15
11- 3- 15-
US20150290 THERAPEUTIC USES OF SELECTED PYRAZOLOPYRIMIDINE
14 -15 15
11- 3- 15-
US20150290 THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE
14 -15 15
11- 3- 15-
US20150290 THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH
194 ANTI-MER TYROSINE KINASE ACTIVITY
14 -15 15
27- 12- 15-

PARION SCIENCES, INC. Jun- Jan Oct-
11 -15 15
24- 21- 15-

US20150290 TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR
Not Available Jan- Apr Oct-
134 MICROSPHERES
06 -15 15
1- 26- 15-
US20150289
SELF SANITIZING FACE MASKS AND METHOD OF MANUFACTURE Not Available Jun- Jun Oct-
573
07 -15 15
21- 21- 8-
US20150284
BISPECIFIC ANTIBODY Not Available Nov- Nov Oct-
475
12 -12 15
29- 29- 8-
US20150284 COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN
451 INFECTION
12 -13 15
16- 16- 8-
US20150284
NOVEL LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES SUZHOU M-CONJ BIOTECH CO., LTD Jun- Jun Oct-
416
15 -15 15
18- 17- 8-
US20150283
Microspotting Device Not Available Apr- Apr Oct-
531
12 -13 15
15- 17- 8-
US20150283
Compositions and Methods for Enhancing Immune Responses Not Available Jun- Jun Oct-
233
12 -13 15
7- 7- 8-
US20150283 ATTENUATED LISTERIA MONOCYTOGENES MUTANT AS A VACCINE
The Board of Trustees of the University of Illinois Apr- Apr Oct-
221 VECTOR FOR THE DELIVERY OF EXOGENEOUS ANTIGENS
14 -15 15
23- 23- 1-
US20150275 Human Betacoronavirus Lineage C and Identification of N-Terminal
Not Available Sep- Sep Oct-
183 Dipeptidyl Peptidase As Its Virus Receptor
12 -13 15
10- 1-
US20150274 Hydrazide Containing Nuclear Transport Modulators And Uses 29-
Not Available Jun Oct-
698 Thereof Jul-11
-15 15
7- 7- 1-
Advanced Inhalation Therapies (AIT) Ltd. Mar- Mar Oct-
988 DISEASES
12 -13 15
14- 14- 24-
US20150267 PRESERVATION OF BIOLOGICAL MATERIALS IN NON-AQUEOUS
GenTegra, LLC Mar- Mar Sep
245 FLUID MEDIA
13 -14 -15
16- 6- 24-
US20150267 ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING
Not Available Sep- Nov Sep
202 ss/RNA VIRAL INFECTION
04 -14 -15
12- 12- 24-
US20150267 DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4
Quark Pharmaceutical, Inc. Sep- Sep Sep
194 AND METHODS OF USE THEREOF
12 -13 -15
17- 4- 24-
US20150266 VIRUS-LIKE PARTICLES, METHODS OF PREPARATION, AND
Not Available May- May Sep
929 IMMUNOGENIC COMPOSITIONS
02 -15 -15
9- 8- 24-
Not Available Feb- Jun Sep
05 -15 -15
19- 18- 24-
US20150266
PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS Not Available Oct- Oct Sep
882
12 -13 -15
23- 23- 24-
US20150265
Compounds and Methods for Modulating an Immune Response Not Available Mar- Dec Sep
721
09 -14 -15
5- 11- 24-
US20150265 HIGH-YIELD TRANSGENIC MAMMALIAN EXPRESSION SYSTEM FOR
Academia Sinica Sep- Feb Sep
697 GENERATING VIRUS-LIKE PARTICLES
06 -15 -15
24- 23- 24-
US20150265 Compositions And Methods For Treating And Preventing Porcine
Not Available Apr- Feb Sep
696 Reproductive And Respiratory Syndrome
12 -15 -15
25- 23- 17-
US20150259
GITR BINDING MOLECULES AND USES THEREFOR Not Available Mar- Mar Sep
427
05 -15 -15

16- 18- 17-
US20150259
ANTIBODIES AND PROCESSES FOR PREPARING THE SAME Not Available May- Mar Sep
399
08 -15 -15
19- 18- 17-
US20150259
NOVEL KINASE INHIBITORS Not Available Oct- Oct Sep
340
12 -13 -15
8- 19- 17-
US20150259
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS Not Available Mar- Mar Sep
292
11 -15 -15
3- 13- 17-
Novartis AG Dec- Mar Sep
09 -15 -15
25- 20- 10-
US20150252
Methods and Compositions for Prostate Cancer Metastasis Not Available Mar- May Sep
439
11 -15 -15
FUSION PROTEINS FOR PROMOTING AN IMMUNE RESPONSE, 7- 9- 10-

US20150252
NUCLEIC ACIDS ENCODING SAME, AND METHODS OF MAKING AND Not Available Sep- Sep Sep
080
USE THEREOF 12 -13 -15
24- 24- 10-

US20150250 HYDROPHILIC LINKERS AND THEIR USES FOR CONJUGATION OF
Hangzhou DAC Biotech Co., Ltd. Nov- Nov Sep
896 DRUGS TO A CELL BINDING MOLECULES
12 -12 -15
5- 4- 3-
US20150247 METHODS AND SYSTEMS FOR MICROFLUIDICS IMAGING AND
190 ANALYSIS
12 -13 -15
4- 14- 3-
US20150246 ADJUVANTED INFLUENZA VACCINES INCLUDING CYTOKINE-
Novartis AG Nov- May Sep
110 INDUCING AGENTS
05 -15 -15
2- 15- 3-
US20150246 COMPOUNDS AND METHODS FOR PREVENTING OR TREATING A
Not Available Nov- May Sep
091 VIRAL INFECTION
07 -15 -15
3- 3- 3-
US20150246 Esters of Short Chains Fatty Acids for Use in the Treatment of
015 Immunogenic Disorders
12 -13 -15
4- 13- 27-
US20150239
COMPOSITIONS AND METHODS FOR VIRUS INHIBITION AUTOIMMUNE TECHNOLOGIES, LLC Nov- May Aug
940
03 -15 -15
21- 12- 27-

US20150239 SUBSTITUTED PYRIDONES AND PYRAZINONES AND THEIR USE AS
875 INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
14 -15 -15
28- 27- 27-

US20150238
AAV Vectors Targeted to Oligodendrocytes Not Available Sep- Sep Aug
550
12 -13 -15
31- 30- 27-
US20150238
HETEROCYCLYL CARBOXAMIDES FOR TREATING VIRAL DISEASES Not Available Aug- Aug Aug
489
12 -13 -15
4- 4- 20-
US20150232 MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS
Not Available Apr- Apr Aug
957 AND USE THEREOF FOR DETECTING NUCLEIC ACIDS
12 -13 -15
7- 7- 20-
EDITAS MEDICINE, INC. Nov- Nov Aug
881 GOVERNING gRNAS
13 -14 -15
28- 20- 20-
US20150232
Construct Not Available Mar- Oct Aug
878
06 -14 -15
11- 11- 20-
US20150232 THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY Sep- Sep Aug
454 AND HYDROXYPYRIDAZINONES
12 -13 -15
18- 18- 20-
US20150231
OUTER MEMBRANE VESICLES Not Available Sep- Sep Aug
232
12 -13 -15
2- 24- 13-
US20150225
COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS Novartis AG Sep- Apr Aug
432
09 -15 -15
18- 13- 6-
Not Available Jun- Apr Aug
04 -15 -15
21- 19- 6-
US20150218
C-REL INHIBITORS AND USES THEREOF Not Available Sep- Sep Aug
109
12 -13 -15
8- 8- 6-
US20150216
METHOD FOR THE INDUCTION OF AN IMMUNE RESPONSE Not Available Aug- Aug Aug
973
12 -13 -15
12- 30-
US20150211 13-
CHIRAL CONTROL Not Available Jul- Jul-
006 Jul-12
13 15
2- 22- 30-
US20150210
NUCLEIC ACID CHEMICAL MODIFICATIONS Not Available Mar- Jan Jul-
733
09 -15 15

US20150210
OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 ASTRAZENECA AB Jan- Jan Jul-
655
INHIBITORS 14 -15 15
23- 31- 23-

US20150203 CHEMICAL MODIFICATIONS OF MONOMERS AND
Not Available Sep- Dec Jul-
847 OLIGONUCLEOTIDES WITH CYCLOADDITION
08 -14 15

4- 26- 23-
US20150203
MEANS AND METHODS FOR INFLUENCING THE STABILITY OF CELLS Not Available Dec- Mar Jul-
816
09 -15 15
11- 20- 23-
METHOD OF MAKING A VACCINE Oct- Jan Jul-
284 Secretary, Dept. of Health & Human Services
08 -15 15
8- 2- 16-
US20150196 EV576 FOR USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE
619 RESPIRATORY TRACT
10 -15 15
14- 10- 16-
US20150196
COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS Not Available Oct- Dec Jul-
578
09 -14 15
30- 19- 16-
US20150196
ANTIVIRAL COMPOSITIONS Long Island University May- Mar Jul-
032
07 -15 15
POXVIRUS-PLASMODIUM RECOMBINANTS, COMPOSITIONS 30- 19- 9-

US20150191
CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND Not Available Dec- Dec Jul-
704
METHODS OF MAKING AND USING SAME 13 -14 15
4- 9-
US20150191 3-Jul-
Anti-fouling Paints and Coatings REACTIVE SURFACES, LTD Dec Jul-
607 03
-13 15
27- 27- 2-
US20150184
BIOAGENT DETECTION OLIGONUCLEOTIDES Not Available Dec- Dec Jul-
231
11 -12 15
17- 13- 2-
US20150183
IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF Not Available Dec- Feb Jul-
837
07 -15 15
GENETICALLY MODIFIED HUMAN UMBILICAL CORD PERIVASCULAR 21- 13- 2-

US20150182
CELLS FOR PROPHYLAXIS AGAINST OR TREATMENT OF BIOLOGICAL Not Available Apr- Mar Jul-
636
OR CHEMICAL AGENTS 08 -15 15
18- 23- 2-
US20150182
SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available Nov- Dec Jul-
588
13 -14 15
17- 16- 25-

Not Available Dec- Jan Jun-
01 -15 15
20- 5- 25-
US20150175
CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS Not Available Mar- Mar Jun-
656
09 -15 15
29- 3- 25-
US20150174 METHODS AND REAGENTS FOR EFFICIENT AND TARGETED GENE
Not Available Apr- Mar Jun-
257 TRANSFER TO MONOCYTES AND MACROPHAGES
09 -15 15
28- 28- 25-

US20150174
USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE Not Available Aug- Jan Jun-
206
03 -15 15
US20150174
LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA Not Available Oct- Nov Jun-
198
7- 7- 25-
Not Available Mar- Mar Jun-
158 DISEASES
12 -13 15
1- 16- 25-
US20150173
PHYSICAL ANTIMICROBIAL METHOD NMS TECHNOLOGIES CO., LTD. Aug- Jul- Jun-
366
12 13 15
16- 24- 18-
US20150168
OLIGONUCLEOTIDE BASED ANALYTE DETECTION METHOD Not Available Feb- Feb Jun-
405
10 -15 15
25- 27- 18-
US20150166 PARTICLE-NUCLEIC ACID CONJUGATES AND THERAPEUTIC USES
Not Available Jun- Feb Jun-
989 RELATED THERETO
12 -13 15
20- 1- 18-
US20150166
REVERSE GENETICS METHODS FOR VIRUS RESCUE Not Available Oct- Oct Jun-
966
09 -14 15
16- 16- 18-
US20150166
NOVEL COMPOUNDS CHIESI FARMACEUTICI S.p.A. Dec- Dec Jun-
548
13 -14 15
11- 15- 18-
Not Available Apr- Mar Jun-
532 VIRUSES
12 -13 15
13- 19- 18-
US20150166 ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPTHELIAL
PARION SCIENCES, INC. Dec- Dec Jun-
13 -14 15
13- 13- 18-
US20150166 ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL
Parion Sciences, Inc. Dec- Dec Jun-
13 -13 15
24- 5- 18-
US20150165
Saccharide Conjugate Vaccines Not Available Dec- Aug Jun-
019
04 -14 15
24- 20- 18-
US20150165 TLR5 LIGANDS, THERAPEUTIC METHODS, AND COMPOSITIONS
Emory University Sep- Sep Jun-
009 RELATED THERETO
10 -11 15

23- 18-
US20150164 REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND 25-
Salk Institute For Biological Studies Jul- Jun-
800 LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYL SERINE Jul-12
13 15
6- 6- 11-
METHODS AND REAGENTS FOR AMPLIFYING NUCLEIC ACIDS Aug- Aug Jun-
205 Secretary, Department of Health and Human
12 -12 15
7- 18- 11-
US20150159
METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR The Trustees of the University of Pennsylvania Apr- Feb Jun-
173
05 -15 15
24- 18- 11-
US20150157
METHODS FOR TREATING VIRAL DISORDERS Not Available Sep- Feb Jun-
636
09 -15 15
9- 21- 4-
US20150152 Peptides Having Activity of Inhibiting Infections of Respiratory
Not Available May- Feb Jun-
149 Viruses and Use of the Same
13 -14 15
5- 5- 4-
US20150150
VACCINATION WITH INTERLEUKIN-4 ANTAGONISTS THE AUSTRALIAN NATIONAL UNIVERSITY Jun- Jun Jun-
963
12 -13 15
18- 31- 4-
US20150150
ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION Not Available Jun- May Jun-
893
12 -13 15
4- 4- 4-
US20150150 Methods For Inhibiting Viruses By Targeting Cathepsin-L Cleavage
878 Sites In The Viruses' Glycoproteins
12 -13 15
1- 9- 28-
US20150148 MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS
NOVARTIS AG Oct- May May
402 OF USE
04 -14 -15
REPLIKIN SEQUENCES AND THEIR ANTIBODIES FOR DIAGNOSTICS,

2- 1- 28-
US20150147 THERAPEUTICS, AND VACCINES AGAINST PRION AND
346 NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMER'S
12 -13 -15
DISEASE
22- 20- 21-

US20150141
IMMUNE RESPONSE MODIFIER CONJUGATES Not Available Feb- Jan May
625
06 -15 -15
18- 14- 21-
US20150141 PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE
Not Available Dec- Jan May
387 INHIBITOR AND A SECOND ACTIVE INGREDIENT
08 -15 -15
8- 10- 21-
US20150140
Compositions and Methods for Tight Junction Modulation Not Available Jun- Jun May
121
12 -13 -15
6- 19- 21-
US20150139
ANTI-VIRAL COMBINATION THERAPY Not Available Apr- May May
949
11 -14 -15
18- 17- 14-
US20150133 MODIFICATION OF PEPTIDES USING A
633 BIS(THIOETHER)ARYLBRIDGE APPROACH
12 -13 -15
20- 7- 14-
US20150133
BORON-CONTAINING SMALL MOLECULES Not Available Jun- Nov May
402
07 -14 -15
7- 7- 14-
US20150133 CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN
391 MICROBIOME AND COMPONENTS THEREOF
13 -14 -15
7- 7- 14-
US20150132 ADJUVANTED FORMULATIONS OF STREPTOCOCCUS PNEUMONIAE
Not Available Mar- Mar May
339 ANTIGENS
12 -13 -15
17- 13- 14-
US20150132
COMBINATION GAS VACCINES AND THERAPEUTICS Not Available Sep- Nov May
337
08 -14 -15
8- 14-
Not Available Jan May
-15 -15
24- 4- 7-
US20150126 OLIGONUCLEOTIDE COMPOUND AND METHOD FOR TREATING
Not Available Dec- Jun May
722 NIDOVIRUS INFECTIONS
03 -14 -15
15- 5- 7-
US20150125
RELEASE OF AGENTS FROM CELLS Not Available Oct- Jan May
540
09 -15 -15
6- 4- 7-
US20150125 DISINFECTING COMPOSITION AND WIPES WITH REDUCED
502 CONTACT TIME
13 -14 -15
27- 29- 7-
US20150125 FUSION PROTEINS OF CILIATE GRANULE LATTICE PROTEINS,
Tetragenetics, Inc. May- May May
483 GRANULAR PROTEIN PARTICLES THEREOF, AND USES THEREFOR
11 -12 -15
7- 7- 7-
US20150125
IMMUNOLOGICALLY USEFUL ARGININE SALTS Not Available Mar- Mar May
475
12 -13 -15
15- 10- 7-
US20150125
MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES Not Available Feb- Nov May
384
07 -14 -15
4- 22- 30-
US20150119
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides Not Available Dec- Jul- Apr-
445
07 14 15
4- 11- 30-
US20150119
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides Not Available Dec- Jul- Apr-
444
07 14 15

4- 15- 30-
US20150119
MODULATORS OF THE RELAXIN RECEPTOR 1 Not Available May- Mar Apr-
426
12 -13 15
16- 10- 30-
US20150119
BORON-CONTAINING SMALL MOLECULES Not Available Feb- Nov Apr-
364
05 -14 15
30- 9- 30-
US20150119 PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING THE ADMINISTRATORS OF THE TULANE EDUCATIONAL
Oct- Jul- Apr-
318 HERPESVIRUS INFECTION FUND
09 14 15
21- 24- 30-
US20150118
INFLUENZA VIRUS REASSORTMENT METHOD Not Available May- Oct Apr-
746
10 -14 15
27- 5- 30-
US20150118 PROTEOLYSIS-RESISTANT CAPSID OF CHIMERIC HEPATITIS E
Not Available Feb- Nov Apr-
319 VIRUS AS AN ORAL DELIVERY VECTOR
09 -14 15
13- 12- 30-
US20150118
MODIFIED ERYTHROCYTE PRECURSOR CELLS AND USES THEREOF Anthrogenesis Corporation Mar- Mar Apr-
265
12 -13 15
PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC 31- 31- 30-

US20150118
CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR CureVac GMBH Jan- Jan Apr-
264
PEPTIDE ANTIGEN 12 -13 15
25- 24- 30-

US20150118 TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND
222 IMMUNOTHERAPY
13 -14 15
30- 22- 30-
US20150118
Directed Evolution and In Vitro Panning of Virus Vectors Not Available Apr- Oct Apr-
201
08 -14 15
31- 31- 30-
US20150118 NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES
CUREVAC GMBH Jan- Jan Apr-
183 FOR IMMUNOSTIMULATION
12 -13 15
17- 19- 23-
US20150111 AAV VECTOR COMPOSITIONS AND METHODS FOR GENE TRANSFER
Not Available Feb- Feb Apr-
955 TO CELLS, ORGANS AND TISSUES
12 -13 15
28- 23-
US20150111 COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS 20-
Not Available Mar Apr-
945 GENE EXPRESSION Jul-09
-14 15
9- 9- 23-
US20150111
Nuclear Transport Modulators and Uses Thereof Not Available May- May Apr-
893
12 -13 15
19- 10- 23-
US20150110
HDC-SIGN BINDING PEPTIDES Sloan-Kettering Institute for Cancer Research Dec- Dec Apr-
807
11 -12 15

14- 18- 16-
Not Available Mar- Dec Apr-
13 -14 15
CATHEPSIN C
29- 2- 16-
US20150104
ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS Baxter Healthcare SA Oct- May Apr-
867
04 -14 15
9- 28- 16-
US20150104
Methods and Compositions for Preventing a Condition Not Available Aug- Aug Apr-
500
10 -14 15
18- 17- 9-
US20150099
CARBOXYLIC ACID COMPOUNDS Not Available May- May Apr-
770
12 -13 15
6- 15- 9-
US20150099 PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE
Not Available Dec- Sep Apr-
769 IN THERAPY
04 -14 15

US20150099
BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER PARION SCIENCES, INC. May- Dec Apr-
764
MUCOSAL DISEASES 12 -14 15
4- 3- 9-
US20150099
Multiplex Immuno Screening Assay Not Available May- May Apr-
656
12 -13 15
5- 15- 9-
US20150099
SELECTIVE DETECTION OF HUMAN RHINOVIRUS Not Available Dec- Dec Apr-
263
08 -14 15
9- 10- 9-
US20150099
RESPIRATORY INFECTION ASSAY Not Available Dec- Dec Apr-
261
11 -12 15
NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-

15- 15- 2-
US20150093 LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL
CureVac GmbH Feb- Feb Apr-
413 FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC
12 -13 15
ANTIGEN
13- 15- 26-

US20150086
SORTASE-MODIFIED VHH DOMAINS AND USES THEREOF Not Available Apr- Apr Mar
576
12 -13 -15
20- 15- 19-
US20150080
Sceletium Extract and Uses Thereof H. L. Hall & Sons Limited Mar- Jul- Mar
447
09 14 -15
21- 26- 19-
US20150080 Novel Pyrimidine Derivatives and Their Use in the Treatment of
ASTRAZENECA AB May- Aug Mar
396 Cancer and Further Diseases
09 -14 -15

14- 29- 19-
US20150080 PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF
Not Available Apr- Sep Mar
10 -14 -15
2- 19- 19-
US20150080
Inhibition Of Tace Activity With Cyclic Peptides Not Available Jun- Sep Mar
319
11 -14 -15
14- 14- 19-
US20150079 Cationic Liposomal Drug Delivery System for Specific Targeting of
155 Human CD14+ Monocytes in Whole Blood
12 -13 -15
Human Respiratory Syncytial Virus Consensus Antigens, Nucleic Acid 10- 10- 19-
US20150079
Constructs And Vaccines Made Therefrom, And Methods Of Using Not Available Apr- Apr Mar
121
Same 12 -13 -15
27- 17- 12-

US20150073
PYRAZINONE DERIVATIVES Not Available Jun- Nov Mar
136
07 -14 -15
NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 13- 17- 12-

US20150072
7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR Not Available Aug- Sep Mar
973
THERAPEUTIC APPLICATIONS 10 -14 -15
11- 11- 12-

023 DISEASES
13 -14 -15
16- 10- 5-
US20150065
459
05 -14 -15
19- 17- 5-
US20150065
Composition for Inactivating an Enveloped Virus Not Available May- Nov Mar
458
06 -14 -15
17- 16- 5-
US20150064 USE OF ENGINEERED VIRUSES TO SPECIFICALLY KILL SENESCENT
Kythera Biopharmaceuticals, Inc. Apr- Apr Mar
137 CELLS
12 -13 -15
26- 26- 26-
US20150056
Transgenic Immunodeficient Mouse Expressing Human SIRP-alpha Not Available Mar- Mar Feb
636
12 -13 -15
23- 13- 26-
US20150056
DITHIOL MUCOLYTIC AGENTS PARION SCIENCES, INC. Aug- Aug Feb
305
13 -14 -15
1- 29- 19-
US20150051
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC Sep- Aug Feb
206
11 -12 -15
25- 19-
US20150050 24-
Technology for the Preparation of Microparticles Not Available Jul- Feb
713 Jul-07
14 -15
18- 13- 19-

US20150050 CORONAVIRUS, NUCLEIC ACID, PROTEIN, AND METHODS FOR THE
308 GENERATION OF VACCINE, MEDICAMENTS AND DIAGNOSTICS
03 -14 -15
16- 14- 19-

US20150050
SOLUBLE ENGINEERED MONOMERIC FC Not Available Mar- Mar Feb
278
12 -13 -15
7- 6- 12-
US20150045 USE OF THE CHROMOSOME 19 MICRORNA CLUSTER (C19MC) FOR
412 TREATING MICROBIAL DISEASE AND PROMOTING AUTHOPHAGY
12 -13 -15
28- 24- 12-

US20150044 METHODS AND COMPOSITIONS FOR PRODUCTION OF
Not Available May- Oct Feb
768 RECOMBINANT PROTEIN IN HBX-EXPRESSING MAMMALIAN CELLS
08 -14 -15
7- 7- 12-
305 DISEASES
12 -13 -15
10- 6- 12-
Not Available Apr- Oct Feb
279 RESPONSE
03 -14 -15
26- 25- 5-
US20150037
METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES Not Available Jan- Jan Feb
288
12 -13 -15
2- 1- 5-
US20150037 VARIANTS OF PROTHYMOSIN ALPHA AND METHODS OF USING
Icahn School of Medicine at Mount Sinai Mar- Mar Feb
281 SAME
12 -13 -15
7- 7- 5-
Advanced Inhalation Therapies (AIT) Ltd. Mar- Mar Feb
084 DISEASES
12 -13 -15
6- 6- 29-
US20150031
SAMPLE PREPARATION METHODS Not Available Sep- Sep Jan-
038
11 -12 15
24- 4- 29-
US20150031 Mixed Cell Diagnostic Systems For Detection Of Respiratory, Herpes
Diagnostic Hybrids Inc. Apr- Aug Jan-
016 and Enteric Viruses
98 -14 15
25- 29-
US20150031 25-
DETECTING ANALYTES WITH A PH METER The Board of Trustees of the University of Illinois Jul- Jan-
014 Jul-13
14 15
17- 8- 29-
US20150030 Trans-complementing, replication deficient lentiviral vectors and
VIRxSYS.CON390 Aug- Oct Jan-
627 methods for making and using them
06 -14 15
9- 9- 29-
US20150030
IMMUNOMODULATORY CONJUGATES Ascend Biopharamaceuticals Ltd Nov- Nov Jan-
626
11 -12 15

12- 13- 29-
US20150030
GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES Not Available Sep- Oct Jan-
625
07 -14 15
20- 9- 29-
US20150030 INFLUENZA HEMAGGLUTININ-SPECIFIC MONOCLONAL ANTIBODIES
607 FOR PREVENTING AND TREATING INFLUENZA VIRUS INFECTION
10 -14 15
20- 18- 22-

ACTELION PHARMACEUTICALS LTD. Jan- Jan Jan-
075 ANTAGONISTS
12 -13 15
16- 19- 22-
US20150024 DETECTION AND QUANTIFICATION OF ANALYTES BASED ON
The Board of Trustees of the University of Illinois Feb- Feb Jan-
415 SIGNAL INDUCED BY ALKALINE PHOSPHATE
12 -13 15
30- 6- 22-
US20150024 ENHANCED DEPOSITION OF CHROMOGENS UTILIZING PYRIMIDINE
Ventana Medical Systems, Inc. Dec- Oct Jan-
405 ANALOGS
10 -14 15
21- 20- 22-
US20150024
ALPHAVIRUS VECTORS FOR RESPIRATORY PATHOGEN VACCINES Not Available May- Aug Jan-
002
04 -14 15
3- 30- 22-
US20150023
ALKOXY SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY Oct- Sep Jan-
990
03 -14 15
22- 22-
US20150023 VARIANT AAV AND COMPOSITIONS, METHODS AND USES FOR 22-
924 GENE TRANSFER TO CELLS, ORGANS AND TISSUES Jul-13
14 15
3- 3- 22-
US20150023
HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS BIOTRON LIMITED Aug- Apr Jan-
921
07 -14 15
8- 8- 22-
US20150023
DIAGNOSTIC CHEWING GUM FOR PATHOGENS Julius-Maximilians-Universitaet Wuerzburg Mar- Mar Jan-
879
12 -13 15
25- 30- 22-
US20150021
AMPEROMETRIC GAS SENSOR Not Available Jun- Sep Jan-
204
12 -14 15
25- 30- 22-
US20150021
AMPEROMETRIC GAS SENSOR Not Available Jun- Sep Jan-
203
12 -14 15
PREVENTION AND TREATMENT OF RESPIRATORY INFECTION WITH 8- 3- 15-

US20150018
PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR DELTA Not Available Mar- Mar Jan-
396
AGONIST 12 -13 15
26- 15-
US20150018 29-
Nuclear Transport Modulators and Uses Thereof KARYOPHARM THERAPEUTICS INC. Jul- Jan-
332 Jul-11
12 15
6- 18- 15-
US20150017
MICROPARTICLES FOR USE IN IMMUNOGENIC COMPOSITIONS NOVARTIS AG Aug- Jul- Jan-
251
08 14 15
4- 11- 8-
US20150011
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides Not Available Dec- Jul- Jan-
615
07 14 15
1- 28- 8-
US20150011
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC Sep- Aug Jan-
508
11 -12 15
5- 19- 8-
Not Available Dec- Sep Jan-
983 GROWTH
08 -14 15
18- 7- 1-
US20150005 METHOD OF TREATING AN ISCHEMIA-REPERFUSION INJURY-
Not Available Sep- Sep Jan-
227 RELATED DISORDER BY ADMINISTERING GPCR LIGANDS
06 -14 15
COMPOSITIONS, COMPRISING IMPROVED IL-12 GENETIC 12- 11- 1-

US20150004
CONSTRUCTS AND VACCINES, IMMUNOTHERAPEUTICS AND Not Available Dec- Dec Jan-
188
METHODS OF USING THE SAME 11 -12 15
PHORBOL TYPE DITERPENE COMPOUND, PHARMACEUTICAL 26- 28- 11-

US20140364 KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND
COMPOSITION FOR TREATMENT OR PREVENTION OF VIRAL Oct- Sep Dec
492 BIOTECHNOLOGY
INFECTIOUS DISEASES INCLUDING SAME 11 -12 -14
29- 11-
US20140364 Hydrazide Containing Nuclear Transport Modulators And Uses 29-
KARYOPHARM THERAPEUTICS INC. Jul- Dec
408 Thereof Jul-11
12 -14
5- 7- 11-
US20140364
Method for Preventing and Treating Hyperpermeability Apeptico Forschung UND Entwicklung GMBH Mar- Mar Dec
358
09 -14 -14
4- 4- 11-
US20140363 MYCOBACTERIAL VACCINE VECTORS AND METHODS OF USING THE
Beth Israel Deaconess Medical Center, Inc. Apr- Apr Dec
465 SAME
11 -12 -14
28- 2- 11-
Not Available Dec- Jan Dec
11 -13 -14
24- 31- 4-
US20140357
Deubiquitinase Inhibitors and Methods for Use of the Same Not Available Sep- Jul- Dec
673
10 14 -14
8- 20- 4-
US20140356 MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF The Government of the United States of America as
Oct- Aug Dec
390 SYNONYMOUS CODONS represented by the Secretary of the Department of
04 -14 -14
30- 12- 27-
US20140349 METHYLSULFONYLMETHANE (MSM) TO MODULATE MICROBIAL
Biogentic Innovations, LLC Oct- Aug Nov
375 ACTIVITY
09 -14 -14

31- 25- 27-
US20140349
METHOD FOR DETECTING TARGET NUCLEIC ACID Not Available Oct- Oct Nov
295
11 -12 -14
21- 21- 27-
US20140349
SIGNAL PROPAGATION BIOMOLECULES, DEVICES AND METHODS STC.UNM May- May Nov
276
13 -14 -14
13- 27-
US20140348 IMMUNOSTIMULATORY COMPOSITIONS COMPRISING LIPOSOME- 17-
Not Available Aug Nov
906 ENCAPSULATED OLIGONUCLEOTIDES AND EPITOPES Jul-09
-14 -14
9- 7- 27-
US20140348 MODIFIED ADENOVIRAL VECTORS AND METHODS OF TREATMENT
Beth Israel Deaconess Medical Center, Inc. Sep- Sep Nov
791 USING SAME
11 -12 -14
7- 7- 27-
US20140348
NEUTRALIZING GP41 ANTIBODIES AND THEIR USE Not Available Nov- Nov Nov
785
11 -12 -14
22- 20- 27-
US20140348 CONJUGATES OF GM-CSF AND IL-9, COMPOSITIONS AND METHODS
CHILDREN'S HEALTHCARE OF ATLANTA, INC May- May Nov
781 RELATED THERETO
13 -14 -14
1- 5- 20-
US20140342
METHOD FOR USING PERMUTED NUCLEIC ACID PROBES Ventana Medical Systems, Inc. Sep- Aug Nov
941
06 -14 -14
7- 4- 20-
NEUTRALIZING GP41 ANTIBODIES AND THEIR USE Nov- Aug Nov
11 -14 -14
22- 21- 13-
US20140336
VIRUS VECTORS FOR HIGHLY EFFICIENT TRANSGENE DELIVERY Not Available Nov- Nov Nov
245
11 -12 -14
10- 14- 13-
US20140335
TAL EFFECTOR-MEDIATED DNA MODIFICATION Iowa State University Research Foundation, Inc. Dec- Apr Nov
618
09 -14 -14
10- 24- 13-
US20140335
TAL EFFECTOR-MEDIATED DNA MODIFICATION Iowa State University Research Foundation, Inc. Dec- Feb Nov
592
09 -14 -14
7- 5- 13-
US20140335 Identification and Attenuation of the Immunosuppressive Domains
117 in Fusion Proteins of Enveloped RNA Viruses
11 -12 -14
4- 28- 13-
US20140335 VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND
The Trustees of the University of Pennsylvania Apr- Apr Nov
111 COMPOSITIONS AND METHODS OF USING THE SAME
08 -14 -14
13- 14- 13-
US20140335 Methods of Detecting Cells with a Disrupted Cell Membrane, Cells
Not Available May- Apr Nov
104 Infected with A Pathogen, Dying Cells or Dead Cells
08 -14 -14
3- 2- 6-
US20140329
CYCLIC DI-NUCLEOTIDE INDUCTION OF TYPE I INTERFERON Not Available May- May Nov
889
13 -14 -14
3- 1- 6-
US20140329 OLIGONUCLEOTIDE MODULATORS OF THE TOLL-LIKE RECEPTOR
Not Available Mar- Mar Nov
878 PATHWAY
11 -12 -14
24- 24- 6-
US20140329 MYXOVIRUS THERAPEUTICS, COMPOUNDS, AND USES RELATED
CHILDREN'S HEATLHCARE OF ATLANTA, INC. Oct- Oct Nov
817 THERETO
11 -12 -14
13- 21- 6-
US20140328 ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORIDE MONOXIDE
07 14 -14
19- 19- 6-
US20140328
SAMPLE QUANTIFICATION BY DISC CENTRIFUGATION Not Available Oct- Oct Nov
874
11 -12 -14
SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT 15- 17- 30-

US20140323
LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE Not Available Mar- Mar Oct-
556
SYSTEM 13 -14 14
28- 28- 30-

UNIVERSITY OF UTAH RESEARCH FOUNDATION Mar- Mar Oct-
392 ENTRY
11 -12 14
23- 9- 30-
US20140323
COMPOUNDS AND COMPOSITIONS AS TLR2 AGONISTS IRM LLC Mar- Jul- Oct-
390
10 14 14
8- 25- 30-
US20140322
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS 3-V BIOSCIENCES, INC. Mar- Jun Oct-
355
11 -14 14
27- 29- 23-
US20140317
ANTIBODY PRODUCING NON-HUMAN MAMMALS Not Available Jun- Apr Oct-
766
08 -14 14
2- 1- 23-
US20140315 DOUBLE-STRANDED NUCLEIC ACID MOLECULE FOR GENE
Osaka City University Nov- Nov Oct-
982 EXPRESSION CONTROL
11 -12 14
14- 14- 23-
US20140315
THERMOSTABLE ASSAY REAGENTS The Secretary of State for Health Sep- Sep Oct-
215
11 -12 14
9- 7- 23-
US20140314 IPNV-ISAV BIVALENT VACCINE USING A VIRUS-LIKE PARTICLE-
Advanced BioNutrition Corporation Sep- Sep Oct-
858 BASED PLATFORM AND METHODS OF USING THE SAME
11 -12 14
2- 30- 23-
US20140314 CONTROLLED-RELEASE PEPTIDE COMPOSITIONS AND USES
Not Available Dec- Nov Oct-
839 THEREOF
11 -12 14
19- 19- 23-
US20140314
MALARIA ANTIGEN SCREENING METHOD Not Available Apr- Apr Oct-
809
13 -13 14

30- 2- 23-
US20140314 YEAST STRAIN FOR THE PRODUCTION OF PROTEINS WITH
Not Available May- Jul- Oct-
797 TERMINAL ALPHA-1,3-LINKED GALACTOSE
08 14 14
27- 30- 23-
US20140314
ANTIBODY PRODUCING NON-HUMAN MAMMALS Not Available Jun- Apr Oct-
755
08 -14 14
18- 19- 23-
US20140314
Vaccine adjuvant composition comprising inulin particles Vaxine Pty Ltd. Jun- Jun Oct-
739
11 -12 14
12- 14- 16-
US20140309 HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF
Achillion Pharmaceuticals, Inc. Apr- Apr Oct-
189 HCV
13 -14 14
12- 14- 16-
US20140309
DEUTERATED NUCLEOSIDE PRODRUGS USEFUL FOR TREATING HCV Achillion Pharmaceuticals, Inc. Apr- Apr Oct-
164
13 -14 14
20- 19- 16-

US20140308 USE OF FLAXSEED AND FLAXSEED DERIVATIVES FOR TREATMENT
The Trustees of the University of Pennsylvania Nov- Nov Oct-
379 OF NEUROLOGICAL DISORDERS AND VIRAL DISEASES
12 -13 14
15- 26- 16-

US20140308 COMPOSITIONS AND METHODS FOR IMMUNISATION USING CD1D
Not Available Mar- Jun Oct-
313 LIGANDS
06 -14 14
11- 5- 16-
Not Available May- May Oct-
211 CHARACTERISTICS
10 -14 14
8- 7- 9-
NOVARTIS AG Mar- Mar Oct-
232 AGENTS
13 -14 14
22- 20- 9-
US20140303
CYCLIC ANTIMICROBIAL PEPTIDES Not Available Dec- Jun Oct-
071
05 -14 14
19- 18- 9-
US20140302 Cytotoxic T Lymphocyte Inducing Immunogens For Prevention
Immunotape, Inc. Oct- Oct Oct-
124 Treatment and Diagnosis of INFLUENZA VIRUS INFECTION
11 -12 14
7- 19- 9-
US20140302
CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR Not Available Feb- Jun Oct-
120
07 -14 14
6- 18- 9-
US20140302
METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES Not Available Apr- Nov Oct-
091
07 -11 14
2- 28- 9-
US20140302
LIVE ATTENUATED INFLUENZA VIRUS Westfaelische Wilhelms-Universitaet Munester Sep- Aug Oct-
077
11 -12 14
11- 5- 2-
Not Available May- May Oct-
500 CHARACTERISTICS
10 -14 14
24- 5- 2-
US20140296 NUTRITIONAL COMPOSITION COMPRISING IMMUNOGLOBULINS
N.V. NUTRICIA Aug- Mar Oct-
179 AND OLIGOSACCHARIDES
04 -14 14
1- 28- 2-
US20140295
SAMPLE FIXATION AND STABILISATION Not Available Mar- Feb Oct-
404
13 -14 14
6- 6- 2-
US20140294 ALPHABODIES SPECIFICALLY BINDING TO VIRAL PROTEINS AND
COMPLIX SA Jan- Jan Oct-
828 METHODS FOR PRODUCING THE SAME
11 -11 14
21- 19- 2-
US20140294 LSR ANTIBODIES, AND USES THEREOF FOR TREATMENT OF
COMPUGEN LTD. Jun- Jun Oct-
765 CANCER
12 -13 14
22- 30- 2-
US20140294 PEPTIDES FOR ASSISTING DELIVERY ACROSS THE BLOOD BRAIN
Children's Medical Center Corporation May- Apr Oct-
727 BARRIER
06 -14 14
1- 31- 2-
US20140294 TRANSPORTABLE VACUUM ASSISTED DECONTAMINATION UNIT
STERIS Inc. Apr- Mar Oct-
670 AND DECONTAMINATION PROCESS
13 -14 14
26- 9- 25-
CITY OF HOPE Jan- Jun Sep
07 -14 -14
3- 1- 25-
3M Innovative Properties Company Jun- Jun Sep
988 MADE THEREFROM
11 -12 -14
10- 9- 25-
US20140283
LOADING VIALS BioFire Diagnostics, LLC Nov- Nov Sep
945
11 -12 -14
15- 12- 18-
US20140275 BERAPROST ISOMER AS AN AGENT FOR THE TREATMENT OF VIRAL
Gemmus Pharma Inc. Mar- Mar Sep
237 INFECTION
13 -14 -14
14- 12- 18-

US20140275 SUBSTITUTED 2-AZA-BICYCLO[2.2.2]OCTANE-3-CARBOXYLIC ACID
BOEHRINGER INGELHEIM INTERNATIONAL GMBH Mar- Mar Sep
159 (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C
13 -14 -14
14- 12- 18-

US20140275 SUBSTITUTED BICYCLIC 1-CARBOXYLIC-ACID (BENZYL-CYANO-
155 METHYL)-AMIDES INHIBITORS OF CATHEPSIN C
13 -14 -14
14- 12- 18-

114 ACID (CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C
13 -14 -14

SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,
6- 19- 18-
US20140275 PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR
Siga Technologies, Inc. Dec- Dec Sep
037 TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING
04 -13 -14
INFECTIONS ASSOCIATED WITH ARENAVIRUSES
SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC 14- 12- 18-

US20140275
ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF BOEHRINGER INGELHEIM INTERNATIONAL GMBH Mar- Mar Sep
025
CATHEPSIN C 13 -14 -14
15- 14- 18-

US20140274
COMPOUND RESPIVERT LTD. Mar- Mar Sep
980
13 -14 -14
10- 28- 18-
GenVec, Inc. Nov- May Sep
05 -14 -14
10- 14- 18-
US20140273
LUCIFERASE BIOSENSOR PROMEGA CORPORATION Oct- Feb Sep
156
03 -14 -14
11- 11- 18-
US20140271 RECOMBINANT SELF-REPLICATING POLYCISTRONIC RNA
829 MOLECULES
11 -12 -14
14- 13- 18-
US20140271 COMPOSITIONS AND METHODS FOR TREATING CLOSTRIDIUM
National Health Research Institutes Mar- Mar Sep
700 DIFFICILE-ASSOCIATED DISEASES
13 -14 -14
14- 14- 18-
US20140271 IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND THE ADMINISTRATORS OF THE TULANE EDUCATIONAL
Mar- Mar Sep
580 METHODS FUND
13 -13 -14
14- 14- 18-
US20140271 Constructs and Methods for Delivering Molecules via Viral Vectors
The Trustees of the University of Pennsylvania Mar- Mar Sep
550 with Blunted Innate Immune Responses
13 -14 -14
15- 14- 18-
US20140270
STAIN-FREE HISTOPATHOLOGY BY CHEMICAL IMAGING The Board of Trustees of the University of Illinois Mar- Mar Sep
457
13 -14 -14
31- 31- 11-
US20140255 PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING
Not Available Aug- Aug Sep
472 RNA
11 -12 -14
13- 1- 11-
US20140255
VIRUS-LIKE PARTICLES AND PROCESS FOR PREPARING SAME FOLIA BIOTECH INC. May- May Sep
439
11 -12 -14
11- 10- 11-
US20140255
WNT PATHWAY INHIBITORS FOR TREATING VIRAL INFECTIONS Children's Healthcare of Atlanta, Inc. Mar- Mar Sep
426
13 -14 -14
30- 28- 11-
US20140255 PEPTIDES WITH VIRAL INFECTION ENHANCING PROPERTIES AND
Centre National de la Recherche Scientique Jun- Jun Sep
349 THEIR USE
11 -12 -14
28- 28- 4-
US20140249 USING SORTASES TO INSTALL CLICK CHEMISTRY HANDLES FOR
Whitehead Institute for Biomedical Research Jun- Jun Sep
296 PROTEIN LIGATION
11 -12 -14
4- 20- 4-
US20140249 Substituted Bicyclic Dihydropyrimidinones And Their Use As
Boehringer Ingelheim International GmbH Mar- Feb Sep
129 Inhibitors Of Neutrophil Elastase Activity
13 -14 -14
25- 23- 4-
US20140248
Methods and Compositions for Prostate Cancer Metastasis Florida Agricultural and Mechanical University (FAMU) Mar- Mar Sep
620
11 -12 -14
7- 7- 4-
US20140248
Respiratory Disease Treatment PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED Aug- Apr Sep
357
08 -14 -14
20- 19- 4-
US20140248 ADJUVANTED INFLUENZA B VIRUS VACCINES FOR PEDIATRIC
320 PRIMING
11 -12 -14
16- 15- 4-
US20140248
COMBINATION ADJUVANT FORMULATION Dalhousie University Oct- Feb Sep
313
08 -13 -14
4- 28- 4-
US20140248 INFLUENZA VACCINES INCLUDING COMBINATIONS OF
NOVARTIS VACCINES AND DIAGNOSTICS SRL Nov- Feb Sep
312 PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS
05 -14 -14
21- 13- 28-

US20140243
BISPECIFIC ANTIBODY WUHAN YZY BIOPHARMA CO., LTD. Nov- Mar Aug
505
12 -14 -14
BROAD-SPECTRUM ANTIVIRALS AGAINST 3C OR 3C-LIKE 27- 27- 28-

US20140243
PROTEASES OF PICORNAVIRUS-LIKE SUPERCLUSTER: Not Available Sep- Sep Aug
341
PICORNAVIRUSES, CALICIVIRUSES AND CORONAVIRUSES 11 -12 -14
10- 11- 28-

US20140242
MAMMALIAN GENES INVOLVED IN TOXICITY AND INFECTION Not Available Dec- Dec Aug
692
10 -11 -14
6- 28-
US20140242 6-Jul-
IMMUNOGENIC COMPOSITIONS AND USES THEREOF Not Available Jul- Aug
152 11
12 -14
22- 22- 28-
US20140242
Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists CAYLA Feb- Feb Aug
108
13 -13 -14
21- 11- 21-
US20140235
Short Interfering RNA (siRNA) Analogues Santaris Pharma A/S Mar- Feb Aug
844
03 -14 -14

19- 21-
Karyopharm Therapeutics, Inc. Mar Aug
-14 -14
4- 1- 21-
US20140235 QUANTITATIVE NUCLEASE PROTECTION ASSAY (QNPA) AND
HTG Molecular Diagnostics, Inc. May- May Aug
460 SEQUENCING (QNPS) IMPROVEMENTS
11 -14 -14
2- 1- 21-
US20140234
ORGANISM IDENTIFICATION PANEL Not Available Apr- Apr Aug
845
07 -08 -14
26- 28- 21-
US20140234 COMPOSITIONS AND METHODS FOR ACTIVATING INNATE AND
ID BIOMEDICAL CORPORATION OF QUEBEC Apr- Apr Aug
374 ALLERGIC IMMUNITY
12 -14 -14
25- 14- 21-
US20140234 NOVEL VLPS DERIVED FROM CELLS THAT DO NOT EXPRESS A
Not Available May- Apr Aug
372 VIRAL MATRIX OR CORE PROTEIN
07 -14 -14
30- 17- 21-
US20140234
Directed Evolution and In Vitro Panning of Virus Vectors University of North Carolina at Chapel Hill Apr- Jan Aug
274
08 -14 -14
1- 22- 14-
US20140228
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC Sep- Apr Aug
347
11 -14 -14
11- 7- 14-
US20140227 METHODS FOR RAPID IDENTIFICATION AND QUANTITATION OF
IBIS BIOSCIENCES, INC. Nov- Oct Aug
704 NUCLEIC ACID VARIANTS
09 -13 -14
6- 14-
US20140227 6-Jul-
IMMUNOGENIC COMBINATION COMPOSITIONS AND USES THEREOF Not Available Jul- Aug
346 11
12 -14

US20140227
SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE 3M INNOVATIVE PROPERTIES COMPANY Jun- Jun Aug
317
THEREFROM 11 -12 -14
25- 1- 14-
US20140227
PD-1 Antagonists and Methods for Treating Infectious Disease AMPLIMMUNE, INC. Aug- Nov Aug
262
08 -13 -14
16- 7- 7-
US20140221
BORON-CONTAINING SMALL MOLECULES Anacor Pharmaceuticals, Inc. Feb- Mar Aug
631
06 -14 -14
12- 7- 7-
US20140221
HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90 Astex Therapeutic Ltd. Oct- Jan Aug
394
06 -14 -14
6- 28- 7-
BOEHRINGER INGELHEIM INTERNATIONAL GMBH Feb- Jan Aug
13 -14 -14
11- 28- 7-
US20140220
MAMMALIAN GENES INVOLVED IN INFECTION VANDERBILT UNIVERSITY Nov- Oct Aug
690
09 -10 -14
19- 7-
US20140220 EMBODIMENTS OF A PROBE AND METHOD FOR TARGETING 19-
University Of Idaho Jul- Aug
573 NUCLEIC ACIDS Jul-11
12 -14
21- 21- 7-
US20140220
Antimicrobial Compositions and Methods of Use Thereof Not Available Sep- Sep Aug
086
11 -12 -14
6- 7-
US20140220 6-Jul-
CATIONIC OIL-IN-WATER EMULSIONS Not Available Jul- Aug
083 11
12 -14
5- 29- 7-
US20140220
VACCINE COMPOSITION Not Available Feb- Jan Aug
063
13 -14 -14
6- 31-
US20140212 6-Jul-
OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS Not Available Jul- Jul-
498 11
12 14
7- 16- 31-
US20140212
BINDING MEMBERS-513 MEDIMMUNE LIMITED Nov- Apr Jul-
429
08 -14 14
1- 31- 24-
US20140206
COMPOUNDS AND COMPOSITIONS AS PDGFR KINASE INHIBITORS IRM LLC Sep- Aug Jul-
682
11 -12 14
6- 19- 24-
US20140206 Systems and Methods for Identifying Replikin Scaffolds and Uses of
Not Available Jun- Jun Jul-
556 Said Replikin Scaffolds
03 -13 14
18- 28- 24-
US20140205
TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS AlphaVax, Inc. May- Mar Jul-
629
04 -14 14
SYSTEMS AND METHODS FOR DISTINGUISHING OPTICAL SIGNALS 24- 21- 24-
US20140203
OF DIFFERENT MODULATION FREQUENCIES IN AN OPTICAL SIGNAL Gen-Probe Incorporated Feb- Mar Jul-
192
DETECTOR 11 -14 14
SYSTEMS AND METHODS FOR DISTINGUISHING OPTICAL SIGNALS 24- 21- 24-
US20140203
OF DIFFERENT MODULATION FREQUENCIES IN AN OPTICAL SIGNAL GEN-PROBE INCORPORATED Feb- Mar Jul-
189
DETECTOR 11 -14 14
6- 6- 17-
US20140200 Methods and compositions for identification of source of microbial
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Mar- Mar Jul-
149 contamination in a sample
12 -13 14
23- 17-
US20140199 COMPOSITIONS HAVING MEANS FOR TARGETING AT LEAST ONE 22-
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS Jul- Jul-
379 ANTIGEN TO DENDRITIC CELLS Jul-11
12 14

10- 7- 17-
US20140199 UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION,
ADJUVANT COMPOSITIONS WITH 4-1BBL Feb- Feb Jul-
347 INC.
11 -12 14
23- 20- 17-
US20140199 SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF
Seres Health, Inc. Nov- Mar Jul-
281 PRODUCTION AND USE THEREOF
12 -14 14
25- 11- 10-
US20140194
SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS 3M INNOVATIVE PROPERTIES COMPANY Nov- Mar Jul-
628
03 -14 14
8- 8- 10-
US20140194
Methods For Treating of SARS Not Available Jan- Jan Jul-
500
13 -13 14
3- 3- 10-
US20140194
NOVEL DEPSIPEPTIDE AND USES THEREOF Not Available Dec- Dec Jul-
345
12 -13 14
1- 7- 10-
US20140193 Biological Specimen Collection and Transport System and Method of
Longhorn Vaccines and Diagnostics, LLC Oct- Jan Jul-
804 Use
07 -14 14
VACCINES AND IMMUNOTHERAPEUTICS COMPRISING IL-15 14- 6- 10-

US20140193
RECEPTOR ALPHA AND/OR NUCLEIC ACID MOLECULES ENCODING Not Available Sep- Jan Jul-
439
THE SAME, AND METHODS FOR USING THE SAME 09 -14 14
28- 6- 3-
US20140186 METHODS FOR STABILIZING INFLUENZA ANTIGEN ENVELOPED
TAKEDA VACCINES, INC. Dec- Mar Jul-
396 VIRUS-BASED VIRUS-LIKE PARTICLE SOLUTIONS
09 -14 14
10- 3-
Providence Health & Services - Oregon Feb Jul-
-14 14
4- 22- 26-
US20140179
TARGETING LIPIDS Tekmira Pharmaceuticals Corporation Dec- Oct Jun-
761
08 -13 14
14- 11- 26-
US20140179
NOVEL COMPOUNDS Chiesi Farmaceutici S.p.A. Sep- Feb Jun-
714
11 -14 14
10- 3- 26-
US20140178 SYSTEMS AND METHODS FOR DETECTING MULTIPLE OPTICAL
Gen-Probe Incorporated Mar- Mar Jun-
977 SIGNALS
05 -14 14
6- 24- 26-
US20140178
Vaccines Including Antigen From Four Strains of Influenza Virus NOVARTIS AG Dec- Sep Jun-
429
06 -13 14
8- 27- 26-
US20140178 QUALITY CONTROL METHODS FOR OIL-IN-WATER EMULSIONS
Novartis AG Nov- Aug Jun-
428 CONTAINING SQUALENE
06 -13 14
21- 15- 26-
US20140178
PRIMARY MESENCHYMAL STEM CELLS AS A VACCINE PLATFORM The Administrators of the Tulane Educational Fund Dec- Nov Jun-
422
12 -13 14
17- 13- 19-
12 -13 14
18- 17- 19-
US20140171
NOVEL COMPOUNDS CHIESI FARMACEUTICI S.p.A. Dec- Dec Jun-
414
12 -13 14
20- 31- 19-
US20140170
VECTOR FOR GENE THERAPY TAKARA BIO INC. Apr- Jan Jun-
709
07 -14 14
17- 13- 19-

12 -13 14
30- 27- 19-

US20140170 D-Amino Acid Derivative-Modified Peptidoglycan and Methods of Use
The Regents of the University of California Nov- Nov Jun-
183 Thereof
12 -13 14
28- 10- 19-
US20140170 POLYCHLORINATED BIPHENYLS AND SQUALENE-CONTAINING
Novartis AG Dec- Dec Jun-
174 ADJUVANTS
07 -13 14
16- 7- 19-
US20140170
HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) GENMAB A/S Dec- Nov Jun-
156
02 -13 14
30- 1- 19-
COMPUGEN LTD. Jun- Jul- Jun-
11 12 14
27- 4- 12-
COLEY PHARMACEUTICAL GMBH Sep- Oct Jun-
06 -13 14
20- 12-
US20140163 HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR 22-
ACTELION PHARMACEUTICALS LTD. Jul- Jun-
035 ANTAGONISTS Jul-11
12 14
26- 12-
US20140162 27-
PROCESS FOR PREPARING BIOLOGICAL SAMPLES BAYLOR COLLEGE OF MEDICINE Jul- Jun-
941 Jul-11
12 14
6- 6- 12-
US20140162
CIRCULATING BIOMARKERS FOR DISEASE Not Available Apr- Apr Jun-
888
10 -11 14
13- 4- 12-
US20140162
METHODS FOR GENERATION OF ANTIBODIES NATIONAL JEWISH HEALTH Mar- Sep Jun-
357
07 -13 14

21- 2- 12-
US20140162
Methods of Modulating Vesicular Trafficking The General Hospital Corporation May- Dec Jun-
285
09 -13 14
8- 12- 12-
US20140161 USE OF ANGIOGENESIS ANTAGONISTS IN CONDITIONS OF
UNIVERSITY OF UTAH RESEARCH FOUNDATION Nov- Jun Jun-
906 ABNORMAL VENOUS PROLIFERATION
07 -13 14
16- 12-
Board of Regents, The University of Texas System Dec Jun-
-13 14
5- 28- 5-
US20140155
NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available Mar- Jun Jun-
370
10 -13 14
13- 1- 5-
US20140154 PAPAYA MOSAIC VIRUS COMPOSITIONS AND USES THEREOF FOR
FOLIA BIOTECH INC. May- May Jun-
288 STIMULATION OF THE INNATE IMMUNE RESPONSE
11 -12 14
26- 26- 5-
US20140154 CONJUGATES UTILIZING PLATFORM TECHNOLOGY FOR
Not Available Jan- Jan Jun-
282 STIMULATING IMMUNE RESPONSE
11 -12 14
21- 21- 5-
US20140154
HETERODIMERIC IMMUNOGLOBULINS AMGEN INC. Nov- Nov Jun-
254
12 -13 14
18- 18- 29-
US20140148
CIRCULATING BIOMARKERS FOR DISEASE Not Available Aug- Aug May
350
10 -11 -14
27- 27- 22-

PARION SCIENCES, INC. Jun- Jun May
11 -12 -14
16- 27- 22-

US20140142
BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. Feb- Jan May
064
05 -14 -14
22- 17- 22-
US20140141
CIRCULATING BIOMARKERS Not Available Feb- Feb May
986
11 -12 -14
18- 27- 22-
US20140141 Methods For Concurrent Identification And Quantification Of An
IBIS BIOSCIENCES, INC. Feb- Jan May
502 Unknown Bioagent
04 -14 -14
23- 23- 22-
US20140141 Method of Determining, Identifying or Isolating Cell-Penetrating
Phylogica Limited May- May May
452 Peptides
11 -12 -14
6- 22-
US20140141 LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA 6-Jul-
070 MOLECULES 11
12 -14
19- 15- 22-
US20140141
CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS CAYLA Nov- Mar May
033
12 -13 -14
1- 15-
US20140135 Lipoparticles Comprising Proteins, Methods Of Making, And Using 30-
Integral Molecular, Inc. Nov May
230 The Same Jul-03
-13 -14
28- 28- 15-
US20140134
NOVEL STABILISATION METHOD FOR VIRUSES OR BACTERIA Leukocare AG Jun- Jun May
699
11 -12 -14
6- 21- 15-
MOREHOUSE SCHOOL OF MEDICINE Oct- Jan May
08 -14 -14
1- 30- 15-
US20140134
INFLAMMATION AND IMMUNITY TREATMENTS OCEAN SPRAY CRANBERRIES, INC. Apr- Mar May
206
11 -12 -14
24- 6- 15-
US20140134 TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR
Ansun Biopharma, Inc. Jan- Jan May
150 MICROSPHERES
06 -14 -14
26- 14- 8-
CITY OF HOPE Jan- Jan May
07 -14 -14
6- 8-
US20140127 6-Jul-
ANTIVIRAL RESIN MEMBER NBC MESHTEC, INC. Jul- May
321 11
12 -14
15- 16- 8-
US20140127 TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE
Marine Polymer Technologies, Inc. Apr- Apr May
310 NANOFIBERS
11 -12 -14
8- 8- 8-
US20140127 NOVEL EXPRESSION CASSETTE FOR EFFICIENT SURFACE DISPLAY
Temasek Life Sciences Laboratory Limited Feb- Feb May
216 OF ANTIGENIC PROTEINS
11 -12 -14
25- 1-
US20140120 METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL 26-
Board of Regents, The University of Texas System Jan May
139 AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE Jul-10
-13 -14
3- 28- 1-
US20140116 ELECTROCHEMISTRY AND ELECTROGENERATED
Board of Regents of the University of Texas System Jun- Oct May
887 CHEMILUMINESCENCE WITH A SINGLE FARADAIC ELECTRODE
05 -13 -14
24- 24- 24-

US20140113
Modified Release Formulations for Oprozomib Not Available Oct- Oct Apr-
855
12 -13 14

US20140107
PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMI Parion Sciences, Inc. Jun- Dec Apr-
133
DOYL)PYRAZINE-2-CARBOXAMIDE 11 -13 14

28- 28- 17-
US20140106
OLIGONUCLEOTIDE PROBE FOR THE DETECTION OF ADENOVIRUS Qiagen Hamburg GMBH Dec- Dec Apr-
335
10 -10 14
6- 20- 17-
US20140105
Antiviral and antibacterial activity from medicinal mushrooms Not Available Jan- Dec Apr-
928
04 -13 14
7- 9- 17-
US20140105
VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER THE TRUSTEES OF DARTMOUTH COLLEGE Sep- Sep Apr-
912
12 -13 14
30- 10-
US20140099 24-
Technology for the Preparation of Microparticles Ansun Biopharma, Inc. Apr Apr-
696 Jul-07
-13 14
8- 30- 10-
US20140099
METHODS FOR TREATMENT OF INFLAMMATORY DISEASES Not Available Apr- Oct Apr-
323
09 -13 14
13- 13- 3-
Not Available Jan- Jan Apr-
11 -12 14
22- 22- 3-
US20140093 Immunogenic Compositions In Particulate Form And Methods For
MUCOSIS B.V. Mar- Mar Apr-
532 Producing The Same
11 -12 14
4- 26- 27-
US20140087 QUANTITATIVE NUCLEASE PROTECTION ASSAY (QNPA) AND
HTG Molecular Diagnostics, Inc. May- Apr Mar
954 SEQUENCING (QNPS) IMPROVEMENTS
11 -12 -14
METHOD FOR GENERATING, STORING, TRANSPORTING, ELUTING 9- 9- 27-

US20140087
AND DETECTING CLINICAL RELEVANT INFORMATION IN PLASMA HVIDOVRE HOSPITAL Dec- Dec Mar
363
USING FILTER PAPER 10 -11 -14
8- 26- 27-
US20140086
Antigenic GM-CSF Peptides and Antibodies to GM-CSF MORPHOTEK, INC. Feb- Nov Mar
928
06 -13 -14
11- 12- 20-
US20140082 MOLECULES AND METHODS FOR INHIBITION AND DETECTION OF
769 PROTEINS
11 -12 -14
31- 28- 20-
US20140080
IMIDAZOLYL AMIDE COMPOUNDS AND USES RELATED THERETO CHILDREN'S HEATLHCARE OF ATLANTA, INC. Mar- Mar Mar
828
11 -12 -14
6- 25- 20-
US20140080
OPTICAL CYTOMETRY The Regents of the University of California May- Nov Mar
171
09 -13 -14
21- 20- 20-
US20140080
PRIMATE T-LYMPHOTROPIC VIRUSES Johns Hopkins University Feb- Sep Mar
121
05 -13 -14
5- 23- 20-
US20140079
TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE Infinity Pharmaceuticals, Inc. May- Aug Mar
667
10 -13 -14
12- 13-
US20140073 MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS 26-
Not Available Mar Mar
683 OF USE Jul-02
-13 -14
22- 21- 13-
US20140073
BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. Feb- Feb Mar
651
11 -12 -14
15- 28- 13-
US20140072
COMPOSITION, DEVICE AND ASSOCIATED METHOD General Electric Company Dec- Feb Mar
956
05 -07 -14
1- 13- 13-
MedImmune Limited Jun- Sep Mar
575 THEM
07 -13 -14
26- 11- 6-
City of Hope Jan- Oct Mar
07 -13 -14
23- 20- 27-
BOEHRINGER INGELHEIM INTERNATIONAL GMBH Aug- Aug Feb
12 -13 -14
23- 20- 27-
12 -13 -14
23- 20- 27-
12 -13 -14
8- 11- 27-
ANTIGEN PRESENTING CELL ASSAY Apr- Oct Feb
10 -13 -14
23- 23- 27-
US20140056 IMMUNOMODULATION BY CONTROLLING INTERFERON-GAMMA The Board of Trustees of the Leland Stanford Junior
Aug- Aug Feb
929 LEVELS WITH THE LONG NON-CODING RNA NeST University
12 -13 -14
22- 15- 20-
US20140051 Cells and Methodology to Generate Non-Segmented Negative-
Centre National De La Recherche Scientifique Dec- Oct Feb
148 Strand RNA Viruses
06 -13 -14
28- 28- 20-
US20140050 NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND
UNIVERSITY OF ROCHESTER Dec- Dec Feb
778 USE THEREOF
10 -11 -14
MODIFIED VIRAL PARTICLES WITH IMMUNOGENIC PROPERTIES 29- 30- 20-

US20140050
AND REDUCED LIPID CONTENT USEFUL FOR TREATING AND ELI LILLY & COMPANY Jun- Oct Feb
763
PREVENTING INFECTIOUS DISEASES 00 -13 -14

8- 8- 20-
US20140050
POLYIONIC PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES THE JOHNS HOPKINS UNIVERSITY Sep- Sep Feb
753
10 -11 -14
28- 5- 20-
Superlab Far East Limited Feb- Sep Feb
698 THEREOF
01 -13 -14
4- 8- 13-
US20140045
Folate Conjugates Alnylam Pharmaceuticals, Inc. Dec- Jul- Feb
919
07 13 -14
26- 21- 13-
US20140045
9-Substituted 8-Oxoadenine Compound AstraZeneca Aktiebolag Mar- Oct Feb
837
04 -13 -14
24- 11- 13-
US20140045
METHODS FOR TREATING VIRAL DISORDERS TRUSTEES OF BOSTON UNIVERSITY Sep- Jun Feb
774
09 -13 -14
4- 8- 13-
US20140045
COMPOSITIONS AND METHODS FOR CORONAVIRUS INHIBITION Autoimmune Technologies, LLC Nov- Aug Feb
743
03 -13 -14
15- 16- 13-

COMPUGEN LTD. Apr- Apr Feb
11 -12 -14
24- 13- 6-
US20140038
HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS AstraZeneca AB Dec- Sep Feb
978
04 -13 -14
26- 8- 6-
US20140038 Compositions and Methods for Detecting and Identifying Nucleic
LONGHORN VACCINES AND DIAGNOSTICS, LLC Apr- Oct Feb
174 Acid Sequences in Biological Samples
11 -13 -14
31- 6-
US20140038 APPARATUS, SYSTEMS, AND METHODS FOR PERFORMING THERMAL 31-
170 MELT ANALYSES AND AMPLIFICATIONS Jul-12
13 -14
20- 19- 6-
US20140037
Composition and Method for Enhancing an Immune Response MICO BIO, INC. Apr- Apr Feb
700
11 -12 -14
20- 20- 30-
US20140031 Regimens and Compositions for AAV-Mediated Passive
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Apr- Apr Jan-
418 Immunization of Airborne Pathogens
11 -12 14
26- 1- 30-
US20140031
POLY AROMATIC SODIUM CHANNEL BLOCKERS PARION SCIENCES, Inc. Feb- Oct Jan-
371
08 -13 14
1- 19- 30-
US20140031
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC Sep- Sep Jan-
333
11 -13 14
2- 19- 30-
US20140031 COMPOUNDS AND METHODS FOR PREVENTING OR TREATING A CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Nov- Jun Jan-
276 VIRAL INFECTION (C.N.R.S.)
07 -13 14
7- 2- 30-
US20140030
Rapid Bioluminescence Detection System The Secretary of State for Health Jan- Aug Jan-
740
09 -13 14
11- 12- 30-
PROMEGA CORPORATION May- Nov Jan-
725 CHARACTERISTICS
10 -12 14
12- 8- 30-
US20140030 Compositions and Methods for Detecting and Identifying Nucleic
LONGHORN VACCINES AND DIAGNOSTICS, LLC Sep- Oct Jan-
703 Acid Sequences in Biological Samples
06 -13 14
28- 30-
US20140030 ANTIVIRAL COMPOSITIONS COMPRISING ETHANOL EXTRACT OF 24-
Not Available Mar Jan-
364 TETRACERA SCANDENS AND USE THEREOF Jul-12
-13 14
7- 17- 30-
US20140030 Use of Sirt1 Activators or Inhibitors to Modulate an Immune
THE J. DAVID GLADSTONE INSTITUTES Feb- Dec Jan-
295 Response
08 -12 14
20- 24- 23-
US20140024
Crystalline Tripeptide Epoxy Ketone Protease Inhibitors Onyx Therapeutics, Inc. Mar- Sep Jan-
804
09 -13 14
5- 15- 23-
US20140024
ORGANIC COMPOUNDS Not Available Jun- Jul- Jan-
583
06 13 14
31- 1- 23-
ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES Jan- Oct Jan-
645 Secretary, Dept. of Health & Human Services
08 -13 14
30- 23-
US20140023 Fraunhofer-Gesellschaft zur Forderung der Angewandten 25-
SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS Sep Jan-
592 Forschung e.V. Jul-07
-13 14
12- 7- 16-
US20140017 Cna-B DOMAIN ANTIGENS IN VACCINES AGAINST GRAM POSITIVE
Not Available Jan- Jun Jan-
727 BACTERIA
09 -13 14
24- 23- 16-
US20140017
ADJUVANT NANOEMULSIONS WITH PHOSPHOLIPIDS NOVARTIS AG Mar- Mar Jan-
285
11 -12 14
27- 27- 16-
US20140017
ADJUVANT NANOEMULSIONS WITH CRYSTALLISATION INHIBITORS Novartis AG Jan- Jan Jan-
279
11 -12 14
6- 12- 9-
US20140011
Antibodies Against Influenza Virus and Methods of Use Thereof BURNHAM INSTITUTE FOR MEDICAL RESEARCH Dec- Aug Jan-
982
07 -13 14
8- 7- 9-
US20140011
Methods of Treating Inflammation Massachusetts Institute of Technology Oct- Oct Jan-
812
10 -11 14
18- 9- 9-
3M INNOVATIVE PROPERTIES COMPANY Jun- Sep Jan-
04 -13 14

1- 19- 9-
US20140011 Biological Specimen Collection and Transport System and Method of
Longhorn Vaccines and Diagnostics, LLC Oct- Mar Jan-
187 Use
07 -13 14
9- 11- 9-
US20140010
Methods and Compositions for Preventing a Condition Cyvax, Inc. Aug- Sep Jan-
837
10 -13 14
15- 17- 2-
US20140005
Suppression of Sars Replication by Sars Helicase Inhibitors The Curators of the University of Missouri Jun- Jun Jan-
241
12 -13 14
23- 1- 2-
US20140005
Oligoadenylate Synthetase (OAS) Kineta Two LLC Nov- Jul- Jan-
102
05 13 14
23- 14- 2-
US20140005
Oligoadenylate Synthetase (OAS) Kineta Two LLC Nov- Jun Jan-
101
05 -13 14
21- 2-
US20140005 12-
BIOACTIVE PEPTIDES AND METHODS OF USING SAME Compugen Ltd. Jun Jan-
097 Jul-07
-13 14
24- 24- 2-
Not Available Apr- Apr Jan-
12 -13 14
17- 19- 2-
US20140004 METHOD FOR PRODUCING VIRUS-LIKE PARTICLE BY USING INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF
Mar- Mar Jan-
146 DROSOPHILA CELL AND APPLICATIONS THEREOF SCIENCES
11 -12 14
17- 13- 2-
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Dec- Sep Jan-
01 -13 14
20- 20- 2-
US20140004
ANTI-IL-18 ANTIBODIES AND THEIR USES Medimmune Limited Dec- Dec Jan-
128
10 -11 14
26- 25- 2-
Institute For Research in Biomedicine Feb- Apr Jan-
123 OF B CELLS
03 -13 14
20- 26- 26-
US20130345
TREATING CANCER WITH VIRAL NUCLEIC ACID Not Available Feb- Jul- Dec
414
07 13 -13
29- 26-
US20130345 siRNA Compositions and Methods for Treatment of HPV and Other 29-
Not Available Jan Dec
284 Infections Jul-10
-13 -13
12- 7- 26-
US20130345
METHODS OF TREATING CANCER AND OTHER DISORDERS Waake Forest University Health Sciences Nov- Nov Dec
270
10 -11 -13
14- 7- 26-
US20130344 USE OF A FLUORESCENT MATERIAL TO DETECT FAILURE OR
GEN-PROBE INCORPORATED Jun- Jun Dec
613 DETERIORATED PERFORMANCE OF A FLUOROMETER
12 -13 -13
22- 22- 26-
US20130344
VIRUS LIKE PARTICLE PRODUCTION IN PLANTS MEDICAGO INC. Dec- Dec Dec
100
10 -11 -13
25- 26- 26-
US20130341
AMPEROMETRIC GAS SENSOR STERIS CORPORATION Jun- Feb Dec
206
12 -13 -13
DECONTAMINATING COMPOSITION HAVING SIMULTANEOUSLY 29- 7- 19-

US20130338
BACTERICIDAL, FUNGICIDAL AND VIROCIDAL PROPERTIES, HIGHTECH BIO-ACTIVITIES HOLDING GMBH Mar- Aug Dec
224
METHODS FOR OBTAINING AND USING SAID COMPOSITION 04 -13 -13
17- 14- 19-

US20130338
PURINE DERIVATIVES ABBOTT PHILLIP Dec- Dec Dec
174
10 -11 -13
30- 19- 19-
US20130338 METHYLSULFONYLMETHANE (MSM) FOR TREATMENT OF DRUG
Biogenic Innovations, LLC Oct- Aug Dec
130 RESISTANT MICROORGANISMS
09 -13 -13
15- 15- 19-
US20130336 NOVEL COMPOSITIONS OF TLR7 AND/OR TLR8 AGONISTS
CAYLA Jun- Mar Dec
996 CONJUGATED TO LIPIDS
12 -13 -13
25- 23- 19-
US20130336 METHODS AND CELLS FOR IDENTIFYING RIG-I PATHWAY
KINETA, INC. Feb- Feb Dec
929 REGULATORS
11 -12 -13
2- 8- 19-
US20130336 Carbonic Anhydrase IX (G250) Antibodies and Methods of Use
DANA-FARBER CANCER INSTITUTE, INC. Dec- May Dec
923 Thereof
05 -13 -13
11- 7- 12-
HEMAQUEST PHARMACEUTICALS INC Mar- Jun Dec
10 -13 -13
14- 14- 12-
US20130330 FLOW CYTOMETRY ANALYSIS OF MATERIALS ADSORBED TO METAL
NOVARTIS AG Dec- Dec Dec
840 SALTS
10 -11 -13
23- 21- 12-
US20130330 BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE
IOGENETICS, LLC Mar- Mar Dec
335 BINDING
10 -11 -13

US20130324
BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER PARION SCIENCES, INC. May- May Dec
559
MUCOSAL DISEASES 12 -13 -13

15- 5-
US20130323 15-
Mammalian Genes Involved in Infection Zirus, Inc. Jul- Dec
835 Jul-09
10 -13
5- 4- 5-
US20130323 EXPRESSION OF ANTIBODY OR A FRAGMENT THEREOF IN
ALVAREZ MIGUEL ANGEL Aug- Aug Dec
819 LACTOBACILLUS
10 -11 -13
15- 14- 28-
US20130317
MODIFIED iRNA AGENTS ALNYLAM PHARMACEUTICALS, INC. Sep- Sep Nov
080
10 -11 -13
9- 9- 28-
US20130317
Nuclear Transport Modulators And Uses Thereof Karyopharm Therapeutics Inc. May- May Nov
031
12 -13 -13
9- 13- 28-
US20130315 ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR
Defyrus, Inc. Jun- Nov Nov
952 TREATMENT OF PATHOGENIC INFECTION
09 -12 -13
2- 31- 14-
US20130302
ANTAGONISM OF THE VIP SIGNALING PATHWAY EMORY UNIVERSITY Feb- Jan Nov
351
11 -12 -13
15- 16- 14-

US20130302 USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO
IMMURX INC Jun- Apr Nov
278 ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS
07 -13 -13
5- 15- 7-
MASSACHUSETTS INSTITUTE OF TECHNOLOGY Apr- Mar Nov
129 THEREOF
12 -13 -13
24- 22- 31-
US20130291
HUMANIZED TRANSGENIC MOUSE MODEL BRUMEANU TEPDPR D Sep- Aug Oct-
134
10 -12 13
15- 27- 31-
US20130289 (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-
AstraZeneca AB Dec- Jun Oct-
043 CARBOXAMIDE DERIVATIVES
08 -13 13
2- 11- 31-
UNIV ROCHESTER May- Jul- Oct-
922 IMMUNE RESPONSE
08 13 13
Rapid High Resolution, High Throughput RNA Structure, RNA- 21- 21- 31-
US20130288 The Board of Trustees of the Leland Stanford Junior
Macromolecular Interaction, and RNA-Small Molecule Interaction Oct- Oct Oct-
917 University
Mapping 10 -11 13
20- 19- 31-

US20130287
SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES Novartis AG Aug- Aug Oct-
832
10 -11 13
28- 26- 31-
US20130287
Method for Producing Viral Vaccines BAXTER HEALTHCARE SA Aug- Jun Oct-
811
07 -13 13
1- 1- 31-
US20130287
BIOMARKERS FOR THERANOSTICS Caris Life Sciences Luxembourg Holdings Mar- Mar Oct-
772
10 -11 13
16- 16- 24-
US20130281 BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND
Nuevolution A/S Apr- Apr Oct-
324 USING SUCH COMPLEXES
10 -11 13
17- 17- 24-
US20130280
MAMMALIAN GENES INVOLVED IN INFECTION HODGE THOMAS May- May Oct-
806
10 -11 13
15- 15- 24-
US20130280 Immunogenic Affinity-Conjugated Antigen Systems Based on
LECLERC DENIS Nov- Mar Oct-
298 Papaya Mosaic Virus and Uses Thereof
06 -13 13
1- 1- 17-
US20130274 ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL
IRM LLC Sep- Sep Oct-
465 SALTS
10 -11 13
4- 4- 17-
ARNOLD MATTHIAS Apr- Apr Oct-
129 KITS AND ASSAYS
12 -13 13
22- 7- 17-
US20130273 METHOD FOR CHROMOGENIC DETECTION OF TWO OR MORE
BIENIARZ CHRISTOPHER A Aug- Jun Oct-
540 TARGET MOLECULES IN A SINGLE SAMPLE
08 -13 13
16- 14- 17-
US20130273
POWDERED POUCH AND METHOD OF MAKING SAME Monosol, LLC. Apr- Mar Oct-
277
12 -13 13
30- 21- 17-
US20130273
Dendritic Cell Marker and Uses Thereof CAMINSCHI IRINA Aug- Mar Oct-
150
07 -13 13
15- 14- 17-
US20130273
METHODS AND COMPOSITIONS FOR INTRANASAL DELIVERY HARUTA SHUNJI Apr- Mar Oct-
120
10 -13 13
12- 15- 17-
US20130273 IMMUNOGENIC APOPTOSIS INDUCING COMPOSITIONS AND
The Regents of the University of Michigan Apr- Mar Oct-
12 -13 13
22- 21- 17-
US20130273
Adjuvanted Influenza Vaccines for Pediatric Use GROTH NICOLA Feb- Jun Oct-
104
08 -13 13
11- 15- 17-
US20130273
SIALOADHESIN-RELATED COMPOSITIONS AND METHODS DELPUTTE PETER May- Mar Oct-
080
06 -13 13
15- 6- 10-
US20130267 COMPOSITIONS AND METHODS FOR INHIBITING NADPH OXIDASE
QUARK PHARMACEUTICALS, INC. Jun- Jun Oct-
578 EXPRESSION
07 -13 13
19- 18- 10-
US20130267 CYCLIC AMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT
HORI SEIJI Nov- Nov Oct-
532 OF DISEASE
10 -11 13

27- 27- 10-
CapitaBio Corporation Oct- Oct Oct-
10 -10 13
BIOLOGICAL SAMPLE TARGET CLASSIFICATION, DETECTION AND 21- 2- 10-

US20130267
SELECTION METHODS, AND RELATED ARRAYS AND GARDNER SHEA Dec- May Oct-
429
OLIGONUCLEOTIDE PROBES 09 -13 13
DERIVATIVES OF STEROID BENZYLAMINES, HAVING AN 6- 6- 10-

US20130266
ANTIPARASITIC ANTIBACTERIAL, ANTIMYCOTIC AND/OR ANTIVIRAL Justus-Liebig-Universitat Giessen Oct- Oct Oct-
645
ACTION 10 -11 13
4- 3- 10-
US20130266
VACCINE COMPOSITION NITTO DENKO CORPORATION Apr- Apr Oct-
612
12 -13 13
11- 10- 3-
US20130261 Nucleic Acids For Multiplex Organism Detection and Methods Of Use
DIAMOND LISA Jun- Jun Oct-
196 And Making The Same
10 -11 13
SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS,

6- 6- 3-
US20130261 PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR
SIGA TECHNOLOGIES INC. Dec- Jul- Oct-
087 TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING
04 11 13
INFECTIONS ASSOCIATED WITH ARENA VIRUSES
6- 2- 3-
US20130261 ALPHABODIES SPECIFICALLY BINDING TO CLASS-I VIRAL FUSION
COMPLIX SA Jan- Dec Oct-
049 PROTEINS AND METHODS FOR PRODUCING THE SAME
11 -11 13
7- 4- 3-
US20130259
REOVIRUS VACCINES AND METHODS OF USE THEREFOR BOEHME KARL W Apr- Apr Oct-
887
10 -11 13
14- 14- 3-
US20130259 Human Monoclonal Antibody with Specificity for Dengue Virus
DSO NATIONAL LABORATORIES Dec- Dec Oct-
871 Serotype 1 E Protein and Uses Thereof
10 -11 13
6- 3-
US20130259 CLIP INHIBITORS AND METHODS OF MODULATING IMMUNE 25-
Viral Genetics, Inc. Jun Oct-
829 FUNCTION Jul-08
-13 13
3- 22- 26-
US20130253
COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS CORTEZ ALEX Mar- Apr Sep
002
08 -13 -13
1- 20- 26-
US20130251
Methods and Compositions for Poxvirus A35R Protein East Carolina University Dec- Dec Sep
746
08 -12 -13
9- 8- 26-
US20130251
USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIALS The Salk Institute for Biological Studies Nov- Mar Sep
734
07 -13 -13
Peracid/Peroxide Composition, Process for Accurately Making the 11- 21- 26-
US20130251
Same, and Method for Use as an Evaporating Film Anti-Microbial BioMed Protect ,LLC Jan- Sep Sep
590
Solution and as a Photosensitizer 05 -09 -13
16- 30- 19-

US20130244
BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. Feb- Apr Sep
980
05 -13 -13
16- 16- 19-
US20130244 WATER SOLUBLE COMPOSITIONS INCORPORATING ENZYMES, AND
LEE DAVID M Mar- Mar Sep
920 METHOD OF MAKING SAME
12 -12 -13
1- 1- 19-
US20130243
CONCENTRATION OF VACCINE ANTIGENS WITH LYOPHILIZATION Novartis AG Jun- Jun Sep
841
10 -11 -13
19- 19-
US20130243 Methods for Treating Diseases and HSV Using Antibodies to 15-
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Feb Sep
756 Aminophospholipids Jul-02
-13 -13
5- 29- 19-
US20130243
TRIAZOLES AS INHIBITORS OF FATTY ACID SYNTHASE INFINITY PHARMACEUTICALS, INC. May- Apr Sep
727
10 -13 -13
3- 17- 12-
US20130237
Novel Amide Compounds BURKAMP FRANK Apr- Apr Sep
507
09 -13 -13
5- 7- 12-
US20130236 COMPOSITIONS FOR USE IN IDENTIFICATION OF
IBIS BIOSCIENCES, INC. Dec- May Sep
884 ORTHOPOXVIRUSES
03 -13 -13
20- 20- 12-
US20130236
METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLES STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK Sep- Sep Sep
493
10 -11 -13
3- 3- 12-
US20130236 NANOPARTICLES PRODUCED FROM RECOMBINANT POLYMERS AND
UNIVERSITY OF UTAH RESEARCH FOUNDATION May- May Sep
396 METHODS OF MAKING AND USING THE SAME
10 -11 -13
10- 9- 5-
US20130231
ANTIMICROBIAL SOLUTIONS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Sep- Sep Sep
302
10 -11 -13
29- 16- 5-
US20130230
ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS Baxter Healthcare S.A. Oct- Apr Sep
919
04 -13 -13
27- 27- 5-
US20130230 CAPTURE OF TARGET DNA AND RNA BY PROBES COMPRISING
QUANTIBACT A/S Oct- Oct Sep
856 INTERCALATOR MOLECULES
10 -11 -13

23- 11- 5-
US20130230
Nanoreporters And Methods Of Manufacturing And Use Thereof NANOSTRING TECHNOLOGIES, INC. Dec- Mar Sep
851
05 -13 -13
17- 16- 5-
3M INNOVATIVE PROPERTIES COMPANY Aug- Aug Sep
10 -11 -13
20- 22- 5-
US20130230
NOVEL PARAMYXOVIRUS AND USES THEREOF The University of Hong Kong Jan- Jan Sep
529
12 -13 -13
4- 4- 29-
US20130225 Combinations of TGFBeta and COX-2 Inhibitors and Methods for
EVANS DAVID May- May Aug
655 Their Therapeutic Application
10 -11 -13
11- 12- 29-
US20130225 siRNA Compositions and Methods for Potently Inhibiting Viral
The University of Hong Kong Dec- Dec Aug
651 Infection
08 -11 -13
24- 25- 29-
US20130225 ISATIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS
HORNE DAVID A Feb- Feb Aug
637 THEREOF, AND METHODS OF USE THEREOF
12 -13 -13
8- 14- 29-
US20130225
Imidazoquinolines with Immuno-Modulating Properties AstraZeneca AB May- Mar Aug
555
07 -13 -13
1- 1- 29-
US20130224 CONCENTRATION OF VACCINE ANTIGENS WITHOUT
Novartis AG Jun- Jun Aug
245 LYOPHILIZATION
10 -11 -13
18- 29-
US20130224 SEQUENTIAL ADMINISTRATION OF A REPLICATION DEFECTIVE 2-Jul-
Etubics Corporation Sep Aug
144 ADENOVIRUS VECTOR IN VACCINATION PROTOCOLS 07
-12 -13
6- 6- 22-
US20130217 MICROARRAY-BASED ASSAY INTEGRATED WITH PARTICLES FOR
CapitalBio Corporation Aug- Aug Aug
584 ANALYZING MOLECULAR INTERACTIONS
10 -10 -13
30- 21- 22-
US20130217 METHODS AND COMPOSITIONS FOR PERFORMING NUCLEIC ACID
MONTESCLAROS LUZ Dec- Dec Aug
071 AMPLIFICATION REACTIONS
11 -12 -13
4- 3- 22-
US20130217
C-CBL MUTATIONS AND USES THEREOF The University of Chicago Jun- Jun Aug
012
10 -11 -13
23- 2- 22-
US20130216
TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS BBB HOLDING B V Mar- May Aug
612
07 -13 -13
19- 15- 22-
US20130216
Carbon Nanotube Compositions and Methods of Use Thereof UNIV YALE Mar- Mar Aug
581
08 -13 -13
21- 20- 22-
US20130216
INFLUENZA VIRUS REASSORTMENT NOVARTIS AG May- May Aug
573
10 -11 -13
Vectors expressing SARS immunogens, compositions containing 20- 21- 22-

US20130216
such vectors or expression products thereof, methods and assays ADAMS DANIEL Jun- Jun Aug
566
for making and using 03 -04 -13
20- 19- 15-

US20130210 APPLICATION OF HIGHLY CONSERVED DOMAIN SEQUENCES FROM
CHEN LI Sep- Sep Aug
894 VIRAL GENOME AS TEMPLATE TO DESIGN THERAPEUTIC SLIRNAS
10 -11 -13
11- 30- 15-

US20130210
Pharmaceutical Compounds ASTEX THERAPEUTICS LIMITED Apr- Jan Aug
820
08 -13 -13
16- 12- 15-
US20130210
PHARMACEUTICAL FORMULATIONS Anacor Pharmaceuticals, Inc. Feb- Apr Aug
770
05 -13 -13
28- 15-
US20130209 28-
Anti-Viral Azide Containing Compounds LIFE TECHNOLOGIES CORPORATION Jul- Aug
550 Jul-10
11 -13
12- 12- 15-
US20130209
METHODS FOR PREPARING SQUALENE Novartis AG May- May Aug
510
10 -11 -13
ALUMINA NANOPARTICLE BIOCONJUGATES AND METHODS OF 27- 26- 15-

US20130209
STIMULATING AN IMMUNE RESPONSE USING SAID HU HONG-MING Aug- Aug Aug
502
BIOCONJUGATES 10 -11 -13
6- 6- 15-
US20130209
RECOMBINANT RNA VIRUSES AND USES THEREOF TENOEVER BENJAMIN R Jun- Jun Aug
406
10 -11 -13
28- 15-
US20130209 28-
Anti-Viral Azide Containing Compounds LIFE TECHNOLOGIES CORPORATION Jul- Aug
364 Jul-10
11 -13
1- 31- 8-
US20130203
2' AND 5' MODIFIED MONOMERS AND OLIGONUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC. Apr- Mar Aug
836
10 -11 -13
12- 9- 8-
US20130203
METHODS FOR PREVENTING OR TREATING VIRAL INFECTION KIELIAN MARGARET Feb- Feb Aug
655
10 -11 -13
26- 26- 8-
US20130203 PRODUCTION OF ALPHAVIRUS REPLICON PARTICLES IN
BALSITIS SCOTT Apr- Apr Aug
151 PACKAGING CELLS
10 -11 -13
31- 31- 8-
US20130202 PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN ENCODING
Lichtstrasse Aug- Aug Aug
684 RNA
10 -11 -13
12- 14- 8-
US20130202
GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES GRANDI GUIDO Sep- Mar Aug
609
07 -13 -13

20- 22- 8-
US20130202 ACTIVATABLE TOXIN COMPLEXES COMPRISING A CLEAVABLE
RAMOT AT TEL-AVIV UNIVERSITY LTD. Sep- Aug Aug
598 INHIBITORY PEPTIDE
10 -11 -13
23- 8-
US20130202 23-
INTRACELLULAR IMMUNITY MEDICAL RESEARCH COUNCIL Jan Aug
593 Jul-10
-13 -13
13- 14- 1-
US20130197
Removing Cells from an Organism DAPPRICH JOHANNES Jan- Jan Aug
296
12 -13 -13
11- 11- 1-
US20130196
Multimeric Inhibitors of Viral Fusion and Uses Thereof JV BIO SRL Aug- Aug Aug
903
10 -11 -13
5- 4- 1-
US20130196 IN VITRO PROCESS FOR THE PREPARATION OF ANTIBODIES OF
JANSEN GABRIELE Feb- Feb Aug
380 THE IGG TYPE
10 -11 -13
31- 31- 1-
US20130195
SMALL LIPOSOMES FOR DELIVERY OF IMMUNOGEN ENCODING RNA NOVARTIS AG Aug- Aug Aug
969
10 -11 -13
6- 1-
US20130195 VIRION-LIKE DELIVERY PARTICLES FOR SELF-REPLICATING RNA 6-Jul-
Novartis AG Jul- Aug
968 MOLECULES 10
11 -13
15- 23- 1-
US20130195 ARCHAEAL POLAR LIPID AGGREGATES FOR ADMINISTRATION TO
NATIONAL RESEARCH COUNCIL OF CANADA Dec- Jan Aug
932 ANIMALS
06 -13 -13
20- 22- 1-
US20130195
Inulin and Inulin Acetate Formulations SOUTH DAKOTA SATE UNIVERSITY Jan- Jan Aug
930
12 -13 -13
12- 8- 1-
US20130195 Expression Of Positive Sense Single Stranded RNA Virus And Uses
Viracine Therapeutics Corporation Apr- Apr Aug
914 Thereof
10 -11 -13
27- 1-
US20130195 USE OF A PNEUMOCOCCAL P4 PEPTIDE FOR ENHANCING The Government of the United States of America as 31-
Mar Aug
893 OPSONOPHAGOCYTOSIS IN RESPONSE TO A PATHOGEN represented by the Secretary of the department of Jul-08
-13 -13
1- 1- 1-
US20130195
METHOD OF TREATING INFLAMMATION CYTOSORBENTS CORPORATION Apr- Apr Aug
792
10 -11 -13
31- 8- 25-
US20130190
PURINE ANALOGS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA May- Mar Jul-
494
06 -13 13
18- 18- 25-
US20130190 INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID
THE TRUSTEES OF PRINCETON UNIVERSITY Feb- Feb Jul-
381 METABOLISM AS BROAD SPECTRUM ANTI-VIRALS
10 -11 13
13- 25-
US20130190 13-
Direct Clone Analysis and Selection Technology Dublin City University Jul- Jul-
206 Jul-10
11 13
23- 18- 25-
US20130189
POLYMER STABILIZATION OF CHROMOGEN SOLUTIONS VENTANA MEDICAL SYSTEMS, INC. Jan- Jan Jul-
680
12 -13 13
31- 31- 25-
US20130189 LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING
NOVARTIS AG Aug- Aug Jul-
351 RNA
10 -11 13
3- 3- 25-
Novartis AG Dec- Dec Jul-
09 -10 13
12- 11- 25-
US20130189
Multimeric Proteins Comprising Immunoglobulin Constant Domains RESEARCH CORPORATION TECHNOLOGIES, INC. Feb- Feb Jul-
247
10 -11 13
5- 4- 18-
US20130184 OLIGONUCLEOTIDE AMPLIFICATION PRIMERS FOR TARGETING
GENERA BIOSYSTEMS LIMITED Apr- Jun Jul-
170 ONCOGENIC HPV
07 -12 13
1- 11- 18-
US20130183
METHOD FOR PRODUCING NUCLEIC ACID PROBES Ventana Medical Systems, Inc. Sep- Mar Jul-
670
06 -13 13
7- 18-
US20130183 DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE 6-Jul-
NOVARTIS AG Jun Jul-
355 POLYMER PARTICLES 10
-11 13
4- 18-
US20130183 INFLUENZA VIRUS-LIKE PARTICLES (VLPS) COMPRISING 13-
MEDICAGO INC. Jan Jul-
341 HEMAGGLUTININ PRODUCED WITHIN A PLANT Jul-07
-13 13
25- 1- 18-
US20130183
GITR BINDING MOLECULES AND USES THEREFOR GITR, INC. Mar- Mar Jul-
321
05 -13 13
4- 4- 11-
ALNYLAM PHARMACEUTICALS, INC Dec- Dec Jul-
07 -12 13

US20130178
PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL) Parion Sciences, Inc. Jun- Jun Jul-
482
CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE 11 -12 13
11- 9- 11-
US20130178
Treatment of Microbial Infections BIOCOPEA LIMITED Nov- Nov Jul-
466
09 -10 13
5- 4- 11-
US20130178
Treatment of Respiratory Disorders BANNISTER ROBIN MARK Feb- Feb Jul-
448
10 -11 13

12- 29- 11-
US20130178
VESICLE ISOLATION METHODS KLASS MICHAEL Nov- Aug Jul-
383
08 -12 13
10- 7- 11-
US20130178 Methods And Computer Systems For Identifying Target-Specific
NANOSTRING TECHNOLOGIES, INC. Apr- Mar Jul-
372 Sequences For Use In Nanoreporters
07 -13 13
7- 11-
US20130177 6-Jul-
DELIVERY OF RNA TO DIFFERENT CELL TYPES NOVARTIS AG Jun Jul-
640 10
-11 13
6- 11-
US20130177 6-Jul-
DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS NOVARTIS AG Jul- Jul-
639 10
11 13
6- 28- 11-
US20130177
DECONTAMINANT DISPENSER SUITABLE FOR USE AS A PROJECTILE STERIS INC. Mar- Feb Jul-
477
07 -13 13
19- 14- 4-
US20130172 SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO
BOEHRINGER INGELHEIM INTERNATIONAL GMBH Sep- Sep Jul-
327 [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C
11 -12 13
6- 4-
US20130171 LIPOSOMES WITH LIPIDS HAVING AN ADVANTAGEOUS PKA-VALUE 6-Jul-
NOVARTIS AG Jul- Jul-
241 FOR RNA DELIVERY 10
11 13
23- 23- 4-
US20130171 CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES
COULIBALY FASSELI JOSEPH Jun- Jun Jul-
129 THEREFOR
10 -11 13
22- 20- 27-
US20130165
TLR AGONISTS The Regents of The University of California Aug- Nov Jun-
455
05 -12 13
23- 23- 27-
US20130165 METHODS AND COMPOSITIONS FOR TREATING ACE2-RELATED
UNIVERSITY OF FLORIDA RESEARCH FOUNDATION Apr- Apr Jun-
417 DISORDERS
10 -11 13
2- 1- 20-
US20130157
Blockade Of Inflammatory Proteases With Cyclic Peptides THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Jun- Jun Jun-
964
11 -12 13
21- 21- 20-
US20130157
Systems and Methods for Detecting Antibiotic Resistance TESSARAE, LLC Aug- Feb Jun-
876
10 -13 13
19- 19- 20-
US20130157
RAPID PATHOGEN DIAGNOSTIC DEVICE AND METHOD PRESIDENT AND FELLOWS OF HARVARD COLLEGE Jan- Jan Jun-
283
10 -11 13
16- 16- 20-
US20130157 Method and apparatus for two-step surface-enhanced raman
Real-Time Analyzers, Inc. Dec- Dec Jun-
254 spectroscopy
11 -11 13
7- 8- 20-
US20130156
CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR The Regents of The University of California Feb- Jan Jun-
807
07 -13 13
6- 13-
US20130149 6-Jul-
IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA GEALL ANDREW Jul- Jun-
375 10
11 13
6- 6- 13-
US20130149 ORGANIC PEROXIDE COMPOUNDS FOR MICROORGANISM
GREGERSEN JENS PETER May- May Jun-
194 INACTIVATION
10 -11 13
27- 25- 6-
US20130145
ANTIBODY PRODUCING NON-HUMAN MAMMALS MERUS B.V. Jun- Jan Jun-
484
08 -13 13
25- 26- 6-
US20130143 Virally-Inactivated Growth Factors-Containing Platelet Lysate
BURNOUF THIERRY May- Nov Jun-
810 Depleted of PDGF and VEGF and Preparation Method Thereof
10 -12 13
3- 21- 6-
US20130143 COMPOSITIONS FOR USE IN IDENTIFICATION OF ADVENTITIOUS
IBIS BIOSCIENCES, INC. Mar- May Jun-
203 VIRUSES
05 -12 13
3- 3- 6-
US20130142 CIRCULATION OF COMPONENTS DURING HOMOGENIZATION OF
Novartis AG Dec- Dec Jun-
833 EMULSIONS
09 -10 13
21- 23- 6-
MEDICAGO, INC. Jan- Jan Jun-
826 PRODUCED IN TRANSGENIC PLANTS EXPRESSING HEMAGGLUTININ
08 -13 13
4- 14- 6-
US20130142
Mutations in OAS1 Genes KINETA TWO, LLC May- Nov Jun-
773
05 -12 13
28- 31- 30-
US20130137
Antiviral Compounds and Uses Thereof MOUNT SINAI SCHOOL OF MEDICINE May- May May
678
10 -11 -13
15- 28- 30-
US20130137
HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS BioFire Diagnostics, Inc. f/k/a Idaho Technology, Inc. May- Jan May
172
09 -13 -13
17- 15- 30-
US20130137 INCREASED PROTEIN EXPRESSION THROUGH INCREASED
UNIVERSITEIT GENT Jun- Jun May
140 MEMBRANE FORMATION
10 -11 -13
14- 14- 30-
US20130136
Recombinant HCMV and RHCMV vectors and uses thereof Oregon Health & Science University May- Nov May
768
10 -12 -13
29- 28- 23-
US20130130
SAMPLE-TO-ANSWER MICROFLUIDIC CARTRIDGE BATTRELL C FREDERICK Jan- Jan May
262
10 -11 -13

COMPOSITION WITH STERILIZING ACTIVITY AGAINST BACTERIA, 18- 18- 23-
US20130129
FUNGUS AND VIRUSES, APPLICATION THEREOF AND METHOD FOR GP&E Nov- Nov May
805
PREPARATION THEREOF 11 -11 -13
3- 3- 23-
US20130129 HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE
Novartis AG Dec- Dec May
786 ADJUVANTS
09 -10 -13
9- 11- 23-
NOVARTIS AG Sep- Jan May
04 -13 -13
15- 15- 23-
US20130129
METHODS AND COMPOSITIONS FOR INTRANASAL DELIVERY HARUTA SHUNJI Apr- Apr May
781
10 -11 -13
30- 17- 23-
US20130129 MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF
UNIVERSITY OF SOUTH FLORIDA Apr- Sep May
702 RNA VIRAL DISEASES
02 -12 -13
10- 10- 16-
US20130122
TAL EFFECTOR-MEDIATED DNA MODIFICATION IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. Dec- Jan May
581
09 -13 -13
1- 16-
BIENIARZ CHRISTOPHER Jul- May
516 SPECTROMETRY 10
11 -13
9- 10- 16-
Novartis AG Sep- Jan May
04 -13 -13
20- 20- 16-
US20130122
MODIFIED POLYPEPTIDES AND PROTEINS AND USES THEREOF WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH Apr- Apr May
043
10 -11 -13
14- 13- 16-
US20130122 HETEROLOGOUS PRIME-BOOST IMMUNIZATION USING MEASLES
Crucell Holland B.V. Nov- Nov May
038 VIRUS-BASED VACCINES
11 -12 -13
27- 16-
US20130122 HMGB1-DERIVED PEPTIDES ENHANCE IMMUNE RESPONSE TO 27-
MESSMER DAVORKA Jul- May
031 ANTIGENS Jul-10
11 -13
16- 12- 9-
US20130115 SUBSTRATES FOR CHROMOGENIC DETECTION AND METHODS OF
Ventana Medical Systems, Inc. Aug- Aug May
593 USE IN DETECTION ASSAYS AND KITS
10 -11 -13
13- 1- 9-
US20130115 Immunogenic Substances Comprising a Polyinosinic Acid -
Yisheng Biopharma (Singapore) PTE. LTD. Jan- Oct May
244 Polycytidilic Acid Based Adjuvant
06 -12 -13
30- 22- 9-
US20130115
IMMUNOSTIMULATORY COMBINATIONS TRUSTEES OF DARTMOUTH COLLEGE Dec- Oct May
228
02 -12 -13
14- 9-
US20130115 14-
DOMAIN INSERTION IMMUNOGLOBULIN ZHOU HONGXING Jul- May
215 Jul-10
11 -13
METHODS AND COMPOSITIONS RELATED TO MODIFIED 23- 23- 25-

US20130102
ADENOSINES FOR CONTROLLING OFF-TARGET EFFECTS IN RNA UNIVERSITY OF UTAH RESEARCH FOUNDATION Mar- Mar Apr-
652
INTERFERENCE 10 -11 13
24- 14- 25-

US20130102 NUTRITIONAL COMPOSITION COMPRISING IMMUNOGLOBULINS
N.V. NUTRICIA Aug- Sep Apr-
560 AND OLIGOSACCHARIDES
04 -12 13
31- 30- 25-
US20130102
Compounds And Their Use Novabiotics Limited Mar- Mar Apr-
524
10 -11 13
15- 15- 25-
US20130101 HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING
NOVARTIS AG Dec- Dec Apr-
629 COMPOUNDS AND USES THEREOF
09 -10 13
23- 7- 25-
US20130101
IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS Novartis AG Mar- May Apr-
622
06 -12 13
24- 24- 25-
US20130101
IRRADIATED BIODEGRADABLE POLYMER MICROPARTICLES NOVARTIS AG Jan- Jan Apr-
609
10 -11 13
14- 19- 18-
US20130096
IMIDAZOQUINOLINE COMPOUNDS NOVARTIS VACCINES & DIAGNOSTICS, INC. Sep- Jun Apr-
103
04 -12 13
1- 5- 18-
US20130096
Casein Derived Peptides And Uses Thereof SIDELMAN ZVI Mar- Sep Apr-
073
00 -12 13
3- 14- 18-
US20130096 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA
XENON PHARMACEUTICALS INC. Jun- Sep Apr-
056 DESATURASE INHIBITORS
05 -12 13
26- 26- 18-
US20130096
GENERATION OF BINDING MOLECULES MERUS BIOPHARMACEUTICALS B.V. Sep- Sep Apr-
020
11 -12 13
22- 27- 18-
US20130095
NOROVIRUS AND SAPOVIRUS ANTIGENS Novartis Vaccines and Diagnostics, Inc. Nov- Nov Apr-
552
05 -12 13
6- 18-
US20130095 PROCESS FOR REMOVING ADVENTITIOUS AGENTS DURING THE 8-Jul-
GlaxoSmithKline Biologicals S.A. Jul- Apr-
135 PRODUCTION OF A VIRUS IN CELL CULTURE 10
11 13
16- 30- 18-

US20130091
Anti-viral Formulations Nanomaterials and Nanoparticles LAMBKIN-WILLIAMS ROBERT Feb- Nov Apr-
611
06 -12 13

11- 11- 11-
US20130087
DIRECT IMPACT IONIZATION (DII) MASS SPECTROMETRY Services, National Institutes of Health Oct- Oct Apr-
700
11 -11 13
29- 28- 4-
US20130085
PROTEIN COMPLEMENTATION REGULATORS Trustees of Boston University Sep- Sep Apr-
095
11 -12 13
7- 19- 4-
US20130084 PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC
BOGOCH ELENORE S Aug- Jul- Apr-
303 COMPOSITIONS COMPRISING SAID PEPTIDES
09 12 13
15- 15- 21-

US20130071 PEPTIDES, CONJUGATES AND METHOD FOR INCREASING
ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC Mar- Mar Mar
428 IMMUNOGENICITY OF A VACCINE
10 -11 -13
1- 27- 7-
US20130059
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC Sep- Aug Mar
846
11 -12 -13
1- 29- 7-
US20130059
COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS IRM LLC Sep- Aug Mar
832
11 -12 -13
16- 7- 7-
US20130059
BORON-CONTAINING SMALL MOLECULES Anacor Pharmaceuticals, Inc. Feb- Sep Mar
803
05 -12 -13
16- 7- 7-
US20130059
BORON-CONTAINING SMALL MOLECULES Anacor Pharmaceuticals, Inc. Feb- Sep Mar
802
05 -12 -13
6- 31- 7-
US20130059
Antiviral Cell-Penetrating Peptides CURRELI FRANCESCA May- Oct Mar
776
08 -12 -13
8- 24- 7-
US20130058
Antigenic GM-CSF Peptides and Antibodies to GM-CSF CHAO QIMIN Feb- Oct Mar
945
06 -12 -13
8- 8- 24-
US20110070
Immunomodulatory Compositions, Combinations and Methods Coley Pharmaceutical Group, Inc. Dec- Dec Mar
575
04 -05 -11
22- 17-
US20110067 Transgenic mice having a human major histocompatibility complex 30-
INSTITUT PASTEUR Dec Mar
121 (MHC) phenotype, experimental uses and applications Jul-03
-09 -11
31- 27- 17-

US20110065
Compositions For Use In Genotyping Of Klebsiella Pneumoniae Ibis Biosciences, Inc. Aug- Aug Mar
111
09 -10 -11
18- 26- 17-
US20110065 Coronavirus, Nucleic Acid, Protein, and Methods for the Generation
VAN DER HOEK CORNELIA MARIA Aug- Jul- Mar
091 of Vaccine, Medicaments and Diagnostics
03 10 -11
2- 6- 17-
US20110065 NOVEL STRAIN OF SARS-ASSOCIATED CORONAVIRUS AND
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE Dec- Apr Mar
089 APPLICATIONS THEREOF
03 -10 -11
24- 17-
US20110064 9-Jul-
VIRAL ADJUVANTS University of North Carolina at Chapel Hill Nov Mar
772 04
-10 -11
7- 4- 3-
US20110053
RESPIRATORY DISEASE TREATMENT FINCH HARRY Aug- Aug Mar
986
08 -10 -11
30- 3-
US20110053 31-
Compounds - 801 ALCARAZ LILIAN Jul- Mar
909 Jul-09
10 -11
17- 17- 3-
US20110053
Broad Spectrum Antiviral and Methods of Use LOVELACE RESPIRATORY RESEARCH INSTITUTE Apr- Apr Mar
894
06 -07 -11
2- 1- 3-
US20110053
COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS IRM LLC Sep- Sep Mar
893
09 -10 -11
COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF 20- 20- 3-

US20110053
ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND CLINICAL Phylogica Limited Jun- Jun Mar
831
DISORDERS ASSOCIATED WITH THEREWITH 07 -08 -11
METHOD FOR CONTINUOUS MODE PROCESSING OF THE CONTENTS 10- 4- 3-

US20110053
OF MULTIPLE REACTION RECEPTACLES IN A REAL-TIME GEN-PROBE INCORPORATED Mar- Nov Mar
169
AMPLIFICATION ASSAY 05 -10 -11
27- 27- 3-
US20110052
Adjuvant Comprising Aluminum, Oligonucleotide and Polycation O'HAGAN DEREK Aug- Aug Mar
716
09 -10 -11
30- 15- 3-
US20110052 MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF
UNIVERSITY OF SOUTH FLORIDA Apr- Dec Mar
558 RNA VIRAL DISEASES
02 -09 -11
12- 12- 24-
US20110046
HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90 FREDERICKSON MARTYN Oct- Oct Feb
155
06 -07 -11
21- 29- 24-
US20110046 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-
BISCHOFF ALEXANDER Jun- Oct Feb
134 CoA DESATURASE
07 -10 -11
20- 20- 24-
US20110046
Multiplex Assay for Respiratory Viruses AUTOGENOMICS, INC. Nov- Nov Feb
001
07 -08 -11
14- 12- 24-
US20110045 COMPOSITIONS FOR USE IN IDENTIFICATION OF ADVENTITIOUS
IBIS BIOSCIENCES, INC. Jun- Jun Feb
456 CONTAMINANT VIRUSES
07 -08 -11

14- 2- 24-
US20110045
RNA VIRUS VACCINES AND METHODS DITTMER DIRK P Dec- Aug Feb
024
05 -10 -11
6- 5- 24-
US20110045 VACCINES INCLUDING ANTIGEN FROM FOUR STRAINS OF
TSAI THEODORE Dec- Dec Feb
022 INFLUENZA VIRUS
06 -07 -11
3- 28- 17-
US20110039
Imidazopyridinones Pfizer Limited Aug- Oct Feb
884
07 -10 -11
6- 8- 17-
US20110038 ANTIBODIES AGAINST INFLUENZA VIRUS AND METHODS OF USE
LIDDINGTON ROBERT C Dec- Dec Feb
935 THEREOF
07 -08 -11
28- 28- 17-
US20110038
NANOPARTICLES FOR USE IN PHARMACEUTICAL COMPOSITIONS NOVARTIS AG Apr- Apr Feb
900
08 -09 -11
28- 27- 17-
US20110038 NATIONAL UNIVERSITY CO., HAMAMATSU UNIVER.
IMMUNOPOTENTIATING AGENT COMPRISING EP1 AGONIST Apr- Apr Feb
884 SCHOOL OF MEDICINE
08 -09 -11
30- 30- 17-
US20110038 IMMUNOGENIC AND THERAPEUTIC COMPOSITIONS FOR
NOVARTIS AG Oct- Oct Feb
879 STREPTOCOCCUS PYOGENES
06 -07 -11
10- 9- 17-
US20110038 ANTIVIRALS THAT TARGET TRANSPORTERS, CARRIERS, AND ION
3-V BIOSCIENCES, INC. Jun- Jun Feb
852 CHANNELS
09 -10 -11
21- 21- 17-
US20110038 INHIBITORY POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR
Intradigm Corporation Dec- Dec Feb
849 TREATING CANCER
06 -06 -11
25- 25- 10-
US20110034 STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THE
FORSCHUNGSVERBUND BERLIN E.V. Sep- Sep Feb
438 PHARMACEUTICAL USE THEREOF
06 -07 -11
METHODS OF PREVENTING AND TREATING VIRAL INFECTIONS BY 5- 7- 10-

US20110033
INHIBITING THE DelSGYLATION ACTIVITY OF OTU DOMAIN- FRIAS-STAHELI NATALIA Apr- Apr Feb
498
CONTAINING VIRAL PROTEINS 07 -08 -11
12- 10- 10-

US20110033
ANALOGUES OF GLYCOLIPIDS USEFUL AS IMMUNOADJUVANTS PANZA LUIGI Oct- Oct Feb
485
07 -08 -11
26- 10-
US20110033 Methods For Treating Diseases Using Antibodies to 15-
Board of Regents, The University of Texas System Aug Feb
454 Aminophospolipids Jul-02
-10 -11
14- 28- 3-
US20110028 Device including altered microorganisms, and methods and systems
Searete LLC, Dec- May Feb
945 of use
05 -10 -11
20- 14- 3-
US20110028
NOVEL ADENINE COMPOUND AstraZeneca Aktiebolag Mar- Oct Feb
715
07 -10 -11
20- 17- 3-
US20110028
NOVEL SIRNA COMPOUNDS FOR INHIBITING RTP801 FEINSTEIN ELENA Mar- Mar Feb
531
08 -09 -11
30- 3-
IBIS BIOSCIENCES, INC. Jul- Feb
10 -11
7- 5- 3-
US20110027
PROTEIN CAGES AND THEIR USES DOUGLAS TREVOR Sep- Sep Feb
315
07 -08 -11
27- 26- 3-
US20110027
Influenza Vaccines Containing Hemagglutinin and Matrix Proteins NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO. KG Jan- Jan Feb
314
06 -07 -11
18- 6- 3-
US20110027
TC-83-Derived Alphavirus Vectors, Particles and Methods AlphaVax, Inc. May- Jul- Feb
306
04 10 -11
9- 10- 3-
US20110027
Fusion Proteins of Mannose Binding Lectins for Treatment of Disease ANAPHORE, INC. Nov- Nov Feb
267
07 -08 -11
7- 7- 3-
US20110027 CLOTTABLE CONCENTRATE OF PLATELET GROWTH FACTORS AND
GWO REI BIOMEDICAL TECHNOLOGY CORPORATION Jan- Jan Feb
257 PREPARATION METHOD THEREOF
08 -09 -11
28- 15- 3-
US20110027
USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE WEI GUANGWEN Aug- Oct Feb
228
03 -10 -11
14- 28- 3-
US20110027 Device including altered microorganisms, and methods and systems
Searete LLC Dec- May Feb
181 of use
05 -10 -11
25- 23- 27-
US20110021
HAZARDOUS SUBSTANCE-REMOVING MATERIAL KOSUGI TAKUJI Mar- Mar Jan-
861
08 -09 11
22- 23- 27-
US20110021 RNAi Modulation of RSV, PIV and Other Respiratory Viruses and
SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION Oct- Jul- Jan-
606 Uses Thereof
04 10 11
30- 29- 27-
US20110021
IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS GUY CYNTHIA A Dec- Sep Jan-
554
04 -10 11
18- 29- 27-
US20110021
ANTIMICROBIAL PEPTIDES NOVABIOTICS LIMITED Aug- Sep Jan-
415
04 -10 11
10- 1- 27-
US20110020 RNA-DEPENDENT DNA POLYMERASE FROM GEOBACILLUS
LAMPSON BERT C Mar- Mar Jan-
897 STEAROTHERMOPHILUS
04 -10 11

18- 18- 27-
US20110020
TREATMENT OF INFLAMMATORY ILLNESSES WITH ACE2 LOIBNER HANS Dec- Dec Jan-
315
07 -08 11
20- 6- 13-
US20110009 HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC
Xenon Pharmaceuticals Inc. Sep- May Jan-
414 AGENTS
04 -09 11
20- 9- 13-
US20110008
SYSTEM FOR DETECTING POLYNUCLEOTIDES INVESTIGEN May- Jun Jan-
905
03 -10 11
21- 13-
US20110008 19-
CHIMERIC VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES PUSHKO PETER Jul- Jan-
838 Jul-07
08 11
7- 13-
US20110008 MIXED MICELLES INCLUDING AMPHIPATHIC CONJUGATES OF RNA 6-Jul-
LEVCHENKO TATYANA S Jul- Jan-
395 AGENTS, AND USES THEREOF 07
08 11
6- 27- 13-
US20110008
Antiviral activity from medicinal mushrooms STAMETS PAUL EDWARD Jan- Mar Jan-
384
04 -07 11
8- 5- 13-
US20110008
INTERFERON FUSION PROTEINS ARTYMIUK PETER Aug- Aug Jan-
283
07 -08 11
2- 20- 13-
US20110008 METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL-
ZymoGenetics, Inc. Apr- May Jan-
280 29 CYSTEINE MUTANTS
04 -10 11
8- 10- 6-
US20110003 USE OF ANGIOGENESIS ANTAGONISTS IN CONDITIONS OF
KENNEDY THOMAS P Nov- Nov Jan-
890 ABNORMAL VENOUS PROLIFERATION
07 -08 11
8- 8- 6-
US20110003 CHIMERIC PCSK9 PROTEINS, CELLS COMPRISING SAME, AND
INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL May- May Jan-
315 ASSAYS USING SAME
06 -07 11
21- 1- 6-
US20110002
Alphavirus Vectors for Respiratory Pathogen Vaccines NOVARTIS VACCINES AND DIAGNOSTICS, INC. May- Jun Jan-
958
04 -10 11
30- 29- 6-
US20110002
Immunostimulatory Combinations AHONEN CORY L Dec- Jul- Jan-
946
02 10 11
21- 3- 6-
US20110002
Albumin Fusion Proteins Human Gemone Sciences, Inc. Dec- Jun Jan-
888
01 -10 11
9- 9- 6-
US20110000 ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR
ENNIS JANE E Jun- Jun Jan-
480 TREATMENT OF PATHOGENIC INFECTION
09 -10 11
29- 29- 30-
US20100330
METHOD FOR DETECTING TRUNCATED MOLECULES KEY MARC E Jan- Jan Dec
592
08 -09 -10
17- 17- 30-
US20100330
IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF BOZIA JADRANKA Dec- Dec Dec
190
07 -08 -10
13- 13- 30-
US20100330
PRODUCT FOR ABSORPTION PURPOSES HJERTEN MARIE-CHRISTINE Jun- Sep Dec
141
03 -10 -10
26- 25- 30-
US20100330 DEVICES AND METHODS FOR DECREASING HUMAN PATHOGEN
FILLIGENT LIMITED Jun- Jun Dec
140 TRANSMISSION
07 -08 -10
21- 30-
US20100330 VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND 19-
PUSHKO PETER Jul- Dec
122 ANTIGENS Jul-07
08 -10
7- 16- 30-
US20100330 Use of SIRT1 Activators or Inhibitors to Modulate an Immune
KWON HYE-SOOK Feb- Jul- Dec
114 Response
08 10 -10
13- 13- 30-
US20100330
MONOCLONAL HUMAN TUMOR-SPECIFIC ANTIBODY ABELA IRENE Mar- Mar Dec
075
07 -08 -10
NOVEL HYDROXY RADICAL GENERATION METHOD, AND ANTI-VIRAL 8- 9- 30-

US20100329
MATERIAL UTILIZING HYDROXYL RADICAL GENERATED BY THE MOCHIGASE CO., LTD. Feb- Feb Dec
971
METHOD 08 -09 -10
6- 6- 16-
US20100319 MULTI-TARGETED RNAI THERAPEUTICS FOR SCARLESS WOUND
SIR NAOMICS, INC. Nov- Nov Dec
074 HEALING OF SKIN
07 -08 -10
Amide and Carbamate Derivatives of N-{2-[4-Amino-2- 9- 8- 16-

US20100317
(Ethoxymethyl)-1H-Imidazo[4,5-c] Quinolin-1-Yl]-1,1- Coley Pharmaceutical Group, Inc. Sep- Sep Dec
684
Dimethylethyl} Methanesulfonamide and Methods 05 -06 -10
1- 28- 16-
US20100317
Casein Derived Peptides And Uses Thereof SIDELMAN ZVI Mar- Jul- Dec
601
00 10 -10
29- 29- 16-
US20100317
PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. Oct- Oct Dec
054
07 -08 -10
21- 1- 16-
US20100317
PRIMATE T-LYMPHOTROPIC VIRUSES and Johns Hopkins University Feb- Jul- Dec
034
05 10 -10
14- 11- 16-
US20100316 CONDENSATION PRODUCTS BASED ON BICYCLIC OR POLYCYCLIC
BASF SE Nov- Nov Dec
695 AROMATICS OR HETEROAROMATICS
07 -08 -10
31- 30- 16-
US20100316
ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES DIMITROV DIMITER S Jan- Jan Dec
641
08 -09 -10

21- 22- 16-
US20100316
TREATMENT OF FIBROSES AND LIVER DISORDERS LOIBNER HANS Dec- Dec Dec
624
07 -08 -10
26- 2- 9-
US20100311
Novel Compounds BONNERT ROGER VICTOR May- Jun Dec
797
06 -10 -10
23- 16- 9-
US20100311 TREATMENT OR PREVENTION OF RESPIRATORY VIRAL INFECTIONS
SciClone Pharmaceuticals, Inc. Apr- Jun Dec
656 WITH ALPHA THYMOSIN PEPTIDES
03 -10 -10
1- 30- 9-
US20100311 NON-TARGET AMPLIFICATION METHOD FOR DETECTION OF RNA
QIAGEN GAITHERSBURG INC. May- Apr Dec
039 SPLICE-FORMS IN A SAMPLE
09 -10 -10
4- 9-
US20100310 15-
LIPOSOMES COMPRISING DURAMYCIN AND ANTI-VIRAL AGENTS Board of Regents, The University of Texas System Mar Dec
638 Jul-02
-10 -10
21- 12- 9-
MEDICAGO INC. Jan- Jan Dec
604 PRODUCED IN TRANSGENIC PLANTS EXPRESSING HEMAGGLUTININ
08 -09 -10
20- 19- 9-
US20100310 SYSTEM FOR DELIVERY INTO XCR1 POSITIVE CELL AND USES Bundesrepublik Deutschland letztvertreten durch das
Nov- Nov Dec
562 THEREOF Robert Koch-Institut vertreten durch seinen
07 -08 -10
15- 2-
US20100305 29-
PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. Jun Dec
138 Jul-03
-10 -10
27- 26- 2-
US20100304 PEPTIDE COMPOUNDS FOR DETECTING OR INHIBITING SARS ELECTRONICS AND TELECOMMUNICATIONS RESEARCH
May- May Dec
363 CORONAVIRUS AND APPLICATION THEREOF INSTITUTE
09 -10 -10
28- 2-
US20100304 METHOD AND DEVICE FOR MONITORING A THERAPEUTIC 26-
DAS DEVELOPMENT PARTNERS Jul- Dec
361 TREATMENT REGIME Jul-07
08 -10
16- 11- 2-
US20100303
HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) GENMAB A/S Dec- Nov Dec
823
02 -09 -10
7- 7- 25-
US20100298 METHODS FOR THE DIRECTED EXPANSION OF EPITOPES FOR USE
BONNIN DUSTAN May- May Nov
547 AS ANTIBODY LIGANDS
07 -08 -10
21- 20- 25-
US20100298
SALTS 756 AstraZeneca AB May- May Nov
364
09 -10 -10
2- 31- 25-
US20100298
COMPOUNDS FOR PREVENTING OR TREATING A VIRAL INFECTION ESTAQUIER JEROME Nov- Oct Nov
209
07 -08 -10
21- 21- 25-
US20100297
Methods of Modulating Vesicular Trafficking THE GENERAL HOSPITAL CORPORATION May- May Nov
651
09 -10 -10
24- 24- 25-
US20100297 IMMUNOSTIMULATORY COMBINATIONS OF TLR LIGANDS AND
Office of Technology Transfer Sep- Sep Nov
165 METHODS OF USE
07 -08 -10
31- 1- 25-
GRIMM JAN Aug- Sep Nov
07 -08 -10
20- 30- 18-

US20100292
BORON-CONTAINING SMALL MOLECULES Anacor Pharmaceuticals, Inc. Jun- Jul- Nov
504
07 10 -10
28- 28- 18-
US20100292
Construct ISIS INNOVATION LIMITED Mar- Mar Nov
307
06 -07 -10
25- 27- 18-
US20100291 COMPOSITIONS FOR USE IN IDENTIFICATION OF STRAINS OF
IBIS BIOSCIENCES, INC. May- May Nov
544 HEPATITIS C VIRUS
07 -08 -10
14- 26- 18-
US20100291
Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES ANTIGEN EXPRESS, INC. Sep- Jul- Nov
145
99 10 -10
22- 24- 18-
US20100291
Norovirus and sapovirus antigens COIT DORIS Nov- Mar Nov
129
05 -09 -10
23- 23- 18-
US20100291 PEPTIDES REGULATING THE SURFACE EXPRESSION OF THE T CELL
MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN Jun- Jun Nov
120 RECEPTOR
06 -07 -10
23- 23- 18-
US20100291 Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Theraclone Sciences, Inc. Apr- Apr Nov
075 Neutralizing Antibodies
09 -10 -10
21- 3- 18-
US20100291
Albumin Fusion Proteins Human Genome Sciences, Inc. Dec- Jun Nov
033
01 -10 -10
11- 5- 11-
US20100286 Mammalian Genes Involved In Viral Infection And Tumor
RUBIN DONALD H Oct- Mar Nov
251 Suppression
06 -10 -10
15- 14- 11-
US20100286 SUPPRESSION OF VIRUSES INVOLVED IN RESPIRATORY INFECTION
ARNDT GREGORY MARTIN May- May Nov
238 OR DISEASE
07 -08 -10
7- 6- 11-
US20100286 SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE
FORD RHONAN May- May Nov
118 COMPOUNDS 750
09 -10 -10
28- 27- 11-
US20100286 SYNTHETIC APOLIPOPROTEIN E MIMICKING POLYPEPTIDES AND
ANANTHARAMAIAH GATTADAHALLI M Aug- Aug Nov
025 METHODS OF USE
07 -08 -10

24- 12- 11-
US20100285 High-Throughput Diagnostic Assay For the Human Virus Causing
CHAN KWOK HUNG Mar- Jun Nov
457 Severe Acute Respiratory Syndrome (SARS)
03 -09 -10
2- 1- 11-
US20100285
Nanoparticles For Use In Immunogenic Compositions NOVARTIS AG Dec- Dec Nov
135
05 -06 -10
15- 15- 11-
US20100284 Use of PS20/WFDC1 and Interferons to Diagnose, Monitor and Treat
BAIG EHTESHAM Oct- Oct Nov
968 Viral Diseases
07 -08 -10
21- 20- 11-
US20100284 MODIFIED PHAGE FOR DISPLAYING POST-TRANSLATIONALLY National Institutes of Health (NIH), U.S. Dept. of Health
Nov- Nov Nov
967 MODIFIED PROTEINS AND USES THEREOF and Human Services (DHHS) U.S. Govt.
06 -07 -10
15- 14- 11-
US20100284 COMPOSITIONS AND METHODS FOR ADOPTIVE AND ACTIVE
Yale University Jan- Jan Nov
965 IMMUNOTHERAPY
08 -09 -10
24- 24- 11-
US20100284 COMPOUNDS AND MARKERS FOR SURFACE-ENHANCED RAMAN
JULIUS-MAXIMILIANS- UNIVERSITAT Sep- Sep Nov
917 SCATTERING
07 -08 -10
6- 6- 11-
US20100284
OPTICAL CYTOMETRY THE REGENTS OF THE UNIVERSITY OF CALIFORNIA May- May Nov
016
09 -09 -10
13- 16- 4-
US20100280 DOUBLE-STRANDED RIBONUCLEIC ACID WITH INCREASED
Alnylam Pharmaceuticals Jun- Jun Nov
102 EFFECTIVENESS IN AN ORGANISM
03 -10 -10
30- 30- 4-
US20100280
INHIBITORS OF ACETYL-COA CARBOXYLASE ACHARYA VINOD PARAMESHWARAN Apr- Apr Nov
067
09 -10 -10
6- 5- 4-
US20100280 Some 2-pyrazinone derivatives and their use as inhibitors of
ASTRAZENECA R&D Nov- Nov Nov
048 neutrophile elastase
07 -08 -10
8- 6- 4-
US20100280
IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES BONNERT ROGER VICTOR May- May Nov
001
07 -08 -10
17- 17- 4-
US20100279
FORMULATIONS COMPRISING AN ANTI-MICROBIAL COMPOSITION BYOTROL PLC Sep- Sep Nov
906
07 -08 -10
5- 4- 4-
US20100279
COMPOSITIONS AND METHODS OF DETECTION GENERA BIOSYSTEMS LIMITED Apr- Apr Nov
888
07 -08 -10
13- 13- 4-
US20100279
Method for Generation of Antibodies NATIONAL JEWISH MEDICAL AND RESEARCH CENTER Mar- Mar Nov
351
07 -08 -10
17- 30- 4-
US20100279
Compositions and methods for analysis of target analytes DANIELZADEH ROBERT Sep- Nov Nov
279
03 -07 -10
17- 6- 4-
US20100279 METHODS FOR DETERMINING THE PRESENCE OF SARS
GEN-PROBE INCORPORATED Apr- Jul- Nov
276 CORONAVIRUS IN A SAMPLE
03 10 -10
17- 4-
US20100279 NUCLEIC ACID SEQUENCES FOR THE AMPLIFICATION AND 17-
UNIVERSITE LAVAL Jul- Nov
273 DETECTION OF RESPIRATORY VIRUSES Jul-07
08 -10
29- 29- 4-
US20100278 METHODS AND COMPOSITIONS FOR PREDICTING EMERGENCE AND
NIMAN HENRY L Jan- Jan Nov
861 EXPANSION OF DRUG RESISTANT STRAINS OF INFLUENZA VIRUS
09 -10 -10
NASAL-ADMINISTERED VACCINES USING MULTI-SCREENED NALT- 23- 11- 4-

US20100278
TARGETING AND PHAGOCYTIC POLYPEPTIDE TRANSPORT FERGUSON IAN A Jun- Dec Nov
846
SEQUENCES 04 -09 -10
DUAL INHIBITION OF IMMUNOPHILIN/CYCLOPHILIN FAMILY 6- 6- 4-

US20100278
MEMBERS AND EMMPRIN IMMUNOGLOBULIN RECEPTOR EDWARDS III CARL KEITH Feb- Feb Nov
829
SUPERFAMILY MEMBERS 09 -10 -10
9- 9- 28-
US20100273
Ribozyme to cleave coronavirus gene FUKUDA NOBORU Aug- Aug Oct-
997
05 -06 10
15- 12- 28-
US20100273 COMPOSITIONS AND METHODS FOR INHIBITING NADPH OXIDASE
FEINSTEIN ELENA Jun- Jun Oct-
854 EXPRESSION
07 -08 10
20- 23- 28-
US20100273 Phospholipids for the Treatment of Infection by Togaviruses, Herpes
FLEMING RONALD A Feb- Nov Oct-
740 Viruses and Coronaviruses
04 -09 10
21- 21- 28-
US20100273 DETECTION OF ANTIVIRAL RESISTANCE IN INFLUENZA A USING
DAWSON ERICA Aug- Aug Oct-
670 DNA MICROARRAY
06 -07 10
RNA SEQUENCE MOTIFS IN THE CONTEXT OF DEFINED 13- 8- 28-

US20100272
INTERNUCLEOTIDE LINKAGES INDUCING SPECIFIC IMMUNE COLEY PHARMACEUTICAL GMBH Aug- Aug Oct-
785
MODULATORY PROFILES 07 -08 10
23- 28- 28-

US20100272 Device including bone cage and method for treatment of disease in Searete LLC, a limited liability corporation of the State of
Apr- Jul- Oct-
776 a subject Delaware
09 09 10
23- 23- 28-
US20100272 Device including bone cage and method for treatment of disease in
HARLOW ED Apr- Apr Oct-
771 a subject
09 -09 10
8- 16- 28-
US20100272
Antigenic GM-CSF Peptides And Antibodies To GM-CSF MORPHOTEK, INC. Feb- Apr Oct-
730
06 -10 10

22- 20- 28-
US20100272
ANTIVIRALS GREBER URS Jun- Jun Oct-
706
07 -08 10
20- 20- 28-
US20100272 ANTIVIRAL SUBSTANCE, ANTIVIRAL FIBER, AND ANTIVIRAL FIBER
Daiwabo Holdings Co., Ltd. Feb- Feb Oct-
668 STRUCTURE
08 -09 10
16- 2- 21-
US20100267
BORON-CONTAINING SMALL MOLECULES Anacor Pharmaceuticals, Inc. Feb- Dec Oct-
981
05 -09 10
24- 1- 21-
US20100267 TARGETING OPPOSITE STRAND REPLICATION INTERMEDIATES OF
ALNYLAM PHARMACEUTICALS, INC. Sep- Mar Oct-
805 SINGLE-STRANDED VIRUSES BY RNAI
04 -10 10
28- 21-
US20100266 26-
NUCLEIC ACID BINDING COMPOUNDS AND METHODS OF USE UNIVERSITY OF ROCHESTER Jul- Oct-
677 Jul-07
08 10
15- 18- 21-
US20100266 ADJUVANCY AND IMMUNE POTENTIATING PROPERTIES OF
NEW YORK BLOOD CENTER, INC. Jun- Feb Oct-
634 NATURAL PRODUCTS OF ONCHOCERCA VOLVULUS
04 -10 10
20- 19- 21-
US20100266
Immunoconjugates for treatment of infectious diseases SUN LE Jan- Jan Oct-
620
06 -07 10
9- 7- 21-
US20100266 USE OF TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND
The Salk Institute for Biological Studies Nov- Nov Oct-
604 TAM ACTIVATORS AS IMMUNOSUPPRESSORS
07 -08 10
9- 28- 21-
US20100266 PEPTIDE THAT ELICITS NEUTRALIZING ANTIBODIES TARGETING Government of the US, as Represented by the Secretary,
Apr- Dec Oct-
598 THE HIV CO-RECEPTOR, CCR5 Department of Health and Human Services
04 -09 10
22- 21- 14-
US20100262
Systems and methods for analyzing nanoreporters HWANG JENQ-NENG May- May Oct-
374
06 -07 10
15- 15- 14-
US20100261 Phosphate-Modified Oligonucleotide Analogs with Enhanced
JURK MARION May- May Oct-
779 Immunostimulatory Activity
08 -08 10
3- 30- 14-
US20100261
NOVEL COMBINATIONS ASTRAZENECA R&D Apr- Mar Oct-
690
09 -10 10
23- 22- 14-
US20100261 Compositions comprising oriented, immobilized macromolecules and
NanoString Technologies, Inc. Dec- Dec Oct-
026 methods for their preparation
05 -06 10
23- 30- 7-
US20100256
Oligoadenylate Synthetase (OAS) ILLUMIGEN BIOSCIENCES, INC. Nov- Mar Oct-
348
05 -10 10
3- 30- 7-
US20100256
NOVEL COMPOUNDS AstraZeneca R&D Apr- Mar Oct-
105
09 -10 10
3- 30- 7-
US20100256
NOVEL AMIDE COMPOUNDS ASTRAZENECA R&D Apr- Mar Oct-
104
09 -10 10
3- 30- 7-
US20100256
NOVEL COMPOUNDS ASTRAZENECA R&D Apr- Mar Oct-
103
09 -10 10
Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides

6- 17- 7-
US20100256 and ureas, pharmaceutical compositions thereof, and methods for
BAILEY THOMAS R Dec- Jan Oct-
096 treating hemorrhagic fever viruses, including infections associated
04 -07 10
with arenaviruses
18- 7-
US20100256 20-
RECOMBINANT VIBRIO CHOLERAE EXOTOXINS SEED BRIAN Jul- Oct-
070 Jul-07
08 10
3- 6- 7-
US20100254
Protein Formulations MEDIMMUNE, LLC Feb- May Oct-
985
06 -10 10
14- 13- 7-
US20100254
Albumin Fusion Proteins STUMP DAVID CARTER Sep- Sep Oct-
944
06 -07 10
3- 4- 7-
US20100254
HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS BIOTRON LIMITED Aug- Aug Oct-
942
07 -08 10
20- 30- 30-
US20100249
Novel Compounds 569 CONNOLLY STEPHEN Dec- Mar Sep
200
06 -10 -10
14- 18- 30-
US20100249 METHOD AND MEDICAMENT FOR INHIBITING THE INFECTION OF INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF
Nov- Dec Sep
021 INFLUENZA VIRUS SCIENCES
07 -07 -10
17- 17- 30-
US20100248
Compositions for use in identification of influenza viruses ESHOO MARK W Oct- Oct Sep
219
05 -06 -10
21- 21- 30-
US20100247
CHIMERIC NEWCASTLE DISEASE VIRUS VLPs MAHMOOD KUTUB Feb- Feb Sep
574
07 -08 -10
27- 26- 30-
ACADEMIA SINICA Mar- Mar Sep
571 VIRUS
09 -10 -10
25- 25- 30-
US20100247 MUTANT BOTULINUM NEUROTOXIN SEROTYPE A POLYPEPTIDE AND
THOMAS JEFFERSON UNIVERSITY Sep- Sep Sep
560 USES THEREOF
07 -08 -10
9- 7- 30-
US20100247
USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIALS BHATTACHARYYA SUCHITA Nov- Nov Sep
554
07 -08 -10

28- 3- 30-
US20100247 SYSTEMS AND METHODS FOR IDENTIFYING REPLIKIN SCAFFOLDS
BOGOCH ELENORE S Apr- Feb Sep
550 AND USES OF SAID REPLIKIN SCAFFOLDS
04 -10 -10
20- 22- 23-
US20100240
CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS Onyx Therapeutics, Inc. Mar- Mar Sep
903
09 -10 -10
3- 23-
US20100240 3-Jul-
STEREOISOMERS OF TRICYCLODECAN-9-YL-XANTHOGENATE LUMAVITA AG Jul- Sep
746 07
08 -10
9- 8- 23-
US20100240 Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring
Coley Pharmaceutical Group, Inc Feb- Feb Sep
693 Compounds and Methods
05 -06 -10
3- 23-
US20100240 5-Jul-
8-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR7 COOK ANTHONY Jul- Sep
623 06
07 -10
10- 1- 23-
US20100240 SYSTEMS AND METHODS FOR DETECTING MULTIPLE OPTICAL
GEN-PROBE INCORPORATED Mar- Jun Sep
063 SIGNALS
05 -10 -10
16- 15- 23-
US20100239
Combination adjuvant formulation BABIUK LORNE Oct- Oct Sep
611
08 -09 -10
11- 23-
US20100239 INFLUENZA VIRUS-LIKE PARTICLES (VLPS) COMPRISING 13-
MEDICAGO INC. Jul- Sep
610 HEMAGGLUTININ PRODUCED WITHIN A PLANT Jul-07
08 -10
1- 30- 23-
MedImmune Limited Jun- May Sep
593 THEM
07 -08 -10
24- 22- 23-
US20100239
ORGANIC COMPOUNDS DALES NATALIE Aug- Aug Sep
520
06 -07 -10
19- 18- 16-
US20100234 ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF
MARTIN BARRIE Jun- Jun Sep
355 CYTOKINE MEDIATED DISEASES
06 -07 -10
19- 20- 16-
US20100233
VACCINE BARAS BENOIT Jun- Jun Sep
250
07 -08 -10
9- 29- 16-
US20100233 Coatings and Surface Treatments Having Active Enzymes and
REACTIVE SURFACES, LTD. Sep- May Sep
146 Peptides
02 -09 -10
15- 13- 16-
US20100233
ORGANIC COMPOUNDS DALES NATALIE Aug- Aug Sep
116
06 -07 -10
22- 22- 16-
US20100233
Method for Delivery Across the Blood Brain Barrier IMMUNE DISEASE INSTITUTE, INC. May- May Sep
084
06 -07 -10
2- 25- 16-
US20100233
Method and Apparatus for Analyzing Bioprocess Fluids BioScale, Inc. May- May Sep
031
05 -10 -10
28- 9-
US20100227 STOCHASTIC CONFINEMENT TO DETECT, MANIPULATE, AND 26-
BOEDICKER JAMES Q Jul- Sep
767 UTILIZE MOLECULES AND ORGANISMS Jul-07
08 -10
24- 24- 9-
US20100226
Compounds for immunopotentiation SILVER JOEL B Jun- Jun Sep
931
04 -05 -10
27- 26- 2-
US20100222 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF
FEINSTEIN ELENA Jun- Jun Sep
409 PRO-APOPTOTIC GENES
07 -08 -10
31- 25- 2-
US20100222
Malaria antigen screening method AGUAIR JOAO CARLOS Aug- Aug Sep
234
05 -06 -10
15- 16- 2-
US20100221 USE OF ANTIBODY SECRETING CELL ELISPOT TO ASSESS
University of Rochester Jun- Jun Sep
755 ANTIBODY RESPONSES FOLLOWING ANTIGEN EXPOSURE
07 -08 -10
1- 1- 2-
US20100221
NUCLEIC ACID CONSTRUCTS Powderject Vaccines, Inc. Feb- Feb Sep
349
05 -06 -10
20- 20- 2-
US20100221 ANTIVIRAL AGENTS, ANTIVIRAL FIBERS AND ANTIVIRAL FIBER
DAIWABO HOLDINGS CO., LTD. Feb- Feb Sep
307 STRUCTURES
08 -09 -10
7- 5- 2-
US20100221
BINDING MEMBERS-513 MEDIMMUNE LIMITED Nov- Nov Sep
257
08 -09 -10
1- 1- 2-
US20100221 ANTI-VIRAL GRIFFITHSIN COMPOUNDS, COMPOSITIONS AND
MCMAHON JAMES B Dec- Dec Sep
242 METHODS OF USE
05 -06 -10
20- 16- 26-
US20100216
NOVEL SALT 628 ASTRAZENECA R&D Feb- Feb Aug
843
09 -10 -10
24- 11- 26-
US20100216
PHENANTHROINDOLIZIDINE ANALOGUES National Health Research Institutes Feb- Feb Aug
773
09 -10 -10
8- 7- 26-
US20100216 National University Corporation, Hamamatsu University
CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST May- May Aug
689 School of Medicine
07 -08 -10
20- 16- 26-
US20100215 PROTECTIVE ANTIGENS FOR GROUP B STREPTOCOCCUS
NOVARTIS AG Feb- Feb Aug
683 HYPERVIRULENT STRAINS
09 -10 -10

REPLIKIN-BASED COMPOUNDS FOR PREVENTION AND TREATMENT 9- 16- 26-
US20100215
OF INFLUENZA AND METHODS OF DIFFERENTIATING INFECTIVITY BOGOCH ELENORE S Jan- Oct Aug
675
AND LETHALITY IN INFLUENZA 09 -09 -10
Molecular Healing of Polymeric Materials, Coatings, Plastics, 9- 29- 19-

US20100210
Elastomers, Composites, Laminates, Adhesives, and Sealants by REACTIVE SURFACES, LTD. Sep- Jan Aug
745
Active Enzymes 02 -10 -10
9- 27- 19-
US20100210
Novel Benzothiazolone Derivatives BONNERT ROGER Aug- Apr Aug
688
05 -10 -10
30- 31- 19-
US20100209
ATTENUATED VIRUSES USEFUL FOR VACCINES CELLO JERONIMO Mar- Mar Aug
454
07 -08 -10
16- 18- 19-
US20100209 Compositions and Methods Related to Adenovirus Based Delivery of
INTROGEN THERAPEUTICS, INC. Jun- Jun Aug
451 Antigens
06 -07 -10
26- 25- 19-
US20100209
Targeted Delivery of siRNA Immune Disease Institute, Inc. Jan- Jan Aug
440
07 -08 -10
12- 11- 12-
US20100204 METHOD FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS
BYRNES JOHN J Feb- Feb Aug
286 OF CYTOTOXIC AGENTS
09 -10 -10
23- 21- 12-
US20100204 COMPOSITIONS FOR USE IN IDENTIFICATION OF MIXED
Ibis Biosciences, INC Mar- Mar Aug
266 POPULATIONS OF BIOAGENTS
07 -08 -10
11- 10- 12-
US20100204 Chemical Compounds 637: Pyridopyrimidinediones as PDE4
BONNERT ROGER VICTOR Jan- Jan Aug
203 Inhibitors
07 -08 -10
12- 12- 12-
US20100203 Protein Expression System Involving Mutated Severe Respiratory
Academia Sinica Feb- Feb Aug
582 Syndrome-Associated Coronavirus 3C-Like Protease
09 -09 -10
17- 5-
US20100197 17-
ANTI-MICROBIAL COMPOSITION BYOTROL PLC Jul- Aug
748 Jul-07
08 -10
7- 7- 5-
US20100197
INDOLE COMPOUNDS BARDEN TIMOTHY Aug- Aug Aug
708
06 -07 -10
7- 6- 5-
US20100196 Use of Deuterium Oxide to Treat Virus-Based Diseases of the
BAYERL THOMAS Jan- Jan Aug
285 Respiratory Tract
09 -10 -10
20- 19- 5-
US20100196
AIR CLEANING APPARATUS FUJIFILM CORPORATION Sep- Sep Aug
222
07 -08 -10
16- 21- 29-
US20100190
BORON-CONTAINING SMALL MOLECULES Anacor Pharmaceuticals, Inc. Feb- Jul- Jul-
748
05 09 10
27- 27- 29-
US20100189
Compositions of TLR ligands and antivirals COLEY PHARMACEUTICAL GMBH Sep- Sep Jul-
772
06 -07 10
21- 21- 29-
US20100186 LIVESTOCK STERILIZING METHOD, LIVESTOCK STERILIZING
HAGIWARA NOBUKO Feb- Feb Jul-
680 APPARATUS, AND LIVESTOCK OR LIVESTOCK MEAT
05 -06 10
8- 8- 22-
US20100184
Methods and Compositions Related to Inhibition of Viral Entry University of Utah Research Foundation Feb- Feb Jul-
663
07 -08 10
10- 9- 22-
US20100184 Proteome Epitope Tags and Methods of Use Thereof in Protein
Millipore Corporation May- Oct Jul-
613 Modification Analysis
02 -09 10
19- 22-
US20100184 11-
AVIAN INFLUENZA CHIMERIC VLPS PUSHKO PETER Jan Jul-
192 Jul-03
-10 10
17- 9- 22-
US20100184
Influencing viral lipid constituents MedImmune, LLC Oct- Oct Jul-
190
06 -07 10
24- 10- 22-
US20100184 Novel Human Virus Causing Severe Acute Respiratory Syndrome
CHAN KWOK HUNG Mar- Feb Jul-
019 (SARS) and Uses Thereof
03 -10 10
4- 22-
US20100183 METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS 2-Jul-
ETUBICS CORPORATION Jan Jul-
673 VECTOR FOR USE WITH MULTIPLE VACCINATIONS 07
-10 10
27- 27- 22-
US20100183
LOW-ADDITIVE INFLUENZA VACCINES Novartis Vaccines & Diagnostics GmbH & Co., KG Jun- Jun Jul-
671
07 -08 10
1- 31- 22-
US20100183
MULTIFUNCTIONAL NUCLEIC ACID NANO-STRUCTURES Cornell University, a New York Corporation Jan- Dec Jul-
634
09 -09 10
25- 22-
US20100183 25-
SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS BARTH STEFAN Jul- Jul-
516 Jul-07
08 10
12- 12- 15-
US20100179
PHARMACEUTICAL COMBINATIONS GALLAGHER NEIL JAMES Oct- Oct Jul-
145
06 -07 10
13- 13- 15-
US20100178 METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE
Northeastern University Feb- Feb Jul-
299 RESPONSES
07 -08 10

28- 2- 8-
Georgetown University Aug- Dec Jul-
006 AND COMMUNICATING EVENT-RELATED INFORMATION
08 -09 10
13- 21- 8-
US20100173
ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV JUTEAU JEAN-MARC Sep- Dec Jul-
980
02 -09 10
6- 6- 8-
US20100173 Substituted 3,4,6,7-Tetrahydro-5H-1,2a,4a,8-
GRIESGRABER GEORGE W Sep- Sep Jul-
906 Tetraazacyclopenta[cd]Phenalenes and Methods
06 -07 10
17- 4- 8-
US20100173
Composition and Method for Analysis of Target Analytes Millipore Corporation Sep- Jul- Jul-
325
03 09 10
20- 19- 8-
US20100173 Systems for Detection and Production of Respiratory, Herpes and
Diagnostic Hybrids, Inc Sep- Sep Jul-
280 Enteric Viruses
05 -06 10
13- 21- 8-
US20100172
ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES JUTEAU JEAN-MARC Sep- Dec Jul-
965
02 -09 10
16- 8-
US20100172 22-
Binding molecules against SARS-coronavirus and uses thereof Crucell Holland B.V. Nov Jul-
917 Jul-03
-09 10
24- 8- 1-
US20100166
Technology for Preparation of Macromolecular Microspheres FANG FANG Jan- Dec Jul-
874
06 -09 10
23- 1-
US20100166 CLIP INHIBITORS AND METHODS OF MODULATING IMMUNE 25-
AGADJANYAN MICHAEL Jul- Jul-
782 FUNCTION Jul-08
09 10
27- 27- 1-
Pfizer Inc Sep- Sep Jul-
06 -07 10
5- 12- 1-
US20100166 High-yield Transgenic Mammalian Expression System for Generating
Academia Sinica Sep- Feb Jul-
769 Virus-like Particles
06 -10 10
11- 11- 1-
US20100166 siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING
LIN YONGPING Dec- Dec Jul-
661 VIRAL INFECTION
08 -09 10
19- 19- 24-
US20100160 POLYOLEFIN ANTIMICROBIAL COMPOSITIONS AND MELT-
BISHOP KEVIN L Dec- Dec Jun-
486 PROCESSING METHODS
08 -08 10
23- 22- 24-
BISCHOFF ALEXANDER Dec- Dec Jun-
323 CoA DESATURASE
08 -09 10
24- 18- 24-
US20100160 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory
BIRKINSHAW TIMOTHY NICHOLAS Aug- Dec Jun-
285 Disease
04 -09 10
16- 24-
US20100160 17-
Quercetin-Containing Compositions Quercegen Pharma LLC Dec Jun-
245 Jul-06
-09 10
4- 6- 24-
US20100158 ADMINISTRATION ROUTES FOR PRIMING/BOOSTING WITH
NOVARTIS VACCINES AND DIAGNOSTICS SRL Nov- Nov Jun-
05 -06 10
21- 24- 24-
US20100158
MUTANT FORMS OF STREPTOLYSIN O NOVARTIS AG Dec- Feb Jun-
935
07 -10 10
25- 20- 24-
US20100158
IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHODS GRIESGRABER GEORGE W Dec- Dec Jun-
928
06 -07 10
2- 1- 17-
US20100152
HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS Pfizer Inc. Sep- Sep Jun-
230
05 -06 10
15- 10- 17-
US20100152 (4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-
ASTRAZENECA AB Dec- Dec Jun-
197 CARBOXAMIDE DERIVATIVES
08 -09 10
3- 5- 17-
US20100152 AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA
XENON PHARMACEUTICALS INC. Jun- Jun Jun-
05 -06 10
16- 12- 17-
US20100152
PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED Nov- Oct Jun-
184
06 -07 10
1- 25- 17-
US20100151
Antigenic Protein Conjugates and Process for Preparing Same ABBOTT LABORATORIES Sep- Feb Jun-
490
06 -10 10
22- 21- 17-
US20100150 COMPOSITIONS AND METHODS FOR CHITOSAN ENHANCED The United States of America, as represented by the
Sep- Sep Jun-
960 IMMUNE RESPONSE Secretary,Department of Health and Human Servi
06 -07 10
26- 17-
US20100150 26-
IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA NOVARTIS AG Jul- Jun-
943 Jul-06
07 10
20- 13- 17-

US20100150 FUSION PROTEINS OF RECOMBINANT SARS CORONAVIRUS Chinese Academy of Medical Sciences, Institute of Basic
Jun- Jun Jun-
923 STRUCTURAL PROTEINS, THEIR PRODUCTION AND USES Medical Sciences
05 -06 10
27- 19- 10-

US20100146
Antibody producing non-human mammals Merus B. V. Jun- Oct Jun-
647
08 -09 10
26- 26- 10-
US20100144
Oligoribonucleotides and uses thereof COLEY PHARMACEUTICAL GMBH Oct- Oct Jun-
846
06 -07 10

22- 25- 10-
US20100144 RNAi Modulation Of RSV, PIV And Other Respiratory Viruses And
BARIK SAILEN Oct- Jun Jun-
833 Uses Thereof
04 -09 10
CAFFEOYLQUINIC ACID DERIVATIVES CONTAINING NITROGEN, 23- 21- 10-

US20100144 ZHEJIANG MEDICINE CO., LTD. XINCHANG
AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION Mar- Mar Jun-
828 PHARMACEUTICA
AND USAGE THEREOF 07 -08 10
12- 8- 10-
US20100144 NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMIDES AS
AstraZeneca AB Dec- Dec Jun-
759 MODULATORS OF CHEMOKINE RECEPTOR CCR4
05 -09 10
20- 19- 10-

US20100144
COMBINATION 408 AstraZeneca AB Jun- Jun Jun-
606
08 -09 10
23- 7- 10-
US20100144 METHODS OF PREDICTING CANCER LETHALITY USING REPLIKIN
BOGOCH ELENORE S Apr- Aug Jun-
589 COUNTS
08 -09 10
22- 21- 10-
US20100144 CELLS AND METHODOLOGY TO GENERATE NON-SEGMENTED
CHARNEAU PIERRE Dec- Dec Jun-
040 NEGATIVE-STRAND RNA VIRUSES
06 -07 10
5- 4- 10-
KINNEY RICHARD Dec- Dec Jun-
015 GROWTH
08 -09 10
23- 25- 10-
US20100143 ENZYMATIC DIAGNOSTIC TEST FOR SARS AND OTHER VIRAL
MND Diagnostic Ltd. Jun- Nov Jun-
888 DISEASES
03 -09 10
5- 5- 10-
US20100143
Selective detection of human rhinovirus and Human Services Dec- Dec Jun-
881
08 -08 10
27- 27- 10-
US20100143 The Government of the U.S.A. as represented by the
METHOD FOR IDENTIFICATION OF T-LYMPHOCYTE ANTIGENS May- May Jun-
411 Secretary, Dept. of Health and Human Service
08 -09 10
30- 27- 10-
US20100143 METHODS OF ENHANCING PROTEIN INCORPORATION INTO VIRUS
PUSHKO PETER Jun- Jun Jun-
406 LIKE PARTICLES
06 -07 10
16- 15- 10-
US20100143 Recombinant Adenoviruses Based on Serotype 26 and 48, and Use
Beth Israel Deaconess Medical Center, Inc Mar- Mar Jun-
302 Thereof
06 -07 10
NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE 24- 24- 27-

US20100130
SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN SANOFI-AVENTIS Oct- Nov May
503
CHAPERONE HSP 90 06 -09 -10
19- 19- 27-

US20100130 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE
BONNERT ROGER VICTOR Mar- Mar May
491 RECEPTOR (TLR7 ) MODULATORS
07 -08 -10
5- 2- 27-
US20100130
STABILIZED THERAPEUTIC SMALL HELICAL ANTIVIRAL PEPTIDES New York Blood Center, Inc Oct- Oct May
430
06 -07 -10
11- 2- 27-
US20100129 COMPOSITIONS FOR USE IN IDENTIFICATION OF PSEUDOMONAS
Ibis Biosciences, Inc. Sep- Oct May
811 AERUGINOSA
03 -09 -10
23- 21- 27-
US20100129
TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS BBB Holding B.V. Mar- Mar May
437
07 -08 -10
22- 12- 27-
US20100129 ATTENUATED VIRUSES, VACCINES AND METHODS OF USE
THE PENN STATE RESEARCH FOUNDATION Dec- Jan May
400 THEREOF
06 -10 -10
24- 24- 27-
US20100129 Composotions And Methods For The Identification And Treatment Of
CONG YINGZI Jan- Jan May
386 Immune-Mediated Inflammatory Diseases
06 -07 -10
15- 6- 27-
US20100129
DIARYL UREA FOR TREATING VIRUS INFECTIONS BAYER HEALTHCARE LLC Dec- Dec May
321
05 -06 -10
24- 24- 13-
US20100119
RECOMBINANT MULTIVALENT VACCINE GOMI YASUYUKI Nov- Nov May
550
05 -05 -10
9- 8- 6-
US20100113 Means and Methods for Influencing the Stability of Antibody
Meibergdreef 9 Dec- Dec May
745 Producing Cells
05 -06 -10
8- 8- 6-
US20100113
IMMUNOSTIMULATORY COMBINATIONS AND METHODS Not Available Dec- Dec May
565
04 -05 -10
19- 17- 6-
US20100113 QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR
FORD RHONAN Dec- Dec May
510 ANTAGONISTS
06 -07 -10
10- 10- 6-
US20100112 METHODS AND COMPUTER SYSTEMS FOR IDENTIFYING TARGET-
NANOSTRING TECHNOLOGIES, INC. Apr- Apr May
710 SPECIFIC SEQUENCES FOR USE IN NANOREPORTERS
07 -08 -10
4- 4- 6-
US20100112 The Government of the United States of America, as
METHOD FOR DIRECT CAPTURE OF RIBONUCLEIC ACID Nov- Nov May
643 represented by the Secretary of the Navy
08 -08 -10
13- 13- 6-
US20100112 ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORINE MONOXIDE
Oculus Innovative Sciences, Inc. Mar- Mar May
07 -08 -10
20- 20- 6-
US20100111
TREATING CANCER WITH VIRAL NUCLEIC ACID HADAC ELIZABETH M Feb- Feb May
873
07 -08 -10

30- 29-
US20100105 INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN 1-Jul-
MEDIMMUNE, INC. Jun Apr-
873 THERAPEUTICS 05
-06 10
18- 18- 29-
US20100105
NOVEL COMPOUNDS 409 ASTRAZENECA AB Jun- Jun Apr-
642
08 -09 10
12- 12- 29-
US20100105
DEVICES FOR GENERATING DETECTABLE POLYMERS Not Available Oct- Oct Apr-
025
06 -07 10
14- 16- 29-
US20100105
RAPID TEST INCLUDING GENETIC SEQUENCE PROBE Transgenex Nanobiotech, Inc. Jan- Apr Apr-
024
08 -09 10
15- 15- 29-
US20100104
MODULAR NANOPARTICLES FOR ADAPTABLE VACCINES CAPLAN MICHAEL J Feb- Feb Apr-
503
07 -08 10
20- 19- 22-
US20100099
NOVEL ADENINE COMPOUND AstraZeneca Aktiebolag Mar- Mar Apr-
870
07 -08 10
18- 16- 22-

US20100099 ENHANCING DISEASE RESISTANCE AGAINST RNA VIRAL
GUO ZHA Oct- Oct Apr-
745 INFECTIONS WITH INTRACYTOPLASMIC PATHOGEN SENSORS
06 -07 10
23- 22-
US20100099 22-
METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. Dec Apr-
672 Jul-04
-09 10
1- 1- 22-
US20100099
ISOQUINOLINONE DERIVATIVES AstraZeneca AB Oct- Oct Apr-
665
08 -09 10
6- 5- 22-
DNA GENOTEK INC. Oct- Oct Apr-
06 -07 10
26- 24- 22-
US20100099 Non-dividing cell-based assay for high throughput antiviral
SAINZ JR BRUNO Sep- Sep Apr-
079 compound screening
08 -09 10
20- 19- 15-
US20100093
NOVEL ADENINE COMPOUND AstraZeneca Aktiebolag Mar- Mar Apr-
998
07 -08 10
6- 6- 15-
US20100093 POTENTIATION OF CELLULAR IMMUNITY USING HISTONE Sapporo Medical Univeristy and Japan Science and
Dec- Dec Apr-
862 DEACETYLASE (HDAC) INHIBITORS. Technology Agency
06 -07 10
14- 14- 15-
US20100093
SILVER POLYAMIDE COMPOSITE BISHOP KEVIN L Oct- Oct Apr-
851
08 -08 10
7- 6- 15-
US20100093
SALT ARGENTA DISCOVERY LTD. Feb- Feb Apr-
816
07 -08 10
8- 6- 15-
US20100093
Salts 668 ASTRAZENECA AB Feb- Feb Apr-
813
07 -08 10
9- 3- 15-
US20100093
ALBUMIN FUSION PROTEINS Human Genome Sciences. Inc. Feb- Aug Apr-
627
04 -09 10
9- 9- 15-
US20100093 Academisch Medisch Centrum bij de Universiteit van
Means and Methods for Influencing the Stability of Cells Dec- Dec Apr-
038 Amsterdam
05 -05 10
12- 12- 15-
US20100092
PHARMACEUTICAL COMBINATIONS GALLAGHER NEIL JAMES Oct- Oct Apr-
474
06 -07 10
22- 21- 15-
US20100092
ANTIBODIES, ANALOGS AND USES THEREOF ICB International, Inc. Sep- Sep Apr-
470
08 -09 10
12- 15-
US20100092 18-
IMMUNE RESPONSE MODIFIER FORMULATIONS Graceway Pharmaceuticals, LLC Jul- Apr-
401 Jul-06
07 10

US20100092
HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL Oculus Innovative Sciences, Inc. Jan- Dec Apr-
399
WATER SOLUTION 06 -09 10
19- 19- 8-
US20100087 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE
443 RECEPTOR (TLR7) MODULATORS
07 -08 10
3- 3- 8-
US20100087
ODCASE INHIBITORS AS ANTI-VIRALS AND ANTIBIOTICS Not Available Oct- Oct Apr-
388
05 -06 10
5- 5- 8-
US20100086
IP-10 BASED IMMUNOLOGICAL MONITORING Hvidovre Hospital Sep- Sep Apr-
950
06 -07 10
21- 4- 8-
US20100086
COMPOUNDS AstraZeneca AB Feb- Dec Apr-
942
07 -09 10
5- 5- 8-
US20100086 METHODS TO DECREASE THE RISK OF METABOLIC SYNDROME
CLASSEN JOHN BARTHELOW Oct- Oct Apr-
571 POST IMMUNIZATION
06 -07 10
23- 23- 25-
US20100075
Method for rapid identification and quantification of microorganisms The Regents of the University of California Sep- Sep Mar
298
08 -08 -10
12- 18-
US20100070 COMPUTER-IMPLEMENTED BIOLOGICAL SEQUENCE IDENTIFIER The Government of the United States of America, as 2-Jul-
Nov Mar
195 SYSTEM AND METHOD represented by the Secretary of the Navy 04
-09 -10

11- 18-
US20100070 METHODS FOR RAPID IDENTIFICATION AND QUANTITATION OF 21-
ECKER DAVID J Nov Mar
194 NUCLEIC ACID VARIANTS Jul-05
-09 -10
27- 29- 18-
US20100069
Antibody producing non-human mammals Merus B.V. Jun- Jun Mar
614
08 -09 -10
11- 10- 18-
US20100069 Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring
COLEY PHARMACEUTICAL GROUP, INC. Feb- Feb Mar
05 -06 -10
24- 23- 18-
US20100068
Storage of Influenza Vaccines Without Refrigeration SCHEFFCZIK HANNO Mar- Mar Mar
223
06 -07 -10
29- 29- 11-
US20100063
Carbazole-Derived Pharmaceutical Compositions JadoLabs GmbH Jun- Jun Mar
126
04 -05 -10
15- 14- 11-
US20100062
C-MET MUTATIONS AND USES THEREOF SALGIA RAVI Mar- Mar Mar
441
07 -08 -10
8- 8- 11-
US20100061
Immunotherapy To Treat Or Prevent Viral Infection CARRAGHER DAMIAN MICHAEL Sep- Sep Mar
995
08 -08 -10
28- 4- 11-
US20100061
RECOMBINANT SUPER-COMPOUND INTERFERON WEI GUANGWEN Aug- Sep Mar
961
03 -09 -10
20- 19- 4-
US20100056 AMINE DERIVATIVES AND THEIR USE IN BETA-2-
ASTRAZENECA AB Dec- Dec Mar
508 ADRENORECEPTOR MEDIATED DISEASES
06 -07 -10
15- 14- 4-
US20100056
HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS JONES DAVID E Nov- Nov Mar
383
06 -07 -10
METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE 20- 4-

US20100055 20-
ACTIVATION OF PROTOXINS THROUGH COMBINATORAL THE GENERAL HOSPITAL CORPORATION Jul- Mar
761 Jul-06
TARGETING 07 -10
13- 13- 4-
US20100055
Methods and Compositions for Targeting c-Rel CHENG SHUHUA Apr- Apr Mar
116
06 -07 -10
2- 25-
US20100048 30-
PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. Sep Feb
584 Jul-03
-09 -10
NOVEL TETRACYCLIC INHIBITORS OF CYSTEINE PROTEASES, THE 30- 25- 25-

US20100048
PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR COLLAND FREDERIC Oct- Oct Feb
575
22- 20- 25-

US20100048
Albumin Fusion Proteins Human Genome Sciences, Inc. Jan- Apr Feb
472
03 -09 -10
2- 5- 25-
US20100047 METHOD OF ACCELERATED VACCINATION AGAINST EBOLA The Government of the USA as represented by the
Aug- Nov Feb
282 VIRUSES Secretary of Health and Human Services, NIH
04 -09 -10
12- 25-
US20100047 VIROSOMES, METHODS OF PREPARATION, AND IMMUNOGENIC 13-
COMPANS RICHARD W Jul- Feb
277 COMPOSITIONS Jul-06
07 -10
15- 25- 25-
US20100047 Immunogenic Affinity-Conjugated Antigen Systems Based on
FOLIA BIOTECH INC. Nov- Oct Feb
264 Papaya Mosaic Virus and Uses Thereof
06 -07 -10
TARGETED SPLIT BIOMOLECULAR CONJUGATES FOR THE 27- 26- 25-

US20100047
TREATMENT OF DISEASES, MALIGNANCIES AND DISORDERS, AND ST. JUDE CHILDREN'S RESEARCH HOSPITAL Oct- Oct Feb
179
METHODS OF THEIR PRODUCTION 06 -07 -10
2- 2- 18-
US20100042 System and Method to Predict the Global Spread of Infectious
KHAN KAMRAN Apr- Apr Feb
394 Agents Via Commercial Air Travel
07 -08 -10
27- 26- 18-
US20100041
Chemical Compounds 293 ANDREWS GLEN May- May Feb
638
08 -09 -10
27- 27- 18-
US20100041
Modulating mxa expression CHUNG EUN J Sep- Sep Feb
617
04 -05 -10
14- 14- 18-
US20100041
ASSAY FOR A HEALTH STATE HUMAN GENETIC SIGNATURES PTY LTD. Sep- Sep Feb
013
05 -06 -10
13- 12- 18-
US20100040
USE OF NITRIC OXIDE MILLER CHRIS Aug- Aug Feb
703
08 -09 -10
5- 22- 18-
US20100040
POLYCISTRONIC HIV VECTOR CONSTRUCTS Novartis Vaccines and Diagnostics, Inc. May- Oct Feb
676
04 -09 -10
16- 16- 18-
US20100040
Anti-viral Formulations Nanomaterials And Nanoparticles INTRINSIQ MATERIALS LIMITED Feb- Feb Feb
655
06 -07 -10
28- 27- 18-
US20100040
NEUTRALIZING ANTIBODIES TO INFLUENZA VIRUSES Sea Lane Biotechnologies Mar- Mar Feb
635
08 -09 -10
13- 11-
US20100035 DISRUPTION OF PROGRAMMED DEATH 1 (PD-1) LIGAND TO 17-
Nationwide Children's Hospital, Inc. Jul- Feb
973 ADJUVANT ADENO-ASSOCIATED VIRUS VECTOR VACCINES Jul-06
07 -10

10- 10- 11-
US20100035
THERAPY FOR DISORDERS OF THE PROXIMAL DIGESTIVE TRACT BARNES THOMAS MICHAEL Mar- Mar Feb
848
08 -09 -10
1- 11-
US20100035 BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC 3-Jul-
BETHELL RICHARD Jul- Feb
836 AGENTS 08
09 -10
5- 5- 11-
US20100035
High-throughput rna structure analysis GIDDINGS MORGAN C Jun- Jun Feb
761
06 -07 -10
11- 17- 11-
US20100035
Compositions for use in identification of bacteria ISIS Pharmaceuticals, Inc. Sep- Feb Feb
239
03 -05 -10
19- 19- 11-
US20100035
VACCINE ASSAYS Novartis AG May- May Feb
234
08 -09 -10
14- 14- 11-
US20100035 TARGETED WHOLE GENOME AMPLIFICATION METHOD FOR
ECKER DAVID J Sep- Sep Feb
232 IDENTIFICATION OF PATHOGENS
06 -07 -10
3- 2- 11-
US20100035
Compositions for use in identification of alphaviruses ISIS Pharmaceuticals, Inc. Mar- Mar Feb
227
04 -05 -10
25- 24- 11-

US20100034 METHODS AND COMPOSITIONS FOR PREDICTING AND TREATING
NIMAN HENRY L Jan- Jan Feb
852 DRUG RESISTANT STRAINS OF INFLUENZA VIRUS
07 -08 -10
8- 6- 4-
US20100029
Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone ASTRAZENECA AB Feb- Feb Feb
732
07 -08 -10
20- 19- 4-
US20100029
ORGANIC COMPOUNDS DALES NATALIE Dec- Dec Feb
722
06 -07 -10
22- 19- 4-
US20100029
ORGANIC COMPOUNDS Novartis AG Sep- Sep Feb
718
06 -07 -10
QUINICLIDINE DERIVATIVES OF (HETERO) 14- 13- 4-

US20100029
ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ASTRAZENECA AB Nov- Nov Feb
713
ANTAGONISTS 06 -07 -10
1- 31- 4-
US20100029
TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE DIETSCH GREGORY Aug- Jul- Feb
585
08 09 -10
17- 15- 4-
US20100029
ALPHA-LACTALBUMIN COMPOSITION GULDMANN MARIANNE Nov- Nov Feb
557
06 -07 -10
20- 22- 4-
US20100029
Peptide inhibitors of c-jun dimerization and uses thereof Phylogica Limited Aug- Aug Feb
552
04 -05 -10
25- 2- 4-
US20100028
OPTICAL DETERMINATION OF LIVING VS. NON LIVING CELLS Not Available Oct- Nov Feb
853
05 -06 -10
19- 18- 4-
US20100028
FORMULATION FOR DELIVERY OF IMMUNE RESPONSE MODIFIERS 3M INNOVATIVE PROPERTIES COMPANY Jun- Jun Feb
381
06 -07 -10
28- 4-
US20100028 Hazardous substance removing material and method for removing 29-
FUJIFILM Corporation Jul- Feb
369 hazardous substance Jul-08
09 -10
4-HYDROXY-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-7YL 20- 19- 28-

US20100022
COMPOUNDS FOR MODULATION OF B2-ADRENORECEPTOR ASTRAZENECA AB Dec- Dec Jan-
491
ACTIVITY 06 -07 10
30- 30- 28-

US20100021
Compositions, Methods, and Kits for Enhancing Protein Expression LIFESENSORS, INC. Dec- Dec Jan-
987
04 -05 10
12- 28-
US20100021 3-Jul-
METHOD OF DETECTING A PLURALITY OF NUCLEIC ACIDS KABUSHIKI KAISHA TOSHIBA Jun Jan-
907 08
-09 10
12- 28-
US20100021 Vectors for Inducing Homozygous Mutations and Methods of Using 12-
RULEY H EARL Jul- Jan-
895 Same Jul-06
07 10
26- 26- 28-
INSTITUTE FOR RESEARCH IN BIOMEDICINE Feb- Feb Jan-
470 OF B CELLS
03 -04 10
1- 29- 21-
US20100016
Salts of a Selective Beta-2 Andrenoceptor Agonist Not Available Mar- Feb Jan-
388
07 -08 10
METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, 26- 29- 21-

US20100016
AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE Masatoshi Hagiwara Dec- Jun Jan-
359
AGENTS THAT CONTROL SR PROTEIN ACTIVITY 03 -09 10
18- 21-
US20100015 18-
METHODS AND KIT FOR ANALYTE DETECTION GENERAL ELECTRIC COMPANY Jul- Jan-
633 Jul-08
08 10
23- 22- 21-
INSTITUTE FOR SYSTEMS BIOLOGY Dec- Dec Jan-
607 THEREOF
05 -06 10
HUMAN PAPILLOMA VIRUS (HPV) DETECTION USING NUCLEIC ACID 10- 9- 21-
US20100015
PROBES, MICROBEADS AND FLUORESCENT-ACTIVATED CELL GOULD TOBY Dec- Dec Jan-
594
SORTER (FACS) 04 -05 10

26- 26- 21-
US20100015 Method of Preparing Powder Kimchi and Kimchi Composition Using
283 the Same
06 -07 10
1- 1- 21-
US20100015
Combination Approaches For Generating Immune Responses BARNETT SUSAN W Nov- Nov Jan-
211
04 -05 10
9- 6- 21-
US20100015 COILED-COIL LIPOPEPTIDE HELICAL BUNDLES AND SYNTHETIC
UNIVERSITÃƒÂ„T ZÃƒÂ“RICH PROREKTORAT FORSCHUNG Dec- Dec Jan-
173 VIRUS-LIKE PARTICLES
06 -07 10
23- 23- 14-
US20100010 METHODS FOR THE PREPARATION OF IMIDAZOLE-CONTAINING
LAN JIONG Mar- Mar Jan-
217 COMPOUNDS
06 -07 10
11- 11- 14-
US20100010
MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS NOVARTIS AG Sep- Sep Jan-
199
06 -07 10
13- 14-
US20100010 13-
USE OF TYLVALOSIN AS ANTIVIRAL AGENT CAMBRIDGE UNIVERSITY TECHNICAL SERVICES Jul- Jan-
080 Jul-06
07 10
12- 28- 14-
US20100009 COMPOSITIONS AND METHOD FOR RAPID, REAL-TIME DETECTION
Longhorn Vaccines & Diagnostics, LLC Sep- Jul- Jan-
343 OF INFLUENZA A VIRUS (H1N1) SWINE 2009
06 09 10
METHODS AND COMPOSITIONS FOR THE TREATMENT OF 16- 1- 7-

US20100004
MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY GIULLANT CESIDIO Mar- Oct Jan-
304
THYROID AND PANCREATIC CANCER 04 -08 10
10- 10- 7-
US20100003 RNA-DEPENDENT DNA POLYMERASE FROM GEOBACILLUS
LAMPSON BERT C Mar- Mar Jan-
723 STEAROTHERMOPHILUS
04 -04 10
13- 12- 7-
US20100003 VACCINES AND IMMUNOTHERAPEUTICS USING CODON OPTIMIZED
KUTZLER MICHELE Jan- Jan Jan-
277 IL-15 AND METHODS FOR USING THE SAME
06 -07 10
28- 7-
US20100003 METHODS AND USES OF CAULIFLOWER AND COLLARD FOR 11-
THOMAS JEFFERSON UNIVERSITY Jun Jan-
269 RECOMBINANT PROTEIN PRODUCTION Jul-06
-07 10
3- 8- 24-
US20090318
PYRAZOLOPYRIDINES AND ANALOGS THEREOF BONK JASON D Oct- Jun Dec
435
03 -09 -09
22- 22- 24-
US20090318 Compositions and methods for activating innate and allergic
ID Biomedical Corporation of Quebec Oct- Oct Dec
337 immunity
03 -04 -09
18- 18- 24-
US20090317 COMPOSITIONS AND METHODS RELATED TO STAPHYLOCOCCAL
BURTS MONICA Jan- Jan Dec
421 BACTERIUM PROTEINS
06 -07 -09
28- 27- 24-
US20090317 Modified AAV Vectors Having Reduced Capsid Immunogenicity and
The Trustees of the University of Pennsylvania Apr- Apr Dec
417 Use Thereof
06 -07 -09
1- 1- 17-
US20090312 BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEM
Longhorn Vaccines & Diagnostics, LLC Oct- Oct Dec
07 -08 -09
6- 6- 17-
US20090311
COMPOSITIONS FOR THE USE IN IDENTIFICATION OF FUNGI IBIS BIOSCIENCES, INC. Apr- Apr Dec
683
06 -07 -09
13- 27- 17-
US20090311 MUCOSAL IMMUNOGENIC SUBSTANCES COMPRISING A
LI LIE TAO VICTOR Jan- Jun Dec
334 POLYINOSINIC ACID - POLYCYTIDILIC ACID BASED ADJUVANT
06 -06 -09
23- 23- 17-
US20090311
IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS Novartis AG Mar- Mar Dec
288
06 -07 -09
29- 29- 10-
US20090306 ANTIBODY PRODUCED USING OSTRICH AND METHOD FOR
JAPAN SCIENCE AND TECHNOLOGY AGENCY Aug- Aug Dec
347 PRODUCTION THEREOF
05 -06 -09
20- 13- 10-
US20090306 HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA
Xenon Pharmaceuticals Inc. Sep- Aug Dec
04 -09 -09
12- 10- 10-
US20090306
Novel Compounds 010 CAGE PETER ALAN Dec- Dec Dec
042
07 -08 -09
1- 10-
US20090305 NOVEL HUMAN VIRUS CAUSING RESPIRATORY TRACT INFECTION 21-
CHAN KWOK HUNG Jun Dec
282 AND USES THEREOF Jul-04
-09 -09
15- 15- 10-
US20090304
Composition and Methods for Immunisation Using CD1D Ligands GALLI GRAZIA Mar- Mar Dec
743
06 -07 -09
4- 6- 10-
US20090304 INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION
Novartis Vaccines and Diagnostics SRL Nov- Nov Dec
742 ADJUVANT
05 -06 -09
4- 6- 10-
US20090304 INFLUENZA VACCINES INCLUDING COMBINATIONS OF
NOVARTIS VACCINES AND DIAGNOSTICS SRL Nov- Nov Dec
739 PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS
05 -06 -09
1- 1- 10-
US20090304 CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL
NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KG Nov- Nov Dec
729 CELL DNA
05 -06 -09
19- 19- 10-
US20090304
Soluble Fragments of The Sars-Cov Spike Glycoprotein DIMITROV DIMITER S Jan- Jan Dec
683
07 -07 -09
27- 10-
US20090304 Methods for the treatment and prevention of infection using anti- 29-
681 selectin agents Jul-04
05 -09

16- 2- 10-
US20090304
Treating severe and acute viral infections HEMISPHERx BIOPHARMA May- Aug Dec
630
03 -07 -09
8- 8- 3-
US20090300
Neutral Sphingomyelinase-E and Its Use HOPPE UTA Feb- Feb Dec
778
06 -07 -09
19- 3-
US20090299 ANTIVIRAL FILTER AND ITS USE IN AN AIR PURIFIER, AIR 19-
Universite De Rouen Jul- Dec
250 CONDITIONER OR AIR HUMIDIFIER Jul-06
07 -09
RNA Interference Mediated Inhibition of Severe Acute Respiratory 15- 17- 3-

US20090298
Syndrome (SARS) Virus Gene Expression Using Short Interfering Sirna Therapeutics, Inc. Apr- Nov Dec
914
Nucleic Acid (siNA) 03 -08 -09
15- 14- 3-
US20090298 HYDROXY AND ALKOXY SUBSTITUTED IH-
Pfizer Inc. Mar- Mar Dec
821 IMIDAZONAPHTHYRIDINES AND METHODS
06 -07 -09
6- 4- 3-
US20090298
Compounds ALCARAZ LILIAN Feb- Feb Dec
807
08 -09 -09
25- 30- 3-
US20090297 RECOMBINANT HUMAN CYTOMEGALOVIRUS AND VACCINES
MEDIMMUNE, LLC Jun- Jun Dec
555 COMPRISING HETEROLOGOUS ANTIGENS
04 -09 -09
4- 3- 19-
US20090286
NOVEL COMPOUNDS AstraZeneca AB Oct- Oct Nov
835
07 -08 -09
13- 12- 19-
US20090286
Thioxanthine Derivatives and Their Use as Inhibitors of MPO ASTRAZENECA AB Apr- Apr Nov
813
06 -07 -09
10- 28- 19-
US20090286 USE OF THE LONG PENTRAXIN PTX3 FOR THE PREVENTION OR
TECNOGEN S.P.A. Mar- Feb Nov
726 TREATMENT OF VIRAL DISEASES
06 -07 -09
24- 16- 19-
US20090286 Mixed Cell Diagnostic Systems For Detection Of Respiratory, Herpes
GOODRUM PATRICIA GAIL RAY Apr- Oct Nov
222 And Enteric Viruses
98 -08 -09
16- 1- 19-
US20090285
PLANT EXTRACT AND ITS THERAPEUTIC USE Veritron Limited May- Dec Nov
921
08 -08 -09
20- 27- 19-
US20090285
Polyamino acid for use as adjuvant AKASHI MITSURU Apr- Jul- Nov
901
05 09 -09
20- 19-
US20090285 20-
FROZEN STOCKPILING OF INFLUENZA VACCINES Novartis AG Jul- Nov
854 Jul-06
07 -09
8- 10- 12-
US20090281 COMPOSITIONS AND METHODS USING SAME FOR THE DETECTION
ARAD DORIT Sep- Sep Nov
042 OF VIRUSES
05 -06 -09
6- 5- 12-
US20090281
ANTIVIRAL CELL-PENETRATING PEPTIDES CURRELI FRANCESCA May- May Nov
041
08 -09 -09
METHOD FOR MEASUREMENT OF SARS VIRUS NUCLEOCAPSID

PROTEIN, REAGENT KIT FOR THE MEASUREMENT, TEST DEVICE, 11- 11- 12-
US20090280
MONOCLONAL ANTIBODY DIRECTED AGAINST SARS VIRUS SYSMEX CORPORATION Oct- Oct Nov
507
NUCLEOCAPSID PROTEIN, AND HYBRIDOMA CAPABLE OF 05 -06 -09
PRODUCING THE MONOCLONAL ANTIBODY
CONDENSATION PRODUCTS, METHOD FOR THEIR PRODUCTION 17- 28- 5-

US20090275
AND USE THEREOF IN MEDICAMENTS, AS DISINFECTANTS OR AS A BASF SE May- Feb Nov
666
TANNIN 06 -07 -09
13- 13- 5-
US20090275
ANTIVIRAL COMPOUNDS AND USE THEREOF Myriad Genetics, Incorporated Oct- Apr Nov
583
06 -09 -09
USE OF THYMOSIN ALPHA 1, ALONE OR IN COMBINATION WITH 2- 12- 5-

US20090275
PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. May- Apr Nov
508
CYTOMEGALOVIRUS INFECTION 06 -07 -09
2- 1- 5-
UNIVERSITY OF ROCHESTER May- May Nov
016 IMMUNE RESPONSE
08 -09 -09
2- 2- 29-
US20090270
1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS Not Available Sep- Sep Oct-
443
04 -05 09
19- 19- 29-
US20090270 Cyclopentenol Nucleoside Compounds Intermediates for their
THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION Oct- Oct Oct-
431 Synthesis and Methods of Treating Viral Infections
05 -06 09
23- 23- 29-
US20090269 METHODS AND COMPOUNDS FOR MITIGATING PATHOGENIC
BOGOCH ELENORE S Apr- Apr Oct-
367 OUTBREAKS USING REPLIKIN COUNT CYCLES
08 -09 09
16- 18- 22-
US20090264
USEFUL INDOLE COMPOUNDS BARDEN TIMOTHY Dec- Dec Oct-
653
05 -06 09
10- 8- 22-
US20090264
Adenoviral vector-based foot-and-mouth disease vaccine GENVEC, INC. Nov- May Oct-
509
05 -08 09
20- 20- 22-
US20090264
Organic compounds CHOWDHURY SULTAN Feb- Feb Oct-
444
08 -09 09

4- 17- 22-
US20090264
Influenza virus inhibiting peptides The Administrators of the Tulane Educational Fund Nov- Feb Oct-
362
03 -09 09
13- 12- 22-
US20090264 ARRAY-BASED POLYMORPHISM MAPPING AT SINGLE NUCLEOTIDE
The Trustees of Princeton University Jan- Jan Oct-
307 RESOLUTION
06 -07 09
1- 1- 22-
Nuevolution A/S Dec- Dec Oct-
300 LARGE LIBRARIES
05 -06 09
2- 21- 22-
ZymoGenetics, LLC Apr- May Oct-
04 -09 09
10- 3- 15-
US20090258 SURFACE FOR LABEL INDEPENDENT DETECTION AND METHOD
BUNCH THOMAS A Apr- Apr Oct-
440 THEREOF
08 -09 09
12- 3- 15-
US20090258 Assay for SARS coronavirus by amplification and detection of the
Becton, Dickinson and Company Sep- Feb Oct-
340 replicase sequence
03 -09 09
17- 28- 15-
US20090258 MIXTURES OF TANNINS, THEIR PRODUCTION AND USE IN
BASF SE May- Feb Oct-
074 MEDICAMENTS OR AS DISINFECTANTS
06 -07 09
21- 6- 15-
US20090258 Antibodies against west nile virus and therapeutic and prophylactic
Washington University Jun- Apr Oct-
011 uses thereof
04 -09 09
20- 10- 15-
US20090257 THE BOARD OF TRUSTEES OF THE UNIVERSITY OF
Membrane Scaffold Proteins Nov- Oct Oct-
950 ILLINOIS
00 -07 09
20- 18- 8-
US20090253
Methods of reducing risk of infection from pathogens Not Available Aug- Aug Oct-
714
03 -04 09
23- 22- 8-
US20090253
Hydroxyalkyl Substituted Imidazonaphthyridines Coley Pharmaceutical Group, Inc, Feb- Feb Oct-
695
05 -06 09
28- 28- 8-
US20090252
VIRUCIDAL DISINFECTANT B. BRAUN MEDICAL AG Jan- May Oct-
775
05 -09 09
8- 28- 8-
US20090252
STERILIZATION METHODS AND SYSTEMS FOR GAMING EQUIPMENT Invention Factory, LLC Jan- May Oct-
646
07 -09 09
4- 4- 1-
US20090247
Folate Conjugates ALNYLAM PHARMACEUTICALS, INC. Dec- Dec Oct-
614
07 -08 09
4- 4- 1-
US20090247
Targeting Lipids ALNYLAM PHARMACEUTICALS, INC. Dec- Dec Oct-
608
07 -08 09
20- 20- 24-
FOREST LABORATORIES HOLDINGS LIMITED Mar- Mar Sep
848 CoA DESATURASE
08 -09 -09
1- 2- 24-
US20090239 Treatment of viral infections by modulation of host cell metabolic
BENNETT BRYSON Jun- Jun Sep
830 pathways
07 -08 -09
16- 13- 24-
US20090239 HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS
Anacor Pharmaceuticals, Inc. Jun- Nov Sep
03 -08 -09
4- 4- 24-
US20090239
Carbohydrate Conjugates as Delivery Agents for Oligonucleotides ALNYLAM PHARMACEUTICALS, INC. Dec- Dec Sep
814
07 -08 -09
20- 20- 24-
Forest Laboratories Holdings Limited Mar- Mar Sep
810 CoA DESATURASE
08 -09 -09
28- 28- 24-
US20090235
FILTER AND ASSOCIATED METHOD GENERAL ELECTRIC COMPANY Sep- Sep Sep
625
07 -07 -09
Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor 24- 23- 17-
US20090233
Antagonist Activity, Useful For Treating E.G. Chronic Bronchial ASTRAZENECA AB Apr- Apr Sep
965
Obstruction, Asthma And Overactive Bladder 06 -07 -09
22- 20- 17-

US20090233
Pyridopyrimidine Derivatives and Their Use as PDE4 Inhibitors ASTRAZENECA AB Mar- Mar Sep
907
06 -07 -09
1- 20- 17-
US20090233 BIOLOGICAL SPECIMEN COLLECTION/TRANSPORT COMPOSITIONS
LONGHORN VACCINES & DIAGNOSTICS, LLC Oct- Apr Sep
309 AND METHODS
07 -09 -09
23- 23- 17-
US20090232
IMMUNOPOTENTIATING COMPOUNDS SUTTON JAMES Mar- Mar Sep
844
06 -07 -09
4- 17-
US20090232 8-Jul-
Identifying and predicting influenza variants and uses thereof NIMAN HENRY L Jan Sep
843 05
-08 -09
28- 27- 17-
US20090232
MOLECULES AND CHIMERIC MOLECULES THEREOF APOLLO LIFE SCIENCES LIMITED Jan- Jan Sep
808
05 -06 -09
7- 18- 17-
US20090232
Virucidal activities of cetylpyridinium chloride ViraTox, L.L.C. Nov- Mar Sep
748
03 -09 -09
15- 6- 10-
US20090227
DIARYL UREAS FOR TREATING VIRUS INFECTIONS RIEDL BERND Dec- Dec Sep
637
05 -06 -09

20- 19- 10-
US20090227
BORON-CONTAINING SMALL MOLECULES Anacor Pharmaceuticals, Inc. Jun- Jun Sep
541
07 -08 -09
17- 31- 10-
US20090227 Adeno-associated virus (AAV) serotype 8 sequences, vectors
The Trustees of the University of Pennsylvania Dec- Oct Sep
030 containing same, and uses therefor
01 -07 -09
27- 28- 10-
US20090227 Searete LLC, a limited liability corporation of the State of
Methods for pathogen detection Mar- Sep Sep
005 Delaware
07 -07 -09
10- 8- 10-
US20090226 Nucleic Acid Sequences That Can Be Used As Primers And Probes In
OVERDIJK MARLIEKE Jun- Mar Sep
885 The Amplification And Detection Of Sars Coronavirus
03 -04 -09
8- 6- 3-
US20090222
Recombinant Expression of Multiprotein Complexes Using Polygenes BERGER IMRE Nov- Nov Sep
936
05 -06 -09
29- 28- 3-
US20090221 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-
AstraZeneca AB Aug- Aug Sep
653 derivatives as beta2 adrenoreceptor agonists
05 -06 -09
16- 15- 3-
US20090221
Novel Crystal Modifications ASTRAZENECA AB Mar- Mar Sep
640
06 -07 -09
3- 15- 3-
US20090221
IMIDAZOPYRIDINONES Not Available Aug- May Sep
631
07 -09 -09
6- 4- 3-
US20090221 4-AMINOQUINOLINE COMPOUNDS FOR TREATING VIRUS-RELATED
BUSCHER BENJAMIN A May- May Sep
624 CONDITIONS
05 -06 -09
21- 23- 3-
AURIGENE DISCOVERY TECHNOLOGIES LIMITED Jun- Jun Sep
583 CoA DESATURASE
07 -08 -09
4- 3- 3-
US20090221 HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES
Pfizer Inc. Nov- Nov Sep
556 AND METHODS
05 -06 -09
15- 14- 3-
US20090221 SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND
Pfizer Inc. Mar- Mar Sep
551 METHODS
06 -07 -09
10- 11- 3-
US20090221 Institute of Pharmacology and Toxicology Academy of
POLYETHLENE GLYCOL MODIFICATIONS OF THYMOSIN ALPHA-1 Nov- Nov Sep
487 Military Medical Sciences P.L.A. China
05 -06 -09
25- 25- 3-
US20090220 COMPOSITIONS FOR- DETECTING OF INFLUENZA VIRUSES AND
MND DIAGNOSTIC LTD Oct- Oct Sep
941 KITS AND METHODS USING SAME
05 -06 -09
3- 3- 3-
US20090220
Compositions for Use in Identification of Adventitious Viruses IBIS BIOSCIENCES, INC. Mar- Mar Sep
937
05 -06 -09
2- 2- 3-
US20090220 Reducing interference between oil-containing adjuvants and
NOVARTIS VACCINES AND DIAGNOSTICS SRL Aug- Aug Sep
547 surfactant-containing antigens
05 -06 -09
22- 20- 3-
US20090220
Adjuvanted influenza vaccines for pediatric use GROTH NICOLA Feb- Feb Sep
546
08 -09 -09
15- 15- 3-
US20090220
Adjuvant-Sparing Multi-Dose Influenza Vaccination Regimen NOVARTIS AG Jun- Jun Sep
545
06 -07 -09
4- 6- 3-
US20090220 ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED
NOVARTIS VACCINES AND DIAGNOSTICS SRL Nov- Nov Sep
544 FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE
05 -06 -09
4- 6- 3-
US20090220 EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT FOR
NOVARTIS VACCINES AND DIAGNOSTICS SRL Nov- Nov Sep
541 ADJUVANTING SPLIT INFLUENZA VACCINES
05 -06 -09
27- 3-
HU HONG-MING Jul- Sep
06 -09
13- 16- 3-
US20090220
ADAM10 and its Uses Related to Infection HODGE THOMAS Jan- Jan Sep
514
06 -07 -09
28- 11- 3-
US20090220
USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE Not Available Aug- Feb Sep
456
03 -09 -09
25- 19- 27-

Georgetown University Feb- Nov Aug
860 AND COMMUNICATING EVENT RELATED INFORMATION
08 -08 -09
25- 28- 27-

US20090216 System and method for detecting, collecting, analyzing, and
Georgetown University- OTC Feb- Aug Aug
747 communicating event-related information
08 -08 -09
5- 26- 27-
US20090215 NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC
BOISSY GUILLAUME Aug- Jul- Aug
786 APPLICATIONS
05 06 -09
26- 26- 27-
US20090214
Virus coated nanoparticles and uses thereof ALBRECHT THOMAS B Sep- Mar Aug
663
06 -09 -09
10- 27-
US20090214 Virus Vaccines Comprising Envelope-Bound Immunomodulatory 8-Jul-
Wayne State University Jul- Aug
590 Proteins and Methods of Use Thereof 05
06 -09

8- 11- 27-
US20090214
Recombinant virus and use thereof Post Genome Institute Co., Ltd. Oct- Oct Aug
587
04 -05 -09
13- 12- 27-
US20090214
Serum Resistance Factors of Gram Positive Bacteria NOVARTIS VACCINES AND DIAGNOSTICS, INC. May- May Aug
537
05 -06 -09
17- 17- 27-
US20090214 THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
METHODS FOR CONVERTING OR INDUCING PROTECTIVE IMMUNITY Aug- Feb Aug
533 NEW YORK
06 -09 -09
21- 21- 27-
US20090214 Government of the US as represented by the Secretary,
Broad Spectrum Antiviral Compositions Feb- Feb Aug
510 Department of Health and Human Services
06 -07 -09
26- 26- 27-
US20090214
POLY AROMATIC SODIUM CHANNEL BLOCKERS PARION SCIENCES, Inc. Feb- Feb Aug
444
08 -09 -09
20- 15- 20-
US20090209
Prevention of and countermeasures against viral infection CHOKO CO., LTD. Nov- Apr Aug
640
03 -09 -09
2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR 8- 7- 20-

US20090209
CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE HANSEN PETER May- May Aug
555
ACTIVITY IS BENEFICIAL 06 -07 -09
22- 20- 20-

US20090209
Novel Compounds AstraZeneca AB Nov- Nov Aug
524
07 -08 -09
20- 7- 20-
US20090209
PRODRUGS OF HETEROARYL COMPOUNDS Koronis Pharmaceuticals, Incorporated Jun- Apr Aug
505
03 -09 -09
4- 4- 20-
US20090209 Cell-penetrating socs polypeptides that inhibit cytokine-induced
VANDERBILT UNIVERSITY Mar- Mar Aug
458 signaling
04 -05 -09
16- 16- 20-
US20090208
ANTIVIRAL AGENTS AND VACCINES AGAINST INFLUENZA National Institutes of Health Office of Technology Feb- Feb Aug
531
06 -07 -09
30- 5- 20-
US20090205
ARTICLE, LAMINATE AND ASSOCIATED METHODS GENERAL ELECTRIC COMPANY Sep- Dec Aug
116
05 -08 -09
29- 28- 13-

US20090203 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-
AstraZeneca AB Aug- Aug Aug
753 derivatives as beta2 adrenoreceptor agonists
05 -06 -09
Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical 6- 6- 13-

US20090203
Compositions Thereof, and Methods for Treating Hemorrhagic Fever SIGA TECHNOLOGIES, INC. Dec- Dec Aug
675
Viruses, Including Infections Associated with Arena Viruses 04 -05 -09
4- 3- 13-
US20090203
VERO CELL LINE WHICH IS ADAPTED TO GROW IN SUSPENSION Ricardo Kratje Oct- Oct Aug
112
05 -06 -09
26- 28- 13-
US20090202
MOLECULAR CARDIOTOXICOLOGY MODELING JOHNSON KORY R Aug- Aug Aug
995
05 -06 -09
4- 6- 13-
US20090202 INFLUENZA VACCINES EXTEMPORANEOUSLY ADSORBED TO
NOVARTIS VACCINES AND DIGNOSTICS SRL Nov- Nov Aug
590 ALUMINIUM ADJUVANTS
05 -06 -09
Piperidine Derivatives, Their Process for Preparation, Their Use as 7- 6- 6-

US20090197
Therapeutic Agents and Pharmaceutical Compositions Containing CAGE PETER Mar- Mar Aug
914
Them 06 -07 -09
21- 14- 6-
US20090197 NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC
XENON PHARMACEUTICALS INC. Dec- Apr Aug
894 AGENTS
01 -09 -09
20- 6-
US20090197 PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC 30-
XENON PHARMACEUTICALS INC. Feb Aug
890 AGENTS Jul-03
-09 -09
7- 7- 6-
US20090197
Method of Increasing the Function of an AAV Vector The Trustees of teh University of Pennsylvania Apr- Apr Aug
338
05 -06 -09
6- 6- 6-
US20090196 Compositions Methods and Kits For Enhancing Immune Response To
The Procter & Gamble Company Feb- Feb Aug
921 A Respiratory Condition
08 -09 -09
5- 5- 30-
US20090192
Method for cryospray ablation Reset Medical, Inc. Dec- Dec Jul-
505
07 -08 09
6- 5- 30-
US20090192
Novel Compounds ASTRAZENECA AB Oct- Oct Jul-
163
05 -06 09
22- 21- 30-
US20090192
NOVEL ADENINE COMPOUND AstraZeneca Aktiebolag A corporation of Sweden Sep- Sep Jul-
153
05 -06 09
20- 30- 30-
US20090192
PRODRUGS OF HETEROARYL COMPOUNDS Koronis Pharmaceuticals, Incorporated Jun- Mar Jul-
099
03 -09 09
25- 31- 30-

US20090192 PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING,
TAKEDA PHARMACEUTICAL COMPANY LIMITED Jun- Dec Jul-
090 ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY
03 -08 09
1- 31- 30-
US20090192
Casein derived peptides and uses thereof SIDELMAN ZVI Mar- Oct Jul-
081
00 -07 09

15- 23- 30-
US20090191 ADJUVANCY AND IMMUNE POTENTIATING PROPERTIES OF
NEW YORK BLOOD CENTER Jun- Mar Jul-
229 NATURAL PRODUCTS OF ONCHOCERCA VOLVULUS
04 -09 09
8- 19- 23-
US20090186
COMPOSITIONS AND METHODS FOR PREVENTING INFECTION LA JOLLA BIOSCIENCES LLC Aug- Mar Jul-
056
02 -09 09
15- 18- 23-
US20090186 ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF
Functional Genetics, Inc. Nov- Apr Jul-
06 -08 09
22- 22- 23-

US20090186 Fusion Protein Comprising an Fc Receptor Binding Polypeptide and
ImmunoBiology Limited Mar- Mar Jul-
025 an Antigenic Polypeptide for Mediating an Immune Response
06 -07 09
10- 9- 23-
US20090186
METHOD FOR TREATMENT OF PANCREATITIS Ore Pharmaceuticals Inc. Oct- Oct Jul-
014
07 -08 09
29- 15- 16-
US20090182 BENZOPYRANONE DERIVATIVES AND THEIR USE AS ANTI-VIRAL Shanghai Institute of Materia Medica Chinese Academy of
Dec- Dec Jul-
133 AGENTS Sciences
05 -06 09
8- 5- 16-
US20090181 Novel Inhibitors of Cysteine Proteases, the Pharmaceutical
BOISSY GUILLAUNE Dec- Dec Jul-
972 Compositions Thereof and their Therapeutic Applications
05 -06 09
14- 14- 16-
US20090181
Rapid test for detecting infection KUMAR ARUN Jan- Jan Jul-
361
08 -08 09
Amide and Carbamate Derivatives of Alkyl Substituted N-[4-(4- 9- 8- 9-

US20090176
Amino-1H-Imidazo[4,5-C] Quinolin-1- COLEY PHARMACEUTICAL GROUP, INC. Sep- Sep Jul-
821
YL)Butyl]Methanesulfonamides and Methods 05 -06 09
16- 9-
US20090176 Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and 19-
ERIKSSON TOMAS Jan Jul-
815 Their Uses as Modulators of Chemokine Receptor Activity Jul-06
-09 09
6- 9-
US20090176 Inhibitors Based on Fusion, Hr1 and Hr2 Sequences in Bacterial 6-Jul-
CHIRON SRL Jul- Jul-
699 Adhesin 04
05 09
30- 26- 9-
US20090175 AEROSOL METHOD FOR NANO SILVER-SILICA COMPOSITE ANTI-
BRINKER C JEFFREY Nov- Nov Jul-
948 MICROBIAL AGENT
07 -08 09
13- 27- 9-
US20090175 Immunogenic Substances Comprising A Polyinosinic Acid-
Not Available Jan- Jun Jul-
902 Polycytidilic Acid Based Adjuvant
06 -06 09
10- 2-
US20090170 The Government of the United States of America, as 2-Jul-
RE-SEQUENCING PATHOGEN MICROARRAY Apr Jul-
717 represented by the Secretary of the Air Force 04
-08 09
24- 24- 2-
US20090169 Microparticles containing biodegradable polymer and cationic
Not Available Feb- Feb Jul-
636 polysaccharide for use in immunogenic compositions
06 -07 09
1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of 1- 31- 25-

US20090163
Cytokine Biosynthesis for the Treatment of Viral Infections and COLEY PHARMACEUTICAL GROUP, INC. Apr- Mar Jun-
533
Neoplastic Diseases 05 -06 09
27- 4- 25-
US20090163
Novel Compounds BONNERT ROGER May- Mar Jun-
518
03 -09 09
24- 24- 25-
US20090162
HUMAN PARVOVIRUS DELWART ERIC L May- May Jun-
831
04 -05 09
21- 19- 25-
US20090162
MUTANT FORMS OF STREPTOLYSIN O NOVARTIS AG Dec- Dec Jun-
392
07 -08 09
25- 25- 25-
US20090162
Novel siRNAS and methods of use thereof FEINSTEIN ELENA Oct- Oct Jun-
365
06 -07 09
US20090162
LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA DNAVEC Corporation Oct- Oct Jun-
320
28- 28- 18-

US20090155
ARTICLE AND ASSOCIATED METHOD GENERAL ELECTRIC COMPANY Sep- Sep Jun-
564
07 -07 09
13- 12- 11-
US20090149
Thioxanthine Derivatives and Their Use as Inhibitors of MPO ASTRAZENECA AB Apr- Apr Jun-
475
06 -07 09
23- 22- 11-
US20090149 Phenoxyacetic Acid Derivatives Useful for Treating Respiratory
ASTRAZENECA AB Nov- Nov Jun-
448 Diseases
04 -05 09
22- 22- 11-
US20090149
ANTIVIRAL COMPOUNDS Myriad Genetics, Incorporated Jun- Jun Jun-
429
05 -06 09
2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR 8- 7- 21-

US20090131
CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE HANSEN PETER May- May May
486
ACTIVITY IS BENEFICIAL 06 -07 -09
5- 4- 21-
US20090131
2-Thioxanthine Derivatives Acting as MPO-Inhibitors ASTRAZENECA AB Jun- Jun May
459
06 -07 -09

22- 21-
US20090131 23-
FURIN INHIBITORS SMITH JUDITH Jul- May
328 Jul-04
05 -09
8- 7- 21-
US20090130
COMBINATION VACCINE CHIRON BEHRING GMBH & CO. KG Oct- Oct May
146
04 -05 -09
6- 24- 21-
US20090130
Antiviral and antibacterial activity from medicinal mushrooms STAMETS PAUL EDWARD Jan- Sep May
138
04 -08 -09
5- 5- 21-
US20090126
Devices for collection and preparation of biological agents BELGRADER PHIL Sep- Sep May
514
07 -07 -09
HAZARDOUS SUBSTANCE REMOVING METHOD, HAZARDOUS

28- 21- 14-
US20090124 SUBSTANCE REMOVING MATERIAL USED THEREIN SUCH AS AIR
843 FILTER, MASK, WIPE SHEET, AND THE LIKE, AND STORAGE
03 -08 -09
METHOD THEREOF
30- 28- 14-

US20090124 Polymorphs of 1-(2-Methylpropyl)-1H-Imidazo[4,5-
Takeda Pharmaceutical Company Limited Dec- Dec May
652 C][1,5]Naphthyridin-4-Amine Ethane-Sulfonate
04 -05 -09
5- 4- 14-
US20090124 Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase
ASTRAZENECA AB Jun- Jun May
640 Inhibitor
06 -07 -09
1- 31- 14-
US20090124
Pyrazolopyridine-1,4-Diamines and Analogs Thereof Coley Pharmaceutical Group, Inc. Apr- Mar May
611
05 -06 -09
11- 10- 14-
US20090124
Chemical Compounds 637 BONNERT ROGER VICTOR Jan- Jan May
596
07 -08 -09
18- 18- 14-
US20090124 DNA ARRAY ANALYSIS AS A DIAGNOSTIC FOR CURRENT AND
REGENTS OF THE UNIVERSITY OF COLORADO Jan- Jan May
512 EMERGING STRAINS OF INFLUENZA
06 -07 -09
31- 14-
US20090123 31-
MOMLV-BASED PSEUDOVIRION PACKAGING CELL LINE FLICK RAMON Jul- May
494 Jul-07
08 -09
30- 17- 14-
US20090123
IMMUNOSTIMULATORY COMBINATIONS 3M Innovative Properties Company Dec- Mar May
460
02 -08 -09
28- 6- 14-
WEI GUANGWEN Feb- Oct May
417 THEREOF
01 -08 -09
20- 20- 7-
US20090118
FAAH INHIBITORS Not Available Jun- Jun May
503
07 -08 -09
19- 7-
US20090118 N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine 21-
ASTRAZENECA AB Jul- May
288 Receptor Jul-05
06 -09
22- 20- 7-
US20090118
Novel Adenine Compound ASTRAZENECA AKTIEBOLAG Sep- Sep May
263
05 -06 -09
27- 10- 7-
US20090117
METHOD FOR DETECTING SARS CORONAVIRUS EIKEN KAGAKU KABUSHIKI KAISHA Jun- Jun May
537
03 -08 -09
28- 28- 7-
US20090117
ARTICLE AND ASSOCIATED METHOD GENERAL ELECTRIC COMPANY Sep- Sep May
367
07 -07 -09
2- 23- 7-
US20090117
IMMUNOPEPTIDES OF HPV E6 AND E7 PROTEINS National Health Research Institutes Nov- Sep May
123
07 -08 -09
9- 9- 7-
US20090117 Binary epitope antibodies and B cell superantigen immune
NISHIYAMA YASUHIRO Nov- Nov May
115 stimulants
06 -07 -09
8- 11- 7-
US20090117 Immunogenic And Therapeutic Compositions For Streptococcus
Chiron Corporation Oct- Oct May
113 Pyogenes
04 -05 -09
23- 22- 30-
US20090111
L-ALANINE DERIVATIVES ASTRAZENECA AB Nov- Nov Apr-
828
05 -06 09
31- 31- 30-
US20090111 SPECIMEN PRETREATMENT LIQUID, KIT FOR MEASURING VIRUS,
SYSMEX CORPORATION Oct- Oct Apr-
091 AND METHOD FOR DETECTING VIRUS
07 -08 09
14- 12- 23-
US20090105
HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES Coley Pharmaceutical Group, Inc. Nov- Nov Apr-
295
03 -04 09
22- 22- 23-
US20090105
NOVEL ADENINE COMPOUND AstraZeneca Aktiebolag a corporation of Sweden Sep- Sep Apr-
212
05 -06 09
16- 16- 23-
US20090105
COMPOUNDS FOR TREATING VIRAL INFECTIONS Myriad Genetics, Incorporated Oct- Oct Apr-
203
06 -07 09
14- 23-
US20090105 AMPHIPATHIC ALPHA-HELICAL PEPTIDE COMPOSITIONS AS 19-
CHEONG KWANG HO Jul- Apr-
151 ANTIVIRAL AGENTS Jul-07
08 09
28- 27- 23-
US20090105 THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
VIRAL DATABASE METHODS Nov- Nov Apr-
092 NEW YORK
06 -07 09
21- 20- 23-
US20090104
Alphavirus Vectors for Respiratory Pathogen Vaccines NOVARTIS VACCINES AND DIAGNOSTICS INC. May- May Apr-
226
04 -05 09

21- 19- 23-
US20090104 METHODS OF REDUCING A VIRAL INFECTION AND KITS
LABONTE PATRICK Sep- Sep Apr-
209 THEREFORE
07 -08 09
11- 11- 23-
US20090104
Sialoadhesin-Related Compositions and Methods DELPUTTE PETER May- May Apr-
147
06 -07 09
22- 22- 16-
US20090099
NOVEL ADENINE COMPOUND AstraZeneca Aktiebolag A corporation of Sweden Sep- Sep Apr-
216
05 -06 09
11- 10- 16-
US20090099
Substituted Imidazoquinolines and Imidazonaphthyridines Coley Pharmaceutial Group, Inc. Feb- Feb Apr-
161
05 -06 09
24- 19- 16-
US20090099
Heterocyclic Compounds as Ccr2b antagonists BOWER JUSTIN FAIRFIELD Dec- Dec Apr-
156
04 -05 09
13- 28- 16-
US20090099
Antiviral oligonucleotides JUTEAU JEAN-MARC Sep- Feb Apr-
110
02 -08 09
21- 16-
US20090099 Construction of pool of interfering nucleic acids covering entire RNA 23-
ZHU YORK YUAN YUAN Nov Apr-
043 target sequence and related compositions Jul-07
-08 09
21- 16-
US20090098 22-
Cell Line For Producing Coronaviruses CRUCELL HOLLAND B.V. Jul- Apr-
530 Jul-05
06 09
24- 16-
US20090098 24-
Technology for the Preparation of Microparticles NexBio, Inc. Jul- Apr-
207 Jul-07
08 09
27- 10- 9-
US20090092
METHOD FOR DETECTING SARS CORONAVIRUS EIKEN KAGAKU KABUSHIKI KAISHA Jun- Jun Apr-
962
03 -08 09
20- 19- 9-
US20090092
Polyamino acid for use as adjuvant AKASHI MITSURU Apr- Apr Apr-
633
05 -06 09
11- 11- 9-
US20090092
Interferons of rhesus and cynomolgus origin and uses thereof CLARK WILLIAM A Apr- Apr Apr-
581
07 -08 09
11- 11- 26-
US20090083
Transgenic Mouse Lines Expressing Human Ace2 and Uses Thereof CHAN TEH-SHENG Jan- Jan Mar
865
06 -07 -09
29- 5- 26-
US20090082 COMPOSITIONS FOR ENHANCING TRANSPORT OF MOLECULES INTO
IVERSEN PATRICK L Apr- Nov Mar
547 CELLS
03 -08 -09
22- 20- 26-
US20090082 PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC
ABBOT PHILIP Sep- Sep Mar
332 DISEASES AND CANCERS
05 -06 -09
METHODS OF ENHANCING MUCOSAL HYDRATION AND MUCOSAL 7- 7- 26-

US20090082
CLEARANCE BY TREATMENT WITH SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. Sep- Sep Mar
287
AND OSMOLYTES 06 -07 -09
24- 21- 26-

US20090081 METHODS, COMPOUNDS AND SYSTEMS FOR DETECTING A
COLSTON JR BILL W Aug- Aug Mar
675 MICROORGANISM IN A SAMPLE
07 -08 -09
9- 9- 26-
CHIRON BEHRING GMBH & CO. Sep- Sep Mar
04 -05 -09
9- 9- 26-
US20090081
Immunostimulatory Combinations for Vaccine Adjuvants Not Available Jan- Jan Mar
157
06 -07 -09

US20090078
removing material used therein such as air filter, mask, wipe sheet, ARAJ JUN-ICHIRO Mar- Nov Mar
263
and the like, and storage method thereof 03 -08 -09
13- 13- 19-

US20090076 INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE
Baylor University Jun- Jun Mar
076 THEREOF
07 -08 -09
3- 31- 19-
US20090075
Pyrazolopyridines and Analogs Thereof Coley Pharmaceutical Group, Inc. Oct- Mar Mar
980
03 -06 -09
28- 27- 19-
US20090074
Modified Adenovirus Hexon Protein and Uses Thereof The Trustees of the University of Pennsylvania Apr- Apr Mar
810
06 -07 -09
23- 22- 12-
US20090069
Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods Coley Pharmaceutical Group, Inc. Feb- Feb Mar
314
05 -06 -09
6- 5- 12-
US20090068
REUSABLE DETECTION SURFACES AND METHODS OF USING SAME BioScale, Inc. Sep- Sep Mar
759
07 -08 -09
30- 31- 12-
US20090068 METHODS AND KITS FOR IDENTIFYING TARGET NUCLEOTIDES IN
APPLIED BIOSYSTEMS INC. Apr- Jul- Mar
665 MIXED POPULATIONS
04 08 -09
2- 19- 12-
US20090068
VIRAL PROTEIN CHANG MING-FU Mar- Sep Mar
636
04 -07 -09
1- 29- 12-
US20090068 COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS
Three Rivers Pharmaceuticals LLC Apr- Jul- Mar
142 INFECTION AND SARS
03 08 -09
2- 4- 12-
US20090068 CARBONIC ANHYDRASE IX (G250) ANITBODIES AND METHODS OF
LO AGNES Dec- Dec Mar
095 USE THEREOF
05 -06 -09

11- 10- 5-
US20090062 Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring
COLEY PHARMACEUTICAL GROUP, INC. Feb- Feb Mar
05 -06 -09
30- 23- 5-
US20090062
IMIDAZOQUINOLINYL SULFONAMIDES BONK JASON D Dec- Dec Mar
272
03 -04 -09
14- 12- 5-
US20090062
Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists ASTRAZENECA AB Mar- Mar Mar
259
06 -07 -09
20- 6- 5-
US20090062 METHOD AND COMPOSITION FOR REDUCING THE EXPRESSION OF
Myriad Genetics, Incorporated Aug- May Mar
229 ROCK-II
03 -08 -09
24- 2- 5-
US20090061 Composition For The Prevention and Treatment Of Common Cold
PANDALIS GEORGIOS Mar- Mar Mar
027 Diseases
06 -07 -09
30- 30- 5-
US20090061 SHELF STABLE, REDUCED CORROSION, READY TO USE
BESSE MICHAEL Aug- Aug Mar
017 PEROXYCARBOXYLIC ACID ANTIMICROBIAL COMPOSITIONS
07 -07 -09
28- 28- 5-
US20090060
Method for Producing Viral Vaccines BAXTER HEALTHCARE Aug- Aug Mar
950
07 -08 -09
Novel 5,6-Dihydropyrazolo[3,4-E] [L,4]Diazepin-4 (IH) -One 3- 2- 26-

US20090054
Derivatives for the Treatment of Asthma and Chronic Obstructive AstraZeneca AB Oct- Oct Feb
413
Pulmonary Disease 05 -06 -09
18- 18- 26-

US20090054
Bioactive peptides and method of using same AYALON-SOFFER MICHAL Sep- Sep Feb
342
06 -07 -09
12- 8- 26-
US20090053 Method and/or Apparatus of Oligonucleotide Design and/or Nucleic
LEE CHARLIE Aug- Aug Feb
708 Acid Detection
05 -06 -09
9- 26-
US20090053 Methods for generating immune response using cationic-liposome- 9-Jul-
Georgetown University Jul- Feb
299 mediated nucleic acid delivery 07
08 -09
6- 10- 26-
US20090053
REPLIKIN PEPTIDES AND USES THEREOF BOGOCH ELENORE S Jun- Jul- Feb
257
03 08 -09
31- 25- 26-
US20090053
Compositions and methods for transepithelial molecular transport Thomas Jefferson University May- Mar Feb
248
02 -08 -09
11- 16- 19-
US20090047
COMPOSITIONS FOR USE IN IDENTIFICATION OF ADENOVIRUSES IBIS BIOSCIENCES, INC. Sep- Sep Feb
665
03 -08 -09
4- 6- 19-
US20090047 CHANGING TH1/TH2 BALANCE IN SPLIT INFLUENZA VACCINES
NOVARTIS VACCINES AND DIAGNOSTICS SRL Nov- Nov Feb
353 WITH ADJUVANTS
05 -06 -09
21- 21- 19-
US20090047
ADJUVANT COMPOSITIONS M N L PHARMA LIMITED Jan- Jan Feb
306
04 -05 -09
Compositions with Modified Nucleases Targeted to Viral Nucleic 14- 14- 19-
US20090047
Acids and Methods of Use for Prevention and Treatment of Viral APPELBAUM JACOB G Apr- Apr Feb
272
Diseases 04 -05 -09
20- 18- 12-

US20090042
Muscarinic Receptor Antagonists ASTRAZENECA AB Apr- Apr Feb
942
05 -06 -09
14- 12- 12-
US20090042
OXIME SUBSTITUTED IMIDAZOQUINOLINES Coley pharmaceutical Group, Inc. Nov- Nov Feb
925
03 -04 -09
16- 16- 12-
US20090042
LACTAM CONTAINING HCV INHIBITORS BARSANTI PAUL Jun- Jun Feb
858
05 -06 -09
13- 10- 12-
US20090042
ANTIVIRAL OLIGONUCLEOTIDES TARGETING HBV JUTEAU JEAN-MARC Sep- Jul- Feb
827
02 08 -09
11- 12-
US20090042 13-
B7-DC Variants The Johns Hopkins University Jul- Feb
292 Jul-07
08 -09
22- 12-
US20090042 27-
Method of Purifying Virus Envelope GENOMIDEA INC. Jul- Feb
274 Jul-04
05 -09
18- 30- 12-
US20090042
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES Maxygen, Inc. Nov- Oct Feb
252
02 -06 -09
12- 10- 12-
US20090041 ANTIVIRAL AGENT, AND FABRIC AND ANTIVIRAL MEMBER
ITO HIROSHI Aug- Aug Feb
818 SUPPORTING ANTIVIRAL AGENT
03 -04 -09
1- 2- 12-
US20090041
Dioscorea Extracts Academia Sinica Dec- Sep Feb
803
03 -08 -09
5- 16- 12-
US20090041
METHODS FOR DETECTING PARVOVIRUS INFECTIONS The Research Foundation of State University of New York May- Oct Feb
781
03 -08 -09
13- 7- 5-
US20090036 Methods for the directed expansion of epitopes for use as antibody
Peptimmune, Inc. Apr- May Feb
653 ligands
06 -08 -09
6- 5- 5-
ASTRAZENECA AB Oct- Oct Feb
535 Disease
05 -06 -09

28- 27- 5-
US20090035
RNAi Medicine Having No Adverse Effects GONDAI TAKUMA Jan- Jan Feb
861
05 -06 -09
22- 21- 5-
US20090035
IMMUNE RESPONSE MODIFIER CONJUGATES Not Available Feb- Feb Feb
323
06 -07 -09
24- 25- 8-
US20090012 OLIGONUCLEOTIDE COMPOUND AND METHOD FOR TREATING
BESTWICK RICHARD K Dec- Apr Jan-
280 NIDOVIRUS INFECTIONS
03 -08 09
3- 8-
US20090012 5-Jul-
Novel Compounds 951 BONNERT ROGER VICTOR Jul- Jan-
151 07
08 09
Piperidine Derivatives, Their Process for Preparation, Their Use as 7- 6- 8-

US20090012
Therapeutic Agents and Pharmaceutical Compositions Containing CAGE PETER Mar- Mar Jan-
125
Them 06 -07 09
18- 30- 8-
US20090011
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES MAXYGEN, INC. Nov- Oct Jan-
465
02 -06 09
26- 17- 8-
US20090011 MICROPOROUS MATERIALS, METHODS OF MAKING, USING, AND
UNIVERSITY OF UTAH RESEARCH FOUNDATION May- May Jan-
403 ARTICLES THEREOF
04 -05 09
2- 1- 1-
US20090005
1-Alkoxy 1H-Imidazo Ring Systems and Methods 3M Innovative Properties Company Sep- Sep Jan-
376
04 -05 09
11- 10- 1-
US20090005 Substituted Fused [1,2]Imidazo[4,5-C] Ring Compounds and
HEPPNER PHILIP D Feb- Feb Jan-
371 Methods
05 -06 09
18- 17- 1-
US20090004 METHODS FOR CONCURRENT IDENTIFICATION AND
ISIS Pharmaceuticals, Inc. Feb- Feb Jan-
643 QUANTIFICATION OF AN UNKNOWN BIOAGENT
04 -05 09
12- 13- 25-
US20080319
Methods and Uses of Antibodies in the Purification of Interferon ViraNative AB Feb- Feb Dec
170
05 -06 -08
9- 8- 25-
US20080318
Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines COLEY PHARMACEUTICAL GROUP, INC. Feb- Feb Dec
998
05 -06 -08
19- 19- 25-
US20080317 METHOD FOR TREATING MICROORGANISMS AND/OR INFECTIOUS
EDGINGTON GARRY Jun- Jun Dec
702 AGENTS
07 -08 -08
13- 13- 18-
US20080311
Adjuvant Activity of Gastrointestinal Peptides Not Available Dec- Dec Dec
138
04 -05 -08
25- 24- 18-
US20080311
Scytovirin Domain 1 Related Polypeptides Office of Technology Transfer May- May Dec
125
05 -06 -08
5- 4- 18-
US20080311 Loop-Variant Pdz Domains as Biotherapeutics, Diagnostics and
DELAGRAVE SIMON Dec- Dec Dec
042 Research Reagents
05 -06 -08
29- 17- 18-
US20080310
APPARATUS AND METHOD FOR USING OZONE AS A DISINFECTANT VIROFORCE SYSTEMS INC. Nov- Jun Dec
992
06 -08 -08
17- 16- 11-
US20080305
Immunogenic Compositions Comprising Hmgb 1 Polypeptides MEDIMMUNE, INC. Jun- Jun Dec
120
04 -05 -08
29- 5- 11-
US20080305
Modified Bacteriophage Vectors and Uses Thereof UNIVERSITY OF ROCHESTER Oct- Oct Dec
119
04 -05 -08
9- 3- 4-
US20080300
Novel Benzothiazolone Derivatives ASTRAZENECA AB Aug- Aug Dec
275
05 -06 -08
14- 13- 4-
US20080300
NOVEL COMPOUNDS AstraZeneca AB Dec- Dec Dec
244
06 -07 -08
6- 6- 4-
US20080300 PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND
CAI SUI XIONG May- May Dec
191 THE USE THEREOF
03 -04 -08
6- 6- 4-
US20080299 CHROMATOGRAPHIC METHODS FOR ASSESSING ADENOVIRUS
CLARKE PETER Mar- Mar Dec
545 PURITY
07 -08 -08
1- 29- 4-
US20080299
METHODS AND FORMULATIONS FOR TOPICAL GENE THERAPY ONISHI ERIC Mar- Feb Dec
182
07 -08 -08
30- 30- 4-
US20080299
Antiviral Compounds ENGEL ROBERT May- May Dec
070
07 -08 -08
1- 1- 4-
US20080295
SELF SANITIZING FACE MASKS AND METHOD OF MANUFACTURE HAAS MARCI B Jun- Jun Dec
843
07 -07 -08
15- 12- 27-
US20080293 Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for
ASTRAZENECA AB Dec- Dec Nov
775 the Treatment of Respiratory Disease
05 -06 -08
12- 11- 27-
US20080293 Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of
CHESHIRE DAVID Dec- Dec Nov
742 Chemokine Receptor Ccr4
05 -06 -08
21- 24- 27-
US20080292
PRIMATE T-LYMPHOTROPIC VIRUSES Centers for Disease Control and Prevention Feb- Feb Nov
657
05 -07 -08
8- 8- 27-
US20080292
Antigenic GM-CSF peptides and antibodies to GM-CSF Morphotek, Inc. Feb- Feb Nov
641
06 -07 -08

21- 18- 20-
US20080287 Piperazine Compounds Useful as Antagonists of C-C Chemokines
BOWER JUSTIN FAIRFIELD Dec- Dec Nov
453 (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases
05 -06 -08
3- 20-
US20080286 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING 29-
THE CHINESE UNIVERSITY OF HONG KONG Apr Nov
756 SEVERE ACUTE RESPIRATORY SYNDROME (SARS) Jul-03
-08 -08
2- 31- 13-
US20080280
Salt Il ASTRAZENECA AB Aug- Jul- Nov
951
05 06 -08
5- 4- 13-
US20080279
Compositions For Treating Respiratory Viral Infections and Their Use Intradigm Corporation Nov- Nov Nov
920
04 -05 -08
8- 13-
US20080279 9-Jul-
Viral Adjuvants JOHNSTON ROBERT E Jul- Nov
891 04
05 -08
5- 19- 13-
US20080279
Disease Prevention and Vaccination Prior to Thymic Reactivation Monash University Dec- Apr Nov
812
03 -04 -08
6- 20- 13-
US20080279 TRANSPORTABLE DECONTAMINATION UNIT AND
BACIK MICHAEL A Mar- Feb Nov
722 DECONTAMINATION PROCESS
07 -08 -08
6- 20- 13-
US20080279
DECONTAMINATION UNIT AND PROCESS CENTANNI MICHAEL A Mar- Feb Nov
721
07 -08 -08
6- 20- 13-
US20080279 DECONTAMINATION UNIT WITH COLLAPSIBLE DECONTAMINATION
CENTANNI MICHAEL A Mar- Feb Nov
720 ENCLOSURE AND DECONTAMINATION PROCESS
07 -08 -08
27- 24- 6-
US20080275
Piperidines for the Treatment of Chemokine Mediated Diseases ASTRAZENECA AB May- May Nov
084
05 -06 -08
19- 18- 6-
US20080274
Vaccines and Methods for Using the Same KUTZLER MICHELE Nov- Nov Nov
140
04 -05 -08
22- 21- 30-
US20080269
Novel Adenine Compound AstraZeneca Aktiebolag A Corporation of Sweden Sep- Sep Oct-
240
05 -06 08
30- 29- 30-
US20080269
Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds Coley Pharmaceutical Group, Inc. Dec- Dec Oct-
192
04 -05 08
26- 26- 30-
US20080269
Inhibitors of RTP801 and their use in disease treament FEINSTEIN ELENA Feb- Feb Oct-
156
07 -08 08
1- 30- 30-
US20080269
Modified Small Interfering Rna Molecules and Methods of Use HAN JANG Oct- Sep Oct-
148
04 -05 08
17- 16- 30-
US20080269
Immunogenic Sars Domain BEADENKOPF ROBERT J Jun- Jun Oct-
115
04 -05 08
29- 9- 30-
US20080267 Modified Viral Particles with Immunogenic Properties and Reduced
Lipid Sciences, Inc. Jun- May Oct-
997 Lipid Content Useful for Treating and Preventing Infectious Diseases
00 -08 08
4- 4- 30-
US20080267 Sars Virus Vaccine with Adenovirus Carrier and Preparation Method
Cancer Center, Sun Yat-Sun University Jun- Jun Oct-
992 Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine
04 -04 08
6- 20- 30-
US20080267 TRANSPORTABLE DECONTAMINATION UNIT AND
BACIK MICHAEL A Mar- Feb Oct-
819 DECONTAMINATION PROCESS
07 -08 08
11- 23-
US20080261 9-Jul-
Immune Cell Biosensors and Methods of Using Same Amaox, Inc. Jul- Oct-
258 04
05 08
20- 20- 23-
US20080261
Fluorescent Proteins and Related Methods and Compounds UNIVERSITY OF MASSACHUSETTS Sep- Sep Oct-
257
04 -05 08
15- 15- 23-
US20080260
New Live Virus Vaccines JOHNSON PHILIP R Feb- Feb Oct-
775
05 -06 08
24- 23- 23-
US20080260
Saccharide Conjugate Vaccines Not Available Dec- Dec Oct-
773
04 -05 08
22- 23-
US20080260 23-
Polypeptides for Oligomeric Assembly of Antigens CAPECCHI BARBARA Jul- Oct-
769 Jul-04
05 08
30- 30- 23-
US20080260
REPLIKIN PEPTIDES AND USES THEREOF BOGOCH ELENORE S May- May Oct-
764
06 -07 08
5- 1- 16-
US20080255
Novel Compounds ASTRAZENECA AB Nov- Nov Oct-
150
05 -06 08
29- 29- 16-
US20080255
Steroid-Derived Pharmaceutical Compositions JadoLabs GmbH Jun- Jun Oct-
076
04 -05 08
31- 29- 16-
US20080254 Anti-Sars Virus Antibody, Hybridoma Producing the Antibody and
FUJII NOBUYUKI Oct- Oct Oct-
440 Immunoassay Reagent Using the Antibody
03 -04 08

8- 7- 9-
US20080249
Salts 668 WHITTOCK ROBERT Feb- Feb Oct-
145
07 -08 08
27- 25- 9-
US20080249
Novel Substituted 3-Sulfur Indoles BONNERT ROGER May- May Oct-
110
03 -04 08
20- 27- 9-
US20080249
PRODRUGS OF HETEROARYL COMPOUNDS Koronis Pharmaceuticals, Incorporation Jun- Dec Oct-
097
03 -06 08
30- 28- 9-
US20080249
Modified Short Interfering Rna (Modified Sirna) SANTARIS PHARMA A/S Jan- Jan Oct-
039
04 -05 08
6- 4- 9-
US20080248
METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES OSORIO JORGE E Apr- Apr Oct-
551
07 -08 08
19- 21- 9-
US20080248
Antibodies to SARS coronavirus Amgen Inc. May- May Oct-
043
06 -07 08
2- 19- 2-
US20080242 MODIFIED POLYNUCLEOTIDES FOR REDUCING OFF-TARGET
DHARMACON, INC. Apr- Sep Oct-
851 EFFECTS IN RNA INTERFERENCE
03 -07 08
30- 30- 2-
US20080242
COLOR STABILIZED ANTIMICROBIAL POLYMER COMPOSITES BLANTON THOMAS N Mar- Mar Oct-
794
07 -07 08
8- 7- 2-
US20080242
New Combination 665 CADOGAN ELAINE BRIDGET Feb- Feb Oct-
649
07 -08 08
27- 27- 2-
Methods for pathogen detection Mar- Mar Oct-
935 Delaware
07 -07 08
27- 27- 2-
Devices for pathogen detection Mar- Mar Oct-
910 Delaware
07 -07 08
27- 27- 2-
Microfluidic chips for pathogen detection Mar- Mar Oct-
909 Delaware
07 -07 08
30- 30- 2-
US20080241 PRODUCTION OF SILVER SULFATE GRAINS USING INORGANIC
BLANTON THOMAS N Mar- Mar Oct-
511 ADDITIVES
07 -07 08
28- 27- 2-
US20080241 Sequential Delivery Of Immunogenic Molecules Via Adenovirus And
The Trustees of the University of Pennsylvania Apr- Apr Oct-
189 Adeno-Associated Virus-Mediated Administrations
04 -05 08
27- 27- 2-
Systems for pathogen detection Mar- Mar Oct-
000 Delaware
07 -07 08
8- 7- 25-
US20080234 METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE
Gene Logic Inc. Sep- Sep Sep
345 DIGESTIVE TRACT
06 -07 -08
22- 21- 25-
US20080234
Novel Compounds 679 EBDEN MARK Mar- Mar Sep
319
07 -08 -08
10- 9- 25-
US20080233 Method for propagating adenoviral vectors encoding inhibitory gene
GENVEC, INC. Nov- May Sep
650 products
05 -08 -08
11- 25- 25-
US20080233
METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA HALL THOMAS A Sep- May Sep
570
03 -07 -08
1- 1- 25-
US20080233
Inhibitors of viral entry screening method Medical Research Council Feb- Aug Sep
558
05 -07 -08
16- 16- 25-
US20080233
RESPIRATORY SYNCYTIAL VIRUS-VIRUS LIKE PARTICLE (VLPS) MAHMOOD KUTUB Nov- Nov Sep
150
06 -07 -08
2- 1- 25-
US20080233
Treatment of Viral Infections KRAUSE WERNER Nov- Nov Sep
128
06 -07 -08
2- 31- 18-
US20080227
New Salt I ASTRAZENECA AB Aug- Jul- Sep
817
05 06 -08
3- 18-
US20080227 Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of 4-Jul-
ASTRAZENECA AB Jul- Sep
797 Inflammatory and Immune Diseases 05
06 -08
17- 16- 18-
US20080227
Electrochemiluminescent assay Not Available Nov- Nov Sep
219
04 -05 -08
18- 25- 18-
US20080227
Interferon-Alpha Polypeptides and Conjugates MAXYGEN, INC. Nov- Oct Sep
149
02 -07 -08
13- 14- 18-
US20080226 Highly Active Glycoproteins-Process Conditions and an Efficient
Glycotope GmbH Feb- Feb Sep
681 Method for their Production
04 -05 -08
18- 17- 18-
US20080226
EVOLVED INTERFERON-ALPHA POLYPEPTIDES MAXYGEN, INC. May- May Sep
597
05 -06 -08
6- 4-
US20080213 21-
RNAi Agents Comprising Universal Nucleobases Alnylam Pharmaceuticals, Inc. Aug Sep
891 Jul-04
-07 -08
14- 14- 4-
US20080213
Imidazoquinoline Compounds CHU DANIEL Sep- Sep Sep
308
04 -05 -08

9- 10- 4-
US20080213 National Health Research Institutes, a Taiwanese
RECEPTOR BINDING POLYPEPTIDES Jan- Jan Sep
284 corporation
04 -05 -08
18- 18- 4-
US20080213
Apparatus and Method for Using Ozone as a Disinfectant Huawei Technologies Co. LTD. Mar- Mar Sep
125
04 -05 -08
30- 11- 4-
US20080210 Systems and methods for receiving pathogen related information Searete LLC, a limited liability corporation of the State of
Nov- Sep Sep
748 and responding Delaware,
05 -07 -08
20- 19- 28-
US20080207
Novel Compounds 569 CONNOLLY STEPHEN Dec- Dec Aug
698
06 -07 -08
19- 28-
US20080207 21-
Novel Piperidine Derivatives ASTRAZENECA AB Jul- Aug
688 Jul-05
06 -08
30- 28- 28-
US20080207
Immune Response Modifier Formulations And Methods Coley Pharmaceutical Group, Inc. Dec- Dec Aug
674
04 -05 -08
11- 10- 28-
US20080207
Chemical Compounds 636 BONNERT ROGER VICTOR Jan- Jan Aug
650
07 -08 -08
HOMOPIPERAZINE COMPOUNDS THAT INHIBIT RIBOSOMAL 22- 20- 28-

US20080207 SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR
FRAMESHIFTING BY BINDING TO RNA PSEUDOKNOT STRUCTURE Dec- Dec Aug
597 CORPORATE COLLABORATION
OF SARS CORONAVIRUS 06 -07 -08
19- 19- 28-

US20080207
Novel compounds 329 MARTIN BARRIE Jun- Jun Aug
596
06 -07 -08
20- 20- 28-
US20080207 Pyridazine Derivatives for Inhibiting Human Stearoyl-Coa-
XENON PHARMACEUTICALS INC. Sep- Sep Aug
587 Desaturase
04 -05 -08
16- 7- 28-
US20080207
COMPOUNDS FOR TREATING VIRAL INFECTIONS Myriad Genetics, Incorporated Oct- May Aug
573
06 -08 -08
17- 17- 28-
US20080206
Vaccine Against Sars DONG JOHN Y Jun- Jun Aug
283
03 -04 -08
27- 27- 28-
US20080206 COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE
Johns Hopkins University Dec- Dec Aug
235 RESPONSE
06 -07 -08
27- 24- 21-
US20080200
Piperidines for the Treatment of Chemokine Mediated Diseases ASTRAZENECA AB May- May Aug
505
05 -06 -08
2- 2- 21-
US20080199
Methods and Kits For Mass Production Of Dsrna RNA-Line Oy May- May Aug
915
03 -03 -08
15- 24- 21-
US20080199
Stimulation of thymus for vaccination development Monash University Apr- May Aug
495
99 -07 -08
16- 16- 21-
US20080199
Sustained Release Vaccine Composition BRANDON MALCOLM Jun- Jun Aug
491
04 -05 -08
21- 19- 21-
US20080199
COMPOUNDS ASTRAZENECA AB Feb- Feb Aug
481
07 -08 -08
7- 28- 14-
US20080194
POTENTIATION FOR MEDICAL THERAPIES HOLDEN JAMES F Sep- Sep Aug
922
05 -07 -08
25- 26- 14-
US20080194
Disinfectant and Germicidal Agent REICHWAGEN SVEN May- May Aug
689
05 -06 -08
1- 31- 14-
US20080194 Novel Piperidine Derivatives as Chemokine Receptor Modulators
ASTRAZENECA AB Aug- Jul- Aug
632 Useful for the Treatment of Respiratory Diseases
05 06 -08
21- 31- 14-
US20080194
Albumin Fusion Proteins Human Genome Sciences, Inc. Dec- Oct Aug
481
01 -07 -08
PCR PRIMER SET DETECTING SEVERE ACUTE RESPIRATORY 12- 21- 14-
US20080194
SYNDROME (SARS)-CORONAVIRUS, METHOD AND KIT FOR SAMSUNG ELECTRONICS CO., LTD. Dec- Apr Aug
422
DETECTING SARS-CORONAVIRUS USING THE SAME 03 -08 -08
30- 22- 14-

US20080193 Systems and methods for receiving pathogen related information Searete LLC, a limited liability corporation of the State of
Nov- Jan Aug
919 and responding Delaware
05 -08 -08
25- 25- 14-
US20080193
Immunostimulatory Compositions GRAM CHRISTOPHER D Apr- Apr Aug
474
05 -06 -08
1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine 30- 28- 7-

US20080188
Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5- taked Pharmaceutical Company Limited Dec- Dec Aug
513
C](1,5]Naphthyridin-4-Amine Methanesulfonate 04 -05 -08
20- 20- 7-
US20080188 Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase
XENON PHARMACEUTICALS INC. Sep- Sep Aug
488 Inhibitors
04 -05 -08
3- 18- 7-
US20080187 Methods and apparatus to prevent, treat, and cure the symptoms of
VAIL MARILYN L Apr- Mar Aug
609 nausea caused by chemotherapy treatments of human cancers
00 -08 -08

15- 15- 7-
US20080187 ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF
Functional Genetics, Inc. Nov- Nov Aug
06 -07 -08
30- 11- 31-
US20080183 Systems and methods for transmitting pathogen related information Searete LLC, a limited libility corporation of the State of
Nov- Sep Jul-
396 and responding Delaware
05 -07 08
21- 26- 31-
US20080182
Method of treatment of virus infections using shikonin compounds WANG FEIXIN Feb- Sep Jul-
900
03 -07 08
30- 28- 31-
US20080182
Novel Compounds ASTRAZENECA AB Nov- Nov Jul-
874
04 -05 08
31- 31- 31-
US20080181
POLYMER COMPOSITE BARNES CRAIG L Jan- Jan Jul-
969
07 -07 08
2- 31- 24-
US20080176
Salt III ASTRAZENECA AB Aug- Jul- Jul-
902
05 06 08
13- 13- 24-
US20080176 THE BOARD OF TRUSTEES OF THE LELAND STANFORD
EPOXIDE INHIBITORS OF CYSTEINE PROTEASES Jun- Jun Jul-
841 JUNIOR UNIVERSITY
06 -07 08
METHOD OF PREDICTING INFLUENZA OUTBREAKS BY 24- 24- 24-

US20080176
CORRELATING AN INCREASE IN REPLIKIN COUNT IN SHRIMP BOGOCH ELENORE S Oct- Oct Jul-
217
WHITE SPOT SYNDROME VIRUS AND/OR TAURA SYNDROME VIRUS 06 -07 08
22- 24- 24-

US20080175 MODIFIED POLYMERASES AND ATTENUATED VIRUSES AND
THE PENN STATE RESEARCH FOUNDATION Dec- Dec Jul-
06 -07 08
30- 17- 24-
US20080175 Materials and Methods for Prevention and Treatment of RNA Viral
BEHERA ARUNA K Apr- Jan Jul-
832 Diseases
02 -08 08
6- 6- 17-
US20080172 Method to Decrease the Risk of a Vaccine-Induced Chronic Immune
CLASSEN IMMUNOTHERAPIES Apr- Apr Jul-
247 Mediated Disorder in Humans With a Family History of the Disorder
04 -05 08
19- 14- 17-

US20080171
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES MAXYGEN, INC. May- Aug Jul-
363
04 -07 08
19- 20- 17-
US20080171
Listeriolysin-Containing Bacillus Spores as Antigen Delivery Agents CUTTING SIMON Feb- Feb Jul-
066
05 -06 08
Reagents, Devices, and Methods For Proteomic Analysis With 21- 19- 17-
US20080171
Applications Including Diagnostics, Vaccines, Quality Control and NETWORK IMMUNOLOGY INC. Apr- Apr Jul-
057
Research 04 -05 08
30- 17-
US20080170 28-
Compositions and Methods for Stimulation of Lung Innate Immunity The Board of Regents of the University of Texas System Jul- Jul-
996 Jul-06
07 08
18- 10-
US20080167 19-
Novel Compounds 243 ELKINS BARRY Jul- Jul-
332 Jul-06
07 08
20- 20- 10-
US20080167
Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase XENON PHARMACEUTICALS INC. Sep- Sep Jul-
321
04 -05 08
4- 4- 10-
US20080167
Filter based detection system COONEY CHRISTOPHER GERARD Jan- Jan Jul-
198
07 -07 08
4- 4- 10-
US20080166 Sorting, amplification, detection, and identification of nucleic acid
The Regents of the University of California Jan- Jan Jul-
793 subsequences in a complex mixture
07 -07 08
24- 10-
US20080166 25-
Immunoassay Method and Immunoassay Kit to Be Used Therein ARKRAY, Inc. Jul- Jul-
701 Jul-05
06 08
26- 25- 10-
US20080166 Immunogenic Compositions Comprising Multiple Gonococcal
CHIRON SRL Jun- Jun Jul-
370 Antigens
03 -04 08
9- 11- 3-
US20080160 Peptide That Elicits Neutralizing Antibodies Targeting the Hiv Co-
The Government of the United States of America as Apr- Apr Jul-
010 Receptor
04 -05 08
19- 19- 3-
US20080159 Use of Inhibitors of the Renin-Angiotensin System for the Treatment IMBA-INSTITUTE FUR MOLEKULARE BIOTECHNOLOGIE
May- May Jul-
962 of Lung Injuries GMBH
05 -06 08
27- 27- 3-
US20080156 HAZARDOUS SUBSTANCE REMOVING MATERIAL, METHOD FOR
FUJIFILM Corporation Dec- Dec Jul-
743 REMOVING HAZARDOUS SUBSTANCES, AND NONWOVEN FABRIC
06 -07 08
28- 25- 26-

US20080154 Mixture for Transdermal Delivery of Low and High Molecular Weight
ORYXE May- May Jun-
210 Compounds
04 -05 08
30- 29- 26-
US20080153
Adamantyl Derivates as P2x7 Receptor Antagonists AstraZeneca AB Aug- Aug Jun-
850
04 -05 08
19- 14- 26-
US20080153 Novel Fluorene Derivatives, Composition Containing Said Derivatives
AVENTIS PHARMA S.A. May- Nov Jun-
837 and the Use Thereof
05 -07 08
25- 26-
US20080152 7-Jul-
Noble gas-chlorine mixture effective against micro organisms GLOBUS ALFRED R Apr Jun-
728 03
-07 08

29- 3- 26-
US20080152
Building decontamination with vaporous hydrogen peroxide STERIS INC. Jan- Mar Jun-
544
04 -08 08
20- 20- 26-
US20080149
Antiviral Heat Treatment DE HAAN PETRUS THEODORUS Dec- Dec Jun-
100
06 -06 08
27- 25- 19-
US20080146
Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor ASTRAZENECA AB Jan- Jan Jun-
612
05 -06 08
11- 25- 19-
US20080146
METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA HALL THOMAS A Sep- May Jun-
455
03 -07 08
11- 25- 19-
US20080145
847
03 -07 08
11- 25- 12-
US20080138
808
03 -07 08
9- 7- 5-
US20080132
5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors ARNOULD JEAN-CLAUDE Nov- Nov Jun-
502
04 -05 08
24- 22- 5-
AstraZeneca AB Aug- Aug Jun-
480 Disease
04 -05 08
27- 27- 5-
US20080131
Group a Streptococcus Crge Protein MANETTI ANDREA Sep- Sep Jun-
465
04 -05 08
17- 9- 5-
US20080131
Vaccine Composition SANOFI PASTEUR SA Nov- Jan Jun-
446
03 -08 08
20- 20- 29-
US20080125 Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase
XENON PHARMACEUTICALS INC. Sep- Sep May
434 Inhibitors
04 -05 -08
24- 24- 29-
US20080124
Nutritional Composition Comprising Indigestible Oligosaccharides N.V. Nutricia Aug- Aug May
323
04 -05 -08
23- 17- 29-
US20080124 Novel pharmaceutical compositions for the treatment of virus
Illumigen Biosciences, Inc. Nov- Nov May
311 infection and cancer
05 -06 -08
12- 12- 29-
US20080124
Methods and compositions for treatment of viral infections Cavit Sciences, Inc Dec- Jul- May
303
05 07 -08
9- 9- 29-
US20080124
Uses of Recombinant Super-Compound Interferons WEI GUANGWEN Mar- Mar May
302
05 -06 -08
8- 7- 22-
US20080118 Modulation of Replicative Fitness By Deoptimization of Synonymous
BURNS CARA C Oct- Oct May
530 Codons
04 -05 -08
16- 27- 22-
US20080118
Human monoclonal antibodies against interleukin 8 (IL-8) GENMAB A/S Dec- Jun May
517
02 -07 -08
27- 27- 22-
US20080118
Mammalian Genes Involved in Infection RUBIN DONALD H Oct- Oct May
495
04 -05 -08
1- 31- 22-
US20080118 Methods of treating a respiratory condition comprising probiotic
Alimentary Health Ltd. Nov- Oct May
473 treatment
06 -07 -08
12- 12- 15-
US20080114
Hydroxylamine Substituted Imidazoquinolines Coley Pharmaceutical Group, Inc. Aug- Aug May
019
03 -04 -08
6- 15-
US20080114 8-Jul-
Substituted Acids for the Treatment of Respiratory Diseases ASTRAZENECA AB Jul- May
002 04
05 -08
15- 1- 15-
US20080113
Transient protein expression methods HATEBOER GUUS Apr- Jun May
409
99 -07 -08
Method of Examining/Judging Presence of Virus Infection such as 12- 10- 15-

US20080113
HIV or Presence of Prion Infection by Near-Infrared Spectroscopy OSAKA UNIVERSITY Nov- Nov May
337
and Device Used in Same 04 -05 -08
20- 20- 8-
US20080108 Heterocyclic Derivatives for the Treatment of Diseases Mediated by
XENON PHARMACEUTICALS INC. Sep- Sep May
629 Stearoyl-Coa Desaturase Enzymes
04 -05 -08
8- 7- 8-
US20080107 METHOD FOR TREATING INFLAMMATORY DISEASES OF THE
Gene Logic Inc. Sep- Sep May
650 DIGESTIVE TRACT
06 -07 -08
30- 11- 1-
US20080103
Systems and methods for pathogen detection and response Searete LLC, a limited liability corporation Nov- Sep May
746
05 -07 -08
NOVEL TETRACYCLIC INHIBITORS OF CYSTEINE PROTEASES, THE 30- 30- 1-

US20080103
PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR COLLAND FREDERIC Oct- Oct May
149
15- 1-
US20080102 6-Jul-
METHODS AND COMPOSITIONS FOR DETECTING RHINOVIRUSES Focus Technologies, Inc. Oct May
444 04
-07 -08
5- 24-
US20080096 7-Jul-
Durable Biocides and Disinfectants MITSUI NORIN CO., LTD. Jul- Apr-
959 04
05 08

14- 24-
US20080096 14-
Methods for treating Hepatitis C AREFOLOV ALEXANDER Jul- Apr-
928 Jul-04
05 08
20- 20- 24-
US20080096 Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase
XENON PHARMACEUTICALS INC. Sep- Sep Apr-
895 Inhibitors
04 -05 08
PCR PRIMER SET FOR DETECTING SEVERE ACUTE RESPIRATORY 12- 24- 24-
US20080096
SYNDROME (SARS)-CORONAVIRUS, METHOD AND KIT FOR HWANG JUNG-JOO Dec- Nov Apr-
186
DETECTING SARS-CORONAVIRUS USING THE SAME 03 -04 08
29- 29- 17-

US20080090
Sphingolipid-Derived Phamaceutical Compositions BRAXMEIER TOBIAS Jun- Jun Apr-
913
04 -05 08
METHODS OF ENHANCING MUCOSAL HYDRATION AND MUCOSAL 7- 7- 17-

US20080090
CLEARANCE BY TREATMENT WITH SODIUM CHANNEL BLOCKERS PARION SCIENCES, Inc. Sep- Sep Apr-
841
AND OSMOLYTES 06 -07 08
13- 13- 17-

US20080090
Cystic fibrosis treatment methods Hollis-Eden Pharmaceuticals, Inc. Oct- Oct Apr-
791
06 -06 08
12- 12- 17-
US20080090
Devices for generating detectable polymers ENGELHARD ERIC K Oct- Oct Apr-
229
06 -06 08
2- 30- 17-
US20080090
Nucleic acid detection HAI KANG LIFE CORPORATION LIMITED May- Apr Apr-
224
03 -04 08
30- 29- 10-
US20080085
Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds DANIELSON MICHAEL M Dec- Dec Apr-
895
04 -05 08
28- 13- 10-
US20080085
Disease treatment methods Hollis-Eden Pharmaceuticals, Inc. Aug- Oct Apr-
873
02 -06 08
5- 6- 3-
US20080081
Anti-Sars Monoclonal Antibodies ANDONOV ANTON Dec- Dec Apr-
047
03 -04 08
19- 4- 27-
US20080076
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES MAXYGEN, INC. May- May Mar
710
04 -07 -08
3- 3- 27-
US20080076 Compositions and Methods for Detecting Severe Acute Respiratory
GILLIM-ROSS LAURA Nov- Nov Mar
115 Syndrome Coronavirus
03 -04 -08
17- 31- 27-
US20080075 Adeno-associated virus (AAV) serotype 8 sequences, vectors
The Trustees of the University of Pennsylvania Dec- Oct Mar
01 -07 -08
17- 6- 27-
US20080075 Adeno-Associated Virus (AAV) serotype 8 sequences, vectors
The Trustees of the University of Pennsylvania Dec- Sep Mar
01 -07 -08
2- 20- 27-
ZymoGenetics, Inc. Apr- Sep Mar
04 -07 -08
3- 2- 20-
US20080071
Protein Formulations MedImmune, Inc. Feb- Feb Mar
063
06 -07 -08
12- 20-
US20080070 Substituted chiral fused [1,2] imidazo [4,5-C] ring compounds and 12-
Coley Pharmaceutical Group, Inc. Jul- Mar
907 methods Jul-06
07 -08
ISOLATION AND CHARACTERIZATION OF THE PRECURSOR VIRUS 22- 24- 20-

US20080069
OF HUMAN SARS VIRUS: SARS-ASSOCIATED CORONA VIRUS-LIKE GUAN YI May- May Mar
839
VIRUS 03 -04 -08
24- 24- 20-

US20080069 NOVEL HUMAN VIRUS CAUSING SEVERE ACUTE RESPIRATORY
CHAN KWOK HUNG Mar- Mar Mar
838 SYNDROME (SARS) AND USES THEREOF
04 -04 -08
1- 26- 20-
US20080069 METHOD OF USING ADENOVIRAL VECTORS WITH INCREASED
and Human Services Sep- Feb Mar
836 IMMUNOGENICITY IN VIVO
04 -07 -08
24- 24- 20-
US20080069 Dna Sequences, Peptides, Antibodies and Vaccines for Prevention
HOFFMAN STEPHEN L Jun- Jun Mar
830 and Treatment of Sars
03 -04 -08
25- 20- 20-
US20080069
Alphavirus Replicon Packaging Constructs PERRI SILVIA May- May Mar
804
04 -05 -08
29- 30- 13-
US20080064
Animal protein-free media for cultivation of cells Baxter Healthcare Corporation Oct- Oct Mar
105
04 -07 -08
29- 30- 13-
US20080064
Animal protein-free media for cultivation of cells Baxter Healthcare Corporation Oct- Oct Mar
080
04 -07 -08
5- 5- 13-
US20080063 High-yield transgenic mammalian expression system for generating
Academia Sinica Sep- Sep Mar
664 virus-like particles
06 -06 -08
26- 6-
US20080058 27-
Novel Compounds 171 ASTRAZENECA AB Jul- Mar
309 Jul-06
07 -08
1- 31- 6-
US20080057
METHOD FOR PRODUCING NUCLEIC ACID PROBES Ventana Medical Systems, Inc. Sep- Aug Mar
513
06 -07 -08

12- 11- 28-
US20080051 Method for determining antigen-specific T cell response in high Centro di Biotecnologie Avanzate and istituto Giannina
Jun- Jun Feb
297 throughput format Gaslini
06 -07 -08
14- 15- 28-
US20080050
Methods, Articles, and Compositions for Identifying Oligonucleotides ATKINS JOHN F Nov- Nov Feb
718
03 -04 -08
12- 13- 21-
US20080044 Assay for Sars Coronavirus by Amplification and Detection of the
BECTON, DICKINSON AND COMPANY Sep- Sep Feb
816 Replicase Sequence
03 -04 -08
21- 21- 21-
US20080044 Reagents and Methods for Detecting Severe Acute Respiratory
HIBBERD MARTIN L Apr- Apr Feb
814 Syndrome Coronavirus
03 -04 -08
17- 16- 21-
US20080044
Yeast Cell Particles As Oral Delivery Vehicles For Antigens OSTROFF GARY R Mar- Mar Feb
438
06 -07 -08
2- 1- 21-
US20080044 Encapsidation System for Production of Recombinant Virus-Like
CHEN QUN Sep- Sep Feb
437 Particles
04 -05 -08
18- 18- 21-
US20080044
Novel Atypical Pneumonia-Causing Virus BESTEBROER THEODORUS MARINUS Nov- Nov Feb
426
03 -04 -08
23- 22- 21-
US20080044
COMPOUNDS COCHRANE DUNCAN Jun- Jun Feb
423
06 -07 -08
25- 24- 21-
US20080044 Recombinant Human Cytomegalovirus And Vaccines Comprising
Medlmmune Vaccines, Inc. Jun- Jun Feb
384 Heterologous Antigens
04 -05 -08
15- 15- 21-
US20080044 Methods and Compositions for Protein Production Using Adenoviral
INTROGEN THERAPEUTICS, INC. May- May Feb
378 Vectors
06 -07 -08
19- 10- 7-
US20080033
Mutagenic Heterocycles Koronis Pharmaceuticals, Incorporated Dec- Dec Feb
172
03 -04 -08
4- 4- 7-
US20080031
USE OF EXTRACTS FOR THE TREATMENT OF VIRAL DISORDERS BODDUPALLI SEKHAR Aug- Aug Feb
979
06 -06 -08
17- 16- 7-
US20080031
Purification of bacterial antigens COVACCI ANTONELLO Feb- Feb Feb
877
06 -07 -08
9- 9- 7-
US20080031 HUMAN LYSOZYME MEDICINE, ITS MANUFACTURING METHOD AND
AN MI Jun- Jun Feb
868 APPLICATION THEREOF
05 -05 -08
19- 15- 7-
US20080031
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES ROCHE PALO ALTO LLC May- Aug Feb
853
04 -07 -08
2- 29- 7-
US20080031
Apparatus and method for using ozone as a disinfectant BOAST NIGEL Aug- Nov Feb
770
06 -06 -08
26- 24- 31-
US20080027 1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives
BONNERT ROGER VICTOR Nov- Nov Jan-
092 Useful for the Treatment of Respiratory Disorders
03 -04 08
12- 14- 31-
US20080027 Compositions And Methods For Modification And Prevention Of Sars
The Regents of the University of Colorado Feb- Feb Jan-
006 Coronavirus Infectivity
04 -05 08
24- 20- 24-
US20080021 Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As
FAULL ALAN Jun- Jun Jan-
038 Modulators Of Chemokine Receptor Ccr5
04 -05 08
Diagnosis and prognosis of infectious diseases clinical phenotypes 5- 7- 24-

US20080020
and other physiologic states using host gene expression biomarkers AGAN BRIAN K Nov- Nov Jan-
379
in blood 04 -05 08
16- 17-
US20080015 17-
QUERCETIN-CONTAINING COMPOSITIONS LINES THOMAS C Jul- Jan-
247 Jul-06
07 08
20- 20- 17-
US20080015 HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC
XENON PHARMACEUTICALS INC. Sep- Sep Jan-
230 AGENTS
04 -05 08
23- 23- 17-
US20080015 METHODS AND COMPOSITIONS OF TARGETED DRUG
Joseph Errico Jan- Jan Jan-
194 DEVELOPMENT
06 -07 08
14- 14- 17-
US20080015 Urea Substituted Imidazopyridines, Imidazoquinolines, and
3M INNOVATIVE PROPERTIES COMPANY Jun- Jun Jan-
184 Imidazonaphthyridines
04 -05 08
11- 10- 17-
US20080014
Compositions Against Sars-Coronavirus and Uses Thereof DE KRUIF CORNELIS A Nov- Nov Jan-
204
04 -05 08
24- 28- 17-
US20080014 Anticancer Agent Containing Dendritic Cell Having Rna Virus
DNAVEC RESEARCH INC. Jun- Apr Jan-
183 Transferred Thereinto
04 -05 08
19- 27- 10-
US20080009
MUTAGENIC HETEROCYCLES Koronis Pharmaceuticals, Inc. Dec- Dec Jan-
496
03 -06 08
29- 20- 10-
US20080009
ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS Baxter Healthcare Corporation Oct- Sep Jan-
040
04 -07 08
6- 7- 3-
US20080004 High Dose, Short Interval Use of Sulfated Polysaccharides for
COMPER WAYNE D Feb- Feb Jan-
236 Treatment of Infections
04 -05 08
9- 25- 3-
US20080004
New Expression Tools for Multiprotein Applications BERGER IMRE Mar- Nov Jan-
228
04 -04 08

21- 31- 3-
US20080004
Albumin fusion proteins BELL ADAM Dec- Jul- Jan-
206
01 06 08
18- 13- 3-
US20080003
ADENOVIRUS FIBER SHAFT COMPOSITION AND METHODS OF USE GenVec, Inc. Oct- Apr Jan-
236
04 -07 08
20- 20- 27-
US20070299 Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa
XENON PHARMACEUTICALS INC. Sep- Sep Dec
081 Desaturase
04 -05 -07
10- 6- 27-
US20070298
Method of Amplifying Nucleic Acid Takara Bio Inc. Dec- Dec Dec
415
03 -04 -07
14- 14- 20-
US20070292
RNA virus vaccines and methods DITTMER DIRK P Dec- Dec Dec
453
05 -06 -07
18- 17- 13-
US20070287 Isoxazole, Dihydroisoxazole, And Oxadiazole Substituted Imidazo
3M INNOVATIVE PROPERTIES COMPANY Jun- Jun Dec
725 Ring Compounds And Method
04 -05 -07
18- 17- 13-
US20070287 Substituted Imidazoquinolines, Imidazopyridines, and
3M INNOVATIVE PROPERTIES COMPANY Jun- Jun Dec
04 -05 -07
22- 22- 13-
US20070286
Live Attenuated Nidovirus Vaccines Vanderbilt University Apr- Apr Dec
872
03 -04 -07
12- 12- 13-
US20070286
Compounds for the Treatment of Periodontal Disease ANACOR PHARMACEUTICALS INC. Jun- Jun Dec
822
06 -07 -07
17- 20- 6-
US20070281 COMPOSITIONS AND METHODS FOR ANALYSIS OF TARGET
DANIELZADEH ROBERT Sep- Jul- Dec
325 ANALYTES
03 06 -07
15- 15- 29-
US20070276
Compositions and Methods for Viral Inhibition CHANG BRYAN Oct- Oct Nov
009
03 -04 -07
28- 12- 29-
US20070275
Therapeutic Treatment Methods AHLEM CLARENCE N Aug- Feb Nov
938
02 -07 -07
28- 12- 29-
US20070275
Therapeutic Treatment Methods AHLEM CLARENCE N Aug- Feb Nov
937
02 -07 -07
28- 6- 29-
US20070275 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment
GOSSELIN GILLES Jun- Sep Nov
883 of flaviviridae infections
02 -06 -07
26- 25- 29-
US20070275 Use of Ulinastatin and Its Pharmaceutical Composition for Treating
GUANGDONG TECHPOOL BIOCHEM PHA May- May Nov
879 Severe Acute Respiratory Syndrome
03 -04 -07
13- 14- 29-
US20070275 Double-Stranded Ribonucleic Acid with Increased Effectiveness in an
Alnylam Pharmaceuticals Jun- Jun Nov
465 Organism
03 -04 -07
30- 30- 29-
US20070275
Compositions And Methods For Improved Mucus Function KING MALCOLM Mar- Mar Nov
091
04 -05 -07
2- 2- 29-
US20070275 Use Of Proteins And Peptides Encoded By The Genome Of A Novel
AZEBI SALIHA Dec- Dec Nov
002 Sars-Associated Coronavirus Strain
03 -04 -07
26- 25- 29-
US20070274
Virulence-Associated Adhesins Novartis Vaccines and Diagnostics, Inc. Jun- Jun Nov
994
03 -04 -07
24- 24- 29-
US20070274 Nutritional Composition Comprising Immunoglobulins and
NUTRICIA NV Aug- Aug Nov
983 Oligosaccharides
04 -05 -07
18- 19- 29-
US20070274
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES MAXYGEN INC Nov- May Nov
950
02 -04 -07
5- 7- 29-
US20070274 Water Soluble Boronic Acid Fluorescent Reporter Compounds and
FANG HAO Sep- Sep Nov
922 Methods of Use Thereof
03 -04 -07
4- 4- 22-
US20070270
Sars Nucleic Acids, Proteins, Vaccines, and Uses Thereof CHOU TE-HUI W Aug- Aug Nov
361
03 -04 -07
Rna Interference Mediated Inhibition of Severe Acute Respiratory 15- 13- 22-
US20070270
Syndrome (Sars) Gene Expression Using Short Interfering Nucleic SIRNA THERAPEUTICS, INC. Apr- Apr Nov
360
Acid 03 -04 -07
Antipathogenic Domestic Livestock House, Disinfectants for 28- 25- 22-

US20070266
Domestic Livestock House, Disinfectants for Living Organisms, TAKAHASHI KAZUO Sep- Aug Nov
957
Feedstuffs and Drinking Water for Animals 04 -05 -07
28- 16- 15-

US20070265
Asthma Treatment Methods AHLEM CLARENCE N Aug- Oct Nov
236
02 -06 -07
2- 2- 15-
US20070265 Hydrolytically-Resistant Boron-Containing Therapeutics And Methods
Anacor Pharmaceuticals May- May Nov
226 Of Use
06 -07 -07
24- 20- 8-
US20070259 Novel Piperidine Derivates as Modulators of Chemokine Receptor
TUCKER HOWARD Jun- Jun Nov
914 Ccr5.
04 -05 -07
18- 17- 8-
US20070259 ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES
PRINCE RYAN B Jun- Jun Nov
907 AND THIAZOLONAPHTHYRIDINES
04 -05 -07

18- 17- 8-
US20070259
Substituted Imidazo Ring Systems and Methods CELEBI AZIM A Jun- Jun Nov
881
04 -05 -07
28- 28- 8-
US20070258
Sars Virus Nucleotide and Amino Acid Sequences and Uses Thereof THE PUBLIC HEALTH AGENCY OF CANADA Apr- Apr Nov
999
03 -04 -07
21- 1-
US20070254 21-
Method of Administration of Dopamine Receptor Agonists DarPharma, Inc. Jul- Nov
906 Jul-04
05 -07
2- 2- 1-
US20070254 Mammalian Genes Involved in Viral Infection and Tumor
RUBIN DONALD H May- May Nov
329 Suppression
02 -03 -07
29- 1-
US20070253 2-Jul-
Copy choice recombination and uses thereof NIMAN HENRY L Dec Nov
978 04
-06 -07
18- 18- 1-
US20070253
Process and device for sterilising ambient air SCHRODER WERNER Oct- Apr Nov
860
04 -07 -07
5- 3- 25-
US20070249 Modulators of Crth-2 Receptor Activity for the Treatment of
ASTRAZENECA AB Oct- Oct Oct-
686 Prostaglandin D2 Mediated Diseases
04 -05 07
11- 13- 25-
US20070248
COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA BLYN LAWRENCE Sep- Mar Oct-
969
03 -07 07
17- 17- 25-
US20070248
Sensitive and Specific Test to Detect Sars Coronavirus AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH Dec- Dec Oct-
949
03 -04 07
4- 31- 18-
US20070244
Thienopyrimidines and Thiazolopyrimidines for Use in Medicine BOWER JUSTIN F Jun- May Oct-
133
04 -05 07
18- 18- 18-
US20070244
Antimicrobial Peptides NOVABIOTICS LIMITED Aug- Aug Oct-
044
04 -05 07
10- 10- 18-
US20070243
System for performing multi-formatted assays GEN-PROBE INCORPORATED Mar- Mar Oct-
600
05 -06 07
11- 13- 18-
US20070243
544
03 -07 07
14- 21- 18-
US20070243
Antiviral Methods AgION Technologies, Inc. Apr- Mar Oct-
263
06 -07 07
7- 7- 11-
US20070238
MODULATION OF ACE2 EXPRESSION BENNETT C F Nov- Dec Oct-
681
06 -06 07
11- 13- 11-
US20070238
116
03 -07 07
28- 27- 4-
US20070231 Immunization Regimen with E4-Deleted Adenovirus Prime and E1-
The Trustees of the University of Pennslyvania Apr- Apr Oct-
347 Deleted Adenovirus Boost
04 -05 07
28- 30- 4-
US20070231
Conjugate vaccines for non-proteinaceous antigens The Brigham and Women's Hospital, Inc. Oct- Oct Oct-
344
05 -06 07
20- 20- 4-
US20070231 METHODS OF GENERATING CHIMERIC ADENOVIRUSES AND USES
The Trustees of the University of Pennsylvania Jun- Jun Oct-
303 FOR SUCH CHIMERIC ADENOVIRUSES
03 -03 07
12- 2- 4-
US20070231
Antimicrobial Silicon Oxide Flakes BUJARD PATRICE May- May Oct-
295
04 -05 07
26- 25- 27-
US20070225
8-Oxoadenine Compound HASHIMOTO KAZUKI Mar- Mar Sep
303
04 -05 -07
19- 14- 27-
US20070225
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES MAXYGEN, INC. May- Sep Sep
205
04 -06 -07
19- 14- 27-
US20070225
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES MAXYGEN, INC. May- Sep Sep
204
04 -06 -07
2- 19- 27-
US20070224
Method and apparatus for analyzing bioprocess fluids BioScale, Inc. May- Dec Sep
700
05 -06 -07
11- 7- 27-
US20070224
COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA BLYN LAWRENCE Sep- Mar Sep
614
03 -07 -07
18- 17- 20-
US20070219
Aryl substituted imidazonaphthyridines AMOS DAVID T Jun- Jun Sep
228
04 -05 -07
20- 20- 20-
US20070219 Bicyclic Heterocyclic Derivatives and Their Use as Inhibitors of
XENON PHARMACEUTICALS INC. Sep- Sep Sep
211 Stearoyl-Coadesaturase (Scd)
04 -05 -07
20- 15- 20-
US20070219
PRODRUGS OF HETEROARYL COMPOUNDS Koronos Pharmaceuticals, Incorporated Jun- May Sep
200
03 -07 -07
24- 24- 20-
US20070219 AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES,
AMOS DAVID T Mar- Mar Sep
196 AND IMIDAZONAPHTHYRIDINES
04 -05 -07
11- 10- 20-
US20070219 Novel Vaccine Containing Adjuvant Capable Of Inducing Mucosal Japan as Represented by the Director-General of National
Aug- Aug Sep
149 Immunity Institute of Infectious Diseases
03 -04 -07

28- 27- 20-
US20070218
Polyvalent Viral Vectors and a System for Production Thereof GAO GUANGPING Apr- Apr Sep
536
04 -05 -07
11- 13- 20-
US20070218
COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA BLYN LAWRENCE Sep- Mar Sep
489
03 -07 -07
21- 20-
US20070218 Methods for rapid identification and quantitation of nucleic acid 21-
ECKER DAVID J Jul- Sep
467 variants Jul-05
06 -07
5- 4- 20-
US20070218
Biotherapeutics, Diagnostics and Research Reagents BIOTECH STUDIO, LLC Jan- Jan Sep
001
04 -05 -07
15- 15- 13-
US20070213 Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and
HARALDSON CHAD A Jun- Jun Sep
04 -05 -07
28- 16- 13-
US20070213
Sepsis Treatment Methods AHLEM CLARENCE N Aug- Oct Sep
309
02 -06 -07
4- 3- 13-
US20070212
Oligopeptide-free cell culture media Baxter Healthcare, S.A. Jan- Jan Sep
770
06 -07 -07
22- 31- 13-
US20070212 Identifying off-target effects and hidden phenotypes of drugs in
Odyssey Thera, Inc. Nov- Aug Sep
677 human cells
04 -06 -07
18- 17- 6-
US20070208 Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and
HEPPNER PHILIP D Jun- Jun Sep
052 thiazolonaphthyridines
04 -05 -07
22- 22- 6-
US20070207
Norovirus and sapovirus antigens COIT DORIS Nov- Nov Sep
526
05 -06 -07
18- 18- 30-
US20070203
Useful indole compounds BARTOLINI WILMIN Aug- Aug Aug
209
05 -06 -07
28- 13- 30-
US20070203
Pharmaceutical compositions Hollis-Eden Pharmaceuticals, Inc. Aug- Oct Aug
107
02 -06 -07
25- 26- 30-
US20070203
RNAI Agents For Anti-SARS Coronavirus Therapy Intradigm Corporation Apr- Apr Aug
082
03 -04 -07
22- 21- 30-
US20070203 SARS and Ebola inhibitors and use thereof, and methods for their
BATES PAUL Jun- Jun Aug
073 discovery
05 -06 -07
1- 1- 30-
US20070203
Casein Derived Peptides And Therapeutic Uses Thereof SIDELMAN ZVI Mar- Sep Aug
060
04 -06 -07
15- 14- 30-
US20070202
Viral Assay University Of Warwick Apr- Apr Aug
492
04 -05 -07
21- 20- 23-
US20070197 SUBSTITUTED TARAXASTANES USEFUL FOR TREATING VIRAL
ACHILLION PHARMACEUTICALS, INC. Feb- Feb Aug
646 INFECTIONS
06 -07 -07
17- 16- 23-
US20070197
NOVEL PHARMACEUTICALS PFIZER LTD Feb- Feb Aug
478
06 -07 -07
22- 22- 23-
US20070196
Using Nucleic Acids for Clinical Microbiology Testing O'HARA STEPHEN Oct- Oct Aug
818
03 -04 -07
20- 22- 23-
US20070196 Methods of preventing or treating sinusitis with oxidative reductive
Oculus Innovative Sciences, Inc. Jan- Jan Aug
434 potential water solution
06 -07 -07
20- 22- 23-
US20070196 Methods of treating or preventing inflammation and hypersensitivity
Oculus Innovative Sciences, Inc. Jan- Jan Aug
357 with oxidative reductive potential water solution
06 -07 -07
23- 23- 23-
US20070196
Composition comprising mixtures of IFN-alpha subtypes HUANG SHIR-LY Feb- Feb Aug
333
06 -06 -07
20- 19- 23-
US20070196 Immunoconjugates with improved efficacy for the treatment of
SUN LE Jan- Jan Aug
274 diseases
06 -07 -07
9- 8- 16-
US20070192
Rice plant having vaccine gene transferred thereinto EBINUMA HIROYASU Apr- Apr Aug
906
04 -05 -07
12- 12- 16-
US20070192
Edible vaccines expressed in soybeans The University of North Carolina Oct- Oct Aug
905
04 -05 -07
21- 22- 16-
US20070191
Short interfering rna (sirna) analogues SANTARIS PHARMA AS Mar- Mar Aug
294
03 -04 -07
24- 24- 16-
US20070190
Technology for preparation of macromolecular microspheres FANG FANG Jan- Jan Aug
163
06 -07 -07
26- 24- 16-
US20070190
9-Substituted 8-oxoadenine compound AstraZeneca Aktiebolag Mar- Mar Aug
071
04 -05 -07
Nucleic acids, polypeptides, methods of expression, and 3- 4- 16-

US20070190
immunogenic compositions associated with SARS corona virus spike ALTMEYER RALF Jun- Dec Aug
065
protein 05 -06 -07

17- 15- 16-
US20070190 Plasmid having three complete transcriptional units and
EGAN MICHAEL Jun- Jun Aug
031 immunogenic compositions for inducing an immune response to hiv
04 -05 -07
8- 8- 9-
US20070185
Modulation of ace2 expression BENNETT C F Mar- Mar Aug
044
05 -05 -07
28- 9- 9-
US20070185 ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND
SEQUOIA PHARMACEUTICALS, INC. Apr- Nov Aug
027 PREVENTION OF INFECTIONS BY CORONAVIRUSES
03 -06 -07
17- 17- 9-
US20070184
Compositions for use in identification of influenza viruses ESHOO MARK W Oct- Oct Aug
434
05 -06 -07
5- 5- 2-
US20070178 Method and diagnostic tests based on flow cytometric analysis of
AGRATI CHIARA Aug- Aug Aug
533 antigen-specific t lymphocytes
03 -04 -07
3- 3- 2-
US20070178
Promoter engineering and genetic control ALPER HAL S Jan- Jan Aug
505
06 -07 -07
12- 2- 2-
US20070178
Antiviral composition comprising p-menthane-3,8-diol CLARKE PAUL D Mar- Mar Aug
048
04 -05 -07
20- 22- 26-
US20070173 Methods of treating or preventing peritonitis with oxidative
Oculus Innovative Sciences, Inc. Jan- Jan Jul-
755 reductive potential water solution
06 -07 07
20- 11- 26-
US20070173
Compositions and methods for preventing infection JOLLA BIOSCIENCES LLC Sep- Dec Jul-
481
02 -06 07
22- 26-
US20070172 8-Jul-
Methods of Producing Antibodies for Diagnostics and Therapeutics CHANG XIAO-JIA Nov Jul-
817 03
-06 07
8- 7- 26-
US20070172
Method for detecting the specificity of activated lymphocyte HU JUN Dec- Dec Jul-
448
03 -04 07
29- 22- 19-
US20070167 Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane
CELEBI AZIM A Dec- Dec Jul-
476 fused imidazo ring compounds
03 -04 07
19- 19- 19-
US20070167 NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED
ZENTARIS GmbH Dec- Dec Jul-
408 CYTOTOXICITY AND USES THEREOF
05 -06 07
5- 5- 19-
US20070166
Methods for detecting parvovirous infections BLUTH MARTIN H May- May Jul-
823
03 -04 07
15- 15- 19-
US20070166
Combination approaches for generating immune responses BARNETT SUSAN W Sep- Sep Jul-
784
03 -04 07
9- 8- 19-
US20070166 Methods , composition and preparations for delivery of immune
ZARRAGA ISIDRO ANGELO E Apr- Apr Jul-
384 response modifiers
04 -05 07
21- 22- 19-
US20070166 Chloroquine coupled antibodies and other proteins with methods for
KOSAK KENNETH M Aug- Feb Jul-
281 their synthesis
04 -07 07
24- 23- 12-
US20070160
VIRAL PROTEASE CHEN XIN Oct- Oct Jul-
981
05 -06 07
4- 3- 5-
US20070155
Sulfone substituted imidazo ring ethers DELLARIA JOSEPH F JR Dec- Dec Jul-
767
03 -04 07
30- 16- 5-
US20070155
Boron-containing small molecules Anacor Pharmaceuticals Dec- Aug Jul-
699
05 -06 07
26- 5-
US20070155 Artificial cpg single-stranded oligodeoxynucleotide and antiviral use 25-
WANG LIYING Jul- Jul-
683 thereof Jul-03
04 07
29- 7- 5-
US20070154 Supports for assaying analytes and methods of making and using
FRUTOS ANTHONY G Dec- Jun Jul-
348 thereof
05 -06 07
8- 7- 28-
US20070149 MAYO FOUNDATION FOR MEDICAL EDUCATION AND
Antiviral Compositions and Methods Nov- Nov Jun-
487 RESEARCH
05 -06 07
28- 25- 28-
US20070148
Methods for detecting conformational changes in bioentities O'MALLEY SHAWN M Dec- Oct Jun-
670
05 -06 07
25- 25- 21-
US20070141 Biomimetic Biodetector of Toxins, Viruses, Bacteria, and Biological
HARMON H J Oct- Oct Jun-
597 Factors
05 -06 07
16- 26- 21-
US20070141
Treating severe acute respiratory syndrome HEMISPHERx BIOPHARMA May- Jan Jun-
080
03 -07 07
9- 7- 21-
US20070141
Treatment of inflammatory respiratory diseases Schering Aktiengesellschaft May- May Jun-
053
03 -04 07
2- 14-
US20070136 3-Jul-
Expression of a recombinant transgene Board of Trustees Operating Michigan State University Jul- Jun-
890 03
04 07
8- 8- 14-
US20070135 Novel inhibitors of cysteine proteases, the pharmaceutical
BOISSY GUILLAUME Dec- Dec Jun-
439 compositions thereof and their therapeutic applications
05 -05 07

Method for controlling sr protein phosphorylation, and antiviral 26- 24- 14-
US20070135
agents whose active ingredients comprise agents that control sr FUKUHARA TAKESHI Dec- Dec Jun-
367
protein activity 03 -04 07
27- 26- 14-

US20070134 Dengue virus detection measured by immunocytometry in a
BURGESS TIMOTHY Oct- Oct Jun-
695 dendritic cell surrogate
05 -06 07
27- 26- 14-
US20070134
Method for the measurement of dengue virus binding inhibition BURGESS TIMOTHY Oct- Oct Jun-
694
05 -06 07
2- 3- 14-
US20070134
Hmpv treatment with ribavirin and anti-hmpv antibody ViroNovative B.V. May- May Jun-
255
03 -04 07
13- 12- 14-
US20070134 Inactivated host cell delivery of polynucleotides encoding
XU FENG Aug- Aug Jun-
214 immunogens
03 -04 07
Isoflavone derivatives of tectoridin, the preparation thereof and the 15- 14- 31-
US20070123
anti-virus medicines containing the same as an effective CHENGDU DIKANG PHARMACEUTICAL INSTITUTE May- May May
566
constituents 03 -04 -07
18- 20- 24-

US20070116
Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant MILLER CHRISTOPHER C Nov- Nov May
785
05 -06 -07
10- 10- 24-
US20070116
Sars coronavirus s proteins and uses thereof FIELDING BURTRAM C Dec- Dec May
716
03 -04 -07
23- 23- 24-
US20070116
Detection device and methods associated therewith COOK RICHARD A Jun- Jun May
600
05 -06 -07
4- 29- 17-
US20070111
Vero cell line adapted to grow in suspension DAELLI MARCELO G Oct- Sep May
309
05 -06 -07
16- 16- 17-
US20070111
Methods and Devices for Quantitative Viral Assays SHU YING Nov- Nov May
296
05 -06 -07
23- 23- 17-
US20070111 Detection of mutations in a gene associated with resistance to viral
Illumigen Biosciences, Inc. Aug- Aug May
231 infection, OAS2 and OAS3
05 -06 -07
16- 12- 10-
US20070105 Severe acute respiratory syndrome DNA vaccine compositions and
Vical Incorporated May- May May
193 methods of use
03 -04 -07
6- 27- 10-
US20070104
COMPOSITIONS AND METHODS FOR TREATMENT OF RHINOVIRUS THE QUIGLEY CORPORATION Aug- Oct May
808
01 -06 -07
13- 14- 10-
US20070104
Vaccines, immunotherapeutics and methods for using the same CHATTERGOON MICHAEL A Jun- Jun May
686
03 -04 -07
24- 24- 3-
US20070099
Antiviral compounds and methods Biotron Limited Jun- Jun May
968
04 -04 -07
25- 24- 3-
US20070099 Hydroxylamine and oxime substituted imidazoquinolines,
3M INNOVATIVE PROPERTIES COMPANY Nov- Nov May
901 imidazopyridines, and imidazonaphthyridines
03 -04 -07
6- 7- 3-
US20070099 Glycyrrhizin or derivatives thereof for for treating or preventing
Johann Wolfgang Goethe University Jun- Jun May
855 severe acute respiratory syndrome (sars)
03 -04 -07
27- 15- 3-
US20070099
Method for detecting sars coronavirus EIKEN KAGAKU KABUSHIKI KAISHA Jun- Jun May
178
03 -04 -07
29- 30- 3-
US20070098 Methods for the Elimination of Pathogens and Other Particulate
CHANDAWARKAR RAJIV Y Oct- Oct May
735 Agents
05 -06 -07
25- 27- 3-
US20070098
GITR binding molecules and uses therefor TolerRx, Inc. Mar- Mar May
719
05 -06 -07
22- 24- 26-
US20070093
Molecular nephrotoxicology modeling CASTLE ARTHUR Nov- Nov Apr-
969
02 -03 07
4- 26-
US20070092 15-
Diagnostics for sars virus Temasek Life Sciences Laboratory Feb Apr-
938 Jul-03
-04 07
8- 10- 26-
US20070092
Severe acute respiratory syndrome HAYNES BARTON F May- May Apr-
936
03 -04 07
20- 20- 26-
US20070092
Microarray for pathogen identification COMBIMATRIX CORP Oct- Oct Apr-
871
05 -06 07
14- 9- 19-
US20070087 TREATMENT OR PREVENTION OF RESPIRATORY VIRAL INFECTIONS
SCICLONE PHARMACEUTICALS, INC. May- Nov Apr-
974 WITH IMMUNOMODULATOR COMPOUNDS
04 -06 07
17- 17- 19-
US20070087
Compositions for use in identification of influenza viruses ESHOO MARK W Oct- Oct Apr-
341
05 -06 07
17- 17- 19-
US20070087
340
05 -06 07
17- 17- 19-
US20070087
339
05 -06 07

17- 17- 19-
US20070087
338
05 -06 07
17- 17- 19-
US20070087
337
05 -06 07
17- 17- 19-
US20070087
336
05 -06 07
17- 17- 19-
US20070087
Pulmonary stem cells, related methods and kits of parts LING THAI-YEN Oct- Oct Apr-
332
05 -05 07
24- 24- 19-
US20070087
Rab9a, rab11a, and modulators thereof related to infectious disease UNIV VANDERBILT Feb- Feb Apr-
008
04 -05 07
23- 27- 12-
US20070082
Use of a plastic composition and a product obtained thereby POLYGIENE AB Feb- Jan Apr-
971
04 -05 07
29- 25- 5-
US20070077
Stem cell expansion and uses DOWDING CHARLES Sep- Mar Apr-
201
04 -06 07
25- 24- 29-
US20070072
Substituted imidazo ring systems and methods AMOS DAVID T Nov- Nov Mar
893
03 -04 -07
24- 24- 29-
US20070072 Use of chimeric receptors in a screening assay for identifying
BATES ELIZABETH E M Mar- Mar Mar
202 agonists and antagonists of cell receptors
05 -06 -07
29- 1- 22-
02 -06 -07
29- 1- 22-
NOZAKI MASAKO Nov- Nov Mar
02 -06 -07
12- 12- 22-
US20070066
Oxime substituted imidazoquinolines AMOS DAVID T Aug- Aug Mar
639
04 -04 -07
21- 20- 22-
US20070066 Topical administration permitting prolonged exposure of target cells
INTROGEN THERAPEUTICS INC Jan- Jan Mar
552 to therapeutic and prophylactic nucleic acids
05 -06 -07
20- 28- 22-
US20070065 Systems for detection and production of respiratory, herpes and
Diagnostic Hybrids, Inc. Sep- Apr Mar
939 enteric viruses
05 -06 -07
18- 30- 22-
US20070065
Interferon-Alpha Polypeptides and Conjugates MAXYGEN INC Nov- Oct Mar
407
02 -06 -07
3- 1- 15-
US20070060
Alkoxy substituted imidazoquinolines HARALDSON CHAD A Oct- Oct Mar
754
03 -04 -07
29- 1- 15-
02 -06 -07
30- 13- 15-
US20070060 Targeted delivery of antiviral compounds through hemoglobin
ADAMSON J G Apr- Nov Mar
535 bioconjugates
98 -06 -07
15- 22- 15-
US20070060
Chloroquine combination drugs and methods for their synthesis KOSAK KENNETH M Sep- Feb Mar
499
05 -06 -07
6- 15-
US20070059 COMPUTER-IMPLEMENTED BIOLOGICAL SEQUENCE IDENTIFIER The Government of the US, as represented by the 2-Jul-
Jun Mar
728 SYSTEM AND METHOD Secretary of the Navy 04
-06 -07
31- 28- 15-
US20070059 Materials and methods for the detection of severe acute respiratory
ERAGEN BIOSCIENCES INC Jan- Jul- Mar
686 syndrome virus (SARS)
04 06 -07
29- 1- 15-
02 -06 -07
29- 1- 8-
02 -06 -07
11- 10- 8-
US20070054
Quaternary ammonium halides for treatment of infectious conditions NANOBIO CORP Apr- Apr Mar
834
05 -06 -07
20- 8-
US20070053 IL28 and IL29 TRUNCATED CYSTEINE MUTANTS AND ANTIVIRAL 20-
SHEPPARD PAUL O Jul- Mar
933 METHODS OF USING SAME Jul-05
06 -07
22- 21- 8-
US20070053
Nematode polypeptide adjuvant Not Available Jan- Jan Mar
920
03 -04 -07
8- 8- 8-
US20070053
Sars FOUCHIER RONALDUS A M Apr- Apr Mar
878
03 -04 -07
10- 12- 1-
US20070048 DETECTION OF TARGET MOLECULES WITH LABELED NUCLEIC ACID
LI YOUGEN Jun- Jun Mar
759 DETECTION MOLECULES
05 -06 -07
1- 1- 1-
US20070048
Methods for assaying analytes LESLIE THOMAS M Sep- Sep Mar
747
05 -05 -07
9- 8- 1-
US20070048
Albumin fusion proteins Human Genome Sciences, Inc. Feb- Aug Mar
282
04 -06 -07

2- 2- 22-
US20070042 Method and apparatus for detecting estradiol and metabolites
BioScale, Inc. May- May Feb
441 thereof using an acoustic device
05 -06 -07
12- 12- 22-
US20070042
Method of probe design and/or of nucleic acids detection LEE CHARLIE Aug- Aug Feb
388
05 -05 -07
BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY 16- 26- 22-

US20070042
VIRAL AND VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES Rosetta Genomics Jan- May Feb
381
THEREOF 03 -04 -07
22- 13- 22-

US20070042
Multi-allelic molecular detection of sars-associated coronavirus KOSTRIKIS LEONDIOS G Aug- Aug Feb
351
03 -04 -07
14- 22-
US20070042 Methods and compositions for detecting sars virus and other 14-
CHENG JING Jul- Feb
350 infectious agents Jul-03
03 -07
13- 14- 22-
US20070041 Nucleic acid sequences encoding and compositions comrpising ige
BOYER JEAN D Jun- Jun Feb
941 signal peptide and/or il-15 and methods for using the same
03 -04 -07
24- 10- 15-
US20070037 Oligonucleotide compound and method for treating nidovirus
AVI BIOPHARMA INC Dec- May Feb
763 infections
03 -06 -07
2- 2- 15-
US20070037 Methods and apparatus for detecting bacteria using an acoustic
231 device
05 -06 -07
2- 2- 15-
US20070037 Methods and apparatus for detecting viruses using an acoustic
142 device
05 -06 -07
9- 9- 15-
US20070037
Methods and compositions for detecting sars virus CAPITAL BIOCHIP COMPANY, LTD. May- May Feb
140
03 -03 -07
30- 30- 15-
US20070036 Adeno-associated virus (aav) clades, sequences, vectors containing
The Trutees of the University of Pennsylvania Sep- Sep Feb
760 same, and uses therefor
03 -04 -07
23- 23- 15-
US20070036 Treatment or prevention of respiratory viral infections with alpha
SciClone Pharmaceuticals, Inc. Apr- Apr Feb
744 thymosin peptides
03 -04 -07
3- 2- 15-
US20070034 Electrochemistry and electrogenerated chemiluminescence with a
BARD ALLEN J Jun- Jun Feb
529 single faradaic electrode
05 -06 -07
5- 5- 8-
US20070032
Novel cysteine protease inhibitors and their therapeutic applications BOISSY GUILLAUME Aug- Aug Feb
499
05 -05 -07
29- 10- 8-
US20070031 Modified viral particles with immunogenic properties and reduced
CHAM BILL E Jun- Apr Feb
923 lipid content useful for treating and preventing infectious diseases
00 -06 -07
5- 20- 8-
US20070031 Methods of constructing biodiverse gene fragment libraries and
Phylogica Limited May- Feb Feb
832 biological modulators isolated therefrom
99 -04 -07
23- 23- 8-
US20070031
Assay cartridges and methods for point of care instruments BLANKFARD MARTIN Jun- Jun Feb
283
05 -06 -07
9- 8- 1-
US20070027
Albumin fusion proteins HASELTINE WILLIAM A Feb- Aug Feb
306
04 -06 -07
11- 6- 1-
US20070026 Methods and compositions for identifying chemical or biological
GHC TECHNOLOGIES INC Apr- Apr Feb
391 agents using multiplexed labeling and colocalization detection
05 -06 -07
16- 31- 1-
US20070026
Anti-coronavirus agent Toagosei Co., Ltd. Oct- Oct Feb
087
03 -03 -07
17- 6- 1-
US20070026
Interferon beta in severe acute respiratory syndrome (sars) ARES TRADING S.A. Apr- Apr Feb
014
03 -04 -07
27- 16- 1-
US20070026 Systems and methods for identifying replikin scaffolds and uses of
BOGOCH ELENORE S Mar- Feb Feb
009 said replikin scaffolds
01 -06 -07
19- 13- 1-
US20070025
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES MAXYGEN, INC. May- Sep Feb
966
04 -06 -07
25- 25-
US20070021 Methods of reducing risk of infection from pathogens with soluble 25-
PARION SCIENCES INC Jul- Jan-
439 amide and ester pyrazinoylguanidine sodium channel blockers Jul-05
05 07
9- 25- 25-
US20070021
Composition and its Therapeutic Use INSIGNION HOLDINGS LTD AND VER Aug- Sep Jan-
326
02 -06 07
19- 13- 25-
US20070020
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES MAXYGEN, INC. May- Sep Jan-
734
04 -06 07
19- 13- 25-
US20070020
INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES MAXYGEN, INC. May- Sep Jan-
235
04 -06 07
19- 2- 18-
US20070015
System and methods for nucleic acid and polypeptide selection WILLIAMS RICHARD B May- May Jan-
181
00 -06 07

1- 30- 18-
US20070015
Expression profiles for microbial infection Z-BioMed, Inc. Jun- Nov Jan-
172
05 -05 07
6- 5- 18-
US20070014
Endoribonuclease and uses thereof LEE CHOW Jun- Jun Jan-
778
05 -06 07
29- 29- 18-
US20070014
Steroid analogs and characterization and treatment methods DOWDING CHARLES Sep- Sep Jan-
719
04 -05 07
27- 26- 11-
US20070009
Promoter engineering and genetic control ALPER HAL S Apr- Apr Jan-
932
05 -06 07
11- 6- 11-
US20070009
Methods and apparatuses for detecting chemical or biological agents GHC TECHNOLOGIES INC Apr- Apr Jan-
884
05 -06 07
10- 10- 4-
US20070004 Signal measuring system for conducting real-time amplification
GEN-PROBE INCORPORATED Mar- Mar Jan-
028 assays
05 -06 07
28- 27- 4-
US20070003 Purified trimeric S protein as vaccine against severe acute
CHU KID Jun- Jun Jan-
577 respiratory syndrome virus infections
05 -06 07
9- 9- 4-
US20070003 Use of hab18g/cd147 molecule as target for antiviral antagonists
CHEN ZHINAN Jun- Jun Jan-
565 and thus obtained antiviral antagonist
03 -03 07
21- 18- 28-
US20060293
Phenoxiacetic acid derivatives BONNERT ROGER V Aug- Aug Dec
352
03 -04 -06
29- 28-
US20060293 29-
Pyridyl derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. Jul- Dec
308 Jul-03
04 -06
13- 13- 28-
US20060293
Dual functional oligonucleotides for use as anti-viral agents UNIVERSITY OF MASSACHUSETTS Apr- Apr Dec
267
05 -06 -06
4- 4- 28-
US20060292 Proteins encoded by the severe acute respiratory syndrome (SARS)
Agency for Science, Technology and Research Aug- Aug Dec
178 coronavirus and a role in apoptosis
04 -05 -06
22- 24- 28-
US20060292 Plasma or serum fraction for the treatment or prevention of
BUCKHEIT ROBERT W JR Apr- Apr Dec
162 bacterial infections
05 -06 -06
26- 28- 28-
US20060292
L-SIGN polymorphisms and methods involving use of same GARDNER JASON P Mar- Mar Dec
151
04 -05 -06
18- 21-
US20060287 Methods and compositions for inducing antigen-specific immune 18-
COLEY PHARMACEUTICAL GROUP LTD Jul- Dec
263 responses Jul-04
05 -06
24- 28- 21-
US20060286
Methods for detection and production of influenza viruses Diagnostic Hybrids, Inc. Apr- Apr Dec
667
98 -06 -06
30- 30- 21-
US20060286
Vaccine compositions and methods of treating coronavirus infection ID Biomedical Corporation of Quebec Jun- Jun Dec
124
04 -05 -06
23- 21-
US20060286 25-
Adenoviral vector-based vaccines BROUGH DOUGLAS E Jan Dec
121 Jul-03
-06 -06
23- 6- 21-
US20060286 Compositions and methods for treatment of chronic and infectious
Biokit S.A. Dec- Apr Dec
119 diseases
03 -06 -06
9- 17- 14-
US20060281 Compositions and methods using lentivirus-based vectors for
VIRXSYS CORPORATION Sep- Aug Dec
128 generating immune responses
03 -06 -06
13- 13- 14-
US20060281
Agonistic Binding Molecules to the Human OX40 Receptor BAKKER ALEXANDER BERTHOLD H Jun- Jun Dec
072
02 -03 -06
Method of preventing virus: cell fusion by inhibiting the function of 4- 3- 14-

US20060280
the fusion initiation region in rna viruses having class i membrane GARRY ROBERT F Nov- Nov Dec
754
fusogenic envelope proteins 03 -04 -06
22- 24- 14-

US20060280 Plasma or serum fraction for treatment or prevention of abnormal
BUCKHEIT ROBERT W JR Apr- Apr Dec
748 cell proliferation
05 -06 -06
19- 19- 14-
US20060280
Interferon for treating or preventing a coronaviral infection Viragen, Inc May- May Dec
723
03 -04 -06
4- 17- 14-
US20060280 Method of treating autoimmune disease by inducing antigen
BOWDISH KATHERINE S Mar- Dec Dec
679 presentation by tolerance inducing antigen presenting cells
03 -04 -06
10- 10- 7-
US20060276
Method for determining the amount of an analyte in a sample Gen-Probe Incorporated Mar- Mar Dec
972
05 -06 -06
20- 19- 7-
US20060275
Assay method and apparatus with reduced sample matrix effects BLANKFARD MARTIN Dec- Dec Dec
841
04 -05 -06
4- 3- 7-
US20060275
Mutations in OAS1 genes FELLIN P C May- May Dec
802
05 -06 -06
5- 24- 7-
US20060275
Compositions for use in identification of orthopoxviruses ISIS Pharmaceuticals, Inc. Dec- Aug Dec
749
03 -05 -06
24- 22- 7-
US20060275
Antiviral preparations obtained from a natural cinnamon extract OVADIA MICHAEL Dec- Jun Dec
515
03 -06 -06

23- 6- 7-
US20060275 Vaccine compositions for prevention of chronic and infectious
Biokit S.A. Dec- Apr Dec
317 diseases
03 -06 -06
23- 6- 30-
US20060270
Diagnosis and treatment of Alzheimer disease Biokit S.A. Dec- Apr Nov
835
03 -06 -06
24- 24- 30-
US20060270
Use of chalcones for the treatment of viral disorders BODDUPALLI SEKHAR May- May Nov
614
05 -05 -06
13- 12- 30-
US20060270
Cell lines for production of replication-defective adenovirus HOWE JOHN A Dec- Dec Nov
041
04 -05 -06
26- 26- 30-
US20060270 Inactivation of a pathogen in a sample by a treatment with formalin
BARRETT NOEL May- May Nov
017 and UV light
05 -05 -06
23- 5- 30-
US20060269
METHOD FOR REDUCING LYSOZYME ENZYMATIC ACTIVITY Biokit S.A. Dec- Apr Nov
976
03 -06 -06
24- 23- 30-
US20060269
Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists DOLLET SANDRA Mar- Mar Nov
936
05 -06 -06
16- 10- 30-
US20060269 Antisense antiviral compound and method for treating ssRNA viral
AVI BIOPHARMA INC Sep- May Nov
911 infection
04 -06 -06
1- 17- 30-
US20060269
Accelerated vaccination GEISBERT THOMAS W Aug- Jan Nov
572
03 -06 -06
27- 26- 30-
US20060269 Serine proteases with altered sensitivity to activity-modulating
COCO WAYNE M May- May Nov
538 substances
05 -06 -06
4- 3- 23-
US20060264
Purine derivatives PFIZER LTD May- May Nov
448
05 -06 -06
18- 16- 23-
US20060264 Substituted indole derivatives for pharmaceutical compositions for
BONNERT ROGER V Aug- Aug Nov
444 treating respiratory diseases
03 -04 -06
7- 6- 23-
US20060264
Novel compounds BONNERT ROGER Apr- Apr Nov
435
03 -04 -06
20- 20- 23-
US20060263 Compositions and methods for treatment of sever acute respiratory
SIBER GEORGE R May- May Nov
847 syndrome (sars)
03 -04 -06
9- 5- 23-
US20060263 Peptides and mixtures thereof for use in the detection of severe
HOUDE MICHEL May- May Nov
765 acute respiratory syndrome-associated coronavirus (sars)
03 -04 -06
3- 3- 16-
US20060259
Rapid identification of microbial agents ECKER DAVID J Mar- Mar Nov
249
04 -05 -06
19- 14- 16-
US20060258 Inhibition of SARS-associated coronavirus (SCoV) infection and
UNIV HONG KONG May- Jun Nov
611 replication by RNA interference
03 -06 -06
28- 28- 16-

US20060258 ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND
ERICKSON JOHN W Apr- Apr Nov
577 PREVENTION OF INFECTIONS BY CORONAVIRUSES
03 -04 -06
27- 22- 16-

US20060257 Integration of fluids and reagents into self-contained cartridges
ANSLYN ERIC Feb- Dec Nov
993 containing sensor elements
04 -04 -06
27- 22- 16-
992 containing sensor elements and reagent delivery systems
04 -04 -06
Integration of fluids and reagents into self-contained cartridges 27- 22- 16-
US20060257
containing particle-based sensor elements and membrane-based ANSLYN ERIC Feb- Dec Nov
991
sensor elements 04 -04 -06
6- 7- 16-
US20060257 Methods and kits for propagating and evolving nucleic acids and
RNA LINE OY Jun- Jun Nov
976 proteins
03 -04 -06
2- 2- 16-
US20060257 Methods and apparatus for detecting cardiac injury markers using
BioScale, Inc. May- May Nov
945 an acoustic device
05 -06 -06
27- 22- 16-
941 containing particle and membrane sensor elements
04 -04 -06
21- 21- 16-
US20060257 Method for isolating intracellular antibodies able to neutralize
LINE GENOMICS S.P.A. Nov- Nov Nov
925 protein interactions
02 -03 -06
24- 16-
US20060257 Methods for identifying small molecules that modulate premature 24-
ALMSTEAD NEIL G Jul- Nov
866 translation termination and nonsense mediated mrna decay Jul-02
03 -06
12- 12- 16-
US20060257 Screening assay for inhibitors of severe acute respiratory syndrome
Wright State University May- May Nov
861 (SARS) using SELDI-TOF Mass Spectrometry
05 -06 -06
27- 22- 16-
US20060257
Membrane assay system including preloaded particles BALLARD KARRI L Feb- Dec Nov
854
04 -04 -06
10- 9- 16-
US20060257
Severe acute respiratory syndrome coronavirus Chiron Corporation Apr- Apr Nov
852
03 -04 -06

2- 2- 9-
US20060253 Method of using oxidative reductive potential water solution in
Oculus Innovative Sciences, Inc. May- May Nov
060 dental applications
05 -06 -06
29- 9-
US20060252 30-
Piperazine derivatives and their use as therapeutic agents XENON PHARMACEUTICALS INC. Jul- Nov
767 Jul-03
04 -06
29- 29- 2-
US20060246
Methods and compositions for polytopic vaccination DEEM MICHAEL W Apr- Apr Nov
081
05 -05 -06
23- 23- 26-
US20060241 Method of treating second and third degree burns using oxidative
Oculus Innovative Sciences, Inc. Mar- Mar Oct-
546 reductive potential water solution
05 -06 06
2- 8- 26-
US20060240 Neutralizing monoclonal antibodies against severe acute respiratory
HE YUXIAN Jun- Feb Oct-
551 syndrome-associated coronavirus
04 -06 06
19- 26-
US20060240 21-
Methods and compositions for infectious cDNA of SARS coronavirus UNIV NORTH CAROLINA Jan Oct-
530 Jul-03
-06 06
19- 26-
US20060240 21-
Soluble fragments of the SARS-CoV spike glycoprotein DIMITROV DIMITER S Jan Oct-
515 Jul-03
-06 06
11- 12- 26-
US20060240
Compositions for use in identification of adenoviruses BLYN LAWRENCE Sep- Apr Oct-
412
03 -06 06
23- 23- 19-
US20060235 Method of treating skin ulcers using oxidative reductive potential
Oculus Innovative Sciences, Inc. Mar- Mar Oct-
350 water solution
05 -06 06
16- 16- 19-
US20060234
Boron-containing small molecules Anacor Pharmaceuticals Feb- Feb Oct-
981
05 -06 06
10- 10- 19-
US20060234 Method for reducing the presence of amplification inhibitors in a
Gen-Probe Incorporated Mar- Mar Oct-
263 reaction receptacle
05 -06 06
12- 11- 12-

US20060229 Use of indomethacin and derivatives as broad-spectrum antiviral
Universita' Degli Studi Di Roma "Tor Vergata" Aug- Aug Oct-
356 drugs and corresponding pharmaceutical compositions
03 -04 06
24- 24- 12-

US20060228 Constructs binding to phosphatidylserine and their use in disease
PEREGRINE PHARMACEUTICALS INC Jan- Jan Oct-
299 treatment
05 -06 06
14- 5-
US20060223 14-
Methods for treating Hepatitis C AREFOLOV ALEXANDER Jul- Oct-
863 Jul-04
05 06
14- 5-
US20060223 15-
Anti-coronavirus drug Arigen, Inc. Jul- Oct-
847 Jul-03
04 06
5- 5- 5-
US20060223 Supports useful in incorporating biomolecules into cells and methods
FRUTOS ANTHONY G Apr- Apr Oct-
184 of using thereof
05 -05 06
5- 5- 5-
US20060223
Spotting compositions and methods of use thereof BUNCH THOMAS A Apr- Apr Oct-
074
05 -05 06
17- 4- 28-
US20060216 Virus-like particles, methods of preparation, and immunogenic
COMPANS RICHARD W May- Apr Sep
702 compositions
02 -06 -06
7- 6- 21-
US20060211
Novel compounds ASTRAZENECA AB Apr- Apr Sep
765
03 -04 -06
Use of phenylmethimazoles, methimazole derivatives, and

16- 17- 21-
US20060211 tautomeric cyclic thiones for the treatment of
BENAVIDES-PERALTA URUGUAYSITO Mar- May Sep
752 autoimmune/inflammatory diseases associated with toll-like
04 -05 -06
receptor overexpression
10- 10- 21-

US20060211 Method for continuous mode processing of multiple reaction
Gen-Probe Incorporated Mar- Mar Sep
130 receptacles in a real-time amplification assay
05 -06 -06
20- 15- 21-
US20060211 Methods of generating chimeric adenoviruses and uses for such
The Trustees of the University of Pennsylvania Jun- Jun Sep
115 chimeric aden oviruses
03 -04 -06
2- 21-
US20060210 2-Jul-
Re-sequencing pathogen microarray AGAN BRIAN K Jul- Sep
967 04
05 -06
10- 10- 21-
US20060210
Signal measuring system having a movable signal measuring device GEN-PROBE INCORPORATED Mar- Mar Sep
433
05 -06 -06
29- 14-
US20060205 29-
Pyridazine derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. Jul- Sep
713 Jul-04
04 -06
3- 3- 14-
US20060205
Compositions for use in identification of adventitious viruses SAMPATH RANGARAJAN Mar- Mar Sep
040
05 -06 -06
10- 10- 14-
US20060204
Method for performing multi-formatted assays Gen-Probe Incorporated Mar- Mar Sep
997
05 -06 -06
29- 7-
US20060199 30-
Pyridyl derivatives and their use as therapeutic agents ABREO MELWYN Jul- Sep
802 Jul-03
04 -06

14- 7-
US20060199 15-
Coronavirus S peptides CHONG PELE C S Jul- Sep
176 Jul-04
05 -06
25- 25- 31-
US20060195
Delivery of immune response modifier compounds KEDL ROSS M Aug- Aug Aug
067
03 -04 -06
28- 27- 31-
US20060193
Virucidal disinfectant ARNDT ANDREAS Jan- Jan Aug
745
05 -06 -06
Reagents, devices and methods for proteomic analysis with 21- 16- 24-
US20060190
applications including diagnostics, vaccines, quality control and HOFFMANN GEOFFREY W Apr- Mar Aug
189
research 04 -06 -06
14- 12- 24-

US20060189
Lipid-modified immune response modifiers WIGHTMAN PAUL D Aug- Aug Aug
644
03 -04 -06
10- 8- 24-
US20060189
Use of lipid conjugates in the treatment of infection YEDGAR SAUL Jan- Sep Aug
571
00 -05 -06
10- 8- 24-
US20060189
570
00 -05 -06
10- 8- 24-
US20060189
Use of lipid conjugates in the treatment of infection OJCIUS DAVID Jan- Sep Aug
569
00 -05 -06
10- 8- 24-
US20060189
568
00 -05 -06
22- 24-
US20060189 22-
Preventive or therapeutic composition for viral infectious disease FURUKAWA SATORU Jul- Aug
542 Jul-03
04 -06
14- 13- 24-
US20060188
Peptides, antibodies, and methods for the diagnosis of SARS AU MUN Y D Jun- Jun Aug
519
04 -05 -06
Composition comprising soluble glucan oligomer from 23- 23- 10-

US20060178
saccharomyces cerevisiae is2 inhibiting the swine influenza (SIV) CHUNG BONG H Jun- Jun Aug
341
and transmissible gastroenteritis coronavirus (tgev) 03 -04 -06
Nucleic acid primer set, nucleic acid probe set and method for 23- 23- 10-
US20060177
detecting respiratory disease virus using the primer set and probe HUH NAM Dec- Dec Aug
849
set 04 -05 -06
13- 15- 10-

US20060177
Systems and methods for identifying diagnostic indicators BOROZAN IVAN Aug- Aug Aug
837
04 -05 -06
8- 8- 10-
US20060177 Novel high-throughput screening method of drug for bioactive
ENDO YAETA Sep- Sep Aug
813 protein
03 -04 -06
3- 2- 3-
US20060171
SARS vaccine Consejo Superior de Investigaciones Cientificas Sep- Sep Aug
962
04 -05 -06
6- 22- 3-
US20060171
Antiviral activity from medicinal mushrooms STAMETS PAUL Jan- Mar Aug
958
04 -06 -06
3- 2- 27-
US20060165 Nucleic acid sequences encoding proteins capable of associating into
Fort Dodge Veterinaria S.A. Sep- Sep Jul-
723 a virus-like particle
04 -05 06
29- 27-
US20060165 Immunogenic compositions for gram positive bacteria such as 29-
BAROCCHI MICHELLE Jul- Jul-
716 streptococcus agalactiae Jul-04
05 06
13- 11- 27-
US20060163
Product for absorption purposes HJERTEN MARIE-CHRISTINE Jun- Jun Jul-
149
03 -04 06
22- 21- 20-
US20060160
Harnessing network biology to improve drug discovery Odyssey Thera, Inc. Nov- Nov Jul-
109
04 -05 06
20- 13-
US20060154 21-
Antigenic peptides of SARS coronavirus and uses thereof GOUDSMIT JAAP Jan Jul-
243 Jul-03
-06 06
9- 9- 13-
US20060153 Inhibition of sars coronavirus infection with clinically approved
STANTON LAWRENCE W Jun- Jun Jul-
803 antiviral drugs
03 -04 06
20- 21- 6-
US20060147
System for detecting polynucleotides CHOI K Y May- Nov Jul-
958
03 -05 06
18- 16- 29-
US20060143
Use of golden hamster as infectivity model of SARS CONTAMIN HUGUES Aug- Aug Jun-
719
04 -05 06
4- 2- 29-
US20060142 3D-Structure model of SARS coronavirus 3CL protease and anti-
SHANGHAI LEAD DISCOVERY PHARMA Jun- Dec Jun-
383 SARS drugs
03 -05 06
8- 23- 29-
US20060142 Compositions and methods for targeted delivery of immune
3M INNOVATIVE PROPERTIES CO Dec- Feb Jun-
202 response modifiers
00 -06 06
4- 4- 29-
US20060140 Cell surface expression vector of sars virus antigen and
CHOI JAE C Jun- Jun Jun-
971 microorganisms transformed thereby
03 -04 06
13- 19- 22-
US20060135
Antiviral oligonucleotides JUTEAU JEAN-MARC Sep- Oct Jun-
458
02 -05 06

17- 31- 22-
US20060135 Use of angiotensin receptor blockers (ARBs) to treat diseases
MOSKOWITZ DAVID W Apr- Mar Jun-
422 associated with excess ACE
03 -04 06
19- 22-
US20060134 21-
Super-antigen fusion proteins and the use thereof Healthbanks Biotech Co., Ltd. Jul- Jun-
753 Jul-04
05 06
17- 16- 22-
US20060134 Compositions and methods for determining the presence of SARS
GETMAN DAMON K Apr- Apr Jun-
609 coronavirus in a sample
03 -04 06
26- 20- 22-
US20060134 Microporous materials, methods, and articles for localizing and
SMITH ROGER E Nov- Nov Jun-
397 quantifying analytes
02 -03 06
15- 15- 15-
US20060128 Human tissue antigen-binding peptides and their amino acid
CHEN SHOW-LI Dec- Dec Jun-
628 sequences
04 -04 06
6- 6- 8-
US20060123 Civet animal model system for Severe Acute Respiratory Syndrome
CHEN JINDING Dec- Dec Jun-
499 (SARS) coronavirus infection and uses thereof
04 -04 06
3- 2- 8-
US20060122
Antigen delivery platform GOVERNMENT OF THE U S A AS REP Dec- Dec Jun-
368
04 -05 06
20- 8-
US20060121 22-
Binding molecules against SARS-coronavirus and uses thereof CRUCELL Jan Jun-
580 Jul-03
-06 06
27- 27- 8-
US20060121 Use of modulators of EphA2 and EphrinA1 for the treatment and
MEDIMMUNE, INC. Oct- Oct Jun-
043 prevention of infections
04 -05 06
30- 11- 1-
US20060115 Detection, characterization and treatment of viral infection and
BROWN EARL Sep- Oct Jun-
875 methods thereof
03 -05 06
27- 27- 1-
US20060113
Electromagnetic wave applicator ZAIDAN HOJIN HANDOTAI KENKYU SHINKOKAI Nov- Nov Jun-
298
02 -03 06
20- 13- 25-
US20060111
ARYL SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES CO Dec- Jan May
387
02 -06 -06
13- 6- 25-
US20060110
Antigenic peptides of SARS coronavirus and uses thereof Crucell Holland B.V. Jun- Dec May
803
03 -05 -06
Synthetic peptide targeting critical sites on the SARS-associated 22- 28- 25-
US20060110
coronavirus spike protein responsible for viral infection and method UNIV HONG KONG Nov- Oct May
758
of use thereof 04 -05 -06
20- 22- 25-

US20060110 Plasma or serum fraction for treatment and prevention of viral
BUCKHEIT ROBERT W JR Aug- Aug May
405 infections and related conditions
04 -05 -06
11- 10- 11-
US20060100 Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl
AGARWAL ATUL Nov- Nov May
232 thiazole ureas and analogues thereof
04 -05 -06
3- 1- 11-
US20060100
Pyrazolopyridines and analogs thereof BONK JASON D Oct- Apr May
229
03 -05 -06
9- 8- 11-
US20060099
Assay to detect viral uncoating NARAYAN SHAKTI Dec- Dec May
606
03 -04 -06
24- 24- 11-
US20060099
Diagnostic assays MIGUEZ MARIA-JOSE Mar- Mar May
573
04 -05 -06
24- 20- 4-
US20060094 Mixed cell diagnostic systems for detection of respiratory, herpes
Diagnostic Hybrids, Inc. Apr- Sep May
105 and enteric viruses
98 -05 -06
29- 29- 4-
US20060094
Animal protein-free media for cultivation of cells DORNER FRIEDRICH Oct- Oct May
104
04 -04 -06
29- 28- 4-
US20060093 Process for vaccinating eucaryotic hosts and for protecting against
ALTMEYER RALF Sep- Sep May
616 SARS-CoV infection
04 -05 -06
22- 14- 27-
US20060089 RNAi modulation of RSV, PIV and other respiratory viruses and uses
BARIK SAILEN Oct- Jun Apr-
324 thereof
04 -05 06
22- 14- 27-
US20060089 RNAi modulation of RSV, PIV and other respiratory viruses and uses
BARIK SAILEN Oct- Jun Apr-
323 thereof
04 -05 06
Method of removing hazardous substance, and hazardous substance 28- 26- 27-
US20060088
removing material using the same such as air cleaning filter, mask DAIKIN IND LTD Mar- Mar Apr-
926
and wipping sheet, and method of storing the same 03 -04 06
17- 19- 27-

US20060088 Virus-like particles, methods of preparation, and immunogenic
COMPANS RICHARD W May- May Apr-
909 compositions
02 -03 06
10- 8- 13-
US20060079
Use of lipid conjugates in the treatment of infection OJCIUS DAVID Jan- Sep Apr-
485
00 -05 06
28- 28- 13-
US20060075 University of Wyoming Research Corporation d/b/a Western
Bioagent air filtration systems Jan- Jan Apr-
894 Research Institute
03 -04 06
28- 28- 6-
US20060070
Charge-based water filtration systems University of Wyoming Research Corporation d/b/a Jan- Jan Apr-
952
03 -04 06

21- 21- 30-
US20060067 Antibodies against West Nile Virus and therapeutic and prophylactic
DIAMOND MICHAEL Jun- Jun Mar
940 uses thereof
04 -05 -06
16- 14- 23-
US20060063 Antisense antiviral compound and method for treating ssRNA viral
IVERSEN PATRICK L Sep- Sep Mar
150 infection
04 -05 -06
23- 6- 23-
US20060063
Compositions and methods for detecting pathogen infection BERTHET FRANCOIS X Dec- Sep Mar
149
03 -05 -06
21- 21- 23-
US20060062
SARS-CoV-specific B-cell epitope and applications thereof National Taiwan University Sep- Sep Mar
804
04 -04 -06
22- 21- 16-
US20060057 Compositions for use in identification of viral hemorrhagic fever
ISIS Pharmaceuticals, Inc. Mar- Mar Mar
605 viruses
04 -05 -06
16- 16- 16-
US20060057
Detection of coronavirus infection CHOU CHIH-MING Sep- Sep Mar
161
04 -04 -06
Genetically modified plants comprising SARS-CoV viral nucleotide 5- 3- 9-

US20060053
sequences and methods of use thereof for immunization against The University of Hong Kong Dec- Dec Mar
516
SARS 03 -04 -06
30- 28- 9-
US20060051 Feline infectious peritonitis (FIP) and systemic multi-organ
AUSTIN KIMBERLY M Jun- Jun Mar
744 coronavirus biomarkers and screening methods
04 -05 -06
28- 28- 9-
US20060051
Compositions and methods for mucosal vaccination 3M Innovative Properties Company Apr- Apr Mar
374
04 -05 -06
13- 15- 16-
US20060035
Benzothiazolium compounds LEE SHIOW-JU Aug- Aug Feb
926
04 -05 -06
16- 6- 16-
US20060035
Treating severe and acute viral infections HEMISPHERx BIOPHARMA May- Oct Feb
859
03 -05 -06
7- 7- 16-
US20060035 Methods for tailoring the immune response to an antigen or
Biomedical Research Models, Inc. Jan- Jan Feb
853 immunogen
04 -05 -06
26- 10- 16-
US20060035
Recombinant super-compound interferon and uses thereof WEI GUANGWEN Aug- Mar Feb
327
04 -05 -06
16- 16-
US20060034 Novel human virus causing respiratory tract infection and uses 21-
CHAN KWOK H May Feb
853 thereof Jul-04
-05 -06
7- 18- 2-
US20060024 Coronavirus, nucleic acid, protein, and methods for the generation
HOEK CORNELIA V D Jan- Aug Feb
668 of vaccine, medicaments and diagnostics
04 -04 -06
15- 13- 2-
US20060024 Treatments for viral infections using IFN cytokines and ribavirin,
ALIBEK KEN Jan- Jan Feb
271 alone or in combination
04 -05 -06
14- 26-
US20060019 22-
Methods for treating Hepatitis C CHEN GUANGMING Jul- Jan-
976 Jul-04
05 06
20- 26-
US20060019 21-
SARS CoV main protease inhibitors HSIEH HSING-PANG Jul- Jan-
967 Jul-04
05 06
14- 14- 26-
US20060019
Anti-viral uses of borinic acid complexes BELLINGER-KAWAHARA CAROLYN Jun- Jun Jan-
927
04 -05 06
18- 26-
US20060019 18-
Methods and compositions for inducing innate immune responses Coley Pharmaceutical Group, Ltd. Jul- Jan-
923 Jul-04
05 06
21- 26-
US20060018 Novel human virus causing respiratory tract infection and uses 21-
CHAN KWOK H Jul- Jan-
923 thereof Jul-04
04 06
29- 29- 26-
US20060018
Intradermal delivery of vacccines and therapeutic agents ALARCON JASON B Jun- Apr Jan-
877
01 -05 06
22- 7- 19-
US20060014
Albumin fusion proteins Human Genome Sciences, Inc. Jan- Jul- Jan-
254
03 05 06
16- 9- 12-
US20060009
Pyridazine derivatives and their use as therapeutic agents ABREO MELWYN Mar- Feb Jan-
459
04 -05 06
6- 12-
US20060008 6-Jul-
Methods and compositions for detecting rhinoviruses Focus Technologies, Inc. Jul- Jan-
810 04
04 06
8- 12-
US20060008 8-Jul-
Room decontamination with hydrogen peroxide vapor STERIS INC. Jul- Jan-
379 04
04 06
27- 26- 12-
US20060006
Door handle cover HERRON ROY H JR May- May Jan-
678
04 -05 06
25- 25- 5-
US20060003 Peptides and peptidomimetics having immune-modulating, anti-
KAWABE TAKUMI Jun- Jun Jan-
941 inflammatory, and anti-viral activity
03 -04 06
29- 28- 5-
US20060003
Mass tag PCR for mutliplex diagnostics BRIESE THOMAS Apr- Apr Jan-
352
04 -05 06
30- 29- 5-
US20060003 Methods and kits for identifying target nucleotides in mixed
Applera Corporation Apr- Apr Jan-
351 populations
04 -05 06

22- 13- 5-
US20060003
Multi-allelic molecular detection of SARS-associated coronavirus Birch Biomedical Research, LLC Aug- Aug Jan-
340
03 -04 06
14- 11- 5-
US20060002
Ii-key/antigenic epitope hybrid peptide vaccines HUMPHREYS ROBERT Sep- Jan Jan-
947
99 -05 06
4- 3- 5-
US20060002 Methods and compositions for enhancement of immunity by in vivo
Duke University Jun- Jun Jan-
932 depletion of immunosuppressive cell activity
04 -05 06
7- 29-
US20050288 Computational method for identifying adhesin and adhesin-like 20-
COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH Feb Dec
866 proteins of therapeutic potential Jul-04
-05 -05
5- 5- 29-
US20050287
Polycistronic HIV vector constructs May- May Dec
167
04 -05 -05
26- 23- 29-
US20050287 Bacterial plasmid with immunological adjuvant function and uses
Nov- Nov Dec
118 thereof
03 -04 -05
29- 28- 22-
US20050282
Expression vector encoding coronavirus-like particle HWU PAUL L May- May Dec
279
03 -04 -05
18- 20- 22-
US20050282
Variable length probe selection ALBERT THOMAS Jun- Jun Dec
209
04 -05 -05
6- 5- 22-
US20050282 Angiotensin-converting enzyme-2 as a receptor for the SARS
Oct- Oct Dec
154 coronavirus
03 -04 -05
28- 1- 22-
US20050281 Method of treating autoimmune disease by inducing antigen
BOWDISH KATHERINE S Feb- Apr Dec
828 presentation by tolerance inducing antigen presenting cells
04 -05 -05
21- 21- 15-
US20050277
Beta-peptides Yale University Apr- Apr Dec
592
04 -05 -05
23- 27- 15-
US20050277
Compositions and methods for detecting pathogen infection BERTHET FRANCOIS X Dec- Apr Dec
181
04 -05 -05
17- 17- 15-
US20050276 Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-
GODZIK ADAM May- May Dec
818 dependent kinase and a target for SARS therapy
04 -05 -05
6- 6- 15-
US20050276
Antiviral activity from medicinal mushrooms STAMETS PAUL Jan- Jan Dec
815
04 -05 -05
26- 25- 8-
US20050271
Therapeutic antimicrobial compositions and methods The Procter & Gamble Company Apr- Apr Dec
711
04 -05 -05
18- 18- 1-
US20050266
TC-83-derived alphavirus vectors, particles and methods Alphavax, Inc. May- May Dec
550
04 -05 -05
19- 18- 1-
US20050266
Interferon-alpha polypeptides and conjugates May- May Dec
465
04 -05 -05
31- 29- 1-
US20050266
Methods for producing and identifying multispecific antibodies Vaccinex, Inc. Dec- Dec Dec
425
03 -04 -05
26- 22- 1-
US20050266
Methods for identification of coronaviruses BLYN LAWRENCE B Apr- Apr Dec
397
03 -04 -05
8- 8- 24-
US20050260
Comparative genomic resequencing ALBERT THOMAS Apr- Apr Nov
645
04 -05 -05
30- 28- 17-
US20050255
Chimeric ebola virus envelopes and uses therefor The Trustees of the University of Pennsylvania Apr- Apr Nov
123
02 -03 -05
1- 1- 10-
US20050250
Glycopeptide antibiotic derivatives BALZARINI JAN Sep- Sep Nov
677
03 -03 -05
27- 22- 10-
US20050249 Compositions and methods for modulating a cytotoxic T lymphocyte
Dana-Farber Cancer Institute, Inc. Jun- Dec Nov
742 immune response
02 -04 -05
25- 24- 10-
US20050249
Antibodies against SARS-CoV and methods of use thereof MARASCO WAYNE Nov- Nov Nov
739
03 -04 -05
2- 4- 3-
US20050244 Methods for treating viral infection using IL-28 and IL-29 cysteine
HENDERSON KATHERINE E Apr- Apr Nov
423 mutants
04 -05 -05
Reagents, devices and methods for proteomic analysis with 21- 4- 27-
US20050240
applications including diagnostics, vaccines, quality control and Apr- Feb Oct-
353
research 04 -05 05
30- 30- 27-

US20050239
Enhancement of immune responses Dec- Dec Oct-
735
03 -04 05
27- 27- 27-
US20050239 Multiplex systems, methods, and kits for detecting and identifying
BRIESE THOMAS Apr- Apr Oct-
086 nucleic acids
04 -04 05
10- 9- 27-
US20050239 Methods and devices for determining a cell characteristic, and
GIMZEWSKI JAMES K Sep- Mar Oct-
047 applications employing the same
02 -05 05
6- 4- 27-
US20050238
Antiviral activity from medicinal mushrooms STAMETS PAUL Jan- Jan Oct-
655
04 -05 05

11- 11- 20-
US20050234
Prevention of and countermeasures against viral infection CHOKO CO., LTD. Mar- Mar Oct-
122
04 -04 05
30- 30- 20-
US20050233 Sensitive and quantitative detection of pathogens by real-time
Jun- Jun Oct-
314 nested PCR
03 -04 05
10- 3- 20-
US20050232
Anti-viral pharmaceutical compositions SD Pharmaceuticals, Inc. Dec- Dec Oct-
895
03 -04 05
1- 22- 6-
US20050223 Modified polynucleotides for reducing off-target effects in RNA
Dharmacon, Inc. Apr- Dec Oct-
427 interference
04 -04 05
21- 14- 6-
US20050222
Pharmaceuticals comprising shikonins as active constituent WANG FEIXIN Feb- May Oct-
258
03 -05 05
31- 31- 6-
US20050220
Mutant viral nucleic acids and vaccine containing same Mar- Mar Oct-
816
04 -04 05
10- 8- 29-
US20050215 Baicalin and its derivatives as a treatment for SARS coronavirus
CHAN KWOK H Nov- Nov Sep
494 infection or other related infections
03 -04 -05
26- 23- 29-
US20050214 Novel "Cleave-N-Read" system for protease activity assay and
BAUDRY MICHEL Nov- Nov Sep
890 methods of use thereof
03 -04 -05
12- 8- 29-
US20050214
Peptide-based diagnostic reagents for SARS CHANG TSENG Y Nov- Nov Sep
748
03 -04 -05
16- 17- 29-
US20050214
Compositions and methods for analysis of target analytes DANIELZADEH ROBERT Jan- Oct Sep
747
04 -04 -05
25- 24- 22-
US20050208
Recombinant baculovirus and virus-like particle CHAO YU-CHAN Nov- Nov Sep
066
03 -04 -05
22- 15- 22-
US20050208
Vaccine composition Aventis Pasteur S.A. Sep- Nov Sep
060
04 -04 -05
12- 10- 22-
US20050208 Enhancement of vaccine-induced immune responses and protection
BRICE GARY T Nov- Nov Sep
020 by heterologous boosting with alphavirus replicon vaccines
03 -04 -05
28- 26- 22-
US20050208
Uses of interferons with altered spatial structure WEI GUANGWEN Aug- Aug Sep
019
03 -04 -05
10- 10- 15-
US20050203
Modulation of ACE2 expression Mar- Mar Sep
038
04 -04 -05
1- 1- 15-
US20050203
Peptides and methods for inducing cellular resistance to infection Dec- Dec Sep
024
03 -04 -05
23- 4- 15-
US20050202
Replikin peptides and uses thereof BOGOCH ELENORE S. Dec- Jun Sep
415
03 -04 -05
5- 19- 8-
US20050196
Antiviral oligonucleotides targeting viral families Dec- Oct Sep
382
02 -04 -05
9- 9- 8-
US20050196 Lentivirus vector-based approaches for generating an immune
DROPULIC BORO Sep- Sep Sep
381 response to HIV in humans
03 -04 -05
27- 22- 1-
US20050191
Particle on membrane assay system BALLARD KARRI L. Feb- Dec Sep
620
04 -04 -05
17- 11- 1-
US20050189
Viral inactivation using ozone KEYSER STEVEN A. Mar- Oct Sep
302
04 -04 -05
20- 20- 25-
US20050187 Phospholipids for the treatment of infection by togaviruses, herpes
Feb- Feb Aug
192 viruses and coronaviruses
04 -04 -05
17- 30- 25-
US20050186
Corona-virus-like particles comprising functionally deleted genomes BOSCH BEREND J. May- Dec Aug
575
02 -03 -05
18- 11- 18-
US20050182
Membrane scaffold proteins BAYBURT TIMOTHY H. Jun- Jan Aug
243
03 -05 -05
24- 24- 18-
US20050181 High-throughput diagnostic assay for the human virus causing
CHAN KWOK H. Mar- Mar Aug
357 severe acute respiratory syndrome (SARS)
03 -04 -05
21- 21- 18-
US20050181 Pharmacological enhancement and manufacturing method of
GONG JIAO Nov- Nov Aug
075 antiviral compound
03 -03 -05
5- 12- 11-
US20050176
Antiviral oligonucleotides Dec- Sep Aug
661
02 -03 -05
24- 22- 4-
US20050171 Oligonucleotide compound and method for treating nidovirus
BESTWICK RICHARD K. Dec- Dec Aug
044 infections
03 -04 -05
28- 26- 4-
US20050169
Recombinant super-compound interferon WEI GUANGWEN Aug- Aug Aug
885
03 -04 -05
28- 28- 28-
US20050164 Method of discovery and development of broad-spectrum antiviral
BUSCHER BENJAMIN A. Jan- Jan Jul-
167 drugs
04 -04 05

26- 26- 28-
US20050163 METHOD AND APPARATUS FOR STERILIZING AIR IN LARGE
LIANG MICHAEL Y. Jan- Jan Jul-
648 VOLUMES BY RADIATION OF ULTRAVIOLET RAYS
04 -04 05
8- 27- 21-
US20050158 Methods and apparatus to prevent, treat, and cure the symptoms of
VAIL MARILYN L. Dec- Nov Jul-
411 nauea caused by chemotherapy treatments of human cancers
03 -04 05
30- 30- 21-

US20050158
Immunomodulatory combinations Dec- Dec Jul-
325
03 -04 05
5- 12- 14-
US20050153
Antiviral oligonucleotides targeting viral families Dec- Sep Jul-
912
02 -03 05
10- 1- 14-
US20050153
Luciferase biosensor BUTLER BRAEDEN Oct- Oct Jul-
310
03 -04 05
5- 5- 7-
US20050148 Method for preventing and treating severe acute respiratory
HENSLEY CHARLES Jan- Jan Jul-
658 syndrome
04 -04 05
6- 14- 7-
US20050147 Compositions and methods for reducing the transmissivity of
ROSENBLOOM RICHARD A. Feb- Dec Jul-
697 illnesses
03 -04 05
30- 30- 30-
US20050142 Method and kit for the detection of a novel coronoavirus associated
LAUE THOMAS Apr- Apr Jun-
536 with the severe acute respiratory syndrome (SARS)
03 -04 05
30- 11- 30-
US20050142 Oxidative reductive potential water solution and methods of using
Oculus Innovative Sciences, Inc. Dec- Aug Jun-
157 the same
03 -04 05
30- 4- 30-
US20050139 Oxidative reductive potential water solution and process for
Oculus Innovative Sciences, Inc. Dec- Jun Jun-
808 producing same
03 -04 05
28- 9-
US20050123 Lipoparticles comprising proteins, methods of making, and using the 30-
DORANZ BENJAMIN J. Jul- Jun-
563 same Jul-03
04 05
30- 30- 2-
US20050119
ANTIVIRAL AGENTS AND METHODS OF USE Wisconsin Alumni Research Foundation - Sep- Sep Jun-
284
03 -04 05
21- 6- 2-
US20050119
Nicotinamide derivatives and their use as therapeutic agents FINE RICHARD M. Dec- Jul- Jun-
251
01 04 05
17- 17- 2-
US20050117
Apparatus for forming nano-grating device CHEN YUNG-HSIN Mar- Mar Jun-
187
04 -04 05
2- 26-
US20050114 Transgenic mice having a human major histocompatibility complex 30-
AURIAULT CLAUDE Jul- May
910 (MHC) phenotype, experimental uses and applications Jul-03
04 -05
15- 13- 26-

US20050113
Receptor binding peptides derived from the SARS S protein Sep- Sep May
298
03 -04 -05
29- 29- 26-
US20050112 Compositions and methods for diagnosing and preventing severe
Sep- Sep May
559 acute respiratory syndrome (SARS)
03 -04 -05
24- 23- 26-
US20050112
Prognostic PCR assay for severe acute respiratory syndrome (SARS) The Chinese University of Hong Kong Sep- Sep May
558
03 -04 -05
3- 3- 26-
US20050112 Cytidine deaminase activators, deoxycytidine deaminase activators,
DEWHURST STEPHEN Sep- Sep May
555 Vif antagonists, and methods of screening for molecules thereof
03 -04 -05
9- 26-
US20050112 Characterization of the earliest stages of the severe acute 9-Jul-
HENG XU RUI Jul- May
554 respiratory syndrome (SARS) virus and uses thereof 04
04 -05
12- 19-
US20050107 12-
Modulation of CEACAM1 expression BENNETT C. F. Jul- May
324 Jul-03
04 -05
8- 8- 19-
US20050106
Epitope profiles of SARS coronavirus Sep- Sep May
563
03 -04 -05
28- 5- 12-
US20050101
Therapeutic treatment methods 2 AHLEM CLARENCE N. Aug- Dec May
581
02 -03 -05
28- 26- 12-
US20050100 Compositions and methods for the treatment of severe acute
BAKER BRENDA F. Apr- Apr May
885 respiratory syndrome (SARS)
03 -04 -05
12- 12- 12-
US20050100
Peptide-based diagnostic reagents for SARS CHANG TSENG Y. Nov- Nov May
883
03 -03 -05
7- 10- 12-
US20050100
Virucidal activities of cetylpyridinium chloride ViraTox, L.L.C. Nov- Sep May
612
03 -04 -05
31- 1- 5-
US20050096
Neutrophil activation by immune response modifier compounds Oct- Nov May
259
03 -04 -05
28- 5-
US20050095 Compositions and methods for diagnosing and treating severe acute 29-
The Chinese University of Hong Kong Jul- May
618 respiratory syndrome (SARS) Jul-03
04 -05
3- 3- 5-
US20050095 Compositions and methods for detecting severe acute respiratory
Diagnostic Hybrids, Inc. Nov- Nov May
582 syndrome coronavirus
03 -03 -05

20- 18- 28-
US20050090
Methods of reducing risk of infection from pathogens HOPKINS SAMUEL E. Aug- Aug Apr-
505
03 -04 05
21- 21- 21-
US20050085 Prenylation inhibitors reduce host cell permissiveness to viral
Oct- Oct Apr-
529 replication
03 -03 05
18- 18- 14-
US20050080
Methods of reducing risk of infection from pathogens HOPKINS SAMUEL E. Aug- Aug Apr-
093
04 -04 05
12- 7-
US20050075 12-
Modulation of aminopeptidase N expression BENNETT C. FRANK Jul- Apr-
307 Jul-03
04 05
6- 6- 7-
US20050074
Method and composition for treating a biological sample CHAPMAN JOHN Oct- Oct Apr-
743
03 -03 05
6- 6- 7-
US20050074
Aircraft and passenger decontamination system STERIS INC. Oct- Oct Apr-
359
03 -03 05
27- 25- 31-
US20050071 Techniques and applications of establishment of SARS-CoV primate
GAO HONG Jun- Jun Mar
892 model
03 -04 -05
5- 5- 31-
US20050070
Infection prophylaxis using immune response modifier compounds 3M Innovative Properties Company Aug- Aug Mar
460
03 -04 -05
10- 5- 31-
US20050069 Proteome epitope tags and methods of use thereof in protein
engeneOS, Inc. May- Feb Mar
911 modification analysis
02 -04 -05
4- 4- 31-
US20050069
SARS nucleic acids, proteins, antibodies, and uses thereof AMBROSINO DONNA Aug- Aug Mar
869
03 -04 -05
23- 31-
US20050069 25-
Crystals and structures of SARS-CoV main protease BONANNO JEFFREY B. Jul- Mar
558 Jul-03
04 -05
27- 29- 31-
US20050069
Thiosemicarbazones as anti-virals and immunopotentiators BARSANTI PAUL A. Dec- Dec Mar
555
02 -03 -05
29- 24-
US20050065 29-
Pyridazine derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. Jul- Mar
143 Jul-04
04 -05
15- 15- 17-
US20050059 Compositions comprising phosphatidylethanolamine-binding
HE JIN Aug- Aug Mar
578 peptides linked to anti-viral agents
03 -03 -05
30- 17- 17-
US20050059 Targeted delivery of antiviral compounds through hemoglobin
ADAMSON J. GORDON Apr- May Mar
576 bioconjugates
98 -04 -05
17- 17- 17-
US20050059
Selective modulation of TLR gene expression 3M Innovative Properties Company Sep- Sep Mar
072
04 -04 -05
25- 17-
US20050058 25-
Modified small interfering RNA molecules and methods of use Chiron Corporation Jul- Mar
982 Jul-03
03 -05
15- 15- 10-
US20050054 Hydrolytically-resistant boron-containing therapeutics and methods
AKAMA TSUTOMU Jun- Jun Mar
644 of use
04 -04 -05
3- 3- 10-
US20050054
1-Amino 1H-imidazoquinolines GRIESGRABER GEORGE W. Sep- Sep Mar
640
04 -04 -05
31- 31- 10-
US20050053
Cleavage of RNA by restriction endonucleases ROBERTS RICHARD J. Aug- Aug Mar
990
04 -04 -05
2- 2- 10-
US20050051
Viral inactivation using ozone KEYSER STEVEN A. Aug- Aug Mar
497
04 -04 -05
23- 23- 3-
US20050048
Enzymatic diagnostic test for SARS and other viral diseases ARAD DORIT Jun- Jun Mar
473
04 -04 -05
Method of collecting nasopharyngeal cells and secretions for 20- 20- 3-

US20050048
diagnosis of viral upper respiratory infections and screening for World Sense Technology Limited Aug- Aug Mar
465
nasopharyngeal cancer 04 -04 -05
25- 25- 3-
US20050048
Immunostimulatory combinations and treatments 3M Innovative Properties Company Aug- Aug Mar
072
04 -04 -05
27- 27- 17-
US20050039
Imageable animal model of SARS infection XU MINGXU May- May Feb
220
04 -04 -05
14- 14- 17-
US20050037 Method and means for detection of severe acute respiratory
TSENG KUO-TANG Aug- Aug Feb
338 syndrome
03 -03 -05
9- 9- 17-
US20050036
Methods of treating lung diseases Arizeke Pharmaceuticals, Inc. Jan- Jan Feb
951
04 -04 -05
29- 21- 10-

US20050032 Modified viral particles with immunogenic properties and reduced
BELLOTTI MARC Jun- Jun Feb
222 lipid content useful for treating and preventing infectious diseases
00 -04 -05
15- 15- 10-

US20050031 Combined cancer treatment methods using selected antibodies to
HUANG XIANMING Aug- Aug Feb
620 aminophospholipids
03 -03 -05
13- 13- 10-
US20050031 Methods and compositions for inducing immune responses and
BRICE GARY L. Nov- Nov Feb
592 protective immunity by priming with alpha virus replicon vaccines
03 -03 -05

4- 4- 3-
US20050025 Systemic delivery of non-viral vector expressing SARS viral genomic
CHOU GEORGE CHIN-SHENG Jun- Jun Feb
788 vaccine
04 -04 -05
15- 15- 3-
US20050025 Anti-viral treatment methods using phosphatidylethanolamine-
Board of Regents, The University of Texas System Aug- Aug Feb
761 binding peptides linked to anti-viral agents
03 -03 -05
15- 30- 27-
US20050020
Hematopoietic stem cell gene therapy Monash University Apr- Dec Jan-
524
99 -03 05
26- 26- 27-
US20050019 Methods and compositions for use in diagnosing and characterizing
DE MEIRLEIR KENNY May- May Jan-
756 diseases involving abnormal apoptosis
04 -04 05
8- 8- 27-
US20050015
Compositions and methods for preventing infection HILDRETH JAMES E. Aug- Aug Jan-
847
03 -03 05
4- 20-
US20050014 17-
Substances for breaking down conformation of microbes CHU SHU FANG Jun Jan-
830 Jul-03
-04 05
31- 31- 20-
US20050014
Prodrugs of heteroaryl compounds Koronis Pharmaceuticals, Incorporated Mar- Mar Jan-
752
04 -04 05
8- 13-
US20050009 8-Jul-
Methods of producing antibodies for diagnostics and therapeutics CHANG XIAO-JIA Jul- Jan-
110 03
03 05
24- 24- 13-
US20050009 Diagnostic assay for the human virus causing severe acute
CHAN KWOK HUNG Mar- Mar Jan-
009 respiratory syndrome (SARS)
04 -04 05
7- 13-
US20050008 7-Jul-
Noble gas-chlorine mixture effective against micro organisms GLOBUS ALFRED R. Jul- Jan-
535 03
03 05
14- 14- 6-
US20050004
Combined use of IMPDH inhibitors with toll-like receptor agonists REGENTS OF THE UNIVERSITY OF CALIFORNIA Apr- Apr Jan-
144
04 -04 05
Charged polysaccharides resistant to lysosomal degradation during 20- 20- 6-

US20050004
kidney filtration and renal passage and their use to treat or prevent COMPER WAYNE D. Apr- Apr Jan-
071
infection by coronaviruses 04 -04 05
19- 19- 6-
US20050004 Inhibition of SARS-associated coronavirus (SCoV) infection and
GUAN YI May- May Jan-
063 replication by RNA interference
04 -04 05
1- 6-
US20050003 1-Jul-
Assay system and methods for detecting SARS-CV AsiaGEN Corporation Jul- Jan-
340 03
03 05
4- 4- 6-
US20050002
SARS-coronavirus virus-like particles and methods of use HEROLD JENS May- May Jan-
953
04 -04 05
15- 15- 6-
US20050002 Combinations and kits for cancer treatment using selected
Board of Regents, The University of Texas System Aug- Aug Jan-
941 antibodies to aminophospholipids
03 -03 05
15- 18- 6-
US20050002
Hematopoietic stem cell gene therapy Monash University Apr- Apr Jan-
913
99 -03 05
30- 30- 6-
US20050002 Compositions and methods for treating coronavirus infection and
BLATT LAWRENCE M. Mar- Mar Jan-
901 SARS
04 -04 05
29- 29- 30-
US20040265
Compositions for enhancing transport of molecules into cells IVERSEN PATRICK L. Apr- Apr Dec
879
04 -04 -04
23- 23- 30-
US20040265
Methods and kits for detecting SARS-associated coronavirus BRIESE THOMAS Jan- Jan Dec
796
04 -04 -04
15- 15- 30-
US20040265 Liposomes coated with selected antibodies that bind to
HUANG XIANMING Aug- Aug Dec
03 -03 -04
9- 9- 30-
US20040265
Methods and compositions for enhancing immune response KEDL ROSS M. Apr- Apr Dec
351
04 -04 -04
27- 27- 23-
US20040259 Inhibiting Coronaviridae viral replication and treating Coronaviridae
CARROLL STEVEN S. Apr- Apr Dec
934 viral infection with nucleoside compounds
04 -04 -04
15- 30- 23-
US20040259
Disease prevention by reactivation of the thymus Monash University Apr- Dec Dec
803
99 -03 -04
9- 9- 23-
US20040258
Delivery of immune response modifier compounds JING NAIYONG Apr- Apr Dec
698
04 -04 -04
26- 26- 16-
US20040253 Microporous materials, methods of making, using, and articles
DURTSCHI JACOB May- May Dec
624 thereof
04 -04 -04
13- 21- 16-
US20040253
Anti-atypical pneumonia decoction HU XIN YUAN Jun- Jul- Dec
328
03 03 -04
15- 30- 2-
US20040241
Stimulation of thymus for vaccination development Monash University Apr- Dec Dec
842
99 -03 -04
2- 2- 2-
US20040237 Protecting shield for performing the insertion of a tube during
YANG JUI KUANG Jun- Jun Dec
198 emergency rescuing or anesthesia
03 -03 -04
27- 27- 25-
US20040235 Inhibitors of severe acute respiratory syndrome (SARS) 3C-like
Agouron Pharmaceuticals, Inc. Apr- Apr Nov
952 proteinase
04 -04 -04

24- 24- 25-
US20040235 Organosulphur prodrugs for the prevention and treatment of
OTT DAVID M. May- May Nov
946 injectious diseases and pathologenic immune system response
04 -04 -04
20- 20- 25-
US20040235 Compositions and methods for treatment of Severe Acute
SIBER GEORGE R. May- May Nov
047 Respiratory Syndrome (SARS)
03 -03 -04
2- 2- 25-
US20040234 Methods of preventing and treating SARS using low pH respiratory
The Procter & Gamble Company Feb- Feb Nov
457 tract compositions
04 -04 -04
12- 12- 18-
US20040229
Antiviral oligonucleotides targeting RSV Replicor, Inc. Sep- Sep Nov
828
03 -03 -04
13- 13- 18-
US20040229 Pharmaceutical compositions of antithrombin III for the treatment of
ELMALEH DAVID R. May- May Nov
778 retroviral diseases
03 -03 -04
Method of inhibiting human metapneumovirus and human 29- 29- 18-

US20040229
coronavirus in the prevention and treatment of severe acute GALLAHER WILLIAM R. Apr- Apr Nov
219
respiratory syndrome (SARS) 04 -04 -04
Sensitive diagnostic testing methodology using multiplex real time 22- 22- 18-
US20040229
PCR with one dye (MOD) and its use as in severe acute respiratory YEUNG WAH HIN ALEX Aug- Aug Nov
211
syndrome (SARS) 03 -03 -04
5- 5- 4-
US20040220
Inhibiting viral infections SCEUSA NICHOLAS A. Nov- Nov Nov
139
03 -03 -04
15- 15- 4-
US20040219
Selected immunoconjugates for binding to aminophospholipids RAN SOPHIA Aug- Aug Nov
155
03 -03 -04
9- 9- 28-
US20040214 Surface sanitizing compositions with improved antimicrobial
Xantech Pharmaceuticals, Inc. Mar- Mar Oct-
785 performance
04 -04 04
15- 15- 28-
US20040214 Anti-viral treatment methods using phosphatidylethanolamine-
HE JIN Aug- Aug Oct-
764 binding peptide derivatives
03 -03 04
15- 15- 28-
US20040213 Methods for treating viral infections using immunoconjugates to
RAN SOPHIA Aug- Aug Oct-
03 -03 04
22- 22- 21-
US20040209
Compositions and methods for preventing infection HILDRETH JAMES E. Sep- Sep Oct-
844
03 -03 04
16- 16- 21-
US20040208
Human monoclonal antibodies against interleukin 8 (IL-8) GENMAB A/S Dec- Dec Oct-
873
03 -03 04
15- 15- 21-
US20040208
Selected antibody CDRs for binding to aminophospholipids Board of Regents, The University of Texas System Aug- Aug Oct-
868
03 -03 04
5- 5- 14-
US20040204
Compounds for modulating RNA interference RANA TARIQ M. Aug- Aug Oct-
420
03 -03 04
9- 9- 14-
US20040202 Delivery of immune response modifier compounds using metal-
3M Innovative Properties Company Apr- Apr Oct-
720 containing particulate support materials
04 -04 04
24- 24- 30-
US20040191 Selective activation of cellular activities mediated through a
3M Innovative Properties Company Mar- Mar Sep
833 common toll-like receptor
04 -04 -04
29- 29- 23-
US20040184
Building decontamination with vaporous hydrogen peroxide STERIS INC. Jan- Jan Sep
950
04 -04 -04
13- 13- 16-
US20040180 Proteome epitope tags and methods of use thereof in protein
engeneOS, Inc. Nov- Nov Sep
380 modification analysis
03 -03 -04
5- 5- 9-
US20040176
1-Amino 1H-imidazoquinolines 3M Innovative Properties Company Mar- Mar Sep
367
04 -04 -04
15- 9-
US20040175 Selected antibody compositions and methods for binding to 15-
Board of Regents, The University of Texas System Jul- Sep
378 aminophospholipids Jul-03
03 -04
12- 12- 2-
US20040171
Antiviral oligonucleotides targeting HIV Replicor, Inc. Sep- Sep Sep
568
03 -03 -04
27- 27- 2-
US20040171
Selective modulation of TLR-mediated biological activity 3M Innovative Properties Company Feb- Feb Sep
086
04 -04 -04
30- 30- 2-
US20040170
Mixed cell diagnostic systems GOODRUM PATRICIA GAIL RAY Mar- Mar Sep
965
04 -04 -04
11- 12- 2-
US20040170
Methods for identifying antiviral oligonucleotides Replicor, Inc. Sep- Sep Sep
959
03 -03 -04
29- 20- 2-
US20040170 Method of treating and preventing infectious diseases via creation of
CHAM BILL E. Jun- Jun Sep
649 a modified viral particle with immunogenic properties
00 -03 -04
15- 2-
US20040170 15-
Selected antibody compositions for binding to aminophospholipids RAN SOPHIA Jul- Sep
620 Jul-03
03 -04
20- 26- 26-
US20040167 Method of treating or inhibiting the development of brain
NOZAKI MASAKO May- Nov Aug
161 inflammation and sepsis
03 -03 -04

1- 1- 26-
US20040167
Casein derived peptides and uses thereof Chay 13 Medical Research Group N.V. Mar- Mar Aug
073
00 -04 -04
12- 12- 19-
US20040162 Methods and compositions related to IRM compounds and toll-like
3M Innovative Properties Company Feb- Feb Aug
309 receptor 8
04 -04 -04
12- 12- 19-
US20040162
Antiviral oligonucleotides targeting HSV and CMV Replicor, Inc. Sep- Sep Aug
254
03 -03 -04
12- 12- 19-
US20040162
Antiviral oligonucleotides targeting HBV Replicor, Inc. Sep- Sep Aug
253
03 -03 -04
18- 18- 29-
US20040147
Aryl substituted imidazoquinolines 3M Innovative Properties Company Dec- Dec Jul-
543
03 -03 04
15- 15- 29-
US20040147
Compositions comprising cell-impermeant duramycin derivatives Board of Regents, The University of Texas System Aug- Aug Jul-
440
03 -03 04
9- 29- 22-
US20040142
Composition and its therapeutic use AL SARI AHMAD M. H. May- May Jul-
852
02 -03 04
7- 7- 22-
US20040142
Continuous non-radioactive polymerase assay Schering Corporation Oct- Oct Jul-
322
03 -03 04
30- 30- 22-
US20040141
Immunostimulatory combinations 3M Innovative Properties Company Dec- Dec Jul-
950
03 -03 04
28- 28- 15-
US20040138
Therapeutic treatment methods AHLEM CLARENCE N. Aug- Aug Jul-
187
03 -03 04
15- 15- 8-
US20040131 Combinations and kits for treating viral infections using
Board of Regents Aug- Aug Jul-
622 immunoconjugates to aminophospholipids
03 -03 04
15- 15- 8-
US20040131 Combinations and kits for treating viral infections using antibodies
RAN SOPHIA Aug- Aug Jul-
621 to aminophospholipids
03 -03 04
15- 15- 8-
US20040131 Methods for treating viral infections using antibodies to
RAN SOPHIA Aug- Aug Jul-
03 -03 04
22- 29-
US20040081 22-
Compositions and methods for treating and preventing infection HILDRETH JAMES E. Jul- Apr-
667 Jul-03
03 04
27- 27- 22-
US20040077 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment
LACOLLA PAOLA Jun- Jun Apr-
587 of flaviviridae infections
03 -03 04
10- 10- 15-
US20040071
Inhalation antiviral patch ROLF DAVID Jun- Jun Apr-
757
03 -03 04
17- 14- 15-
US20040071
Corona-virus-like particles comprising functionally deleted genomes BOSCH BEREND-JAN May- Apr Apr-
709
01 -03 04
Nebulizer formulations of dehydroepiandrosterone and methods of 17- 17- 8-

US20040067
treating asthma or chronic obstructive pulmonary disease using JOHNSON KEITH A. Jun- Jun Apr-
920
compositions thereof 03 -03 04
12- 12- 15-

US20040009
Pathogen vaccines and methods for using the same Inex Pharmaceuticals Corporation May- May Jan-
943
03 -03 04
Methods and apparatus to prevent, treat and cure infections of the 2- 2- 15-
US20040009
human respiratory system by pathogens causing severe acute VAIL MARILYN L. May- May Jan-
245
respiratory syndrome (SARS) 03 -03 04
30- 30- 15-

US20040009 Materials and methods for prevention and treatment of RNA viral
BEHERA ARUNA K. Apr- Apr Jan-
152 diseases
03 -03 04
Method for preparation of large volume batches of poly-ICLC with 1- 8-

US20040005 1-Jul-
increased biological potency; therapeutic, clinical and veterinary ONCOVIR, INC. Jul- Jan-
998 03
uses thereof 03 04
24- 24- 4-
US20030224 Antisense antiviral agent and method for treating ssRNA viral
IVERSEN PATRICK L. Apr- Apr Dec
353 infection
03 -03 -03
24- 19- 2-
US10669245 ASTRAZENECA AB Jan- Mar Jun-
carboxamides dipeptidyl peptidase 1 inhibitors
14 -19 20
22- 31- 26-

US10666592 RNA targeting methods and compositions Salk Institute for Biological Studies Aug- Dec May
17 -18 -20
27- 13- 26-
US10662485 Bioagent detection oligonucleotides IBIS BIOSCIENCES, INC. Dec- Apr May
11 -18 -20
29- 26-
31-
US10662464 Methods of analyzing virus-derived therapeutics American International Biotechnology, LLC Jul- May
Jul-15
16 -20
21- 12- 26-
US10662423 Compositions for and methods of identifying antigens President and Fellows of Harvard College Feb- Feb May
06 -18 -20

Devices, system and method to control the delivery of oral 11- 11- 26-
US10660824 medications to ensure they are efficacious , taken as prescribed, Not Available Aug- Aug May
and to avoid unwanted side effects 15 -16 -20
1- 1- 19-
US10655108 Cell-derived viral vaccines with low levels of residual cell DNA Seqirus UK Limited Nov- Nov May
05 -06 -20
29- 29- 19-
US10655099 Animal protein-free media for cultivation of cells Baxalta GmbH Oct- Oct May
04 -18 -20
20- 20- 19-
Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) The United States of America, as represented by the
US10654898 Jan- Jan May
expressing a chimeric RSV/BPIV3 F protein and uses thereof Secretary, Department of Health and Human Serices
15 -16 -20
29- 20- 12-
Tissue preferential codon modified expression cassettes, vectors
US10647998 The Trustees of the University of Pennsylvania Apr- Jun May
containing same, and uses thereof
13 -17 -20
26- 22- 12-
US10647781 Generation of binding molecules Merus N.V. Sep- Nov May
11 -17 -20
13- 2- 12-
Compositions comprising AAV expressing dual antibody constructs
US10647758 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA May- Jul- May
and uses thereof
14 19 -20
4- 11- 12-
US10646563 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Apr- Sep May
methods of using
08 -18 -20
10- 12-
Methods for inducing an immune response via buccal and/or 26-
US10646438 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM May May
sublingual administration of a vaccine Jul-10
-17 -20
24- 21- 5-
US10641707 Gen-Probe Incorporated Feb- Mar May
11 -14 -20
7- 24- 5-
US10640788 CRISPR-related methods and compositions with governing gRNAs Editas Medicine, Inc. Nov- Jan May
13 -19 -20
22- 21- 5-
US10640785 Virus vectors for highly efficient transgene delivery The Children's Hospital of Philadelphia Nov- Nov May
11 -12 -20
10- 7- 5-
Method for propagating adenoviral vectors encoding inhibitory gene
US10640776 GenVec, Inc. Nov- Sep May
products
05 -17 -20
31- 16- 5-
US10640763 Molecular indexing of internal sequences Cellular Research, Inc. May- May May
16 -17 -20
16- 9- 28-
US10633447 Soluble engineered monomeric Fc Mar- May Apr-
12 -17 20
7- 28-
28-
US10632133 Anti-viral azide containing compounds LIFE TECHNOLOGIES CORPORATION Dec Apr-
Jul-10
-17 20
7- 27- 21-
US10626415 Method of increasing the function of an AAV vector The Trustees of the University of Pennsylvania Apr- Oct Apr-
05 -17 20
24- 25- 21-
Commonwealth Scientific and Industrial Research
US10626379 Production of viruses in cell culture Nov- Jan Apr-
Organisation
15 -19 20
11- 8- 14-
US10619186 Methods and compositions for library normalization Cellular Research, Inc. Sep- Sep Apr-
15 -16 20
10- 5- 14-
US10619153 TAL effector-mediated DNA modification Iowa State University Research Foundation, Inc. Dec- Oct Apr-
09 -17 20
9- 17- 14-
US10617677 Nuclear transport modulators and uses thereof Biogen MA Inc. May- Jul- Apr-
12 18 20
26- 21- 7-
Descriptive measurements and quantification of staining artifacts for
US10614284 Ventana Medical Systems, Inc. May- Nov Apr-
in situ hybridization
15 -17 20
28- 27- 7-
Non-human primate-derived pan-ebola and pan-filovirus monoclonal
US10611827 INTEGRATED BIOTHERAPEUTICS, INC. Oct- Oct Apr-
antibodies directed against envelope glycoproteins
14 -15 20
16- 7-
31-
US10610584 Reverse genetics systems Seqirus UK Limited Oct Apr-
Jul-09
-17 20
3- 7- 7-
Cytokine conjugates for the treatment of proliferative and infectious
US10610571 SYNTHORX, INC. Aug- Jun Apr-
diseases
17 -19 20
27- 27- 31-
US10605808 Antibody producing non-human animals Merus N.V. Jun- Apr Mar
08 -16 -20
8- 21- 31-
US10604729 Liquid loading composition, method of making and use thereof DEVMAR PRODUCTS, LLC Sep- May Mar
16 -18 -20
30- 25- 31-
US10604574 Oncolytic viral delivery of therapeutic polypeptides ONCORUS, INC. Jun- Oct Mar
16 -18 -20
16- 15- 31-
Anti-dengue virus antibodies, polypeptides containing variant Fc
US10604561 Agency for Science, Technology and Research Sep- Sep Mar
regions, and methods of use
16 -17 -20
30- 30- 31-
FUNDACIÃ“ INSTITUT D'INVESTIGACIÃ“ BIOMÃˆDICA DE
US10604549 Adenovirus comprising an albumin-binding moiety Apr- Apr Mar
BELLVITGE (IDIBELL)
14 -15 -20

2- 21- 31-
Compositions and method for treatment of inflammatory bowel
US10603356 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Jun- Apr Mar
disease
11 -16 -20
2- 3- 31-
US10603299 Prevention and treatment of viral infections Not Available Jun- Jul- Mar
16 19 -20
29- 27- 24-
US10597736 Compositions and methods for detecting viruses in a sample Washington University Jan- Jan Mar
16 -17 -20
30- 28- 24-
US10596264 Peptides with viral infection enhancing properties and their use Centre National de la Recherche Scientique Jun- Jun Mar
11 -12 -20
7- 1- 24-
Red blood cell membrane-derived microparticles and their use for University of Pittburghâ€”Of the Commonwealth System of
US10596197 Nov- Jun Mar
the treatment of lung disease Higher Education
13 -18 -20
7- 31- 17-
ELECTRONICS AND TELECOMMUNICATIONS RESEARCH
US10591714 Endoscopic apparatus for thermal distribution monitoring Sep- May Mar
INSTITUTE
16 -17 -20
17- 26- 17-
US10590435 The Trustees of the University of Pennsylvania Dec- Sep Mar
01 -18 -20
17- 17-
13-
US10590413 Chiral control WAVE LIFE SCIENCES LTD. Mar Mar
Jul-12
-17 -20
9- 7- 17-
US10590112 Dihydropyrimidinyl benzazepine carboxamide compounds Hoffmann-La Roche Inc. Jun- Dec Mar
17 -18 -20
15- 6- 17-
US10588966 Methods and compositions for inhibiting Akt3 Augusta University Research Institute, Inc. Jan- Feb Mar
16 -19 -20
24- 25- 10-
US10583086 Technology for preparation of macromolecular microspheres Ansun Biopharma, Inc. Jan- Sep Mar
06 -17 -20
30- 28- 3-
Derivatives of porphyrins, their process of preparation and their use
US10577375 CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE Oct- Oct Mar
for treating viral infections
15 -16 -20
18- 11- 25-
US10570416 TC-83-derived alphavirus vectors, particles and methods ALPHAVAX, INC. May- Aug Feb
04 -16 -20
Methods for inducing or enhancing an immune response by 25- 28- 25-

US10570209 administering agonistic glucocorticoid-induced TNFR-family-related GITR, Inc. Mar- Jun Feb
receptor (GITR) antibodies 05 -18 -20
28- 28- 18-

US10564160 Antibody-secreting cell assay MABTECH AB Aug- Aug Feb
08 -09 -20
1- 8- 18-
Method and device for detecting antigen-specific antibodies in a The United States of America, as represented by the
US10564152 Sep- Aug Feb
biological fluid sample by using neodymium magnets Secretary, Department of Health and Human Services
15 -16 -20
24- 15- 18-
US10563224 Replication defective adenovirus vector in vaccination Etubics Corporation Aug- Feb Feb
12 -17 -20
16- 15- 18-
Disinfecting aqueous foam, process for preparing same and use COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX
US10563154 Jun- Jun Feb
thereof ENERGIES ALTERNATIVES
15 -16 -20
18- 23- 18-
US10562861 Carboxylic acid compounds Sumitomo Dainippon Pharma Co., Ltd. May- Oct Feb
12 -18 -20
21- 13- 18-
US10561743 AAV vectors targeted to the central nervous system The University of North Carolina at Chapel Hill Nov- Jun Feb
14 -19 -20
3- 3- 18-
US10561722 Methods and compositions for enhancing immune responses Bavarian Nordic A/S Sep- Sep Feb
14 -15 -20
13- 16- 18-
Genetically modified non-human animals and methods of use
US10561126 Institute for Research in Biomedicine (IRB) Apr- Apr Feb
thereof
15 -18 -20
12- 12- 11-
US10557136 In vivo delivery of oligonucleotides Oncolmmunin Inc. Dec- Dec Feb
11 -12 -20
18- 10- 11-
US10557119 Erythroid cells comprising phenylalanine ammonia lyase RUBIUS THERAPEUTICS, INC. Nov- May Feb
13 -19 -20
14- 23- 11-
US10555993 Dimethyl fumarate and vaccination regimens Biogen MA Inc. Mar- Apr Feb
14 -19 -20
17- 10- 4-
Composition comprising a gene vector that selectively depletes P16
US10550378 Kythera Biopharmaceuticals, Inc. Apr- Jun Feb
positive senescent cells
12 -19 -20

US10550174 and polypeptides comprising the same for the treatment of viral Ablynx N.V. Jun- Oct Feb
diseases 08 -17 -20
29- 29- 4-
US10548971 MERS-CoV vaccine INOVIO PHARMACEUTICALS, INC. Nov- Jun Feb
13 -18 -20
23- 23- 4-
Compositions and methods for modified dendrimer nanoparticle
US10548959 Massachusetts Institute of Technology Sep- Sep Feb
delivery
16 -16 -20

16- 15- 28-
US10544405 Cas9-nucleic acid complexes and uses related thereto Emory University Jan- Jan Jan-
13 -14 20
22- 28-
11-
US10544399 Highly efficient influenza matrix (M1) proteins Novavax, Inc. Mar Jan-
Jul-03
-18 20
19- 9- 28-
Compositions and methods for treating diseases by inhibiting
US10544193 MOREHOUSE SCHOOL OF MEDICINE Dec- Jul- Jan-
exosome release
16 18 20
28- 28-
29-
US10544108 Hydrazide containing nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. Nov Jan-
Jul-11
-18 20
19- 13- 28-
Benzazepine dicarboxamide compounds with secondary amide
US10544102 Hoffmann-La Roche Inc. May- Nov Jan-
function
17 -18 20
24- 25- 28-
US10543485 Slip chip device and methods University of Chicago Mar- May Jan-
09 -16 20
22- 28- 28-
US10543269 hMPV RNA vaccines ModernaTX, Inc. Oct- Mar Jan-
15 -19 20
1- 14- 21-
US10539488 Sample fixation and stabilisation RNASSIST LTD. Mar- Aug Jan-
13 -17 20
30- 22- 21-
US10538558 Inhibition of TCR signaling with peptide variants SIGNABLOK, INC Sep- Oct Jan-
09 -18 20
27- 28- 21-
US10538554 Peptides and uses therefor as antiviral agents VIRAMATIX SDN BHD Nov- Nov Jan-
15 -16 20
20- 28- 14-
US10533021 Boron-containing small molecules Anacor Pharmaceuticals, Inc. Jun- Sep Jan-
07 -17 20
16- 18- 14-
Recombinant adeno-associated virus capsids resistant to pre- The Board of Trustees of the Leland Stanford Junior
US10532111 Feb- Aug Jan-
existing human neutralizing antibodies University
16 -17 20
21- 20- 14-
US10532110 AAV vectors targeted to the central nervous system The University of North Carolina at Chapel Hill Nov- Nov Jan-
14 -15 20
22- 20- 14-
US10532107 Modified virus-like particles of CMV SAIBA GMBH Oct- Oct Jan-
14 -15 20
5- 14-
6-Jul-
US10532067 Delivery of RNA to trigger multiple immune pathways GlaxoSmithKline Biologicals S.A. Oct Jan-
10
-17 20
30- 18- 7-
Method of predicting a performance characteristic of a plant or yeast
US10527551 Baxalta GmbH Dec- Dec Jan-
hydrolysate and its use
13 -14 20
5- 7-
14-
US10526596 Purification of nucleic acids using metal-titanium oxides Abbott Molecular Inc. Jul- Jan-
Jul-15
19 20
31- 30- 7-
US10526295 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. Dec- Dec Jan-
15 -16 20
29- 20- 7-
US10526292 Parion Sciences, Inc. May- Dec Jan-
12 -17 20
30- 2- 7-
US10526283 Prodrugs of dithiol mucolytic agents PARION SCIENCES, INC. Apr- May Jan-
15 -16 20
6- 22- 7-
US10525120 Methods and compositions for live attenuated viruses TAKEDA VACCINES, INC. Apr- Jul- Jan-
07 16 20
15- 20- 7-
US10525049 Specific Akt3 inhibitor and uses thereof Augusta University Research Institute, Inc. Jan- May Jan-
16 -19 20
5- 2- 31-
US10519130 FORMA Therapeutics, Inc. Feb- Nov Dec
7 inhibitors
15 -18 -19
5- 2- 31-
7 inhibitors
15 -18 -19
5- 2- 31-
7 inhibitors
15 -18 -19
5- 2- 31-
7 inhibitors
15 -18 -19
12- 14- 31-
US10517947 Methods for preparing squalene NOVARTIS AG May- Dec Dec
10 -17 -19
6- 6- 31-
US10517923 Immunosuppressive agents and their use in therapy Norwegian University of Science and Technology Nov- Nov Dec
13 -14 -19
3- 8- 31-
US10517881 Pharmaceutical compositions and methods POP TEST ONCOLOGY LLC Aug- Jan Dec
15 -19 -19
5- 2- 24-
7 inhibitors
15 -18 -19

5- 11- 24-
US10513507 FORMA Therapeutics, Inc. Feb- Dec Dec
7 inhibitors
15 -17 -19
26- 25- 24-
Methods and compositions for intra-nasal immunization with
US10512684 Bavarian Nordic A/S Sep- Sep Dec
recombinant MVA encoding flagellin
14 -15 -19
2- 1- 24-
US10512669 Blockade of inflammatory proteases with cyclic peptides The Regents of the University of California Jun- Jun Dec
11 -12 -19
8- 2- 24-
US10512665 Methods and compositions related to inhibition of viral entry UNIVERSITY OF UTAH RESEARCH FOUNDATION Feb- Jun Dec
07 -16 -19
5- 2- 17-
7 inhibitors
15 -18 -19
1- 19- 17-
US10507244 Anti-TIGIT antigen-binding proteins and methods of use thereof Potenza Therapeutics, Inc. Oct- Jun Dec
15 -17 -19
25- 27- 10-
US10503347 Georgetown University Feb- Jul- Dec
08 17 -19
27- 29- 10-
US10501733 Polypeptide assemblies and methods for the production thereof University of Utah Research Foundation Feb- Feb Dec
15 -16 -19
8- 7- 10-
Mast cell stabilizers for treatment of hypercytokinemia and viral
US10501527 Emergo Therapeutics, Inc. Sep- Sep Dec
infection
16 -17 -19
10- 10- 10-
US10501507 Griffithsin mutants Feb- Feb Dec
15 -16 -19
12- 10-
12-
US10501412 Conjugates of cell binding molecules with cytotoxic agents HANGZHOU DAC BIOTECH CO., LTD. Jul- Dec
Jul-12
12 -19
2- 12- 10-
Manufacture of surfactant-containing compositions with enhanced
US10500272 NOVARTIS AG Dec- Mar Dec
stability
14 -19 -19
17- 21- 10-
US10500267 Influenza virus vectors and uses therefor FluGen, Inc. Mar- Aug Dec
14 -17 -19
6- 13- 3-
US10495640 MOREHOUSE SCHOOL OF MEDICINE Oct- Dec Dec
diseases
08 -16 -19
8- 15- 3-
US10494420 Emergo Therapeutics, Inc. Sep- Nov Dec
infection
16 -18 -19
23- 26-
Apparatus and system for performing thermal melt analyses and 31-
US10488353 GEN-PROBE INCORPORATED Feb Nov
amplifications Jul-12
-17 -19
8- 16- 26-
US10487350 Methods for diagnosing infectious diseases using adsorption media ExThera Medical Corporation Nov- Oct Nov
13 -15 -19
6- 26-
6-Jul-
US10487332 Immunisation of large mammals with low doses of RNA GlaxoSmithKline Biologicals SA Jul- Nov
10
11 -19
31- 22- 26-
US10487081 Guanidine substituted imidazo[4,5-c] ring compounds 3M Innovation Properties Company Aug- Oct Nov
15 -18 -19
30- 15- 26-
Adeno-associated virus (AAV) clades, sequences, vectors containing
US10485883 The Trustees of the University of Pennsylvania Sep- Feb Nov
03 -17 -19
14- 14- 26-
US10485861 Nanoparticle-based compositions Massachusetts Institute of Technology Mar- Mar Nov
13 -14 -19
19- 17- 26-
US10485856 Carbon nanotube compositions and methods of use thereof Yale University Mar- Mar Nov
08 -17 -19
24- 16- 26-
US10485761 Irradiated biodegradable polymer microparticles GLAXOSMITHKLINE BIOLOGICALS, S.A. Jan- May Nov
10 -18 -19
16- 6- 19-
Antisense antiviral compound and method for treating ss/RNA viral
US10479996 Sarepta Therapeutics, Inc. Sep- Nov Nov
infection
04 -14 -19
5- 4- 19-
US10479781 Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors Neuprozyme Therapeutics APS Mar- Mar Nov
15 -16 -19
22- 27- 12-
US10476825 RNA targeting methods and compositions Salk Institue for Biological Studies Aug- Mar Nov
17 -18 -19
21- 15- 12-
US10472647 Primary mesenchymal stem cells as a vaccine platform The Administrators of the Tulane Educational Fund Dec- Nov Nov
12 -13 -19
22- 20- 12-
US10472420 Immune response modifier conjugates 3M Innovative Properties Company Feb- Jan Nov
06 -15 -19
26- 23- 12-
US10472332 Antiviral compounds and methods Biotron Limited Jun- May Nov
03 -17 -19
18- 5- 12-
US10471408 Microspotting device BioFire Diagnostics, LLC Apr- Jan Nov
12 -17 -19

3- 2- 12-
Bisphosphonate-containing vaccine pharmaceutical composition for
US10471141 NITTO DENKO CORPORATION Sep- Sep Nov
humoral immunity
14 -15 -19
4- 18- 12-
Composition for enhancing induction of humoral immunity, and
US10471140 NOTTO DENKO CORPORATION Aug- Apr Nov
vaccine pharmaceutical composition
14 -19 -19
15- 5- 12-
Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor
US10471063 Verona Pharma PLC Mar- Jun Nov
antagonist
13 -17 -19
20- 8- 5-
Covalently linked thermostable kinase for decontamination process
US10466245 The Secretary of State for Health Feb- Jul- Nov
validation
08 16 -19
23- 4- 5-
US10464988 Antibody/T-cell receptor chimeric constructs and uses thereof EUREKA THERAPEUTICS, INC. Oct- Sep Nov
15 -18 -19
1- 5-
2-Jul-
US10464975 Stabilized anti-microbial peptides Dana-Farber Cancer Institute, Inc. Jul- Nov
15
16 -19
28- 28- 5-
US10464955 Charged linkers and their uses for conjugation HANGZHOU DAC BIOTECH CO., LTD. Feb- Feb Nov
14 -14 -19
10- 9- 5-
US10464060 Loading vials BioFare Diagnostics, LLC Nov- Nov Nov
11 -12 -19
15- 14- 5-
US10463723 Methods and compositions for intranasal delivery Shin Nippon Biomedical Laboratories, Ltd. Apr- Mar Nov
10 -13 -19
3- 26- 5-
Circulation of components during microfluidization and/or
US10463615 NOVARTIS AG Dec- Jun Nov
homogenization of emulsions
09 -17 -19
8- 2- 29-
US10457974 Methods for diagnosing infectious diseases using adsorption media ExThera Medical Corporation Nov- Nov Oct-
13 -16 19
8- 19- 29-
US10457901 Cleaning composition, method of making and use thereof DevMar Products, LLC Sep- Sep Oct-
16 -18 19
4- 4- 29-
Liquid immunity induction-promoting composition and vaccine
US10456464 NITTO DENKO CORPORATION Aug- Aug Oct-
pharmaceutical composition that include thrombosis treatment drug
14 -15 19
7- 7- 22-
Cell-free nucleic acids for the analysis of the human microbiome and The Board of Trustees of the Leland Stanford Junior
US10450620 Nov- Nov Oct-
components thereof University
13 -14 19
2- 9- 22-
Carbonic anhydrase IX (G250) antibodies and methods of use
US10450383 DANA-FARBER CANCER INSTITUTE, INC. Dec- May Oct-
thereof
05 -17 19
24- 24- 15-
Active low molecular weight variants of angiotensin converting
US10443049 Northwestern University Jan- Jan Oct-
enzyme 2 (ACE2)
17 -18 19
16- 23- 15-
US10442853 Antibodies and processes for preparing the same TAIGA BIOTECHNOLOGIES, INC. May- Aug Oct-
08 -16 19
22- 7- 8-
US10434158 Combination of vaccination and inhibition of the PD-1 pathway CureVac AG Feb- Feb Oct-
13 -18 19
7- 7- 8-
United States Government as represented by the
US10434116 Methods of treating coronavirus infection Apr- Apr Oct-
14 -15 19
7- 9- 1-
Helix-grafted proteins as inhibitors of disease-relevant protein-
US10428128 Colorodo State University Research Foundation Nov- Nov Oct-
protein interactions
14 -15 19
4- 7- 1-
Glycolipids and pharmaceutical compositions thereof for use in
US10428102 THE UNIVERSITY OF NOTTINGHAM Apr- Apr Oct-
therapy
14 -15 19
26- 21- 1-
Heterocyclylmethyl-thienouracile as antagonists of the adenosine-
US10428083 BAYER PHARMA AKTIENGESELLSCHAFT Mar- Mar Oct-
A2B-receptor
15 -16 19
17- 8- 1-
US10428027 Sulfinylphenyl or sulfonimidoylphenyl benzazepines Hoffmann La-Roche Inc. Sep- Mar Oct-
15 -18 19
19- 17- 1-
US10426737 Lipids and lipid compositions for the delivery of active agents Novartis AG Dec- Dec Oct-
13 -14 19
19- 11- 24-
US10421991 Rapid epidemiologic typing of bacteria BioFire Diagnostics, LLC May- Nov Sep
08 -15 -19
12- 15- 24-
Double-stranded oligonucleotide molecules to DDIT4 and methods
US10421962 Quark Pharmaceuticals, Inc. Sep- Feb Sep
of use thereof
12 -17 -19
2- 1- 24-
US10420837 Vaccine pharmaceutical composition for transdermal administration NITTO DENKO CORPORATION Oct- Oct Sep
14 -15 -19
12- 11- 24-
US10420685 Mobile clinics Baylor College of Medicine Nov- Nov Sep
14 -15 -19
7- 17-
7-Jul-
US10416171 Influenza potency assays Seqirus UK Limited Jul- Sep
15
16 -19
6- 20- 17-
US10416161 MOREHOUSE SCHOOL OF MEDICINE Oct- Sep Sep
diseases
08 -16 -19

3- 15- 17-
US10414800 Methods for producing a depsipeptide NovoBiotic Pharmaceuticals, LLC Dec- Jun Sep
12 -16 -19
26- 1- 17-
Fused [1,2]imidazo[4,5-C] ring compounds substituted with
US10414779 3M Innovative Properties Company Aug- Aug Sep
guanidino groups
16 -17 -19
US10407492 and polypeptides comprising the same for the treatment of viral Ablynx N.V. Jun- Oct Sep
diseases 08 -17 -19
17- 14- 10-

Fusion proteins, recombinant bacteria, and methods for using
US10407472 Spogen Biotech Inc. Sep- Dec Sep
recombinant bacteria
14 -17 -19
1- 27- 10-
US10407431 Compounds and compositions as toll-like receptor 7 agonists Novartis AG May- Feb Sep
14 -18 -19
21- 17- 10-
US10407405 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. Jun- Jul- Sep
13 17 -19
28- 2- 10-
US10406229 Methods and compositions related to inhibition of viral entry UNIVERSITY OF UTAH RESEARCH FOUNDATION Mar- Mar Sep
11 -17 -19
29- 10-
31-
US10406177 Modified cells and methods of therapy Intima Bioscience, Inc. Aug Sep
Jul-15
-16 -19
3- 6- 10-
US10406142 3M lnnovative Properties Company Jun- Mar Sep
therefrom
11 -17 -19
18- 16- 3-
Fluorogenic probes and their use in quantitative detection of target
US10400274 Jan Biotech, Inc. Jun- Jun Sep
RNA sequences
16 -17 -19
10- 21- 3-
US10400225 TAL effector-mediated DNA modification Iowa State University Research Foundation, Inc. Dec- Aug Sep
09 -17 -19
6- 5- 3-
Cleavage and exchange of major histocompatibility complex ligands
US10400024 SANQUIN REAGENTS B.V. Jun- Jun Sep
employing azobenzene-containing peptides
14 -15 -19
4- 3-
Substituted benzofuranyl and benzoxazolyl compounds and uses 3-Jul-
US10399963 Karyopharm Therapeutics Inc. Dec Sep
thereof 13
-17 -19
16- 3-
12-
US10399941 Conjugates of cell binding molecules with cytotoxic agents HANGZHOU DAC BIOTECH CO., LTD. Apr Sep
Jul-12
-14 -19
29- 29- 3-
US10398795 Decontamination device and method using ultrasonic cavitation TOMI ENVIRONMENTAL SOLUTIONS, INC. Dec- Dec Sep
17 -17 -19
1- 30- 27-
US10393633 Sample fixation and stabilisation RNASSIST LTD. Mar- May Aug
13 -17 -19
13- 27-
14-
US10392613 Purification of nucleic acids using copper-titanium oxides ABBOTT MOLECULAR INC. Jul- Aug
Jul-15
16 -19
29- 11- 27-
US10391188 Decontamination device and method using ultrasonic cavitation TOMI ENVIRONMENTAL SOLUTIONS, INC. Dec- Sep Aug
17 -18 -19
3- 2- 27-
US10391167 Mucosal vaccine composition NITTO DENKO CORPORATION Oct- Oct Aug
13 -14 -19
14- 13- 27-
US10391160 Dimethyl fumarate and vaccination regimens Biogen MA Inc. Mar- Mar Aug
14 -15 -19
2- 2- 20-
Recombinant adeno-associated virus capsids with enhanced human The Board of Trustees of the Leland Stanford Junior
US10385320 Dec- Dec Aug
skeletal muscle tropism University
15 -16 -19
13- 15- 20-
US10385119 Trustees of the University of Pennsylvania May- Oct Aug
and uses thereof
14 -18 -19
17- 24- 20-
US10383938 3M Innovative Properties Company Aug- Jul- Aug
10 18 -19
23- 31- 20-
US10383935 Methods of making and using live attenuated viruses Regents of the University of Minnesota Sep- Oct Aug
15 -17 -19
2- 27- 20-
US10383852 Prevention and treatment of viral infections Not Available Jun- Nov Aug
16 -18 -19
6- 5- 13-
US10378008 Method and apparatus for automated processing of pooled samples GFE BLUT MBH Aug- Aug Aug
14 -15 -19
17- 6- 13-
US10378002 Replication conditional virus that specifically kills senescent cells Kythera Biopharmaceuticals, Inc. Apr- Jul- Aug
12 18 -19
5- 27- 13-
Isothiazolopyrimidinones, pyrazolopyrimidinones, and
US10377773 FORMA Therapeutics, Inc. Feb- Feb Aug
pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors
15 -18 -19
5- 1- 13-
US10377767 Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors FORMA Therapeutics, Inc. Feb- Mar Aug
15 -18 -19

30- 18- 13-
Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7
US10377760 FORMA Therapeutics, Inc. Dec- Jan Aug
inhibitors
14 -18 -19
8- 6- 6-
US10370625 Cleaning composition, method of making and use thereof DEVMAR PRODUCTS, LLC Sep- Sep Aug
16 -17 -19
5- 7- 6-
Identification of VSIG8 as the putative VISTA receptor (V-R) and
US10370455 IMMUNEXT, INC. Dec- Dec Aug
use thereof to produce VISTA/VSIG8 agonists and antagonists
14 -15 -19
23- 13- 6-
US10370338 Benzazepine dicarboxamide compounds with tertiary amide function Hoffmann-La Roche Inc. May- Nov Aug
16 -18 -19
4- 4- 6-
US10369219 NITTO DENKO CORPORATION Aug- Aug Aug
14 -15 -19
1- 1- 6-
Polymeric carrier cargo complex for use as an immunostimulating
US10369216 CureVac AG Apr- Apr Aug
agent or as an adjuvant
14 -15 -19
7- 7- 6-
US10369205 Immunomodulatory compositions and methods of use thereof Not Available Jan- Jan Aug
14 -15 -19
2- 2- 6-
US10369204 Molecular vaccines for infectious disease Dako Denmark A/S Oct- Oct Aug
08 -09 -19
11- 11- 30-
US10363303 Microneedle compositions and methods of using same VERNDARI, INC. Jan- Jul- Jul-
16 18 19
29- 12- 30-
US10363282 Analogs of C5a and methods of using same Board of Regents of The University of Nebraska Jun- Jan Jul-
10 -18 19
(S,E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3- 18- 18- 30-

US10363247 methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran- Karyopharm Therapeutics Inc. Aug- Aug Jul-
2-yl)methyl)acrylamide for the treatment of cancer 15 -16 19
31- 2- 23-
US10358481 Engineered antibody constant domain molecules Jan- Dec Jul-
08 -16 19
24- 23- 23-
US10357568 Adjuvant nanoemulsions with phospholipids GLAXOSMITHKLINE BIOLOGICALS S.A. Mar- Mar Jul-
11 -12 19
14- 17- 23-
US10357562 Immunoprotective primary mesenchymal stem cells and methods Autoimmune Technologies, LLC Mar- Jul- Jul-
13 15 19
7- 7- 23-
US10357510 Metal nanoclusters and uses thereof THE REGENTS OF THE UNIVERSITY OF MICHIGAN Aug- Aug Jul-
14 -15 19
30- 24- 16-
Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific
US10351571 FORMA Therapeutics, Inc. Dec- May Jul-
protease 7 inhibitors
14 -18 19
1- 30- 16-
US10350255 Polygonum cuspidatum extracts PhotoDynamic Inc. Oct- Sep Jul-
15 -16 19
6- 5- 9-
US10344320 Capacitive liquid crystal biosensors The Johns Hopkins University May- May Jul-
15 -16 19
18- 29- 9-
US10344263 Synthetic membrane-receiver complexes RUBIUS THERAPEUTICS, INC. Nov- Mar Jul-
13 -17 19
9- 9- 9-
US10344261 Immunomodulatory conjugates ASCEND BIOPHARMACEUTICALS LTD Nov- Nov Jul-
11 -12 19
23- 24- 9-
US10344027 Compositions and methods for inhibiting kinases Inhibikase Therapeutics, Inc. Apr- Oct Jul-
15 -18 19
15- 17- 9-
US10342868 Methods and compositions for inhibiting Akt3 Augusta University Research Institute, Inc. Jan- Jan Jul-
16 -17 19
15- 15- 9-
US10342825 Solution containing hypochlorous acid and methods of using same Sonoma Pharmaceuticals, Inc. Jun- Jun Jul-
09 -10 19
18- 13- 2-
US10336725 Chemical compounds AstraZeneca AB Mar- Dec Jul-
14 -17 19
8- 8- 2-
US10335484 Methods of generating robust passive and active immune responses HUMABS BIOMED SA Jan- Jan Jul-
13 -14 19
9- 4- 2-
US10335393 Nuclear transport modulators and uses thereof Biogen MA Inc. May- Dec Jul-
12 -17 19
14- 10- 2-
Compositions with modified nucleases targeted to viral nucleic acids
US10335372 Jacob G. Appelbaum Apr- Mar Jul-
and methods of use for prevention and treatment of viral diseases
04 -17 19
18- 13- 25-

US10329531 Synthetic membrane-receiver complexes RUBIUS THERAPEUTICS, INC. Nov- Oct Jun-
13 -17 19

7- 28- 25-
Fusion proteins for promoting an immune response, nucleic acids
US10329329 UNIVERSITY OF MIAMI Sep- Aug Jun-
encoding same, and methods of making and use thereof
12 -18 19
3- 25-
US10328157 HANGZHOU DAC BIOTECH CO., LTD. Feb Jun-
-17 19
29- 12- 18-
US10323074 Cryptic polypeptides and uses thereof BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY Jan- Dec Jun-
15 -17 19
5- 18-
15-
US10322104 Disulfur bridge linkers for conjugation of a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD. Apr Jun-
Jul-15
-17 19
23- 24- 11-
US10316031 Compositions and methods for inhibiting kinases Inhibikase Therapeutics, Inc. Apr- Oct Jun-
15 -18 19
Oral delivery of angiotensin converting enzyme 2 (ACE2) or

18- 18- 11-
angiotensin-(1-7) bioencapsulated in plant cells attenuates
US10314893 The Trustees of the University of Pennsylvania Oct- Apr Jun-
pulmonary hypertension, cardiac dysfunction and development of
13 -16 19
autoimmune and experimental induced ocular disorders
2- 3- 4-
Chimeric viruses presenting non-native surface proteins and uses
US10308913 Icahn School of Medicine at Mount Sinai Dec- Mar Jun-
thereof
05 -16 19
6- 5- 4-
Optimized human clotting factor VIII gene expression cassettes and
US10308705 The University of North Carolina at Chapel Hill Feb- Feb Jun-
their use
15 -16 19
25- 4-
17-
US10308685 Inhibitory peptides of viral infection UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION May Jun-
Jul-14
-17 19
27- 18- 4-
US10307475 Methods and compositions for immunization against virus Academia Sinica Mar- Feb Jun-
09 -14 19
12- 12- 4-
US10307472 Combination of vaccination and OX40 agonists CureVac AG Mar- Mar Jun-
14 -14 19
24- 2- 4-
US10307439 Substituted nucleosides, nucleotides and analogs thereof Alios Biopharma, Inc. Jun- Feb Jun-
14 -17 19
27- 4-
6-Jul-
US10307434 Nucleic acid prodrugs and methods of use thereof WAVE LIFE SCIENCES LTD. May Jun-
09
-16 19
5- 4-
15-
US10307391 Disulfur bridge linkers for conjugation of a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD. Apr Jun-
Jul-15
-17 19
24- 4-
6-Jul-
US10307374 Oil-in-water emulsions that contain nucleic acids GLAXOSMITHKLINE BIOLOGICALS S.A. Apr Jun-
11
-17 19
17- 1- 28-
US10301650 The Trustees of the University of Pennsylvania Dec- May May
01 -17 -19
7- 18- 28-
US10301648 Method of increasing the function of an AAV vector The Trustees of the University of Pennsylvania Apr- Feb May
05 -15 -19
18- 19- 28-
US10301594 Synthetic membrane-receiver complexes RUBIUS THERAPEUTICS, INC Nov- Nov May
13 -18 -19
18- 19- 28-
US10301593 Synthetic membrane-receiver complexes RUBIUS THERAPEUTICS, INC. Nov- Mar May
13 -18 -19
24- 24- 28-
Middle east respiratory syndrome coronavirus immunogens, The United States of America, as Represented by the
US10301377 Feb- Feb May
antibodies, and their use Secretary, Department of Health and Human Services
15 -16 -19
29- 10- 28-
US10300149 Compositions for enhancing transport of molecules into cells SAREPTA THERAPEUTICS, INC. Apr- Jan May
03 -17 -19
14- 28-
Synthetic nanoparticles for delivery of immunomodulatory 15-
US10300145 Massachusetts Institute of Technology Jul- May
compounds Jul-16
17 -19
20- 21- 28-
US10300127 Immune complex The Rockefeller University Mar- Mar May
15 -16 -19
15- 14- 28-
US10300124 Rodent hepadnavirus cores with reduced carrier-specific antigenicity VLP BIOTECH, INC. Mar- Mar May
13 -14 -19
9- 10- 21-
US10294534 Respiratory infection assay THE SECRETARY OF STATE FOR HEALTH Dec- Dec May
11 -12 -19
14- 1- 21-
Human monoclonal antibody with specificity for dengue virus
US10294293 DSO National Laboratories Dec- Jun May
serotype 1 E protein and uses thereof
10 -16 -19
21- 21-
21-
US10294280 Constrained proteins and uses therefor Monash University Jul- May
Jul-14
15 -19
21- 19- 21-
US10293060 Method for increasing expression of RNA-encoded proteins CureVac AG Aug- Feb May
14 -16 -19
3- 21-
US10293055 HANGZHOU DAC BIOTECH CO., LTD. Mar May
-17 -19

7- 7- 21-
Attenuated Listeria monocytogenes mutant as a vaccine vector for
US10293039 Montana State University Apr- Apr May
the delivery of exogeneous antigens
14 -15 -19
15- 17- 21-
US10292978 Specific Akt3 inhibitor and uses thereof Augusta University Research Institute, Inc. Jan- Jan May
16 -17 -19
15- 21-
15-
US10292961 Disulfur bridge linkers for conjugation of a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD. Jul- May
Jul-15
15 -19
23- 11- 14-
Method of determining, identifying or isolating cell-penetrating
US10288601 Phylogica Limited May- Dec May
peptides
11 -17 -19
1- 12- 14-
US10287576 Enzymatic encoding methods for efficient synthesis of large libraries NUEVOLUTION A/S Dec- Dec May
05 -16 -19
24- 19- 14-

US10287258 ASTRAZENECA AB Jan- Sep May
14 -17 -19
5- 4- 14-
Substituted pyrimidines containing acidic groups as TLR7
US10287253 APROS THERAPEUTICS, INC. Dec- Dec May
modulators
16 -17 -19
4- 4- 14-
US10286067 NITTO DENKO CORPORATION Aug- Aug May
14 -15 -19
27- 27- 14-
US10286056 Adjuvant nanoemulsions with crystallisation inhibitors GLAXOSMITHKLINE BIOLOGICALS S.A. Jan- Jan May
11 -12 -19
7- 4- 7-
US10280199 Coronavirus proteins and antigens Phibro Animal Health Corporation Feb- Aug May
14 -16 -19
25- 27- 7-
US10279029 Immunogenic compositions and uses thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Mar- Feb May
15 -18 -19
24- 14- 7-
US10279028 Ohio State Innovation Foundation Apr- Dec May
12 -17 -19
2- 6- 7-
US10279027 Transgenic Vero-CD4/CCR5 cell line INTERNATIONAL AIDS VACCINE INITIATIVE Oct- Apr May
15 -17 -19
9- 2- 30-
US10273454 Dec- Jun Apr-
05 -17 19
18- 21- 30-
Hydrocarbon double-stapled stabilized HIV-1 GP41 heptad repeat
US10273290 DANA-FARBER CANCER INSTITUTE, INC. Jun- Sep Apr-
domain peptides
09 -17 19
22- 20- 30-
US10272150 Combination PIV3/hMPV RNA vaccines ModernaTX, Inc. Oct- Jul- Apr-
15 18 19
5- 4- 30-
US10272149 Modified bat influenza viruses and their uses J. CRAIG VENTER INSTITUTE Sep- Sep Apr-
14 -15 19
9- 9- 23-
US10266887 CRISPR effector system based diagnostics MASSACHUSETTS INSTITUTE OF TECHNOLOGY Dec- Mar Apr-
16 -18 19
9- 9- 23-
US10266886 CRISPR effector system based diagnostics MASSACHUSETTS INSTITUTED OF TECHNOLOGY Dec- Mar Apr-
16 -18 19
17- 20- 23-
US10266846 The Trustees of the University of Pennsylvania Dec- Oct Apr-
01 -16 19
2- 2- 23-
Coumarin derivative as antiviral agent, pharmaceutical composition
US10266545 I-NOVA MEDICINSKA ISTRAZIVANJA D.O.O. Feb- Feb Apr-
thereof, its preparation and use
16 -16 19
30- 3- 23-
Adeno-associated virus (AAV) clades, sequences, vectors containing
US10265417 The Trustees of the University of Pennsylvania Sep- Aug Apr-
03 -16 19
15- 10- 23-
US10265407 Modular nanodevices for smart adaptable vaccines Yale University Feb- Nov Apr-
07 -14 19
24- 23- 23-
US10265395 Adjuvant compositions and related methods Not Available Mar- Mar Apr-
15 -17 19
CENTRO DE INVESTIGACION BIOMEDICA EN RED EN 13- 10- 23-
Methods and reagents for efficient and targeted delivery of
US10265371 BIOINGENIERIA BIOMATERIALES Y NANOMEDICINA (CIBER Jan- Jan Apr-
therapeutic molecules to CXCR4 cells
BBN) 11 -17 19
13- 23-
15-
US10265291 Disulfur bridge linkers for conjugation of a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD. Feb Apr-
Jul-15
-17 19
27- 26- 16-
US10260071 COLEY PHARMACEUTICAL GMBH Sep- May Apr-
06 -16 19
15- 15- 16-
Anti-pneumococcal hyperimmune globulin for the treatment and
US10259865 ADMA Biologics, Inc. Mar- Mar Apr-
prevention of pneumococcal infection
17 -17 19
23- 4- 16-
Compositions and methods comprising hydrocarbon-stapled
US10259848 DANA-FARBER CANCER INSTITUTE, INC. Jan- May Apr-
polypeptides
08 -16 19

25- 25- 16-
Synergistic bacterial compositions and methods of production and
US10258655 Seres Therapeutics, Inc. Nov- Nov Apr-
use thereof
13 -14 19
7- 3- 9-
US10254204 Membrane-assisted purification Accelerate Diagnostics, Inc. Mar- May Apr-
11 -17 19
6- 5- 9-
US10253353 Enhanced methods of ribonucleic acid hybridization The Broad Institute, Inc. Dec- Dec Apr-
13 -14 19
26- 14- 9-
US10253318 CITY OF HOPE Jan- Jun Apr-
diseases
07 -17 19
18- 28- 9-
US10253296 Synthetic membrane-receiver complexes RUBIUS THERAPEUTICS, INC. Nov- Nov Apr-
13 -17 19
16- 30- 9-
US10253093 Human monoclonal antibodies against interleukin 8 (IL-8) CORMORANT PHARMACEUTICALS AB Dec- Apr Apr-
02 -18 19
16- 16- 9-
US10251904 Methods for treating arenaviridae and coronaviridae virus infections GILEAD SCIENCES, INC. Sep- Sep Apr-
15 -16 19
5- 5- 2-
Media elaborated with newly synthesized antibodies (MENSA) and
US10247729 MICROBPLEX, INC. May- May Apr-
uses thereof
14 -15 19
17- 29- 2-
3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl)
US10246425 Parion Sciences, Inc. Dec- Jun Apr-
pyrazine-2-carboxamide compounds
12 -17 19
2- 2- 26-
Manufacture of surfactant-containing compositions with enhanced
US10238739 NOVARTIS AG Dec- Dec Mar
stability
14 -15 -19
11- 26-
6-Jul-
US10238733 Cationic oil-in-water emulsions GLAXOSMITHKLINE BIOLOGICALS S.A. Mar Mar
10
-16 -19
3- 29- 26-
US10238666 Pharmaceutical compositions and methods Pop Test Oncology LLC Aug- Nov Mar
15 -17 -19
Methods for treating pulmonary emphysema using substituted 2- 14- 6- 26-

US10238633 Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- Boehringer Ingelheim International GmbH Mar- Jun Mar
amides inhibitors of Cathepsin C 13 -17 -19
7- 27- 19-
Hand, foot, and mouth vaccines and methods of manufacture and
US10233429 Takeda Vaccines, Inc. Nov- Oct Mar
use thereof
14 -17 -19
16- 16- 19-
CD137 enrichment for efficient tumor infiltrating lymphocyte
US10233425 The Trustees of the University of Pennsylvania Sep- Sep Mar
selection
13 -14 -19
21- 21- 19-
US10233237 Heterodimeric immunoglobulins AMGEN INC. Nov- Nov Mar
12 -13 -19
13- 4- 19-
Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel
US10233158 Parion Sciences, Inc. Dec- Apr Mar
blocking compounds
13 -18 -19
3- 19-
US10232051 HANGZHOU DAC BIOTECH CO., LTD. Mar Mar
-17 -19
22- 19- 12-
US10227376 Radiolabeled cationic steroid antimicrobials and diagnostic methods BRIGHAM YOUNG UNIVERSITY Aug- Aug Mar
14 -15 -19
4- 17- 12-
US10227373 Enantiomers of the 1â€²,6â€²-isomer of neplanocin A Auburn University Aug- May Mar
14 -17 -19
20- 19- 12-
US10226449 Heterocyclic modulators of lipid synthesis and combinations thereof 3-V Biosciences, Inc. Dec- Dec Mar
13 -14 -19
30- 2- 12-
Design, synthesis and methods of use of acyclic fleximer nucleoside Katholieke Universiteit Leuven/Lieden University Medical
US10226434 Jan- Jul- Mar
analogues having anti-coronavirus activity Center, RC Leiden
15 18 -19
8- 9- 5-
Univeersity of Pittsburghâ€”Of the Commonwealth System
US10222374 B-cell antigen presenting cell assay Apr- Aug Mar
of Higher Education
10 -17 -19
21- 3- 5-
US10221446 Signal propagation biomolecules, devices and methods STC.UNM May- Oct Mar
13 -16 -19
2- 30- 5-
US10220002 Controlled-release peptide compositions and uses thereof BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA Dec- Nov Mar
11 -12 -19
3- 3- 26-
US10213383 Hydrophilic filtration during manufacture of vaccine adjuvants NOVARTIS AG Dec- Dec Feb
09 -10 -19
9- 9- 19-
Chips, detection systems, and methods for multiplex pneumococcus
US10209254 The UAB Research Foundation Oct- Oct Feb
serology
13 -14 -19
4- 19- 19-
US10209248 Multiplex immuno screening assay Institut Pasteur May- Jul- Feb
12 17 -19
28- 28- 19-
RNA virus attenuation by alteration of mutational robustness and
US10206994 INSTITUT PASTEUR Jan- Jan Feb
sequence space
15 -16 -19

7- 30- 12-
Single cell analysis of T cells using high-throughput multiplex The Board of Trustees of the Leland Stanford Junior
US10202640 May- Apr Feb
amplification and deep sequencing University
14 -15 -19
8- 8- 12-
US10202617 Expression cassette for efficient surface display of antigenic proteins Temasek Life Sciences Laboratory Limited Feb- Feb Feb
11 -12 -19
10- 11- 12-
US10202615 Mammalian genes involved in toxicity and infection VANDERBILT UNIVERSITY Dec- Dec Feb
10 -11 -19
5- 3- 12-
US10202578 Chicken cells for improved virus production THE PIRBRIGHT INSTITUTE Jun- Jun Feb
13 -14 -19
12- 12- 12-
US10202367 Heterocyclic compounds and methods of use thereof Jun- Jun Feb
14 -15 -19
Protective masks with coating comprising different electrospun 23- 10- 12-
US10201198 fibers interweaved with each other, formulations forming the same, Profit Royal Pharmaceutical Limited Dec- Dec Feb
and method of producing thereof 14 -15 -19
31- 23- 29-

Systems and methods for analyzing a sample and for monitoring the
US10190984 GEN-PROBE INCORPORATED Dec- Dec Jan-
performance of an optical signal detector
15 -16 19
7- 29- 29-
US10190137 CRISPR-related methods and compositions with governing gRNAS Editas Medicine, Inc. Nov- Nov Jan-
13 -17 19
21- 2- 29-
Recombinant influenza virus-like particles (VLPs) produced in
US10190132 MEDICAGO INC. Jan- Sep Jan-
transgenic plants expressing hemagglutinin
08 -16 19
19- 15- 29-
US10189822 Heterocyclic modulators of lipid synthesis 3-V Biosciences, Inc. Mar- Mar Jan-
15 -16 19
7- 3- 29-
US10189820 Heterocyclic amides useful as protein modulators GlaxoSmithKline Intellectual Property Development Limited Apr- Jan Jan-
16 -18 19
23- 22-
6-Jul-
US10183074 Cationic oil-in-water emulsions GLAXOSMITHKLINE BIOLOGICALS S.A. Mar Jan-
11
-17 19
16- 16- 15-
Recombinant adeno-associated virus capsids resistant to pre- The Board of Trustees of the Leland Stanford Junior
US10179176 Feb- Feb Jan-
existing human neutralizing antibodies University
16 -17 19
8- 15-
28-
US10179143 Anti-viral azide containing compounds Life Technologies Corporation Aug Jan-
Jul-10
-17 19
21- 8-
29-
US10173987 Hydrazide containing nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. Jun Jan-
Jul-11
-17 19
31- 26- 8-
Pyrazolone compounds having human neutrophil elastase inhibitory
US10172830 Chiesi Farmaceutici S.p.A. May- May Jan-
properties
16 -17 19
24- 24- 1-
US10168336 Quinone methide analog signal amplification Ventana Medical Systems, Inc. Feb- Aug Jan-
14 -16 19
5- 2- 1-
Luminophore-labeled molecules coupled with particles for
US10167499 CAPITALBIO TECHNOLOOGY CORPORATION Dec- Dec Jan-
microarray-based assays
13 -14 19
16- 15- 1-
Neutralizing human monoclonal antibodies against hepatitis B virus
US10167333 Not Available Jan- Jan Jan-
surface antigen
14 -15 19
Nucleic acid comprising or coding for a histone stem-loop and a 15- 21- 1-
US10166283 poly(A) sequence or a polyadenylation signal for increasing the CureVac AG Feb- Mar Jan-
expression of an encoded pathogenic antigen 12 -17 19
29- 1-
31-
US10166255 Intracellular genomic transplant and methods of therapy INTIMA BIOSCIENCE, INC. Jul- Jan-
Jul-15
16 19
8- 17- 25-
US10160796 Emergo Therapeutics, Inc. Sep- Nov Dec
infection
16 -17 -18
15- 20- 25-
US10159731 Methods and compositions for inhibiting Akt3 Augusta University Research Institute, Inc. Jan- Feb Dec
16 -18 -18
13- 12- 25-
US10159729 Antigen and method for production thereof Sallpro Biotech AB Sep- Sep Dec
13 -14 -18
27- 15- 25-
US10159672 PARION SCIENCES, INC. Jun- Dec Dec
11 -17 -18
16- 15- 18-
US10156562 Assay for detecting Th1 and Th2 cell populations AMGEN INC. May- May Dec
14 -15 -18
15- 1- 18-
US10155980 Compositions and methods for detecting rare sequence variants ACCURAGEN HOLDINGS LIMITED Aug- Nov Dec
16 -17 -18
25- 9- 18-
US10155946 Particle-nucleic acid conjugates and therapeutic uses related thereto Emory University Jun- Oct Dec
12 -17 -18
9- 9- 18-
US10155932 Novartis AG Sep- May Dec
vaccines
04 -16 -18

31- 26- 11-
US10150768 Guanidine substituted imidazo[4,5-c] ring compounds 3M Innovative Properties Company Aug- Aug Dec
15 -16 -18
18- 11- 11-
US10150743 Carboxylic acid compounds Sumitomo Dainippon Pharma Co., Ltd. May- May Dec
12 -16 -18
10- 27- 11-
US10149901 Influenza vaccines with reduced amounts of squalene Seqirus UK Limited Feb- Jan Dec
09 -16 -18
11- 10- 11-
Nucleotide and nucleoside therapeutic compositions and uses
US10149859 Emory University Sep- Sep Dec
related thereto
13 -14 -18
27- 23- 11-
US10149461 Immunocompromised ungulates Revivicor, Inc. Oct- Mar Dec
08 -15 -18
22- 25- 4-
US10144735 Immune response modifier compositions and methods 3M Innovative Properties Company Dec- Jun Dec
06 -18 -18
6- 6- 4-
US10143709 Use of ASC and ASC-CM to treat ARDS, SARS, and MERS Indiana University Research and Technology Corporation May- May Dec
14 -15 -18
23- 2- 4-
US10143652 Methods for the preparation of liposomes CuriRx Inc. Sep- Aug Dec
09 -16 -18
29- 22- 27-
US10138461 Animal protein-free media for cultivation of cells Baxalta Gmbh Oct- Sep Nov
04 -17 -18
13- 13- 27-
US10138295 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA May- May Nov
and uses thereof
14 -15 -18
30- 30- 27-
US10138276 Inhibition of TCR signaling with peptide variants SIGNABLOK, Inc. Sep- Sep Nov
09 -10 -18
28- 7- 20-
Nucleic acid molecules encoding monoclonal antibodies specific for
US10131709 ImmunoQure AG Dec- Sep Nov
IL-22
11 -16 -18
25- 27- 20-
Middle east respiratory syndrome coronavirus neutralizing
US10131704 DANA-FARBER CANCER INSTITUTE, INC. Apr- Apr Nov
antibodies and methods of use thereof
14 -15 -18
24- 24- 20-
Hydrophilic linkers and their uses for conjugation of drugs to a cell
US10131682 HANGZHOU DAC BIOTECH CO., LTD. Nov- Nov Nov
binding molecules
12 -12 -18
23- 20-
23-
US10130701 Coronavirus THE PIRBRIGHT INSTITUTE Jul- Nov
Jul-14
15 -18
4- 25- 13-
THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF
US10125112 Modulators of the relaxin receptor 1 May- Aug Nov
TRUSTEES
12 -16 -18
5- 4- 13-
US10125092 Lipids and lipid compositions for the delivery of active agents Novartis AG Sep- Sep Nov
14 -15 -18
8- 6- 13-
US10124065 Lipids and lipid compositions for the delivery of active agents Novartis AG Mar- Mar Nov
13 -14 -18
10- 27- 13-
US10124048 Adenovirus vectors Oxford University Innovation Limited Apr- Apr Nov
07 -15 -18
13- 12- 13-
Genetically modified non-human animals and methods of use
US10123518 Institute For Research In Biomedicine (IRB) Apr- Apr Nov
thereof
15 -16 -18
4- 3- 6-
US10119967 Multiplex immuno screening assay Institut Pasteur May- May Nov
12 -13 -18
15- 6-
Capture primers and capture sequence linked solid supports for 31-
US10119164 IBIS BIOSCIENCES, INC. Aug Nov
molecular diagnostic tests Jul-09
-16 -18
31- 26- 6-
Imidazo[4,5-c] ring compounds containing substituted guanidine
US10118925 3M Innovative Properties Company Aug- Aug Nov
groups
15 -16 -18
23- 7- 6-
US10118923 Compositions and methods for inhibiting kinases Inhibikase Therapeutics, Inc. Apr- Nov Nov
15 -17 -18
22- 7- 6-
US10117920 Combination of vaccination and inhibition of the PD-1 pathway CureVac AG Feb- Feb Nov
13 -18 -18
8- 20- 30-
US10114011 Antigen presenting cell assay Apr- Jul- Oct-
Higher Education
10 17 18
4- 4- 23-
Virus vaccination and treatment methods with OX40 agonist
US10106619 La Jolla Institute for Allergy and Immunology Oct- Oct Oct-
compositions
06 -07 18
30- 29- 23-
US10106551 Monothiol mucolytic agents PARION SCIENCES, INC. Jan- Jan Oct-
15 -16 18
30- 10- 23-
US10105426 Immunostimulatory combinations TRUSTEES OF DARTMOUTH COLLEGE Dec- Sep Oct-
02 -15 18
28- 18-
2-Jul-
US10078083 Detecting targets using mass tags and mass spectrometry Ventana Medical Systems, Inc. Dec Sep
10
-15 -18

26- 26- 18-
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT
US10077427 Means and methods for influencing the stability of cells Mar- Mar Sep
VAN AMSTERDAM
15 -15 -18
5- 29- 18-
US10076491 Vaccine composition NITTO DENKO CORPORATION Feb- Jan Sep
13 -14 -18
8- 6- 11-
Methods for real-time multiplex isothermal detection and
US10072309 Not Available May- May Sep
identification of bacterial, viral, and protozoan nucleic acids
15 -16 -18
15- 16- 11-
US10072064 Composition comprised of antigen linked to a TNF superfamily ligand Not Available Mar- Mar Sep
13 -14 -18
29- 29- 11-
Chimeric virus-like particles incorporating fusion GPI anchored GM-
US10072058 Children's Healthcare of Atlanta, Inc. Apr- Apr Sep
CSF and IL-4 conjugates
15 -16 -18
7- 5- 11-
SANFORD BURNHAM PREBYS MEDICAL DISCOVERY
US10071976 Small molecule fatty acid synthase inhibitors Mar- Mar Sep
INSTITUTE
14 -15 -18
17- 7- 11-
Chloro-pyrazine carboxamide derivatives with epithelial sodium
US10071970 Parion Sciences, Inc. Dec- Mar Sep
channel blocking activity
12 -17 -18
3- 2- 11-
US10071155 Nasal mucosal vaccine composition NITTO DENKO CORPORATION Oct- Oct Sep
13 -14 -18
4- 6- 11-
US10071154 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Apr- Apr Sep
methods of using the same
08 -09 -18
12- 27- 11-
US10071076 Methods of treating cancer and other disorders Wake Forest University Health Sciences Nov- Jun Sep
10 -16 -18
11- 11- 4-
UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION,
US10066238 Methods for producing antibodies Feb- Feb Sep
INC.
13 -14 -18
16- 26- 4-
US10066012 Human monoclonal antibodies against interleukin 8 (IL-8) CORMORANT PHARMACEUTICALS AB Dec- Apr Sep
02 -16 -18
22- 11- 4-
US10064934 Combination PIV3/hMPV RNA vaccines ModernaTX, Inc. Oct- Aug Sep
15 -17 -18
4- 4- 4-
US10064900 Methods of populating a gastrointestinal tract Seres Therapeutics, Inc. Feb- Feb Sep
13 -14 -18
13- 13- 28-
US10059769 Anti-PD-L1 antibodies and uses thereof I-MAB Jun- Jun Aug
16 -17 -18
1- 28-
1-Jul-
US10059741 Peptidomimetic macrocycles Aileron Therapeutics, Inc. Jul- Aug
15
16 -18
19- 17- 28-
US10059655 Lipids and lipid compositions for the delivery of active agents Novartis AG Dec- Dec Aug
13 -14 -18
16- 15- 28-
Recombinant promoters and vectors for protein expression in liver
US10058624 Children's Healthcare of Atlanta, Inc. Apr- Apr Aug
and use thereof
15 -16 -18
9- 24- 28-
US10058535 Nuclear transport modulators and uses thereof Biogen MA Inc. May- Jan Aug
12 -17 -18
30- 28- 28-
Design, synthesis and methods of use of acyclic fleximer nucleoside
US10058516 Katholieke Universiteit Leuven Jan- Jan Aug
analogues having anti-coronavirus activity
15 -16 -18
25- 23- 21-
US10055502 Georgetown University Feb- Sep Aug
communicating event related information
08 -16 -18
15- 16- 21-
US10053728 High density self-contained biological analysis BioFire Diagnostics, LLC Nov- Jul- Aug
06 15 -18
8- 23- 21-
Additive compositions for pigmented disinfection and methods
US10052398 Kinnos Inc. Dec- May Aug
thereof
14 -15 -18
17- 27- 21-
US10052380 3M Innovative Properties Company Aug- Nov Aug
10 -17 -18
30- 28- 14-
US10047375 Artificial nucleic acid molecules CureVac AG Dec- Jun Aug
14 -16 -18
7- 8- 14-
US10047148 Neutralizing GP41 antibodies and their use Nov- Sep Aug
11 -17 -18
7- 4- 14-
The United States of American, as represented by the
US10047147 Neutralizing GP41 antibodies and their use Nov- Aug Aug
11 -14 -18
15- 5- 14-
Homogenous suspension of immunopotentiating compounds and
US10046048 GLAXOSMITHKLINE BIOLOGICALS S.A. Dec- Jul- Aug
uses thereof
09 16 -18
19- 19- 7-
Compositions and methods for treating diseases by inhibiting
US10040831 MOREHOUSE SCHOOL OF MEDICINE Dec- Dec Aug
exosome release
16 -16 -18
Human respiratory syncytial virus consensus antigens, nucleic acid 10- 10- 7-
US10040828 constructs and vaccines made therefrom, and methods of using THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Apr- Apr Aug
same 12 -13 -18

19- 21- 7-
US10040820 Method for the purification of protein complexes Immunobiology Limited Jun- Jun Aug
09 -10 -18
24- 24- 7-
US10039781 Pulse inhalation of nitric oxide for treating respiratory diseases AIT THERAPEUTICS, INC. Mar- Mar Aug
15 -16 -18
24- 23- 7-
Compositions and methods for inhibiting bacterial and viral
US10039758 Keck Graduate Institute of Applied Life Sciences Oct- Oct Aug
pathogens
14 -15 -18
23- 23- 31-
Use of EGFR pathway inhibitors to increase immune responses to
US10034931 Emory University Sep- Sep Jul-
antigens
13 -14 18
1- 28- 31-
US10034894 Method of treating inflammation CYTOSORBENTS CORPORATION Apr- Jun Jul-
10 -17 18
27- 12- 24-
US10031134 Ventana Medical Systems, Inc. Apr- Sep Jul-
10 -16 18
12- 25- 24-
US10030250 Edible vaccines expressed in soybeans Not Available Oct- Jan Jul-
04 -10 18
25- 7- 24-
Methods of inducing or enhancing an immune response in a subject
US10030074 GITR, Inc. Mar- Nov Jul-
having cancer by administering GITR antibodies
05 -16 18
17- 13- 24-
US10030053 Immunogenic compositions and methods of use thereof Emory University Dec- Feb Jul-
07 -15 18
5- 2- 24-
US10029016 Immunostimulatory compositions and methods of use thereof Massachusetts Insitute of Technology Apr- Jul- Jul-
12 15 18
28- 28- 24-
Disinfecting and deodorizing compositions and methods with novel
US10028482 OxiScience LLC Aug- Aug Jul-
polymeric binding system
14 -15 18
30- 7- 17-
The Research Foundation for The State University of New
US10023845 Methods of making modified viral genomes Mar- Sep Jul-
York
07 -16 18
8- 18- 17-
US10023632 Antigenic GM-CSF peptides and antibodies to GM-CSF Morphotek, Inc. Feb- Jul- Jul-
06 16 18
31- 22- 17-
US10023558 Compounds CHIESI FARMACEUTICI S.P.A. May- Sep Jul-
16 -17 18
11- 11- 17-
US10022436 Microneedle compositions and methods of using same VERNDARI, INC. Jan- Jan Jul-
16 -17 18
23- 1- 17-
US10022435 Nucleic acid vaccines ModernaTX, Inc. Apr- Apr Jul-
14 -16 18
14- 7- 17-
US10022422 Peptidomimetic macrocycles Alleron Therapeutics, Inc. Jan- Apr Jul-
09 -16 18
7- 19- 10-
US10018369 Air curtain device KAWANO GIKEN CO., LTD. Aug- Nov Jul-
15 -15 18
28- 17- 10-
Gene transfer into airway epithelial stem cell by using lentiviral
US10017784 ID PHARMA CO., LTD. Oct- Nov Jul-
vector pseudotyped with RNA virus or DNA virus spike protein
05 -14 18
30- 14- 10-
US10016498 The Regents of the University of California Nov- Sep Jul-
thereof
12 -17 18
29- 26- 10-
US10016497 MERS-CoV vaccine INOVIO PHARMACEUTICALS, INC. Nov- Nov Jul-
13 -14 18
30- 9- 10-
Method of preventing or treating influenza with oxidative reductive
US10016455 Sonoma Pharmaceuticals, Inc. Dec- May Jul-
potential water solution
03 -17 18
15- 2- 3-
US10013760 Stain-free histopathology by chemical imaging BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS Mar- Aug Jul-
13 -17 18
1- 28- 3-
US10010718 Device to kill micro-organisms inside the respiratory tract Not Available Apr- Mar Jul-
16 -17 18
16- 16- 3-
Method for preparing viral particles with cyclic dinucleotide and use INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA
US10010607 Sep- Sep Jul-
of said particles for inducing immune response RECHERCHE MEDICALE)
14 -15 18
10- 19- 26-
Continuous process for performing multiple nucleic acid
US10006862 GEN-PROBE INCORPORATED Mar- May Jun-
amplification assays
05 -17 18
2- 31- 26-
Methods of treating inflammation associated airway diseases and THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS
US10005833 Jan- Dec Jun-
viral infections SYSTEM
15 -15 18
22- 20- 26-
US10005772 Immune response modifier compositions and methods 3M Innovative Properties Company Dec- Dec Jun-
06 -07 18
7- 6- 26-
Red blood cell membrane-derived microparticles and their use for University of Pittsburghâ€”Of the Commonwealth System of
US10004764 Nov- Nov Jun-
the treatment of lung disease Higher Education
13 -14 18
11- 30- 26-
Therapeutic uses of selected pyrrolopyrimidine compounds with
US10004755 The University of North Carolina at Chapel Hill Apr- Jan Jun-
anti-mer tyrosine kinase activity
14 -17 18

30- 4-
17-
USRE47838 Inhibitory peptides of viral infection UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION Jan Feb
Jul-14
-18 -20
12- 30- 8-
USRE47636 Substituted spirocycles Boehringer Ingelheim International GmbH Sep- Nov Oct-
14 -17 19
20- 26- 9-
USRE47493 Boehringer Ingelheim International GmbH Feb- Mar Jul-
14 -18 19
3- 13- 26-
USRE46906 Methods for producing vaccine adjuvants NOVARTIS AG Dec- Oct Jun-
09 -15 18
6- 26- 29-
USRE46873 Multi-targeted RNAi therapeutics for scarless wound healing of skin Sirnaomics, Inc. Nov- May May
07 -16 -18
23- 18- 12-
USRE46630 Boehringer Ingelhelheim International GmbH Aug- Sep Dec
elastase activity
12 -15 -17
3- 13- 20-
USRE46441 Circulation of components during homogenization of emulsions NOVARTIS AG Dec- Oct Jun-
09 -15 17
27- 27- 3-
USH2284 Vaccines for protecting against influenza Novartis AG Apr- Apr Sep
09 -10 -13
27- 27- 3-
USH2283 Vaccines for protecting against influenza Novartis AG Apr- Apr Sep
09 -10 -13
2- 31- 31-
EP2517720A
Stabilized therapeutic small helical antiviral peptides New York Blood Center, Inc. Oct- Oct Oct-
1
07 -12 12
7- 17- 17-
EP2510946A
Conjugates of synthetic tlr agonists and uses therefor The Regents of The University of California Feb- Oct Oct-
1
08 -12 12
24- 24- 4-
EP2471938A
Recombinant polyvalent vaccine National Institute of Biomedical Innovation Nov- Nov Jul-
2
05 -05 12
24- 24- 4-
EP2471937A
2
05 -05 12
24- 24- 4-
EP2471936A
2
05 -05 12
9- 4- 4-
EP2471551A Decreasing potential iatrogenic risks associated with influenza
Novartis Vaccines and Diagnostics GmbH Sep- Jul- Jul-
2 vaccines
05 12 12
4- 4-
EP2167534B 11-
BIOACTIVE PEPTIDES AND METHOD OF USING SAME Compugen Ltd. Jul- Jul-
1 Jul-08
12 12
6- 4- 4-
EP2121732B COILED-COIL LIPOPEPTIDE HELICAL BUNDLES AND SYNTHETIC
UniversitÃ¤t ZÃ¼rich Prorektorat Forschung Dec- Jul- Jul-
1 VIRUS-LIKE PARTICLES
07 12 12

The Fauci COVID-19 Dossier

Загружено:

Сведения о документе

Авторское право

Доступные форматы

Поделиться этим документом

Поделиться или встроить документ

Параметры публикации

Этот документ был вам полезен?

Это неприемлемый материал?

Авторское право:

Доступные форматы

The Fauci COVID-19 Dossier

Загружено:

Авторское право:

Доступные форматы

The Fauci/COVID-19 Dossier

This document is prepared for humanity by Dr. David E. Martin.

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 1

1 U.S. Provisional Application No. 60/206,537, filed May 21, 2000

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 3

35 U.S.C. § 101 ........................................................................................................................................................................ 5

18 U.S.C. § 1001 – Lying to Congress .................................................................................................................................... 12

15 U.S.C. §1-3 – Conspiring to Criminal Commercial Activity ............................................................................................... 16

15 U.S.C. §8 – Market Manipulation and Allocation............................................................................................................. 20

15 U.S.C. § 19 – Interlocking Directorates ............................................................................................................................ 21

35 U.S.C. §200 - 206 – Disclosure of Government Interest .................................................................................................. 23

21 C.F.R. § 50.24 et seq., Illegal Clinical Trial ........................................................................................................................ 25

The Commercial Actors ......................................................................................................................................................... 27

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 4

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 6

Dr. Peter Daszak of EcoHealth Alliance offered the following assessment:

Economics will follow the hype.

Progress indicator(s) by September 2020

The answer, regrettably, is that no accountability exists to answer these questions.

Dr. Anthony Fauci’s Own Patent Track Record:

Filed May 19, 1993

Filed May 6, 1999

US Patent 7,368,114 Fusion protein including of CD4

Filed October 24, 2002

A sample of the convoluted flow of funds that evades public disclosure.

Additional references can be found at:

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 15

27 U.S. Provisional Application No. 60/206,537, filed May 21, 2000

The paper first published from the NIAID grant is

1990s Work focused on CoV association with cardiomyopathy (see above)

Early reference to the “emergence” of CoV as a respiratory pathogen in

2002 Asia CoV SARS outbreak

Review timeline from https://www.youtube.com/watch?v=rO_EeYB0i0U and

2012 MERS isolated in Egypt

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 18

2019 March, https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technology-to-create-

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 19

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 20

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 21

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 22

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 23

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 26

12- 26- 29-

28- 28- 22-

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 27

18- 23- 10-

Anionically modified polyallylamine derivative, use of anionically

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 28

18- 17- 23-

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 29

Amino acid sequences directed against envelope proteins of a virus 5- 29- 5-

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 30

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 31

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 32

Methods for treating pulmonary emphysema using substituted 2- 14- 1- 25-

15- 14- 18-

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 33

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 34

Chimeric polynucleotides and polypeptides enabling the secretion of 24- 23- 4-

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 35

14- 14- 14-

3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6- 27- 18- 7-

Fauci/COVID-19 Dossier CC-BY-NC-SA Dr. David E. Martin 36

Chimeric polynucleotides and polypeptides enabling secretion of a 18- 18- 17-